{
  "experiment_metadata": {
    "model": "nemotron-nano-30b",
    "experiment": "e2_page_window",
    "pattern": "qualitative_3hop_intra_doc_type1",
    "total_questions": 600,
    "successful": 600,
    "failed": 0,
    "elapsed_seconds": 4538.7,
    "timestamp": "2026-02-03T21:41:40.621046"
  },
  "results": [
    {
      "question_id": 1,
      "question": "How does Emerson's $7.8 billion cash payment to acquire National Instruments align with the strategic positioning of its newly formed Test & Measurement segment, which focuses on software-connected automated test systems?",
      "original_answer": "Emerson paid $7.8 billion in cash to acquire National Instruments (NI), a company that provides software-connected automated test and measurement systems. This acquisition led to the formation of the Test & Measurement segment, which now offers a full range of modular instrumentation, data acquisition and control solutions, and general-purpose development software. The segment's strategic focus on enabling enterprises to bring products to market faster and at lower cost directly aligns with NI's value proposition, indicating that the acquisition was a targeted move to strengthen Emerson’s capabilities in this domain. The segment’s description in the broader business portfolio highlights the integration of NI’s offerings as central to its Test & Measurement strategy.",
      "llm_answer": "Emerson's $7.8 billion cash payment to acquire National Instruments aligns directly with the strategic positioning of its newly formed Test & Measurement segment, which focuses on software‑connected automated test systems. The acquisition brings NI’s automated‑test hardware and software capabilities into Emerson’s portfolio, expanding the Test & Measurement segment’s offering of software‑connected test platforms that help customers bring products to market faster and at lower cost. This move is highlighted in the document as the primary driver for the segment’s creation and for adding roughly $1.3 billion of backlog to the company’s pipeline.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_2_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_3_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 66668,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16899,
        "completion_tokens": 162,
        "total_tokens": 17062
      }
    },
    {
      "question_id": 17,
      "question": "How does ConocoPhillips' preemptive purchase of an additional 10% stake in APLNG, based on Origin Energy's sale price reflecting market participant valuation, reconcile with the $688 million before-tax charge recorded due to the fair value write-down of APLNG investment?",
      "original_answer": "ConocoPhillips exercised its preemption right to acquire an additional 10% stake in APLNG in 2021, based on a sale price that reflected a market participant valuation of APLNG which was lower than ConocoPhillips' carrying value. As a result, the company was required to write down its investment in APLNG to the fair value of $5,574 million, leading to a before-tax charge of $688 million. This write-down indicates that the fair value of APLNG, as determined by the transaction price from Origin Energy’s sale, was significantly lower than ConocoPhillips’ previous carrying value, highlighting a valuation impairment driven by market conditions and expectations at the time.",
      "llm_answer": "ConocoPhillips recorded a $688 million pre‑tax impairment of its existing APLNG investment in Q4 2021 because the preemption‑sale price implied a market‑participant fair value below the carrying amount of that stake. The impairment was recognized as a non‑cash charge in the “Impairments” line of the consolidated income statement, while the subsequent purchase of the additional 10 % stake was accounted for at the fair‑value price that reflected that observable market participant valuation.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 72330,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18328,
        "completion_tokens": 123,
        "total_tokens": 18452
      }
    },
    {
      "question_id": 22,
      "question": "How does Chevron's reliance on crude oil exports through the Caspian Pipeline Consortium (CPC) align with the level of investment disclosed in the equity affiliates note, especially in light of the increased production capacity from the Tengiz Future Growth Project?",
      "original_answer": "Chevron's upstream operations in Kazakhstan, particularly the Tengizchevroil (TCO) affiliate, rely heavily on the Caspian Pipeline Consortium (CPC) for crude oil exports, as noted on page 35. In 2024, most of TCO's crude oil production was exported through the CPC pipeline. This dependency is further contextualized by the completion of the Future Growth Project (FGP), which added 260,000 barrels per day of crude oil production capacity. Given this increased throughput, Chevron's 15% ownership stake in CPC, disclosed on page 85, becomes strategically significant as CPC transports an average of 1.4 million barrels per day of crude oil, including Chevron's share from TCO and Karachaganak. The alignment suggests that Chevron's investment in CPC is critical to supporting the increased production volumes from its upstream growth projects in Kazakhstan, reinforcing the importance of midstream infrastructure to upstream monetization strategies.",
      "llm_answer": "Chevron’s 2024 equity‑affiliate note shows a $3,033 million investment in Tengizchevroil (TCO) and a $719 million stake in the Caspian Pipeline Consortium (CPC), reflecting the capital tied up in the CPC export route.  This investment aligns with the $4,500 million loan to TCO for the Future Growth Project, which boosted Tengiz’s production capacity by 260,000 bbl/d, underscoring Chevron’s reliance on CPC‑facilitated crude exports to support the higher output from the Tengiz Future Growth Project.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 82743,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20934,
        "completion_tokens": 125,
        "total_tokens": 21060
      }
    },
    {
      "question_id": 24,
      "question": "How does Duke Energy's legal obligation for coal ash basin closure under the 2024 CCR Rule relate to the expanded regulatory scope compared to the 2015 CCR Rule, and what does this imply about the company's long-term environmental liability estimates?",
      "original_answer": "Duke Energy's legal obligation for coal ash basin closure, as outlined in the 2024 CCR Rule (which expands the 2015 CCR Rule), increases the company's long-term environmental liabilities. The 2024 Rule introduces requirements for previously unregulated coal ash sources, such as inactive surface impoundments at retired facilities, which were not covered under the 2015 Rule. This expansion significantly affects Duke Energy’s asset retirement obligations (AROs), as noted in the balance sheet and detailed in Notes 4 and 10. The company estimates that the total cost to permanently close all coal ash basins in North and South Carolina will be approximately $8 billion to $9 billion, with $4.4 billion already spent through 2024. The 2015 CCR Rule had already imposed closure and monitoring requirements on active and certain inactive coal ash facilities, but the 2024 Rule extends these obligations to legacy and previously unregulated units, thereby increasing Duke Energy’s liability base and extending the timeline for compliance. This implies that the company must revise its ARO estimates upward as the scope of regulatory obligations grows, with the majority of remaining expenditures expected over the next decade.",
      "llm_answer": "Duke Energy's legal obligation for coal ash basin closure under the 2024 CCR Rule expands regulatory scope beyond the 2015 rule by requiring closure of inactive surface impoundments at retired facilities and previously unregulated coal ash sources at regulated facilities, significantly increasing the number of sites subject to closure requirements. This expansion implies substantially higher long-term environmental liability estimates, with the company projecting $8–9 billion in total costs to permanently close all coal ash basins across North and South Carolina, of which $4.4 billion has already been spent through 2024, with the majority of remaining expenditures expected over the next decade.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 102292,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 25813,
        "completion_tokens": 175,
        "total_tokens": 25988
      }
    },
    {
      "question_id": 25,
      "question": "How does Chevron's operational dependency on crude oil production in Kazakhstan relate to its financial investment in the Caspian Pipeline Consortium (CPC), and what does this imply about the strategic importance of CPC in Chevron's upstream operations?",
      "original_answer": "Chevron's upstream operations in Kazakhstan, particularly its 50% interest in Tengizchevroil (TCO) and 18% nonoperated interest in Karachaganak, rely heavily on the Caspian Pipeline Consortium (CPC) for crude oil export, as most of TCO's 2024 crude oil production was exported through CPC. Chevron also has a 15% ownership interest in CPC, which it describes as a critical export route for its Kazakh assets. Financially, Chevron's investment in CPC is part of its broader equity affiliate portfolio, and the company emphasizes its strategic alignment with upstream production by maintaining infrastructure access. This dual role—as both a major crude oil producer in Kazakhstan and a shareholder in CPC—highlights the pipeline's strategic importance in enabling Chevron to monetize upstream reserves and maintain operational continuity in the region.",
      "llm_answer": "Chevron's upstream operations in Kazakhstan, particularly through its 50 % stake in Tengizchevroil (TCO), rely on the Caspian Pipeline Consortium (CPC) to transport crude from the Tengiz and Korolev fields to export markets. This operational dependency ties Chevron’s financial performance directly to CPC’s capacity and reliability, making the pipeline a critical strategic asset that underpins the company’s upstream revenue and resource development plans.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 82743,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20931,
        "completion_tokens": 114,
        "total_tokens": 21045
      }
    },
    {
      "question_id": 25,
      "question": "How does Chevron's financial exposure to Tengizchevroil, including its $4,500 loan for the FGP/WPMP development, intersect with its ongoing tax uncertainties in Kazakhstan, particularly given that the most recent finalized tax audit in that country was for the year 2012?",
      "original_answer": "Chevron's financial exposure to Tengizchevroil, where it holds a 50% equity stake and has extended a $4,500 loan to fund the FGP/WPMP development, indicates a significant operational and financial commitment to Kazakhstan. This is further contextualized by the fact that Tengizchevroil contributed to improved equity affiliate income in 2021, highlighting its strategic importance. However, Chevron also faces ongoing tax uncertainties in Kazakhstan, where the most recent finalized tax audit was for 2012, leaving over a decade of potential exposure unresolved. Given Chevron's deep operational involvement through Tengizchevroil and the magnitude of its financial commitments, the lack of recent tax audit closure in Kazakhstan raises material risk regarding potential adjustments to Chevron’s unrecognized tax benefits, which could significantly impact its effective tax rate if recognized.",
      "llm_answer": "Chevron’s $4,500 loan to fund the FGP/WPMP development at Tengizchevroil is recorded as part of its $23,727 investment in TCO (Note 15), and the loan is included in the “net loans to affiliates” disclosed in the equity‑affiliate summary.  The most recent finalized tax audit in Kazakhstan was for 2012, so Chevron’s current tax exposure in that country remains tied to ongoing uncertainties—particularly the unresolved 2012 audit and the broader risk of additional adjustments to prior years’ tax positions that could affect the carrying value of its investment and loan.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2022.pdf",
          "target_page": 78,
          "pages": [
            76,
            77,
            78,
            79,
            80
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2022.pdf",
          "target_page": 42,
          "pages": [
            40,
            41,
            42,
            43,
            44
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2022.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 91402,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 23099,
        "completion_tokens": 142,
        "total_tokens": 23242
      }
    },
    {
      "question_id": 28,
      "question": "What is the fair value of MDLZ's net investment hedge contracts as of December 31, 2021, and how does the valuation methodology for these contracts reflect their classification within Level 2 financial liabilities?",
      "original_answer": "As of December 31, 2021, the fair value of MDLZ's net investment hedge contracts was $71 million, as disclosed in the fair value hierarchy table. These contracts are included within Level 2 financial liabilities, which are valued using observable market inputs. Specifically, the valuation methodology for Level 2 instruments, including net investment hedge contracts, relies on income-based approaches using observable market data such as forward rates, commodity prices, and interest rate curves, as detailed in the description of Level 2 financial assets and liabilities. This classification and valuation approach reflects the use of significant other observable inputs rather than direct market quotes (Level 1) or unobservable assumptions (Level 3).",
      "llm_answer": "The fair value of MDLZ's net investment hedge contracts as of December 31 2021 was $71 million (net asset), and these contracts are classified as Level 2 financial liabilities because their fair values are derived using observable market inputs—such as quoted forward rates, commodity indices, and interest‑rate curves—rather than quoted prices in an active market.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 111,
          "pages": [
            109,
            110,
            111,
            112,
            113
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 78234,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19787,
        "completion_tokens": 91,
        "total_tokens": 19878
      }
    },
    {
      "question_id": 29,
      "question": "How does Nike's foreign exchange risk management strategy for product purchases through the Nike Trading Company (NTC) reflect both the currency exposure created by NTC's functional currency and the broader transactional exposure management approach described in the financial statements?",
      "original_answer": "Nike manages foreign exchange risk related to product purchases through the NTC, which operates with the U.S. Dollar as its functional currency. When NTC sells products to Nike entities with different functional currencies, it creates foreign currency exposure. This exposure is managed under Nike’s broader foreign currency risk management program, which uses cash flow hedges and natural offsets to mitigate the impact of exchange rate fluctuations on consolidated financial results. The strategy reflects both the structural exposure created by NTC's role as a U.S. Dollar-based sourcing hub and Nike’s systematic approach to hedging transactional exposures across the business.",
      "llm_answer": "Nike manages foreign‑exchange risk on product purchases through the Nike Trading Company (NTC) by using NTC’s U.S.‑dollar functional currency as the pricing basis for its sourcing hub, then selling to Nike entities with other functional currencies. This creates a foreign‑currency exposure for NTC that is hedged primarily with designated cash‑flow forwards and options, which are recorded in accumulated other comprehensive income until the underlying hedged transaction impacts net income. The hedging program is designed to offset both transactional exposures (e.g., product‑cost purchases denominated in non‑functional currencies) and translation exposures, and the resulting gains or losses are re‑classified to earnings in the same period as the related cost of sales or other income.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2024.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 89145,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22535,
        "completion_tokens": 197,
        "total_tokens": 22733
      }
    },
    {
      "question_id": 30,
      "question": "How does NIKE's foreign exchange risk management strategy for product costs relate to its reliance on the NIKE Trading Company (NTC) for sourcing, and what impact does this have on inventory cost volatility?",
      "original_answer": "NIKE manages foreign exchange risk related to product costs by hedging exposures generated through non-functional currency denominated purchases, including those made through the NIKE Trading Company (NTC). The NTC, which operates in U.S. Dollars, sources products from third-party factories and sells them to NIKE entities in their respective functional currencies, creating foreign currency exposure. A stronger U.S. Dollar increases inventory costs for these entities, while a weaker Dollar reduces them. NIKE mitigates this volatility using a combination of natural offsets and derivative instruments, such as currency forwards and options, which are accounted for as cash flow hedges. This layered approach helps stabilize inventory costs despite fluctuations in foreign exchange rates tied to NTC transactions.",
      "llm_answer": "NIKE manages foreign exchange risk for product costs primarily through its wholly owned sourcing hub, the NIKE Trading Company (NTC), which purchases products from third‑party factories in U.S. dollars and then sells them to NIKE entities worldwide in their local functional currencies. This structure creates foreign‑currency exposure for the NTC and for other NIKE entities that buy directly from factories, and the company mitigates that exposure with cash‑flow hedges using forward contracts and options. Consequently, inventory cost volatility is directly tied to fluctuations in exchange rates; when the U.S. dollar strengthens, inventory costs fall, but a weaker dollar raises costs, leading to variability in inventory valuation that is reflected in cost of sales and ultimately in earnings.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 86785,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21925,
        "completion_tokens": 199,
        "total_tokens": 22125
      }
    },
    {
      "question_id": 34,
      "question": "How does Nike's foreign exchange risk management strategy for product purchases through the Nike Trading Company (NTC) reflect both the cost exposure dynamics described in the hedging section and the functional currency mismatch risks outlined in the transactional exposures section?",
      "original_answer": "Nike manages foreign exchange risk related to product purchases through the NTC by using cash flow hedges, which are designed to offset the variability in cash flows caused by currency fluctuations. The NTC, whose functional currency is the U.S. Dollar, purchases products from third-party factories predominantly in U.S. Dollars and then sells them to Nike entities in their respective functional currencies. This creates a foreign currency exposure for the NTC when selling to Nike subsidiaries with different functional currencies. According to the transactional exposures section, this exposure is significant and is managed through a portfolio-based approach that includes natural offsets and the use of currency forward and option contracts. The hedging section explains that these contracts are generally accounted for as cash flow hedges, aligning with the need to stabilize the consolidated financial results against the volatility introduced by the functional currency mismatch between the NTC and other Nike entities.",
      "llm_answer": "Nike's foreign exchange risk management strategy for product purchases through the Nike Trading Company (NTC) directly addresses both the cost exposure dynamics and functional currency mismatch risks. The NTC, operating in U.S. dollars, purchases products from third-party factories (often in U.S. dollars) and sells them to Nike entities with different functional currencies, creating foreign currency exposure for the NTC. This exposure is managed through derivatives designated as cash flow hedges, which lock in exchange rates for future product purchases, thereby mitigating the impact of currency fluctuations on inventory costs. Simultaneously, the company's functional currency mismatch—where subsidiaries operate in non-U.S. dollar currencies but report in U.S. dollars—creates translation exposure. This is managed via the foreign currency adjustment program and hedging of translation gains/losses, ensuring that currency movements in non-functional currency revenues and costs (e.g., European sales in pounds) do not materially distort consolidated earnings. Together, these strategies stabilize costs and earnings by offsetting currency volatility in both procurement and reported results.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2024.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 89145,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22534,
        "completion_tokens": 300,
        "total_tokens": 22834
      }
    },
    {
      "question_id": 45,
      "question": "How does ConocoPhillips' reliance on DeGolyer and MacNaughton to review over 85% of its proved reserves estimation processes align with the inclusion of their independent report as Exhibit 99 in the 10-K filing?",
      "original_answer": "ConocoPhillips utilizes DeGolyer and MacNaughton (D&M) to independently review over 85% of its proved reserves estimation processes, ensuring compliance with SEC regulations and internal policy. This third-party review is a key part of the company’s internal control framework for reserves reporting. The results of D&M's evaluation are formally documented in a report that is included as Exhibit 99 in the 10-K filing, demonstrating transparency and external validation of the company’s reserves estimation methodology. This linkage shows how ConocoPhillips integrates external expert analysis into its regulatory disclosures to reinforce the credibility of its reserves reporting.",
      "llm_answer": "ConocoPhillips' reliance on DeGolyer and MacNaughton to review over 85% of its proved reserves estimation processes is formally documented in its 10-K filing, where the company states that D&M's independent review of its reserves processes and controls for December 31, 2024, confirmed compliance with SEC regulations. This review, which included an objective third-party assessment of ConocoPhillips' internal controls and reserve estimation methods, is explicitly referenced in the filing as Exhibit 99, thereby incorporating D&M's report as a formal exhibit validating the company's reserves estimation framework.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 166,
          "pages": [
            164,
            165,
            166,
            167,
            168
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 77716,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19661,
        "completion_tokens": 154,
        "total_tokens": 19815
      }
    },
    {
      "question_id": 57,
      "question": "How does Disney's exclusion of forecasted foreign currency transactions from its Value at Risk (VAR) model impact the assessment of its foreign exchange risk exposure, given its $9.9 billion notional amount of foreign exchange cash flow hedges and a VAR estimate of $255 million?",
      "original_answer": "Disney actively manages its foreign exchange risk by hedging forecasted foreign currency transactions, with a notional amount of $9.9 billion in cash flow hedges as of September 28, 2024. However, these forecasted transactions are explicitly excluded from the company’s Value at Risk (VAR) model, which focuses only on existing financial instruments like derivatives and market-sensitive equity investments. The VAR model estimates a maximum one-day loss of $255 million under a 95% confidence level, based on historical market volatility. This creates a divergence in how foreign exchange risk is quantified: the hedging program reflects proactive risk management of future exposures, while the VAR model does not account for these forward-looking transactions. Therefore, the $255 million VAR figure may understate the company's total foreign exchange risk exposure since it omits forecasted transactions that are economically relevant and actively hedged.",
      "llm_answer": "Disney’s VAR model deliberately omits forecasted foreign‑currency cash‑flow transactions, even though it hedges $9.9 billion of such exposures. Consequently, the $255 million VAR figure understates the true one‑day potential loss from foreign‑exchange movements, meaning the reported market‑risk exposure is lower than the actual risk the company faces. This exclusion leads analysts to underestimate Disney’s foreign‑exchange risk relative to its hedged notional amount.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 66790,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16945,
        "completion_tokens": 117,
        "total_tokens": 17063
      }
    },
    {
      "question_id": 61,
      "question": "How does the cessation of future benefit accruals in the UPS Retirement Plan for non-union participants, effective January 1, 2023, align with the IRS limits on tax-qualified defined benefit plans and the subsequent shift toward defined contribution plan structures, such as the UPS 401(k) Savings Plan with IRS-prescribed limits?",
      "original_answer": "The cessation of future benefit accruals in the UPS Retirement Plan for non-union participants as of January 1, 2023, reflects a strategic shift away from defined benefit plans toward defined contribution plans, such as the UPS 401(k) Savings Plan. This shift aligns with the IRS-prescribed limits on tax-qualified plans, which constrain the maximum compensation and contributions that can be made on behalf of employees. In response, UPS transitioned non-union employees to a defined contribution model, where they now receive annual retirement contributions of 5% to 8% of eligible compensation based on years of service (up from 3% to 8% in 2023), subject to IRS limits. Additionally, UPS sponsors the UPS Restoration Savings Plan, a non-qualified plan that accommodates contributions exceeding IRS limits. This transition reflects both regulatory constraints and a broader strategic move to reduce long-term pension liabilities while maintaining competitive retirement benefits.",
      "llm_answer": "The cessation of future benefit accruals in the UPS Retirement Plan for non‑union participants, effective January 1 2023, was required to stay within the IRS‑prescribed maximum benefit limits for tax‑qualified defined‑benefit plans. As a result, UPS shifted those participants to its defined‑contribution structure—the UPS 401(k) Savings Plan—where contributions are made up to the IRS‑prescribed limits for tax‑qualified defined‑contribution plans. This transition allows the company to comply with IRS caps while providing retirement benefits through a DC vehicle.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 87,
          "pages": [
            85,
            86,
            87,
            88,
            89
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 64651,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16418,
        "completion_tokens": 141,
        "total_tokens": 16560
      }
    },
    {
      "question_id": 65,
      "question": "How does UPS's reliance on net asset value (NAV) estimates for its U.S. pension plan investments reconcile with the illiquidity and long-term nature of its real estate fund commitments totaling $3.3 billion?",
      "original_answer": "UPS utilizes estimated NAV to value its U.S. pension plan investments in hedge funds, private debt, private equity, and real estate, which totaled $9.9 billion as of December 31, 2023. These NAV-based valuations are derived from fund managers’ financial reports and involve subjective adjustments due to the lack of active trading and readily determinable market values. This valuation approach introduces estimation risk, as the reported values may differ from what would be determined with more transparent market data. Meanwhile, the company has unfunded commitments of $3.3 billion to limited partnerships, including real estate funds, which are typically locked up for 10–15 years with limited redemption rights. The long-term, illiquid nature of these commitments contrasts with the NAV estimation process, which relies on periodic and potentially delayed financial reports. This creates a tension between the subjective, audit-intensive valuation methodology and the binding, long-duration investment profile of the real estate and private market assets.",
      "llm_answer": "UPS values its U.S. pension plan investments using estimated net asset value (NAV) for illiquid real estate, private debt, and private equity fund commitments totaling $3.3 billion, recognizing that these assets cannot be readily priced and must rely on subjective fund‑provided NAV estimates adjusted for activity between reporting dates. The company discloses that the NAV estimates are based on audited or unaudited fund financial statements and are subject to management’s judgment, which creates inherent estimation risk despite the lack of market‑observable pricing.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 63,
          "pages": [
            61,
            62,
            63,
            64,
            65
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 76967,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19470,
        "completion_tokens": 143,
        "total_tokens": 19613
      }
    },
    {
      "question_id": 83,
      "question": "How does AMD's binding commitment under the 2022-2025 Wafer Supply Agreement with GLOBALFOUNDRIES, including pre-payment obligations and minimum capacity allocation, reconcile with their broader supply chain risk disclosures regarding lack of long-term commitments with third-party manufacturers and potential inventory cost impacts?",
      "original_answer": "AMD has a binding Wafer Supply Agreement (WSA) with GLOBALFOUNDRIES U.S. Inc. through 2025, which includes minimum annual capacity allocation from GF and corresponding annual wafer purchase targets for AMD. If AMD fails to meet these targets, it must pay a portion of the shortfall, and the company is obligated to pre-pay GF certain amounts for wafers in 2022 and 2023. This represents a significant long-term commitment, contrasting with AMD’s broader supply chain risk disclosures where they note that they do not have long-term commitment contracts with some third-party manufacturers and instead rely on purchase orders. This lack of guaranteed supply from other manufacturers introduces risks around capacity allocation, pricing, and delivery timelines. Furthermore, if AMD’s actual wafer requirements fall short of the purchase targets under the WSA, the company could face excess inventory or higher inventory unit costs, which may adversely impact gross margins. The WSA introduces both stability and risk, depending on AMD’s ability to forecast and meet its wafer demand over the agreement’s term.",
      "llm_answer": "AMD’s binding 2022‑2025 Wafer Supply Agreement with GLOBALFOUNDRIES obligates the company to purchase a minimum annual wafer capacity and to pre‑pay for those wafers, while also granting it full flexibility to source from other foundries. This contractual commitment directly conflicts with AMD’s broader risk disclosures that it has no long‑term purchase commitments with third‑party manufacturers and that inventory cost impacts and supply constraints could materially affect its business. The agreement’s minimum‑capacity and pre‑payment obligations therefore create a concrete supply‑chain commitment that the company’s general risk factors do not fully acknowledge.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMD_10k_2022.pdf",
          "target_page": 97,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_2_rel": {
          "source_file": "AMD_10k_2022.pdf",
          "target_page": 97,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "AMD_10k_2022.pdf",
          "target_page": 23,
          "pages": [
            21,
            22,
            23,
            24,
            25
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 83589,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21157,
        "completion_tokens": 167,
        "total_tokens": 21325
      }
    },
    {
      "question_id": 86,
      "question": "How does Cisco's disclosure of interest rate sensitivity for its senior fixed-rate notes reconcile with its short-term commercial paper financing program, particularly in light of the $1.5 billion in hedged debt?",
      "original_answer": "Cisco disclosed that a 50 BPS change in interest rates would impact the fair value of its senior fixed-rate debt (excluding $1.5 billion of hedged debt) by $0.3 billion. This sensitivity analysis applies to the $9.0 billion in senior fixed-rate notes, which are partially hedged through $1.5 billion in interest rate swaps that convert fixed rates to floating rates tied to LIBOR. These hedged senior notes rank at par with the commercial paper notes Cisco issues under its $10.0 billion short-term financing program. While the long-term fixed-rate notes are exposed to fair value changes from rate movements, the commercial paper notes, being short-term instruments, are inherently less sensitive to interest rate fluctuations. Thus, Cisco manages interest rate exposure through a combination of hedging and balancing fixed and floating rate debt instruments across its capital structure.",
      "llm_answer": "Cisco discloses that it hedges $1.5 billion of its fixed‑rate senior notes with interest‑rate swaps, and it reports that a 50‑basis‑point shift in market rates would affect the fair value of the un‑hedged portion of that debt by roughly $0.3 billion, while the hedged portion is protected from such interest‑rate movements. This arrangement reconciles with its short‑term commercial paper program, which provides up to $10 billion of financing for general corporate purposes, by separating the hedged debt (which is insulated from rate changes) from the un‑hedged floating‑rate commercial paper exposure.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2022.pdf",
          "target_page": 57,
          "pages": [
            55,
            56,
            57,
            58,
            59
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2022.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2022.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 80077,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20250,
        "completion_tokens": 151,
        "total_tokens": 20401
      }
    },
    {
      "question_id": 94,
      "question": "How does AIG's announcement of the full redemption of its Series A Preferred Stock relate to the Depositary Shares disclosed in the securities registration, and what does this imply about the structure and treatment of these financial instruments?",
      "original_answer": "AIG disclosed in its securities registration on page 1 that it issued 20,000,000 Depositary Shares, each representing a 1/1,000th interest in a share of Series A 5.85% Non-Cumulative Perpetual Preferred Stock. On page 238, AIG announced that it would redeem all 20,000 outstanding shares of the Series A Preferred Stock, which corresponds to all 20,000,000 Depositary Shares. This redemption, priced at $25.00 per Depositary Share ($25,000 per Series A Preferred Stock share), illustrates the direct proportional relationship between the Depositary Shares and the underlying Preferred Stock. The fact that AIG is redeeming both in full highlights that the Depositary Shares are structured as a divisible proxy for ownership in the Series A Preferred Stock, and that both instruments are treated in alignment for purposes of redemption and capital structure management.",
      "llm_answer": "AIG's announcement of the full redemption of its Series A Preferred Stock—specifically the 20,000 outstanding shares of Series A Preferred Stock and the corresponding 20 million Depositary Shares (each representing a 1/1,000th interest in a share of Series A Preferred Stock)—directly addresses the securities that were registered in the SEC filing under the Depositary Shares description. The redemption price of $25,000 per share (or $25.00 per Depositary Share) will be paid on March 15, 2024, effectively retiring the entire Series A Preferred Stock issue. This action removes the preferred equity component from AIG’s capital structure, simplifying the equity hierarchy and eliminating the non‑cumulative dividend obligations and redemption rights that previously applied to those shares. Consequently, the Depositary Shares will cease to exist after the redemption, and any remaining dividend considerations tied to the Series A Preferred Stock will no longer be applicable.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 1,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        },
        "hop_2_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 239,
          "pages": [
            237,
            238,
            239,
            240,
            241
          ]
        },
        "hop_3_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 238,
          "pages": [
            236,
            237,
            238,
            239,
            240
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 138122,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 34770,
        "completion_tokens": 245,
        "total_tokens": 35015
      }
    },
    {
      "question_id": 104,
      "question": "How does the maturity of the 3.625% 2024 Notes impact the fair value and balance sheet presentation of interest rate swap contracts, given Amgen's stated hedging strategy?",
      "original_answer": "The maturity of the $1.4 billion 3.625% 2024 Notes resulted in the termination of associated interest rate swap contracts, which contributed to the reduction in the fair value of derivative liabilities related to interest rate swaps on the balance sheet. As of December 31, 2024, interest rate swap contracts are not listed among derivative liabilities, contrasting with the $571 million liability reported for these instruments as of December 31, 2023. This aligns with Amgen's stated hedging strategy of using interest rate swaps to convert fixed-rate debt to floating-rate debt, where the termination of the hedged debt (3.625% 2024 Notes) would logically result in the removal of the related hedging instruments from the balance sheet.",
      "llm_answer": "The 3.625% 2024 Notes matured in 2024, causing interest‑rate swap contracts with a $1.4 billion notional amount to settle and be replaced by new swaps on the 5.25% 2033 Notes. These swaps are designated as fair‑value hedges that convert the fixed‑rate debt to floating‑rate SOFR‑based payments; the resulting fair‑value adjustments are recorded in the carrying amount of the hedged debt and affect interest expense. Consequently, the maturity of the 2024 Notes impacts the fair‑value presentation of the related interest‑rate swap contracts and their balance‑sheet classification as hedging instruments.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 149,
          "pages": [
            147,
            148,
            149,
            150,
            151
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 148,
          "pages": [
            146,
            147,
            148,
            149,
            150
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 151,
          "pages": [
            149,
            150,
            151,
            152,
            153
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 87038,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21979,
        "completion_tokens": 150,
        "total_tokens": 22130
      }
    },
    {
      "question_id": 111,
      "question": "How does the maturity of the 3.625% 2024 Notes impact the fair value and liability treatment of Amgen's interest rate swap contracts as disclosed in the derivative instruments section?",
      "original_answer": "The maturity of the $1.4 billion 3.625% 2024 Notes resulted in the termination of associated interest rate swap contracts during the year ended December 31, 2024. This event reduced the notional amount of active interest rate swaps from $6.7 billion at the beginning of the year. As of December 31, 2024, Amgen no longer held any derivative assets related to these terminated interest rate swaps, and the remaining liability related to interest rate swaps stood at $571 million as per the consolidated balance sheets. This reflects the dynamic relationship between debt maturities and the corresponding hedging instruments, which directly affects the fair value and liability recognition of derivatives.",
      "llm_answer": "The maturity of the 3.625% 2024 Notes required termination of the related interest‑rate swap contracts during 2024, which resulted in a realized gain on the swap that was recorded as an adjustment to the carrying value of the debt and amortized into interest expense over the remaining term of the previously hedged liability. This termination and the associated hedge accounting treatment directly affect the fair‑value measurement and liability presentation of those swaps in the derivative‑instruments disclosures.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 149,
          "pages": [
            147,
            148,
            149,
            150,
            151
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 148,
          "pages": [
            146,
            147,
            148,
            149,
            150
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 151,
          "pages": [
            149,
            150,
            151,
            152,
            153
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 87038,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21983,
        "completion_tokens": 129,
        "total_tokens": 22112
      }
    },
    {
      "question_id": 146,
      "question": "How does BMY's revenue from Orencia in 2023 relate to its joint commercialization arrangement with Ono, particularly considering the co-promotion fee structure and BMY's responsibility for product supply in Japan?",
      "original_answer": "BMY reported $3,601 million in revenue from Orencia in 2023, which is directly tied to its joint commercialization agreement with Ono. Under the arrangement, BMY is responsible for product supply and order fulfillment for the intravenous formulation of Orencia, while Ono handles the subcutaneous formulation. Both parties jointly promote the drug in Japan, with a co-promotion fee of 60% paid when a sale is made to the other party's assigned customer. This fee structure and shared promotional responsibility likely influence the revenue distribution and operational dynamics of Orencia in the Japanese market, as BMY remains the primary supplier despite shared promotion.",
      "llm_answer": "Based on the document, BMY's revenue from Orencia in Japan is generated through a joint commercialization arrangement with Ono where BMY is responsible for product supply. The document specifically states that \"BMS and Ono also jointly develop and commercialize Orencia in Japan. BMS is responsible for the order fulfillment and distribution of the intravenous formulation and Ono is responsible for the subcutaneous formulation. Both formulations are jointly promoted by both parties with assigned customer accounts and BMS is responsible for the product supply. A copromotion fee of 60% is paid when a sale is made to the other party's assigned customer.\" This indicates that BMY's revenue from Orencia sales in Japan is derived from its role as the product supplier under the co-promotion agreement with Ono, with the revenue structure involving shared profits and a 60% copromotion fee paid to the other party on sales to their customers.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 68874,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17447,
        "completion_tokens": 235,
        "total_tokens": 17682
      }
    },
    {
      "question_id": 208,
      "question": "How does Capital One's adoption of ASU 2022-02 impact the accounting treatment of loan modifications previously classified as Troubled Debt Restructurings, and what new framework replaced TDRs under this standard effective January 1, 2023?",
      "original_answer": "Capital One adopted ASU 2022-02 on January 1, 2023, which eliminated the accounting guidance for Troubled Debt Restructurings (TDRs). As a result, loan modifications that were previously classified as TDRs are now accounted for under a new framework called Financial Difficulty Modifications (FDMs). FDMs capture modifications made to borrowers experiencing financial difficulty, including principal forgiveness, interest rate reductions, payment delays, or term extensions, but are treated differently under the updated standard, reflecting a shift in how such credit events are recognized and disclosed.",
      "llm_answer": "Capital One adopted ASU 2022-02 effective January 1, 2023, which eliminated the accounting guidance for Troubled Debt Restructurings (TDRs). Under the new framework, loan modifications previously classified as TDRs are no longer accounted for under TDR rules; instead, they are evaluated under the general CECL framework for credit losses, which assesses expected credit losses based on the loan's status and modification terms without the specific TDR designation. This change simplifies the accounting treatment and removes the separate TDR classification for such modifications.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COF_10k_2024.pdf",
          "target_page": 125,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        },
        "hop_2_rel": {
          "source_file": "COF_10k_2024.pdf",
          "target_page": 125,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        },
        "hop_3_rel": {
          "source_file": "COF_10k_2024.pdf",
          "target_page": 122,
          "pages": [
            120,
            121,
            122,
            123,
            124
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 46450,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 11849,
        "completion_tokens": 145,
        "total_tokens": 11994
      }
    },
    {
      "question_id": 1,
      "question": "How does MetLife's inclusion of credit insurance in the EMEA segment compare with the overall performance of that segment in 2023, and what does this suggest about the contribution of credit insurance in that region?",
      "original_answer": "MetLife offers credit insurance as part of its product portfolio in the EMEA segment, which reported earnings of $265 million in 2023. This relatively low adjusted earnings contribution compared to other segments like Group Benefits ($1,655 million) or RIS ($1,708 million) suggests that the EMEA segment, despite offering credit insurance alongside other products, had a limited overall financial impact on the company in 2023. This could indicate either a smaller market presence in EMEA or lower profitability from products like credit insurance in that region.",
      "llm_answer": "MetLife's inclusion of credit insurance in the EMEA segment contributed modestly to the segment's overall performance in 2023, as evidenced by the segment's adjusted premiums, fees and other revenues of $2.281 billion (up from $2.341 billion in 2022) and its adjusted earnings of $249 million. This suggests that credit insurance provided a stable, though not dominant, source of revenue and profitability for the EMEA segment, helping to offset broader regional pressures and supporting the segment's overall financial results.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 169,
          "pages": [
            167,
            168,
            169,
            170,
            171
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 85722,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21667,
        "completion_tokens": 132,
        "total_tokens": 21799
      }
    },
    {
      "question_id": 1,
      "question": "How does Philip Morris International's characterization of illicit trade as a systemic risk factor reconcile with the reported decline in illicit trade prevalence in Pakistan, where the company recently incurred $20 million in plant closure costs?",
      "original_answer": "Philip Morris International identifies illicit trade in tobacco products as a major risk factor that negatively impacts its business, volume, results of operations, and financial position (Page 40). However, in South & Southeast Asia, including Pakistan, the company notes a 17.3% market increase driven partly by a lower prevalence of illicit trade during the pandemic (Page 58). Despite this favorable trend, the company recorded $20 million in asset impairment and exit costs related to a cigarette plant closure in Pakistan (Page 126), suggesting that market dynamics, even with reduced illicit trade, did not justify continued local production. This indicates a complex interplay between risk mitigation and operational restructuring in response to evolving market conditions.",
      "llm_answer": "PMI characterizes illicit trade as a systemic risk that can undermine public‑health goals and fiscal objectives, yet it simultaneously reports a measurable decline in illicit trade prevalence in Pakistan—evidenced by the $20 million plant‑closure costs incurred there—reflecting that reduced illicit activity can coexist with the company’s risk‑focused narrative.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PM_10k_2022.pdf",
          "target_page": 40,
          "pages": [
            38,
            39,
            40,
            41,
            42
          ]
        },
        "hop_2_rel": {
          "source_file": "PM_10k_2022.pdf",
          "target_page": 58,
          "pages": [
            56,
            57,
            58,
            59,
            60
          ]
        },
        "hop_3_rel": {
          "source_file": "PM_10k_2022.pdf",
          "target_page": 126,
          "pages": [
            124,
            125,
            126,
            127,
            128
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 70464,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17861,
        "completion_tokens": 90,
        "total_tokens": 17951
      }
    },
    {
      "question_id": 1,
      "question": "How does LLY's reliance on biologics data protection for Emgality in the U.S., which expires in 2030, align with their broader strategy of managing market exclusivity given the complex interaction between patent and regulatory protections?",
      "original_answer": "LLY relies on both compound patents and biologics data protection for Emgality, with U.S. data protection expiring in 2030 and compound patents extending until 2033. This staggered protection suggests a strategy to prolong market exclusivity by leveraging multiple forms of intellectual property. However, the company acknowledges on page 11 that predicting the actual length of exclusivity is difficult due to the complex interaction between patent and regulatory protections, as well as uncertainties in litigation and exclusivity extensions like pediatric or orphan drug designations. This implies that while LLY plans for extended exclusivity through layered protections, the real-world outcome may vary significantly from the estimated expiry dates.",
      "llm_answer": "LLY's reliance on biologics data protection for Emgality (expiring in 2030) aligns with its broader strategy of managing market exclusivity by leveraging the complex interplay between patent protection and regulatory data exclusivity. While compound patents for Emgality extend to 2033–2035 in key markets, the biologics data protection period (2030 in the U.S.) provides a critical buffer to maintain market exclusivity beyond the compound patent expiry, accounting for the inherent uncertainty in patent litigation and regulatory challenges that could shorten effective exclusivity. This strategy ensures continued revenue protection for a key neuroscience product despite the expiration of its core patent rights.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 12,
        "total_chars": 57088,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14505,
        "completion_tokens": 179,
        "total_tokens": 14684
      }
    },
    {
      "question_id": 1,
      "question": "How does Chevron's joint venture in Louisiana for soybean oil production align with the legal risks the company faces in the same state related to coastal erosion from historical oil and gas operations?",
      "original_answer": "Chevron holds a 50% working interest in Bunge Chevron Ag Renewables LLC, which operates soybean oil processing facilities in Destrehan, Louisiana. This renewable feedstock is critical for Chevron’s renewable fuels strategy, including renewable diesel and sustainable aviation fuel production. Meanwhile, Chevron faces 39 lawsuits in Louisiana related to coastal erosion from historical oil and gas operations, with a trial set for October 2024 and potential material financial impact. While the soybean operations in Louisiana support Chevron’s strategic pivot toward lower-carbon energy, the state also represents a significant legal liability due to legacy fossil fuel activities, creating a dual exposure where operational growth and legal risk coexist in the same geographic region.",
      "llm_answer": "Chevron's joint venture in Louisiana for soybean oil production aligns with the legal risks it faces in the state related to coastal erosion from historical oil and gas operations, as the company is a defendant in numerous lawsuits under Louisiana's State and Local Coastal Resources Management Act (SLCRMA). These cases, brought by coastal parishes and the state, allege that Chevron's historical operations caused coastal erosion and seek damages for wetland restoration, with one case scheduled for trial in October 2024; Chevron maintains the claims lack legal merit and will vigorously defend against them.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 18,
          "pages": [
            16,
            17,
            18,
            19,
            20
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 18,
          "pages": [
            16,
            17,
            18,
            19,
            20
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 79846,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20189,
        "completion_tokens": 152,
        "total_tokens": 20342
      }
    },
    {
      "question_id": 1,
      "question": "How does GM's strategic emphasis on crossovers as a key product category align with its financial transactions and equity stake in nonconsolidated affiliates involved in crossover production?",
      "original_answer": "GM highlights crossovers as a core product category within its automotive operations, noting that these vehicles help maintain sales volumes and contribute to fuel efficiency goals. The company also engages in transactions with nonconsolidated affiliates involved in the development, production, and marketing of crossovers, indicating a strategic reliance on these partners. However, since these affiliates are not consolidated, their financial performance does not directly appear in GM’s consolidated results, despite their importance to crossover output. This structure allows GM to leverage external manufacturing capacity without fully absorbing the financial risks associated with direct ownership, aligning with its broader approach to managing costs and scaling production efficiently.",
      "llm_answer": "GM's strategic focus on crossovers aligns with its financial involvement in nonconsolidated affiliates that produce crossovers, as evidenced by its equity stakes in China joint ventures (e.g., SAIC-GM-Wuling) and its $2.268 billion investment in Ultium Cells Holdings LLC, which supplies battery cells for electric crossovers. These investments are reflected in the company's $10.613 billion equity in nonconsolidated affiliates and $1.893 billion of net income from those affiliates, underscoring how GM leverages its ownership in crossover‑producing entities to support its broader product strategy.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GM_10k_2023.pdf",
          "target_page": 101,
          "pages": [
            99,
            100,
            101,
            102,
            103
          ]
        },
        "hop_2_rel": {
          "source_file": "GM_10k_2023.pdf",
          "target_page": 78,
          "pages": [
            76,
            77,
            78,
            79,
            80
          ]
        },
        "hop_3_rel": {
          "source_file": "GM_10k_2023.pdf",
          "target_page": 78,
          "pages": [
            76,
            77,
            78,
            79,
            80
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 103828,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 26182,
        "completion_tokens": 150,
        "total_tokens": 26333
      }
    },
    {
      "question_id": 1,
      "question": "How does Alphabet's stock repurchase strategy for Class A shares align with the use of Class C shares in employee compensation plans, given the identical economic rights of both share classes?",
      "original_answer": "Alphabet repurchases Class A and Class C shares based on economic cost and market conditions (page 81), while the company issues Class C shares specifically through its 2021 Stock Plan for employee compensation, with 723 million shares reserved for this purpose (page 83). Despite these different uses, both share classes have identical liquidation and dividend rights (page 81), suggesting the company maintains economic parity between the two while strategically deploying Class C shares for equity compensation and repurchasing both based on market dynamics.",
      "llm_answer": "Alphabet's stock repurchase program treats Class A and Class C shares identically in economic terms—both classes have the same dividend, liquidation and other rights—so the company can repurchase either class without creating a material economic distinction. However, the repurchases are executed in a way that considers market conditions and relative trading prices of the two share classes, and the resulting retired shares are recorded at the aggregate cost of the purchases. Employee compensation plans primarily use Class C shares (e.g., RSU awards are settled in Class C stock), but because both classes have identical economic rights, the choice of share class for compensation does not affect the economic outcome of the repurchase strategy.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "hop_2_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "hop_3_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 90121,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22753,
        "completion_tokens": 187,
        "total_tokens": 22940
      }
    },
    {
      "question_id": 1,
      "question": "How does AMT's strategic decision to divest ATC TIPL and the resulting $1.2 billion loss impact its financial strategy, particularly in relation to the capital repurposing agreement with DIT valued at approximately $2.5 billion?",
      "original_answer": "AMT's decision to divest ATC TIPL was part of a broader strategic review of its India operations aimed at repurposing capital to drive long-term shareholder value. The transaction with DIT, valued at approximately $2.5 billion, culminated in the completion of the sale on September 12, 2024, with AMT receiving $2.2 billion in total consideration. Despite the strategic intent, the company recorded a $1.2 billion loss on the sale, primarily due to the reclassification of cumulative translation adjustments in India. The proceeds were used to repay existing indebtedness under the 2021 Multicurrency Credit Facility, aligning with AMT's financial strategy to reduce leverage and reallocate capital more effectively.",
      "llm_answer": "The divestiture of ATC TIPL generated a $1.2 billion loss—primarily the $1.1 billion reclassification of cumulative translation adjustment—while the transaction yielded roughly $2.5 billion of consideration (approximately $2.2 billion received at closing). This proceeds were earmarked for repaying the 2021 Multicurrency Credit Facility and other indebtedness, effectively freeing up capital that the company can now redeploy toward its strategic capital‑repurposing initiatives, including the $2.5 billion capital‑repurposing agreement with Data Infrastructure Trust (DIT).",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 40,
          "pages": [
            38,
            39,
            40,
            41,
            42
          ]
        },
        "hop_2_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_3_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 64172,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16278,
        "completion_tokens": 143,
        "total_tokens": 16422
      }
    },
    {
      "question_id": 1,
      "question": "How does Disney's disclosure about potential withdrawal liabilities from multiemployer pension plans reconcile with their contributions to plans that have eligibility requirements tied to collective bargaining units?",
      "original_answer": "Disney disclosed that if a participating employer withdraws from multiemployer pension plans, it may be required to pay an amount based on the underfunded status of the plan (page 109). The company contributes to several such plans that cover union-represented employees, with benefits determined by specific eligibility and participation requirements under collective bargaining agreements (page 108). These contributions are expensed as incurred, and the company faces risks such as the potential assumption of unfunded obligations from other employers’ withdrawal. The eligibility requirements directly shape which employees are covered and thus influence the company’s exposure to future liabilities, creating a link between the structure of the plans and the financial risks Disney faces.",
      "llm_answer": "Disney discloses that its multiemployer pension plans are governed by collective bargaining agreements and may require employers to pay amounts based on the plan’s underfunded status if they withdraw or stop contributing. This aligns with the risk that contributions from one employer can fund benefits for employees of other participating employers, meaning withdrawal liabilities could arise if an employer ceases participation. The company’s contributions to these plans are made as incurred under the terms of the collective bargaining units, and the plans’ eligibility requirements are tied to those bargaining units.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 78530,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19861,
        "completion_tokens": 155,
        "total_tokens": 20016
      }
    },
    {
      "question_id": 1,
      "question": "How does Duke Energy Indiana's disclosure of fair value estimates for AFS debt investments in 2023 align with the company's broader accounting policy that defers unrealized gains and losses on AFS securities to regulatory accounts?",
      "original_answer": "Duke Energy Indiana specifically presents the estimated fair value of its AFS debt investments in a table on page 187, indicating a structured reporting of these financial instruments. These debt investments are classified as AFS, which, as disclosed on page 184, means that unrealized gains and losses are generally deferred to other comprehensive income and only realized gains or losses impact net income. However, the 10-K also states on page 184 that substantially all of Duke Energy’s AFS debt and equity securities qualify for regulatory accounting, and as such, the associated unrealized gains and losses are deferred as regulatory assets or liabilities. This alignment shows that while Duke Energy Indiana quantitatively discloses the fair value of AFS debt investments, the broader company policy ensures that the financial statement impact of unrealized movements is deferred through regulatory mechanisms, preserving income stability.",
      "llm_answer": "Duke Energy Indiana reports that its AFS debt investments are classified as “available‑for‑sale” and that unrealized gains and losses on these securities are deferred to regulatory accounts, reflecting the company’s broader accounting policy of deferring such gains and losses for regulatory purposes. This treatment aligns with the company’s overall approach of recognizing unrealized gains and losses on AFS securities in regulatory assets or liabilities rather than in earnings.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 187,
          "pages": [
            185,
            186,
            187,
            188,
            189
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 187,
          "pages": [
            185,
            186,
            187,
            188,
            189
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 184,
          "pages": [
            182,
            183,
            184,
            185,
            186
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 104946,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 26471,
        "completion_tokens": 120,
        "total_tokens": 26591
      }
    },
    {
      "question_id": 1,
      "question": "How does MetLife's disclosure of surplus notes at face value of $507 million reconcile with the statutory accounting treatment that classifies surplus notes as surplus rather than debt, and what implications does this have for regulatory capital compliance?",
      "original_answer": "MetLife discloses surplus notes totaling $507 million at face value in its long-term debt schedule, treating them as debt instruments under GAAP. However, statutory accounting practices, as described in the notes to financial statements, treat surplus notes as surplus rather than debt, which directly impacts regulatory capital calculations. This classification increases statutory capital and surplus, aiding compliance with risk-based capital requirements. MetLife's statutory capital and surplus, particularly for its U.S. insurance subsidiaries, benefit from this treatment, contributing to a Statement-Based Combined RBC Ratio in excess of 360% at year-end 2021.",
      "llm_answer": "MetLife classifies its surplus notes as surplus rather than debt under statutory accounting, which treats them as a component of policyholder surplus due to their subordination to other obligations of the issuing insurance subsidiary and regulatory requirements. This classification allows the notes to be included in surplus calculations while still reflecting their face value of $507 million, supporting regulatory capital compliance by maintaining the necessary surplus ratios required by insurance regulators.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 276,
          "pages": [
            274,
            275,
            276,
            277,
            278
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 136,
          "pages": [
            134,
            135,
            136,
            137,
            138
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 292,
          "pages": [
            290,
            291,
            292,
            293,
            294
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 75200,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19050,
        "completion_tokens": 128,
        "total_tokens": 19178
      }
    },
    {
      "question_id": 1,
      "question": "How does GD's reliance on commercial paper issuances for liquidity needs align with the $4 billion credit facility's role in supporting those issuances, given the company's emphasis on maintaining a strong balance sheet?",
      "original_answer": "GD emphasizes cash flow generation and prudent capital deployment to maintain a strong balance sheet. It views commercial paper issuances as a supplement to operating cash flow for meeting liquidity needs. However, the company also maintains a $4 billion committed credit facility that explicitly supports these commercial paper issuances, acting as a backup liquidity source. This dual approach reflects a strategy that balances operational flexibility with financial stability, especially as the credit facility is set to expire in March 2027, prompting potential renewal or replacement planning.",
      "llm_answer": "General Dynamics relies on commercial paper for short‑term liquidity, but it backs that need with a $4 billion revolving credit facility that can fund commercial‑paper issuances and other working‑capital requirements, allowing the company to maintain a strong balance sheet while continuing to issue paper as needed.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GD_10k_2024.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "hop_2_rel": {
          "source_file": "GD_10k_2024.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        },
        "hop_3_rel": {
          "source_file": "GD_10k_2024.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 44064,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 11248,
        "completion_tokens": 79,
        "total_tokens": 11327
      }
    },
    {
      "question_id": 1,
      "question": "How does ExxonMobil's current production growth of 111 thousand oil-equivalent barrels per day reconcile with its planned acquisition of Pioneer Natural Resources, which adds over 700 thousand oil-equivalent barrels per day in production capacity?",
      "original_answer": "ExxonMobil reported a net production growth of 111 thousand oil-equivalent barrels per day in 2023, excluding divestments and entitlements. The acquisition of Pioneer Natural Resources, expected to close in Q2 2024, adds over 700 thousand oil-equivalent barrels per day of production capacity as of Q3 2023. This suggests that the Pioneer acquisition significantly accelerates ExxonMobil's production scale, potentially increasing its daily output by more than sixfold compared to its organic growth in 2023.",
      "llm_answer": "ExxonMobil's current production growth of 111 thousand oil‑equivalent barrels per day reflects net organic growth after accounting for entitlement changes, divestments, government‑mandated curtailments and other factors; this growth is separate from the capacity added by its acquisitions. The company plans to acquire Pioneer Natural Resources, which alone contributes more than 700 thousand oil‑equivalent barrels per day of production capacity, a addition that will be reflected in future reported production figures once the transaction closes.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "XOM_10k_2023.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_2_rel": {
          "source_file": "XOM_10k_2023.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_3_rel": {
          "source_file": "XOM_10k_2023.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 61251,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15553,
        "completion_tokens": 137,
        "total_tokens": 15690
      }
    },
    {
      "question_id": 2,
      "question": "How does Target's profit-sharing arrangement with TD on Target Credit Card receivables align with the observed decline in RedCard penetration between fiscal years 2022 and 2023?",
      "original_answer": "Target receives a percentage of profits from the Target Credit Card and Target MasterCard receivables under a program agreement with TD, as disclosed in the accrued liabilities section (page 48). This financial arrangement incentivizes Target to promote RedCard usage. However, the RedCard Penetration metric, which includes the Target Credit Card, declined from 19.8% in fiscal 2022 to 18.6% in fiscal 2023 (page 27), suggesting reduced guest adoption or usage of these payment instruments. This decline may impact future profit-sharing revenue from TD unless offset by higher per-customer spending among existing RedCard users.",
      "llm_answer": "Target's profit-sharing arrangement with TD on Target Credit Card receivables aligns with the observed decline in RedCard penetration between fiscal years 2022 and 2023 by reflecting the financial impact of reduced credit card usage. The revenue from credit card profit sharing decreased from $734 million in 2022 to $667 million in 2023, directly correlating with the drop in RedCard Penetration from 19.8% to 18.6%. This decline indicates fewer RedCards in circulation and usage, which reduces the profit-sharing income Target receives from TD under their agreement, where TD underwrites, funds, and owns the Target Credit Card and Target MasterCard receivables while Target performs account servicing and primary marketing functions. The reduced revenue from this arrangement is a direct consequence of the lower RedCard Penetration rate.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "TGT_10k_2023.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        },
        "hop_2_rel": {
          "source_file": "TGT_10k_2023.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        },
        "hop_3_rel": {
          "source_file": "TGT_10k_2023.pdf",
          "target_page": 27,
          "pages": [
            25,
            26,
            27,
            28,
            29
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 48850,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12434,
        "completion_tokens": 210,
        "total_tokens": 12644
      }
    },
    {
      "question_id": 2,
      "question": "How does BMY's shared liability with AstraZeneca for Onglyza-related litigation risk, as disclosed in the legal proceedings section, reconcile with its continued financial stake in the product as indicated in the trademark disclosure?",
      "original_answer": "BMY shares potential liability with AstraZeneca for Onglyza-related litigation, as noted in the legal proceedings section where both companies are co-defendants in ongoing cardiovascular injury claims from the product's use. Despite divesting Onglyza to AstraZeneca in 2014, BMY still retains a financial stake in the product, as evidenced by the trademark disclosure in the document. This dual exposure—both legal and financial—suggests that while BMY no longer directly markets or profits from Onglyza, it remains vulnerable to legacy liabilities and maintains a residual economic interest in the product through its trademark rights.",
      "llm_answer": "BMY's legal disclosures reconcile the shared liability for Onglyza-related litigation with its retained financial stake by explicitly stating that any potential liability \"is expected to be shared with AstraZeneca\" following its 2014 sale of the product, while simultaneously maintaining ownership of the Onglyza trademark through its SEC filing disclosures. This arrangement reflects the structural separation of liability (transferred to AstraZeneca per the merger agreement) from trademark rights (retained by BMY), ensuring the company's continued financial interest in the product's intellectual property despite the shared litigation exposure.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 118,
          "pages": [
            116,
            117,
            118,
            119,
            120
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 138,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 138,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 106397,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 26837,
        "completion_tokens": 162,
        "total_tokens": 26999
      }
    },
    {
      "question_id": 2,
      "question": "How does ExxonMobil's 2023 production performance of 3.7 million oil-equivalent barrels per day align with its planned $65 billion merger with Pioneer Natural Resources, which holds over 2.3 billion barrels of proved reserves?",
      "original_answer": "ExxonMobil's 2023 production remained flat at 3.7 million oil-equivalent barrels per day, with growth in Permian and Guyana offsetting divestments and curtailments. The company plans to enhance future production through its $65 billion merger with Pioneer Natural Resources, which brings over 2.3 billion barrels of proved reserves and over 700 thousand oil-equivalent barrels per day of production capacity. This strategic move is expected to offset current production stagnation and expand ExxonMobil's resource base in the Midland Basin, aligning with its long-term upstream growth objectives.",
      "llm_answer": "ExxonMobil's 2023 upstream production of 3.7 million oil‑equivalent barrels per day is consistent with its 2022 output, reflecting growth from Permian and Guyana that more than offsets divestments and curtailments. The company's planned $65 billion merger with Pioneer Natural Resources—holding over 2.3 billion barrels of proved reserves—will add significant reserve volume to its portfolio and support its long‑term production strategy.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "XOM_10k_2023.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_2_rel": {
          "source_file": "XOM_10k_2023.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_3_rel": {
          "source_file": "XOM_10k_2023.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 61251,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15547,
        "completion_tokens": 109,
        "total_tokens": 15657
      }
    },
    {
      "question_id": 2,
      "question": "How does Microsoft's redemption of $986 million in Nuance convertible senior notes relate to the strategic integration of Nuance's AI solutions within Microsoft's enterprise services portfolio?",
      "original_answer": "Microsoft's redemption of $986 million in Nuance convertible senior notes indicates a financial restructuring milestone following the acquisition, aligning with the strategic integration of Nuance's conversational AI and ambient intelligence solutions into Microsoft's Enterprise and Partner Services. This integration supports Microsoft's broader cloud and AI strategy, as Nuance's offerings now contribute to Microsoft's competitive positioning in enterprise AI and developer tools.",
      "llm_answer": "Microsoft's redemption of $986 million of Nuance's convertible senior notes was a routine financing action that cleared legacy debt on Nuance's balance sheet. This cleanup allowed the company to present a stronger financial footing for the integration of Nuance's AI capabilities, positioning the combined entity to more effectively embed Nuance's conversational‑AI and healthcare‑AI solutions within Microsoft's Intelligent Cloud and Enterprise Services portfolio, thereby accelerating the rollout of AI‑enhanced offerings to enterprise customers.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2023.pdf",
          "target_page": 77,
          "pages": [
            75,
            76,
            77,
            78,
            79
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2023.pdf",
          "target_page": 77,
          "pages": [
            75,
            76,
            77,
            78,
            79
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2023.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 50484,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12846,
        "completion_tokens": 137,
        "total_tokens": 12983
      }
    },
    {
      "question_id": 2,
      "question": "How does Disney's reported subscriber base for Lifetime compare with its equity stake in A+E Networks, particularly considering the financial implications of A+E's international distribution and Disney's investment valuation on its balance sheet?",
      "original_answer": "Disney reports that Lifetime, which is part of the A+E Networks portfolio, reaches 69 million domestic subscribers, similar to A&E's reach. A+E Networks is a 50%-owned equity investee of Disney, and its international distribution through multi-year licensing agreements likely contributes to the $0.8 billion excess of Disney’s book value over A+E’s underlying net assets, as noted in the equity investments section. This valuation premium, combined with A+E’s global presence and subscriber base, reflects strategic financial and operational alignment in Disney’s media portfolio.",
      "llm_answer": "Disney reports 151 million subscribers for Disney Channel internationally, while its equity stake in A+E Networks is 50 % (shared with Hearst). A+E’s domestic subscriber counts for Lifetime and its related channels range from 52 million to 70 million, reflecting a substantially larger subscriber base for Disney Channel than the Lifetime channel, and Disney’s equity investment in A+E is recorded on its balance sheet as an equity‑method investment, meaning the financial performance of A+E is reflected in Disney’s consolidated statements but does not directly affect Disney’s subscriber totals.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 51544,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 13124,
        "completion_tokens": 149,
        "total_tokens": 13274
      }
    },
    {
      "question_id": 2,
      "question": "Given Simon Property Group's disclosure of $5.2 billion in mortgage indebtedness tied to non-recourse mortgage notes with cross-default provisions on certain property pools, how does the company's compliance with covenants at year-end 2023 reconcile with the material adverse effect risk posed by potential defaults under these cross-default provisions?",
      "original_answer": "Simon Property Group disclosed $5.2 billion in mortgage indebtedness at December 31, 2023, secured by 38 properties under 35 non-recourse mortgage notes, including two pools of cross-defaulted and cross-collateralized mortgages covering five properties. While the company confirmed compliance with all covenants related to these notes at year-end, the cross-default provisions mean that a default on any mortgage in a pool could trigger acceleration of all indebtedness in that pool. This creates a material adverse effect risk on the company's financial condition and liquidity if any single default were to occur. The disclosure on page 70 reinforces that covenant compliance assessments specifically considered these cross-default provisions, indicating proactive risk mitigation in a potentially volatile real estate environment.",
      "llm_answer": "Simon Property Group maintains compliance with covenant requirements on its unsecured debt and non‑recourse mortgage notes, reporting that all covenants were satisfied as of December 31 2023. However, the company acknowledges that a material adverse effect could arise if a default were to occur under the cross‑default provisions of certain mortgage pools, which could accelerate indebtedness across multiple properties and strain liquidity. Consequently, while current compliance mitigates immediate risk, the potential for a cross‑default‑triggered acceleration remains a material adverse risk that could affect the company’s financial condition and ability to access capital.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SPG_10k_2023.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "hop_2_rel": {
          "source_file": "SPG_10k_2023.pdf",
          "target_page": 120,
          "pages": [
            118,
            119,
            120,
            121,
            122
          ]
        },
        "hop_3_rel": {
          "source_file": "SPG_10k_2023.pdf",
          "target_page": 70,
          "pages": [
            68,
            69,
            70,
            71,
            72
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 73947,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18754,
        "completion_tokens": 169,
        "total_tokens": 18924
      }
    },
    {
      "question_id": 2,
      "question": "How does AMT's strategic handling of the VIL Optionally Convertible Debentures (VIL OCDs) in 2024, including their conversion and subsequent sale, reconcile with the earlier goodwill impairment charge related to its India business in 2023?",
      "original_answer": "AMT initially faced financial uncertainty with VIL in India, leading to a $322.0 million goodwill impairment charge in 2023 due to the Indian Supreme Court's rulings and VIL's partial payments. In response, AMT accepted VIL OCDs in February 2023 as a payment mechanism, which were later converted into VIL equity in March 2024 and fully sold off by June 2024, yielding a $46.4 million gain. This strategic financial maneuver allowed AMT to recover from earlier impairments and manage exposure to a volatile Indian market, reflecting a shift from operational risk mitigation to a capital realization strategy.",
      "llm_answer": "The 2023 goodwill impairment of $322 million for the India reporting unit was recorded before the company converted and sold the VIL Optionally Convertible Debentures in 2024, which generated a $46.4 million gain on the subsequent sale of the resulting VIL shares. Thus, the earlier impairment reflected the then‑current fair‑value shortfall of the India unit, while the later conversion and sale of those debentures provided cash proceeds that offset part of the earlier write‑down, reconciling the two events.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "hop_2_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 45,
          "pages": [
            43,
            44,
            45,
            46,
            47
          ]
        },
        "hop_3_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 89076,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22508,
        "completion_tokens": 127,
        "total_tokens": 22636
      }
    },
    {
      "question_id": 2,
      "question": "How does CVS's acquisition of Oak Street Health, which contributed to a goodwill increase in 2023, align with the regulatory risks associated with participation in CMS Innovation Center models like ACO REACH, particularly given the uncertainty around ongoing participation and potential payment reductions in those models?",
      "original_answer": "CVS acquired Oak Street Health in 2023, which contributed to an increase in the company’s goodwill (from $6.6 billion in cumulative impairments as of 2024). Oak Street Health participates in CMS Innovation Center models such as ACO REACH, which are described as subject to annual changes that typically reduce available payments and lack a defined path for ongoing participation beyond their end date. These regulatory and financial risks, outlined in the risk factors section, could threaten the long-term value and performance of the acquired business, thereby placing downward pressure on the goodwill associated with the acquisition. This creates a tension between the strategic investment made in 2023 and the potential for future impairment due to external regulatory instability.",
      "llm_answer": "The CVS acquisition of Oak Street Health contributed to a $2.6 billion increase in goodwill reported in 2023, reflecting the strategic value of its senior‑focused primary‑care network. However, Oak Street Health’s growth is tied to participation in CMS Innovation Center models such as ACO REACH, which carry regulatory uncertainty—payment benchmarks can shift after performance years, participation may end without renewal, and any reduction in shared‑savings payments could erode the profitability of that business. Consequently, while the acquisition boosts goodwill, the firm must monitor the evolving CMS model rules and potential payment reductions that could affect the long‑term viability of the Oak Street Health operations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "target_page": 150,
          "pages": [
            148,
            149,
            150,
            151,
            152
          ]
        },
        "hop_2_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "target_page": 44,
          "pages": [
            42,
            43,
            44,
            45,
            46
          ]
        },
        "hop_3_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "target_page": 44,
          "pages": [
            42,
            43,
            44,
            45,
            46
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 72140,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18294,
        "completion_tokens": 183,
        "total_tokens": 18477
      }
    },
    {
      "question_id": 2,
      "question": "How does Emerson's acquisition investment of $7,833 million in National Instruments align with the strategic positioning of Automated Test Systems within the newly formed Test & Measurement segment?",
      "original_answer": "Emerson's acquisition of National Instruments (NI) for $7,833 million in cash paid to acquire the remaining shares reflects a strategic move to expand its capabilities in software-connected automated test systems. NI's core offering—automated test and measurement systems—now forms the foundation of Emerson’s newly created Test & Measurement segment, which is positioned to enable enterprises to bring products to market faster and at lower cost. This strategic alignment is reinforced by the segment’s description in the Control Systems & Software section, where it emphasizes the full range of customer needs addressed by modular instrumentation, data acquisition, and general-purpose development software. Thus, the acquisition investment directly supports the positioning and scope of the Automated Test Systems within Emerson’s broader software and control business strategy.",
      "llm_answer": "Emerson's $7,833 million cash investment in National Instruments aligns with its strategic push to expand the Test & Measurement segment within the newly formed Software and Control business group. The acquisition creates a dedicated Test & Measurement segment that complements Emerson’s existing control and automation offerings, positioning the combined entity to provide end‑to‑end software‑connected automated test and measurement solutions that accelerate product development and reduce costs for customers. This move also adds significant recurring revenue streams from contracts and maintenance, bolstering the segment’s long‑term growth prospects.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_2_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_3_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 66668,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16893,
        "completion_tokens": 163,
        "total_tokens": 17057
      }
    },
    {
      "question_id": 2,
      "question": "Why is Mississippi Power Company able to file its 2022 Form 10-K using the reduced disclosure format, and how does this streamlined reporting approach align with its status as a subsidiary that does not issue separate annual reports to its parent company, The Southern Company?",
      "original_answer": "Mississippi Power Company files its 2022 Form 10-K using the reduced disclosure format because it meets the conditions outlined in General Instructions I(1)(a) and (b) of Form 10-K, which apply to certain subsidiaries of a registrant. This reduced format aligns with its operational structure as a subsidiary that does not issue separate annual reports to its sole shareholder, The Southern Company, as disclosed in the supplemental information. This streamlined reporting approach reflects a regulatory accommodation for entities like Mississippi Power that are fully owned and whose financial information is consolidated within the parent company's disclosures, thereby reducing redundant reporting obligations.",
      "llm_answer": "Mississippi Power Company can file its 2022 Form 10-K using the reduced disclosure format because it meets the conditions in General Instruction I(1)(a) and (b) for filing a simplified 10-K, and it is explicitly identified as one of the registrants that meets those conditions and therefore uses the reduced disclosure format under General Instruction I(2)(b), (c), and (d). This streamlined reporting approach aligns with its status as a subsidiary that does not issue separate annual reports to its parent, The Southern Company, as stated in the document’s description of the filing structure.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 372,
          "pages": [
            344,
            345,
            346,
            347,
            348
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 66851,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16959,
        "completion_tokens": 148,
        "total_tokens": 17107
      }
    },
    {
      "question_id": 3,
      "question": "How does MS's Enterprise Risk Management (ERM) framework, which includes oversight of operational risk, address the potential impact of physical climate risks on its facilities and people, as highlighted in the Climate Risk section?",
      "original_answer": "Morgan Stanley’s ERM framework, described on page 55, is designed to identify, monitor, and mitigate principal risks—including operational risk—across all business segments. On page 75, the firm acknowledges that physical climate risks, such as floods, hurricanes, and rising sea levels, could pose increased operational risk to its facilities and personnel. The Climate Risk section further explains that these risks are integrated into the firm’s broader risk management processes through oversight by the Board’s Risk Committee (BRC) and the Climate Risk Committee, co-chaired by the Chief Risk Officer and Chief Sustainability Officer. This demonstrates that while operational risk is a core component of the ERM framework, the firm has specifically adapted its governance to incorporate physical climate risk as a subset of operational risk, ensuring it is managed within the same structured oversight mechanisms.",
      "llm_answer": "Morgan Stanley’s Enterprise Risk Management (ERM) framework integrates climate‑risk considerations into its governance structure: the Board’s Risk Committee oversees firm‑wide risks, including climate risk, and receives regular updates on scenario analyses and risk‑management approaches; the Climate Risk Committee, co‑chaired by the Chief Risk Officer and Chief Sustainability Officer, shapes how physical and transition climate risks are embedded across the ERM processes. This oversight ensures that potential impacts of physical climate risks on the Firm’s facilities, people and overall operations are identified, assessed and managed within the broader ERM and risk‑governance framework.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MS_10k_2024.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_2_rel": {
          "source_file": "MS_10k_2024.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        },
        "hop_3_rel": {
          "source_file": "MS_10k_2024.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 73469,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18602,
        "completion_tokens": 173,
        "total_tokens": 18775
      }
    },
    {
      "question_id": 3,
      "question": "How does MDLZ's classification of Net Investment Hedge Contracts within Level 2 financial assets align with the specific fair value disclosure of $71 million for these contracts as of December 31, 2021?",
      "original_answer": "MDLZ classifies Net Investment Hedge Contracts as part of Level 2 financial assets because their fair value is determined using observable market inputs, such as forward rates and commodity prices, rather than relying on unobservable assumptions. This classification is consistent with the $71 million fair value of these contracts disclosed in the derivatives table, which falls entirely under the Level 2 category, indicating that no Level 1 or Level 3 inputs were used for their valuation. The alignment between the valuation methodology and the disclosed amount underscores the company's consistent application of fair value accounting principles for these instruments.",
      "llm_answer": "MDLZ classifies its Net Investment Hedge Contracts as Level 2 financial assets, and the footnote on derivative fair values explicitly reports a $71 million fair‑value amount for these contracts as of December 31 2021, confirming that the Level 2 classification aligns with the disclosed $71 million valuation.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 111,
          "pages": [
            109,
            110,
            111,
            112,
            113
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 78234,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19784,
        "completion_tokens": 77,
        "total_tokens": 19861
      }
    },
    {
      "question_id": 3,
      "question": "How does COP's investment in PALNG, which involved interest rate swaps under ASC Topic 815, impact its revenue recognition policy for derivative contracts governed by the same accounting standard?",
      "original_answer": "COP's investment in PALNG, which included interest rate swaps under ASC Topic 815, demonstrates its use of derivative instruments to manage financial risk. In 2024, COP recognized $35 million in 'Equity in earnings of affiliates' related to de-designated swaps on PALNG’s term loans. Separately, ASC Topic 815 also governs COP’s revenue recognition policy for physical gas contracts that qualify as derivatives, though these contracts are not accounted for under ASC Topic 606. This reveals a dual application of ASC Topic 815: once in managing financing risk through affiliate investments and again in revenue recognition for commodity derivatives, suggesting a coordinated approach to financial and operational risk management under the same accounting framework.",
      "llm_answer": "The interest‑rate swaps that PALNG entered into to hedge the financing of its Phase‑1 project are accounted for as cash‑flow hedges under ASC Topic 815. Because they are designated and qualify as hedges, the effective portion of the swaps’ fair‑value changes is recorded in other comprehensive income and only re‑classified into earnings when the hedged forecasted cash flows affect income. This hedge accounting therefore does not alter the company’s revenue‑recognition policy for its derivative contracts; instead, it governs how the interest‑rate swap gains or losses are presented in the financial statements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 107,
          "pages": [
            105,
            106,
            107,
            108,
            109
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 69590,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17631,
        "completion_tokens": 153,
        "total_tokens": 17784
      }
    },
    {
      "question_id": 3,
      "question": "How does AMT's strategic decision to convert and sell VIL OCDs and shares relate to the prior revenue deferrals and impairment charges associated with VIL in India?",
      "original_answer": "AMT initially faced uncertainty with VIL's partial payments in 2022, leading to $27.3 million in deferred revenue and asset impairments totaling $508.6 million in 2022 and 2023. In response, AMT accepted VIL OCDs in 2023 as part of a payment arrangement. By 2024, AMT converted and sold these VIL OCDs and shares, generating $238 million in net proceeds and recognizing a $46.4 million gain. This sequence reflects a strategic pivot from a distressed receivables position to a monetization strategy that ultimately offset prior losses and supported capital recovery.",
      "llm_answer": "The Company’s strategic move to convert and sell the VIL OCDs and the resulting VIL Shares was undertaken to monetize the previously deferred revenue and recover value from the India business after the goodwill impairment and revenue deferrals related to VIL. The proceeds from the sale were used to repay debt and settle obligations, effectively closing out the VIL receivable that had been reserved and impaired, thereby eliminating the need for further revenue deferrals or impairment charges associated with VIL in India.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "hop_2_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 45,
          "pages": [
            43,
            44,
            45,
            46,
            47
          ]
        },
        "hop_3_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 89076,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22489,
        "completion_tokens": 131,
        "total_tokens": 22620
      }
    },
    {
      "question_id": 3,
      "question": "How does Mississippi Power Company's status as a separate registrant in the combined 10-K filing reflect the application of the reduced disclosure format, and what does this imply about its reporting obligations compared to The Southern Company's consolidated disclosures?",
      "original_answer": "Mississippi Power Company, as a separate registrant in the combined 10-K filing, is subject to the reduced disclosure format under General Instructions I(2)(b), (c), and (d) of Form 10-K because it meets the conditions outlined in General Instructions I(1)(a) and (b). This format limits the extent of disclosures it must provide, particularly in Part III, where it incorporates by reference specified portions of The Southern Company's and Alabama Power Company's proxy statements. Unlike The Southern Company, which provides consolidated disclosures and full proxy materials, Mississippi Power Company is not required to prepare or file an annual report or proxy statement with the SEC, underscoring a distinction in reporting obligations based on registrant classification and regulatory relief afforded under the reduced disclosure framework.",
      "llm_answer": "Mississippi Power Company's separate registration in the combined 10-K filing reflects the application of the reduced disclosure format under General Instruction I(2)(b), (c), and (d), which allows it to omit Items 10, 11, 12, and 13 from Part III (as specified for entities meeting the conditions in General Instructions I(1)(a) and (b)). This means Mississippi Power is not required to provide full corporate governance, executive compensation, or director information in its own filing, unlike The Southern Company’s consolidated disclosures, which include these details. Instead, Mississippi Power’s reporting obligations are satisfied through the combined filing’s reduced format, with its specific obligations (e.g., Item 14 fees) included in the consolidated document, while it relies on The Southern Company’s proxy statement for referenced items like governance and executive compensation.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 372,
          "pages": [
            344,
            345,
            346,
            347,
            348
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 66851,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16957,
        "completion_tokens": 224,
        "total_tokens": 17182
      }
    },
    {
      "question_id": 3,
      "question": "How does the restricted voting structure of Class C Common Stock, which limits voting rights to only specific corporate events, influence its treatment in the diluted earnings per share calculation that assumes conversion into Class A Common Stock?",
      "original_answer": "The restricted voting structure of Class C Common Stock, which only allows voting in specific circumstances such as mergers or amendments to the certificate of incorporation, reflects its subordinate governance position relative to Class A Common Stock. Despite this limited voting power, the diluted earnings per share calculation assumes the conversion of Class C Common Stock into Class A Common Stock on an as-converted basis, effectively granting it equal economic treatment in financial reporting. This creates a contrast between the governance rights (limited voting) and economic treatment (full conversion for EPS), suggesting a separation between shareholder influence and financial equity in the company’s reporting framework.",
      "llm_answer": "The restricted voting structure of Class C Common Stock—limited to specific corporate events—does not affect its treatment in the diluted earnings‑per‑share calculation, because the diluted EPS model assumes conversion of all potentially dilutive securities (including Class C) into Class A Common Stock on an as‑converted basis, regardless of voting rights. Consequently, the conversion of Class C Preferred Stock (which can be converted into Class A Common Stock) is incorporated into the as‑converted share count used to compute diluted EPS, while the voting restrictions on Class C itself are irrelevant to the EPS calculation.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "V_10k_2023.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_2_rel": {
          "source_file": "V_10k_2023.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_3_rel": {
          "source_file": "V_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 107265,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 27051,
        "completion_tokens": 157,
        "total_tokens": 27208
      }
    },
    {
      "question_id": 3,
      "question": "How does UPS's use of net asset value (NAV) to measure certain investments relate to its $2.7 billion in unfunded commitments to private equity funds, and what implications does this have for liquidity risk management?",
      "original_answer": "UPS utilizes NAV as a practical expedient to value certain alternative investments, including private equity funds, due to the lack of readily determinable fair values. These NAV-based investments include UPS’s $2.7 billion in unfunded commitments to private equity and other limited partnerships, which are expected to be funded over the next three to six years. Given that redemptions in these funds are generally restricted until the end of the partnership term (10–15 years), this creates a liquidity risk, as UPS must manage its cash flow commitments without the ability to easily liquidate these positions. The use of NAV introduces valuation uncertainty, which compounds the challenge of managing liquidity against these long-term, illiquid commitments.",
      "llm_answer": "UPS measures its investments in private‑equity, private‑debt and real‑estate funds at the funds’ NAV per share (a practical expedient), which is why the $2.7 billion of unfunded commitments to those limited‑partner interests is disclosed as “expected contributions” rather than as a recorded liability. Because these commitments represent capital that must be called in the future, they create liquidity risk: the plan may need to fund the shortfall if investors redeem or the partnership terminates before the scheduled contribution dates. Consequently, UPS monitors these commitments closely and includes them in its liquidity‑risk management framework to ensure sufficient cash or liquid assets are available to meet the timing of capital calls.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 70592,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17875,
        "completion_tokens": 187,
        "total_tokens": 18062
      }
    },
    {
      "question_id": 4,
      "question": "How does Mastercard's concern about technology companies developing competitive products relate to its reliance on those same companies to enhance payment safety and deliver services, and what operational or strategic risks does this dual relationship introduce?",
      "original_answer": "Mastercard identifies that technology companies may develop products that compete with or replace its own payment offerings, potentially forcing changes in its pricing or practices (page 31). At the same time, Mastercard collaborates with these same technology firms to enhance payment safety and deliver services efficiently (page 32). This dual relationship introduces strategic risks, such as giving partners access to Mastercard data, which could provide them with a competitive advantage if not properly managed. Additionally, if Mastercard cannot keep pace technologically, these partners may opt to use their own platforms, reducing their reliance on Mastercard’s network and increasing competitive pressure.",
      "llm_answer": "Mastercard’s risk stems from a paradoxical reliance on technology firms that could also become its competitors. While the company depends on these firms to “enhance payment safety and deliver services,” they are simultaneously developing products that could displace or bypass Mastercard’s network, creating a dual relationship of partnership and competition. This dynamic introduces strategic risks, including loss of market share and reduced control over emerging payment ecosystems, and operational risks such as regulatory scrutiny, data‑sharing vulnerabilities, and the need to continually adapt to new, potentially disruptive technologies.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MA_10k_2022.pdf",
          "target_page": 31,
          "pages": [
            29,
            30,
            31,
            32,
            33
          ]
        },
        "hop_2_rel": {
          "source_file": "MA_10k_2022.pdf",
          "target_page": 31,
          "pages": [
            29,
            30,
            31,
            32,
            33
          ]
        },
        "hop_3_rel": {
          "source_file": "MA_10k_2022.pdf",
          "target_page": 32,
          "pages": [
            30,
            31,
            32,
            33,
            34
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 87956,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22227,
        "completion_tokens": 161,
        "total_tokens": 22388
      }
    },
    {
      "question_id": 4,
      "question": "How does MDLZ's use of Level 1 commodity futures for hedging specific raw material costs, such as cocoa and sugar, reflect in their fair value measurement methodology and exposure management strategy?",
      "original_answer": "MDLZ utilizes Level 1 commodity futures, which are exchange-traded instruments valued based on quoted market prices on commodity exchanges, to hedge price risks related to forecasted purchases of raw materials like cocoa, sugar, and sweeteners. These futures are part of a broader risk management strategy that also includes Level 2 instruments and are managed through counterparties with investment-grade ratings to mitigate credit risk. The fair value methodology for Level 1 instruments ensures transparency and reduces pricing model risk, aligning with MDLZ's approach to managing market and credit risks across its derivative portfolio.",
      "llm_answer": "MDLZ's use of Level 1 commodity futures for hedging specific raw material costs, such as cocoa and sugar, is reflected in its fair value measurement methodology through the disclosure that commodity derivatives (including futures) are classified as Level 1 financial instruments, with fair values determined based on quoted market prices on commodity exchanges. These derivatives are part of the company's broader hedging strategy to manage exposure to commodity price volatility, and their fair values are included in the Level 1 category of the fair value hierarchy disclosed in the financial statements. This approach supports MDLZ's exposure management strategy by allowing precise, market-based valuation of commodity hedges, ensuring that gains or losses on these instruments are transparently measured and reflected in the company's financial position.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 69212,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17531,
        "completion_tokens": 214,
        "total_tokens": 17746
      }
    },
    {
      "question_id": 4,
      "question": "How does SPG's redemption of 75,000 preferred units in 2024 relate to Simon's ability to redeem Series J 8 3/8% Preferred Stock starting in 2027, and what does this imply about the structure of noncontrolling interests in the Operating Partnership?",
      "original_answer": "SPG's Operating Partnership redeemed 75,000 preferred units in 2024, reducing the carrying value of these units to $15.5 million by year-end. These preferred units are linked to Simon, which issues Series J 8 3/8% Preferred Stock that it can redeem starting in 2027 at $50 per share plus unpaid dividends. The redemption of preferred units by the Operating Partnership reflects Simon's broader control over capital structure decisions, as Simon, acting as the general partner, governs all operational and distribution decisions. This structure implies that noncontrolling interests in the Operating Partnership, including preferred units, are ultimately subject to Simon’s discretion, as highlighted in the governance section on page 108, where Simon may choose to settle exchange rights in common stock rather than cash, reinforcing its control and influence over equity classification.",
      "llm_answer": "The 75,000 preferred units redeemed in 2024 are part of the 7.50% cumulative redeemable preferred units classified as temporary equity; their redemption reduces the temporary‑equity balance and reflects that these units can be settled in cash or registered common stock. This structure shows that the noncontrolling redeemable interests in the Operating Partnership are recorded as temporary equity and are adjusted to their redemption amount, while the Series J 8 3⁄8% Preferred Stock (and its corresponding preferred units) remains redeemable only starting in 2027, illustrating a tiered hierarchy where only the later‑dated preferred securities retain permanent‑equity status.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 129,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        },
        "hop_2_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 129,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        },
        "hop_3_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 73788,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18688,
        "completion_tokens": 169,
        "total_tokens": 18858
      }
    },
    {
      "question_id": 4,
      "question": "How does Disney's equity stake in A+E, which operates Lifetime and A&E channels with 69 million domestic subscribers each, relate to the $0.8 billion excess book value attributed to amortizable intangible assets and goodwill in their equity investments?",
      "original_answer": "Disney's equity stake in A+E, a joint venture with Hearst that operates channels including A&E and Lifetime—both with 69 million domestic subscribers—forms a key part of their media investment portfolio. As a 50% owner, Disney reports its share of A+E's financial results under 'Equity in the income (loss) of investees, net.' On the other hand, Disney's broader equity investments, including A+E, show a $0.8 billion excess of book value over the underlying net assets, attributed to intangible assets and goodwill from acquisitions. This suggests that despite A&E and Lifetime having similar subscriber bases, the valuation premium in intangible assets reflects strategic value from brand equity, programming rights, or distribution agreements embedded in A+E's operations, which Disney indirectly owns part of through its stake.",
      "llm_answer": "Disney's 50% equity stake in A+E (which operates Lifetime and A&E with 69 million domestic subscribers each) is reflected in the $0.8 billion excess book value of its equity investments, which includes amortizable intangible assets and goodwill from acquisitions. This excess value arises from the acquisition of its stake in A+E, where the book value of the investment ($2.678 billion as of October 1, 2022) exceeds its share of the underlying net assets of the investee, indicating intangible assets and goodwill that are being amortized over time.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 51544,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 13126,
        "completion_tokens": 137,
        "total_tokens": 13264
      }
    },
    {
      "question_id": 4,
      "question": "How does AMT's decision to terminate the $10.5 billion JPM Bridge Loan Commitment without drawing on it relate to their broader financing strategy for the CoreSite Acquisition, especially in light of the $4.5 billion in USD Delayed Draw Term Loans they ultimately utilized?",
      "original_answer": "AMT entered into the $10.5 billion JPM Bridge Loan Commitment as a contingency to finance the CoreSite Acquisition, but terminated it after securing $4.5 billion in USD Delayed Draw Term Loans through a combination of a $3.0 billion 364-day loan and a $1.5 billion two-year loan. This indicates that AMT's financing strategy prioritized long-term committed credit facilities over bridge financing, allowing them to proceed with the acquisition without incurring immediate bridge loan obligations. The termination of the JPM Bridge Loan Commitment reflects AMT's confidence in its alternative financing arrangements.",
      "llm_answer": "AMT terminated the $10.5 billion JPM Bridge Loan Commitment because it had secured sufficient alternative financing for the CoreSite acquisition—specifically the $4.5 billion of USD Delayed Draw Term Loans (along with the 2021 Multicurrency Credit Facility, 2021 Credit Facility, 2021 Term Loan and other committed facilities)—making the bridge financing unnecessary. Consequently, the company relied on the $4.5 billion of USD Delayed Draw Term Loans to fund the CoreSite purchase rather than drawing on the terminated bridge facility.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMT_10k_2022.pdf",
          "target_page": 77,
          "pages": [
            75,
            76,
            77,
            78,
            79
          ]
        },
        "hop_2_rel": {
          "source_file": "AMT_10k_2022.pdf",
          "target_page": 52,
          "pages": [
            50,
            51,
            52,
            53,
            54
          ]
        },
        "hop_3_rel": {
          "source_file": "AMT_10k_2022.pdf",
          "target_page": 113,
          "pages": [
            111,
            112,
            113,
            114,
            115
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 12,
        "total_chars": 65528,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16633,
        "completion_tokens": 134,
        "total_tokens": 16767
      }
    },
    {
      "question_id": 4,
      "question": "How does Duke Energy's use of storm recovery property to secure $1,007 million in storm recovery bonds relate to the restricted cash balances reported in their consolidated balance sheets?",
      "original_answer": "Duke Energy Carolinas and Duke Energy Progress transferred storm recovery property worth $237 million and $770 million respectively to special purpose subsidiaries to secure storm recovery bonds issued in November 2021. These bonds, which are secured solely by the storm recovery property and customer charges, created restricted cash balances that appear in the consolidated balance sheets under 'Other' within current and noncurrent assets. The restricted cash balances directly reflect the financial structure established through the storm recovery bond issuance.",
      "llm_answer": "Duke Energy’s storm‑recovery bonds are issued by the bankruptcy‑remote special‑purpose entities DECNCSF (for Duke Energy Carolinas) and DEPNCSF (for Duke Energy Progress). The proceeds from these bonds are used to purchase “storm‑recovery property,” which represents the right to collect a non‑bypassable charge from customers to repay the bonds. Because the bonds are secured only by that regulatory‑asset‑like property, the entities are classified as VIEs and are consolidated by their respective parent companies. The financing is reflected on the consolidated balance sheets as long‑term debt (the bond liability) and a corresponding regulatory asset (the right to collect the recovery charge). Thus, the storm‑recovery bonds and the associated restricted cash balances appear in the consolidated balance sheets as both a liability (long‑term debt) and an offsetting regulatory asset, ensuring that the cash needed for repayment is earmarked and restricted.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 194,
          "pages": [
            192,
            193,
            194,
            195,
            196
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 194,
          "pages": [
            192,
            193,
            194,
            195,
            196
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 127,
          "pages": [
            125,
            126,
            127,
            128,
            129
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 93832,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 23684,
        "completion_tokens": 240,
        "total_tokens": 23925
      }
    },
    {
      "question_id": 5,
      "question": "How does Mastercard's concern about technology companies developing competitive platforms relate to its reliance on those same companies to enhance payment safety and security, and what specific risks does this dual relationship pose to its ability to maintain transaction volumes?",
      "original_answer": "Mastercard identifies that technology companies could develop platforms that disintermediate it from digital payments, threatening its transaction volumes and competitive position. However, the company also partners with these same technology firms to enhance payment safety and security and deliver payment-related services. This dual relationship creates a strategic tension: while collaboration is necessary to remain technologically competitive and maintain customer trust, it also risks giving these partners access to Mastercard data, which could be used to build competing offerings. Additionally, if Mastercard cannot keep pace with technological innovation, customers may opt to use alternative technologies developed by these companies, further reducing transaction volumes and negatively impacting revenue.",
      "llm_answer": "Mastercard worries that tech firms are building rival payment platforms that could erode its market share, yet it still depends on those same companies to supply the data and infrastructure that keep its own network secure and compliant. This creates a dual‑risk: if sanctions, data‑sharing rules, or cyber incidents affect those partners, Mastercard could lose transaction volume, face higher compliance costs, and see its payment flow decline.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MA_10k_2022.pdf",
          "target_page": 31,
          "pages": [
            29,
            30,
            31,
            32,
            33
          ]
        },
        "hop_2_rel": {
          "source_file": "MA_10k_2022.pdf",
          "target_page": 31,
          "pages": [
            29,
            30,
            31,
            32,
            33
          ]
        },
        "hop_3_rel": {
          "source_file": "MA_10k_2022.pdf",
          "target_page": 32,
          "pages": [
            30,
            31,
            32,
            33,
            34
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 87956,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22232,
        "completion_tokens": 111,
        "total_tokens": 22343
      }
    },
    {
      "question_id": 5,
      "question": "How does the valuation methodology for MDLZ's net investment hedge contracts, which are categorized under Level 2 financial assets, reconcile with the $71 million fair value disclosed for these contracts as of December 31, 2021?",
      "original_answer": "MDLZ categorizes its net investment hedge contracts under Level 2 financial assets, which are valued using observable market inputs such as forward rates and commodity index prices. As of December 31, 2021, the fair value of these contracts was reported at $71 million. This valuation aligns with the Level 2 methodology, which relies on income-based approaches using observable inputs rather than direct market prices or unobservable assumptions. The $71 million figure reflects the application of these valuation techniques, specifically tailored for over-the-counter derivatives without active quoted market prices, thus ensuring consistency between the disclosed fair value and the valuation methodology described for Level 2 financial assets.",
      "llm_answer": "The $71 million fair‑value amount disclosed for MDLZ’s net‑investment hedge contracts is derived from the Level 2 valuation inputs described in the footnote tables (the “Net investment hedge derivative contracts” line shows a $71 million net asset as of 12/31/2021). This valuation methodology—using observable market forward rates, discounted cash‑flow analyses, and other market‑based inputs (Level 2)—is consistent with the $71 million figure reported in the consolidated balance sheet for those contracts.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 111,
          "pages": [
            109,
            110,
            111,
            112,
            113
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 78234,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19790,
        "completion_tokens": 127,
        "total_tokens": 19917
      }
    },
    {
      "question_id": 5,
      "question": "How does the spin-off of Greenstone and its combination with Mylan impact Pfizer's segment reporting structure and revenue classification post-2020, particularly in relation to contract manufacturing and transitional supply agreements?",
      "original_answer": "Pfizer spun off its Upjohn Business, including Greenstone, on November 16, 2020, and combined it with Mylan to form Viatris. Following this transaction, Pfizer reorganized its commercial operations and began managing its business through two operating segments: Biopharma and PC1. PC1 includes revenues from contract manufacturing, such as Comirnaty-related manufacturing activities for BioNTech ($320 million in 2021), as well as revenues from manufacturing and supply agreements with former legacy Pfizer businesses, including transitional agreements with Viatris. This reorganization and the spin-off directly influenced how Pfizer classified its revenues post-2020, separating innovative biopharma operations from contract and transitional manufacturing activities.",
      "llm_answer": "The spin-off of the Upjohn Business and its combination with Mylan to form Viatris was accounted for as a discontinued operation, and the transition service arrangements and contract manufacturing activities (including certain Comirnaty manufacturing for BioNTech) are now reported within the new PC1 operating segment, which replaced the former Hospital therapeutic area; this restructuring impacted Pfizer's segment reporting structure and revenue classification post-2020, particularly for contract manufacturing and transitional supply agreements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "target_page": 8,
          "pages": [
            6,
            7,
            8,
            9,
            10
          ]
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "target_page": 8,
          "pages": [
            6,
            7,
            8,
            9,
            10
          ]
        },
        "hop_3_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "target_page": 113,
          "pages": [
            111,
            112,
            113,
            114,
            115
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 117341,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 29571,
        "completion_tokens": 137,
        "total_tokens": 29709
      }
    },
    {
      "question_id": 5,
      "question": "How does Microsoft's redemption of $986 million in Nuance convertible senior notes relate to the strategic integration of Nuance's AI solutions within Microsoft's Intelligent Cloud segment and its broader competitive positioning in enterprise AI?",
      "original_answer": "Microsoft's redemption of $986 million in Nuance convertible senior notes indicates a significant financial step in the post-acquisition restructuring of Nuance, aligning its financial obligations with Microsoft's balance sheet. This financial integration supports the strategic assignment of Nuance-related goodwill to the Intelligent Cloud segment, attributed to anticipated synergies from integrating Nuance’s conversational AI and ambient intelligence solutions. The inclusion of Nuance professional services within Microsoft’s Enterprise and Partner Services highlights the operational integration of Nuance’s offerings, enhancing Microsoft’s competitive positioning in enterprise AI against rivals like Amazon and Google. Together, these elements show a coordinated effort to embed Nuance’s AI capabilities into Microsoft’s broader cloud and enterprise service portfolio to drive competitive differentiation and customer value.",
      "llm_answer": "Microsoft's redemption of Nuance's $986 million convertible senior notes—fully settled in cash—cleared the last legacy financing obligation from the 2022 acquisition and reinforced the strategic integration of Nuance’s AI capabilities into Microsoft’s Intelligent Cloud segment. By removing this debt, Microsoft strengthened its balance sheet and cash‑flow flexibility, enabling continued investment in AI‑driven cloud services and enhancing its competitive positioning against other hyperscale AI platforms. This financial cleanup also underscored the successful consolidation of Nuance’s technology and talent, accelerating Microsoft’s broader enterprise‑AI agenda across Azure, Dynamics, and industry‑specific cloud offerings.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2023.pdf",
          "target_page": 77,
          "pages": [
            75,
            76,
            77,
            78,
            79
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2023.pdf",
          "target_page": 77,
          "pages": [
            75,
            76,
            77,
            78,
            79
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2023.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 50484,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12859,
        "completion_tokens": 182,
        "total_tokens": 13042
      }
    },
    {
      "question_id": 5,
      "question": "How does the termination of the $10.5 billion JPM Bridge Loan Commitment relate to AMT's broader financing strategy as evidenced by the 2-year term loan agreement with JPMorgan Chase Bank, N.A.?",
      "original_answer": "AMT initially secured a $10.5 billion JPM Bridge Loan Commitment to finance the CoreSite Acquisition, but terminated it upon securing sufficient committed amounts under other facilities, including the 2021 Multicurrency Credit Facility and the 2021 Term Loan. Despite the termination, AMT maintained a strategic relationship with JPMorgan Chase Bank, N.A., as evidenced by the subsequent 2-Year Term Loan Agreement entered into on December 8, 2021. This indicates that while AMT did not need to draw on the bridge loan, it continued to rely on JPMorgan as a key financing partner, aligning with its broader strategy of diversifying and optimizing capital structure.",
      "llm_answer": "The termination of the $10.5 billion JPM Bridge Loan Commitment was directly tied to AMT’s broader financing strategy of replacing bridge financing with longer‑term, fully‑committed facilities. By securing the 2021 USD Delayed Draw Term Loan and the 2021 Multicurrency Credit Facility—both with maturities extending to 2025‑2027—AMT eliminated the need for the temporary bridge loan, thereby locking in lower‑cost, longer‑duration debt to fund the CoreSite acquisition and other growth initiatives.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMT_10k_2022.pdf",
          "target_page": 44,
          "pages": [
            42,
            43,
            44,
            45,
            46
          ]
        },
        "hop_2_rel": {
          "source_file": "AMT_10k_2022.pdf",
          "target_page": 52,
          "pages": [
            50,
            51,
            52,
            53,
            54
          ]
        },
        "hop_3_rel": {
          "source_file": "AMT_10k_2022.pdf",
          "target_page": 77,
          "pages": [
            75,
            76,
            77,
            78,
            79
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 74137,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18765,
        "completion_tokens": 124,
        "total_tokens": 18889
      }
    },
    {
      "question_id": 5,
      "question": "How does AMT's decision to report ATC TIPL as discontinued operations relate to the specific financial terms of the DIT acquisition agreement, and what does the resulting $1.2 billion loss indicate about the strategic repurposing of capital from the India market?",
      "original_answer": "AMT initially reported ATC TIPL as discontinued operations (page 40), signaling a strategic shift away from its India operations. This decision culminated in the ATC TIPL Transaction with DIT, an infrastructure investment trust sponsored by Brookfield, where DIT acquired 100% of ATC TIPL for up to 210 billion INR (~$2.5 billion), with final proceeds at closing amounting to 182 billion INR (~$2.2 billion). The $1.2 billion loss recorded on the sale primarily stemmed from the reclassification of cumulative translation adjustments in India upon exiting the market. This loss indicates that while the transaction provided liquidity to repay $2.2 billion of debt under the 2021 Multicurrency Credit Facility, the long-term currency translation exposure and operational costs in India outweighed the benefits of continued ownership, supporting the strategic rationale for divestiture.",
      "llm_answer": "The $1.2 billion loss recorded on the sale of ATC TIPL—primarily the $1.1 billion reclassification of cumulative translation adjustment as the company exited the India market—reflects the strategic repurposing of capital that had been tied up in India. By selling the India tower portfolio to Data Infrastructure Trust, AMT freed up roughly $2.2 billion of proceeds that it used to retire debt under its 2021 Multicurrency Credit Facility, effectively reallocating capital from the India operations to other growth initiatives elsewhere.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 40,
          "pages": [
            38,
            39,
            40,
            41,
            42
          ]
        },
        "hop_2_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_3_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 64172,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16287,
        "completion_tokens": 134,
        "total_tokens": 16421
      }
    },
    {
      "question_id": 5,
      "question": "How does Merck's revenue growth from Verquvo in its own marketing territories compare with the potential future milestone payments to Bayer AG, and what does this imply about the financial dynamics of their collaboration?",
      "original_answer": "Merck reported that sales of Verquvo (alongside Adempas) in its marketing territories grew 14% in 2021, primarily driven by higher demand in Europe. In the same collaboration framework, Merck made a $375 million sales-based milestone payment to Bayer in 2020 and anticipated a further $400 million in potential milestone payments triggered by future sales performance. This indicates that while Merck is experiencing growth in its own commercial regions, the collaboration includes significant contingent liabilities tied to Bayer's development contributions, which could impact Merck's future profitability if Verquvo continues to scale globally.",
      "llm_answer": "Merck’s revenue from Verquvo in its own marketing territories grew 22% in 2021 (reaching $342 million in alliance revenue) and is projected to generate up to $400 million of additional sales‑based milestone payments to Bayer, indicating that the near‑term upside from Verquvo sales exceeds the size of the pending Bayer milestone. This suggests that the financial upside of the collaboration is currently being driven more by Verquvo’s market performance than by the future milestone payments themselves.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 62,
          "pages": [
            60,
            61,
            62,
            63,
            64
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 71672,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18151,
        "completion_tokens": 126,
        "total_tokens": 18277
      }
    },
    {
      "question_id": 5,
      "question": "How does Southern Company's use of intra-contract netting in derivative agreements affect its exposure to events of default, particularly in light of the $106 million in cash collateral posted by Southern Power and the potential for collateral requirements triggered by credit downgrades?",
      "original_answer": "Southern Company utilizes intra-contract netting in derivative agreements to offset receivables and payables, including those arising from events of default, which helps mitigate counterparty credit risk. This netting is reflected in the fair value presentation of derivative assets and liabilities on the balance sheet. However, the company remains exposed to events of default as certain agreements may require collateral posting, particularly if a subsidiary's credit rating drops below investment grade. Southern Power had $106 million in cash collateral posted under PPAs that could require additional collateral upon a credit downgrade, even though accelerated payment is not mandated. This highlights how intra-contract netting reduces exposure in derivative settlements but does not eliminate the liquidity risk associated with collateral calls triggered by credit events.",
      "llm_answer": "Southern Company's use of intra-contract netting in derivative agreements mitigates exposure to events of default by allowing the netting of derivative receivables and payables across product lines and against cash collateral, as disclosed in the \"Derivative Financial Statement Presentation and Amounts\" note. The company specifically utilizes master netting agreements to mitigate counterparty credit risk, and the fair value of derivative assets and liabilities on the balance sheet is presented net to the extent such netting arrangements exist with counterparties. This netting mechanism reduces the gross exposure shown in the balance sheet (e.g., gross derivative liabilities of $744 million were offset by $85 million in gross amounts offset, resulting in net liabilities of $659 million), thereby limiting the potential impact of counterparty defaults on the company's financial position.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 290,
          "pages": [
            288,
            289,
            290,
            291,
            292
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 290,
          "pages": [
            288,
            289,
            290,
            291,
            292
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 115,
          "pages": [
            113,
            114,
            115,
            116,
            117
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 79036,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20010,
        "completion_tokens": 224,
        "total_tokens": 20234
      }
    },
    {
      "question_id": 6,
      "question": "What was the contribution of Cheese & Grocery in the AMEA region as a percentage of MDLZ's total net revenues in 2021, and how does this compare to its absolute revenue contribution in 2022?",
      "original_answer": "In 2021, Cheese & Grocery in the AMEA region contributed 1.7% of MDLZ's total net revenues, which equates to $450 million. In 2022, the absolute revenue contribution from Cheese & Grocery in the AMEA region was $437 million. This shows a slight decline in absolute terms despite the percentage contribution remaining relatively aligned year-over-year.",
      "llm_answer": "In 2021, Cheese & Grocery contributed roughly 7 % of MDLZ’s total net revenues in the AMEA region, and that share rose to about 8 % of total net revenues in 2022.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 137,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 136,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 82546,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20862,
        "completion_tokens": 40,
        "total_tokens": 20902
      }
    },
    {
      "question_id": 6,
      "question": "How does the growth in EVENITY's contribution to Amgen's 2024 product sales align with the financial impact of Amgen's profit-sharing arrangement with UCB, given the $547 million global profit and loss share expense recorded in 2024?",
      "original_answer": "Amgen reported that EVENITY was among the brands contributing to a 26% U.S. volume growth and 17% ROW volume growth in 2024, indicating strong performance of the product. However, under Amgen's collaboration with UCB for EVENITY, Amgen shares global development costs and commercialization profits and losses equally with UCB. In 2024, this profit-sharing arrangement resulted in a $547 million expense recorded under Cost of Sales. Therefore, while EVENITY contributed positively to product sales volume, the financial benefit was partially offset by the shared profit obligations with UCB, reducing the net margin impact of EVENITY's growth.",
      "llm_answer": "The $547 million profit‑sharing expense recorded in 2024 reflects Amgen’s 50/50 cost‑share with UCB for EVENITY, and the growth in EVENITY’s contribution to total product sales (up 35% YoY to $1.563 billion) is directly tied to that arrangement—EVENITY’s sales expansion is a key driver of the overall product‑sales increase that helped offset the profit‑sharing charge.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 63672,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16160,
        "completion_tokens": 92,
        "total_tokens": 16252
      }
    },
    {
      "question_id": 6,
      "question": "How does Chevron's financial exposure to Tengizchevroil, including its loan of $4.5 billion for the FGP/WPMP development, intersect with its ongoing tax uncertainties in Kazakhstan, where audits remain unresolved since 2012?",
      "original_answer": "Chevron has a 50% equity stake in Tengizchevroil (TCO), which operates major oil fields in Kazakhstan, and has extended a $4.5 billion loan to TCO to fund the Future Growth Project and Wellhead Pressure Management Project (FGP/WPMP). This indicates a significant financial and operational commitment to Kazakhstan. However, Chevron also faces unresolved tax matters in Kazakhstan, where tax audits have not been finalized since 2012, contributing to $5,288 million in total unrecognized tax benefits at the end of 2021. The combination of Chevron's large-scale investment and ongoing tax exposure in Kazakhstan suggests that regulatory or financial risks in the region could materially impact both its operational projects and tax liabilities.",
      "llm_answer": "Chevron’s $4.5 billion loan to fund the FGP/WPMP development at Tengizchevroil is recorded as a major component of its $23.7 billion investment in the affiliate (Note 15), and the loan is highlighted as part of the “loan to TCO to fund the development of the FGP/WPMP” in the description of the Tengizchevroil investment.  At the same time, the company continues to face unresolved tax audits in Kazakhstan that have remained open since 2012, creating ongoing tax uncertainty for that investment.  Consequently, Chevron’s financial exposure to Tengizchevroil is intertwined with its lingering Kazakh tax disputes, as the loan and equity stake are subject to potential adjustments or liabilities stemming from those unresolved tax matters.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2022.pdf",
          "target_page": 78,
          "pages": [
            76,
            77,
            78,
            79,
            80
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2022.pdf",
          "target_page": 42,
          "pages": [
            40,
            41,
            42,
            43,
            44
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2022.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 91402,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 23087,
        "completion_tokens": 184,
        "total_tokens": 23272
      }
    },
    {
      "question_id": 6,
      "question": "How does Apple's characterization of Taiwan as a geopolitical and supply chain risk factor align with the financial performance of the Greater China segment, which includes Taiwan, given the segment's $74.2 billion in net sales and $31.153 billion in operating income in 2022?",
      "original_answer": "Apple identifies Taiwan as a critical part of its supply chain and highlights it as a geopolitical risk due to its location within a region prone to trade disputes, public health crises, and other disruptions. Despite these concerns, the Greater China segment—which includes Taiwan—delivered strong financial results in 2022 with $74.2 billion in net sales and $31.153 billion in operating income, reflecting the region's importance to Apple's revenue and profitability. This juxtaposition suggests that while Apple is exposed to operational and political risks in Taiwan, the region remains a key contributor to the company's financial success, highlighting a tension between risk exposure and economic benefit.",
      "llm_answer": "Apple characterizes Taiwan as a geopolitical and supply chain risk factor in its \"Risk Factors\" section, noting that political events, trade disputes, and international conflicts—including tensions involving Taiwan—could materially disrupt its supply chain and operations. This aligns with the Greater China segment's financial performance, which reported $74.2 billion in net sales and $31.153 billion in operating income for 2022, making it a significant contributor to Apple's overall revenue and profitability despite geopolitical risks.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "hop_2_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 25,
          "pages": [
            23,
            24,
            25,
            26,
            27
          ]
        },
        "hop_3_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 52,
          "pages": [
            50,
            51,
            52,
            53,
            54
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 61958,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15740,
        "completion_tokens": 135,
        "total_tokens": 15875
      }
    },
    {
      "question_id": 6,
      "question": "How does the expansion of Booking.com's flight offering into 34 markets align with the increase in merchant transaction costs tied to Booking.com's accommodation services, given BKNG's strategic focus on the Connected Trip?",
      "original_answer": "BKNG's strategic focus on the Connected Trip emphasizes offering a seamless travel experience, which includes expanding flight offerings as a core component. In 2021, Booking.com expanded its flight offering into 34 markets, aligning with the company's vision to integrate travel elements such as flights, accommodations, and ground transportation. This expansion is directly tied to the increase in merchant transaction costs of $215 million, primarily driven by the growth in merchant accommodation reservation services at Booking.com. The increase in costs reflects the rising transaction volume and operational scale associated with BKNG's strategic push to enhance its service offerings and provide a more comprehensive travel experience. The alignment between the flight expansion and the rise in transaction costs highlights how BKNG's investment in diversified and integrated travel services supports its broader goal of driving consumer loyalty and frequency through the Connected Trip.",
      "llm_answer": "The expansion of Booking.com’s flight offering into 34 markets directly supports its Connected Trip strategy, which aims to create a seamless, integrated travel experience by linking flight bookings with accommodation and other services. This expansion is tied to the increase in merchant transaction costs associated with accommodation services, as the growth in merchant revenues—driven by expanded flight offerings and enhanced payment capabilities—reflects higher transaction volumes and associated costs, such as payment processing fees and outsourced call center expenses, which rose by $215 million in 2021. These merchant transaction costs are a direct result of scaling the flight product alongside accommodation services to deliver a more cohesive Connected Trip.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BKNG_10k_2022.pdf",
          "target_page": 6,
          "pages": [
            4,
            5,
            6,
            7,
            8
          ]
        },
        "hop_2_rel": {
          "source_file": "BKNG_10k_2022.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        },
        "hop_3_rel": {
          "source_file": "BKNG_10k_2022.pdf",
          "target_page": 63,
          "pages": [
            61,
            62,
            63,
            64,
            65
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 63608,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16134,
        "completion_tokens": 193,
        "total_tokens": 16328
      }
    },
    {
      "question_id": 6,
      "question": "How does the voting power structure of CMCSA's Class A and Class B common stock, where Class B shares carry 15 votes each and are fully owned by Brian L. Roberts, relate to the company's stock repurchase activity and equity changes reported in 2024?",
      "original_answer": "CMCSA's Class A common stockholders hold 66 2/3% of the combined voting power, while Class B common stock, which carries 15 votes per share and is fully owned by Brian L. Roberts, accounts for the remaining 33 1/3%. Despite this concentrated voting structure, the company repurchased $7.25 billion worth of common stock in 2024, primarily from Class A shares, reducing retained earnings and impacting equity balances. Notably, Class B common stock had no change in balance during the year, indicating that repurchases did not affect the concentrated voting power held by Roberts.",
      "llm_answer": "The voting power structure gives Class B shares (held entirely by Brian L. Roberts) 15 votes per share, while Class A shares carry one vote each, creating a dominant controlling interest that can influence corporate decisions such as share‑repurchase authorizations. This concentrated control underpins the company’s ability to execute its $15 billion share‑repurchase program and manage equity changes reported in 2024, even though the repurchase activity itself is disclosed separately in the cash‑flow and equity statements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 67,
          "pages": [
            65,
            66,
            67,
            68,
            69
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 31,
          "pages": [
            29,
            30,
            31,
            32,
            33
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 70003,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17741,
        "completion_tokens": 131,
        "total_tokens": 17873
      }
    },
    {
      "question_id": 6,
      "question": "How does the fair value of the VIL OCDs issued by VIL in 2023 relate to the impairment charges recorded by AMT on tenant-related intangible assets tied to VIL during the same period?",
      "original_answer": "The fair value of the VIL OCDs at issuance was approximately $116.5 million, significantly lower than their face value of $193.2 million, reflecting the financial instability of VIL. This instability was a contributing factor to AMT recording impairment charges on tenant-related intangible assets tied to VIL, including $411.6 million in 2022 and continued exposure in 2023, as AMT updated its fair value estimates and carried $344.8 million in tenant-related intangible assets for VIL as of December 31, 2023.",
      "llm_answer": "The fair value of the VIL OCDs issued in 2023 was approximately $116.5 million, which was recorded as a reduction of the tenant‑related intangible assets tied to VIL; as a result of the impairment assessments triggered by VIL’s payment shortfalls, the Company recognized $411.6 million of impairment charges on those tenant‑related intangible assets during 2022, and the subsequent goodwill and intangible asset impairments in 2023 (including a $322 million goodwill charge) reflected the diminished fair value of the VIL‑related assets.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMT_10k_2023.pdf",
          "target_page": 98,
          "pages": [
            96,
            97,
            98,
            99,
            100
          ]
        },
        "hop_2_rel": {
          "source_file": "AMT_10k_2023.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_3_rel": {
          "source_file": "AMT_10k_2023.pdf",
          "target_page": 58,
          "pages": [
            56,
            57,
            58,
            59,
            60
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 81027,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20484,
        "completion_tokens": 134,
        "total_tokens": 20619
      }
    },
    {
      "question_id": 6,
      "question": "How does SPG's redemption of Series J 8 3/8% Cumulative Redeemable Preferred Stock in 2024 relate to Simon's ability to issue common stock as a redemption option, and what does this imply about SPG's capital structure flexibility as analyzed in the consolidated financial statements?",
      "original_answer": "SPG redeemed 75,000 preferred units for $7.5 million in 2024, which included the liquidation value and accrued distributions. These preferred units are linked to Simon, which issued the Series J 8 3/8% Cumulative Redeemable Preferred Stock and retains the right to redeem it in cash or common stock. The Operating Partnership’s ability to redeem units held by limited partners is tied to Simon’s discretion to issue shares of common stock, which is highlighted in the consolidated financial statements as a key factor in classifying these units as permanent equity. This structure provides SPG with flexibility to manage its capital structure without necessarily using cash, aligning with Simon’s governance and control over the Operating Partnership.",
      "llm_answer": "SPG’s redemption of its Series J 8 3⁄8 % Cumulative Redeemable Preferred Stock in 2024—allowing the company to retire that preferred equity and replace it with common‑stock redemption rights—demonstrates that the firm can satisfy preferred‑stock redemption obligations through the issuance of common stock. This flexibility, highlighted in the “Common Stock and Unit Issuances and Repurchases” and “Temporary Equity” sections, shows that SPG can manage its capital structure by using either cash or newly issued common shares to retire preferred securities, thereby preserving liquidity and maintaining the ability to issue additional equity when needed. Consequently, the consolidated financial statements reflect a capital‑structure regime that can readily adjust between permanent equity, temporary equity, and debt to meet financing and redemption requirements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 129,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        },
        "hop_2_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 129,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        },
        "hop_3_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 73788,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18697,
        "completion_tokens": 216,
        "total_tokens": 18913
      }
    },
    {
      "question_id": 6,
      "question": "How does BMY's increased royalty revenue from Keytruda in 2023 relate to Merck's obligation to pay declining royalties on global Keytruda sales through 2026, and how does this reflect on BMY's intellectual property licensing strategy?",
      "original_answer": "BMY reported increased royalty revenue in 2023 due to higher Keytruda royalties, which aligns with Merck's obligation to pay a 6.5% royalty on global Keytruda sales through 2023, decreasing to 2.5% from 2024 to 2026 under the global patent license agreement with BMS and Ono. BMY’s trademark ownership of Keytruda, as noted in the exhibit list, supports its ongoing entitlement to a share of these royalties. This declining royalty structure reflects a strategic licensing framework that secures near-term revenue while allowing for long-term market expansion by reducing Merck’s cost burden post-2023.",
      "llm_answer": "BMY's increased royalty revenue from Keytruda in 2023 reflects the ongoing 6.5% royalty payments Merck owes on global Keytruda sales through 2026 under their patent license agreement, which is a key component of BMY's intellectual property licensing strategy that leverages long-term royalty streams from major oncology products like Keytruda and Opdivo. This arrangement, detailed in Note 4 of the financial statements, demonstrates BMY's focus on securing sustainable, high-margin revenue through strategic patent licensing deals with partners like Merck, rather than relying solely on direct product sales.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 138,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 84661,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21407,
        "completion_tokens": 152,
        "total_tokens": 21559
      }
    },
    {
      "question_id": 6,
      "question": "How does MetLife's treatment of surplus notes under statutory accounting practices affect its regulatory capital position compared to GAAP reporting, given the carrying value of surplus notes at year-end 2021?",
      "original_answer": "MetLife's statutory accounting practices treat surplus notes as surplus rather than debt, which enhances the statutory capital position of its insurance subsidiaries. This contrasts with GAAP reporting, where surplus notes would typically be classified as liabilities. At December 31, 2021, the carrying value of surplus notes was $505 million, which contributed to the statutory capital and surplus of MetLife's U.S. insurance subsidiaries. This favorable treatment under statutory accounting supports a stronger regulatory capital position, as it increases the reported surplus without increasing liabilities, thereby improving key solvency ratios like the Statement-Based Combined RBC Ratio, which was in excess of 360% at year-end 2021.",
      "llm_answer": "MetLife’s surplus notes are treated as surplus rather than debt under statutory accounting, so they are included in the calculation of statutory surplus but not in GAAP‑reported liabilities. This treatment enhances the company’s regulatory capital position relative to GAAP, where surplus notes would be recorded as debt and reduce net income and equity. At year‑end 2021 the carrying value of those surplus notes was $505 million (reflected in the statutory capital figures).",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 292,
          "pages": [
            290,
            291,
            292,
            293,
            294
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 136,
          "pages": [
            134,
            135,
            136,
            137,
            138
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 276,
          "pages": [
            274,
            275,
            276,
            277,
            278
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 75200,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19038,
        "completion_tokens": 119,
        "total_tokens": 19157
      }
    },
    {
      "question_id": 6,
      "question": "How does Target's profit-sharing arrangement with TD on the Target Credit Card receivables align with the observed decline in RedCard penetration from 2022 to 2023, and what might this imply about the financial performance of the credit card program?",
      "original_answer": "Target receives a percentage of the profits generated by the Target Credit Card and Target MasterCard receivables through a program agreement with TD, which underwrites, funds, and owns the receivables. Meanwhile, RedCard penetration, which includes the Target Credit Card, declined from 19.8% in 2022 to 18.6% in 2023. This drop suggests a reduction in the proportion of sales made using RedCards, which could negatively impact the volume of credit card receivables and, consequently, the profit-sharing revenue from TD. Therefore, despite TD managing the credit risk and receivables, the decline in RedCard usage may signal a potential headwind for Target’s ancillary income from the credit card program.",
      "llm_answer": "Target's credit card profit-sharing arrangement with TD Bank generates revenue based on profits from Target Credit Card and Target Mastercard receivables, but this revenue declined from $734 million in 2022 to $667 million in 2023, mirroring the observed drop in RedCard penetration (from 20.5% to 18.6%). This decline suggests the credit card program's financial performance is weakening, likely due to reduced consumer adoption of RedCards despite the 5% discount incentive, which may be pressuring overall program profitability and contributing to the modest 1.6% total revenue decline in 2023.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "TGT_10k_2023.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        },
        "hop_2_rel": {
          "source_file": "TGT_10k_2023.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        },
        "hop_3_rel": {
          "source_file": "TGT_10k_2023.pdf",
          "target_page": 27,
          "pages": [
            25,
            26,
            27,
            28,
            29
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 48850,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12452,
        "completion_tokens": 149,
        "total_tokens": 12601
      }
    },
    {
      "question_id": 6,
      "question": "How does the divestiture of KO Transmission's pipeline facilities in February 2023 impact Duke Energy's exposure to FERC cybersecurity compliance risks outlined in the risk factors section, given KO Transmission's prior role as an interstate pipeline operator subject to FERC regulations?",
      "original_answer": "The divestiture of KO Transmission's pipeline facilities in February 2023 likely reduces Duke Energy's direct exposure to FERC cybersecurity compliance risks associated with operating interstate natural gas infrastructure, as KO Transmission is no longer an active subsidiary. However, since Duke Energy remains subject to FERC regulations through other entities like Piedmont and Duke Energy Ohio's remaining operations, the company still faces cybersecurity compliance obligations under FERC-enforced standards such as those from the North American Electric Reliability Corporation (NERC). The risk factors section highlights that cybersecurity breaches could lead to operational disruption, financial loss, and regulatory penalties, which remain relevant even after the divestiture due to Duke Energy’s continued regulated operations under FERC oversight.",
      "llm_answer": "The February 2023 divestiture of KO Transmission’s pipeline facilities removes KO Transmission’s status as an FERC‑regulated interstate pipeline operator, thereby eliminating the specific FERC cybersecurity compliance obligations that previously applied to those assets. Consequently, Duke Energy’s exposure to FERC cybersecurity risk stemming from that pipeline is no longer present, although the company remains subject to general FERC‑related regulatory and compliance requirements across its other regulated operations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 24,
          "pages": [
            22,
            23,
            24,
            25,
            26
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 18,
          "pages": [
            16,
            17,
            18,
            19,
            20
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 30,
          "pages": [
            28,
            29,
            30,
            31,
            32
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 101668,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 25671,
        "completion_tokens": 130,
        "total_tokens": 25802
      }
    },
    {
      "question_id": 7,
      "question": "How does ConocoPhillips' $688 million before-tax charge related to its APLNG investment reconcile with the ongoing production of CBM in the Bowen and Surat basins, given APLNG's $4.7 billion outstanding project finance balance as of December 31, 2023?",
      "original_answer": "ConocoPhillips recorded a $688 million before-tax charge in 2021 when exercising its preemption right to purchase an additional 10% stake in APLNG, reflecting a market participant view of APLNG's fair value that was below the carrying value of COP's existing investment. Despite this write-down, APLNG continues to produce coal bed methane (CBM) from the Bowen and Surat basins in Queensland, Australia, which is processed into LNG and sold under long-term agreements. As of December 31, 2023, APLNG still carried $4.7 billion in outstanding project finance debt, indicating continued capital intensity and operational commitment to the CBM production and LNG export infrastructure. This suggests that while COP recognized a significant impairment in value earlier, the asset remains strategically important and operationally active, supported by long-term financing and sales agreements.",
      "llm_answer": "The $688 million before‑tax charge recorded in 2021 reflects the impairment of ConocoPhillips’ equity investment in APLNG, which was written down to fair value because the observable market‑based price for APLNG’s interest fell below its carrying amount. This impairment charge is separate from the ongoing production of coal‑bed methane (CBM) in the Bowen and Surat basins, where APLNG continues to operate and generate cash flow; the $4.7 billion outstanding project‑finance balance as of 31 Dec 2023 relates to APLNG’s long‑term financing arrangements and does not offset the impairment recorded on the investment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 72330,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18323,
        "completion_tokens": 154,
        "total_tokens": 18478
      }
    },
    {
      "question_id": 7,
      "question": "How does Qualcomm's exposure to revenue volatility from licensee disputes over royalty payments reconcile with their accounting policy that recognizes royalty revenue based on preliminary licensee estimates before final reporting is completed?",
      "original_answer": "Qualcomm faces material exposure from licensees who may delay, underreport, or refuse to pay royalties owed under license agreements (page 27), which directly conflicts with their accounting policy that recognizes royalty revenues based on preliminary estimates provided by these same licensees before final royalty reports are submitted (page 69). This creates a risk of significant revenue reversals if the preliminary estimates materially differ from actual reported sales, especially in cases where licensees are already disputing or non-compliant with contractual obligations. Although the company applies judgment to constrain revenue recognition when significant reversal risks exist, the binding arbitration provisions in license agreements do not prevent revenue recognition delays, further amplifying the volatility and uncertainty in reported licensing revenues.",
      "llm_answer": "Qualcomm recognizes royalty revenue using preliminary licensee estimates of sales‑based royalties, which are calculated on a per‑unit basis from the licensee’s forecasted wholesale price and updated each reporting period. Because these estimates are based on incomplete or provisional information, the company records revenue in the period the licensee’s sales occur and later adjusts the amounts when final royalty reports are received, ensuring that any over‑ or under‑recorded revenue is corrected in the subsequent period. This approach reconciles the exposure to revenue volatility from licensee disputes by allowing the company to recognize revenue provisionally while continuously monitoring and revising estimates as more accurate data become available.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "QCOM_10k_2024.pdf",
          "target_page": 27,
          "pages": [
            25,
            26,
            27,
            28,
            29
          ]
        },
        "hop_2_rel": {
          "source_file": "QCOM_10k_2024.pdf",
          "target_page": 27,
          "pages": [
            25,
            26,
            27,
            28,
            29
          ]
        },
        "hop_3_rel": {
          "source_file": "QCOM_10k_2024.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 99765,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 25179,
        "completion_tokens": 190,
        "total_tokens": 25369
      }
    },
    {
      "question_id": 7,
      "question": "How does Intel's strategic decision to divest its NAND memory business to SK hynix, including the Fab Assets in Dalian, relate to its continued manufacturing and sale of NAND wafers using those same assets, and what does this imply about Intel's ongoing involvement in NAND production post-divestiture?",
      "original_answer": "Intel signed an agreement with SK hynix in October 2020 to divest its NAND memory business, including the Fab Assets in Dalian, China. The first closing of the transaction, completed on December 29, 2021, included the sale of the Fab Assets and the NAND SSD Business to SK hynix. Despite this divestiture, Intel entered into a NAND wafer manufacturing and sale agreement, under which it continues to manufacture NAND memory wafers using the Dalian Fab Assets for SK hynix until the second closing. This implies that although Intel is exiting direct ownership of NAND manufacturing infrastructure, it maintains a transitional operational role in NAND production, supporting SK hynix’s ramp-up while gradually reducing its own exposure to NAND manufacturing.",
      "llm_answer": "Intel’s 2020 agreement to sell its NAND memory business—including the Dalian fab assets—to SK hynix required the company to retain a manufacturing relationship with the buyer: it entered into a wafer‑supply pact that obligates Intel to continue producing NAND wafers at the Dalian facility and sell them to SK hynix after the transaction closes. Consequently, even though the NAND OpCo was de‑consolidated and the fab assets were divested, Intel remains actively involved in NAND production by fabricating wafers for SK hynix, effectively extending its ongoing role in NAND manufacturing despite the divestiture.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_2_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_3_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 30751,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 7936,
        "completion_tokens": 153,
        "total_tokens": 8089
      }
    },
    {
      "question_id": 7,
      "question": "How does Southern Company's increasing investment in SNG, which stood at $1,245 million as of December 31, 2024, align with the financial and regulatory risks associated with SNG's $3 billion pipeline project that is still pending FERC approval and not expected to be completed until 2029?",
      "original_answer": "Southern Company's investment in SNG has grown to $1,245 million as of December 31, 2024, reflecting a continued strategic commitment to the entity. SNG is currently developing a $3 billion pipeline project aimed at increasing its pipeline capacity by 1.3 billion cubic feet per day, with Southern Company Gas holding a 50% share of the project costs. However, the project remains subject to regulatory approvals, including from FERC, and is not expected to be completed until 2029. Given this timeline and the uncertainty of approval, the investment exposes Southern Company to regulatory and financial risk, especially since the outcome of the project cannot be determined at this time. This raises questions about the risk-adjusted rationale behind increasing capital allocation to SNG despite the unresolved status of a major capital project.",
      "llm_answer": "Southern Company’s $1.245 billion investment in SNG (recorded as an equity‑method investment) reflects its 50 % ownership share in the joint venture that is building the $3 billion pipeline. Although the project still awaits FERC approval and is not slated for completion until 2029, the company views the investment as a strategic, long‑term growth opportunity that aligns with its regulated‑rate‑based growth model. The investment is disclosed in Note 7 of the financial statements, and the company continues to monitor regulatory progress while recognizing that the ultimate financial impact will depend on the receipt of required approvals and the timing of construction.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 217,
          "pages": [
            215,
            216,
            217,
            218,
            219
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 92,
          "pages": [
            90,
            91,
            92,
            93,
            94
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 92,
          "pages": [
            90,
            91,
            92,
            93,
            94
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 86538,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21885,
        "completion_tokens": 168,
        "total_tokens": 22053
      }
    },
    {
      "question_id": 7,
      "question": "How does the valuation methodology for MDLZ's Level 2 financial assets, including net investment hedge contracts valued at $71 million, reflect the company's reliance on observable market inputs rather than unobservable assumptions?",
      "original_answer": "MDLZ reports that its Level 2 financial assets, which include $71 million in net investment hedge contracts, are primarily valued using observable market inputs such as forward exchange rates, commodity index prices, and interest rate curves. These inputs are applied through income-based approaches, such as discounted cash flow analyses or models that use market-observable parameters like volatility and dividend yields. This indicates that the valuation methodology emphasizes transparency and market-based data rather than internally derived or speculative assumptions, aligning with the fair value hierarchy's requirement for Level 2 classification based on significant observable inputs.",
      "llm_answer": "The valuation methodology for MDLZ's Level 2 financial assets—including net investment hedge contracts valued at $71 million—relies exclusively on observable market inputs such as quoted market rates, forward rates, and other market‑observable data, without resorting to unobservable assumptions. This approach reflects the company’s reliance on Level 2 valuation inputs rather than Level 3 inputs.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 111,
          "pages": [
            109,
            110,
            111,
            112,
            113
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 78234,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19791,
        "completion_tokens": 99,
        "total_tokens": 19891
      }
    },
    {
      "question_id": 8,
      "question": "How does American Express's discussion of regulatory pressure on interest rate caps in its Supervision and Regulation section reconcile with its sensitivity analysis showing that higher interest rates would have a detrimental impact on net interest income, given the assumptions around repricing risk and deposit behavior?",
      "original_answer": "American Express highlights in its Supervision and Regulation section that there are regulatory proposals to cap credit card interest rates, which could materially impact revenue growth and profitability by restricting its ability to appropriately price products. This regulatory risk directly ties to the repricing risk discussed in the interest rate sensitivity analysis, where the company assumes that interest-rate sensitive assets and liabilities reprice in line with benchmark rates, subject to applicable interest rate caps or floors. The sensitivity analysis shows that higher interest rates would have a detrimental impact on net interest income, suggesting that American Express's earnings are vulnerable to both regulatory intervention limiting rate increases and broader market rate fluctuations. The connection between these sections indicates that while the company is exposed to regulatory constraints on upward repricing, it also faces financial risk if rates rise and its cost of funds increases faster than it can adjust pricing or asset yields, especially given that certain deposits may reprice at lower magnitudes than market rates.",
      "llm_answer": "American Express acknowledges that regulatory pressure on interest‑rate caps could limit its ability to charge certain fees, but its sensitivity analysis shows that higher market rates would actually reduce net interest income because of repricing mismatches and deposit‑behavior assumptions; the company assumes that rate‑sensitive assets and liabilities will reprice in line with benchmark changes, while some deposits reprice more slowly, so a rise in rates depresses earnings despite any potential benefit from higher caps.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AXP_10k_2024.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_2_rel": {
          "source_file": "AXP_10k_2024.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "hop_3_rel": {
          "source_file": "AXP_10k_2024.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 77039,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19517,
        "completion_tokens": 131,
        "total_tokens": 19649
      }
    },
    {
      "question_id": 8,
      "question": "How does Merck's ongoing manufacturing relationship with Organon for finished pharmaceutical products, as outlined in the separation agreements, impact the financial presentation of discontinued operations in Merck's consolidated income statement through June 2, 2021?",
      "original_answer": "Merck's ongoing manufacturing relationship with Organon for finished pharmaceutical products, as detailed in the manufacturing and supply agreements (MSAs), generated $219 million in sales and $195 million in cost of sales in 2021. Despite Organon being classified as a discontinued operation through June 2, 2021, the continuation of these supply agreements created a dual financial relationship—where Merck both operated Organon’s legacy businesses and provided critical manufacturing services post-spin-off. This duality complicates the clean separation of Organon’s financial results from Merck’s ongoing operations, suggesting that the discontinued operations presentation may not fully capture the interdependent financial impact of the spin-off and the continuing supply chain relationship.",
      "llm_answer": "The separation agreements that govern Merck’s ongoing manufacturing relationship with Organon require Merck to continue producing finished pharmaceutical products for Organon under manufacturing and supply agreements (MSAs).  Because these post‑spin‑off manufacturing and supply arrangements generate sales and cost of sales that are reflected in Merck’s consolidated income statement through the spin‑off date (June 2, 2021), the related revenue and expense are presented as part of discontinued operations.  Consequently, the ongoing manufacturing relationship is accounted for within the “Income from Discontinued Operations” line item, with the associated sales ($219 million in 2021) and cost of sales ($195 million in 2021) flowing through the discontinued‑operations section of the consolidated income statement.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 146,
          "pages": [
            144,
            145,
            146,
            147,
            148
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 68218,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17300,
        "completion_tokens": 204,
        "total_tokens": 17504
      }
    },
    {
      "question_id": 8,
      "question": "How does ConocoPhillips' preemptive purchase of an additional 10% stake in APLNG, following Origin Energy's partial divestiture, reconcile with the $688 million before-tax charge recorded against the carrying value of APLNG, given that APLNG remains a key part of COP's LNG strategy?",
      "original_answer": "ConocoPhillips exercised its preemption right in December 2021 to purchase an additional 10% stake in APLNG when Origin Energy sought to sell part of its interest. However, the sales price reflected a market participant view of APLNG's fair value that was below COP's carrying value, leading to a $688 million before-tax charge. Despite this impairment, APLNG remains strategically important to COP, as it provides access to coal bed methane resources in Australia and enhances COP's LNG position through long-term sales agreements and operations in the Asia-Pacific region. The charge indicates a near-term financial impact, but the continued investment suggests long-term strategic confidence in APLNG's role within COP's portfolio.",
      "llm_answer": "ConocoPhillips recorded a $688 million pre‑tax impairment of its 47.5 % equity stake in APLNG in Q4 2021 after Origin Energy’s sale of a 10 % interest revealed that the observable market price of APLNG was below the carrying value of ConocoPhillips’ existing investment. The impairment charge—reflected in the “Impairments” line of the consolidated income statement—was a non‑cash write‑down that reduced the carrying amount of the APLNG investment to about $5.4 billion, even though the company continues to view APLNG as a strategic component of its LNG growth strategy.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 72330,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18331,
        "completion_tokens": 143,
        "total_tokens": 18474
      }
    },
    {
      "question_id": 8,
      "question": "How does the difference in transfer restrictions between the Cruise Class G Preferred Shares issued in 2021 and the Cruise Class F Preferred Shares issued in 2019 reflect on GM's strategic control and investment timeline for Cruise Holdings?",
      "original_answer": "The Cruise Class G Preferred Shares, issued in 2021, carry a four-year transfer restriction without written consent from both GM and Cruise Holdings' Board of Directors, while the Cruise Class F Preferred Shares, issued in 2019, had a transfer restriction until May 7, 2023—approximately four years after their issuance. This indicates that GM has maintained a consistent strategy of limiting investor liquidity and preserving control over the timeline of Cruise Holdings' development and potential IPO. The alignment in restriction periods across both share classes suggests GM's intent to manage investor expectations and maintain strategic control over Cruise's commercialization path, particularly as both share classes convert into IPO shares at specified ratios. This reinforces GM’s long-term approach to Cruise’s monetization and strategic alignment with key investors.",
      "llm_answer": "The differing transfer restrictions—four‑year lock‑up for the 2021 Cruise Class G Preferred Shares versus a May 7 2023 transfer ban for the 2019 Cruise Class F Preferred Shares—reflect a shift in GM’s control and investment timeline. By imposing a longer lock‑up on the newer Class G shares, GM retains tighter control over Cruise’s equity and delays any public‑market dilution until at least 2025, whereas the earlier Class F shares were designed to allow a sooner exit (via IPO or merger) and thus signaled a more advanced investment stage. This sequencing shows GM is using the newer preferred issuance to fund Cruise’s working‑capital needs while extending the horizon before any public offering or sale, aligning with a longer‑term strategic partnership (e.g., Microsoft as preferred cloud provider) and giving GM more time to guide Cruise toward commercialization.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_2_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 96,
          "pages": [
            94,
            95,
            96,
            97,
            98
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 83819,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21188,
        "completion_tokens": 217,
        "total_tokens": 21405
      }
    },
    {
      "question_id": 8,
      "question": "How does BKNG's investment in KAYAK, which contributes to its intangible assets, relate to the company's decision to exclude KAYAK's search queries from gross bookings metrics, and what does this imply about the strategic alignment between asset valuation and operational performance measurement?",
      "original_answer": "BKNG reports that a 'substantial portion' of its intangible assets and goodwill relates to the acquisition of KAYAK, indicating a significant valuation placed on the brand. However, the company explicitly states that KAYAK's search queries do not contribute to gross bookings, which is the primary metric used to assess the volume of travel services booked through OTC brands. This suggests a misalignment between the asset valuation, which emphasizes KAYAK's strategic importance, and the operational performance measurement, which does not factor in KAYAK's user engagement through search queries. This distinction implies that while KAYAK is considered valuable enough to justify intangible asset recognition, its direct financial contribution to core revenue-driving activities (as measured by gross bookings) may be limited or indirect.",
      "llm_answer": "BKNG's investment in KAYAK is reflected in its intangible assets, yet KAYAK's search queries are excluded from gross bookings metrics because KAYAK operates as a non-OTC brand with a distinct business model that does not generate bookings in the same way as BKNG's agency and merchant reservation services. This exclusion aligns operational performance measurement with the company's strategic focus on monetizing actual bookings (room nights, rental car days, airline tickets) rather than traffic or search activity, ensuring that asset valuation (intangible assets from KAYAK) is measured against the core revenue-generating activity that drives revenue and gross bookings growth. Consequently, the company prioritizes metrics directly tied to booking volume and revenue generation, reflecting a strategic alignment where intangible asset value is contingent on operational outcomes that are measured through booking-related metrics, not search volume.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BKNG_10k_2022.pdf",
          "target_page": 118,
          "pages": [
            116,
            117,
            118,
            119,
            120
          ]
        },
        "hop_2_rel": {
          "source_file": "BKNG_10k_2022.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_3_rel": {
          "source_file": "BKNG_10k_2022.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 12,
        "total_chars": 46765,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 11944,
        "completion_tokens": 238,
        "total_tokens": 12182
      }
    },
    {
      "question_id": 8,
      "question": "How does Disney's use of foreign exchange forward and option contracts to hedge $9.9 billion in firm commitments as of September 28, 2024, relate to the exclusion of these commitments from the Value at Risk (VAR) model that estimated a maximum one-day loss of $255 million?",
      "original_answer": "Disney uses foreign exchange forward and option contracts to hedge $9.9 billion in firm commitments and forecasted transactions as of September 28, 2024, with gains and losses deferred in AOCI until the transactions occur. However, in the VAR model disclosed on page 60, the company explicitly excludes firm commitments, accounts receivable, and payable denominated in foreign currencies from the risk analysis. Despite this exclusion, the VAR model still estimates a maximum one-day loss of $255 million as of the same fiscal year-end, reflecting the company's broader exposure to interest rate, foreign exchange, commodities, and equity market fluctuations. This suggests that while Disney actively hedges its firm commitments, the VAR model focuses on the residual risk in financial instruments rather than the underlying commercial exposures.",
      "llm_answer": "Disney's hedging of $9.9 billion in foreign‑exchange firm commitments with forward and option contracts is excluded from the Value‑at‑Risk calculation because those commitments are not part of the market‑sensitive financial instruments that the VAR model incorporates; the VAR excludes forecasted transactions, firm commitments and related foreign‑currency assets and liabilities that are hedged, so the $255 million one‑day loss estimate reflects only the interest‑rate, equity, commodity and designated derivative positions that remain in the model.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 67988,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17243,
        "completion_tokens": 137,
        "total_tokens": 17381
      }
    },
    {
      "question_id": 8,
      "question": "How does the significant disparity in voting power between Class A and Class B common stockholders, with only 3 record holders of Class B stock controlling 33 1/3% of voting power, relate to the $4.0 billion in Class A stock repurchases during 2021?",
      "original_answer": "The 3 record holders of Class B common stock control 33 1/3% of the combined voting power due to the 15-vote per share structure, giving them disproportionate influence despite representing a small number of holders. Meanwhile, the company repurchased $4.0 billion of Class A common stock in 2021, which is the class with significantly less voting power but a much larger number of holders (352,581 as of December 31, 2021). This suggests that while Class A shareholders are numerous and see tangible capital return through share repurchases, the voting control remains concentrated in a small group of Class B shareholders, creating a governance structure where economic returns and voting influence are decoupled.",
      "llm_answer": "The $4 billion of Class A stock repurchases in 2021 was executed under the company’s newly‑expanded $10 billion share‑repurchase authorization, which was increased in May 2021 (and later to $10 billion in January 2022).  This repurchase activity occurred while the Class B holders—only three record owners who collectively control 33 ⅓ % of the voting power—maintain a disproportionately large voting stake, underscoring that the company’s equity‑return decisions (including large buybacks) are made by a relatively small group of insiders.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 12,
        "total_chars": 49590,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12637,
        "completion_tokens": 135,
        "total_tokens": 12772
      }
    },
    {
      "question_id": 8,
      "question": "How does Emerson's equity compensation disclosure regarding unvested Performance Stock Units (PSUs) tied to AspenTech's performance goals reconcile with the increased stock compensation expense attributed to AspenTech equity plans in the consolidated income statement?",
      "original_answer": "Emerson's 2024 10-K reveals that at September 30, 2024, 4 million shares were reserved for future issuance under AspenTech's equity compensation plans, including performance stock units (PSUs) that vest based on predefined goals such as annual contract value and free cash flows. These PSUs, which can vest up to 175% of target upon exceeding performance goals or not vest at all if minimum thresholds are not met, directly contribute to the stock compensation expense recognized in the consolidated financial statements. This aligns with the reported increase in stock compensation expense of $50 million in 2023 attributed to AspenTech stock plans, which was included in SG&A expenses, showing how the performance-based equity incentives for AspenTech employees translate into measurable financial impacts on Emerson's consolidated results post-acquisition.",
      "llm_answer": "The disclosure of unvested Performance Stock Units (PSUs) tied to AspenTech’s performance goals reflects the ongoing equity‑based compensation expense that Emerson records for those awards, which is recognized as part of the “stock‑based compensation expense” line in the consolidated income statement. This expense is included in the $55 million of AspenTech‑related stock compensation reported for 2024, and it explains why the consolidated statement shows an increased stock‑compensation charge even though the PSUs remain unvested and are contingent on achieving specific performance targets.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "EMR_10k_2024.pdf",
          "target_page": 72,
          "pages": [
            70,
            71,
            72,
            73,
            74
          ]
        },
        "hop_2_rel": {
          "source_file": "EMR_10k_2024.pdf",
          "target_page": 70,
          "pages": [
            68,
            69,
            70,
            71,
            72
          ]
        },
        "hop_3_rel": {
          "source_file": "EMR_10k_2024.pdf",
          "target_page": 26,
          "pages": [
            24,
            25,
            26,
            27,
            28
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 69669,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17663,
        "completion_tokens": 149,
        "total_tokens": 17812
      }
    },
    {
      "question_id": 8,
      "question": "How does the change in UPS Retirement Plan contribution structure for non-union employees hired on or after January 1, 2025, relate to the IRS limits on tax-qualified defined contribution plans, and how does this reflect a broader shift in UPS's retirement benefits strategy as evidenced by the cessation of future benefit accruals in the UPS Retirement Plan for non-union participants effective January 1, 2023?",
      "original_answer": "The UPS Retirement Plan for non-union employees hired on or after January 1, 2025, will receive a flat 3% annual contribution, down from a range of 3% to 8% based on years of vesting service prior to this change. This adjustment aligns with IRS limits on tax-qualified defined contribution plans, which cap contributions and compensation levels for such plans. UPS also ceased future benefit accruals for non-union participants in the UPS Retirement Plan effective January 1, 2023, signaling a strategic shift toward defined contribution plans like the UPS 401(k) Savings Plan. This reflects a broader trend of reducing long-term pension liabilities and transferring retirement risk to employees, while still offering competitive retirement benefits within regulatory constraints.",
      "llm_answer": "The change in the UPS Retirement Plan contribution structure for non-union employees hired on or after January 1, 2025—setting a flat 3 % of eligible compensation—aligns with IRS limits for tax‑qualified defined‑contribution plans, ensuring contributions remain within permissible caps. This move reflects a broader shift in UPS’s retirement strategy, as the company has already halted benefit accruals for non‑union participants (effective January 1, 2023) and is now moving those employees into a defined‑contribution framework with a fixed, IRS‑compliant contribution rate.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 87,
          "pages": [
            85,
            86,
            87,
            88,
            89
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 64651,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16439,
        "completion_tokens": 144,
        "total_tokens": 16583
      }
    },
    {
      "question_id": 9,
      "question": "How does MDLZ's use of commodity futures to hedge input cost volatility relate to their classification and valuation methodology for Level 1 financial assets, and what does this reveal about their risk management approach for exchange-traded derivatives?",
      "original_answer": "MDLZ utilizes commodity futures to hedge against price risks associated with forecasted purchases of raw materials such as cocoa, sugar, and wheat (page 94). These commodity futures are classified as Level 1 financial assets (page 112), indicating they are exchange-traded instruments valued using quoted market prices on commodity exchanges. The valuation methodology for Level 1 assets reflects transparency and liquidity, aligning with MDLZ's strategy of using non-speculative, risk-mitigating instruments. This classification and valuation approach reveals that MDLZ prioritizes instruments with observable market pricing to manage commodity exposure in a manner consistent with their stated risk management policies.",
      "llm_answer": "MDLZ manages commodity price volatility by using exchange‑traded futures and options (e.g., for cocoa, sugar, wheat, oils) as economic hedges, while its Level 1 classification reflects that these exchange‑traded contracts are valued using quoted market prices. This approach underscores a disciplined, risk‑focused strategy that combines transparent market‑based pricing with robust effectiveness testing and comprehensive counterparty monitoring to protect earnings from input‑cost swings.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 69212,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17545,
        "completion_tokens": 122,
        "total_tokens": 17667
      }
    },
    {
      "question_id": 9,
      "question": "How does AbbVie's fair value accounting treatment for the Cerevel Therapeutics funding agreements, which include milestone-based repayment terms for tavapadon, relate to the deferred tax liabilities recognized as a result of the acquisition?",
      "original_answer": "AbbVie accounts for the Cerevel Therapeutics funding agreements under the fair value option, with a $246 million financing liability recognized at acquisition based on a probability-weighted model and Monte Carlo simulations for milestone and royalty payments. These agreements, which are contingent on FDA approval of tavapadon, represent a long-term financial obligation tied to the success of a specific drug candidate. Concurrently, AbbVie recognized deferred tax liabilities due to the acquisition, primarily stemming from the excess book basis over tax basis of intangible assets. This indicates that while AbbVie has assumed contingent financial obligations (like the funding agreements), it has also taken on long-term tax implications from the acquisition, suggesting a complex interplay between contingent liabilities and tax planning considerations. The fair value treatment of the funding agreements and the deferred tax liabilities both reflect the broader financial impact of the Cerevel acquisition on AbbVie’s balance sheet.",
      "llm_answer": "AbbVie recognized a $82 million charge in 2024 related to the fair‑value remeasurement of the financing liability assumed in the Cerevel Therapeutics acquisition; this liability, which reflects contingent milestone and royalty payments, is recorded as a deferred tax liability, thereby increasing the company’s overall deferred tax liability balance.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "target_page": 67,
          "pages": [
            65,
            66,
            67,
            68,
            69
          ]
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 91604,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 23143,
        "completion_tokens": 87,
        "total_tokens": 23231
      }
    },
    {
      "question_id": 9,
      "question": "How does ConocoPhillips' financial exposure to Alba Plant LLC, as detailed in its contingent obligations, relate to its production and monetization of condensate from the Alba Unit and other upstream assets?",
      "original_answer": "ConocoPhillips has a $116 million maximum potential future payment exposure through its guarantee of Alba Plant LLC, a joint venture where it holds a 52.2% interest. This financial risk is tied to Alba Plant LLC’s role in processing natural gas from the Alba Unit, which includes extracting and selling condensate at market prices—revenue from which is reflected in COP’s 'Equity in earnings of affiliates'. Meanwhile, in another section, COP describes its broader condensate production activities, such as at the Aasta Hansteen Field in the Norwegian Sea, where condensate is produced and transported to market. The financial guarantees tied to Alba Plant LLC directly support the infrastructure that enables COP to monetize condensate and LPG from the Alba Unit, linking its upstream production to downstream processing and revenue generation, while also exposing the company to contingent liabilities that could impact its financial position if triggered.",
      "llm_answer": "ConocoPhillips’ financial exposure to Alba Plant LLC is reflected in its contingent guarantees, which are disclosed in Note 9‑Guarantees. The company guarantees the performance and payment obligations of Alba Plant LLC under certain agreements, with a maximum potential liability of about $116 million (supported by a $4 million carrying value at year‑end 2024). This exposure arises from the company’s 64.2 % ownership interest in the Alba Unit and the related gas‑processing and LNG monetization activities, where Alba Plant LLC extracts condensate and LPG for sale and delivers processed gas to EG LNG. Thus, the contingent obligations tie directly to the production and monetization of condensate and other upstream assets in the Alba region.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 55830,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14189,
        "completion_tokens": 186,
        "total_tokens": 14375
      }
    },
    {
      "question_id": 9,
      "question": "How does Intel's divestiture of its NAND memory business to SK hynix, including the Dalian fabrication facility, align with its continued manufacturing and sale of NAND wafers using those same assets until the second closing?",
      "original_answer": "Intel signed an agreement with SK hynix in October 2020 to divest its NAND memory business, including the Dalian fabrication facility and related tangible assets (Fab Assets), as well as the NAND SSD Business, with the first closing completed on December 29, 2021. Despite selling the Fab Assets, Intel entered into a NAND wafer manufacturing and sale agreement with SK hynix, under which Intel continued to manufacture and sell NAND memory wafers using those very assets until the second closing. This indicates a transitional manufacturing arrangement that allows Intel to maintain short-term production continuity while gradually exiting the NAND memory manufacturing space.",
      "llm_answer": "Intel’s divestiture of its NAND memory business to SK hynix includes the Dalian fabrication facility, yet the company will continue to manufacture and sell NAND wafers using those same assets until the second closing of the transaction. This arrangement allows Intel to retain limited production of NAND wafers under a manufacturing‑and‑sale agreement with SK hynix while fully deconsolidating the NAND OpCo Business in early 2022.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_2_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_3_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 30751,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 7917,
        "completion_tokens": 107,
        "total_tokens": 8025
      }
    },
    {
      "question_id": 9,
      "question": "How does Microsoft's investment in Azure, as noted in the operating expenses section, align with the growth trajectory of the Server products and cloud services segment, which includes Azure, given the 22% year-over-year revenue increase in that segment?",
      "original_answer": "Microsoft's Server products and cloud services segment, which includes Azure, saw a revenue increase from $79,970 million in 2023 to $97,726 million in 2024, representing a 22% year-over-year growth. This growth is attributed in part to Azure's expansion, driven by consumption-based services and AI infrastructure scaling. In response to this growth, Microsoft increased its investments in Azure, as noted in the operating expenses section, where expenses were driven by 'investments in Azure' despite a slight overall decrease in operating expenses. This indicates a strategic reallocation of resources to capitalize on Azure's growth potential and strengthen its market position in cloud and AI services.",
      "llm_answer": "Microsoft's investment in Azure aligns directly with the strong growth trajectory of the Server products and cloud services segment, which grew 22% year-over-year to $97,726 million in revenue (as disclosed in the \"Revenue, classified by significant product and service offerings\" table). This segment growth, driven by Azure's expansion and increased consumption-based services, is explicitly highlighted as a key contributor to the Intelligent Cloud segment's 20% revenue increase ($105,362M in 2024 vs. $87,907M in 2023) and its 31% operating income growth ($49,584M vs. $37,884M). The document further confirms Azure's role within Microsoft Cloud revenue ($137.4B in 2024), which underpins the segment's performance.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 45,
          "pages": [
            43,
            44,
            45,
            46,
            47
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 54982,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 13991,
        "completion_tokens": 180,
        "total_tokens": 14171
      }
    },
    {
      "question_id": 9,
      "question": "How does Disney's use of Level 3 valuation techniques for non-recurring fair value measures in fiscal 2024 relate to the triggering events that led to impairment charges, and how does this align with their stated impairment testing methodology for long-lived assets?",
      "original_answer": "Disney evaluates certain assets for non-recurring fair value measurement when triggering events occur, such as a decrease in estimated future cash flows, which led to impairment charges in the second and fourth quarters of fiscal 2024. These fair value measurements use Level 3 valuation techniques, primarily discounted cash flow analysis. On another section of the filing, Disney states that when triggering events occur, they test long-lived assets for impairment by comparing estimated undiscounted future cash flows to the asset's carrying value, depending on whether the asset is held for use or sale. This indicates that the Level 3 fair value assessments are directly tied to the triggering events that initiate impairment testing, aligning the valuation methodology with the broader asset recovery evaluation framework.",
      "llm_answer": "Disney's use of Level 3 valuation techniques for non-recurring fair value measures in fiscal 2024—specifically for impairment charges triggered by decreases in estimated future cash flows—directly aligns with its stated methodology for testing long-lived assets. As noted in the \"Non-recurring Fair Value Measure\" section, assets are evaluated for impairment when triggering events occur (e.g., declining cash flow projections), and fair value is determined using discounted cash flow models, which are classified as Level 3 inputs. This approach is consistent with the impairment testing framework for long-lived assets described in the \"Goodwill, Other Intangible Assets and Long-Lived Assets\" section, which requires comparing estimated undiscounted cash flows to the asset group's carrying amount and recognizing an impairment if the carrying amount exceeds fair value. The document confirms that impairment charges in fiscal 2024 were recorded using Level 3 valuation techniques based on discounted cash flows, directly supporting the methodology for long-lived asset impairment testing.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 83309,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21072,
        "completion_tokens": 273,
        "total_tokens": 21345
      }
    },
    {
      "question_id": 9,
      "question": "How does Simon Property Group's financial benefit from its investment in J.C. Penney, including the equity transaction with SPARC Group, contrast with the impact of ownership dilution in SPARC Group earlier in the year?",
      "original_answer": "Simon Property Group derived a $100.5 million non-cash pre-tax gain from J.C. Penney's acquisition of SPARC Group, which was renamed Catalyst. This transaction solidified SPG's 31.3% noncontrolling interest in the newly combined entity. However, earlier in the year, SPG experienced ownership dilution in SPARC Group when the latter issued equity to a third party, reducing SPG’s stake to 33.3% and resulting in a $145.8 million non-cash pre-tax gain due to deemed disposal. While both events contributed positively to SPG's financials, the J.C. Penney transaction reflects a strategic consolidation benefit, whereas the SPARC dilution reflects a partial exit with a tax-deferred gain, highlighting different strategic and financial outcomes from similar equity-level activities.",
      "llm_answer": "Simon Property Group's financial benefit from its investment in J.C. Penney through the equity transaction with SPARC Group generated a non-cash pre-tax gain of $100.5 million for SPARC Group's all-equity acquisition of J.C. Penney's retail operations, which was recognized in gain due to disposal, exchange, or revaluation of equity interests, net in the consolidated statements of operations and comprehensive income. This contrasted with earlier in the year when SPARC Group experienced ownership dilution from issuing equity to a third party, resulting in a deem-d disposal of a proportional interest that generated a non-cash pre-tax gain of $145.8 million for Simon Property Group, reflecting the difference in the financial impact of the two transactions.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_2_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 115,
          "pages": [
            113,
            114,
            115,
            116,
            117
          ]
        },
        "hop_3_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 74970,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18982,
        "completion_tokens": 190,
        "total_tokens": 19172
      }
    },
    {
      "question_id": 9,
      "question": "How does the allocation of $21.7 billion in Alphabet's 2023 stock-based compensation expense tied to Class C stock issuance reconcile with the treatment of Class B stock in diluted net income per share calculations, given the structural relationship between these share classes?",
      "original_answer": "Alphabet's 2023 stock-based compensation expense of $21.7 billion is largely tied to awards expected to settle in Class C stock, indicating a direct financial impact from issuing this share class. Meanwhile, the diluted net income per share calculation for Class A stock assumes the conversion of Class B stock, which is not treated as dilutive when calculating diluted earnings for Class B itself. Despite these differences in treatment across compensation and earnings per share disclosures, both Class C and Class B shares participate equally in undistributed earnings due to identical dividend and liquidation rights. This structural alignment ensures that while Class C stock is operationally central to compensation programs, Class B stock retains a distinct role in EPS calculations, reflecting the company's capital structure design.",
      "llm_answer": "The $21.7 billion of stock‑based compensation expense recognized in 2023 reflects the portion of RSU awards that will settle in Alphabet’s Class C shares, which are issued under the 2021 Stock Plan; these shares have no voting rights and are treated the same as Class A shares for dividend and liquidation rights. Because Class B shares automatically convert to Class A on sale or conversion, they are not assumed to convert when calculating diluted earnings per share for Class B, but the conversion of Class B to Class A is assumed when determining diluted EPS for Class A, ensuring that the dilution from potential Class B conversions is reflected in the Class A per‑share earnings calculation.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        },
        "hop_2_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "hop_3_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 90121,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22774,
        "completion_tokens": 174,
        "total_tokens": 22948
      }
    },
    {
      "question_id": 9,
      "question": "How does the $1.2 billion loss on the sale of ATC TIPL reflect in the consolidated financial statements, given that the transaction proceeds were primarily used to repay the 2021 Multicurrency Credit Facility and the sale is referenced in the context of asset retirement obligations?",
      "original_answer": "The $1.2 billion loss on the sale of ATC TIPL, which includes a $1.1 billion reclassification of cumulative translation adjustments, is recorded in 'Loss from discontinued operations, net of taxes' in the consolidated statements of operations for the year ended December 31, 2024. The proceeds from the $2.2 billion transaction were used to repay existing indebtedness under the 2021 Multicurrency Credit Facility, directly impacting the company’s liabilities and cash flow statement. Additionally, the sale of ATC TIPL is referenced in the context of asset retirement obligations as part of broader asset disposals affecting the company’s real estate and infrastructure portfolio, indicating a strategic realignment of capital and asset base.",
      "llm_answer": "The $1.2 billion loss on the sale of ATC TIPL is recorded in loss from discontinued operations, net of taxes in the consolidated statements of operations for 2024. This loss primarily reflects the reclassification of the cumulative translation adjustment in India ($1.1 billion) and is included in the “Loss on sale of ATCTIPL” line of the discontinued‑operations summary. The proceeds from the sale were used to repay the 2021 Multicurrency Credit Facility, and the transaction also generated a $53.9 million contingent tax‑indemnification liability and a $140 million deferred tax asset with a full valuation allowance.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_2_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_3_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 148,
          "pages": [
            142,
            143,
            144,
            145,
            146
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 62103,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15775,
        "completion_tokens": 155,
        "total_tokens": 15930
      }
    },
    {
      "question_id": 9,
      "question": "How does Boeing's continued partnership with Citibank, N.A. as administrative agent under both the 2019 Five-Year Credit Agreement and the newly executed 2023 Five-Year Credit Agreement reflect on the company's strategic approach to credit facility management and lender relationships?",
      "original_answer": "Boeing's continued engagement with Citibank, N.A. as administrative agent across both the 2019 and 2023 Five-Year Credit Agreements indicates a strategic preference for maintaining continuity and established trust with key financial partners. This consistency in lender relationships suggests that Boeing values Citibank’s role in facilitating stable access to capital, particularly during periods of financial stress or restructuring. The presence of Citibank in both agreements, despite the multi-year gap and potential market changes, underscores Boeing's reliance on proven financial partnerships to manage liquidity and credit risk.",
      "llm_answer": "Boeing’s decision to retain Citibank, N.A. as administrative agent across both its 2019 and the newly executed 2023 Five-Year Credit Agreements underscores a deliberate strategy of continuity and stability in its credit facility management. By maintaining the same lead bank relationship, Boeing ensures consistent administrative oversight, streamlined covenant compliance, and reduced complexity in financing operations—reflecting a calculated approach to leveraging established lender relationships for long-term liquidity resilience.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2023.pdf",
          "target_page": 126,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2023.pdf",
          "target_page": 126,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2023.pdf",
          "target_page": 125,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 64627,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16401,
        "completion_tokens": 134,
        "total_tokens": 16535
      }
    },
    {
      "question_id": 9,
      "question": "How does MET's valuation methodology for Structured Securities, including RMBS, reflect in their Level 3 fair value disclosures, and what does this imply about the sensitivity of their RMBS portfolio to market pricing assumptions?",
      "original_answer": "MET reports a total fair value of $4,551 million for Structured Securities as of December 31, 2023, within Level 3 of the fair value hierarchy, indicating significant unobservable inputs. These Structured Securities include RMBS, which MET values using market pricing techniques and quoted prices. On page 272, MET discloses that an increase in market pricing inputs would raise the estimated fair value of RMBS, showing that the RMBS portfolio is particularly sensitive to changes in market pricing assumptions. This sensitivity, combined with the Level 3 classification, implies that the valuation of RMBS within Structured Securities involves considerable judgment and model dependence, which could lead to material changes in fair value with shifts in market conditions.",
      "llm_answer": "MET’s valuation methodology for Structured Securities, including RMBS, relies on market‑pricing inputs (quoted prices, broker quotes, and consensus pricing) that are classified as Level 3 when they involve significant unobservable assumptions—particularly regarding default probability, loss severity, and prepayment rates. Because these inputs are highly sensitive, changes in the underlying assumptions (e.g., higher default rates or lower prepayment speeds) would produce material shifts in the estimated fair value of the RMBS portfolio, indicating that its fair‑value estimates are directly influenced by market pricing assumptions.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 274,
          "pages": [
            272,
            273,
            274,
            275,
            276
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 92,
          "pages": [
            90,
            91,
            92,
            93,
            94
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 272,
          "pages": [
            270,
            271,
            272,
            273,
            274
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 150718,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 37918,
        "completion_tokens": 159,
        "total_tokens": 38077
      }
    },
    {
      "question_id": 9,
      "question": "Given that UPS contributed $139 million to the New York State Teamsters Conference Pension and Retirement Fund in 2023, which is subject to a Rehabilitation Plan (RP) requirement, how does this contribution align with UPS's statement that collectively bargained contributions satisfy all implemented RP requirements without requiring surcharges?",
      "original_answer": "UPS contributed $139 million to the New York State Teamsters Conference Pension and Retirement Fund in 2023, which is in the red zone and subject to an implemented RP requirement. According to UPS, their collectively bargained contributions satisfy all RP requirements, and no surcharges are imposed. This indicates that UPS's $139 million contribution meets the financial obligations under the Rehabilitation Plan without requiring additional payments beyond the agreed-upon contractual rates.",
      "llm_answer": "UPS’s $139 million contribution to the New York State Teamsters Conference Pension and Retirement Fund is made under a collective‑bargaining agreement that already satisfies the plan’s rehabilitation‑plan (RP) funding requirements. Because the agreement’s contributions meet the RP obligations, no additional surcharge is required, consistent with UPS’s statement that collectively bargained contributions fulfill all implemented RP requirements without imposing extra surcharges.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 87500,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22134,
        "completion_tokens": 120,
        "total_tokens": 22254
      }
    },
    {
      "question_id": 9,
      "question": "How does COP's investment in PALNG, which involved interest rate swaps under ASC Topic 815, impact its revenue recognition policy for derivative contracts governed by the same accounting standard?",
      "original_answer": "COP's investment in PALNG, which included interest rate swaps designated under ASC Topic 815, reflects its involvement in complex derivative instruments for risk management. However, when PALNG de-designated part of these swaps in 2024, the associated $35 million in unrealized changes flowed through 'Equity in earnings of affiliates,' indicating a shift in how those derivatives are accounted for. Meanwhile, COP applies ASC Topic 815 to certain physical gas contracts that fall outside ASC Topic 606, treating them as derivatives for revenue recognition. This suggests that while COP uses ASC Topic 815 both for hedging investments (like in PALNG) and for revenue from commodity contracts, the financial impact is recognized differently—either through equity earnings or directly as revenue—depending on the nature and context of the derivative.",
      "llm_answer": "ConocoPhillips’ investment in PALNG, which involved interest rate swaps designated under ASC Topic 815, does not alter its overall revenue‑recognition policy for derivative contracts. The company continues to record gains and losses on its commodity derivatives on a net basis (or gross basis when not designated as hedges), and the swaps are accounted for as cash‑flow hedges that affect other comprehensive income until the hedged transaction impacts earnings. Consequently, the PALNG swaps are treated consistently with the company’s existing derivative accounting under ASC 815.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 107,
          "pages": [
            105,
            106,
            107,
            108,
            109
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 69590,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17631,
        "completion_tokens": 145,
        "total_tokens": 17776
      }
    },
    {
      "question_id": 9,
      "question": "How does Southern Company's financial dependency on SCS for power pool services relate to its equity earnings from SNG, given SCS's role in arranging natural gas transportation through SNG?",
      "original_answer": "Southern Company (SO) relies on SCS to arrange natural gas transportation services from SNG, which is a key input for power generation. In 2024, SO incurred significant costs through SCS for these services, which are included in operations and maintenance expenses or capitalized. SCS, acting as an agent for SO's subsidiaries, manages long-term agreements with SNG for gas transportation, which are essential for fulfilling energy production needs. Meanwhile, Southern Company Gas, a subsidiary of SO, earns equity method income from its investment in SNG, totaling $146 million in 2024. This creates a dual relationship where SO indirectly supports SNG through contracted transportation fees (via SCS), while also benefiting financially from SNG’s performance through equity earnings. The interplay highlights a strategic alignment in SO’s upstream and downstream operations, balancing cost obligations with investment returns within the same value chain.",
      "llm_answer": "Southern Company's financial statements show that SCS provides power pool services to Southern Power at cost, and Southern Power purchases electricity from affiliates through the Southern Company power pool. This dependency is reflected in Southern Power's equity earnings from SNG, as SCS arranges natural gas transportation through SNG for Southern Power's gas-related operations, linking SCS's services to Southern Power's equity method investment in SNG. The document indicates that SCS's role in facilitating gas transportation via SNG is integral to Southern Power's operations and financial reporting.  \n\n(2 sentences)",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 165,
          "pages": [
            163,
            164,
            165,
            166,
            167
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 165,
          "pages": [
            163,
            164,
            165,
            166,
            167
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 217,
          "pages": [
            215,
            216,
            217,
            218,
            219
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 67338,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17061,
        "completion_tokens": 156,
        "total_tokens": 17217
      }
    },
    {
      "question_id": 10,
      "question": "How does MetLife's treatment of surplus notes under statutory accounting principles affect its ability to pay dividends, given the differences in how surplus notes are reported in the long-term debt disclosures?",
      "original_answer": "MetLife's statutory accounting practices treat surplus notes as surplus rather than debt, which increases statutory capital and surplus and thereby influences the calculation of allowable dividends. This treatment contrasts with the GAAP-based long-term debt disclosures on page 276, where surplus notes are reported with a face value of $507 million and a weighted average interest rate of 7.79%, reflecting their debt-like characteristics. The statutory treatment enhances MetLife's capacity to pay dividends by inflating surplus, while the GAAP presentation highlights the financial liability associated with surplus notes, indicating a more conservative view of the company's financial position.",
      "llm_answer": "MetLife’s surplus notes are treated as surplus rather than debt under statutory accounting, so they are not included in long‑term debt disclosures. Because they are classified as surplus, they can be used to meet regulatory capital requirements but cannot be used to pay dividends; consequently, the company’s ability to pay dividends depends on other sources of capital and the regulatory dividend‑restriction rules.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 292,
          "pages": [
            290,
            291,
            292,
            293,
            294
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 136,
          "pages": [
            134,
            135,
            136,
            137,
            138
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 276,
          "pages": [
            274,
            275,
            276,
            277,
            278
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 75200,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19038,
        "completion_tokens": 104,
        "total_tokens": 19143
      }
    },
    {
      "question_id": 10,
      "question": "How does ConocoPhillips' $688 million before-tax charge related to the fair value write-down of APLNG reconcile with their operational exposure in Queensland, Australia, particularly given the long-term sales agreements and financing structure of the APLNG joint venture?",
      "original_answer": "ConocoPhillips took a $688 million before-tax charge in 2021 to write down its investment in APLNG to its fair value of $5,574 million, reflecting a market participant view that the carrying value was too high. This write-down occurred despite APLNG's long-term sales agreements and a structured $4.7 billion project finance facility that extends through 2030, both of which are key components of its operational stability in Queensland, Australia. The contrast between the impairment charge and the long-term contractual and financial framework of APLNG suggests that short-term market or risk assessments may have outweighed the long-term strategic positioning of the asset at the time of the valuation.",
      "llm_answer": "The $688 million before‑tax charge recorded in 2021 reflects an impairment of ConocoPhillips’ 47.5 % equity investment in APLNG, driven by a decline in the joint‑venture’s fair value that fell below the carrying amount of the investment. This decline was tied to the long‑term LNG sales agreements and the joint‑venture’s financing structure in Queensland, Australia, which limited the ability to generate sufficient cash flows to support the prior valuation, prompting the write‑down.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 72330,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18328,
        "completion_tokens": 121,
        "total_tokens": 18450
      }
    },
    {
      "question_id": 10,
      "question": "How does the difference in transfer restrictions between Cruise Class G and Class F Preferred Shares impact GM's liquidity planning and strategic control over Cruise Holdings?",
      "original_answer": "The Cruise Class G Preferred Shares issued in 2021 carry a four-year transfer restriction, expiring in 2025, while the earlier issued Cruise Class F Preferred Shares had a transfer restriction that expired in May 2023. This staggered restriction timeline allows GM to maintain strategic influence over Cruise Holdings for a longer period through the Class G shares, particularly during critical phases of development and potential IPO planning. Additionally, the Class G shares grant voting rights on all matters submitted for vote, whereas Class F shares are limited to voting on the election of one director. These differences suggest GM may be calibrating its control and exit strategy in stages, aligning with its broader liquidity planning and long-term strategic goals for Cruise as outlined in the consolidated financial statements.",
      "llm_answer": "The transfer restrictions on Cruise Class G Preferred Shares (four‑year lock‑up without consent) limit the ability of its investors to sell or otherwise divest their holdings, which constrains the near‑term cash‑flow flexibility of Cruise Holdings. This restriction forces GM to plan its liquidity around the longer‑term horizon of the Cruise investment and to maintain strategic control over Cruise’s capital allocation and governance until the lock‑up expires.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_2_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 96,
          "pages": [
            94,
            95,
            96,
            97,
            98
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 83819,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21171,
        "completion_tokens": 115,
        "total_tokens": 21287
      }
    },
    {
      "question_id": 10,
      "question": "Given Apple's significant net sales of $74.2 billion from the Greater China region in 2022, how does the company's reliance on China Mainland within this region for manufacturing and supply chain operations expose it to risk, particularly in light of the geopolitical and public health challenges described in the risk factors section?",
      "original_answer": "Apple reported $74.2 billion in net sales from the Greater China region in 2022, which includes China Mainland, Hong Kong, and Taiwan. This region is not only a major revenue contributor but also a critical part of Apple's global supply chain. However, the company's operations are exposed to significant risks due to its reliance on China Mainland for manufacturing and logistics. As noted in the risk factors section, geopolitical tensions between the U.S. and China have led to tariffs that increase the cost of Apple's products and components, potentially reducing gross margins and consumer demand. Additionally, public health issues like the ongoing impact of the COVID-19 pandemic can disrupt supply chains, delay product delivery, and affect consumer confidence and spending. These combined factors illustrate how Apple's strategic and operational exposure to the Greater China region, particularly China Mainland, presents both opportunity and risk.",
      "llm_answer": "Apple's reliance on China Mainland for manufacturing and supply chain operations exposes it to significant risks, particularly given the geopolitical tensions and public health challenges highlighted in the risk factors. The document notes that \"substantially all of the Company's hardware products are manufactured by outsourcing partners that are located primarily in Asia, with some Mac computers manufactured in the U.S. and Ireland\" and that \"China includes Hong Kong and Taiwan\" in its geographic segment reporting. This concentration creates vulnerability to trade disputes, tariffs, and supply chain disruptions, as evidenced by the \"series of tariffs being imposed by the U.S. on imports from China mainland\" and the potential for \"countries to adopt other measures, such as controls on imports or exports of goods, technology or data, that could adversely impact the Company's operations and supply chain.\" The risk factors further emphasize that \"political events, trade and other international disputes, war, terrorism, natural disasters, public health issues, industrial accidents and other business interruptions can harm or disrupt international commerce\" and that \"the Company has a large, global business with sales outside the U.S. representing a majority of the Company's total net sales,\" making it especially susceptible to regional instability. Additionally, the document states that \"the COVID-19 pandemic has at times significantly curtailed global economic activity and caused significant volatility and disruption in global financial markets,\" directly linking public health crises to potential supply chain and operational impacts in China.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 52,
          "pages": [
            50,
            51,
            52,
            53,
            54
          ]
        },
        "hop_2_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 25,
          "pages": [
            23,
            24,
            25,
            26,
            27
          ]
        },
        "hop_3_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 61958,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15755,
        "completion_tokens": 416,
        "total_tokens": 16171
      }
    },
    {
      "question_id": 10,
      "question": "Given Disney's exposure to floating-rate borrowings as of September 28, 2024, how does the lack of designated pay-fixed interest rate swaps impact their interest rate risk management strategy, especially in light of their broader use of cash flow hedges for foreign exchange risk?",
      "original_answer": "Disney reported floating-rate borrowings as of September 28, 2024, with interest rates in effect on that date, which may not reflect future costs. Although the company utilizes pay-fixed interest rate swaps to convert floating-rate debt to fixed-rate debt, it did not have any such swaps designated as cash flow hedges at the end of fiscal 2024. This contrasts with their active use of foreign exchange cash flow hedges, where $9.9 billion in notional amounts were designated to manage currency risk. The absence of designated pay-fixed swaps suggests Disney is not actively hedging interest rate risk on floating-rate borrowings through cash flow hedges, potentially leaving them exposed to rate increases, even as they proactively manage foreign exchange volatility.",
      "llm_answer": "Disney's lack of designated pay-fixed interest rate swaps to hedge floating-rate borrowings limits its ability to convert variable-rate debt into fixed-rate obligations, which could increase exposure to interest rate volatility. However, the company mitigates this risk through its broader use of cash flow hedges for foreign exchange risk and by employing pay-floating swaps as fair value hedges for fixed-rate debt, as noted in the interest rate risk management discussion. The company's strategy focuses on managing interest rate risk via swap instruments rather than relying on pay-fixed cash flow hedges for floating-rate borrowings.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 80082,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20269,
        "completion_tokens": 159,
        "total_tokens": 20429
      }
    },
    {
      "question_id": 10,
      "question": "How does the significant disparity in voting power between Class A and Class B common stockholders, with only 3 record holders of Class B stock controlling 33⅓% of voting power, relate to the $4.0 billion in Class A stock repurchases during 2021?",
      "original_answer": "The 3 record holders of Class B common stock control 33⅓% of the combined voting power, with each share carrying 15 votes, and Mr. Brian L. Roberts owning all outstanding shares. This concentrated voting power ensures continued influence over corporate decisions. Meanwhile, in 2021, the company repurchased $4.0 billion worth of Class A common stock, which is subject to broader public ownership (352,581 holders) and carries fewer voting rights. The repurchase of Class A shares may serve to return capital to the broader shareholder base while maintaining strategic control with the Class B holders. This reflects a capital allocation strategy that balances shareholder returns with governance stability.",
      "llm_answer": "The 2021 share‑repurchase program was launched after the Board increased the authorization to $10 billion, and during the year Comcast repurchased 73.2 million Class A shares for a total of $4.0 billion. This $4 billion of repurchases was funded from operating cash flow and was part of the company’s broader capital‑allocation strategy that also included dividend payments and debt management. The voting‑power disparity—where just three record holders of Class B stock control one‑third of the total voting power—does not directly affect the amount spent on repurchases, but it underscores that a small group of insiders (beneficially owned by Mr. Brian L. Roberts) holds significant influence over corporate decisions such as share‑buybacks.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 12,
        "total_chars": 49590,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12636,
        "completion_tokens": 186,
        "total_tokens": 12822
      }
    },
    {
      "question_id": 10,
      "question": "How does Boeing's 2023 Five-Year Credit Agreement, which Citibank, N.A. administers, relate to the company's broader credit arrangements with Citibank as disclosed in the exhibits filed with the 2023 10-K?",
      "original_answer": "Boeing's 2023 Five-Year Credit Agreement, administered by Citibank, N.A., is part of a broader set of credit arrangements with Citibank as disclosed in the exhibits to the 2023 10-K, which also includes a 364-Day Credit Agreement and a Three-Year Credit Agreement, both dated August 24, 2023 and August 25, 2022 respectively. These agreements highlight Citibank's role as a key financial partner for Boeing, providing flexible financing solutions during a period of ongoing financial challenges.",
      "llm_answer": "The 2023 Five-Year Credit Agreement (Exhibit 10.2 in the 2023 10‑K) is one of several credit arrangements the company has with Citibank, N.A., and it is disclosed alongside the older Five‑Year Credit Agreement dated October 30, 2019 (Exhibit 10.4) and its amendment (Exhibit 10.5). Together with the 364‑day facility (Exhibit 10.1) and the 2019 agreement, these exhibits illustrate the full suite of revolving credit facilities that Citibank administers for Boeing.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2023.pdf",
          "target_page": 126,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2023.pdf",
          "target_page": 126,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2023.pdf",
          "target_page": 125,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 64627,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16381,
        "completion_tokens": 116,
        "total_tokens": 16497
      }
    },
    {
      "question_id": 10,
      "question": "How does The Goldman Sachs Group, Inc.'s guarantee of Goldman Sachs Bank USA's obligations relate to the stricter 'Category I' capital and liquidity standards it is subject to under U.S. federal bank regulations?",
      "original_answer": "The Goldman Sachs Group, Inc. provides guarantees for certain obligations of Goldman Sachs Bank USA, as evidenced by the Amended and Restated General Guarantee Agreement dated September 28, 2018. This financial backing implies a direct corporate responsibility for the Bank USA's liabilities. Goldman Sachs Bank USA, in turn, is subject to 'Category I' standards under the Federal Reserve Board's Capital Framework because of the firm's designation as a global systemically important bank (G-SIB). These standards impose advanced risk-based capital and leverage requirements, which are quantitatively measured and also subject to qualitative regulatory judgment. The combination of direct liability guarantees and elevated regulatory scrutiny highlights the strategic and regulatory interdependence between the parent company and its banking subsidiary in maintaining financial stability.",
      "llm_answer": "The Goldman Sachs Group’s guarantee of Goldman Sachs Bank USA’s obligations subjects the bank to the stricter “Category I” capital and liquidity standards that apply to global systemically important banks (G‑SIBs). Because the bank is designated as a Category I institution, it must meet the more demanding risk‑based capital, leverage and liquidity buffers (including the G‑SIB surcharge, counter‑cyclical buffer and other Basel III‑derived requirements) that go beyond the standards applicable to other banks.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GS_10k_2024.pdf",
          "target_page": 248,
          "pages": [
            243,
            244,
            245,
            246,
            247
          ]
        },
        "hop_2_rel": {
          "source_file": "GS_10k_2024.pdf",
          "target_page": 14,
          "pages": [
            12,
            13,
            14,
            15,
            16
          ]
        },
        "hop_3_rel": {
          "source_file": "GS_10k_2024.pdf",
          "target_page": 14,
          "pages": [
            12,
            13,
            14,
            15,
            16
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 80759,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20421,
        "completion_tokens": 127,
        "total_tokens": 20548
      }
    },
    {
      "question_id": 10,
      "question": "How does ConocoPhillips' impairment of its APLNG investment in 2021 relate to its operational exposure in Queensland, Australia, particularly considering the structure of APLNG's long-term gas sales agreements in the region?",
      "original_answer": "ConocoPhillips impaired its APLNG investment by $688 million in 2021 due to a decline in fair value, as noted on page 119. APLNG operates in Queensland, Australia, where it produces coal bed methane (CBM) from the Bowen and Surat basins and exports LNG, primarily under long-term sales agreements, as detailed on page 100. Page 99 confirms ConocoPhillips' 37.5% ownership in APLNG, underscoring its significant operational exposure in Queensland. The impairment suggests that despite long-term contracts, market conditions or operational risks in Queensland may have negatively impacted the investment's valuation, highlighting a contrast between contractual stability and asset valuation risk.",
      "llm_answer": "ConocoPhillips' 2021 $688 million impairment of its APLNG investment stemmed from a decline in the fair value of that investment, which was driven by the structure of APLNG’s long‑term gas sales agreements and the resulting operational exposure to Queensland’s gas market.  The impairment reflected a market‑based valuation that fell below the carrying amount of the investment, prompting the write‑down.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 100,
          "pages": [
            98,
            99,
            100,
            101,
            102
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 65535,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16620,
        "completion_tokens": 101,
        "total_tokens": 16721
      }
    },
    {
      "question_id": 11,
      "question": "How does MET's disclosure of $72 million in collateral pledged to the FHLB of Des Moines in one section relate to the $2 million in liabilities reported to the same institution in another section, and what does this imply about MET's financial relationship with this counterparty?",
      "original_answer": "MET reports $72 million in collateral pledged to the FHLB of Des Moines in the collateral table on page 199, while on page 198, it shows only $2 million in liabilities to the same institution. This suggests that MET's exposure to the FHLB of Des Moines is primarily secured through collateral rather than direct liabilities, indicating a limited but collateral-backed financial relationship with this counterparty.",
      "llm_answer": "MET disclosed $72 million of collateral pledged to the FHLB of Des Moines in the “Obligations Under Funding Agreements” table, while the liability reported to that same institution was only $2 million. This disparity shows that the $72 million figure represents the estimated fair‑value of the collateral (primarily mortgage‑backed securities) that backs the FHLB’s funding agreements, whereas the $2 million liability reflects the actual outstanding funding‑agreement obligation of the Company to the FHLB of Des Moines. Consequently, MET’s financial relationship with the FHLB is that of a collateralized borrower: it receives cash from the FHLB in exchange for funding agreements that are secured by the pledged collateral, creating a contingent claim on the collateral that far exceeds the recorded liability.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 199,
          "pages": [
            197,
            198,
            199,
            200,
            201
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 199,
          "pages": [
            197,
            198,
            199,
            200,
            201
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 198,
          "pages": [
            196,
            197,
            198,
            199,
            200
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 233674,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 58663,
        "completion_tokens": 203,
        "total_tokens": 58866
      }
    },
    {
      "question_id": 11,
      "question": "How does MDLZ's inclusion of net investment hedge contracts within Level 2 financial liabilities reflect both the valuation methodology and the fair value disclosure practices for derivative instruments?",
      "original_answer": "MDLZ categorizes net investment hedge contracts as part of Level 2 financial liabilities, indicating that their fair value is determined using observable market inputs rather than quoted prices or unobservable data. Specifically, the fair value of these contracts is derived from an income approach based on observable market factors, aligning with the broader Level 2 valuation methodology. On page 111, the company discloses that the fair value of net investment hedge contracts was $71 million as of December 31, 2021, and this entire amount falls under Level 2 inputs, confirming that no Level 1 or Level 3 valuations are involved. This synthesis reveals that MDLZ relies on market-observable models for these contracts and transparently reports their fair value within the appropriate hierarchy level.",
      "llm_answer": "MDLZ’s Level 2 classification for net investment hedge contracts reflects that these derivatives—cross‑currency interest‑rate swaps and forwards used to hedge non‑U.S.‑dollar debt—are valued using observable market inputs (e.g., forward rates, observable market curves) rather than quoted prices in an active market, which aligns with the fair‑value disclosure requirement to present derivative instruments at their current fair value and to disclose the methodology (Level 2 inputs) used in that valuation. This approach ensures that the hedge’s fair‑value changes are transparently linked to observable market data while still being classified as a liability (or asset) in the financial statements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 111,
          "pages": [
            109,
            110,
            111,
            112,
            113
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 78234,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19784,
        "completion_tokens": 175,
        "total_tokens": 19959
      }
    },
    {
      "question_id": 11,
      "question": "How does Chevron's acquisition of Hess Corporation, valued at $53 billion, reflect compliance with the Hart-Scott-Rodino Act, and what implications does this have given the ongoing arbitration related to the Stabroek Block operating agreement?",
      "original_answer": "Chevron's acquisition of Hess Corporation, valued at $53 billion, required compliance with the Hart-Scott-Rodino Act, as evidenced by the FTC's review and the consent agreement entered into by Chevron, Hess, and the FTC to address antitrust concerns. Despite this regulatory clearance, the transaction remains subject to the outcome of an arbitration related to the Stabroek Block operating agreement, where a decision against Hess Guyana could prevent the deal from closing. This highlights a dual dependency: regulatory compliance under the Hart-Scott-Rodino Act was satisfied, but external legal uncertainties tied to Hess’s Guyana assets still pose a material risk to the completion of the acquisition.",
      "llm_answer": "Chevron’s $53 billion acquisition of Hess complies with the Hart‑Scott‑Rodino Act because the companies filed the required pre‑merger notification and are subject to the FTC’s consent agreement that cleared the deal, although completion remains contingent on the outcome of the Stabroek Block arbitration. The arbitration—potentially favoring Exxon and CNOOC over Hess—could block the transaction, creating a material risk that the merger may not close.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 104,
          "pages": [
            102,
            103,
            104,
            105,
            106
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 104,
          "pages": [
            102,
            103,
            104,
            105,
            106
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 93548,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 23626,
        "completion_tokens": 113,
        "total_tokens": 23739
      }
    },
    {
      "question_id": 11,
      "question": "How does Nike's foreign exchange hedging strategy for product cost exposures through the Nike Trading Company (NTC) align with the financial impact of U.S. Dollar fluctuations on inventory costs described in the transactional exposures section?",
      "original_answer": "Nike manages foreign exchange risk related to product cost exposures by using derivatives designated as cash flow hedge instruments, particularly for purchases made through the Nike Trading Company (NTC), which operates in U.S. Dollars and sells to Nike entities in their respective functional currencies. This creates foreign currency exposure for the NTC when selling to entities with different functional currencies. In the transactional exposures section, it is explained that a stronger U.S. Dollar increases inventory costs for Nike entities purchasing in non-functional currencies, while a weaker Dollar reduces these costs. This indicates that Nike’s hedging strategy through the NTC is designed to mitigate the financial volatility caused by these currency fluctuations, aligning with the broader risk management approach described in the transactional exposures section.",
      "llm_answer": "Nike's foreign exchange hedging strategy for product cost exposures through the Nike Trading Company (NTC) aligns with the financial impact of U.S. Dollar fluctuations on inventory costs by using cash flow hedges to offset foreign currency exposure from non-functional currency product purchases. Specifically, the NTC's sales to Nike entities with different functional currencies create foreign currency exposure for the NTC, and the company hedges this exposure to lessen the positive and negative effects of currency fluctuations on consolidated results of operations, financial position, and cash flows. As noted in the document, \"Product cost foreign currency exposures are primarily generated through non-functional currency denominated product purchases\" and the hedging program is designed to \"lessen both the positive and negative effects of currency fluctuations on the Company's consolidated results of operations, financial position and cash flows.\" The hedges are typically designated as cash flow hedges, with effective results classified in the same manner as the underlying exposure, and deferred gains/losses in accumulated other comprehensive income are reclassified to net income when the underlying hedged transactions affect earnings.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2024.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 89145,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22524,
        "completion_tokens": 313,
        "total_tokens": 22838
      }
    },
    {
      "question_id": 11,
      "question": "How does the foreign currency exposure associated with NTC's product sales to NIKE entities in different functional currencies impact the inventory cost management strategy, especially in light of NIKE's acquisition-related inventory holdings at held-for-sale entities as of May 31, 2022?",
      "original_answer": "NTC, which operates with the U.S. Dollar as its functional currency, sells products to NIKE entities in their respective functional currencies, creating foreign exchange exposure for the NTC. A stronger U.S. Dollar increases NIKE's product cost, while a weaker Dollar reduces it. This exposure is partially offset by NIKE’s foreign currency adjustment program with factories, which affects inventory cost recognition. As of May 31, 2022, NIKE reported $59 million of Inventories in held-for-sale entities, indicating that inventory cost fluctuations from foreign exchange could directly affect the valuation and profitability of these acquired/divested assets. This suggests that foreign exchange risk management is critical not only for ongoing operations but also for managing the financial implications of inventory in entities being divested.",
      "llm_answer": "The foreign currency exposure from NTC product sales to NIKE entities in differing functional currencies raises inventory costs when the U.S. Dollar strengthens, as higher purchase prices are incurred in foreign currencies that are then recorded in inventory. This exposure is managed through NTC’s sourcing model and the Company’s foreign currency adjustment program, which uses natural offsets and hedging to mitigate cost impacts. Additionally, NIKE’s acquisition-related inventory holdings at held-for-sale entities as of May 31, 2022, reflect the ongoing management of foreign currency risks in global supply chain operations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 81019,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20509,
        "completion_tokens": 157,
        "total_tokens": 20666
      }
    },
    {
      "question_id": 11,
      "question": "How does SPG's treatment of Simon's governance authority over the Operating Partnership influence the redemption terms and carrying value of the Series J 8 3/8% Cumulative Redeemable Preferred Stock as of December 31, 2024?",
      "original_answer": "SPG's governance structure gives Simon, as the sole general partner, full authority to make decisions regarding the Operating Partnership, including the redemption of preferred units and preferred stock. This control is evident in the Operating Partnership's structure, where Simon can elect to redeem preferred units either in cash or shares of common stock. In 2024, the redemption of 75,000 preferred units for $7.5 million and the resulting carrying value of $15.5 million for remaining preferred units reflect this discretion. Similarly, the Series J 8 3/8% Cumulative Redeemable Preferred Stock, issued at a $7.5 million premium, has an unamortized premium of $0.9 million as of December 31, 2024, and can be redeemed by Simon starting in 2027. The governance control Simon exerts directly affects the redemption policy and valuation of these instruments, linking the governance structure to the financial treatment of preferred equity.",
      "llm_answer": "The Series J 8 3⁄8 % Cumulative Redeemable Preferred Stock is classified in permanent equity, and its redemption price is fixed at $50 per share plus accrued dividends (subject to the Operating Partnership’s redemption rights). Because the Operating Partnership’s governance authority over the partnership determines whether redemption can be required, the redemption terms and the carrying value of the Series J preferred units are directly tied to Simon’s control over the Operating Partnership’s redemption provisions. Consequently, the carrying value of the Series J preferred stock ($0.9 million unamortized premium as of 12/31/2024) reflects the redemption price set by the partnership agreement, which is governed by Simon’s authority as sole general partner.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "hop_2_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 129,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        },
        "hop_3_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 129,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 73788,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18682,
        "completion_tokens": 191,
        "total_tokens": 18874
      }
    },
    {
      "question_id": 11,
      "question": "How does Amgen's stock-based compensation expense for performance units in 2024 relate to the maximum potential share issuance under the Amended 2009 Plan, given the plan's fungible share-counting formula and performance-based vesting conditions?",
      "original_answer": "Amgen reported a stock-based compensation expense of $133 million for performance units in 2024. These units are governed by the Amended 2009 Plan, which allows for up to 59 million shares available for future grants, calculated using a fungible share-counting formula where each performance unit counts as 1.9 shares. The plan also specifies that performance units can vest at up to 200% of the target grant based on performance outcomes. Therefore, the $133 million expense reflects the cost of units that may ultimately result in nearly double the number of shares being issued, depending on performance results, which directly affects the remaining share availability under the plan's formula.",
      "llm_answer": "Amgen's stock-based compensation expense for performance units in 2024 ($133 million) reflects the portion of the $87 million of unrecognized compensation cost related to non‑vested performance units that will be recognized over the next year, while the maximum potential share issuance under the Amended 2009 Plan is governed by the plan’s fungible share‑counting formula—each performance unit counts as 1.9 shares—so the 1.4 million outstanding performance units could generate up to roughly 2.7 million shares if the performance targets are fully achieved.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 124,
          "pages": [
            122,
            123,
            124,
            125,
            126
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 124,
          "pages": [
            122,
            123,
            124,
            125,
            126
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 92,
          "pages": [
            90,
            91,
            92,
            93,
            94
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 72148,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18277,
        "completion_tokens": 139,
        "total_tokens": 18417
      }
    },
    {
      "question_id": 11,
      "question": "How does American Express's discussion of regulatory pressure on interest rate caps in its supervision and regulation section influence its quantitative assumptions about repricing risk in the interest rate sensitivity analysis?",
      "original_answer": "American Express discusses regulatory scrutiny and potential caps on credit card interest rates in its supervision and regulation section (page 34), which introduces a qualitative risk around pricing constraints. This regulatory pressure directly affects the company's interest income model, as seen in the interest rate sensitivity analysis on page 81, where the company assumes repricing of interest-rate sensitive assets and liabilities is subject to applicable interest rate caps. The sensitivity analysis quantifies the risk by projecting a detrimental impact on net interest income under higher rate scenarios, assuming repricing aligned with benchmark movements but constrained by these caps. Therefore, the regulatory risk described qualitatively on page 34 is embedded into the quantitative modeling of repricing risk on page 81, showing how external constraints shape internal financial forecasting.",
      "llm_answer": "American Express’s supervision and regulation discussion warns that interest‑rate caps imposed by regulators could force the company to adjust its pricing and hedging strategies, which directly shapes the assumptions used in its interest‑rate sensitivity analysis. Consequently, the quantitative repricing‑risk calculations in the analysis incorporate the potential impact of those caps—assuming that certain rate‑sensitive assets and liabilities will reprice by the full benchmark movement only where caps do not limit such changes, and that some deposits will reprice by a smaller amount—reflecting the regulatory constraints on interest‑rate adjustments.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AXP_10k_2024.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_2_rel": {
          "source_file": "AXP_10k_2024.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "hop_3_rel": {
          "source_file": "AXP_10k_2024.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 77039,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19494,
        "completion_tokens": 164,
        "total_tokens": 19658
      }
    },
    {
      "question_id": 11,
      "question": "Given that UPS contributed $21 million in 2023 to the Employer-Teamsters Local Nos. 175 & 505 Pension Trust Fund, which is subject to an implemented Financial Improvement Plan (FIP), how does this contribution align with UPS's overall compliance strategy for red-zone pension funds under FIP requirements?",
      "original_answer": "UPS contributed $21 million in 2023 to the Employer-Teamsters Local Nos. 175 & 505 Pension Trust Fund, which is categorized as red-zone and under an implemented FIP. According to the FIP requirements section, UPS's contributions are aligned with the stipulations of implemented FIPs, and the company confirms that these contributions satisfy the necessary obligations without requiring additional surcharges. Furthermore, UPS emphasizes that collectively bargained contributions meet all FIP/RP requirements, indicating a proactive approach to managing underfunded pension liabilities.",
      "llm_answer": "UPS’s $21 million contribution to the Employer‑Teamsters Local Nos. 175 & 505 Pension Trust Fund—classified as a red‑zone plan with an implemented Financial Improvement Plan—fits within its overall compliance strategy by satisfying the mandatory funding obligations set out in the collective bargaining agreement and the Pension Protection Act. Because the plan’s FIP/RP has already been implemented, UPS’s collectively‑bargained contribution meets the required funding levels and avoids any additional surcharge, ensuring continued compliance with the red‑zone pension fund’s regulatory and contractual requirements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 87500,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22124,
        "completion_tokens": 154,
        "total_tokens": 22278
      }
    },
    {
      "question_id": 11,
      "question": "How does ConocoPhillips' characterization of coalbed methane (CBM) as a distinct raw material in disclosures relate to their equity investment write-down in APLNG, given APLNG's role in producing and exporting CBM-derived LNG?",
      "original_answer": "ConocoPhillips identifies coalbed methane (CBM) as a distinct raw material in their disclosures, highlighting its importance in upstream operations. APLNG, in which ConocoPhillips holds a significant stake, is specifically focused on producing CBM from the Bowen and Surat basins in Queensland, Australia, and converting it into LNG for export. In 2021, ConocoPhillips exercised its preemption right to purchase an additional 10% interest in APLNG; however, due to a market participant valuation below the carrying value, the company wrote down its investment to a fair value of $5,574 million, incurring a $688 million pre-tax charge. This write-down reflects the financial impact of market conditions on an asset central to CBM-based LNG production, illustrating how the valuation of a core raw material (CBM) directly affects the financial treatment of downstream infrastructure and equity investments.",
      "llm_answer": "ConocoPhillips explicitly characterizes coalbed methane (CBM) as a distinct raw material in its disclosures, noting that APLNG converts CBM into LNG for export. This distinction is directly tied to its equity investment in APLNG, where the company recognized a $688 million write-down of its APLNG investment in 2021 after determining the fair value of its existing stake was below its carrying value—likely influenced by the unique economics of CBM-derived LNG production.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 3,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 63237,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16048,
        "completion_tokens": 118,
        "total_tokens": 16166
      }
    },
    {
      "question_id": 12,
      "question": "How does MetLife's exposure to interest rate sensitivity in Structured Settlements, as part of the Retirement and Income Solutions business, align with the segment's broader positioning and strategic emphasis on capital market products in a low-rate environment?",
      "original_answer": "MetLife's Retirement and Income Solutions (RIS) business includes Structured Settlements, which are sensitive to interest rate changes due to their long-duration liabilities and fixed-income asset backing. In a declining interest rate scenario (as noted on page 61), this exposure leads to gross margin compression because the company cannot lower crediting rates on certain products, such as retained asset accounts and disability policy claim reserves, which are at their minimum crediting rates. To mitigate this, MetLife uses interest rate derivatives. Meanwhile, page 9 emphasizes RIS's strategic role in offering capital market products and pension risk transfers, suggesting a focus on managing longevity and interest rate risk through structured financial solutions. This aligns with the broader positioning of RIS as a capital-intensive, risk-transfer-oriented business that must actively manage asset-liability mismatches, especially in a low-rate environment where reinvestment yields are compressed. The inclusion of Structured Settlements within RIS (as detailed on page 184) underscores their integration into a portfolio designed to manage long-duration liabilities through both product design and hedging strategies.",
      "llm_answer": "MetLife's exposure to interest rate sensitivity in Structured Settlements—part of its Retirement and Income Solutions (RIS) segment—aligns with the segment's broader positioning as a capital market product driver in a low-rate environment. While RIS leverages capital market products to generate income, the document notes that declining interest rates would negatively impact adjusted earnings through lower reinvestment yields and derivative income, whereas rising rates would provide a net favorable impact due to higher-yielding reinvestments, partially offset by increased crediting rates. This underscores RIS's strategic emphasis on capital market products, but also highlights its vulnerability to interest rate shifts, particularly in a low-rate setting where reinvestment risks and margin compression are heightened.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 61,
          "pages": [
            59,
            60,
            61,
            62,
            63
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 184,
          "pages": [
            182,
            183,
            184,
            185,
            186
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 77628,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19655,
        "completion_tokens": 206,
        "total_tokens": 19861
      }
    },
    {
      "question_id": 12,
      "question": "How does Altria's reliance on PM USA's unconditional guarantees for $3.0 billion in debt obligations reconcile with the indemnification framework under the Distribution Agreement, where PMI and PM USA only partially indemnify each other for tobacco-related liabilities based on manufacturing responsibility?",
      "original_answer": "Altria Group, Inc. (MO) depends on PM USA as a guarantor for its $3.0 billion Credit Agreement and other debt obligations, with PM USA providing unconditional guarantees that are not limited by contingent liabilities. However, under the Distribution Agreement following the 2008 spin-off of PMI, indemnification for tobacco-related liabilities between PM USA and PMI is conditional and based on manufacturing responsibility—PMI indemnifies Altria and PM USA only for liabilities related to products it manufactured or had contract manufactured, and vice versa. This creates a potential misalignment: PM USA guarantees Altria’s full debt obligations without limitation, yet its indemnification exposure to Altria is restricted to only those liabilities tied to its own manufacturing, which could expose PM USA to disproportionate financial risk relative to the indemnification protections it receives.",
      "llm_answer": "Altria’s $3 billion debt‑guarantee framework is covered by the unconditional guarantees that PM USA provides to Altria under the Distribution Agreement, which obligate PM USA to fully and unconditionally guarantee Altria’s debt‑related obligations. This guarantee structure operates alongside the limited indemnification provisions in the Distribution Agreement, where PMI and PM USA only share responsibility for tobacco‑related liabilities based on manufacturing ownership, but the debt guarantees remain absolute and unconditional, ensuring that Altria’s $3 billion of debt obligations are backed without any carve‑outs for the partial indemnity scheme.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 51,
          "pages": [
            49,
            50,
            51,
            52,
            53
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 65961,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16745,
        "completion_tokens": 164,
        "total_tokens": 16909
      }
    },
    {
      "question_id": 12,
      "question": "How does Gilead's revenue recognition approach for Symtuza, which is commercialized by Janssen, reflect the contractual revenue-sharing terms and the accounting treatment of the intellectual property and supply obligations outlined in the collaboration agreement?",
      "original_answer": "Gilead recognizes its share of Symtuza revenue in the period when Janssen reports corresponding sales, as the license to the Gilead Compounds is deemed the predominant item in the agreement. This approach aligns with the contractual terms where Janssen sets the price of Symtuza and both parties share revenue based on the ratio of the net selling prices of their respective components, subject to restrictions and adjustments. Additionally, the intellectual property license and supply obligations related to the Gilead Compounds are accounted for as a single performance obligation, which supports the timing and pattern of revenue recognition. This treatment reflects Gilead's role as the exclusive supplier of the Gilead Compounds and its ongoing involvement in the intellectual property underpinning Symtuza.",
      "llm_answer": "Gilead recognizes revenue from Symtuza under a contractual revenue‑sharing arrangement with Janssen, where Janssen commercializes the product and shares net sales revenue based on the relative net selling prices of the component drugs; Gilead supplies the Gilead‑derived compounds and holds the related intellectual‑property rights, and the license and supply obligations are treated as a single performance obligation, so Gilead records its share of Symtuza sales as product revenue when Janssen’s sales occur.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "target_page": 40,
          "pages": [
            38,
            39,
            40,
            41,
            42
          ]
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "target_page": 78,
          "pages": [
            76,
            77,
            78,
            79,
            80
          ]
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "target_page": 79,
          "pages": [
            77,
            78,
            79,
            80,
            81
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 80787,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20441,
        "completion_tokens": 127,
        "total_tokens": 20568
      }
    },
    {
      "question_id": 12,
      "question": "How does ConocoPhillips' $210 million maximum exposure under its APLNG guarantee relate to its production of CBM in the Bowen and Surat basins, and how might this liability impact the company's strategic positioning in Australian LNG markets?",
      "original_answer": "ConocoPhillips has a $210 million maximum exposure under a guarantee related to its 47.5% ownership in APLNG, which is responsible for producing CBM from the Bowen and Surat basins in Queensland, Australia. APLNG processes and exports LNG derived from this CBM, which is central to ConocoPhillips' strategic positioning in the region. The liability associated with this guarantee, although currently carried at $14 million, represents a contingent risk tied directly to APLNG’s ability to meet its financial obligations. Given that APLNG is a core asset for CBM production and LNG export in Australia, any material drawdown on this guarantee could affect ConocoPhillips' investment returns and strategic flexibility in the region. This risk must be weighed against the company's stated access to CBM resources and its long-term LNG market commitments in Asia Pacific.",
      "llm_answer": "ConocoPhillips’ maximum exposure under its APLNG guarantee is approximately $210 million, which represents the company’s contingent liability if enforcement actions are taken against APLNG. This exposure is tied to its 47.5 % ownership of APLNG, the joint venture that produces coal‑bed methane (CBM) from the Bowen and Surat basins in Queensland, Australia, and processes and exports LNG. Because the guarantee could require ConocoPhillips to cover up to $210 million in obligations should APLNG fail to meet its commitments, the liability adds a non‑trivial risk to its strategic positioning in the Australian LNG market, potentially limiting flexibility in capital allocation and affecting investor perception of its exposure to downstream LNG projects.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 63691,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16162,
        "completion_tokens": 189,
        "total_tokens": 16351
      }
    },
    {
      "question_id": 12,
      "question": "How does BKNG's reliance on meta-search marketing channels, which contributed significantly to traffic in 2021, relate to its ownership stake in KAYAK, which itself provides meta-search services, and what does this imply about the strategic alignment and financial valuation of KAYAK within BKNG's portfolio?",
      "original_answer": "BKNG relies on meta-search and travel research websites as a key marketing channel, contributing significantly to traffic and tied directly to growth and ROI objectives. KAYAK, which is owned by BKNG, is a meta-search platform offering price comparisons across hundreds of travel platforms, operating in over 60 countries. Despite this strategic alignment, BKNG recorded a $1.1 billion goodwill impairment charge for KAYAK in 2020, indicating a disconnect between KAYAK’s expected strategic value and its financial performance. This suggests that while KAYAK's meta-search capabilities align with BKNG’s marketing and traffic acquisition strategy, its financial valuation and performance fell short of expectations, raising questions about the effectiveness of internal integration and the return on strategic ownership.",
      "llm_answer": "BKNG’s heavy reliance on meta‑search channels—primarily through its KAYAK subsidiary—directly fuels the traffic that drives its agency‑revenue streams, while its ownership stake in KAYAK aligns strategically with the company’s broader goal of expanding a global, AI‑enabled “Connected Trip” and diversifying its revenue base beyond pure merchant bookings. This integration positions KAYAK as a high‑growth, high‑margin asset that enhances BKNG’s overall valuation, as its meta‑search traffic contributes significantly to gross bookings and advertising revenue, supporting a more resilient, scalable portfolio.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BKNG_10k_2022.pdf",
          "target_page": 62,
          "pages": [
            60,
            61,
            62,
            63,
            64
          ]
        },
        "hop_2_rel": {
          "source_file": "BKNG_10k_2022.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        },
        "hop_3_rel": {
          "source_file": "BKNG_10k_2022.pdf",
          "target_page": 66,
          "pages": [
            64,
            65,
            66,
            67,
            68
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 58643,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14918,
        "completion_tokens": 152,
        "total_tokens": 15070
      }
    },
    {
      "question_id": 12,
      "question": "Given that forecasted transactions are excluded from Disney's VAR model for risk analysis, how does the company's use of foreign exchange hedging instruments on forecasted transactions reconcile with the limitations of its VAR model in capturing potential losses from these exposures?",
      "original_answer": "Disney's VAR model excludes forecasted transactions, firm commitments, and foreign-denominated receivables/payables from its risk analysis, focusing instead on existing financial instruments like debt, derivatives, and equity investments. The VAR model estimates a maximum one-day loss of $255 million at September 28, 2024, based on a 95% confidence level and assumes normal market conditions. However, the company actively manages foreign exchange risk on forecasted transactions through forward and option contracts, with $9.9 billion in notional hedging exposure as of September 28, 2024. These hedging instruments are designated as cash flow hedges and their gains or losses are deferred in AOCI until the forecasted transactions occur. This suggests that while the VAR model does not account for forecasted transactions, Disney mitigates the risk associated with these transactions through proactive hedging strategies, which are separately accounted for and disclosed in the financial statements.",
      "llm_answer": "The Company’s VAR model explicitly excludes forecasted transactions from its risk‑analysis calculations, yet it hedges those same forecasted foreign‑exchange exposures using cash‑flow and forward contracts to protect the U.S.‑dollar value of expected revenues and costs. This creates a reconciliation gap: the VAR model cannot capture potential losses from the very hedges it omits, so the company must rely on separate hedge accounting and sensitivity analyses to assess the financial impact of those excluded exposures.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 66790,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16947,
        "completion_tokens": 130,
        "total_tokens": 17077
      }
    },
    {
      "question_id": 12,
      "question": "How does Disney's exclusion of firm commitments from its Value at Risk (VAR) model impact the assessment of its foreign exchange risk exposure, given the $9.9 billion in net foreign exchange cash flow hedges outstanding as of September 28, 2024?",
      "original_answer": "Disney utilizes a VAR model to estimate its maximum potential one-day loss across financial instruments, but explicitly excludes firm commitments and forecasted transactions from this model, even though these are the very exposures that its foreign exchange hedging program is designed to mitigate. As of September 28, 2024, Disney had $9.9 billion in net foreign exchange cash flow hedges in place to protect against fluctuations in currencies like the euro and Japanese yen. This suggests that while the VAR model provides a quantitative risk metric under normal market conditions, it does not fully capture the risk profile associated with these hedged firm commitments and forecasted transactions. Therefore, the stated VAR of $255 million at fiscal year-end may understate the true exposure that Disney manages through its active hedging program.",
      "llm_answer": "Disney’s foreign‑exchange VAR model deliberately omits firm commitments, even though it hedges about $9.9 billion of net foreign‑exchange cash‑flow contracts. Because those commitments are excluded, the VAR‑based estimate of potential one‑day fair‑value loss (≈ $40 million for currency‑sensitive instruments) does not capture the full risk associated with the $9.9 billion of hedged cash‑flow exposures. Consequently, the VAR figure understates the company’s true foreign‑exchange risk, and the actual risk‑mitigating effect of its hedging program cannot be fully reflected in the reported market‑risk metrics.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 67988,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17236,
        "completion_tokens": 152,
        "total_tokens": 17389
      }
    },
    {
      "question_id": 12,
      "question": "How does the treatment of the VIL OCDs in the property and equipment footnote reconcile with the impairment charges recorded for VIL-related intangible assets and the strategic review of the India business?",
      "original_answer": "The VIL OCDs, valued at $116.5 million upon issuance and totaling INR 16.0 billion (~$193.2 million), are disclosed in the property and equipment footnote as part of AMT's assets. These OCDs represent a financial instrument issued by VIL, a key tenant in India, which had previously caused payment uncertainty and partial payments in 2022 and early 2023, leading to impairment charges of $411.6 million on VIL-specific tenant-related intangible assets. Despite VIL resuming full payments in the second half of 2023, the uncertainty surrounding its financial stability contributed to a broader strategic review of AMT's India operations, culminating in the Pending ATC TIPL Transaction. This strategic move, along with updated fair value estimates, led to a $322.0 million goodwill impairment charge for the India reporting unit in Q3 2023. Thus, while the VIL OCDs are treated as an asset in the property and equipment section, they are also central to the impairment and strategic risk analysis in the India segment, reflecting both the financial and strategic challenges tied to VIL.",
      "llm_answer": "The impairment charges recorded for VIL‑related intangible assets and the goodwill impairment recognized in 2023 reflect the uncertainty and payment shortfalls experienced with VIL in India, which were identified during the strategic review of the India business; this review concluded with the Pending ATC TIPL transaction and led to updated fair‑value assessments that resulted in additional goodwill and other impairment charges. Consequently, the treatment of the VIL OCDs as a recoverable asset in the property and equipment footnote aligns with the impairment charges recorded for VIL‑related intangible assets and the strategic review’s assessment of the India market’s recoverability.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMT_10k_2023.pdf",
          "target_page": 98,
          "pages": [
            96,
            97,
            98,
            99,
            100
          ]
        },
        "hop_2_rel": {
          "source_file": "AMT_10k_2023.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_3_rel": {
          "source_file": "AMT_10k_2023.pdf",
          "target_page": 58,
          "pages": [
            56,
            57,
            58,
            59,
            60
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 81027,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20490,
        "completion_tokens": 173,
        "total_tokens": 20663
      }
    },
    {
      "question_id": 12,
      "question": "How does FedEx's emphasis on maintaining service commitments to customers, including its integrated global air network flexibility, reconcile with the risk posed by the USPS's strategic shift away from air transportation and its competitive positioning in the domestic delivery market?",
      "original_answer": "FedEx emphasizes the importance of maintaining service commitments to customers, supported by the flexibility of its integrated global air network, which allows interchangeable use of aircraft across routes and geographies to adapt to changing economic conditions. However, the USPS, FedEx's largest customer for domestic air transportation, is actively reducing its reliance on FedEx's air network as part of its own strategic changes, which has already negatively impacted FedEx's results of operations in 2022. Additionally, the USPS is not only a major client but also a competitor in the domestic delivery market, further complicating FedEx’s ability to maintain service levels and pricing power while managing the loss of a key revenue source. This dynamic highlights the dual challenge FedEx faces: sustaining its service commitments amid operational flexibility while confronting a major client’s strategic withdrawal and competitive pressure in the same market.",
      "llm_answer": "FedEx emphasizes maintaining service commitments through its integrated global air network, which provides flexibility to meet customer demands across its worldwide operations. However, this approach faces competitive pressure from USPS's strategic shift away from air transportation and its evolving role in the domestic delivery market, potentially challenging FedEx's market positioning.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "FDX_10k_2022.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "hop_2_rel": {
          "source_file": "FDX_10k_2022.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_3_rel": {
          "source_file": "FDX_10k_2022.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 80603,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20404,
        "completion_tokens": 97,
        "total_tokens": 20501
      }
    },
    {
      "question_id": 12,
      "question": "How does Duke Energy Progress' use of Storm Recovery Bonds in 2023 to finance $177 million in storm costs relate to its consolidation of DEPNC SF, and what does this imply about the company's approach to managing long-term storm-related liabilities?",
      "original_answer": "Duke Energy Progress utilized Storm Recovery Bonds in 2023 to finance $177 million in historical storm-related costs, which were then securitized through a special purpose subsidiary, DEPNC SF. As a bankruptcy-remote, wholly owned entity, DEPNC SF was formed specifically to issue these bonds and acquire storm recovery property, which grants the right to collect non-bypassable charges from retail customers. Since Duke Energy Progress consolidates DEPNC SF, the company retains control over the entity's operations despite its separate legal structure. This approach reflects a structured financing mechanism that allows Duke Energy Progress to recover storm-related regulatory assets over time, while isolating the associated debt within a VIE structure, minimizing broader balance sheet impact.",
      "llm_answer": "Duke Energy Progress financed $177 million of storm‑related costs in 2024 through a new issuance of storm‑recovery bonds, which were backed by a non‑bypassable charge to its North and South Carolina retail customers.  This financing mechanism is part of the company’s broader strategy to consolidate and manage long‑term storm‑related liabilities, allowing it to recover these expenses over time through regulated rates rather than absorbing them directly into earnings.  By securitizing the costs, Duke Energy Progress can spread the burden across ratepayers and maintain more stable financial performance while the underlying regulatory assets and liabilities continue to be reflected on its balance sheet.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 152,
          "pages": [
            150,
            151,
            152,
            153,
            154
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 205,
          "pages": [
            203,
            204,
            205,
            206,
            207
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 205,
          "pages": [
            203,
            204,
            205,
            206,
            207
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 103621,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 26147,
        "completion_tokens": 177,
        "total_tokens": 26324
      }
    },
    {
      "question_id": 12,
      "question": "How does Mastercard's reliance on technology companies for innovation, including risks related to intellectual property and talent acquisition, interact with the threat posed by those same partners developing competitive products that could disintermediate Mastercard from digital payments?",
      "original_answer": "Mastercard acknowledges on page 32 that it works closely with technology companies to enhance payment safety and deliver services efficiently, but also highlights risks such as difficulty attracting technology experts and potential patent infringement claims from third parties. These challenges could hinder its ability to develop and adopt new technologies. On page 31, the company warns that these same technology companies could develop competing platforms that disintermediate Mastercard from digital payments, especially if data-sharing arrangements provide them with a competitive advantage. Furthermore, the emergence of competitive products from these partners could force Mastercard to alter pricing models or lose market share, particularly in light of regulatory changes like PSD2 that enable third-party providers to route transactions away from its network. The combination of innovation dependency and competitive risk creates a strategic tension where collaboration could inadvertently accelerate disintermediation, undermining Mastercard’s role in the digital economy.",
      "llm_answer": "Mastercard’s strategy of partnering with technology firms to drive innovation creates a paradox: while these collaborations provide access to cutting‑edge capabilities and talent, they also expose the company to the risk that those same partners could develop competing platforms or products that bypass Mastercard’s network, thereby disintermediating it from digital‑payment flows and eroding its competitive position. This dynamic intensifies the need for Mastercard to safeguard intellectual‑property rights, manage talent acquisition, and maintain control over shared data, lest its partners become direct rivals capable of replacing its core payment‑switching services.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MA_10k_2022.pdf",
          "target_page": 32,
          "pages": [
            30,
            31,
            32,
            33,
            34
          ]
        },
        "hop_2_rel": {
          "source_file": "MA_10k_2022.pdf",
          "target_page": 31,
          "pages": [
            29,
            30,
            31,
            32,
            33
          ]
        },
        "hop_3_rel": {
          "source_file": "MA_10k_2022.pdf",
          "target_page": 31,
          "pages": [
            29,
            30,
            31,
            32,
            33
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 87956,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22234,
        "completion_tokens": 168,
        "total_tokens": 22403
      }
    },
    {
      "question_id": 12,
      "question": "How does the involvement of DeGolyer and MacNaughton in reviewing over 85% of ConocoPhillips' proved reserves estimation processes align with their role as a third-party consultant whose report is explicitly included as Exhibit 99 in the 10-K filing?",
      "original_answer": "ConocoPhillips discloses that DeGolyer and MacNaughton (D&M) reviewed over 85% of its proved reserves estimation processes to ensure compliance with SEC regulations and internal controls. This review was conducted to obtain independent third-party validation of the company’s reserves estimation methodology. D&M’s findings, which concluded that ConocoPhillips’ processes were in accordance with SEC definitions, are included as Exhibit 99 in the 10-K filing. This demonstrates a direct alignment between D&M’s role as an independent reviewer and the formal documentation of their findings, reinforcing the credibility and transparency of ConocoPhillips’ reserves reporting.",
      "llm_answer": "The involvement of DeGolyer and MacNaughton as an independent third‑party consultant whose review covered more than 85 % of ConocoPhillips’ proved reserves was explicitly disclosed in the filing, and their assessment and opinion are included as Exhibit 99 of the 10‑K, confirming that their role aligns with the consultant function described in the reserves‑governance discussion.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 166,
          "pages": [
            164,
            165,
            166,
            167,
            168
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 77716,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19671,
        "completion_tokens": 95,
        "total_tokens": 19766
      }
    },
    {
      "question_id": 12,
      "question": "How does the $1.007 billion in storm recovery bonds issued by Duke Energy Carolinas and Progress in 2021 relate to the restricted cash balances reported under the Cash, Cash Equivalents and Restricted Cash section, and what does this imply about the financial structure of storm cost recovery?",
      "original_answer": "Duke Energy Carolinas and Duke Energy Progress issued $237 million and $770 million, respectively, in storm recovery bonds in November 2021, forming a total of $1.007 billion in financing to recover storm costs from 2018 and 2019. These bonds are secured by storm recovery property, which includes the right to impose non-bypassable charges on retail customers until the bonds are fully paid. The bond issuance is linked to restricted cash balances reported on page 127, which are specifically tied to VIEs (Variable Interest Entities) formed for storm recovery bonds. This implies that the financial structure of storm cost recovery is asset-backed and ring-fenced through special-purpose entities, with restricted cash serving as collateral to ensure bondholder security without recourse to the parent companies.",
      "llm_answer": "The $1.007 billion of storm‑recovery bonds issued by Duke Energy Carolinas and Duke Energy Progress in 2021 is reflected in the “Restricted cash balances” line of the Cash, Cash Equivalents and Restricted Cash disclosure.  Those restricted cash balances (reported in “Other” within current assets) are funded by the bond proceeds and are used to finance the storm‑related regulatory assets, illustrating that storm‑cost recovery is structured through VIE‑issued bonds that are backed by non‑bypassable customer charges and recorded as restricted cash on the utilities’ balance sheets.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 194,
          "pages": [
            192,
            193,
            194,
            195,
            196
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 194,
          "pages": [
            192,
            193,
            194,
            195,
            196
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 127,
          "pages": [
            125,
            126,
            127,
            128,
            129
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 93832,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 23711,
        "completion_tokens": 146,
        "total_tokens": 23857
      }
    },
    {
      "question_id": 13,
      "question": "Given PM USA's role in guaranteeing Altria's debt obligations and its posting of $50 million in appeal bonds collateralized by restricted cash, how does Altria's liquidity risk profile reflect both its legal exposure through PM USA's litigation liabilities and its structural financial guarantees?",
      "original_answer": "Altria's liquidity risk is heightened by PM USA's legal exposure, which includes over $896 million in cumulative payments for adverse tobacco-related litigation judgments and settlements as of December 31, 2021. To maintain appeal stays, PM USA has posted $50 million in appeal bonds backed by restricted cash, directly impacting Altria's liquidity by tying up capital that could otherwise be used for operations or debt servicing. Furthermore, PM USA fully and unconditionally guarantees Altria's debt obligations, meaning that if Altria defaults, PM USA must fulfill these liabilities. However, if PM USA itself becomes insolvent or is unable to meet its own obligations due to litigation costs, the guarantees could be voided under fraudulent conveyance laws, leaving Altria's creditors exposed. This dual exposure—through both litigation risk and structural guarantees—creates a complex liquidity risk profile where Altria's financial health is tightly linked to PM USA's legal and financial stability.",
      "llm_answer": "Altria’s liquidity risk is heightened by its legal exposure stemming from PM USA’s ongoing tobacco‑related litigation, which can generate substantial judgments, settlements, and related interest costs that must be funded. At the same time, Altria’s structural financial guarantees—particularly PM USA’s posting of roughly $50 million in appeal bonds that are collateralized with restricted cash—create additional contingent outflows that must be supported by operating cash flows and external financing. Together, these factors mean Altria must maintain strong cash‑generation capacity and access to capital markets to meet both its litigation‑related liabilities and its debt‑service and guarantee obligations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 59,
          "pages": [
            57,
            58,
            59,
            60,
            61
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 51,
          "pages": [
            49,
            50,
            51,
            52,
            53
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 70960,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17996,
        "completion_tokens": 177,
        "total_tokens": 18174
      }
    },
    {
      "question_id": 13,
      "question": "How does AbbVie's ongoing exposure to securities litigation tied to Allergan's textured breast implants and generic drug pricing practices reconcile with the strategic rationale provided for the $120.30 per share cash and stock acquisition of Allergan in 2020?",
      "original_answer": "AbbVie's 2020 acquisition of Allergan for $120.30 per share in cash and stock aimed to diversify its business across multiple therapeutic areas, including aesthetics and generics. However, post-acquisition, AbbVie inherited ongoing securities litigation against Allergan related to its textured breast implants (In re: Allergan plc Securities Litigation) and alleged anticompetitive conduct in its former Actavis generics unit (In re: Allergan Generic Drug Pricing Securities Litigation), with class certification granted in both cases by 2021. These legal risks, which were still pending or recently settled as of 2022, could expose AbbVie to significant financial liabilities and reputational damage, potentially undermining the strategic benefits of diversification and commercial strength that the acquisition was intended to deliver.",
      "llm_answer": "The $120.30 per share cash and stock price paid for Allergan reflects the strategic rationale of gaining access to its diversified portfolio (including immunology and aesthetics) and pipeline, which justified the premium despite the ongoing litigation risks tied to Allergan’s textured breast implants and generic drug pricing practices that remain part of AbbVie’s broader legal exposure.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "target_page": 134,
          "pages": [
            111,
            112,
            113,
            114,
            115
          ]
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "target_page": 134,
          "pages": [
            111,
            112,
            113,
            114,
            115
          ]
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 12,
        "total_chars": 56480,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14363,
        "completion_tokens": 97,
        "total_tokens": 14461
      }
    },
    {
      "question_id": 13,
      "question": "How does HD's accrual of dividend equivalents on performance shares and restricted stock units compare with the treatment of dividend equivalents on deferred shares granted to non-employee directors, and what does this reveal about the company's stock-based compensation strategy for different stakeholder groups?",
      "original_answer": "HD accrues dividend equivalents on performance shares and restricted stock units as reinvested shares, which are paid out upon vesting or award payout. For performance shares, this is tied to a three-year performance cycle based on ROIC and operating profit, while for restricted stock units, it occurs upon vesting, which can be up to five years after the grant date. In contrast, dividend equivalents on deferred shares granted to non-employee directors accrue and are paid out in the form of additional shares upon termination of Board service. This reveals a strategic distinction in HD's stock-based compensation: performance-based and time-vesting equity awards for associates emphasize long-term alignment with company performance and retention, while deferred shares for non-employee directors focus on service duration and post-service value retention. The immediate expensing of deferred shares also contrasts with the multi-year expense recognition for performance shares and restricted stock units, highlighting a differentiated approach to stakeholder compensation.",
      "llm_answer": "HD's accrual of dividend equivalents on performance shares and restricted stock units is treated consistently with the accrual of dividend equivalents on deferred shares granted to non-employee directors: dividend equivalents accrue on unvested awards (performance shares, restricted stock units, and deferred shares) and are paid out in cash or additional shares upon vesting or payout, with the fair value of the awards based on the closing stock price at grant and expensed over the restriction period. This approach reflects a uniform strategy for all stakeholder groups under the stock-based compensation plans, ensuring that dividend equivalents are systematically accrued and recognized as part of the overall compensation expense for both employee and non-employee director awards.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "HD_10k_2023.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_2_rel": {
          "source_file": "HD_10k_2023.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_3_rel": {
          "source_file": "HD_10k_2023.pdf",
          "target_page": 52,
          "pages": [
            50,
            51,
            52,
            53,
            54
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 66783,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16951,
        "completion_tokens": 197,
        "total_tokens": 17148
      }
    },
    {
      "question_id": 13,
      "question": "How does Intel's strategic rationale for entering into the NAND wafer manufacturing agreement with SK hynix relate to the timing and structure of the divestiture of its NAND memory business, particularly in light of the continued use of the Dalian fabrication facility?",
      "original_answer": "Intel's strategic rationale for entering into the NAND wafer manufacturing agreement with SK hynix was to maintain continuity in NAND wafer production while transitioning ownership of the NAND business. This agreement was structured as part of a two-stage divestiture initiated in October 2020 and finalized in 2022, with the first closing in December 2021 involving the sale of the NAND SSD Business and the Dalian fabrication facility. The agreement ensured that Intel could continue manufacturing NAND wafers using the Dalian facility until the second closing, allowing SK hynix to ramp up operations while Intel phased out its involvement. This transitional manufacturing arrangement reflects Intel's strategic goal of exiting the NAND memory business while maintaining short-term supply chain stability for both parties.",
      "llm_answer": "Intel’s strategic rationale for entering the NAND wafer manufacturing agreement with SK hynix was to preserve a revenue stream from its Dalian fabrication facility while it divested the NAND memory business, allowing the company to monetize existing wafer production until the second closing of the transaction. This arrangement supports the broader divestiture plan by leveraging the Dalian fab for wafer sales to SK hynix, even as Intel fully de‑consolidates its NAND OpCo interests in early 2022.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_2_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_3_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 30751,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 7928,
        "completion_tokens": 124,
        "total_tokens": 8053
      }
    },
    {
      "question_id": 13,
      "question": "How does the treatment of Class B stock in the net income per share calculation relate to the use of Class C stock in employee compensation plans, given the company's approach to share repurchases?",
      "original_answer": "The company's net income per share calculation treats Class B stock as convertible for the purpose of computing diluted earnings per share of Class A stock, but does not assume conversion of Class B shares when calculating their own diluted earnings per share. This distinction affects how earnings are distributed across share classes. Meanwhile, Class C shares are actively used in employee compensation plans, with over $21.7 billion in stock-based compensation expenses tied to equity awards in 2023, and 723 million shares reserved for future issuance under the Alphabet 2021 Stock Plan. The company's share repurchase program, which includes both Class A and Class C shares, is executed based on market conditions and economic cost considerations. This creates a dynamic where Class C shares are both issued for compensation and repurchased from the market, while Class B shares are primarily retained for voting control purposes without active issuance or repurchase. The interplay between these share classes reflects a capital structure strategy that balances employee incentives, earnings allocation, and shareholder value management.",
      "llm_answer": "The company's Class B stock is treated as having equal dividend and liquidation rights to Class A and Class C shares, but it carries 10 votes per share and can be converted to Class A shares. This structure means that when calculating net income per share using the two-class method, the allocation of undistributed earnings to Class B is based on the same per-share rights as the other classes, even though Class B shares have more voting power. The company's share repurchase program, which targets Class A and Class C shares, does not directly affect the net income per share calculation for Class B, as the earnings allocation is determined by contractual rights rather than the number of shares repurchased.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "hop_2_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "hop_3_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 90121,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22754,
        "completion_tokens": 178,
        "total_tokens": 22932
      }
    },
    {
      "question_id": 13,
      "question": "How does the non-dilutable 33 1/3% voting power of Class B common stock influence the potential impact of dividend decisions on the voting structure and shareholder control dynamics, especially considering the 8% dividend increase approved by the Board in January 2022?",
      "original_answer": "The 8% dividend increase approved by the Board in January 2022 applies to both Class A and Class B common stock, but the structural voting disparity remains intact due to the non-dilutable 33 1/3% voting power of Class B shares, which are entirely owned by Brian L. Roberts. This means that while both classes of stock benefit from the dividend increase, the control dynamics are not affected because Class B shares retain disproportionate influence over corporate decisions, including mergers, asset sales, and amendments to the corporate charter. This creates a scenario where economic returns to shareholders (via dividends) are aligned across both classes, but governance control remains concentrated in the hands of the CEO through Class B voting rights.",
      "llm_answer": "The non‑dilutable 33 ⅓ % voting power of the Class B common stock—held entirely by Brian L. Roberts—means that even after the Board’s 8 % dividend increase to $1.08 per share (approved in January 2022), the Class B shares continue to control roughly one‑third of the total voting power. Because this voting interest is generally non‑dilutable, any future issuance of Class A shares or other equity that could dilute the percentage of Class B voting power is limited, preserving Roberts’ ability to influence key corporate actions (such as director elections and major transactions) despite the dividend change. Consequently, dividend decisions do not alter the underlying voting structure, and the concentration of voting power remains a dominant factor shaping shareholder control dynamics.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 12,
        "total_chars": 50822,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12948,
        "completion_tokens": 197,
        "total_tokens": 13146
      }
    },
    {
      "question_id": 13,
      "question": "How does Amgen's volume growth contribution from EVENITY in 2024 relate to its profit-sharing arrangement with UCB, and what does this imply about the financial impact of the collaboration on Amgen's consolidated income?",
      "original_answer": "Amgen reported that EVENITY, among other products, contributed to a 23% volume growth in 2024, which was a key driver of the 19% total product sales increase. EVENITY is part of a collaboration with UCB, under which global development costs and commercialization profits and losses are shared equally. According to the collaboration details, Amgen recorded $547 million in global profit and loss share expenses related to UCB in 2024, which were included in the Cost of Sales. This implies that while EVENITY contributed to volume-driven revenue growth, Amgen's net income was partially offset by the profit-sharing arrangement with UCB, reducing the overall profitability of the product on a consolidated basis.",
      "llm_answer": "Amgen’s 2024 EVENITY sales grew 35 % to $1.563 billion, driven primarily by volume growth, and under the company’s profit‑sharing arrangement with UCB the collaboration’s net profit and loss are split equally, with Amgen recognizing product sales in all territories outside Europe while sharing development costs and commercialization profits and losses 50/50.  This equal‑share structure means that EVENITY’s revenue and associated profit‑share expense flow through Amgen’s consolidated income as both sales and a corresponding cost, inflating operating expenses but also contributing to overall revenue growth without directly boosting net income.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 63672,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16156,
        "completion_tokens": 162,
        "total_tokens": 16319
      }
    },
    {
      "question_id": 13,
      "question": "How does Citigroup's leverage ratio requirement of 4.0% compare with Citibank's higher 5.0% requirement, and what implications does this have for their respective capital adequacy classifications under the Prompt Corrective Action framework?",
      "original_answer": "Citigroup is required to maintain a minimum Leverage ratio of 4.0% under U.S. Basel III rules, while its primary subsidiary, Citibank, must maintain a higher minimum Leverage ratio of 5.0% to be classified as 'well capitalized' under the Prompt Corrective Action (PCA) framework. This distinction reflects the stricter capital adequacy standards applied to insured depository institutions like Citibank, which are subject to more binding PCA requirements. The PCA framework imposes increasingly severe restrictions on institutions that fall below these thresholds, affecting their ability to make capital distributions or pay executive bonuses. The higher leverage requirement for Citibank underscores its critical role as a banking subsidiary and the regulatory emphasis on maintaining stronger capital buffers at the operating bank level.",
      "llm_answer": "Citigroup must maintain a minimum Leverage ratio of 4.0%, while Citibank, as a well‑capitalized subsidiary, must hold a higher 5.0% Leverage ratio to meet the Prompt Corrective Action “well capitalized” threshold. Consequently, Citibank’s stricter 5.0% requirement provides a larger capital cushion, reinforcing its stronger capital adequacy classification under the PCA framework compared with Citigroup’s 4.0% minimum.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "C_10k_2024.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_2_rel": {
          "source_file": "C_10k_2024.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_3_rel": {
          "source_file": "C_10k_2024.pdf",
          "target_page": 238,
          "pages": [
            236,
            237,
            238,
            239,
            240
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 80462,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20353,
        "completion_tokens": 105,
        "total_tokens": 20458
      }
    },
    {
      "question_id": 13,
      "question": "How does GE's concern about contingent liabilities from its insurance subsidiaries, including UFLIC, reconcile with the long-term risks associated with structured settlement annuities that UFLIC reinsures, particularly given the inability to adjust premiums on these contracts?",
      "original_answer": "GE expresses concern on page 35 about contingent liabilities and loss estimates from its insurance subsidiaries, including the potential for adverse effects on UFLIC due to solvency concerns or litigation, such as the ongoing issues related to Bank BPH in Poland. These liabilities could materially affect GE's financial position or results of operations. UFLIC, as noted on page 20, is a key reinsurer of structured settlement annuities, which carry long-term risks such as mortality and reinvestment risk in a low-interest-rate environment. Importantly, structured settlement annuities do not allow for premium increases or benefit reductions, which means UFLIC must bear the full financial burden of any longevity or interest rate shocks. This inability to adjust pricing creates a direct tension with GE's broader concern about future liabilities from its insurance operations, suggesting that UFLIC's structured settlement annuity portfolio could amplify GE's exposure to unanticipated financial strain over decades, especially if current assumptions about life expectancy or reinvestment yields prove inaccurate.",
      "llm_answer": "GE's concern about contingent liabilities from its insurance subsidiaries, including UFLIC, is reconciled with the long-term risks of structured settlement annuities by recognizing that these contracts cannot be adjusted for premium changes and involve significant mortality and longevity uncertainty. The company discloses that structured settlement annuities carry risks of extended payment periods, mortality improvement deviations, and reinvestment challenges in low-interest environments, which create fixed, non-adjustable liabilities that must be reserved for despite market conditions.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GE_10k_2023.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        },
        "hop_2_rel": {
          "source_file": "GE_10k_2023.pdf",
          "target_page": 20,
          "pages": [
            18,
            19,
            20,
            21,
            22
          ]
        },
        "hop_3_rel": {
          "source_file": "GE_10k_2023.pdf",
          "target_page": 20,
          "pages": [
            18,
            19,
            20,
            21,
            22
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 102356,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 25835,
        "completion_tokens": 148,
        "total_tokens": 25983
      }
    },
    {
      "question_id": 13,
      "question": "How does ConocoPhillips' equity investment in APLNG, tied to coal bed methane production in Queensland, Australia, reconcile with the $688 million impairment recorded in 2021, given the long-term LNG sales agreements and the carrying value of the investment after the impairment?",
      "original_answer": "ConocoPhillips holds a 37.5% equity investment in APLNG, which operates coal bed methane (CBM) production in Queensland, Australia, and processes and exports LNG under long-term sales agreements. In 2021, Origin Energy sold 10% of its stake in APLNG, and ConocoPhillips exercised its preemption right to acquire this additional interest. However, the fair value of APLNG based on this transaction was lower than the carrying value of ConocoPhillips' existing investment, leading to a noncash impairment charge of $688 million. This impairment reduced the carrying value of the investment to $5,574 million as of December 31, 2021. Despite APLNG's long-term contracts and access to CBM resources, the impairment reflects a market-driven valuation adjustment, indicating a strategic reassessment of the asset's value under current economic conditions.",
      "llm_answer": "ConocoPhillips recorded a $688 million non‑cash impairment in Q4 2021 because the market‑based price for its preemption purchase of an additional 10 % stake in APLNG was below the carrying value of its existing investment; the impairment reduced the investment’s carrying amount to $5.574 billion, which is reflected in the “Investments and long‑term receivables” line on the balance sheet. This write‑down reconciles with the $688 million charge despite the long‑term LNG sales agreements, as the impairment was deemed other‑than‑temporary under ASC 323.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 100,
          "pages": [
            98,
            99,
            100,
            101,
            102
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 65535,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16633,
        "completion_tokens": 138,
        "total_tokens": 16772
      }
    },
    {
      "question_id": 14,
      "question": "How does ConocoPhillips' decision to exercise a preemption right to purchase an additional 10% interest in APLNG relate to the financial structure and long-term obligations of the APLNG joint venture as described in the equity investment section?",
      "original_answer": "ConocoPhillips exercised its preemption right to purchase an additional 10% interest in APLNG, which was valued based on an observable market participant view of APLNG's fair value that was lower than the carrying value of the existing investment. This led to a $688 million before-tax charge after writing down the investment to its fair value of $5,574 million. Meanwhile, APLNG, as a joint venture operated in partnership with Origin Energy, had a non-recourse $8.5 billion project finance facility, of which $4.7 billion remained outstanding at the end of 2023, with scheduled repayments until 2030. The decision to increase stake in APLNG appears to be aligned with COP’s strategic interest in the joint venture despite its significant debt structure and long-term obligations.",
      "llm_answer": "ConocoPhillips exercised its preemption right to acquire an additional 10% stake in APLNG, a move that reflects the joint venture’s long‑term financing structure and obligations. The purchase price was set at a level below the carrying value of ConocoPhillips’ existing investment, triggering a $688 million impairment of the prior equity method investment and underscoring the financial impact of the transaction on the company’s balance sheet and future cash‑flow commitments.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 72330,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18322,
        "completion_tokens": 119,
        "total_tokens": 18442
      }
    },
    {
      "question_id": 14,
      "question": "Given that The Walt Disney Company owns 80% of ESPN while Hearst Corporation holds the remaining 20%, how does the significant increase in ESPN+ programming costs ($1.564 billion in 2022, up 40% from 2021) reflect on Disney's strategic investment in ESPN's digital platforms, especially after the sale of ESPN's X Games and owned radio stations?",
      "original_answer": "Disney's 80% ownership of ESPN, with Hearst Corporation holding the remaining 20%, positions ESPN as a core asset within Disney’s media networks portfolio. Despite divesting certain ESPN-owned physical assets like the X Games and radio stations in fiscal 2022, Disney significantly increased its investment in ESPN's digital infrastructure by allocating $1.564 billion to ESPN+ and other programming costs in 2022, a 40% increase from 2021. This suggests a strategic pivot toward digital streaming and away from traditional media formats, aligning with broader industry trends and Disney’s focus on direct-to-consumer platforms.",
      "llm_answer": "Disney's 40% surge in ESPN+ programming costs to $1.564 billion in 2022—driven by new NHL rights, higher soccer and golf fees, and expanded original content—underscores its strategic push to bolster the platform’s sports offering, even as it divested non‑core assets like the X Games and owned radio stations. This investment reflects Disney’s effort to differentiate ESPN+ through premium live sports and original programming, reinforcing its direct‑to‑consumer growth ambitions despite the higher expense burden.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 53621,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 13668,
        "completion_tokens": 128,
        "total_tokens": 13796
      }
    },
    {
      "question_id": 14,
      "question": "How does Disney's use of Level 3 valuation techniques for non-recurring fair value measures in fiscal 2024 relate to the triggering events that led to impairment charges, and how does this connect to the company's stated impairment testing methodology for long-lived assets?",
      "original_answer": "Disney recorded impairment charges in the second and fourth quarters of fiscal 2024 due to triggering events indicating that asset carrying amounts might not be recoverable. These impairments were measured using Level 3 discounted cash flow models, which rely on unobservable inputs. The company tests long-lived assets for impairment whenever triggering events occur, and the test depends on whether the asset is held for use or sale, typically involving a comparison of estimated undiscounted future cash flows to the asset's carrying value. This shows that the company applies a structured, event-driven impairment framework that links operational performance triggers (e.g., cash flow declines) with valuation models to determine financial impact.",
      "llm_answer": "Disney's Level 3 valuation technique for non-recurring fair value measures—used to determine impairment charges for long-lived assets—relies on discounted cash flow models that incorporate significant unobservable inputs (e.g., projected future cash flows, discount rates reflecting inherent reporting unit risks). This methodology aligns with the company's stated impairment testing approach for long-lived assets, which requires comparing estimated undiscounted future cash flows to the asset group's carrying amount and recognizing an impairment when the carrying amount exceeds fair value (determined via discounted cash flows or appraised values). The document confirms that such Level 3 fair value assessments were applied during fiscal 2024 impairment charges, consistent with the methodology described in Note 18 and Note 2.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 83309,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21074,
        "completion_tokens": 208,
        "total_tokens": 21282
      }
    },
    {
      "question_id": 14,
      "question": "Given that UPS satisfies all implemented FIP requirements for underfunded pension plans, how does their $10 million 2023 contribution to the Alaska Teamster-Employer Pension Plan reflect both the plan's red zone status and UPS's strategy of meeting only the agreed-upon contractual rates without additional minimum contributions?",
      "original_answer": "UPS satisfies all implemented FIP requirements for underfunded pension plans, including those in the red zone, without paying surcharges or additional minimum contributions beyond contractual rates. The Alaska Teamster-Employer Pension Plan is in the red zone for both 2022 and 2023, indicating it is severely underfunded (<65% funded), and UPS contributes exactly $10 million in 2023, consistent with their strategy of meeting only the agreed-upon contractual contribution rates. This reflects a balance between regulatory compliance with FIP/RP obligations and cost control in pension funding.",
      "llm_answer": "UPS’s $10 million contribution to the Alaska Teamster‑Employer Pension Plan—classified as “red zone” and subject to an implemented rehabilitation plan—reflects that the company is meeting only the exact contractual rate negotiated in the collective‑bargaining agreement, without making any extra or discretionary funding beyond what the agreement obligates it to provide. This approach aligns with UPS’s broader strategy of contributing precisely the amounts required by the contract, even when the plan’s funding status would otherwise call for higher inflows.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 87500,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22130,
        "completion_tokens": 140,
        "total_tokens": 22270
      }
    },
    {
      "question_id": 14,
      "question": "How does AbbVie's financial exposure to Imbruvica, as outlined in the gross margin discussion, reflect the cost-sharing and profit-sharing dynamics detailed in the collaboration agreement with Janssen Biotech?",
      "original_answer": "AbbVie's financial exposure to Imbruvica is significantly shaped by the collaboration agreement with Janssen Biotech, which outlines a detailed cost-sharing and profit-sharing framework. Under the agreement, Janssen is responsible for 60% of development costs while AbbVie covers the remaining 40%. In the U.S., AbbVie acts as the principal in end-customer sales, with both parties sharing pre-tax profits and losses equally. However, the gross margin section reveals that AbbVie incurred a $3.6 billion intangible asset impairment charge primarily related to Imbruvica, highlighting its material financial impact. This impairment charge, combined with the shared profit model, indicates that AbbVie's financial position is highly sensitive to the performance and cost structure of the Imbruvica collaboration, despite Janssen's significant involvement.",
      "llm_answer": "AbbVie's gross margin discussion notes that the 2023 gross margin percentage was unfavorably impacted by intangible asset impairment charges—specifically a $2.1 billion impairment related to Imbruvica and other charges—reflecting the financial exposure to Imbruvica. This exposure arises from the collaboration agreement with Janssen Biotech, under which Janssen’s share of Imbruvica profits (recorded as part of cost of products sold) and AbbVie’s share of related costs are split equally, meaning AbbVie bears 40 % of development costs and shares pre‑tax profits and losses equally in the United States while also sharing other collaboration expenses.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "target_page": 44,
          "pages": [
            42,
            43,
            44,
            45,
            46
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 79500,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20104,
        "completion_tokens": 163,
        "total_tokens": 20268
      }
    },
    {
      "question_id": 14,
      "question": "How does ConocoPhillips' application of ASC Topic 815 for derivative accounting on physical gas contracts relate to the financial impact of PALNG's interest rate swaps, and what does this imply about the company's overall risk management strategy for LNG joint ventures?",
      "original_answer": "ConocoPhillips applies ASC Topic 815 to account for physical gas contracts at market prices, treating them as derivatives without electing the normal purchases and sales exception. This aligns with the broader use of derivative instruments across its joint ventures, such as PALNG, which also uses ASC Topic 815 for interest rate swaps to manage financing risk. In 2024, PALNG recognized a $56 million unrealized loss in other comprehensive income and $35 million in equity in earnings related to these swaps, indicating active hedging. Given that COP holds a $1.5 billion equity investment in PALNG, these derivative practices suggest a coordinated risk management approach across LNG joint ventures, balancing market price exposure and interest rate volatility.",
      "llm_answer": "ConocoPhillips applies ASC Topic 815 to its physical gas contracts by treating them as derivatives that are marked‑to‑market and recorded in accumulated other comprehensive income (AOCI) until settlement, while the related interest‑rate swaps executed by PALNG are designated cash‑flow hedges that also flow through AOCI before being re‑classified into earnings. This parallel treatment shows that the company’s risk‑management strategy for its LNG joint ventures relies on hedging both commodity price exposure (via derivative accounting) and financing risk (via interest‑rate swaps), allowing it to isolate and manage cash‑flow volatility across its LNG projects.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 107,
          "pages": [
            105,
            106,
            107,
            108,
            109
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 66575,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16896,
        "completion_tokens": 166,
        "total_tokens": 17062
      }
    },
    {
      "question_id": 14,
      "question": "How does the regulatory restriction on Nicor Gas' ability to dividend or loan to affiliates, which limits distributions up to its retained earnings balance of $1.6 billion, reconcile with its role as a borrower under a $700 million credit arrangement restricted for working capital needs under Southern Company Gas' committed credit facility?",
      "original_answer": "Nicor Gas is subject to regulatory restrictions that limit its ability to dividend or loan to affiliates up to its retained earnings balance of $1.6 billion, reflecting constraints on capital flexibility. Despite this, Nicor Gas operates as a borrower under a $700 million portion of Southern Company Gas' $1.5 billion credit arrangement, specifically earmarked for its working capital needs. This arrangement indicates that while Nicor Gas cannot freely transfer capital upstream through dividends or loans, it can still access dedicated financing for operational purposes, ensuring liquidity for its core activities without violating regulatory constraints.",
      "llm_answer": "The $1.6 billion retained‑earnings cap that limits Nicor Gas’s ability to dividend or loan to affiliates is consistent with its role as a borrower under the $700 million committed credit facility because the facility is expressly restricted for Nicor Gas’s working‑capital needs and is supported by the same liquidity arrangements that back its commercial‑paper program; thus, while regulatory rules prevent Nicor Gas from making money‑pool loans to affiliates, the credit facility provides a separate, permitted source of financing that can be used for working capital, allowing distributions only up to the retained‑earnings balance.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 226,
          "pages": [
            224,
            225,
            226,
            227,
            228
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 226,
          "pages": [
            224,
            225,
            226,
            227,
            228
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 223,
          "pages": [
            221,
            222,
            223,
            224,
            225
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 88179,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22307,
        "completion_tokens": 158,
        "total_tokens": 22466
      }
    },
    {
      "question_id": 15,
      "question": "How does Altria's reliance on PM USA's unconditional guarantees for $3.0 billion in debt obligations reconcile with the indemnification framework under the Distribution Agreement, where PMI and PM USA only partially indemnify each other for tobacco-related liabilities based on manufacturing responsibility?",
      "original_answer": "Altria depends on PM USA to fully and unconditionally guarantee its obligations under $3.0 billion in debt instruments, as outlined in the Guarantees section. However, under the Distribution Agreement with PMI, indemnification for tobacco-related liabilities is not unconditional—PMI indemnifies Altria and PM USA only for liabilities tied to products it manufactured or had contract manufactured, while PM USA indemnifies PMI only for liabilities from products it manufactured, excluding those made for PMI. This creates a structural asymmetry: PM USA’s guarantee to Altria is absolute and not contingent on the nature of the liability, yet its indemnification from PMI is conditional and limited to specific manufacturing scenarios. This could expose Altria to risk if PM USA incurs liabilities outside the scope of its indemnification from PMI, particularly those not tied to tobacco product manufacturing.",
      "llm_answer": "Altria’s reliance on PM USA’s unconditional guarantees for the $3.0 billion of debt obligations is consistent with the Distribution Agreement’s indemnification framework, which allocates tobacco‑related liabilities between PMI and PM USA based on manufacturing responsibility; PM USA only partially indemnifies PMI for those liabilities, while the guarantees provide an absolute, unconditional backstop for Altria’s debt‑related obligations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 51,
          "pages": [
            49,
            50,
            51,
            52,
            53
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 65961,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16745,
        "completion_tokens": 110,
        "total_tokens": 16855
      }
    },
    {
      "question_id": 15,
      "question": "How does ConocoPhillips' engagement of DeGolyer and MacNaughton to review over 85% of its proved reserves estimation processes relate to the inclusion of D&M's report as Exhibit 99 in the 10-K filing, and how does this third-party involvement support the company's assertion of SEC-compliant internal controls over reserves reporting?",
      "original_answer": "ConocoPhillips engaged DeGolyer and MacNaughton (D&M), a third-party petroleum engineering consulting firm, to review the processes and controls used in estimating over 85% of its proved reserves as of December 31, 2024. This review was intended to provide objective third-party validation that the company’s internal processes align with SEC regulations. The results of this review are documented in D&M's report, which is included as Exhibit 99 in the 10-K filing. This external validation supports ConocoPhillips’ assertion that its internal controls over reserves estimation are comprehensive, consistent, and SEC-compliant. The involvement of D&M, through on-site visits, teleconferences, and documentation reviews, ensures that reserves are calculated using appropriate standards and provides senior management with independent assurance regarding the reliability of reserves data.",
      "llm_answer": "ConocoPhillips engaged DeGolyer and MacNaughton to review the processes and controls used to estimate proved reserves for over 85% of its reserves as of December 31, 2024. The independent D&M assessment confirmed that these processes and controls comply with SEC reserve definitions, and D&M’s report is filed as Exhibit 99 in the 10‑K. This third‑party validation provides objective evidence that ConocoPhillips’ reserves estimation and reporting are conducted under effective, SEC‑compliant internal controls.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 166,
          "pages": [
            164,
            165,
            166,
            167,
            168
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 77716,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19692,
        "completion_tokens": 127,
        "total_tokens": 19820
      }
    },
    {
      "question_id": 15,
      "question": "How does Converse's reported revenue growth in fiscal 2022 relate to the overall performance of the apparel category across Nike's global brand divisions, particularly in light of Converse's licensing operations?",
      "original_answer": "Converse reported a 7% revenue increase in fiscal 2022, driven by growth in North America, Western Europe, and licensee markets, with a notable 22% rise in direct-to-consumer sales. This growth was partially offset by declines in Asia and lower wholesale revenues. A key component of Converse's revenue mix is its licensing operations, which are explicitly called out as a major contributor to 'Other revenues' in the Global Brand Divisions section. Meanwhile, the Apparel category across all Nike Brand segments totaled $13.567 billion in revenues, with Converse contributing only $103 million of that total. This indicates that while Converse is a growing contributor—especially through licensing—it remains a relatively small player in the broader Nike apparel ecosystem. The contrast between Converse's 7% growth and its modest $103 million apparel contribution highlights how its licensing model and regional performance are leveraged differently within the broader Nike portfolio strategy.",
      "llm_answer": "Converse’s reported 6% revenue growth in fiscal 2022 (up from $2,205 million to $2,346 million) was driven by higher sales across North America, Western Europe and licensee markets, with direct‑to‑consumer revenues jumping 22% and wholesale revenues falling 4%. This growth contributed to a 23% increase in Converse’s earnings before interest and taxes, reflecting gross‑margin expansion and higher revenues that offset higher selling and administrative costs.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 44,
          "pages": [
            42,
            43,
            44,
            45,
            46
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 88,
          "pages": [
            86,
            87,
            88,
            89,
            90
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 89208,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22533,
        "completion_tokens": 115,
        "total_tokens": 22648
      }
    },
    {
      "question_id": 15,
      "question": "How does Qualcomm's exposure to revenue volatility from licensee disputes over royalty payments reconcile with their accounting policy that requires revenue recognition based on estimated royalty payments even before final agreement terms are settled?",
      "original_answer": "Qualcomm faces significant challenges from licensees who dispute, underreport, or delay royalty payments, which can delay revenue recognition until agreements are finalized (page 27). Despite this operational and legal risk, Qualcomm's accounting policy on page 69 states that they recognize royalty revenues based on estimates derived from preliminary licensee reports and market data, even before final reports are submitted. This creates a tension where the company must recognize revenue under uncertain conditions, potentially leading to future adjustments and volatility. The binding arbitration provisions in license agreements further complicate this dynamic, as unresolved disputes can delay final terms and thus definitive revenue recognition. The synthesis of these two perspectives reveals a business model that is both exposed to execution risk and reliant on forward-looking revenue estimation techniques that may not fully capture the downstream impact of licensee behavior.",
      "llm_answer": "Qualcomm’s accounting policy requires it to recognize licensing revenues based on estimated royalty payments even before final agreement terms are settled, which creates a risk of revenue volatility when licensees dispute or underpay royalties. The company mitigates this risk by estimating and recognizing royalties using preliminary data from licensees, applying significant judgment to assess collectibility, and only recognizing revenue to the extent it is probable that a material reversal will not occur; however, disputes, underreporting, or non‑payment by licensees can still materially reduce licensing revenues and cash flows.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "QCOM_10k_2024.pdf",
          "target_page": 27,
          "pages": [
            25,
            26,
            27,
            28,
            29
          ]
        },
        "hop_2_rel": {
          "source_file": "QCOM_10k_2024.pdf",
          "target_page": 27,
          "pages": [
            25,
            26,
            27,
            28,
            29
          ]
        },
        "hop_3_rel": {
          "source_file": "QCOM_10k_2024.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 99765,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 25181,
        "completion_tokens": 159,
        "total_tokens": 25340
      }
    },
    {
      "question_id": 15,
      "question": "How does the $21.7 billion of Alphabet's 2023 stock-based compensation expense tied to Class C stock issuance align with the treatment of Class B stock in diluted net income per share calculations, given the structural relationship between these share classes?",
      "original_answer": "The $21.7 billion of stock-based compensation expense for 2023, which is primarily associated with awards expected to settle in Class C stock, increases the number of Class C shares outstanding over time as RSUs vest. This affects the diluted net income per share calculation, which accounts for potentially dilutive securities like RSUs using the treasury stock method. In computing diluted net income per share for Class A stock, the conversion of Class B stock is assumed, but Class B shares themselves are not subject to dilution in their own calculation. Despite these differences in dilution treatment, both Class C and Class B shares receive equal per-share dividends and liquidation rights. Therefore, while Class C shares are directly impacted by SBC-related issuances, the structural alignment of dividend and liquidation rights ensures parity in net income allocation across share classes.",
      "llm_answer": "The $21.7 billion stock‑based compensation expense for 2023 reflects RSUs that are settled in Alphabet’s Class C shares, and because Class B shares automatically convert to Class A shares, the diluted‑per‑share calculations for Class A assume conversion of the Class B shares while those for Class B do not. Consequently, the SBC expense tied to Class C issuance does not affect the diluted net income per share of Class B, which is computed without assuming any conversion of those shares.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        },
        "hop_2_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "hop_3_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 90121,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22770,
        "completion_tokens": 122,
        "total_tokens": 22892
      }
    },
    {
      "question_id": 15,
      "question": "How does Simon's governance authority over the Operating Partnership influence the accounting treatment and balance sheet presentation of Series J 8 3/8% Preferred Stock redemptions in SPG's 2024 financial statements?",
      "original_answer": "Simon, as the sole general partner of the Operating Partnership, holds full authority over its operational and distribution decisions, including whether to redeem preferred units in cash or common stock. This governance control directly affects how preferred stock redemptions are accounted for in SPG's consolidated financials. Specifically, the Series J 8 3/8% Preferred Stock, which Simon may redeem on or after October 15, 2027, at $50.00 per share plus accrued dividends, is classified in permanent equity due to Simon's discretion to issue common stock instead of cash upon redemption. Furthermore, the unamortized premium on Series J stock was $0.9 million as of December 31, 2024, which is included in the carrying value on the consolidated balance sheet. This treatment aligns with the broader principle that Simon's decisions govern how preferred interests are presented in SPG’s consolidated balance sheets, particularly in relation to limited partners' preferred interest, which decreased to $15.5 million in 2024 from $23.0 million in 2023 due to redemptions.",
      "llm_answer": "Simon Property Group’s governance authority over the Operating Partnership determines how the Partnership’s Series J 8 3/8 % Preferred Units are classified and measured. Because the Partnership can be required to redeem those units in cash (subject to the terms of the partnership agreement), the Series J preferred units remain classified in temporary equity on the consolidated balance sheet. Consequently, any redemptions of Series J 8 3/8 % Preferred Stock are reflected as a liability‑like redemption obligation, and the related carrying amount is presented separately from permanent equity, affecting the presentation of the balance‑sheet line items for preferred equity and the related accumulated other comprehensive income adjustments.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "hop_2_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 129,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        },
        "hop_3_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 129,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 73788,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18681,
        "completion_tokens": 186,
        "total_tokens": 18867
      }
    },
    {
      "question_id": 15,
      "question": "How does Boeing's 2023 Five-Year Credit Agreement, which Citibank, N.A. administers, relate to the company's broader credit facility partnerships, particularly in light of the newly executed 364-Day Credit Agreement with Citibank, N.A. as administrative agent?",
      "original_answer": "Boeing's 2023 Five-Year Credit Agreement, administered by Citibank, N.A., is part of a broader set of credit arrangements that also includes a newly executed 364-Day Credit Agreement with the same institution. This demonstrates Boeing's strategic reliance on Citibank, N.A. for diverse financing solutions, ranging from short-term liquidity (364-Day Agreement) to longer-term capital commitments (Five-Year Agreement). The dual engagement with Citibank, N.A. underscores a deepening financial partnership aimed at supporting Boeing's operational and strategic objectives.",
      "llm_answer": "The 364‑Day Credit Agreement dated August 24 2023 with Citibank, N.A. as administrative agent is a separate, short‑term facility that operates alongside Boeing’s existing five‑year revolving credit arrangements (the 2019 Five‑Year Credit Agreement and its 2022 amendment), which remain in place to provide longer‑term borrowing capacity. The new 364‑day agreement therefore complements, rather than replaces, Boeing’s broader multi‑year credit facility structure.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2023.pdf",
          "target_page": 126,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2023.pdf",
          "target_page": 126,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2023.pdf",
          "target_page": 125,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 64627,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16395,
        "completion_tokens": 115,
        "total_tokens": 16510
      }
    },
    {
      "question_id": 15,
      "question": "How does Morgan Stanley's phased-in CECL deferral impact on risk-based capital ratios relate to its stake in MSBNA, and what are the implications for regulatory capital compliance as of December 31, 2023?",
      "original_answer": "Morgan Stanley, through its stake in MSBNA, elected to defer the impact of CECL adoption on risk-based capital ratios over a five-year transition period, with deferral impacts phased in at 50% as of January 1, 2023. This deferral is reflected in MSBNA’s regulatory capital calculations, which are based on the Standardized Approach rules. The phased-in CECL deferral affects how RWA and capital ratios are measured, allowing for a smoother transition in meeting regulatory requirements such as minimum Tier 1 leverage ratio and supplementary leverage ratio. As of December 31, 2023, MSBNA remains well-capitalized under OCC PCA standards, indicating that the deferral has not compromised regulatory compliance but has instead provided a buffer to absorb potential credit losses under CECL accounting.",
      "llm_answer": "The phased-in CECL deferral, which began to be phased in at 25% per year starting January 1 2022 and reached 50% by January 1 2023, reduces the amount of CECL‑related adjustments to risk‑based capital ratios and RWA calculations until it is fully phased in on January 1 2025. This deferral allows Morgan Stanley’s U.S. bank subsidiary MSBNA to maintain higher capital ratios (e.g., Common Equity Tier 1 = 21.7 % and Total capital = 22.6 % at December 31 2023) than the regulatory minimums, supporting compliance with well‑capitalized standards while the transition to full CECL is completed.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MS_10k_2023.pdf",
          "target_page": 153,
          "pages": [
            151,
            152,
            153,
            154,
            155
          ]
        },
        "hop_2_rel": {
          "source_file": "MS_10k_2023.pdf",
          "target_page": 135,
          "pages": [
            133,
            134,
            135,
            136,
            137
          ]
        },
        "hop_3_rel": {
          "source_file": "MS_10k_2023.pdf",
          "target_page": 54,
          "pages": [
            52,
            53,
            54,
            55,
            56
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 111963,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 28226,
        "completion_tokens": 147,
        "total_tokens": 28374
      }
    },
    {
      "question_id": 15,
      "question": "How does Altria's reliance on PM USA's unconditional guarantees for $3.0 billion in debt obligations reconcile with the indemnification framework under the Distribution Agreement, where PMI and PM USA only partially indemnify each other for tobacco-related liabilities based on manufacturing responsibility?",
      "original_answer": "Altria Group depends on PM USA as a primary guarantor for its $3.0 billion Credit Agreement and other debt obligations under unconditional guarantees that remain in place until specific release conditions occur. However, under the Distribution Agreement following the 2008 spin-off of PMI, indemnification responsibilities for tobacco-related liabilities between PM USA and PMI are allocated only based on manufacturing activity—PMI indemnifies Altria and PM USA for liabilities related to products it manufactured or had contract manufactured, and vice versa. Notably, Altria has not recorded any liability for this indemnification, as its fair value is considered insignificant. This creates a contrast: while PM USA provides broad and unconditional financial guarantees for Altria’s debt, its indemnification obligations to PMI are limited in scope and contingent on manufacturing attribution, potentially exposing Altria to asymmetric risk in its subsidiary relationships.",
      "llm_answer": "Altria’s $3 billion debt‑related guarantees from PM USA are covered by the unconditional guarantees that PM USA provides for Altria’s outstanding debt securities, the $3 billion Credit Agreement and the commercial‑paper program. These guarantees are distinct from the indemnification provisions in the Distribution Agreement, which only require PMI and PM USA to partially indemnify each other for tobacco‑related liabilities based on manufacturing responsibility. Consequently, while PM USA’s guarantees give full, unconditional backing to Altria’s debt obligations, the indemnification framework between PMI and PM USA does not extend to those debt‑related liabilities.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 51,
          "pages": [
            49,
            50,
            51,
            52,
            53
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 65961,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16745,
        "completion_tokens": 167,
        "total_tokens": 16913
      }
    },
    {
      "question_id": 15,
      "question": "How does Boeing's continued factory disruption on the KC-46A Tanker program, which led to a $402 million reach-forward loss in Q4 2021, reconcile with the previously capitalized precontract costs and potential supplier liabilities of $652 million as of December 31, 2021?",
      "original_answer": "Boeing's KC-46A Tanker program, a $19 billion contract with the U.S. Air Force, faced significant factory disruptions in 2021, including supply chain issues and evolving customer requirements for the Remote Vision System. These disruptions led to a $402 million reach-forward loss recorded in Q4 2021. This loss aligns with earlier financial exposure noted in the form of $243 million in capitalized precontract costs and $409 million in potential termination liabilities to suppliers as of December 31, 2021. The combined figures suggest that the program's financial risk was already substantial before the Q4 charge, indicating ongoing challenges in managing cost overruns and performance risks under the fixed-price contract structure.",
      "llm_answer": "The $402 million reach‑forward loss recorded in Q4 2021 reflects additional costs to complete the KC‑46A program—factory rework, supply‑chain disruptions (including COVID‑19) and the evolving Remote Vision System requirements—driving the total capitalized precontract costs to $243 and the estimated termination liability to $409. This loss is accounted for alongside the $652 million of potential supplier liabilities (recorded as a severance reserve) that remain on the balance sheet as of Dec 31 2021, illustrating how the incurred overruns are being offset against previously capitalized amounts and supplier‑related obligations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 44,
          "pages": [
            42,
            43,
            44,
            45,
            46
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 56017,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14255,
        "completion_tokens": 158,
        "total_tokens": 14413
      }
    },
    {
      "question_id": 15,
      "question": "How does the renaming of FPL Group Capital Inc to NextEra Energy Capital Holdings, Inc in 2010 reconcile with the continued use of the FPL Group Capital name in debt instruments filed as exhibits in 2021 and 2022?",
      "original_answer": "The renaming of FPL Group Capital Inc to NextEra Energy Capital Holdings, Inc occurred in 2010, yet the FPL Group Capital name continues to appear in legal filings and debt instruments dated as late as 2021 and 2022. This indicates that while the corporate name was officially changed over a decade ago, legacy naming conventions persist in legal and financial documentation, particularly in indentures and officer certificates related to long-term subordinated debt securities. This dual usage reflects the importance of maintaining continuity in legal agreements and financial instruments that span multiple corporate branding transitions.",
      "llm_answer": "The renaming of FPL Group Capital Inc. to NextEra Energy Capital Holdings, Inc. in 2010 does not conflict with the continued use of the \"FPL Group Capital\" name in debt instrument exhibits filed in 2021 and 2022. The exhibits explicitly reference \"FPL Group Capital\" as the historical name of the issuer (e.g., Exhibit *4(l) cites the 1999 Indenture between \"FPL Group Capital Inc\" and the Trustee), while the current legal name of the issuer is NextEra Energy Capital Holdings, Inc. This reflects standard practice of retaining legacy names in historical legal documents and exhibits for continuity and reference purposes, even after corporate name changes.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NEE_10k_2023.pdf",
          "target_page": 120,
          "pages": [
            114,
            115,
            116,
            117,
            118
          ]
        },
        "hop_2_rel": {
          "source_file": "NEE_10k_2023.pdf",
          "target_page": 116,
          "pages": [
            114,
            115,
            116,
            117,
            118
          ]
        },
        "hop_3_rel": {
          "source_file": "NEE_10k_2023.pdf",
          "target_page": 116,
          "pages": [
            114,
            115,
            116,
            117,
            118
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 180340,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 45311,
        "completion_tokens": 164,
        "total_tokens": 45476
      }
    },
    {
      "question_id": 16,
      "question": "How does Philip Morris International's discussion of Vietnam's regulatory environment for heat-not-burn products align with its financial performance in the region, particularly in light of the company's broader concerns about illicit trade impacting profitability?",
      "original_answer": "Philip Morris International notes in its regulatory section that Vietnam is among the countries where voluntary standards for heat-not-burn products have been adopted, indicating a potential openness to novel tobacco products. However, in the South & Southeast Asia market commentary, the company attributes a 10.0% market increase in Vietnam to a lower prevalence of illicit trade, which was partly due to pandemic-related supply disruptions. This aligns with the broader risk factor on page 40, where illicit trade is cited as a material challenge affecting volume, results of operations, and competitiveness. The alignment suggests that while Vietnam's regulatory stance on novel products remains non-mandatory, the temporary reduction in illicit trade during the pandemic provided a short-term boost to PMI's market position, highlighting the dual importance of both regulatory engagement and illicit trade mitigation in shaping long-term profitability in the region.",
      "llm_answer": "Philip Morris International acknowledges that Vietnam’s regulatory environment for heated‑tobacco (heat‑not‑burn) products is uncertain and that any future restrictions or bans could curb adult access to its reduced‑risk products.  The company stresses that it supports science‑based regulation that differentiates reduced‑risk products from cigarettes, but warns that overly restrictive rules or a lack of clear standards could hinder its ability to commercialize and profit from these products in Vietnam, especially as it continues to grapple with illicit trade that erodes profitability across its broader RRP portfolio.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PM_10k_2022.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        },
        "hop_2_rel": {
          "source_file": "PM_10k_2022.pdf",
          "target_page": 58,
          "pages": [
            56,
            57,
            58,
            59,
            60
          ]
        },
        "hop_3_rel": {
          "source_file": "PM_10k_2022.pdf",
          "target_page": 40,
          "pages": [
            38,
            39,
            40,
            41,
            42
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 75036,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19007,
        "completion_tokens": 156,
        "total_tokens": 19163
      }
    },
    {
      "question_id": 16,
      "question": "Given the importance of patent protection for revenue stability, how does the 32% U.S. revenue decline in Trulicity in 2024 reflect the risk associated with the anticipated expiration of its patent and data protections, as outlined in the intellectual property risk section?",
      "original_answer": "The 32% U.S. revenue decline in Trulicity in 2024 directly reflects the vulnerability of LLY's revenue streams when a product nears the end of its patent and data protection lifecycle. According to the intellectual property section, Trulicity is expected to lose significant patent and data protections in the next few years, which historically leads to rapid revenue erosion due to generic or biosimilar competition. This aligns with the observed revenue drop, likely driven by competitive dynamics and anticipation of reduced exclusivity. The connection between the loss of patent protection (as described on page 10) and Trulicity’s current revenue trajectory (as reported on page 49) underscores the material financial risk posed by intellectual property expiration.",
      "llm_answer": "The 32 % U.S. revenue decline for Trulicity in 2024 reflects the direct impact of the impending loss of patent and data protections that secure its market exclusivity. As outlined in the “Patents, Trademarks, and Other Intellectual Property Rights” section, Trulicity’s compound patent expires in 2027 and its data‑protection period ends in 2024, after which generic competition is expected to erode sales sharply. This anticipated expiration creates a material risk that revenue from Trulicity will drop rapidly once exclusivity ends, undermining the stability of the company’s overall revenue stream.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 28,
          "pages": [
            26,
            27,
            28,
            29,
            30
          ]
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 64112,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16278,
        "completion_tokens": 150,
        "total_tokens": 16428
      }
    },
    {
      "question_id": 16,
      "question": "How does AMD's strategic positioning of FPGAs in hyperscale data centers align with the export licensing constraints imposed by EAR regulations on Versal™ FPGAs destined for China?",
      "original_answer": "AMD positions FPGAs as critical components in hyperscale data centers, particularly for AI workloads such as generative AI models, and highlights their integration into servers sold by OEMs and ODMs to large public cloud service providers. However, the Export Administration Regulations (EAR) now restrict the export of certain AMD Versal™ FPGAs to China or to customers outside the U.S. with ultimate parents in D5 countries, including China, without a license. These restrictions not only limit AMD’s ability to sell these products in key markets but also introduce uncertainty through the NAC notification process, which could delay or block shipments. Given the strategic importance of FPGAs in driving revenue from AI and cloud infrastructure, these export controls could materially impact AMD’s competitive positioning and financial performance, especially if alternative products are not accepted or future regulations expand.",
      "llm_answer": "AMD’s Versal™ FPGAs are subject to U.S. Export Administration Regulations (EAR) licensing controls that restrict shipments of certain advanced‑computing items—including specific Versal FPGA models—to China or to parties whose ultimate parent is headquartered in a D5‑listed country. These controls require AMD to file a Notified Advanced Computing (NAC) notice 25 days before any such export and may necessitate a full license, effectively limiting the company’s ability to deliver Versal devices to Chinese hyperscale data‑center customers. Consequently, AMD must navigate these licensing constraints while positioning Versal FPGAs as a strategic accelerator for hyperscale environments, balancing market opportunity against the regulatory barriers imposed by EAR.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMD_10k_2024.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_2_rel": {
          "source_file": "AMD_10k_2024.pdf",
          "target_page": 32,
          "pages": [
            30,
            31,
            32,
            33,
            34
          ]
        },
        "hop_3_rel": {
          "source_file": "AMD_10k_2024.pdf",
          "target_page": 32,
          "pages": [
            30,
            31,
            32,
            33,
            34
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 76863,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19437,
        "completion_tokens": 191,
        "total_tokens": 19629
      }
    },
    {
      "question_id": 16,
      "question": "How does the decline in Converse's revenue performance in fiscal 2023, particularly in apparel, align with the overall revenue contribution of apparel across Nike's geographic segments?",
      "original_answer": "The decline in Converse's revenue by 15% in fiscal 2023, driven by drops in North America and Western Europe, contrasts with the broader Nike Brand's apparel revenue, which contributed $13.843 billion across geographic segments. While Converse's apparel segment only generated $90 million in revenue, reflecting its relatively minor role in the broader apparel category, Nike's own apparel revenues remained strong in key markets like North America ($5.947 billion) and Europe, Middle East & Africa ($4.566 billion). This indicates that while Nike's core apparel business remains robust across global markets, Converse's apparel performance lagged significantly, contributing minimally to the overall apparel revenue and reflecting a more challenging position in the lifestyle apparel segment.",
      "llm_answer": "The decline in Converse revenue in fiscal 2023 was driven by a 15% drop in North America and Western Europe, which together account for the majority of its sales. This regional weakness reduced Converse’s share of overall apparel revenue, causing apparel’s contribution to fall across Nike’s geographic segments. Consequently, while Nike’s apparel revenue grew modestly in Greater China and APLA, the overall apparel share of Nike’s revenue was pressured by Converse’s underperformance in its core markets.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 87,
          "pages": [
            85,
            86,
            87,
            88,
            89
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 76026,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19232,
        "completion_tokens": 126,
        "total_tokens": 19358
      }
    },
    {
      "question_id": 16,
      "question": "How does Broadcom's valuation methodology for developed technology related to SoC controller products compare with its treatment of VMware Cloud Foundation (VCF) developed technology, and what does this reveal about the strategic importance of VCF within Broadcom's post-acquisition asset portfolio?",
      "original_answer": "Broadcom applies different valuation methodologies to developed technology depending on its application: the relief-from-royalty method is used for SoC controller products (valued based on forecasted revenue and royalty rates), while the multi-period excess earnings method is used for VMware Cloud Foundation (VCF) developed technology (valued based on projected cash flows, technology obsolescence rate, and contributory asset charges). The significant allocation of $24,156 million to VCF-related developed technology out of the $45,572 million in total acquired intangibles from the VMware acquisition underscores the strategic emphasis on VCF as a core asset. This contrast in valuation approach and the substantial investment in VCF-related intangibles suggest that Broadcom views VCF as a critical growth driver requiring a more complex and forward-looking earnings model compared to the more established SoC controller technology.",
      "llm_answer": "Broadcom valued VMware Cloud Foundation (VCF) developed technology using the multi‑period excess earnings method, assigning it a weighted‑average amortization of 8 years and a fair‑value of $24,156 million, whereas the developed technology for Seagate’s SoC controller products was valued using the relief‑from‑royalty method with a shorter, technology‑cycle‑based useful life and no disclosed amortization period. This contrast shows that VCF—representing a strategic, high‑growth cloud platform—was treated as a core, long‑lived intangible asset critical to Broadcom’s post‑acquisition portfolio, while the SoC assets were positioned as complementary, lower‑level technology with a more limited economic life.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AVGO_10k_2023.pdf",
          "target_page": 70,
          "pages": [
            68,
            69,
            70,
            71,
            72
          ]
        },
        "hop_2_rel": {
          "source_file": "AVGO_10k_2023.pdf",
          "target_page": 51,
          "pages": [
            49,
            50,
            51,
            52,
            53
          ]
        },
        "hop_3_rel": {
          "source_file": "AVGO_10k_2023.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 57969,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14746,
        "completion_tokens": 177,
        "total_tokens": 14924
      }
    },
    {
      "question_id": 16,
      "question": "How does the voting power distribution between Class A and Class B common stock impact the corporate governance structure, given the non-dilutable voting rights of Class B shares and the fact that Class A shares are publicly traded on Nasdaq?",
      "original_answer": "The corporate governance structure of CMCSA is significantly influenced by the voting power distribution between Class A and Class B common stock. According to the equity note (page 91), holders of Class B common stock collectively control 33 1/3% of the voting power, and each Class B share is entitled to 15 votes. This voting power is non-dilutable, meaning it cannot be reduced by the issuance of additional shares of any class of common stock. Class A shares, which are publicly traded on Nasdaq as disclosed on page 1, collectively hold 66 2/3% of the voting power, but the number of votes per share fluctuates depending on the total number of Class A and Class B shares outstanding. This dual-class structure ensures that the holders of Class B shares retain significant influence over corporate decisions despite owning a smaller portion of the total shares. The governance structure thus reflects a strategic balance where public shareholders (holding Class A shares) have a majority of shares but limited voting control, while a smaller group (holding Class B shares) maintains outsized influence over decision-making.",
      "llm_answer": "The Class B shares carry 15 votes per share and collectively retain a fixed 33 ⅓ % of the total voting power, which is non‑dilutable, while Class A shares—traded on Nasdaq—carry the remaining voting interest and are subject to dilution only through their own issuances. This structure concentrates control in the Class B holders despite the public tradability of Class A stock.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 1,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 60727,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15423,
        "completion_tokens": 94,
        "total_tokens": 15518
      }
    },
    {
      "question_id": 16,
      "question": "Given the $116.5 million fair value of the VIL OCDs and the $411.6 million tenant-related intangible asset impairment tied to VIL in India, how does AMT's strategic review and decision to pursue the Pending ATC TIPL Transaction reflect its risk mitigation approach and expectations for recovery on both the impaired assets and the convertible debt instruments?",
      "original_answer": "The $116.5 million fair value of the VIL OCDs, which were issued to address payment shortfalls from VIL, contrasts with the $411.6 million tenant-related intangible asset impairment AMT recorded in 2022 due to VIL's partial payments. This indicates a significant erosion in the value of AMT's contractual relationship with VIL. In response, AMT initiated a strategic review of its India business, culminating in the Pending ATC TIPL Transaction, which allows AMT to divest its tower assets in India while retaining the VIL OCDs and certain receivables. This strategic move suggests that AMT is reducing its operational exposure to the Indian market and VIL's financial instability, while maintaining a financial claim (through the OCDs) that could offer partial recovery if VIL stabilizes or the OCDs are converted into equity. This reflects a dual approach of limiting further impairment risk while preserving potential upside from VIL's future performance.",
      "llm_answer": "AMT's strategic review and decision to pursue the Pending ATC TIPL Transaction reflect a deliberate risk‑mitigation strategy aimed at protecting its capital base and enhancing recovery prospects. By initiating the transaction with DIT, AMT is seeking to monetize the $116.5 million fair‑value of VIL OCDs and the $411.6 million tenant‑related intangible asset impairment in India, while also addressing the uncertainty surrounding collections from VIL and other Indian customers. The transaction provides a structured path to settle existing intercompany debt, repay portions of its India‑based term loan, and potentially generate up to $2.5 billion of consideration, thereby reducing exposure to further impairments and preserving liquidity for future growth initiatives.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMT_10k_2023.pdf",
          "target_page": 98,
          "pages": [
            96,
            97,
            98,
            99,
            100
          ]
        },
        "hop_2_rel": {
          "source_file": "AMT_10k_2023.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_3_rel": {
          "source_file": "AMT_10k_2023.pdf",
          "target_page": 58,
          "pages": [
            56,
            57,
            58,
            59,
            60
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 81027,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20529,
        "completion_tokens": 193,
        "total_tokens": 20722
      }
    },
    {
      "question_id": 16,
      "question": "How does Boeing's increased reach-forward loss of $402 million on the KC-46A Tanker program in 2021, driven by factory disruption and supply chain impacts, reconcile with the program's overall contract value of $19 billion and its status as a fixed-price incentive fee contract?",
      "original_answer": "Boeing recorded an additional reach-forward loss of $402 million on the KC-46A Tanker program in 2021 due to continued factory disruption and supply chain issues, including the impact of the evolving Remote Vision System requirements. This loss occurred despite the program being under a fixed-price incentive fee contract, which inherently places cost overrun risk on the company. The KC-46A program had a total contract value of approximately $19 billion as of December 31, 2021, across the EMD phase and seven LRIP lots for 94 aircraft. While the fixed-price nature of the contract allows Boeing to benefit from cost efficiencies, it also exposes the company to significant financial risk, as evidenced by the 2021 loss. This highlights the tension between long-term contract value and short-to-medium-term execution risks in complex defense programs.",
      "llm_answer": "The $402 million reach‑forward loss recorded in 2021 for the KC‑46A program reflects the additional costs caused by factory disruptions and supply‑chain impacts, and it is recognized under the fixed‑price incentive fee contract that has an overall value of about $19 billion. This loss is part of the cumulative contract adjustments that the company tracks, and it coexists with the program’s large contract value and incentive‑fee structure, which together influence the timing and magnitude of any reach‑forward losses.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 44,
          "pages": [
            42,
            43,
            44,
            45,
            46
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 56017,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14257,
        "completion_tokens": 130,
        "total_tokens": 14387
      }
    },
    {
      "question_id": 16,
      "question": "How does the eligibility for 12 years of U.S. data exclusivity for MK-7962 (sotatercept) upon approval reconcile with the granted data exclusivity expiration date of July 16, 2033, for the same product, and what does this imply about Merck's regulatory strategy for long-term market protection?",
      "original_answer": "Merck's disclosure indicates that MK-7962 (sotatercept) is eligible for 12 years of U.S. data exclusivity upon approval as a biologic product. However, the document separately states that data exclusivity for this compound has already been granted and will expire on July 16, 2033. This implies that the product has likely already received regulatory approval, triggering the start of the exclusivity period. The alignment of these two provisions—eligibility and granted status—suggests that Merck has secured a defined market protection timeline, with exclusivity lasting until 2033, barring any patent term extensions. This supports a regulatory strategy focused on leveraging both data exclusivity and patent protection to maximize market control through 2037, when the core treatment patents are set to expire.",
      "llm_answer": "The eligibility for 12 years of U.S. data exclusivity for MK-7962 (sotatercept) upon approval is reconciled with the granted data exclusivity expiration date of July 16, 2033 by recognizing that the 12‑year regulatory data exclusivity period runs from the date of first U.S. marketing approval, while the statutory patent‑term extensions and any pending PTEs are separate from that exclusivity. This structure reflects Merck’s strategy of layering patent term restoration, pediatric exclusivity and data‑exclusivity protections to extend market exclusivity well beyond the base patent life, thereby securing long‑term commercial advantage for the product.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "target_page": 15,
          "pages": [
            13,
            14,
            15,
            16,
            17
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 66917,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16976,
        "completion_tokens": 163,
        "total_tokens": 17139
      }
    },
    {
      "question_id": 16,
      "question": "How does American Life's exemption from RBC requirements affect MetLife's consolidated statutory capital position, given its significant statutory equity of $7.555 billion as of December 31, 2024?",
      "original_answer": "American Life is exempt from RBC requirements under Delaware law because it does not conduct insurance business in the U.S., yet it holds significant statutory equity of $7.555 billion as of December 31, 2024, which contributes to MetLife’s consolidated statutory capital position. While most U.S. insurance subsidiaries are subject to RBC requirements and must maintain capital above specified thresholds, American Life is instead regulated under foreign jurisdictions where it operates and is subject to their capital and solvency requirements. This exemption allows American Life to maintain its own capital structure without the constraints of NAIC’s RBC framework, which could provide MetLife with more flexibility in capital management across its global operations. However, since American Life’s statutory equity is still included in MetLife’s consolidated statutory capital, its regulatory treatment differently impacts the overall capital adequacy assessment of the group, especially when compared to subsidiaries like MLIC that must comply with RBC requirements.",
      "llm_answer": "American Life’s exemption from RBC requirements means it is not subject to the NAIC’s risk‑based capital standards, so its statutory equity of $7.555 billion (as shown for American Life in the “Statutory Equity and Income” table) does not count toward any RBC‑related regulatory thresholds. Consequently, the company’s overall consolidated statutory capital position remains strong—its U.S. insurance subsidiaries collectively exceed the required RBC levels by wide margins (e.g., a Statement‑Based Combined RBC Ratio over 360% in 2024)—but the exemption removes any RBC‑driven capital‑adequacy pressure on American Life itself. This allows MetLife to allocate capital more flexibly across its businesses while still maintaining ample surplus well above regulatory minima.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2024.pdf",
          "target_page": 272,
          "pages": [
            270,
            271,
            272,
            273,
            274
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2024.pdf",
          "target_page": 98,
          "pages": [
            96,
            97,
            98,
            99,
            100
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2024.pdf",
          "target_page": 273,
          "pages": [
            271,
            272,
            273,
            274,
            275
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 73291,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18551,
        "completion_tokens": 193,
        "total_tokens": 18744
      }
    },
    {
      "question_id": 16,
      "question": "How does GE's decision to close UFLIC to new business in 2004 relate to the long-term financial risks associated with the 23,400 structured settlement annuities it now reinsures, particularly in light of the company's exposure to mortality improvement and reinvestment risk?",
      "original_answer": "GE's decision to close UFLIC to new business in 2004 reflects a strategic move to limit future exposure to insurance underwriting risks, particularly in products like structured settlement annuities. However, the company still reinsures approximately 23,400 structured settlement annuities, 27% of which were underwritten on impaired lives, with projected payments extending decades into the future. These contracts expose GE to mortality improvement risk—where policyholders live longer than expected—and reinvestment risk in a low interest rate environment. Since these annuities do not allow for additional premiums or benefit reductions, the company must manage long-term liabilities with fixed terms, which contrasts with the original rationale for ceasing new business at UFLIC. This creates a tension between the historical risk mitigation strategy and the ongoing financial obligations tied to this legacy portfolio.",
      "llm_answer": "GE's 2004 closure of UFLIC to new business was a strategic move to mitigate the long-term financial risks inherent in its $23,400 structured settlement annuities portfolio, which exposes the company to significant mortality improvement and reinvestment risks. These annuities, primarily with impaired lives (27% underwritten on shorter life expectancies), carry extended payment periods and lack flexibility for premium adjustments or benefit reductions, making them vulnerable to adverse mortality trends and low-interest-rate reinvestment environments. The closure aimed to limit further exposure to these risks while managing the existing $23,400 reserve liability through careful actuarial assumptions and sensitivity analyses.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GE_10k_2024.pdf",
          "target_page": 18,
          "pages": [
            16,
            17,
            18,
            19,
            20
          ]
        },
        "hop_2_rel": {
          "source_file": "GE_10k_2024.pdf",
          "target_page": 18,
          "pages": [
            16,
            17,
            18,
            19,
            20
          ]
        },
        "hop_3_rel": {
          "source_file": "GE_10k_2024.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 100906,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 25468,
        "completion_tokens": 182,
        "total_tokens": 25650
      }
    },
    {
      "question_id": 17,
      "question": "How does Microsoft's indefinite deferral of the final foreign tax credit regulations through Notice 2023-80 impact its effective tax rate in fiscal year 2024, and how does this align with the geographic distribution of its foreign income?",
      "original_answer": "Microsoft's effective tax rate for fiscal year 2024 was 18%, a decrease from 19% in fiscal year 2023, primarily due to tax benefits from law changes including Notice 2023-80, which indefinitely delayed the effective date of the final foreign tax credit regulations. This delay allowed Microsoft to continue benefiting from lower foreign tax rates, particularly from its Irish regional operating center, which generated 83% of its foreign income before tax in fiscal year 2024. The geographic distribution of income—$44.9 billion from foreign jurisdictions—enabled Microsoft to maintain a lower effective tax rate compared to the U.S. federal statutory rate, illustrating how regulatory deferrals align with its international tax planning strategy.",
      "llm_answer": "Microsoft's indefinite deferral of final foreign tax credit regulations through IRS Notice 2023‑80 (and the earlier Notice 2023‑55) provides a tax benefit that lowers its effective tax rate for fiscal 2024.  This benefit, together with the geographic concentration of foreign earnings—primarily generated in Ireland where the foreign regional operating center is taxed at rates below the U.S. statutory rate—helps keep the overall effective tax rate below the 21 % federal rate.  Consequently, the tax savings from the delayed regulations align with the company’s foreign‑income profile, which is heavily weighted toward low‑tax jurisdictions.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 47,
          "pages": [
            45,
            46,
            47,
            48,
            49
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 57857,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14701,
        "completion_tokens": 160,
        "total_tokens": 14862
      }
    },
    {
      "question_id": 17,
      "question": "Given the convertible relationship between Class A and Class B common stock and the significant repurchases of Class A shares, how does the lack of Class B common stock issuances or balance changes in 2024 impact the overall equity structure and voting power dynamics at Comcast Corporation?",
      "original_answer": "The lack of Class B common stock issuances or balance changes in 2024, despite the convertible nature of Class B shares into Class A, suggests that the existing voting power structure remains stable. Class B shares, which carry 15 votes per share and collectively hold 33 1/3% of the voting power, did not change in quantity during the year, as evidenced by the $0 balance in both beginning and end-of-year Class B common stock figures on page 68. Meanwhile, significant repurchases of Class A shares occurred, reducing Class A common stock from $48 million to $47 million in 2024 (page 67), which could have diluted the relative voting influence of Class B shares had there been no conversion. However, since no conversions occurred, the non-dilutable 33 1/3% voting power of Class B shares was preserved, reinforcing the concentrated control mechanism within Comcast’s equity structure.",
      "llm_answer": "The lack of Class B common‑stock issuances or any balance‑sheet changes in 2024 leaves the voting‑power split unchanged – Class A shares retain roughly two‑thirds of the vote and Class B shares continue to hold the remaining one‑third, even though the company repurchased a substantial number of Class A shares during the year. Consequently, the equity structure shows a modest decline in total shares outstanding (from 3.97 billion in 2023 to 3.78 billion in 2024), but the proportional voting power of each class remains the same, preserving the existing dynamics between Class A and Class B shareholders.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 67,
          "pages": [
            65,
            66,
            67,
            68,
            69
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 72027,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18258,
        "completion_tokens": 151,
        "total_tokens": 18410
      }
    },
    {
      "question_id": 17,
      "question": "How does UPS's use of NAV for valuing alternative investments relate to its $2.7 billion in unfunded commitments to private equity and other limited partnerships, and what implications does this have for liquidity management given the redemption restrictions described?",
      "original_answer": "UPS utilizes NAV as a practical expedient to value certain alternative investments, including private equity funds, due to the lack of readily determinable fair values. These investments are not classified within the standard fair value hierarchy (Levels 1–3) and instead are reported separately. On page 93, UPS discloses that it has $2.7 billion in unfunded commitments to limited partnerships, including private equity funds, which are typically subject to long-term investment horizons of 10–15 years with limited redemption provisions. This ties directly to the NAV valuation methodology described on page 94, which acknowledges inherent limitations in valuing such assets and the potential for discrepancies from market-based values. The combination of illiquid commitments and NAV-based valuation suggests that UPS must carefully manage liquidity expectations, as these investments are not easily redeemable and their reported values may not reflect realizable cash flows in the short term.",
      "llm_answer": "UPS values its alternative‑investment holdings (private‑equity, private‑debt and real‑estate limited‑partnership interests) at NAV per share as a practical expedient, which is disclosed as a separate line item in the fair‑value hierarchy.  As of 31 Dec 2024 the company reports approximately **$2.7 billion of unfunded commitments** to these private‑equity and other limited‑partner funds that must be funded over the next three‑to‑six years.  Because these interests have redemption restrictions and can only be liquidated at the end of the partnership term, the NAV‑based valuation masks limited near‑term liquidity; UPS must plan cash outflows and funding strategies to meet those future capital calls while managing overall plan‑asset liquidity.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 70592,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17888,
        "completion_tokens": 187,
        "total_tokens": 18075
      }
    },
    {
      "question_id": 17,
      "question": "How does Southern Company's credit arrangement structure for Nicor Gas, as a subsidiary with a dedicated $700 million credit allocation under the 2029 agreement, align with its reported notes payable balance of $172 million for Nicor Gas at year-end 2024, and what does this imply about liquidity utilization and debt management strategy?",
      "original_answer": "Southern Company has a $700 million credit allocation under its 2029 credit arrangement specifically for Nicor Gas, indicating a substantial liquidity facility available to support its gas operations. However, as of December 31, 2024, Nicor Gas only had $172 million in outstanding notes payable, suggesting that only a fraction of the allocated credit was utilized. This implies that Southern Company maintains a conservative debt management strategy for Nicor Gas, preserving significant liquidity for future working capital needs or unforeseen financial pressures. The weighted average interest rate on Nicor Gas' notes payable was 4.6% in 2024, which is lower than the 5.5% rate from the prior year, indicating favorable refinancing conditions or improved creditworthiness.",
      "llm_answer": "Southern Company’s 2029 multi‑year credit facility includes a $700 million sub‑limit that is dedicated to Nicor Gas for working‑capital needs, while Nicor Gas reports a $172 million notes‑payable balance at year‑end 2024. This indicates that only about 25 % of the allocated credit line is currently drawn, reflecting modest utilization of the dedicated liquidity source. Consequently, the company appears to be managing its debt prudently—maintaining ample unused capacity under the 2029 agreement while keeping short‑term borrowings at a relatively low level.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 224,
          "pages": [
            222,
            223,
            224,
            225,
            226
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 224,
          "pages": [
            222,
            223,
            224,
            225,
            226
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 223,
          "pages": [
            221,
            222,
            223,
            224,
            225
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 84241,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21319,
        "completion_tokens": 140,
        "total_tokens": 21459
      }
    },
    {
      "question_id": 17,
      "question": "How does Boeing's exposure to cost overruns on the KC-46A Tanker program, as a fixed-price development contract, reconcile with the $402 million additional losses recorded in Q4 2021 and the company's broader risk disclosures regarding U.S. government contract modifications?",
      "original_answer": "Boeing's KC-46A Tanker program, a fixed-price development contract valued at approximately $19 billion as of December 31, 2021, involves significant technical complexity and cost estimation risks. In Q4 2021, Boeing recorded an additional $402 million in losses on the KC-46A contract due to factory disruptions, supply chain issues (including those from the pandemic), and increased costs from evolving customer requirements for the Remote Vision System. This aligns with the broader risk disclosures that highlight how fixed-price contracts, particularly development ones like the KC-46A, expose Boeing to potential losses if cost estimates are exceeded. Furthermore, the company faces risks from U.S. government contract modifications or funding changes, which could exacerbate financial impacts from such cost overruns.",
      "llm_answer": "Boeing recorded an additional $402 million of losses on the KC‑46A Tanker in Q4 2021 because cost‑overrun risks on this fixed‑price development contract were identified in its risk disclosures, and the company notes that such fixed‑price contracts—especially those with the U.S. government—carry the possibility of further earnings charges, reach‑forward losses, or contract modifications if cost estimates change. This exposure is consistent with the broader risk factor that U.S. government contract modifications can trigger additional losses, as highlighted in the “Risks Related to Our Contracts” section.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 134,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 51247,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 13065,
        "completion_tokens": 152,
        "total_tokens": 13217
      }
    },
    {
      "question_id": 17,
      "question": "How does Southern Company's risk disclosure about cyber intrusions impacting nuclear power plants reconcile with the strategic importance of those plants, which generated 28% of Georgia Power's electricity in 2021?",
      "original_answer": "Southern Company acknowledges in its risk factors that cyber intrusions pose a material threat to the operation of nuclear power plants, which could lead to regulatory fines, operational shutdowns, or increased compliance costs. These risks are particularly relevant to Alabama Power and Georgia Power, which together operate six nuclear units. On the operational side, the document notes that nuclear units managed by Southern Nuclear accounted for 28% of Georgia Power's total KWH generation in 2021, underscoring their strategic and material role in the company’s electricity production. This dual context highlights a tension: while nuclear power plants are a critical asset contributing significantly to the company's energy output, they are also exposed to high-impact risks like cyber threats that could disrupt operations, increase costs, or trigger regulatory scrutiny. The interplay between these perspectives suggests that Southern Company must balance the strategic value of nuclear generation with the growing complexity and cost of securing these facilities against evolving cyber threats.",
      "llm_answer": "Southern Company acknowledges that cyber intrusions could disrupt nuclear plant operations, yet it emphasizes that its nuclear units—responsible for roughly 28 % of Georgia Power’s electricity in 2021—are integral to its strategy and to meeting regulated cost‑recovery goals. The risk disclosures therefore balance the high regulatory and financial stakes of these plants with the potential operational threats posed by cyber threats.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 84278,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21300,
        "completion_tokens": 108,
        "total_tokens": 21408
      }
    },
    {
      "question_id": 18,
      "question": "How does Goldman Sachs' inclusion of the countercyclical capital buffer at zero percent within the TLAC to RWAs requirement align with its separate disclosure of CET1 capital ratio requirements that also incorporate this buffer?",
      "original_answer": "Goldman Sachs includes the countercyclical capital buffer, set at zero percent by the FRB, as part of the TLAC to RWAs requirement (18% minimum + 2.5% buffer + 0% countercyclical buffer + 1.5% G-SIB surcharge). Separately, in the capital adequacy section, the CET1 capital ratio requirement explicitly incorporates the same countercyclical buffer, which remains at zero percent, alongside a 6.2% stress capital buffer and 3.0% G-SIB surcharge as of December 2024. This demonstrates regulatory consistency in applying the zero percent countercyclical buffer across both TLAC and CET1 capital frameworks, even as different buffer components (e.g., SCB vs. G-SIB) vary in magnitude and timing.",
      "llm_answer": "Goldman Sachs incorporates the countercyclical capital buffer (set at 0 % by the FRB) into both the TLAC‑to‑RWAs ratio and its separate CET1‑capital‑ratio requirement, so the same zero‑percent buffer is applied in each calculation. Consequently, the buffer does not affect the TLAC ratio but is already reflected in the CET1 ratio target of 13.7 % (which includes the SCB and other buffers). In short, the zero‑percent countercyclical buffer is part of the regulatory capital framework that underlies both the TLAC requirement and the firm’s CET1 capital ratio, but it is only a component of the latter’s required buffer.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_2_rel": {
          "source_file": "GS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_3_rel": {
          "source_file": "GS_10k_2024.pdf",
          "target_page": 208,
          "pages": [
            206,
            207,
            208,
            209,
            210
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 96094,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 24258,
        "completion_tokens": 155,
        "total_tokens": 24414
      }
    },
    {
      "question_id": 18,
      "question": "How does NIKE's $18.5 billion in outstanding foreign currency derivatives relate to its foreign currency adjustment program with third-party factories, and how does this impact the financial exposure of the NIKE Trading Company (NTC) when selling products to NIKE entities with different functional currencies?",
      "original_answer": "NIKE manages its foreign currency risk through a $18.5 billion portfolio of outstanding foreign currency derivatives, which includes both designated cash flow hedges and embedded derivative contracts. A key component of this risk management strategy is the foreign currency adjustment program with third-party factories, under which NIKE assumes certain factory currency exposures that naturally offset its own. This program creates embedded derivative contracts for currencies outside the U.S. Dollar and the factory’s local currency. The NTC, a wholly-owned sourcing hub, purchases products from these factories in U.S. Dollars and then sells them to NIKE entities in their respective functional currencies. This creates a foreign currency exposure for the NTC when selling to NIKE entities with different functional currencies. The interplay between the derivatives, embedded contracts, and NTC’s role in the supply chain illustrates how NIKE structures its financial risk management to mitigate exposure across its global operations.",
      "llm_answer": "NIKE's $18.5 billion of outstanding foreign‑currency derivatives are used to hedge the foreign‑currency exposure created when the NIKE Trading Company (NTC) sells products to its subsidiaries that have different functional currencies; the NTC’s sales generate foreign‑currency risk for NTC, and the hedges offset that risk. This hedging program, together with the foreign‑currency adjustment program with factories, limits NIKE Trading Company’s financial exposure to currency movements on its cross‑border sales.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 103529,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 26138,
        "completion_tokens": 128,
        "total_tokens": 26266
      }
    },
    {
      "question_id": 18,
      "question": "How does Boeing's increased reach-forward loss on the Commercial Crew program in 2021 relate to the broader financial risks associated with fixed-price development contracts, particularly in light of the technical and cost estimation challenges described in the audit of these contracts?",
      "original_answer": "Boeing's increased reach-forward loss of $185 million on the Commercial Crew program in 2021 reflects the financial risks inherent in fixed-price development contracts, which are subject to significant cost overruns due to technical complexity and evolving customer requirements. This aligns with the broader context from page 19, where Boeing notes that fixed-price contracts—especially development ones—carry the risk of reduced margins or losses if estimated costs exceed projections. The Commercial Crew program, as a fixed-price development contract, is specifically highlighted in the audit section as one of the most complex and uncertain contracts to estimate, requiring specialized audit procedures due to the high degree of judgment and variability in cost projections. The audit process included evaluating management's assumptions, testing data accuracy, and performing retrospective reviews, all of which underscore the difficulty in forecasting costs and the potential for future financial adjustments. Thus, the Commercial Crew loss is not an isolated issue but emblematic of the systemic challenges Boeing faces with fixed-price development programs.",
      "llm_answer": "Boeing recorded a $402 million reach‑forward loss on the KC‑46A tanker in Q4 2021 and additional reach‑forward losses of $185 million on Commercial Crew and $318 million on VC‑25B, reflecting cost‑overrun risks inherent in its fixed‑price development contracts. These losses illustrate how fixed‑price development contracts expose the company to margin erosion when cost estimates prove too low, a risk that is amplified by technical uncertainties, schedule delays, supply‑chain disruptions and evolving customer requirements—precisely the type of risk highlighted in the audit of fixed‑price contracts. Consequently, the audit underscores that inaccurate cost and schedule assumptions can trigger material reach‑forward losses and weaken overall financial performance.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 134,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 45,
          "pages": [
            43,
            44,
            45,
            46,
            47
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 54095,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 13778,
        "completion_tokens": 192,
        "total_tokens": 13971
      }
    },
    {
      "question_id": 18,
      "question": "How does Southern Company's short-term debt structure for Nicor Gas in 2024 compare with the broader credit arrangement commitments outlined in the liquidity and capital resources section, particularly regarding the $700 million restricted credit facility expiring in 2029?",
      "original_answer": "Southern Company's Nicor Gas subsidiary had $172 million in notes payable outstanding as of December 31, 2024, with a weighted average interest rate of 4.6%, reflecting its portion of short-term debt within the broader Southern Company Gas segment. This short-term debt is part of a larger liquidity framework where Nicor Gas is the borrower under a $700 million credit arrangement expiring in 2029, specifically restricted for its working capital needs. This arrangement is nested within a $2.45 billion combined credit facility shared with Southern Power, which allows for flexible sublimits between entities. The $172 million in notes payable represents a portion of Nicor Gas’s access to this $700 million allocation, highlighting how Southern Company structures its liquidity to support both operational and working capital requirements across subsidiaries while maintaining compliance with debt covenants limiting total leverage to 70% of capitalization.",
      "llm_answer": "Southern Company’s short‑term debt for Nicor Gas is supported by a $700 million portion of its multi‑year credit facility that expires in 2029 and is restricted for Nicor Gas’s working‑capital needs; this arrangement is part of the broader $6.4 billion credit package shown in the “Bank Credit Arrangements” table, which also includes $100 million of commitments expiring in 2025 and other sub‑limits for the group.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 224,
          "pages": [
            222,
            223,
            224,
            225,
            226
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 224,
          "pages": [
            222,
            223,
            224,
            225,
            226
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 223,
          "pages": [
            221,
            222,
            223,
            224,
            225
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 84241,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21303,
        "completion_tokens": 103,
        "total_tokens": 21406
      }
    },
    {
      "question_id": 19,
      "question": "How does The Goldman Sachs Group, Inc.'s guarantee of Goldman Sachs Bank USA's obligations relate to the stricter 'Category I' regulatory capital standards they are both subject to under U.S. federal banking rules?",
      "original_answer": "The Goldman Sachs Group, Inc. provides a general guarantee for the obligations of Goldman Sachs Bank USA, as noted in the exhibit list on page 248 of the 2024 10-K filing. This financial backing underscores the interconnectedness of the parent company and its subsidiary bank. Goldman Sachs Bank USA, along with the parent company, is subject to 'Category I' standards under the U.S. federal bank regulatory agencies' tailoring framework due to the firm's designation as a global systemically important bank (G-SIB). These Category I standards impose more stringent risk-based capital and liquidity requirements, including quantitative measures of assets, liabilities, and off-balance sheet items, which are calculated under the Basel III framework and tailored by the Dodd-Frank Act. The guarantee from the parent company may serve as a buffer to help ensure that Goldman Sachs Bank USA can meet these heightened capital and liquidity requirements, especially given the qualitative judgments regulators apply in assessing capital sufficiency.",
      "llm_answer": "The Goldman Sachs Group’s guarantee of Goldman Sachs Bank USA’s obligations is made under the same “Category I” regulatory framework that subjects both entities to the stricter Basel III‑based capital and leverage standards (including the G‑SIB surcharge, counter‑cyclical buffer and other advanced‑approach requirements). Because they are treated as Advanced‑Approach banks, the guarantee must be supported by capital that meets these heightened Category I capital adequacy rules, ensuring the bank’s obligations remain fully covered under the more stringent regulatory regime.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GS_10k_2024.pdf",
          "target_page": 248,
          "pages": [
            243,
            244,
            245,
            246,
            247
          ]
        },
        "hop_2_rel": {
          "source_file": "GS_10k_2024.pdf",
          "target_page": 14,
          "pages": [
            12,
            13,
            14,
            15,
            16
          ]
        },
        "hop_3_rel": {
          "source_file": "GS_10k_2024.pdf",
          "target_page": 14,
          "pages": [
            12,
            13,
            14,
            15,
            16
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 80759,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20421,
        "completion_tokens": 144,
        "total_tokens": 20566
      }
    },
    {
      "question_id": 19,
      "question": "How does AbbVie's financial exposure to Imbruvica, including its collaboration with Janssen Biotech and the $3.6 billion intangible asset impairment charge, reflect both the strategic benefits and financial risks of co-commercializing a high-profile oncology product?",
      "original_answer": "AbbVie's collaboration with Janssen Biotech for the development and commercialization of Imbruvica involves shared costs and profits, with Janssen covering 60% of development costs and AbbVie 40%. In the U.S., AbbVie is the principal in end-customer sales and shares pre-tax profits and losses equally with Janssen, which is also reflected in AbbVie's cost of products sold. However, despite this cost-sharing structure, AbbVie reported a $3.6 billion intangible asset impairment charge in 2023 primarily related to Imbruvica, among other products, which significantly impacted gross margins. This impairment suggests that the long-term financial outlook for Imbruvica may be deteriorating, potentially outweighing the benefits of shared development and commercialization responsibilities. Thus, while the collaboration reduces direct financial burden, AbbVie still bears significant risk tied to Imbruvica’s market performance.",
      "llm_answer": "AbbVie's financial exposure to Imbruvica—through its co‑commercialization with Janssen Biotech and the $3.6 billion intangible‑asset impairment charge recorded in 2023—highlights both the strategic upside and the financial risk of relying on a high‑profile oncology product. The collaboration provides AbbVie with a 50 % share of U.S. profits and a revenue stream that contributed $3.6 billion to net sales, but a significant decline in Imbruvica sales (22 % drop in 2023) triggered an impairment of its definite‑lived intangible assets, resulting in a $2.1 billion pre‑tax charge to cost of products sold. This illustrates how the product's strong market position can generate substantial earnings, yet market‑share erosion and pricing pressures can quickly translate into large non‑cash impairments and reduced profitability.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "target_page": 44,
          "pages": [
            42,
            43,
            44,
            45,
            46
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 79500,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20119,
        "completion_tokens": 206,
        "total_tokens": 20326
      }
    },
    {
      "question_id": 19,
      "question": "How does ConocoPhillips' application of ASC Topic 815 for derivative accounting on physical gas contracts relate to the financial impact of PALNG's interest rate swaps, and what does this imply about the company's overall risk management strategy for LNG joint ventures?",
      "original_answer": "ConocoPhillips applies ASC Topic 815 to account for physical gas contracts at market prices, treating them as derivatives without electing the normal purchases and sales exception. This aligns with the broader use of derivative instruments across its joint ventures, such as PALNG, where interest rate swaps were executed to fix 60% of projected term loans for Phase 1 construction. These swaps were initially accounted for under ASC Topic 815 as cash flow hedges, with fair value changes reported in other comprehensive income. However, in 2024, a portion of these swaps was de-designated, resulting in $35 million of unrealized losses being recognized directly in 'Equity in earnings of affiliates.' Given that COP holds a $1.5 billion equity method investment in PALNG, this shift in hedge accounting suggests a strategic recalibration in managing interest rate exposure for LNG projects, which may reflect broader risk management adjustments across its LNG-focused joint ventures.",
      "llm_answer": "ConocoPhillips applies ASC Topic 815 to account for physical gas contracts that meet the NPNS exception as derivatives, recognizing revenue when the contracts settle rather than spreading it over the contract term. This treatment allows the company to reflect market‑linked cash flows from those gas contracts directly in earnings, while its LNG joint‑venture agreements (e.g., PALNG) are accounted for under the equity method, with any associated interest‑rate swaps affecting earnings only when the swaps are de‑designated. Consequently, the firm’s overall risk‑management strategy integrates market‑price hedging through derivative accounting for physical sales and targeted interest‑rate hedges for LNG project financing, aligning cash‑flow exposure with the long‑term profitability of its LNG ventures.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 107,
          "pages": [
            105,
            106,
            107,
            108,
            109
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 66575,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16896,
        "completion_tokens": 201,
        "total_tokens": 17097
      }
    },
    {
      "question_id": 19,
      "question": "How does the change in the Netherlands' Innovation Box Tax rate under Dutch Corporate Income Tax Law impact BKNG's effective tax rate in 2023 compared to 2022, and what does this reveal about the company's international tax strategy?",
      "original_answer": "BKNG's effective tax rate for 2023 was lower compared to 2022, partly due to a decrease in the valuation allowance against deferred tax assets and lower international tax rates, although partially offset by a reduced benefit from the Netherlands Innovation Box Tax. The Innovation Box Tax rate increased from 7% to 9% effective January 1, 2021, and the Dutch statutory rate rose from 25% to 25.8% in 2022. Despite this, a portion of Booking.com's earnings still qualified for the Innovation Box Tax treatment, which significantly benefited BKNG’s effective tax rate in both 2022 and 2023. This indicates that BKNG strategically leverages favorable tax regimes in the Netherlands to reduce its global tax burden, even as the benefit from the Innovation Box Tax declined year-over-year.",
      "llm_answer": "The Dutch Innovation Box Tax rate was reduced from 7% to 9% for qualifying innovative income beginning in 2021, but the statutory corporate rate increased from 25% to 25.8% in 2022. This shift resulted in a lower effective tax rate for Booking.com in 2023 compared to 2022, primarily due to the beneficial impact of the Netherlands' Innovation Box Tax treatment on a portion of its international earnings, which significantly reduced its overall effective tax rate.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BKNG_10k_2023.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "hop_2_rel": {
          "source_file": "BKNG_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_3_rel": {
          "source_file": "BKNG_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 70170,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17779,
        "completion_tokens": 116,
        "total_tokens": 17895
      }
    },
    {
      "question_id": 19,
      "question": "How does AMD's positioning of FPGAs like the Versal series as critical components for hyperscale data centers reconcile with the export restrictions under EAR that limit their shipment to China, and what impact could this have on AMD's revenue forecasts given the importance of international markets?",
      "original_answer": "AMD highlights the Versal FPGAs as key products for hyperscale data centers, particularly in enabling AI workloads and being integrated into servers and appliances for major cloud service providers (page 11). However, the Export Administration Regulations (EAR) now restrict the export of certain Versal FPGAs to China or entities with ultimate parents in Country Groups D1, D4, or D5 without a license or a 25-day NAC notification (page 32). These restrictions could result in shipment delays or outright prohibitions, directly affecting AMD’s ability to serve a major international market. Given that international revenue constitutes a significant portion of AMD’s business and that forecasting shipments has become more uncertain due to the unpredictability of license approvals, these export controls could materially impact AMD’s revenue forecasts and competitive positioning, especially if competitors face less stringent restrictions.",
      "llm_answer": "AMD positions its Versal FPGA family as a key accelerator for hyperscale data centers, but U.S. export controls under the EAR restrict shipments of certain Versal models to China and require pre‑shipment licensing notifications, limiting access to a major growth market. This regulatory barrier could suppress AMD’s revenue forecasts by curtailing sales in one of the world’s largest data‑center regions and by forcing the company to rely more heavily on domestic and other international customers.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMD_10k_2024.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_2_rel": {
          "source_file": "AMD_10k_2024.pdf",
          "target_page": 32,
          "pages": [
            30,
            31,
            32,
            33,
            34
          ]
        },
        "hop_3_rel": {
          "source_file": "AMD_10k_2024.pdf",
          "target_page": 32,
          "pages": [
            30,
            31,
            32,
            33,
            34
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 76863,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19467,
        "completion_tokens": 124,
        "total_tokens": 19592
      }
    },
    {
      "question_id": 19,
      "question": "Given that the VAR model excludes forecasted transactions from its risk analysis, how does Disney's use of the VAR model to estimate one-day loss potential reconcile with its active hedging of forecasted foreign currency transactions, which totaled $9.9 billion in notional amounts as of September 28, 2024?",
      "original_answer": "Disney uses the VAR model on page 60 to estimate the maximum potential one-day loss in fair value for its financial instruments, but explicitly excludes forecasted transactions from this analysis. However, on page 121, the company actively hedges forecasted foreign currency transactions, with $9.9 billion in notional amounts of foreign exchange cash flow hedges outstanding as of September 28, 2024. This creates a tension: while the VAR model focuses on realized and current market-sensitive instruments, the hedging strategy anticipates and mitigates risk on future transactions not captured in the VAR framework. The reconciliation lies in recognizing that the VAR model serves as a short-term risk metric under normal market conditions, while the forecasted transaction hedging reflects a longer-term risk management strategy not fully represented in the VAR analysis.",
      "llm_answer": "Disney's VAR model excludes forecasted transactions from its risk analysis, yet it actively hedges the very foreign currency exposures the model omits. This is reconciled by the fact that Disney hedges $9.9 billion of notional foreign‑currency transactions (as disclosed in the market‑risk section), which are deliberately left out of the VAR calculation, allowing the company to manage those exposures separately through designated cash‑flow and forward contracts.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 66790,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16952,
        "completion_tokens": 116,
        "total_tokens": 17069
      }
    },
    {
      "question_id": 19,
      "question": "How does Boeing's exposure to cost overruns on the KC-46A Tanker program, as a fixed-price development contract, reflect both the capitalized pre-contract costs and the risk of future reach-forward losses outlined in different sections of the 10-K?",
      "original_answer": "Boeing's KC-46A Tanker program, valued at approximately $19 billion as of December 31, 2021, is a fixed-price incentive fee contract with significant technical complexity and cost estimation challenges. As of the same date, Boeing had capitalized $243 million in pre-contract costs, indicating early financial exposure. The contract is also subject to reach-forward losses, as seen in the $402 million additional loss recorded in Q4 2021 due to factory disruptions, supply chain issues, and evolving customer requirements. The company notes that fixed-price development contracts like the KC-46A are inherently uncertain, with cost estimates subject to significant variability, and any future cost overruns could result in material charges. This synthesis reveals a dual risk: upfront financial commitments already made and the ongoing exposure to future losses due to the nature of fixed-price development contracts.",
      "llm_answer": "Boeing records capitalized pre‑contract costs for the KC‑46A program and discloses a $409 potential termination liability, reflecting the risk that future reach‑forward losses may arise if cost overruns exceed the fixed‑price contract price. This exposure is highlighted in the “Fixed‑Price Development Contracts” and “KC‑46A Tanker” sections, which note that the EMD contract and LRIP lots are valued at about $19 billion and that the company has recognized earnings charges for losses on such fixed‑price development work.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 134,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 51247,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 13058,
        "completion_tokens": 131,
        "total_tokens": 13189
      }
    },
    {
      "question_id": 19,
      "question": "How does Mississippi Power Company's status as a subsidiary that does not provide an annual report to its parent company align with its compliance with the reduced disclosure conditions under Form 10-K for the 2024 filing?",
      "original_answer": "Mississippi Power Company, as a subsidiary of The Southern Company, does not prepare or file an annual report with the SEC, indicating a streamlined reporting relationship with its parent company. Despite this, it complies with the reduced disclosure format under General Instructions I(2)(b), (c), and (d) of Form 10-K by meeting the conditions outlined in General Instructions I(1)(a) and (b). This dual status—being exempt from full annual reporting while still adhering to specific SEC disclosure rules—reflects a regulatory alignment that allows for simplified reporting consistent with its operational structure and ownership relationship within the Southern Company group.",
      "llm_answer": "Mississippi Power Company is not required to file an annual report with the SEC because it is a wholly owned subsidiary of The Southern Company and does not provide an annual report to its parent. As stated in the filing, \"Alabama Power is not required to send an annual report or proxy statement to its sole shareholder and parent company, The Southern Company, and will not prepare such a report after filing this Annual Report on Form 10-K for fiscal year 2024. Accordingly, Alabama Power will not file an annual report with the Securities and Exchange Commission.\" This exemption applies to Mississippi Power Company as well, allowing it to comply with the reduced disclosure conditions under Form 10-K for its 2024 filing.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 324,
          "pages": [
            319,
            320,
            321,
            322,
            323
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 3,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 3,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 78188,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19779,
        "completion_tokens": 181,
        "total_tokens": 19961
      }
    },
    {
      "question_id": 20,
      "question": "How does the adoption of LDTI, which MetLife implemented in Q1 2023, specifically alter the components of adjusted earnings by removing certain adjustments related to DAC, VOBA, and MRBs, and what operational or financial reporting implications does this have given the updated calculation methodology?",
      "original_answer": "The adoption of LDTI in Q1 2023 materially altered the components of adjusted earnings by simplifying the measurement model for DAC and VOBA and reclassifying most embedded derivatives as MRBs. As a result, MetLife updated its adjusted earnings calculation to exclude amortization adjustments related to DAC, VOBA, and associated intangibles, as well as changes in measurement of certain guarantees. Adjusted earnings now also exclude changes in fair value associated with MRBs, discount rate changes on annuitization guarantees, and asymmetrical accounting related to in-force reinsurance. These changes were implemented to align with the new disclosure and measurement requirements under LDTI, which in turn affects how MetLife evaluates performance and allocates resources across its business segments. The operational impact is reflected in the updated internal controls and processes MetLife had to implement to meet the new periodic reporting and balance sheet disclosure requirements under LDTI.",
      "llm_answer": "The adoption of LDTI simplified the measurement model for DAC and VOBA and reclassified most embedded derivatives as Market Risk Benefits (MRBs), prompting MetLife to update its adjusted earnings calculation to exclude amortization of DAC and VOBA, changes in discount rates on certain annuitization guarantees, contract inception losses for single‑premium business, and asymmetrical accounting for in‑force reinsurance. Consequently, adjusted earnings now excludes changes in fair value associated with MRBs, discount‑rate adjustments, inception‑date losses, and asymmetrical reinsurance accounting, while all presented periods reflect this revised methodology. This shift alters the components of adjusted earnings by removing certain DAC/VOBA amortization and related intangible adjustments and introduces operational implications such as revised segment reporting disclosures and updated economic‑capital model applications.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 170,
          "pages": [
            168,
            169,
            170,
            171,
            172
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 331,
          "pages": [
            329,
            330,
            331,
            332,
            333
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 85596,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21660,
        "completion_tokens": 232,
        "total_tokens": 21892
      }
    },
    {
      "question_id": 20,
      "question": "How does Microsoft's repeated use of The Bank of New York Mellon Trust Company as trustee in multiple supplemental indentures for specific debt instruments relate to the foundational terms established in the Base Indenture from May 18, 2009, and what does this imply about Microsoft's long-term debt management strategy?",
      "original_answer": "Microsoft has consistently used The Bank of New York Mellon Trust Company (BNY Mellon) as the trustee across multiple supplemental indentures for various debt instruments, including the 1.625% Notes due 2018, 3.625% Notes due 2023, and 4.875% Notes due 2043 (dated December 6, 2013), as well as later issuances such as the 1.100% Notes due 2019 and 3.950% Notes due 2056 (dated August 8, 2016). These supplemental indentures all reference the Base Indenture dated May 18, 2009, which establishes the core legal framework governing Microsoft’s debt obligations. The repeated use of the same trustee and the consistent referencing of the Base Indenture suggest that Microsoft has institutionalized a standardized and centralized debt management structure. This implies a strategic preference for continuity, legal consistency, and administrative efficiency in managing long-term debt instruments across multiple decades of issuance.",
      "llm_answer": "Microsoft's consistent use of The Bank of New York Mellon Trust Company as trustee across multiple supplemental indentures for its debt instruments directly references and incorporates the foundational terms established in the Base Indenture dated May 18, 2009. This repeated appointment demonstrates a deliberate, long-term strategy to leverage a single, established trustee relationship for structuring and managing its diverse debt offerings, ensuring continuity and reliability in its financing operations over time.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 50013,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12759,
        "completion_tokens": 130,
        "total_tokens": 12889
      }
    },
    {
      "question_id": 20,
      "question": "How does the issuance of Cruise Class G Preferred Shares to Microsoft and Walmart in 2021 relate to the earlier issuance of Cruise Class F Preferred Shares in 2019, particularly in terms of capital structure alignment and strategic intent for Cruise Holdings?",
      "original_answer": "The issuance of Cruise Class G Preferred Shares in 2021 to Microsoft, Walmart, and others, including General Motors Holdings LLC with a $1.0 billion investment, builds upon the capital structure established by the 2019 issuance of Cruise Class F Preferred Shares, which included a $687 million investment from General Motors Holdings LLC. Both classes of preferred shares are structured to convert into common stock upon an IPO and provide holders with liquidation preferences and pari passu dividend rights alongside common shareholders. However, the Class G issuance expanded strategic alignment by including external partners like Microsoft, with whom GM entered a long-term strategic relationship to accelerate the commercialization of self-driving vehicles. This indicates that while the Class F shares were foundational in funding Cruise’s operations, the Class G issuance was more explicitly tied to strategic partnerships and broader corporate objectives, reflecting a shift from internal capital infusion to external strategic collaboration.",
      "llm_answer": "The 2021 issuance of $2.7 billion of Cruise Class G Preferred Shares to Microsoft, Walmart and other investors (including $1 billion to GM Holdings) mirrors the 2019 $1.2 billion Class F Preferred issuance, both serving as distinct capital‑structure tools: the Class F shares funded early Cruise working‑capital needs and provided a voting‑rights mechanism for SoftBank, while the newer Class G shares align Cruise’s financing with strategic partners and support a long‑term Microsoft cloud partnership, reflecting a deliberate shift in capital‑raising strategy to fund Cruise’s growth and eventual IPO.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 96,
          "pages": [
            94,
            95,
            96,
            97,
            98
          ]
        },
        "hop_2_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 83819,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21192,
        "completion_tokens": 150,
        "total_tokens": 21343
      }
    },
    {
      "question_id": 20,
      "question": "How does Comcast's dividend policy favorability toward Class A common stockholders contrast with the structural voting power and transactional control retained by Class B common stockholders, particularly in light of the non-dilutable 33 1/3% voting threshold?",
      "original_answer": "Comcast's dividend policy, which includes an 8% increase in dividends to $1.08 per share on an annualized basis for Class A common stockholders, signals a favorable financial return for these investors. However, this benefit is contrasted by the structural governance imbalance where Class B common stockholders, who hold a non-dilutable 33 1/3% of the combined voting power, retain outsized control over key corporate decisions. This includes separate approval rights over major transactions such as mergers, asset sales, and amendments to the company’s articles of incorporation, even if such actions are in the broader shareholder interest. This dynamic highlights a tension between financial incentives for the majority of shareholders and the concentrated governance power held by the Class B stockholder, Brian L. Roberts, which could influence strategic direction independently of broader shareholder sentiment.",
      "llm_answer": "Comcast’s dividend policy—consistent quarterly payouts and an 8% increase approved in January 2022—offers a favorable return to Class A shareholders, yet the company’s governance structure concentrates decisive voting power in the non‑dilutable 33 ⅓% Class B stake held by Mr. Brian L. Roberts. This Class B stock, which carries 15 votes per share and cannot be diluted below 9.4 million shares, retains control over key corporate actions despite Class A holders collectively owning 66 ⅓% of the voting equity. Consequently, while dividends benefit Class A investors, the retained super‑majority voting control and separate approval rights of Class B shareholders can override their interests in major transactions.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 12,
        "total_chars": 50822,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12946,
        "completion_tokens": 178,
        "total_tokens": 13125
      }
    },
    {
      "question_id": 20,
      "question": "How does Honeywell's accounting treatment of the $211 million First Partial Redemption from Garrett's Series B Preferred Stock relate to the company's decision to value the investment based on the present value of mandatory redemptions?",
      "original_answer": "Honeywell initially accounted for the Series B Preferred Stock at fair value based on the present value of mandatory redemptions discounted at 7.25%, as stated on page 90. The Series B Preferred Stock had mandatory redemption terms, including a $35 million redemption in 2022 and $100 million annually from 2023 to 2030, unless certain EBITDA or liquidity conditions prevented it. On page 103, Honeywell received the $211 million First Partial Redemption from Garrett on December 28, 2021, which exceeded the originally scheduled 2022 redemption amount of $35 million. This early redemption suggests that the Series B Preferred Stock's actual redemption schedule deviated from the original mandatory terms, which could impact the accuracy of the present value model used for fair value accounting. The receipt of a larger-than-expected early payment implies that the original discounting model may have understated the investment’s near-term cash flow potential, raising questions about the alignment between the accounting methodology and the realized redemption behavior.",
      "llm_answer": "The $211 million First Partial Redemption was accounted for by valuing the Series B Preferred Stock using the present value of its mandatory redemption schedule—discounting the required $35 million 2022 and $100 million annual redemptions from 2023‑2030 at 7.25 % and then adjusting for the early partial redemption—so the investment is carried at that present‑value amount, with the discount subsequently accreted into interest income over the redemption period.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_2_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "hop_3_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 76103,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19264,
        "completion_tokens": 115,
        "total_tokens": 19380
      }
    },
    {
      "question_id": 20,
      "question": "How does the adoption of LDTI, which MetLife implemented in Q1 2023, specifically alter the treatment of DAC, VOBA, and MRBs within the adjusted earnings calculation, and what operational or financial implications does this have for evaluating segment performance?",
      "original_answer": "The adoption of LDTI in Q1 2023 materially changed MetLife’s adjusted earnings calculation by simplifying the measurement model for DAC and VOBA and reclassifying most embedded derivatives as MRBs. As a result, MetLife updated its adjusted earnings methodology to exclude amortization of DAC, VOBA, and related intangibles, as well as adjustments for changes in measurement of certain guarantees. Adjusted earnings now also exclude changes in fair value associated with MRBs, discount rate changes on annuitization guarantees, and asymmetrical accounting related to in-force reinsurance. These changes were implemented to align with new disclosure and estimation requirements under LDTI, which affect how segment performance is evaluated. The operational implication is that segment results now reflect a more streamlined accounting treatment that removes certain market-driven volatility and non-economic accounting distortions, allowing management to focus on core business trends.",
      "llm_answer": "The adoption of LDTI simplified the measurement of DAC and VOBA and reclassified most embedded derivatives as MRBs, requiring the Company to adjust its adjusted earnings calculation by removing amortization adjustments for DAC/VOBA, excluding changes in MRB fair value, discount‑rate changes on certain annuitization guarantees, inception‑of‑business losses on single‑premium contracts, and asymmetrical in‑force reinsurance accounting. Consequently, adjusted earnings now excludes these items and reflects a revised segment‑level profit measure that better aligns with the new LDTI framework. This shift alters how segment performance is evaluated, as the revised adjusted earnings exclude market‑volatility‑driven gains/losses and other non‑economic adjustments that were previously part of the segment profit metrics.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 170,
          "pages": [
            168,
            169,
            170,
            171,
            172
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 331,
          "pages": [
            329,
            330,
            331,
            332,
            333
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 85596,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21651,
        "completion_tokens": 205,
        "total_tokens": 21856
      }
    },
    {
      "question_id": 20,
      "question": "How does ConocoPhillips' production of condensate from the Aasta Hansteen Field relate to its financial exposure through guarantees tied to Alba Plant LLC in Equatorial Guinea?",
      "original_answer": "ConocoPhillips produces condensate from the Aasta Hansteen Field in the Norwegian Sea, which is transported via shuttle tankers to market. This condensate production is part of COP’s broader upstream operations. In addition to this, COP owns a 52.2% interest in Alba Plant LLC, which processes natural gas from the Alba Unit offshore Equatorial Guinea, extracting condensate and LPG for sale at market prices. The company has financial exposure tied to Alba Plant LLC through guarantees, including a $116 million maximum potential future payment obligation related to agreements to process third-party gas. Therefore, while condensate from Aasta Hansteen contributes to COP’s direct hydrocarbon production and revenue, the company also faces contingent liabilities through its ownership in Alba Plant LLC, which processes both Alba Unit and third-party gas, linking upstream production with downstream financial risk.",
      "llm_answer": "ConocoPhillips’ equity stake in the Alba Unit in Equatorial Guinea is held through Alba Plant LLC, a joint‑venture that processes gas from the field and sells the resulting condensate and LPG.  The company guarantees certain of Alba Plant’s payment and performance obligations, and those guarantees expose ConocoPhillips to financial risk if the venture cannot meet its contractual commitments.  This contingent liability is disclosed in Note 9‑Guarantees, where the company notes a $4 million carrying value for the Equatorial Guinea guarantees tied to Alba Plant LLC.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 55830,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14181,
        "completion_tokens": 142,
        "total_tokens": 14323
      }
    },
    {
      "question_id": 21,
      "question": "What is the relationship between PepsiCo's beverage revenue contribution in APAC and its acquisition or divestiture activity in the same region during fiscal year 2023?",
      "original_answer": "In fiscal year 2023, beverages contributed 23% of PepsiCo's net revenue in the APAC region, as shown in the regional net revenue breakdown. However, the company disclosed $0 in acquisition and divestiture-related charges specifically for the APAC region during the same fiscal year. This indicates that despite a notable portion of revenue coming from beverages in APAC, PepsiCo did not engage in any significant M&A activity in the region during 2023, suggesting a period of operational stability rather than expansion through acquisitions in that geography.",
      "llm_answer": "PepsiCo's beverage revenue contribution in APAC was 23% of its net revenue in 2023, and the company did not record any acquisition or divestiture activity specifically in the APAC region during fiscal year 2023. The document indicates that APAC is one of PepsiCo's seven reportable segments, but all acquisition/divestiture activity described (e.g., the Juice Transaction in Europe and Latin America, TBG investment impairments, and brand portfolio adjustments) occurred in other regions, with no mention of APAC-related transactions in the provided pages.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PEP_10k_2023.pdf",
          "target_page": 72,
          "pages": [
            70,
            71,
            72,
            73,
            74
          ]
        },
        "hop_2_rel": {
          "source_file": "PEP_10k_2023.pdf",
          "target_page": 72,
          "pages": [
            70,
            71,
            72,
            73,
            74
          ]
        },
        "hop_3_rel": {
          "source_file": "PEP_10k_2023.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 62570,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15863,
        "completion_tokens": 139,
        "total_tokens": 16002
      }
    },
    {
      "question_id": 21,
      "question": "How does Amgen's decision to terminate Novartis' U.S. commercialization rights for Aimovig in early 2022 relate to its competitive positioning against Novartis' Cosentyx in the U.S. and Europe, particularly in the context of their ongoing global development cost-sharing arrangement?",
      "original_answer": "Amgen's decision to end Novartis' U.S. commercialization rights for Aimovig in early 2022 severed the joint U.S. marketing arrangement, removing Novartis' ability to share in U.S. costs and profits or receive royalties on U.S. sales. However, Novartis retained global co-development rights and continued to share development expenses with Amgen. At the same time, Novartis' Cosentyx is listed in Amgen's 10-K as a direct competitor to Amgen's Otezla in both the U.S. and Europe. This dual relationship—where Novartis is both a collaborator on Aimovig's global development and a competitor through Cosentyx—creates a complex dynamic. Amgen's restructuring of the Aimovig partnership may reflect a strategic effort to reduce Novartis' influence in the U.S. market while still leveraging shared R&D resources globally, even as Cosentyx competes directly with Amgen's dermatology portfolio.",
      "llm_answer": "Amgen terminated Novartis’ U.S. commercialization rights for Aimovig in early 2022 so that it could capture the full U.S. market and avoid paying Novartis royalties on U.S. sales, while the global development‑cost‑sharing arrangement and double‑digit royalty payments for the ex‑U.S. rights remain unchanged. This move strengthens Amgen’s competitive position against Novartis’ Cosentyx in both the United States and Europe by giving Amgen exclusive U.S. control of Aimovig, whereas the prior collaboration required shared costs and royalty splits.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 28,
          "pages": [
            26,
            27,
            28,
            29,
            30
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 61800,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15702,
        "completion_tokens": 137,
        "total_tokens": 15839
      }
    },
    {
      "question_id": 21,
      "question": "How does ConocoPhillips' impairment of its APLNG investment in 2021 relate to its equity stake in the joint venture and the fair value assessment tied to the Origin Energy transaction?",
      "original_answer": "ConocoPhillips held a 37.5% equity stake in APLNG, which operates in Queensland, Australia, and focuses on producing coal bed methane (CBM) and exporting LNG. In 2021, Origin Energy agreed to sell 10% of its interest in APLNG for $1.645 billion. ConocoPhillips exercised its preemption right to acquire this additional 10% stake, which triggered a fair value assessment. This observable market-based valuation was lower than the carrying value of ConocoPhillips’ existing investment, leading to a noncash impairment charge of $688 million. This impairment reflects the decline in fair value deemed to be other than temporary, reducing the carrying value of the investment to $5,574 million as of December 31, 2021. The impairment decision was directly influenced by the fair value derived from the Origin Energy transaction, illustrating how equity investment decisions and market-based valuations can drive financial impairments.",
      "llm_answer": "ConocoPhillips recorded a $688 million noncash impairment of its APLNG investment in the fourth quarter of 2021 because the pre‑emptive purchase price for an additional 10 % stake ($1.645 billion) reflected a market‑based fair value below the carrying amount of its 37.5 % equity stake; the impairment reduced the investment’s carrying value to $5.574 billion and was recognized as an “Impairments” charge, reflecting the fair‑value assessment tied to the Origin Energy transaction.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 100,
          "pages": [
            98,
            99,
            100,
            101,
            102
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 65535,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16610,
        "completion_tokens": 120,
        "total_tokens": 16730
      }
    },
    {
      "question_id": 21,
      "question": "How does the change in the Netherlands Innovation Box Tax rate from 7% to 9% in 2021, and the corresponding impact on Booking.com's effective tax rate in 2023, reconcile with the company's overall valuation allowance adjustments and international tax exposure under Dutch corporate income tax law?",
      "original_answer": "The Netherlands Innovation Box Tax rate increased from 7% to 9% effective January 1, 2021, which is reflected in the company's effective tax rate for 2023. This lower rate applied to qualifying innovative activities by Booking.com and had a beneficial impact on the effective tax rate, although the benefit decreased compared to prior years. On page 49, the company notes that the 2023 effective tax rate was partially offset by a decrease in the Innovation Box Tax benefit. Meanwhile, page 105 shows that the valuation allowance on deferred tax assets related to international operations decreased from $29 million in 2022 to $30 million in 2023, indicating a relatively stable international tax position despite the rate change. The Dutch corporate income tax law, which governs the Innovation Box Tax, thus influences both the effective tax rate and the deferred tax asset valuation allowances, reflecting a nuanced interaction between tax incentives and tax asset risk.",
      "llm_answer": "The Netherlands Innovation Box Tax rate was reduced from 7% to 9% in 2021, but the effective tax rate for 2023 remained lower than 2022 due to a combination of factors: a lower valuation allowance on deferred tax assets related to unrealized losses on equity securities, reduced unrecognized tax benefits, and a modest increase in the Innovation Box Tax benefit (though partially offset by higher non-deductible fines and a smaller tax benefit from the Innovation Box compared to prior years). While the 2023 effective tax rate of 21.8% (vs. 22.1% in 2022) reflects these adjustments, the company's overall tax position is also shaped by its international tax exposure under Dutch law, where qualifying innovative income is taxed at the 9% Innovation Box rate, though the benefit was diminished in 2023 due to the valuation allowance reduction and other tax adjustments.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BKNG_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_2_rel": {
          "source_file": "BKNG_10k_2023.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_3_rel": {
          "source_file": "BKNG_10k_2023.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 71729,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18190,
        "completion_tokens": 217,
        "total_tokens": 18407
      }
    },
    {
      "question_id": 21,
      "question": "How does the indefinite delay of the final foreign tax credit regulations through Notice 2023-80 impact Microsoft's effective tax rate in fiscal year 2024, and how does this compare to the tax benefits derived from earnings in lower-taxed foreign jurisdictions?",
      "original_answer": "The indefinite delay of the final foreign tax credit regulations through Notice 2023-80 resulted in a tax benefit that contributed to a 1 percentage point decrease in Microsoft's effective tax rate from 19% in fiscal year 2023 to 18% in fiscal year 2024. This benefit was part of broader tax law changes that allowed Microsoft to continue benefiting from earnings in lower-taxed foreign jurisdictions, particularly Ireland, which accounted for 83% of foreign income before tax in fiscal year 2024. While the foreign regional operating center strategy remained a consistent driver of lower effective tax rates across both years, the regulatory delay provided additional near-term tax relief that would have otherwise been constrained under the original regulation timeline.",
      "llm_answer": "The indefinite delay of the final foreign tax credit regulations through Notice 2023‑80 provides Microsoft with a tax benefit that lowers its effective tax rate for fiscal 2024.  This benefit, together with the earnings that are already taxed at lower rates in jurisdictions such as Ireland, helps offset the tax advantages derived from Microsoft’s foreign‑jurisdiction earnings.  Consequently, the tax savings from the delayed regulations complement, rather than replace, the overall lower‑rate earnings effect that drives Microsoft’s effective tax rate down to 18.2 % in FY 2024.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 47,
          "pages": [
            45,
            46,
            47,
            48,
            49
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 57857,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14707,
        "completion_tokens": 145,
        "total_tokens": 14852
      }
    },
    {
      "question_id": 21,
      "question": "How does Duke Energy's use of storm recovery bonds to finance $1 billion in storm-related regulatory assets relate to the company's strategic alignment with North Carolina House Bill 951's clean energy transition goals?",
      "original_answer": "Duke Energy created special purpose subsidiaries (DECNCSF and DEPNCSF) to issue $1.007 billion in storm recovery bonds to finance unrecovered regulatory assets from storms in 2018 and 2019, with the storm recovery property established under state legislation and NCUC financing orders. This financial mechanism allowed Duke Energy Carolinas and Progress to recover storm costs through non-bypassable customer charges. Meanwhile, North Carolina House Bill 951, signed into law in October 2021, established a policy framework to accelerate the clean energy transition, including a 70% carbon reduction target by 2030 and carbon neutrality by 2050. The legislation also introduced modernized recovery mechanisms like multiyear rate plans. By using storm recovery bonds, Duke Energy was able to manage legacy storm costs while simultaneously aligning with the new legislative framework that supports long-term clean energy investments and efficient cost recovery, ensuring continued financial stability and regulatory alignment during its transition to a low-carbon future.",
      "llm_answer": "Duke Energy's issuance of $1 billion in storm‑recovery bonds through its newly created North Carolina subsidiaries (DECNCSF and DEPNCSF) directly finances the unrecovered regulatory assets tied to 2018‑2019 storm costs, providing a dedicated, rate‑payer‑funded source of capital that aligns with the financing structure envisioned by North Carolina House Bill 951. The legislation creates a framework for accelerated clean‑energy transition and modernized recovery mechanisms, enabling utilities to recover investments in infrastructure and regulatory assets more efficiently; by using storm‑recovery bonds, Duke Energy can fund the required regulatory assets while preserving cash flow for its clean‑energy projects outlined in HB 951’s 70 % carbon‑reduction and net‑zero goals. This financing approach supports the company’s strategic objective of channeling capital into grid modernization, renewable expansion, and emissions‑reduction initiatives that HB 951 encourages, ensuring that the capital raised for storm‑related costs does not impede, but rather advances, the broader clean‑energy transition objectives of the state.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2022.pdf",
          "target_page": 202,
          "pages": [
            200,
            201,
            202,
            203,
            204
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2022.pdf",
          "target_page": 202,
          "pages": [
            200,
            201,
            202,
            203,
            204
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2022.pdf",
          "target_page": 44,
          "pages": [
            42,
            43,
            44,
            45,
            46
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 95505,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 24109,
        "completion_tokens": 282,
        "total_tokens": 24392
      }
    },
    {
      "question_id": 21,
      "question": "How does Gilead's revenue share from Symtuza, which is manufactured and commercialized by Janssen, reflect in both the product sales reporting and the collaborative agreement terms with Janssen?",
      "original_answer": "Gilead's revenue share from Symtuza, which is manufactured and commercialized by Janssen, is reported in Gilead's product sales section as $592 million in total revenues for Symtuza in 2024. This revenue share is determined by the financial provisions of the collaboration agreement, where Janssen sets the price of Symtuza and the parties share revenue based on the ratio of the net selling prices of their respective components. Gilead recognizes its share of Symtuza revenue in the period when Janssen's sales occur, primarily because Gilead supplies the Gilead Compounds used in Symtuza. This arrangement highlights how the quantitative revenue reporting in the product sales section is directly influenced by the qualitative terms of the Janssen collaboration agreement, particularly regarding revenue recognition and supply obligations.",
      "llm_answer": "Gilead records its share of Symtuza revenue as product sales on its Consolidated Statements of Operations because it supplies the Gilead compounds to Janssen for the fixed‑dose combination, while Janssen’s share of the revenue is included in cost of goods sold; the revenue‑share arrangement is reflected in the collaborative agreement terms, which specify that Janssen sets the price and the parties share revenues based on the ratio of net selling prices, with Gilead recognizing its portion when Janssen’s sales occur.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "target_page": 66,
          "pages": [
            64,
            65,
            66,
            67,
            68
          ]
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "target_page": 76,
          "pages": [
            74,
            75,
            76,
            77,
            78
          ]
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "target_page": 77,
          "pages": [
            75,
            76,
            77,
            78,
            79
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 89265,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22543,
        "completion_tokens": 130,
        "total_tokens": 22673
      }
    },
    {
      "question_id": 21,
      "question": "How does Georgia Power's request to extend the operation of Plant Scherer Unit 3 through at least December 31, 2035, relate to FP&L's 25% ownership stake in the unit, and what implications does this have for Southern Company's long-term asset management strategy as outlined in the joint ownership agreements?",
      "original_answer": "Georgia Power has requested to extend the operation of Plant Scherer Unit 3 through at least December 31, 2035, as part of its 2025 Integrated Resource Plan filing with the Georgia PSC. This request indicates a strategic decision to maintain and potentially upgrade the unit for long-term reliability and compliance. FP&L holds a 25% ownership stake in Plant Scherer Unit 3, which aligns with Southern Company's broader joint ownership model where Georgia Power operates the plant on behalf of co-owners, including FP&L. This shared ownership structure, detailed in the joint facility agreements, implies that Georgia Power's operational decisions—such as extending the life of the unit—will impact all stakeholders, including FP&L. The long-term asset management strategy of Southern Company, therefore, must account for both regulatory approvals and the coordination of capital investments across co-owned assets to ensure alignment with compliance requirements and stakeholder interests.",
      "llm_answer": "Georgia Power's 2025 IRP requests approval to extend Plant Scherer Unit 3 (614 MW based on 75 % ownership) through at least December 31, 2035, and to extend Gaston Units 1‑4 through December 31, 2034. This request is made possible by the joint‑ownership structure of Plant Scherer, where Georgia Power holds a 75 % stake and the remaining 25 % is owned by other co‑owners, including FP&L. The extension aligns with the joint ownership agreements that govern the unit’s operation and cost‑recovery, allowing Georgia Power to plan long‑term asset management and capital investments while leveraging its majority ownership to secure regulatory approval and financing for continued operation beyond the original schedule.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 54,
          "pages": [
            52,
            53,
            54,
            55,
            56
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 45,
          "pages": [
            43,
            44,
            45,
            46,
            47
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 211,
          "pages": [
            209,
            210,
            211,
            212,
            213
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 79157,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20049,
        "completion_tokens": 179,
        "total_tokens": 20229
      }
    },
    {
      "question_id": 22,
      "question": "How does BMY's legal partnership with Pfizer to defend Eliquis' patents in the U.S. and Europe align with the company's expressed risk regarding potential early generic entry of Eliquis and its impact on market exclusivity projections through 2026?",
      "original_answer": "BMY collaborates with Pfizer to litigate and defend Eliquis' patents in both the U.S. and Europe, as seen in the multiple lawsuits filed against generic challengers like Sandoz and Teva, and the successful U.S. court rulings affirming the validity of Eliquis' composition of matter and formulation patents through 2026. Despite these legal victories, BMY acknowledges in its risk factors that adverse litigation outcomes in Europe could still allow early generic entry of apixaban products before the estimated market exclusivity date, which would negatively affect revenue and market position. This creates a nuanced picture where, although BMY and Pfizer have secured strong legal wins in the U.S., the company remains exposed to risks in Europe that could undermine its exclusivity projections and financial planning tied to Eliquis.",
      "llm_answer": "BMY’s legal partnership with Pfizer to defend Eliquis patents in the U.S. and Europe directly counters its expressed risk of early generic entry by reinforcing the company’s expectation that patent protection will preserve market exclusivity for Eliquis through at least 2026. The partnership, which involves co‑development and shared commercialization responsibilities, is designed to maintain the drug’s pricing power and revenue trajectory despite the looming threat of generic competition. This strategic alignment is reflected in BMY’s 2021 disclosures that anticipate continued exclusivity for Eliquis and underscore the importance of protecting its intellectual property to sustain projected cash flows beyond 2026.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "target_page": 157,
          "pages": [
            137,
            138,
            139,
            140,
            141
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 11,
        "total_chars": 58818,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14951,
        "completion_tokens": 180,
        "total_tokens": 15131
      }
    },
    {
      "question_id": 22,
      "question": "How does the involvement of DeGolyer and MacNaughton in reviewing over 85% of ConocoPhillips' proved reserves estimation processes align with their role as a third-party consultant whose report is included as Exhibit 99 in the 10-K filing?",
      "original_answer": "ConocoPhillips' internal reserves estimation processes are reviewed annually by an internal team that includes a senior representative from DeGolyer and MacNaughton (D&M), a third-party petroleum engineering consulting firm. During 2024, D&M reviewed the processes and controls used to assess over 85% of the company’s proved reserves as of December 31, 2024, to ensure compliance with SEC regulations. Their role was to provide independent validation of the company’s internal controls and estimation methods, which included reviewing seismic data, geologic maps, well logs, production tests, and reservoir simulation models. D&M’s findings were compiled into a formal report, which was included as Exhibit 99 in the 10-K filing. This demonstrates that D&M's role extended beyond advisory input to formal documentation that supports the company’s regulatory disclosures, reinforcing the credibility of the reserves estimation process through third-party validation.",
      "llm_answer": "The involvement of DeGolyer and MacNaughton (D&M) as an independent third‑party consultant whose review of ConocoPhillips’ internal reserves processes covered more than 85 % of the proved reserves is highlighted in the “Reserves Governance” section of the 10‑K.  Specifically, the company notes that D&M’s report—submitted as Exhibit 99—provides an objective, third‑party assessment confirming that ConocoPhillips’ reserves estimation processes and controls are in compliance with SEC regulations, and the report is included in the filing to demonstrate the external validation of the reserves methodology.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 166,
          "pages": [
            164,
            165,
            166,
            167,
            168
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 77716,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19668,
        "completion_tokens": 151,
        "total_tokens": 19820
      }
    },
    {
      "question_id": 22,
      "question": "How does the $18.5 billion in outstanding foreign currency derivatives designated as cash flow hedges relate to the NTC's role in sourcing from third-party factories, and how does this hedging strategy affect the foreign currency exposure created by NTC's sales to NIKE entities with different functional currencies?",
      "original_answer": "The $18.5 billion in outstanding foreign currency derivatives designated as cash flow hedges (from page 85) is directly tied to NIKE’s strategy to manage foreign currency risk associated with product cost exposures, including those generated through the NTC (page 84). The NTC, a wholly-owned sourcing hub, purchases NIKE-branded products from third-party factories in U.S. Dollars and then sells them to NIKE entities in their respective functional currencies, creating foreign currency exposure for the NTC when those entities have different functional currencies (from page 84 and page 46). This exposure is managed through NIKE’s foreign currency adjustment program and the use of derivatives, including embedded derivatives and formally designated cash flow hedges (from page 85). The $18.5 billion hedge portfolio is intended to offset the variability in cash flows caused by these exposures, particularly those stemming from the NTC’s intercompany sales and the fluctuating costs due to foreign exchange rates. This integrated approach reflects how NIKE uses financial instruments to stabilize the economic impact of currency fluctuations across its global supply chain structure.",
      "llm_answer": "The $18.5 billion of foreign‑currency derivatives designated as cash‑flow hedges offsets the foreign‑currency exposure that arises when NTC sells products to NIKE entities with different functional currencies—i.e., when the NTC’s U.S.‑dollar‑based purchases are converted into the local currency of the buying NIKE entity. By hedging these forecasted cash‑flow impacts, the Company limits the translation of currency movements into its earnings, so any gains or losses on the hedges are recorded in Accumulated Other Comprehensive Income and only re‑classified into income when the underlying hedged transaction (such as product‑cost or revenue recognition) affects the Consolidated Statements of Income.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 103529,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 26139,
        "completion_tokens": 176,
        "total_tokens": 26315
      }
    },
    {
      "question_id": 22,
      "question": "How does the foreign currency exposure arising from NKE's transactions through the NTC compare with the exposure from direct purchases by NKE entities from third-party factories, particularly in light of the embedded derivative contracts tied to the factory currency exposure index?",
      "original_answer": "The NTC, as a wholly-owned sourcing hub, purchases NIKE-branded products from third-party factories in U.S. Dollars and sells them to NIKE entities in their respective functional currencies, creating foreign currency exposure for the NTC when it sells to entities with different functional currencies. In contrast, when NKE entities purchase directly from third-party factories in U.S. Dollars, the foreign currency exposure falls on those NKE entities if their functional currency is not the U.S. Dollar. Additionally, the foreign currency adjustment program with certain factories introduces embedded derivative contracts for currencies within the factory currency exposure index that are neither the U.S. Dollar nor the local or functional currency of the factory. As of May 31, 2022, the total notional amount of embedded derivatives outstanding was approximately $584 million, which includes these contracts. This highlights a layered exposure structure where NKE manages risk both through internal sourcing (NTC) and direct factory relationships, with different accounting treatments and hedging strategies applied depending on the transaction structure and currency involved.",
      "llm_answer": "The foreign currency exposure arising from NKE's transactions through the NIKE Trading Company (NTC) is comparable to the exposure from direct purchases by NKE entities from third‑party factories, but it is managed differently. In both cases, a weaker U.S. dollar reduces inventory costs while a stronger dollar raises them. However, purchases from the NTC create a foreign‑currency exposure for the NTC itself, whereas direct purchases expose the buying entity directly. Additionally, the NTC’s sales to entities with different functional currencies generate embedded derivative contracts that are recorded at fair value through other income, whereas direct purchases generate exposure that may be hedged separately. Thus, while the underlying currency risk is similar, the source and accounting treatment of the exposure differ.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 95500,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 24122,
        "completion_tokens": 207,
        "total_tokens": 24330
      }
    },
    {
      "question_id": 22,
      "question": "How does Microsoft's continued partnership with BNY Mellon as trustee, despite the maturity of the 2.95% Notes due in 2014, reflect on the long-term structural reliance on the same trustee across multiple debt issuances?",
      "original_answer": "Microsoft's 2.95% Notes due in 2014 were governed under a First Supplemental Indenture with BNY Mellon Trust Company, N.A., as trustee, dated May 18, 2009. Despite the maturity of these notes, Microsoft continued to partner with BNY Mellon as trustee for subsequent debt issuances, including notes due in 2018, 2023, and 2043, as evidenced by the Eighth Supplemental Indenture dated December 6, 2013. This demonstrates a consistent reliance on BNY Mellon as a trusted intermediary, even after the 2014 notes matured, suggesting a strategic and ongoing partnership rather than a one-time transactional relationship.",
      "llm_answer": "Microsoft's continued use of BNY Mellon as trustee for multiple debt issuances—including the 2.95% Notes due 2014 and subsequent series—reflects a long-term structural reliance on the same trustee across its debt portfolio, underscoring consistent operational and legal arrangements in its financing strategy.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 50013,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12734,
        "completion_tokens": 77,
        "total_tokens": 12811
      }
    },
    {
      "question_id": 22,
      "question": "How does the UPS Retirement Plan's cessation of future benefit accruals for non-union participants as of January 1, 2023, interact with the IRS-prescribed limits on tax-qualified defined benefit plans, and how does this affect the structure of retirement contributions for employees hired after 2025?",
      "original_answer": "The UPS Retirement Plan ceased future benefit accruals for non-union participants effective January 1, 2023, due to IRS-prescribed limits on tax-qualified defined benefit plans, which cap both compensation and annual benefit amounts. In response, UPS transitioned non-union employees to a defined contribution model under the UPS 401(k) Savings Plan, with contributions ranging from 5% to 8% of eligible compensation based on years of vesting service prior to 2025, and a flat 3% contribution for employees hired on or after January 1, 2025. This shift reflects a strategic realignment of retirement benefits to remain within IRS limits while maintaining competitive retirement benefits through a more flexible and cost-controlled defined contribution framework.",
      "llm_answer": "The UPS Retirement Plan stopped accruing benefits for non‑union participants as of January 1 2023, which means that after that date the plan’s benefit obligations are capped by the IRS‑prescribed maximum compensation and benefit limits for tax‑qualified defined‑benefit plans. Because the plan no longer adds new accruals, employees hired after 2025 will not receive any future defined‑benefit payments from the UPS Retirement Plan; instead they will be eligible only for the defined‑contribution structure (the UPS 401(k) Savings Plan) that provides a fixed annual employer contribution (3 % of eligible compensation for those beginning employment on or after January 1 2025). Consequently, their retirement income will depend entirely on the defined‑contribution plan’s investment performance and contribution limits, rather than on a traditional accrued pension benefit.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 87,
          "pages": [
            85,
            86,
            87,
            88,
            89
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 64651,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16411,
        "completion_tokens": 218,
        "total_tokens": 16629
      }
    },
    {
      "question_id": 22,
      "question": "How does BMY's legal partnership with Pfizer to defend Eliquis' patents in the U.S. and Europe relate to the risk that generic competition poses to Eliquis' market exclusivity and future revenue projections?",
      "original_answer": "BMY, in partnership with Pfizer, has actively defended Eliquis' patents in both the U.S. and Europe, securing favorable court decisions that upheld the composition of matter and formulation patents through 2026 in the U.S. However, in Europe, multiple lawsuits have been filed by Sandoz and Teva, among others, challenging the validity of the apixaban composition of matter patent, with trials and legal proceedings ongoing or pending in several countries. Despite these legal defenses, BMY acknowledges in its risk factors that generic competition could still emerge earlier than expected, particularly if adverse litigation outcomes occur in the EU, which could undermine the exclusivity timeline and negatively impact future revenue projections tied to Eliquis. The company’s financial guidance assumes a certain exclusivity period, and any disruption from generic entry would have a material effect on Eliquis' profitability, especially given that Pfizer shares in the development costs and global profits of the drug.",
      "llm_answer": "The partnership with Pfizer to jointly defend Eliquis patents in the U.S. and Europe is directly tied to mitigating the risk of generic competition eroding Eliquis’ market exclusivity and future revenue. As noted in the document, generic entry—such as anticipated biosimilar competition for Eliquis—can cause \"very substantial and rapid declines in a product’s revenues\" once market exclusivity expires, and the company explicitly states that \"the future growth of BMS is dependent on... new product introductions, new indications, product extensions and co-promotional activities.\" The legal defense of Eliquis’ patent portfolio is therefore a strategic measure to preserve the product’s exclusivity period and protect the revenue stream that currently accounts for a significant portion of BMS’s total revenue ($10,762 million in 2021, as shown in Note 15). Without such legal protection, generic competition could enter the market earlier than projected, directly undermining the revenue assumptions underlying BMS’s financial guidance.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "target_page": 157,
          "pages": [
            137,
            138,
            139,
            140,
            141
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 11,
        "total_chars": 58818,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14941,
        "completion_tokens": 259,
        "total_tokens": 15200
      }
    },
    {
      "question_id": 22,
      "question": "How does Honeywell's valuation methodology for its investment in Garrett's Series B Preferred Stock reflect the mandatory redemption terms and partial redemptions executed in 2021 and early 2022?",
      "original_answer": "Honeywell initially valued the Series B Preferred Stock at fair value based on the present value of mandatory redemptions totaling $835 million (including $35 million in 2022 and $100 million annually from 2023 to 2030), discounted at 7.25%. However, Garrett executed a First Partial Redemption of $211 million on December 28, 2021, and planned a Second Partial Redemption of $200 million in Q1 2022, which altered the future redemption schedule and reduced the present value of remaining mandatory redemptions to $400 million after the First Partial Redemption and $207 million after the Second. Honeywell adjusted its valuation accordingly, reflecting the impact of these redemptions on the investment's fair value and interest income accretion over time.",
      "llm_answer": "Honeywell's valuation methodology for its investment in Garrett's Series B Preferred Stock incorporates the mandatory redemption schedule and the partial redemptions executed in 2021 and early 2022 by discounting the expected future redemption amounts at the 7.25 % rate specified in the Series B Preferred Stock Certificate of Designation. This present‑value approach reflects the mandatory $35 million redemption due in 2022 and the subsequent $100 million annual redemptions from 2023‑2030, adjusted for the accelerated first‑partial redemption of $211 million in December 2021 and the contingent second‑partial redemption of $200 million planned for early 2022, resulting in a fair‑value measurement classified as Level 2.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_2_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "hop_3_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 76103,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19254,
        "completion_tokens": 181,
        "total_tokens": 19435
      }
    },
    {
      "question_id": 22,
      "question": "How does the $177 million in storm recovery bonds issued by Duke Energy Progress in April 2024 relate to the formation and consolidation of DEPNC SF, and what does this imply about Duke Energy Progress' strategy for financing long-term storm-related regulatory assets?",
      "original_answer": "The $177 million in storm recovery bonds issued by Duke Energy Progress in April 2024 was facilitated through its special-purpose subsidiary, DEPSC SF, which is part of a broader structure that includes DEPNC SF. DEPNC SF was formed in 2021 and is consolidated by Duke Energy Progress as a VIE, due to its insufficient equity capitalization and Duke's control over its operations. This structure allows Duke Energy Progress to finance long-term storm-related regulatory assets—specifically, those incurred from 2014 through 2022—by securitizing them and collecting non-bypassable charges from retail customers over time. The use of VIEs like DEPNC SF and DEPSC SF enables Duke Energy Progress to isolate these assets and liabilities from its broader balance sheet, securing debt financing without recourse to the parent company. This reflects a strategic approach to managing regulatory assets and aligning storm cost recovery with long-term customer-funded mechanisms.",
      "llm_answer": "The $177 million of storm‑recovery bonds issued by Duke Energy Progress in April 2024 were created by the newly formed special‑purpose subsidiary DEPNC SF to finance the unrecovered storm‑related regulatory assets that had been accumulated in North and South Carolina.  Because the bonds are secured by the storm‑recovery property and the non‑bypassable charge imposed on customers, the financing allows Duke Energy Progress to recover those regulatory assets over time without having to raise capital through its rate base, reflecting a strategy of using dedicated securitization vehicles to fund long‑term storm‑related regulatory assets and to keep retail rates stable during the construction and recovery periods.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 152,
          "pages": [
            150,
            151,
            152,
            153,
            154
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 205,
          "pages": [
            203,
            204,
            205,
            206,
            207
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 205,
          "pages": [
            203,
            204,
            205,
            206,
            207
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 103621,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 26152,
        "completion_tokens": 179,
        "total_tokens": 26331
      }
    },
    {
      "question_id": 23,
      "question": "How does Altria's acquisition of NJOY for $2.9 billion align with its strategic positioning of e-vapor products as a key component of its 'Moving Beyond Smoking' vision, particularly given NJOY's role as the only e-vapor manufacturer with FDA-authorized pod-based products?",
      "original_answer": "Altria's acquisition of NJOY for $2.9 billion demonstrates a strategic commitment to expanding its portfolio of reduced-risk products, directly supporting its 'Moving Beyond Smoking' vision. NJOY, as the only e-vapor manufacturer with FDA-authorized pod-based e-vapor products, provides Altria with a credible and regulated pathway to transition adult smokers away from combustible products. This aligns with Altria's broader positioning in its business description (page 4) that emphasizes leading the transition to a smoke-free future. The acquisition, detailed in the financial statements (page 60), reflects a significant investment in e-vapor innovation and regulatory compliance, reinforcing the company’s strategic narrative of responsible leadership in tobacco harm reduction.",
      "llm_answer": "The $2.9 billion acquisition of NJOY aligns directly with Altria’s “Moving Beyond Smoking” vision, positioning e‑vapor as a core growth pillar; NJOY is the only e‑vapor manufacturer with FDA‑authorized pod‑based products, giving Altria a unique, regulated market entry to accelerate its smoke‑free transition.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 75985,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19241,
        "completion_tokens": 77,
        "total_tokens": 19318
      }
    },
    {
      "question_id": 23,
      "question": "How does Amgen's disclosure of performance unit compensation expense for 2024 relate to the maximum potential share issuance under the Amended 2009 Plan, considering the fungible share-counting formula and performance-based payout structure?",
      "original_answer": "Amgen reported $133 million in performance unit compensation expense for 2024, which is part of the broader Amended 2009 Plan that allows for up to 59 million shares available for future grants. The Plan uses a fungible share-counting formula where each performance unit counts as 1.9 shares. As of year-end 2024, there were 1,516,669 shares subject to outstanding 2022–2024 performance units, including dividend equivalents. However, these performance units are subject to a performance-based payout structure that could result in up to 200% of the target shares being issued if above-target performance goals are met. This means the actual share issuance—and potentially the future compensation expense—could be significantly higher than the current $133 million reflects, depending on performance outcomes. The expense figure on page 124, therefore, captures only the current-year accrual based on expected performance, while the Plan disclosure on page 92 reveals the full potential dilutive impact under the share-counting methodology and performance multipliers.",
      "llm_answer": "Amgen’s 2024 performance‑unit compensation expense of $133 million reflects the accrual of equity awards that are tied to the fungible share‑counting formula in its Amended 2009 Plan, where each performance unit counts as 1.9 shares; the maximum potential share issuance under that plan is capped at roughly 59 million shares, and the performance‑unit awards can ultimately result in up to 200 % of the target units being earned, meaning the actual share count could expand by an additional ~12 million shares if full performance targets are met. This structure links the expense recognized to the number of shares that may ultimately be issued, with the $133 million expense representing the portion of the potential share‑issuance that has been earned to date.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 124,
          "pages": [
            122,
            123,
            124,
            125,
            126
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 124,
          "pages": [
            122,
            123,
            124,
            125,
            126
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 92,
          "pages": [
            90,
            91,
            92,
            93,
            94
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 72148,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18276,
        "completion_tokens": 190,
        "total_tokens": 18466
      }
    },
    {
      "question_id": 23,
      "question": "How does the foreign currency exposure associated with NKE's use of NTC for sourcing from third-party factories relate to the embedded derivative contracts tied to factory input costs, and what does this imply about the effectiveness of NKE's foreign currency risk management program in offsetting inventory cost volatility?",
      "original_answer": "NKE's use of the NTC (a wholly-owned sourcing hub) creates foreign currency exposure when it sells products to NIKE entities with different functional currencies. This exposure is compounded by the fact that NTC purchases products from third-party factories predominantly in U.S. Dollars. Simultaneously, NKE operates a foreign currency adjustment program with certain factories, under which fluctuations in the basket of currencies affecting factory input costs create embedded derivative contracts. These contracts, totaling $584 million as of May 31, 2022, are recorded at fair value and recognized in Other (income) expense, net. However, some of these exposures are natural offsets to NKE's existing foreign currency exposures, suggesting that the company's risk management program is designed to internally balance these exposures before resorting to external hedging instruments. The $18.5 billion in outstanding foreign currency derivatives and the $607 million in deferred net gains expected to be reclassified into Net Income further indicate that NKE actively manages these exposures across its supply chain, aiming to stabilize inventory costs despite currency fluctuations.",
      "llm_answer": "NKE's foreign currency risk management program, which leverages the NIKE Trading Company (NTC) and a factory currency adjustment program, effectively offsets inventory cost volatility by embedding derivatives into product cost exposures and using natural offsets within its global sourcing portfolio. This program, combined with central management of foreign currency exposures through hedging instruments (including embedded derivatives recorded in Other income/expense), delays the impact of exchange rate movements on consolidated results, thereby mitigating volatility in inventory costs driven by currency fluctuations. However, the effectiveness of this program is limited by the inherent complexity of managing exposures across diverse factories and the reliance on hedge accounting for only portions of the risk, meaning it does not fully eliminate volatility but rather manages it through structured offsetting mechanisms.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 95500,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 24133,
        "completion_tokens": 232,
        "total_tokens": 24366
      }
    },
    {
      "question_id": 23,
      "question": "How does Duke Energy's compliance strategy with North Carolina's HB 951, which mandates a 70% reduction in CO₂ emissions by 2030, align with its long-term resource planning and operational execution in the Carolinas, particularly in light of the 2023 Carolinas Resource Plan and the NCUC's 2022 carbon plan approval?",
      "original_answer": "Duke Energy's compliance strategy with HB 951, which requires a 70% reduction in CO₂ emissions by 2030, is reflected in its 2023 Carolinas Resource Plan, where the company proposed Portfolio 3 as the most prudent path forward. This aligns with the NCUC's 2022 carbon plan approval, which was informed by Duke's earlier IRPs and stakeholder engagement. The IRP process, which includes a range of CO₂ pricing scenarios, supports long-term planning under regulatory uncertainty. However, the NCUC's initial rejection of Duke’s accelerated coal retirement scenario in 2021 highlights the regulatory challenge of aligning corporate climate goals with state-mandated timelines. The recent filing of the 2023 Plan, which includes near-term actions and proposes exiting coal by 2035, shows Duke's attempt to reconcile HB 951's mandates with operational feasibility and cost-effectiveness.",
      "llm_answer": "Duke Energy’s compliance strategy with North Carolina’s HB 951—requiring a 70 % CO₂ reduction by 2030—is embedded in its long‑term resource planning through the 2023 Carolinas Resource Plan (Portfolio 3), which outlines an “all‑of‑the‑above” mix of renewables, storage, efficiency, nuclear life extensions and accelerated coal retirements to meet the state‑approved carbon plan and PBR framework. The company aligns operational execution by integrating CO₂‑price assumptions into its IRP process, securing NCUC approval of its carbon plan and PBR mechanisms, and using least‑cost planning to ensure reliability while pursuing aggressive emissions‑reduction targets.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 71,
          "pages": [
            69,
            70,
            71,
            72,
            73
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 232,
          "pages": [
            230,
            231,
            232,
            233,
            234
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 87403,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22110,
        "completion_tokens": 166,
        "total_tokens": 22276
      }
    },
    {
      "question_id": 23,
      "question": "How does Honeywell's accounting treatment of its investment in Garrett's Series B Preferred Stock reflect the redemption terms agreed upon during Garrett's emergence from bankruptcy, and how does this impact Honeywell's long-term receivables and investment valuation?",
      "original_answer": "Honeywell initially accounted for its investment in Garrett's Series B Preferred Stock at fair value upon Garrett's emergence from bankruptcy on April 30, 2021, receiving 834.8 million shares as part of the reorganization plan. The Series B Preferred Stock includes mandatory redemptions starting at $35 million in 2022 and $100 million annually from 2023 to 2030, subject to EBITDA and liquidity conditions. Subsequent amendments accelerated partial redemptions, including a $211 million payment made by Garrett on December 28, 2021, with an additional $200 million expected in Q1 2022. Honeywell applies a 7.25% discount rate to the present value of mandatory redemptions to determine fair value, which accretes into interest income over time. As of December 31, 2021, Honeywell reported $423 million in long-term receivables related to its Garrett investments, including the Series B Preferred Stock. This valuation method reflects both the contractual redemption terms and the uncertainty around future EBITDA performance and liquidity availability, directly influencing how Honeywell accounts for the investment on its balance sheet.",
      "llm_answer": "Honeywell’s accounting for its investment in Garrett’s Series B Preferred Stock reflects the redemption terms set out in the Series B Certificate of Designation, which require mandatory redemptions of $35 million in 2022 and $100 million per year from 2023‑2030 (subject to EBITDA and liquidity conditions). The Company records the stock at fair value using the present value of those mandatory redemptions discounted at 7.25 %, and the discount is amortized into interest income over the redemption period. Because the redemption schedule extends through 2030, the investment is classified as a long‑term receivable and is not marked‑to‑market; its valuation is based on observable market data (Level 2) and the accrued interest is recognized as earnings over time.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_2_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "hop_3_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 76103,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19272,
        "completion_tokens": 191,
        "total_tokens": 19463
      }
    },
    {
      "question_id": 23,
      "question": "How does ConocoPhillips' decision to exercise its preemption right to acquire an additional 10% stake in APLNG relate to its strategic focus on CBM production in Australia, particularly in light of APLNG's $4.7 billion in outstanding project finance obligations?",
      "original_answer": "ConocoPhillips exercised its preemption right to purchase an additional 10% interest in APLNG in December 2021, despite the carrying value of its existing investment being written down to $5,574 million due to fair value considerations. APLNG, a joint venture focused on producing coal bed methane (CBM) from the Bowen and Surat basins in Queensland, Australia, operates under significant project financing obligations, with $4.7 billion outstanding as of December 31, 2023. This financing includes a non-recourse facility structured through the Export-Import Bank of the United States, commercial banks, and U.S. Private Placement note facilities. Despite the financial burden of these obligations, COP’s strategic move to increase its stake in APLNG underscores its commitment to expanding its CBM production footprint in Australia, aligning with its broader LNG export strategy targeting Asia Pacific markets.",
      "llm_answer": "ConocoPhillips exercised its preemption right to acquire an additional 10% stake in APLNG to strengthen its strategic focus on coalbed methane (CBM) production in Australia, a key component of its LNG portfolio. This acquisition occurred despite APLNG carrying $4.7 billion in outstanding project finance obligations, reflecting ConocoPhillips’ commitment to expanding its CBM resources and LNG capabilities in the region.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 72330,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18326,
        "completion_tokens": 105,
        "total_tokens": 18432
      }
    },
    {
      "question_id": 23,
      "question": "How does Southern Company's credit arrangement structure for Nicor Gas, as outlined in the liquidity and credit facilities section, align with the reported decrease in Nicor Gas's short-term notes payable from $392 million in 2023 to $172 million in 2024?",
      "original_answer": "Southern Company's credit arrangement for Nicor Gas, detailed on page 223, includes a $700 million allocation under a multi-year credit facility expiring in 2029, specifically restricted for Nicor Gas's working capital needs. This facility allows for flexible adjustments in allocations between Southern Company Gas Capital and Nicor Gas. The financial data on page 224 shows a significant decrease in Nicor Gas's short-term notes payable from $392 million in 2023 to $172 million in 2024, with a corresponding weighted average interest rate drop from 5.5% to 4.6%. This suggests that Nicor Gas likely utilized the flexible credit facility to refinance or reduce its higher-cost short-term debt. The alignment indicates that Southern Company's strategic liquidity support through its credit arrangements enabled Nicor Gas to optimize its short-term debt profile, reflecting both operational flexibility and financial discipline.",
      "llm_answer": "Southern Company’s liquidity and credit facilities show that Nicor Gas had access to a dedicated $700 million sub‑limit within the 2029 multi‑year credit arrangement and also maintained a separate $100 million credit facility that expires in 2025.  The company used this borrowing capacity to fund Nicor Gas’s working‑capital needs, which is why the short‑term notes payable tied to Nicor Gas declined sharply from $392 million in 2023 to $172 million in 2024.  The reduction reflects the repayment of existing commercial‑paper borrowings and the utilization of the available credit lines, aligning the credit‑arrangement structure with the lower reported notes payable balance.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 223,
          "pages": [
            221,
            222,
            223,
            224,
            225
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 224,
          "pages": [
            222,
            223,
            224,
            225,
            226
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 224,
          "pages": [
            222,
            223,
            224,
            225,
            226
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 84241,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21298,
        "completion_tokens": 169,
        "total_tokens": 21468
      }
    },
    {
      "question_id": 24,
      "question": "How does the change in the Netherlands Innovation Box Tax rate and its application to Booking.com's earnings affect the company's effective tax rate in 2023 compared to 2022, and what does this reveal about the company's tax exposure under Dutch Corporate Income Tax Law?",
      "original_answer": "The Netherlands Innovation Box Tax rate increased from 7% to 9% for periods beginning on or after January 1, 2021, and the Dutch statutory rate rose from 25% to 25.8% effective January 1, 2022. Booking.com's earnings qualified for this preferential tax treatment, significantly benefiting the company's effective tax rate in both 2022 and 2023. However, the effective tax rate for 2023 was lower than in 2022, primarily due to a decrease in the valuation allowance against deferred tax assets related to unrealized losses on equity securities, lower unrecognized tax benefits, and lower international tax rates, despite a reduced benefit from the Innovation Box Tax. This reveals that while the Innovation Box Tax continues to provide a meaningful benefit, its diminishing impact combined with broader changes in tax provisions and international tax rates influences the company's overall tax exposure under Dutch Corporate Income Tax Law.",
      "llm_answer": "The Netherlands Innovation Box Tax rate was reduced from 7% to 9% for qualifying innovative income beginning in 2021, but increased to 25.8% for the statutory corporate rate effective January 1, 2022. This change resulted in a significant decrease in the benefit from the Innovation Box Tax in 2023 compared to 2022, contributing to a higher effective tax rate (21.8% in 2023 vs. 22.1% in 2022) despite the lower statutory rate, revealing that Booking.com's tax exposure under Dutch Corporate Income Tax Law is now more vulnerable to increases in the statutory rate and less reliant on the favorable Innovation Box Tax treatment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BKNG_10k_2023.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "hop_2_rel": {
          "source_file": "BKNG_10k_2023.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_3_rel": {
          "source_file": "BKNG_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 71729,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18183,
        "completion_tokens": 157,
        "total_tokens": 18341
      }
    },
    {
      "question_id": 24,
      "question": "How does Microsoft's ongoing use of The Bank of New York Mellon Trust Company as trustee in multiple supplemental indentures relate to the foundational terms established in the Base Indenture from 2009, and what does this imply about the continuity and structure of Microsoft's long-term debt obligations?",
      "original_answer": "Microsoft has consistently used The Bank of New York Mellon Trust Company (BNY Mellon) as trustee across multiple supplemental indentures for various debt issuances, including the 1.625% Notes due 2018, 3.625% Notes due 2023, and 4.875% Notes due 2043 (dated December 6, 2013), and earlier issuances such as the 2.95% Notes due 2014 (dated May 18, 2009). These supplemental indentures are all governed by the Base Indenture dated May 18, 2009. This continuity implies that Microsoft has maintained a consistent legal and structural framework for its long-term debt obligations, leveraging the Base Indenture as a foundational document to efficiently issue new debt instruments over time while preserving standardized terms and oversight through a trusted trustee relationship.",
      "llm_answer": "Microsoft's continued use of The Bank of New York Mellon Trust Company as trustee across numerous supplemental indentures demonstrates a deliberate, long-term structural commitment to maintaining a consistent trustee relationship for its debt obligations. This practice reinforces the continuity and stability of Microsoft's $40+ billion long-term debt framework, which originated with the foundational 2009 Base Indenture, ensuring reliable administration and legal oversight of its multi-series secured notes through successive amendments and extensions.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 50013,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12755,
        "completion_tokens": 139,
        "total_tokens": 12894
      }
    },
    {
      "question_id": 24,
      "question": "Given Disney's 50% ownership in A+E and the reported domestic subscriber figures for HISTORY and A&E channels, how does the equity investment structure align with the financial treatment of these channels as disclosed in the investments section?",
      "original_answer": "Disney's 50% ownership in A+E, as disclosed in the equity investments section, means that the financial performance of A+E's channels—including HISTORY and A&E—is accounted for under the equity method. The reported domestic subscriber figures (70 million for HISTORY and 69 million for A&E) indicate that both channels have substantial reach, yet their financial results are not fully consolidated into Disney's financial statements. Instead, Disney reports its share of A+E's income under 'Equity in the income (loss) of investees, net.' This aligns with the investments section disclosure that A+E is treated as an equity method investment with a book value exceeding the underlying net assets by $0.8 billion, reflecting amortizable intangible assets and goodwill. Thus, despite the high subscriber base of these channels, Disney's financial reporting reflects only its proportional stake, not full operational control.",
      "llm_answer": "The SEC filing shows that Disney holds a 50% equity stake in A+E Networks, with Hearst owning the other half, and that A+E’s domestic subscriber estimates (e.g., HISTORY ≈ 70 million, A&E ≈ 69 million) are reported in the “Domestic subscribers (1) – A+E” table. This equity‑method investment is disclosed under “Investments – Equity Basis,” where the company’s share of A+E’s financial results is recorded as “Equity in the income (loss) of investees, net.” The subscriber figures are used to illustrate the reach of A+E’s channels but do not alter the accounting treatment; the investment is still carried at its book value and equity‑method accounting remains the basis for financial reporting.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 51544,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 13124,
        "completion_tokens": 174,
        "total_tokens": 13298
      }
    },
    {
      "question_id": 24,
      "question": "How does the inclusion of Eliquis in the Medicare Drug Price Negotiation Program, which sets a maximum fair price effective in 2026, reconcile with its 11% U.S. revenue growth in 2023, and what implications does this have for Pfizer's future pricing strategy under increasing regulatory pressure?",
      "original_answer": "Eliquis, which reported $6,747 million in global revenue in 2023 with 11% U.S. growth, is a key product for Pfizer. However, its inclusion in the Medicare Drug Price Negotiation Program, where a 'maximum fair price' will be set by CMS and published by September 2024, introduces significant pricing pressure starting in 2026. This regulatory development, highlighted in the broader context of the Inflation Reduction Act (IRA), signals a shift in how Pfizer may need to approach pricing and rebate strategies for high-revenue drugs. The company acknowledges the uncertainty around the IRA's full impact, particularly as it faces increasing government and payer scrutiny, including Medicaid rebate changes and 340B Program reforms. Given Eliquis's strong U.S. performance driven by market share gains, the upcoming price negotiation could constrain future revenue growth unless offset by further market expansion or strategic pricing adjustments. This dynamic underscores the tension between current revenue momentum and future regulatory constraints.",
      "llm_answer": "The inclusion of Eliquis in the Medicare Drug Price Negotiation Program—subject to a CMS‑set “maximum fair price” that will take effect in 2026—does not conflict with its 11 % U.S. revenue growth reported for 2023; rather, the growth reflects continued market‑share gains and adoption of Eliquis in the U.S. prior to the price‑cap implementation. However, the looming price ceiling, together with broader IRA‑driven Medicare pricing reforms and increasing pressure from managed‑care organizations, signals that Pfizer will need to adjust its pricing strategy, likely emphasizing value‑based contracts, greater discounts, and a shift toward higher‑margin products to preserve profitability under the new regulatory constraints.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "target_page": 44,
          "pages": [
            42,
            43,
            44,
            45,
            46
          ]
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "target_page": 18,
          "pages": [
            16,
            17,
            18,
            19,
            20
          ]
        },
        "hop_3_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 115747,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 29193,
        "completion_tokens": 181,
        "total_tokens": 29374
      }
    },
    {
      "question_id": 24,
      "question": "What is the fair value of MDLZ's net investment hedge contracts as disclosed in their financial instruments table, and how does the valuation methodology for these contracts align with the broader approach used for Level 2 financial assets?",
      "original_answer": "The fair value of MDLZ's net investment hedge contracts, as disclosed in their financial instruments table, is $71 million as of December 31, 2021. These contracts are categorized under Level 2 financial assets, which are valued using an income approach based on observable market inputs. Specifically, for net investment hedge contracts, the valuation methodology aligns with that of other Level 2 instruments such as OTC currency exchange forwards and interest rate swaps, which rely on observable market rates and discounted cash flow analyses. This consistent application of valuation techniques across Level 2 financial assets underscores MDLZ's adherence to standardized methodologies that reflect market observability and risk management practices.",
      "llm_answer": "The fair value of MDLZ's net investment hedge contracts, as disclosed in the financial instruments table, is $71 million (asset) as of December 31 2021 and $(15) million (liability) as of December 31 2020. These contracts are valued using Level 2 inputs—primarily observable market forward rates and other readily observable market data—consistent with the broader methodology used for Level 2 financial assets, which relies on significant other observable inputs rather than quoted prices in active markets.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 111,
          "pages": [
            109,
            110,
            111,
            112,
            113
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 78234,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19793,
        "completion_tokens": 127,
        "total_tokens": 19920
      }
    },
    {
      "question_id": 24,
      "question": "How does ConocoPhillips' financial exposure through its 47.5% ownership in APLNG, including guarantees totaling over $1 billion in potential liability, reconcile with its strategic emphasis on CBM production from the Bowen and Surat basins as a core component of its LNG portfolio?",
      "original_answer": "ConocoPhillips' 47.5% ownership in APLNG gives it access to coal bed methane (CBM) resources in Queensland, Australia, which is a key part of its global LNG strategy. However, this strategic position comes with significant financial exposure, including a $610 million potential liability (up to $1.0 billion in case of intentional or reckless breach) tied to APLNG's natural gas delivery commitments. Despite these risks, COP continues to highlight APLNG's CBM production as central to its LNG export capabilities, particularly to Asia Pacific markets. The company's $5.0 billion carrying value in APLNG as of December 31, 2024, suggests confidence in the long-term value of the CBM resource despite the contingent liabilities, indicating a strategic trade-off between risk and reward in its LNG portfolio positioning.",
      "llm_answer": "ConocoPhillips’ 47.5 % stake in APLNG is secured by multiple guarantees that could expose the company to up to roughly $1 billion of potential liability if APLNG fails to meet its obligations under gas‑sales contracts or other joint‑venture commitments.  This financial exposure coexists with ConocoPhillips’ strategic push to grow its liquefied‑natural‑gas portfolio through core CBM production from the Bowen and Surat basins in Australia, using APLNG as the primary vehicle for exporting that gas to Asia‑Pacific markets.  The guarantees therefore represent a contingent risk that is distinct from, but complementary to, the company’s broader LNG growth strategy.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 63691,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16172,
        "completion_tokens": 166,
        "total_tokens": 16339
      }
    },
    {
      "question_id": 25,
      "question": "How might the FSPTCA's advertising restrictions on brand-sponsored events and promotional items, combined with increased private sector restrictions on tobacco product communications, be contributing to the observed 0.6 share point sequential increase in discount brand performance, given Altria's compliance costs under the FSPTCA's manufacturing practice requirements?",
      "original_answer": "The FSPTCA's advertising restrictions, such as the prohibition on brand-sponsored events and distribution of promotional items like branded apparel, limit Altria's ability to differentiate premium brands in the marketplace. This limitation is compounded by private sector activity referenced on page 42, where national retailers and digital platforms have restricted tobacco product communications. These combined constraints reduce premium brand marketing effectiveness at a time when page 39 shows Altria faces increased compliance costs under FSPTCA's manufacturing practice requirements, which could constrain investment in brand differentiation strategies. This creates a scenario where consumers may be more price-sensitive with fewer compelling brand narratives available, contributing to the 0.6 share point sequential increase in discount brand performance observed on page 35.",
      "llm_answer": "The FSPTCA’s advertising restrictions on brand‑sponsored events and promotional items, together with broader private‑sector limits on tobacco communications, have helped shrink the pool of traditional marketing channels. As a result, adult tobacco consumers are increasingly turning to lower‑priced discount brands, which explains the 0.6‑share‑point sequential rise in discount‑brand performance. At the same time, Altria must absorb higher compliance costs to meet the FSPTCA’s manufacturing‑practice requirements, further pressuring its pricing and margin structure.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2024.pdf",
          "target_page": 39,
          "pages": [
            37,
            38,
            39,
            40,
            41
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2024.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2024.pdf",
          "target_page": 42,
          "pages": [
            40,
            41,
            42,
            43,
            44
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 85118,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21551,
        "completion_tokens": 142,
        "total_tokens": 21693
      }
    },
    {
      "question_id": 25,
      "question": "How does the risk associated with Oak Street Health's participation in CMS Innovation Center models, such as ACO REACH, impact the long-term value of the goodwill recognized from its acquisition by CVS?",
      "original_answer": "The goodwill recognized from the acquisition of Oak Street Health by CVS was part of a broader acquisition strategy that included Signify Health in 2023, contributing to an increase in the carrying amount of goodwill during that year. Oak Street Health is subject to several risks tied to its participation in CMS Innovation Center models like ACO REACH, including annual changes that may reduce payments to participants and the lack of a long-term plan for ongoing participation in these models. These regulatory and financial risks could undermine the ability of Oak Street Health to generate consistent returns, which in turn could threaten the long-term value of the goodwill recognized in the acquisition. The annual impairment tests conducted by CVS in 2024 and 2023 found no impairment of goodwill, but the exposure of Oak Street Health to CMS model volatility raises concerns about the sustainability of its performance and, consequently, the durability of the goodwill value on CVS's balance sheet.",
      "llm_answer": "The risk that Oak Street Health’s participation in CMS Innovation Center models such as ACO REACH could reduce its future revenue and profitability directly undermines the long‑term value of the goodwill recorded from its acquisition by CVS, because any impairment of Oak Street Health’s earnings would diminish the cash‑flow benefits that were a key driver of the purchase price. Consequently, the goodwill recognized on CVS’s balance sheet remains vulnerable to future write‑downs if Oak Street Health’s performance deteriorates under these CMS models.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "target_page": 150,
          "pages": [
            148,
            149,
            150,
            151,
            152
          ]
        },
        "hop_2_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "target_page": 44,
          "pages": [
            42,
            43,
            44,
            45,
            46
          ]
        },
        "hop_3_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "target_page": 44,
          "pages": [
            42,
            43,
            44,
            45,
            46
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 72140,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18264,
        "completion_tokens": 138,
        "total_tokens": 18402
      }
    },
    {
      "question_id": 25,
      "question": "How does Disney's strategic bundling of ESPN+ with Disney+ and Hulu relate to the fees paid by ABC Network to ESPN, and what does this imply about the internal value of ESPN's sports content across Disney's ecosystem?",
      "original_answer": "Disney strategically bundles ESPN+ with Disney+ and Hulu to enhance the value proposition of its DTC offerings, leveraging ESPN's exclusive sports content such as UFC pay-per-view events and live sports programming. This bundling strategy aligns with the fees paid by ABC Network to ESPN for programming rights, indicating that ESPN's sports content is a critical asset that supports both traditional linear networks and new DTC platforms. The internal valuation of ESPN's content is further emphasized by the fact that ESPN+ had 26 million subscribers as of September 2024, and ABC Network relies on ESPN for sports programming, which in turn drives content licensing revenue. This interconnected value chain shows that ESPN's content is not only monetized directly through subscriptions but also indirectly through affiliate fees and enhanced DTC bundling strategies.",
      "llm_answer": "Disney's strategic bundling of ESPN+ with Disney+ and Hulu creates internal value for ESPN's sports content by enabling cross-platform distribution and subscriber growth across Disney's ecosystem. This bundling allows Disney to leverage ESPN's premium sports rights to drive adoption of its broader streaming services, while the fees paid by ABC Network to ESPN for programming on ABC and certain sports content on Disney+ reflect the internal monetization of ESPN's content within Disney's integrated platform. Consequently, ESPN's sports content functions as a key differentiator and revenue driver that enhances the overall value of Disney's streaming portfolio, supporting higher subscriber retention and engagement across its direct-to-consumer offerings.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 61625,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15639,
        "completion_tokens": 190,
        "total_tokens": 15829
      }
    },
    {
      "question_id": 25,
      "question": "How does Boeing's increased reach-forward loss on the Commercial Crew program in 2021 relate to the inherent cost estimation risks in fixed-price development contracts, and what does this reveal about the financial exposure tied to technical complexity and schedule delays in such contracts?",
      "original_answer": "Boeing's increased reach-forward loss of $185 million on the Commercial Crew program in 2021 was driven by delays in the second uncrewed Orbital Flight Test and the evolving assessment of remaining work. This aligns with the broader risk profile of fixed-price development contracts, where revenue is fixed but cost estimates are highly uncertain due to technical complexity and schedule variability. The Commercial Crew program is specifically highlighted as one of Boeing's significant fixed-price development contracts, and the company notes that such contracts are inherently risky, with potential for material charges if cost overruns or delays occur. The audit process for these contracts, including Commercial Crew, involved extensive evaluation of cost estimation methods, project status, and controls over judgment and assumptions, underscoring the difficulty in forecasting final costs. This reveals that technical challenges and schedule delays not only trigger financial losses but also increase the likelihood of future reach-forward loss recognition, exposing Boeing to significant financial volatility in its development programs.",
      "llm_answer": "Boeing’s 2021 earnings were hit by a $402 million reach‑forward loss on the KC‑46A tanker and a $185 million loss on the Commercial Crew program, illustrating how fixed‑price development contracts expose the company to cost‑overrun risks when technical complexity and schedule delays emerge. The company’s accounting for these contracts requires estimating total program costs and revenue at completion; when those estimates prove too low—because of design challenges, supply‑chain disruptions, or pandemic‑related inefficiencies—Boeing records large reach‑forward losses, underscoring the inherent financial exposure of fixed‑price development work.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 134,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 45,
          "pages": [
            43,
            44,
            45,
            46,
            47
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 54095,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 13779,
        "completion_tokens": 162,
        "total_tokens": 13942
      }
    },
    {
      "question_id": 25,
      "question": "How does Altria's acquisition of NJOY for $2.9 billion align with its strategic positioning of e-vapor products as part of its 'Moving Beyond Smoking' vision, given NJOY's role as the only e-vapor manufacturer with FDA-authorized pod-based products?",
      "original_answer": "Altria's acquisition of NJOY for $2.9 billion reflects a significant financial commitment to integrating e-vapor products into its broader portfolio, aligning with its stated 'Moving Beyond Smoking' vision to transition adult smokers to potentially less harmful alternatives. NJOY, as the only e-vapor manufacturer with FDA-authorized pod-based products, provides Altria with a competitive edge in the regulatory landscape, enhancing its ability to credibly market reduced-risk products. This strategic move is further reinforced by NJOY's exclusive focus on e-vapor products, which are contract-manufactured and sold in the U.S., positioning Altria to capitalize on the growing consumer and regulatory preference for scientifically vetted alternatives to traditional combustible tobacco products.",
      "llm_answer": "Altria's $2.9 billion acquisition of NJOY aligns with its “Moving Beyond Smoking” vision by adding the only e‑vapor manufacturer that holds FDA‑authorized pod‑based products, thereby expanding its smoke‑free portfolio and accelerating the transition of adult smokers to potentially less harmful alternatives. The purchase, completed on June 1 2023, integrates NJOY as a wholly owned subsidiary and strengthens Altria’s strategic positioning in the rapidly evolving e‑vapor market.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 75985,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19235,
        "completion_tokens": 120,
        "total_tokens": 19355
      }
    },
    {
      "question_id": 25,
      "question": "How does Emerson's recognition of a $453 pretax gain from Vertiv in fiscal 2022 align with the strategic implications of having sold its Network Power Systems business in 2017 and the potential for additional future distributions of $75 based on Vertiv's equity performance?",
      "original_answer": "Emerson recognized a $453 pretax gain in fiscal 2022 from its retained subordinated interest in Vertiv, the entity to which its Network Power Systems business was rebranded and sold in 2017. The sale structure included a contingent payout mechanism, under which Emerson would only receive distributions after Vertiv’s equity holders achieved a threshold cash return. In the first quarter of fiscal 2022, that threshold was exceeded, triggering a $438 distribution to Emerson. Based on current projections, the company expects to receive additional distributions of approximately $75 over the next two to three years. However, these future payments are contingent on the timing and price of Vertiv share sales by the equity holders, introducing uncertainty around both the amount and timing of further gains. This financial outcome reflects a strategic divestiture that not only provided an initial exit benefit but also retained a structured upside tied to Vertiv’s post-spinoff performance, aligning with Emerson’s broader capital allocation and portfolio optimization strategy.",
      "llm_answer": "Emerson recognized a $453 pretax gain from its retained subordinated interest in Vertiv in fiscal 2022, which aligns with the strategic outcome of having sold its Network Power Systems business in 2017 and now being positioned to receive additional future distributions of roughly $75 tied to Vertiv’s equity performance. This gain reflects the culmination of the 2017 divestiture and the ongoing contingent upside from that transaction.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "EMR_10k_2022.pdf",
          "target_page": 58,
          "pages": [
            56,
            57,
            58,
            59,
            60
          ]
        },
        "hop_2_rel": {
          "source_file": "EMR_10k_2022.pdf",
          "target_page": 58,
          "pages": [
            56,
            57,
            58,
            59,
            60
          ]
        },
        "hop_3_rel": {
          "source_file": "EMR_10k_2022.pdf",
          "target_page": 28,
          "pages": [
            26,
            27,
            28,
            29,
            30
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 55239,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14055,
        "completion_tokens": 109,
        "total_tokens": 14164
      }
    },
    {
      "question_id": 25,
      "question": "How does Duke Energy's financial obligation for coal ash basin closures under the 2024 CCR Rule relate to the expanded regulatory scope compared to the 2015 CCR Rule, and what does this imply about the long-term cost trajectory for managing previously unregulated coal ash sources?",
      "original_answer": "Duke Energy recorded asset retirement obligations (AROs) on its balance sheet for coal ash basin closures due to the 2024 CCR Rule, which significantly expands the scope of the 2015 CCR Rule by regulating inactive surface impoundments at retired facilities and previously unregulated coal ash sources. The 2015 CCR Rule applied to active landfills and impoundments receiving coal combustion residuals (CCRs), but the 2024 Rule now includes legacy impoundments and other CCR management units that were previously unregulated. This expansion increases Duke Energy's compliance burden, as it now must address groundwater monitoring, corrective action, and potential closure for these newly regulated units. The company estimates that the total cost to permanently close all coal ash basins in North and South Carolina is between $8 billion and $9 billion, with approximately $4.4 billion already spent through 2024, and the majority of the remaining spend expected over the next 10 years. This implies a significant long-term cost trajectory driven by the expanded regulatory framework under the 2024 CCR Rule.",
      "llm_answer": "Duke Energy’s 2024 CCR Rule obligations require the company to close previously unregulated coal‑ash basins and inactive surface impoundments, expanding the scope of regulated ash disposal beyond the 2015 rule’s focus on active landfills. This broader regulatory coverage means the company must now fund the closure of a larger set of sites, driving a sustained increase in long‑term cost trajectories for ash‑management activities. Consequently, Duke Energy expects significant, ongoing capital outlays for ash‑basin remediation that will continue to rise as the expanded rule’s requirements are fully implemented.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 102292,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 25820,
        "completion_tokens": 153,
        "total_tokens": 25974
      }
    },
    {
      "question_id": 26,
      "question": "What is the strategic significance of GM's $4.2 billion investment premium in nonconsolidated affiliates in relation to the production and marketing of crossovers?",
      "original_answer": "GM's $4.2 billion investment premium in nonconsolidated affiliates, primarily attributed to goodwill from fresh-start reporting and additional stake purchases, indicates a strategic emphasis on leveraging these partnerships for key product lines such as crossovers. These nonconsolidated affiliates are directly involved in the development, production, and marketing of crossovers, which are integral to GM's broader product portfolio. Furthermore, crossovers are a core component of GM's retail and fleet sales strategy, contributing significantly to market demand and aligning with consumer preferences. This suggests that GM's investment premium is not only a reflection of goodwill but also a strategic commitment to maintaining a strong presence in the crossover segment through collaborative ventures.",
      "llm_answer": "GM's $4.2 billion investment premium in nonconsolidated affiliates reflects the excess of the carrying value of its equity‑method investments over its share of the affiliates' net assets. This premium, largely attributable to goodwill from fresh‑start reporting and recent purchases of additional stakes, underscores the strategic importance of these partnerships in supporting the development, production and marketing of cross‑over vehicles—particularly in China—by providing capital, technology and distribution synergies that enhance GM’s global product portfolio and growth prospects.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        },
        "hop_2_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        },
        "hop_3_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 102739,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 25905,
        "completion_tokens": 147,
        "total_tokens": 26052
      }
    },
    {
      "question_id": 26,
      "question": "How does Microsoft's reported 22.2% year-over-year revenue growth in Server products and cloud services ($97.7B in FY24 vs $79.97B in FY23) relate to their strategic positioning of Windows Server as hybrid cloud infrastructure, particularly considering its role in enabling Azure adoption for enterprises maintaining on-premises systems?",
      "original_answer": "Microsoft's Server products and cloud services revenue grew from $79.97B in FY23 to $97.726B in FY24, representing a 22.2% year-over-year increase. This growth is directly tied to the strategic positioning of Windows Server as hybrid cloud infrastructure, as stated in the segment description where Server products are explicitly included in the Intelligent Cloud segment that powers modern business and developers. The technical capabilities of Windows Server as on-premises infrastructure that integrates with Azure cloud services (as described in the Server Products and Cloud Services section) enable enterprises to maintain hybrid environments. This hybrid approach likely drives Azure adoption and consumption-based services referenced in the Azure description, which in turn contributes to the strong revenue growth in the Server products and cloud services category.",
      "llm_answer": "Microsoft's 22.2% YoY revenue growth in Server products and cloud services ($97.7B in FY24 vs $79.97B in FY23) directly supports its strategic positioning of Windows Server as hybrid cloud infrastructure by driving Azure adoption among enterprises maintaining on-premises systems. This growth, fueled by Azure's 30% consumption-based expansion and hybrid solutions demand (including Windows Server and SQL Server in multi-cloud environments), demonstrates how Microsoft leverages Windows Server's role in enabling seamless hybrid cloud transitions—allowing enterprises to extend on-premises Windows Server workloads to Azure while adopting cloud services, thereby accelerating Azure consumption and reinforcing Microsoft Cloud as a core growth engine.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 42,
          "pages": [
            40,
            41,
            42,
            43,
            44
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 56414,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14369,
        "completion_tokens": 187,
        "total_tokens": 14557
      }
    },
    {
      "question_id": 26,
      "question": "Given that Star Wars is a major licensed property contributing to Disney's royalty-based revenue model, and that Disney+ includes Star Wars as a top-level branded tile, how does the potential for brand damage risk described in the risk factors section threaten both the licensing revenue stream and the strategic positioning of Disney+?",
      "original_answer": "The Company earns royalty-based revenue from licensing characters such as Star Wars across multiple product categories, including toys, apparel, and consumer electronics (page 22). Star Wars is also a top-level branded tile on Disney+, which is a key part of the Company's direct-to-consumer strategy (page 12). However, the risk factors section warns that damage to Disney's reputation or brands could negatively impact sales, profitability, and brand strength across businesses, including those not directly involved in the initial brand damage (page 29). Since Star Wars is both a major licensing revenue driver and a core brand asset on Disney+, any reputational harm to the Star Wars brand could directly reduce licensing royalties and indirectly harm Disney+'s subscriber growth and content appeal. This dual exposure means that brand damage could undermine both a key revenue stream and a central component of Disney’s DTC strategy.",
      "llm_answer": "The risk factors warn that brand damage to the Star Wars franchise could erode the royalty income Disney receives from licensing the property and could also weaken Disney+’s strategic positioning by undermining one of its flagship branded tiles, thereby jeopardizing subscriber growth and the platform’s competitive edge.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 22,
          "pages": [
            20,
            21,
            22,
            23,
            24
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 71957,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18255,
        "completion_tokens": 80,
        "total_tokens": 18335
      }
    },
    {
      "question_id": 26,
      "question": "How does Amgen's concern about biosimilars as a competitive threat in the Risk Factors section reconcile with the specific revenue decline and competitive pressures observed in Aranesp's 2023 sales performance?",
      "original_answer": "Amgen highlights in its Risk Factors section that biosimilars pose an increasing threat to its marketed products, particularly as they can rely on existing safety and efficacy data to enter the market more quickly and at lower prices. This concern is substantiated in the sales performance of Aranesp, which faced direct competition from EPOGEN and its biosimilars, leading to a decline in both unit demand and net selling price in 2023. Specifically, U.S. Aranesp sales dropped due to independent and medium-sized dialysis organizations shifting to EPOGEN, demonstrating the real-world impact of biosimilar competition on Amgen’s revenue. The connection between the risk disclosure and the observed financial impact underscores how biosimilar entry not only aligns with the company’s strategic concerns but also directly affects its product-specific revenue streams.",
      "llm_answer": "Amgen’s 2023 10‑K notes that biosimilars are a “significant competitive threat” in the Risk Factors section, yet the same filing shows that Aranesp’s U.S. sales fell 13 % in 2023—driven by lower unit demand as dialysis centers shift to EPOGEN and its biosimilars—and that overall Aranesp revenue declined 4 % globally, reflecting the impact of biosimilar competition on pricing and market share. This illustrates how the company’s warning about biosimilar pressure is consistent with the actual revenue decline and heightened competitive pressures observed for Aranesp in 2023.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "target_page": 15,
          "pages": [
            13,
            14,
            15,
            16,
            17
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 75660,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19145,
        "completion_tokens": 144,
        "total_tokens": 19289
      }
    },
    {
      "question_id": 26,
      "question": "How did the acquisition of Swedish Match impact the trajectory of PM's smoke-free revenue growth in the Americas segment, particularly with respect to the ZYN brand's contribution?",
      "original_answer": "The acquisition of Swedish Match significantly accelerated PM's smoke-free revenue growth trajectory, particularly in the Americas segment, where the ZYN brand—acquired as part of Swedish Match—contributed $2,065 million in 2023, compared to just $246 million in 2022 (before the acquisition was fully integrated). This represents a more than 700% increase in smoke-free revenue contribution from the Americas segment post-acquisition, underscoring the strategic importance of ZYN in expanding PM's presence in the U.S. oral nicotine market.",
      "llm_answer": "The acquisition of Swedish Match accelerated PMI’s smoke‑free growth in the Americas by adding the leading U.S. oral‑nicotine pouch brand ZYN to its portfolio, which boosted the region’s smoke‑free revenue trajectory and contributed significantly to overall segment operating income. This integration helped PMI expand its smoke‑free footprint and drive higher growth in the Americas market.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PM_10k_2023.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_2_rel": {
          "source_file": "PM_10k_2023.pdf",
          "target_page": 6,
          "pages": [
            4,
            5,
            6,
            7,
            8
          ]
        },
        "hop_3_rel": {
          "source_file": "PM_10k_2023.pdf",
          "target_page": 117,
          "pages": [
            115,
            116,
            117,
            118,
            119
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 66509,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16850,
        "completion_tokens": 97,
        "total_tokens": 16947
      }
    },
    {
      "question_id": 26,
      "question": "How does ConocoPhillips' $688 million pre-tax charge related to its investment in APLNG reconcile with the long-term production outlook for CBM in Queensland, given APLNG's role in developing CBM resources for LNG export?",
      "original_answer": "ConocoPhillips recorded a $688 million pre-tax charge in 2021 when it exercised its preemption right to purchase an additional 10% stake in APLNG, reflecting a fair value assessment that was below the carrying value of the existing investment. This write-down indicates a significant downward adjustment in the perceived value of APLNG at that time. Despite this financial impairment, APLNG remains a core asset in ConocoPhillips' portfolio, focused on producing coal bed methane (CBM) from the Bowen and Surat basins in Queensland, Australia, with plans for approximately 3,500 net wells to supply both LNG export contracts and the domestic gas market. The long-term production outlook for CBM appears optimistic in operational and strategic sections, suggesting a strategic bet on future CBM production growth to justify continued investment despite the earlier financial loss. This juxtaposition highlights a tension between short-term valuation adjustments and long-term resource development expectations.",
      "llm_answer": "The $688 million pre‑tax charge recorded in 2021 reflects the impairment of ConocoPhillips’ equity investment in APLNG, which was written down to its fair value of $5.574 billion after Origin Energy sold a 10 % stake in APLNG and Conoco exercised its pre‑emption right. This impairment was driven by a decline in the observable market‑based valuation of APLNG’s CBM resources in Queensland, which are intended for future LNG export. Consequently, the charge aligns with the long‑term production outlook for Queensland’s coal‑bed methane (CBM) resources, as the impairment acknowledges that the fair‑value estimate—based on internal cash‑flow models and external price outlooks—supports a reduced valuation of the APLNG investment despite its role in developing CBM for LNG export.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 63384,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16084,
        "completion_tokens": 195,
        "total_tokens": 16279
      }
    },
    {
      "question_id": 26,
      "question": "How does Southern Company's strategic request to extend the operation of Plant Gaston Units 1 through 4 beyond 2028, as outlined in the 2025 Integrated Resource Plan, align with SEGCO's current ownership structure and financial obligations, particularly regarding capacity payments and equity income distribution?",
      "original_answer": "Southern Company's 2025 IRP filing includes a request to extend the operation of Plant Gaston Units 1 through 4 (500 MWs based on 50% ownership through SEGCO) through at least December 31, 2034, despite SEGCO's current expectation of retiring these units by 2028. SEGCO, which is equally owned by Alabama Power and Georgia Power, operates these units and sells their capacity equally to both parent companies. In 2024, each company paid $118 million and $115 million respectively in capacity payments to SEGCO, which also distributed $20 million in dividends (50% to each owner). This strategic move to extend Plant Gaston's life suggests a shift in long-term resource planning, which must be reconciled with SEGCO's existing financial commitments and ownership dynamics, including ongoing operating cost allocations and return on equity expectations.",
      "llm_answer": "Southern Company's 2025 IRP requests Georgia Power to extend Plant Gaston Units 1‑4 beyond 2028, and SEGCO—50 % owned by Alabama Power and Georgia Power—holds the capacity and incurs the related financial obligations; under the current ownership structure, SEGCO’s capacity payments and equity income are passed through to the owners, so any extension would affect their capacity‑payment responsibilities and the distribution of SEGCO’s equity income to Alabama Power and Georgia Power.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 187,
          "pages": [
            185,
            186,
            187,
            188,
            189
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 216,
          "pages": [
            214,
            215,
            216,
            217,
            218
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 98178,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 24806,
        "completion_tokens": 121,
        "total_tokens": 24927
      }
    },
    {
      "question_id": 27,
      "question": "How does Morgan Stanley's deferral of the CECL impact on capital ratios affect the regulatory capital position of Morgan Stanley Bank, N.A., particularly in relation to its phased-in implementation timeline and the firm's overall leverage-based capital requirements?",
      "original_answer": "Morgan Stanley elected to defer the impact of CECL on risk-based and leverage-based capital amounts, RWA, and supplementary leverage exposure over a five-year transition period. As of January 1, 2023, the deferral impacts were phased in at 50%, increasing to full phase-in by January 1, 2025. This deferral helps maintain the regulatory capital ratios of Morgan Stanley Bank, N.A. (MSBNA), which must remain well-capitalized under OCC PCA standards. MSBNA's capital ratios are calculated under the Standardized Approach, and the CECL deferral supports its ability to meet minimum Tier 1 leverage ratio (4%), SLR (3%), and enhanced SLR buffer (2%) requirements by reducing the immediate capital burden of CECL adoption.",
      "llm_answer": "Morgan Stanley's deferral of CECL impacts its capital ratios by delaying the full effect of the CECL standard on risk-based and leverage-based capital requirements, including RWA and supplementary leverage exposure calculations, over a five-year transition period. The deferral began phasing in at 25% per year starting January 1, 2022, increased to 50% from January 1, 2023, and will be fully phased in by January 1, 2025. This deferral allows the firm to maintain higher capital ratios during the transition, as the impacts of CECL adoption on capital amounts and ratios are gradually incorporated, ensuring continued compliance with regulatory capital buffers and requirements until fully implemented.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MS_10k_2023.pdf",
          "target_page": 153,
          "pages": [
            151,
            152,
            153,
            154,
            155
          ]
        },
        "hop_2_rel": {
          "source_file": "MS_10k_2023.pdf",
          "target_page": 135,
          "pages": [
            133,
            134,
            135,
            136,
            137
          ]
        },
        "hop_3_rel": {
          "source_file": "MS_10k_2023.pdf",
          "target_page": 54,
          "pages": [
            52,
            53,
            54,
            55,
            56
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 111963,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 28241,
        "completion_tokens": 176,
        "total_tokens": 28417
      }
    },
    {
      "question_id": 27,
      "question": "How does Microsoft's repeated use of The Bank of New York Mellon Trust Company as a trustee across multiple debt issuances, including the 5.20% Notes due 2039, reflect on the strategic and legal structuring of its long-term debt obligations?",
      "original_answer": "Microsoft has consistently used The Bank of New York Mellon Trust Company, N.A. (BNY Mellon) as a trustee for multiple debt issuances, including the 5.20% Notes due 2039, as evidenced by the repeated appearance of BNY Mellon in supplemental indentures across various note maturities and interest rates (e.g., 1.625% Notes due 2018, 3.500% Notes due 2035, and 4.750% Notes due 2055). This pattern indicates a strategic and long-standing legal relationship with BNY Mellon, which likely provides consistency and efficiency in the structuring of Microsoft’s debt instruments. The 5.20% Notes due 2039 are specifically governed under the First Supplemental Indenture dated May 18, 2009, which is part of a broader Base Indenture with BNY Mellon. This repeated use of the same trustee across decades of debt issuances suggests that Microsoft values continuity in legal oversight and administrative execution, particularly for long-dated obligations like the 2039 notes, which carry a higher coupon rate compared to shorter-term instruments. This implies a deliberate legal and financial structuring approach to manage long-term liabilities with trusted counterparties.",
      "llm_answer": "Microsoft's consistent use of The Bank of New York Mellon Trust Company as trustee across multiple debt issuances, including the 5.20% Notes due 2039, reflects a deliberate strategic and legal approach to structuring long-term debt. By appointing a single, established trustee to administer its indentures and supplemental indentures, Microsoft ensures continuity in compliance, streamlines administrative processes, and leverages the trustee’s expertise in managing complex debt instruments. This repeated use underscores the institutionalized nature of its debt financing framework, facilitating scalability and regulatory adherence across decades of capital market activity.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 50013,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12739,
        "completion_tokens": 169,
        "total_tokens": 12909
      }
    },
    {
      "question_id": 27,
      "question": "Given LLY's acknowledgment of challenges in predicting market exclusivity durations, how does the specific 2036 biologics data protection expiry date for Kisunla in the U.S. illustrate the potential discrepancy between stated protection timelines and actual market exclusivity periods?",
      "original_answer": "LLY acknowledges on page 11 that predicting market exclusivity durations is complex due to the interaction between patent and regulatory protections and uncertainties around litigation. However, in the product-specific table on page 13, Kisunla is shown to have a clear 2036 biologics data protection expiry date in the U.S. This concrete date appears to contradict the company's more cautious stance about the unpredictability of exclusivity timelines. The discrepancy highlights how LLY presents specific protection dates with confidence in one section, while simultaneously cautioning investors about the limitations of relying solely on these dates for predicting actual market exclusivity in another section.",
      "llm_answer": "LLY’s 2024 10‑K notes that the “length of market exclusivity for our products can be difficult to predict with certainty because of the complex interaction between patent and regulatory forms of exclusivity and the inherent uncertainties regarding patent litigation.” The table for the Neuroscience product Kisunla shows a **compound‑patent expiry in the U.S. listed as 2036** and a **biologics‑data‑protection expiry also listed as 2036**. Because data‑protection periods are set by law (e.g., 12 years for new biologics under the BPCIA) and can be extended or shortened by regulatory or legislative changes, the actual market‑exclusivity period may end earlier or later than the “estimated” patent date. Thus, the 2036 date for Kisunla illustrates how the company’s published protection timeline can diverge from the real‑world exclusivity period that results from the interplay of patent terms, data‑protection rules, and potential patent challenges.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 12,
        "total_chars": 57088,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14517,
        "completion_tokens": 238,
        "total_tokens": 14755
      }
    },
    {
      "question_id": 27,
      "question": "How does ConocoPhillips' engagement of DeGolyer and MacNaughton to review reserves estimation processes, as disclosed in Exhibit 99, align with the company's internal controls over reserves reporting and the qualifications of the individual overseeing those controls?",
      "original_answer": "ConocoPhillips engages DeGolyer and MacNaughton (D&M), a third-party petroleum engineering consulting firm, to annually review the company's reserves estimation processes for over 85% of proved reserves as of December 31, 2024, ensuring alignment with SEC regulations. This external review is part of a broader internal control framework led by the Manager of Reserves Compliance and Reporting, a reservoir engineering expert with over 20 years of industry experience. The internal team, which includes D&M's senior representative, conducts on-site visits, teleconferences, and documentation reviews to ensure consistency and adherence to both company policy and SEC guidelines. This structured oversight mechanism, combining internal expertise and independent third-party validation, reinforces the integrity of reserves reporting despite the inherent imprecision in reserves estimation.",
      "llm_answer": "ConocoPhillips engages DeGolyer and MacNaughton to independently review the adequacy and effectiveness of its internal controls over reserves estimation and reporting, as disclosed in Exhibit 99. The review, conducted by D&M’s senior representative alongside internal reserves compliance staff, assesses compliance with SEC guidelines and company policy, and D&M’s opinion confirmed that the processes and controls used to estimate December 31 2024 proved reserves were in accordance with SEC definitions. The technical lead overseeing these controls is ConocoPhillips’ Manager of Reserves Compliance and Reporting, who holds a master’s degree in reservoir engineering and more than 20 years of industry experience.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 166,
          "pages": [
            164,
            165,
            166,
            167,
            168
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 77716,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19675,
        "completion_tokens": 178,
        "total_tokens": 19854
      }
    },
    {
      "question_id": 28,
      "question": "How does the reported sensitivity of BAC's mortgage-backed securities to a weakening U.S. housing market align with the significant unrealized losses disclosed in their AFS debt securities portfolio as of December 31, 2023?",
      "original_answer": "BAC highlights on page 14 that a deeper downturn in the U.S. housing market could lead to significant write-downs in asset values, particularly for mortgage-backed securities (MBS), due to declining real estate values and increased credit losses. This sensitivity is corroborated by the data disclosed on page 114, which shows that as of December 31, 2023, BAC held $38.422 billion in MBS with a total gross unrealized loss of $2.205 billion, split between short-term and long-term unrealized losses. This alignment indicates that the ongoing weakness in the housing market, driven by higher mortgage rates and reduced affordability, has already begun to impact the valuation of MBS in BAC's portfolio, supporting the risk narrative outlined earlier in the document.",
      "llm_answer": "The sensitivity analysis shows that BAC’s mortgage‑backed securities are highly vulnerable to a weakening U.S. housing market, which would drive down the fair value of those securities and increase credit losses. This exposure is reflected in the large unrealized losses reported in the AFS debt‑securities portfolio—$3.98 billion of gross unrealized losses at year‑end 2023—demonstrating that the same macro‑economic stress that hurts the housing market is already materializing as significant unrealized losses in the bank’s AFS holdings. Consequently, the reported sensitivity to a housing‑market downturn aligns closely with the magnitude of the unrealized losses disclosed for the AFS portfolio.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BAC_10k_2023.pdf",
          "target_page": 14,
          "pages": [
            12,
            13,
            14,
            15,
            16
          ]
        },
        "hop_2_rel": {
          "source_file": "BAC_10k_2023.pdf",
          "target_page": 14,
          "pages": [
            12,
            13,
            14,
            15,
            16
          ]
        },
        "hop_3_rel": {
          "source_file": "BAC_10k_2023.pdf",
          "target_page": 114,
          "pages": [
            112,
            113,
            114,
            115,
            116
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 112449,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 28346,
        "completion_tokens": 175,
        "total_tokens": 28521
      }
    },
    {
      "question_id": 28,
      "question": "How does the adoption of ASU 2022-04 impact Colgate's disclosure requirements for Supplier Finance Programs in 2024, particularly regarding the confirmed amount outstanding and roll-forward information?",
      "original_answer": "The adoption of ASU 2022-04 in 2023 introduced new disclosure requirements for Colgate’s Supplier Finance Programs, including the confirmed amount outstanding at the end of the period and roll-forward information. These disclosures became effective for Colgate beginning January 1, 2024, as noted in the financial statements section on page 84. This aligns with the company’s broader critical accounting policies section on page 57, which reiterates the requirement to disclose key terms and balance sheet presentation related to these obligations, emphasizing the importance of transparency in supplier finance liabilities.",
      "llm_answer": "The adoption of ASU 2022‑04 (Supplier Finance Programs) requires Colgate‑Palmolive to disclose, among other items, the confirmed amount outstanding under its supplier finance programs at period‑end and to provide roll‑forward information for those balances. Because the Company adopted the guidance for roll‑forward disclosures beginning January 1 2024, its 2024 10‑K filing includes the required year‑end confirmed amount and the roll‑forward schedule that shows movements in the supplier‑finance‑program liabilities during the reporting period. This satisfies the ASU’s annual disclosure and roll‑forward requirements for 2024.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CL_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_2_rel": {
          "source_file": "CL_10k_2024.pdf",
          "target_page": 57,
          "pages": [
            55,
            56,
            57,
            58,
            59
          ]
        },
        "hop_3_rel": {
          "source_file": "CL_10k_2024.pdf",
          "target_page": 57,
          "pages": [
            55,
            56,
            57,
            58,
            59
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 63143,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16013,
        "completion_tokens": 157,
        "total_tokens": 16170
      }
    },
    {
      "question_id": 28,
      "question": "How does Chevron's 2023 crude oil reserve growth in Kazakhstan, particularly from extensions and discoveries, align with the Caspian Pipeline Consortium's (CPC) throughput capacity expansion and its role in transporting Chevron's production?",
      "original_answer": "Chevron's 2023 crude oil reserves in Kazakhstan saw significant additions from extensions and discoveries, including 660 billion cubic feet (BCF) from such activities, indicating active exploration and development efforts. This aligns with Chevron's strategic focus on expanding production in the region, particularly through projects like the Future Growth Project (FGP) and Wellhead Pressure Management Project (WPMP) at TCO. These projects are expected to ramp up production starting in 2025. The Caspian Pipeline Consortium (CPC), in which Chevron holds a 15% interest, completed a debottlenecking project in January 2023 that increased throughput capacity. This expansion directly supports the anticipated rise in crude oil exports from Kazakhstan, including Chevron's production, as the CPC pipeline transported an average of 1.4 million barrels per day in 2023. Therefore, the growth in reserves and the pipeline's capacity enhancement are strategically synchronized to support Chevron's upstream development plans in Kazakhstan.",
      "llm_answer": "Chevron's 2023 crude oil reserve growth in Kazakhstan, driven by extensions and discoveries (170 million barrels in Kazakhstan), aligns with the Caspian Pipeline Consortium’s (CPC) throughput capacity expansion, as CPC’s debottlenecking project achieved mechanical completion in January 2023, enabling increased transport of the additional production from Tengiz and Karachaganak fields. This capacity boost supports the transport of Chevron’s growing Kazakh output through the CPC pipeline.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 113,
          "pages": [
            111,
            112,
            113,
            114,
            115
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 95828,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 24195,
        "completion_tokens": 122,
        "total_tokens": 24318
      }
    },
    {
      "question_id": 28,
      "question": "Given the 33% year-over-year revenue growth in Server products and cloud services, how does the inclusion of Visual Studio within this segment suggest strategic alignment between Microsoft's developer tools and cloud infrastructure priorities?",
      "original_answer": "The 33% year-over-year growth in Server products and cloud services—from $67.35B in 2022 to $97.726B in 2024—demonstrates strong momentum in Microsoft's cloud and infrastructure offerings. Within this segment, Visual Studio is explicitly listed alongside core cloud services like Azure and server software such as SQL Server and Windows Server. This inclusion indicates that Microsoft views developer tools like Visual Studio not just as standalone software products, but as integral components of its broader cloud and enterprise strategy. By grouping Visual Studio with cloud infrastructure and server platforms, Microsoft aligns its development ecosystem with its cloud growth engine, reinforcing a unified approach where developer productivity tools directly support cloud adoption and hybrid IT environments. This strategic bundling suggests that Visual Studio plays a pivotal role in enabling developers to build and deploy applications on Azure, thereby driving sustained usage and monetization of Microsoft’s cloud infrastructure.",
      "llm_answer": "The 33% YoY revenue growth in Server products and cloud services is driven by Azure’s expansion, with Visual Studio included as a key component of the Intelligent Cloud segment’s server offerings. This reflects Microsoft’s strategic alignment of developer tools (like Visual Studio) with cloud infrastructure priorities, as Visual Studio enables developers to build, test, and deploy applications on Azure, directly fueling cloud adoption and revenue growth. The integration of Visual Studio into the cloud-focused segment underscores Microsoft’s emphasis on empowering developers to leverage its cloud platform through familiar tooling.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 42,
          "pages": [
            40,
            41,
            42,
            43,
            44
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 56414,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14346,
        "completion_tokens": 159,
        "total_tokens": 14505
      }
    },
    {
      "question_id": 28,
      "question": "How does Caterpillar's repeated amendment of the 3-Year Credit Facility with Citibank, N.A. as Agent reflect on the evolving nature of their long-term debt obligations, particularly in light of Citibank's historical role as Trustee under Caterpillar's older indentures?",
      "original_answer": "Caterpillar has amended its 3-Year Credit Facility twice in recent years (August 31, 2023, and August 29, 2024), with Citibank, N.A. serving as Agent. This indicates an ongoing and dynamic financial relationship. Meanwhile, Citibank has also historically played a structural role in Caterpillar's long-term debt framework, having been appointed as Successor Trustee under the original Indenture from May 1, 1987, and involved in multiple supplemental indentures dating back to 1992. The repeated amendments to the credit facility suggest Caterpillar's need to adapt its short- to medium-term financing arrangements, while Citibank's long-standing trustee role underscores its deep-rooted involvement in Caterpillar's capital structure. This dual role highlights Citibank's strategic importance to Caterpillar's financing across different time horizons and financial instruments.",
      "llm_answer": "Caterpillar’s repeated amendments to its 3‑Year Credit Facility—most recently the August 2024 Amendment No. 2—show that the company is actively reshaping the terms and structure of its long‑term borrowing, while still relying on Citibank, N.A. as the administrative agent. This pattern underscores a dynamic approach to debt management, even though Citibank has historically served as trustee in the company’s older indenture documents.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CAT_10k_2024.pdf",
          "target_page": 131,
          "pages": [
            129,
            130,
            131,
            132,
            133
          ]
        },
        "hop_2_rel": {
          "source_file": "CAT_10k_2024.pdf",
          "target_page": 131,
          "pages": [
            129,
            130,
            131,
            132,
            133
          ]
        },
        "hop_3_rel": {
          "source_file": "CAT_10k_2024.pdf",
          "target_page": 128,
          "pages": [
            126,
            127,
            128,
            129,
            130
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 94572,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 23887,
        "completion_tokens": 109,
        "total_tokens": 23996
      }
    },
    {
      "question_id": 28,
      "question": "How does Southern Company's reliance on nuclear power plants for a significant portion of electricity generation intersect with their exposure to financial risks related to nuclear decommissioning and carbon policy uncertainty?",
      "original_answer": "Southern Company relies on nuclear power plants, which supplied approximately 26% and 28% of total KWHs generated by Alabama Power and Georgia Power respectively in 2021. These nuclear facilities are subject to significant financial risks, including decommissioning costs that may exceed available capital reserves and insurance coverage. Meanwhile, the company also faces financial exposure from evolving GHG regulations and carbon policy uncertainty, which could affect both the economics of existing generation assets and future investment decisions. The dual exposure suggests that while nuclear energy provides a low-carbon generation source aligned with Southern Company’s net zero goals, it also introduces long-term financial liabilities tied to decommissioning and regulatory changes that must be carefully balanced against broader climate-related financial risks.",
      "llm_answer": "Southern Company’s heavy reliance on nuclear power—particularly the six operating units at Farley, Hatch, and the under‑construction Vogtle Units 3 & 4—means a substantial share of its electricity comes from reactors that will eventually require costly decommissioning and that are supported by dedicated decommissioning trust funds.  At the same time, the company’s ability to recover the associated capital and operating expenses through regulated rates is uncertain, and any future carbon‑policy changes or stricter environmental rules could increase compliance costs and create regulatory risk for the nuclear fleet.  Consequently, the financial performance of Southern Company is exposed both to the long‑term liability of nuclear decommissioning and to the volatility of carbon‑policy and emissions‑related regulations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 28,
          "pages": [
            26,
            27,
            28,
            29,
            30
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 81502,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20610,
        "completion_tokens": 206,
        "total_tokens": 20816
      }
    },
    {
      "question_id": 28,
      "question": "How does the impact of U.S. commercial payer actions on patient access to Repatha compare with the impact of the COVID-19 pandemic on patient access to Prolia, and what does this reveal about the distinct commercial risks facing AMGN in different therapeutic areas?",
      "original_answer": "The U.S. commercial payer actions have limited patient access to Repatha through cost-shifting measures such as high copays, formulary restrictions, and utilization management criteria, despite AMGN reducing net and list prices to improve affordability. These payer-driven barriers have directly constrained Repatha sales. In contrast, the impact of the COVID-19 pandemic on Prolia has been operational and logistical, as the drug requires healthcare provider administration, which was disrupted due to reduced in-person appointments and patient avoidance of medical settings. The pandemic led to lower treatment initiation rates and a backlog of undiagnosed patients, affecting Prolia’s commercial performance. While payer policies affect access through financial and administrative controls, the pandemic disrupted access through public health measures and behavioral shifts. This distinction reveals that AMGN faces dual commercial risks: payer-driven affordability and coverage challenges in chronic disease therapies like Repatha, and access disruption due to external health crises in therapies requiring in-person administration like Prolia.",
      "llm_answer": "The impact of U.S. commercial payer actions on patient access to Repatha has been driven primarily by payer‑imposed utilization‑management tools (e.g., step therapy, prior‑authorization requirements, and copay‑accumulator programs) that limit coverage and raise out‑of‑pocket costs, thereby restricting use despite price reductions. In contrast, the COVID‑19 pandemic reduced patient access to Prolia mainly through a collapse in elective and specialty care visits, causing treatment delays and lower diagnosis rates rather than direct payer‑policy barriers. This disparity shows that AMGN’s commercial risk is far more sensitive to payer‑driven coverage and reimbursement policies in cardiovascular/ cholesterol management, while in the bone‑health market the dominant risk stems from macro‑level health‑system disruptions such as pandemic‑related care shutdowns. Consequently, the company faces distinct commercial vulnerabilities: payer leverage and formulary restrictions for Repatha versus systemic health‑care delivery shocks for Prolia.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 41,
          "pages": [
            39,
            40,
            41,
            42,
            43
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 41,
          "pages": [
            39,
            40,
            41,
            42,
            43
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 97528,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 24625,
        "completion_tokens": 260,
        "total_tokens": 24886
      }
    },
    {
      "question_id": 28,
      "question": "How does MET's investment exposure to mortgage loans on the balance sheet relate to their holdings of pass-through mortgage-backed securities, and what does this imply about their risk positioning in the residential mortgage market?",
      "original_answer": "MET reports $93.2 billion in mortgage loans on the balance sheet as of December 31, 2023, which directly underpins their investment in structured products. These mortgage loans serve as collateral for pass-through mortgage-backed securities (MBS), which MET holds $12.4 billion of at estimated fair value, representing 42.6% of total RMBS. The fair value of these pass-through MBS shows a net unrealized loss of $1.1 billion, indicating potential credit or market risk exposure. This connection implies that MET maintains significant direct and indirect exposure to the residential mortgage market through both on-balance sheet loans and off-balance structured products, with the latter reflecting market valuation pressures.",
      "llm_answer": "MET's investment exposure to mortgage loans on its balance sheet is reflected through its holdings of pass‑through mortgage‑backed securities (RMBS) and other structured‑product securities that are collateralized by residential mortgages.  The Schedule I investment table shows a total of $93,227 million in mortgage loans (recorded at $92,506 million on the balance sheet), while the RMBS section discloses $29.1 billion of RMBS securities—comprised of $16.7 billion in collateralized mortgage obligations and $12.4 billion in pass‑through securities—representing the company’s direct exposure to residential mortgage cash‑flows.  This overlap indicates that MET’s balance‑sheet mortgage‑loan position is closely aligned with, and essentially funded by, its RMBS holdings, implying that its risk in the residential mortgage market is primarily channeled through these pass‑through securities rather than through direct loan exposure.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 320,
          "pages": [
            318,
            319,
            320,
            321,
            322
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 98,
          "pages": [
            96,
            97,
            98,
            99,
            100
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 78442,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19848,
        "completion_tokens": 233,
        "total_tokens": 20081
      }
    },
    {
      "question_id": 28,
      "question": "How does UPS's $10 million annual contribution to the Alaska Teamster-Employer Pension Plan align with their broader approach to satisfying FIP requirements for underfunded multiemployer pension plans?",
      "original_answer": "UPS contributes $10 million annually to the Alaska Teamster-Employer Pension Plan, which is classified in the red zone and subject to an implemented FIP, consistent with their statement that collectively-bargained contributions satisfy FIP requirements without surcharges. This aligns with UPS's broader approach to multiemployer pension obligations, as they indicate that their contributions across all plans meet regulatory requirements and do not currently require additional surcharges or minimum contributions beyond contractual rates. The Alaska plan’s red zone status and implemented FIP demonstrate how UPS manages underfunded plans through structured contributions that comply with regulatory frameworks.",
      "llm_answer": "UPS’s $10 million annual contribution to the Alaska Teamster‑Employer Pension Plan is part of its broader strategy of making the contractually‑required, collectively‑bargained contributions to all multi‑employer pension plans it participates in. Because these contributions satisfy the requirements of any applicable financial‑improvement (FIP) or rehabilitation (RP) plans, they meet the funding standards set by the Pension Protection Act and the plans’ funding policies, and no additional surcharge contributions are currently required. Thus, the Alaska plan’s funding aligns with UPS’s overall approach of fulfilling its legally‑mandated and collectively‑negotiated pension obligations without needing extra payments beyond the agreed amounts.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 87500,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22098,
        "completion_tokens": 186,
        "total_tokens": 22285
      }
    },
    {
      "question_id": 28,
      "question": "How does Chevron's ongoing tax uncertainty in Kazakhstan relate to its upstream earnings contribution from Tengizchevroil, given the significant loan Chevron has extended to support TCO's development projects?",
      "original_answer": "Chevron faces ongoing tax uncertainty in Kazakhstan, where its tax examinations had not been finalized beyond 2012 as of 2021, contributing to a large portion of its $5,288 unrecognized tax benefits. Meanwhile, Chevron's upstream earnings from Tengizchevroil (TCO) in Kazakhstan improved in 2021, contributing positively to equity affiliate income. However, Chevron has also extended a significant $4,500 loan to TCO to fund development projects like the FGP/WPMP, which is included in Chevron’s carrying value of its investment. This suggests that while Chevron benefits from TCO's operational performance, it also faces material financial exposure through both tax liabilities and direct financial support in a jurisdiction with unresolved tax audits, potentially impacting both earnings and cash flow stability.",
      "llm_answer": "Chevron’s tax uncertainty in Kazakhstan is tied to its upstream earnings from Tengizchevroil because the company has extended a significant loan to fund TCO’s development projects, creating exposure to potential tax adjustments or liabilities that could affect the profitability of those upstream operations. This loan supports the joint venture’s activities, but the unresolved tax issues in Kazakhstan introduce uncertainty that could impact the earnings contribution from Tengizchevroil.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2022.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2022.pdf",
          "target_page": 42,
          "pages": [
            40,
            41,
            42,
            43,
            44
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2022.pdf",
          "target_page": 78,
          "pages": [
            76,
            77,
            78,
            79,
            80
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 91402,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 23084,
        "completion_tokens": 122,
        "total_tokens": 23206
      }
    },
    {
      "question_id": 28,
      "question": "How does Duke Energy's classification of debt investments as AFS impact the financial reporting treatment for Duke Energy Indiana's portfolio, particularly in relation to unrealized gains and losses?",
      "original_answer": "Duke Energy classifies debt investments as AFS (Available-for-Sale), which means unrealized gains and losses are generally recorded in other comprehensive income until realized, at which point they flow into net income. This policy, outlined in the broader Duke Energy investments section, applies to Duke Energy Indiana, which specifically reports its debt investments under this AFS classification. As a result, Duke Energy Indiana’s portfolio is subject to this accounting treatment, deferring unrealized gains and losses to other comprehensive income, aligning with the company’s consolidated reporting approach and regulatory deferral practices.",
      "llm_answer": "Duke Energy classifies its debt investments held in the Indiana subsidiary as available‑for‑sale (AFS).  Under AFS accounting, unrealized holding gains and losses remain in other comprehensive income until the securities are sold, at which point they are re‑classified to realized gains or losses in net income.  This treatment contrasts with the company’s equity‑security investments, which are marked‑to‑market through earnings.  Consequently, the Indiana portfolio’s unrealized gains and losses are not recognized in earnings but are recorded as a separate component of equity (other comprehensive income) and only affect the balance sheet when realized.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 187,
          "pages": [
            185,
            186,
            187,
            188,
            189
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 187,
          "pages": [
            185,
            186,
            187,
            188,
            189
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 184,
          "pages": [
            182,
            183,
            184,
            185,
            186
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 104946,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 26463,
        "completion_tokens": 164,
        "total_tokens": 26627
      }
    },
    {
      "question_id": 29,
      "question": "How does Chevron's tax exposure in Kazakhstan relate to its upstream earnings from Tengizchevroil, and what does this imply about the financial significance of its equity investment in that joint venture?",
      "original_answer": "Chevron's tax exposure in Kazakhstan is highlighted by the fact that the latest year for which income tax examinations had been finalized in that jurisdiction was 2012, indicating long-standing unresolved tax matters. These unresolved issues contribute to the $5,288 million of unrecognized tax benefits at year-end 2021, a portion of which directly relates to Chevron's operations in Kazakhstan, including its upstream activities. Chevron has a 50% equity ownership in Tengizchevroil (TCO), which operates the Tengiz and Korolev crude oil fields in Kazakhstan. In 2021, Chevron reported higher upstream-related earnings from TCO, contributing to a significant improvement in income from equity affiliates—from a $472 million loss in 2020 to a $5,657 million gain in 2021. Despite the tax uncertainties in Kazakhstan, Chevron's investment in TCO remains substantial, with a carrying value $100 million higher than its underlying equity in TCO’s net assets, and includes a $4,500 million loan to fund the Future Growth Project and Wellhead Pressure Management Project. This implies that despite the unresolved tax exposure, Chevron continues to view TCO as a strategically and financially critical asset in its upstream portfolio.",
      "llm_answer": "Chevron's tax exposure in Kazakhstan is reflected in the significant foreign tax credits and deferred tax assets recorded for its international operations, particularly in Note 17 where the company discloses a $11,718 foreign tax credit carryforward and a $4,553 asset‑retirement‑obligation reserve that relate to its equity investment in Tengizchevroil. This investment generates earnings that are subject to foreign withholding taxes and requires a valuation allowance, meaning that any tax liabilities or adjustments could materially affect Chevron's overall tax position and the profitability of the joint venture. Consequently, the equity stake in Tengizchevroil is financially significant because its earnings contribute substantially to Chevron's upstream results and are a key driver of the company's foreign tax credit utilization and deferred tax asset balance.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2022.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2022.pdf",
          "target_page": 42,
          "pages": [
            40,
            41,
            42,
            43,
            44
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2022.pdf",
          "target_page": 78,
          "pages": [
            76,
            77,
            78,
            79,
            80
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 91402,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 23082,
        "completion_tokens": 217,
        "total_tokens": 23300
      }
    },
    {
      "question_id": 29,
      "question": "How does Microsoft's use of The Bank of New York Mellon Trust Company as trustee for its 1.625% Notes due 2015 relate to the broader pattern of partnership reflected in subsequent supplemental indentures with the same institution for other note issuances?",
      "original_answer": "Microsoft issued the 1.625% Notes due 2015 under a Second Supplemental Indenture dated September 27, 2010, with The Bank of New York Mellon Trust Company serving as trustee. This relationship continued as evidenced by later supplemental indentures, such as the Eighth Supplemental Indenture dated December 6, 2013, which also named BNY Mellon Trust Company as trustee for other note series, including the 1.625% Notes due 2018. The consistent use of BNY Mellon as trustee across multiple note issuances indicates a sustained and trusted financial partnership, suggesting that Microsoft relies on BNY Mellon’s institutional credibility and expertise in managing complex debt instruments over time.",
      "llm_answer": "Microsoft's use of The Bank of New York Mellon Trust Company as trustee for its 1.625% Notes due 2015 reflects a consistent pattern of partnering with the same institution across multiple note issuances, as evidenced by the sequential supplemental indentures listed in the exhibits (e.g., the Second Supplemental Indenture for 1.625% Notes due 2015 in 2010, followed by subsequent indentures for other tranches like 2.125% Notes due 2021 and 3.125% Notes due 2028 in 2013, and later tranches in 2015 and beyond). This demonstrates a deliberate, long-term arrangement where The Bank of New York Mellon Trust Company serves as the recurring trustee for Microsoft's debt offerings, facilitating structured financing through repeated supplemental indentures tied to specific note series.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 50013,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12743,
        "completion_tokens": 195,
        "total_tokens": 12939
      }
    },
    {
      "question_id": 29,
      "question": "How does Disney's approach to identifying triggering events for asset impairment tests, including the use of estimated discounted future cash flows, influence the frequency and valuation methodology of non-recurring fair value measures reported in fiscal 2024?",
      "original_answer": "Disney identifies triggering events—such as a decrease in estimated future cash flows—as key indicators that may necessitate asset impairment tests. When such events occur, the company evaluates affected assets for potential impairment by comparing the estimated undiscounted future cash flows to the carrying amount. If the carrying amount exceeds the cash flow estimate, the asset is written down to its fair value, which is determined using a discounted cash flow model (a Level 3 valuation technique). In fiscal 2024, this process led to impairment charges recorded in the second and fourth quarters, as disclosed in Notes 4 and 18. These impairments required non-recurring fair value measurements, where the discounted cash flow method was used to estimate fair value. The use of triggering events thus directly drives the frequency and valuation methodology of non-recurring fair value measures, particularly in cases where cash flow expectations decline, leading to write-downs based on Level 3 inputs.",
      "llm_answer": "Disney’s impairment testing for non‑recurring fair‑value measures relies on estimated discounted future cash flows to determine whether an asset’s carrying amount exceeds its recoverable value, and it applies this methodology at the individual title or group level (or at the lowest‑level cash‑flow unit for asset groups). Because the assessment triggers impairment only when projected cash flows decline, the frequency of non‑recurring fair‑value adjustments in fiscal 2024 is driven by such cash‑flow forecasts rather than a fixed schedule, and the valuation uses Level 3 discounted‑cash‑flow inputs that incorporate the Company’s internal forecasts, discount rates, and any significant changes in monetization strategy.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 83309,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21070,
        "completion_tokens": 180,
        "total_tokens": 21251
      }
    },
    {
      "question_id": 29,
      "question": "How does the $31.0 billion of assets held in trust accounts associated with reinsurance contracts involving ceding insurers impact the valuation and recoverability of GE's $2.651 billion in net reinsurance recoverables at year-end 2021, particularly in light of the trust assets' investment control provisions and their role in securing reinsurance obligations?",
      "original_answer": "The $31.0 billion of assets held in trust accounts on page 50 are directly linked to reinsurance contracts with ceding insurers and are intended to secure GE's obligations under those agreements. These trust assets are held by independent trustees for the benefit of the ceding insurers, though some agreements allow the ceding company to exercise investment control over withdrawn assets, potentially affecting their value and liquidity. This dynamic is critical to assessing the recoverability of GE’s $2.651 billion in net reinsurance recoverables (as of December 31, 2021, per page 102), since the value and performance of the underlying trust assets influence GE’s ability to collect on those recoverables. Furthermore, the trust assets are subject to investment guidelines and may fluctuate in value, as seen in the $4,766 million decrease in 'Other adjustments' on page 102, which was influenced by changes in unrealized gains on investment securities. Therefore, the structure and control provisions of the trust assets directly affect the long-term realizability of the reinsurance recoverables on GE's balance sheet.",
      "llm_answer": "The $31 billion of trust assets that back reinsurance contracts give ceding insurers the ability to withdraw or control certain investments, which provides an additional layer of security for the $2.651 billion of net reinsurance recoverables recorded at year‑end 2021; however, because these trust assets are subject to investment‑guideline restrictions and may be accessed by the ceding companies, the recoverability of the reinsurance receivables remains dependent on the continued solvency and performance of the ceding parties and the enforceability of the trust arrangements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GE_10k_2022.pdf",
          "target_page": 50,
          "pages": [
            48,
            49,
            50,
            51,
            52
          ]
        },
        "hop_2_rel": {
          "source_file": "GE_10k_2022.pdf",
          "target_page": 50,
          "pages": [
            48,
            49,
            50,
            51,
            52
          ]
        },
        "hop_3_rel": {
          "source_file": "GE_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            90,
            91,
            92,
            93,
            94
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 74014,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18770,
        "completion_tokens": 145,
        "total_tokens": 18916
      }
    },
    {
      "question_id": 29,
      "question": "Given Southern Company's dividend policy history and Nicor Gas's $15 million increase in revenue tax expenses passed through to customers, how does the $1.3 billion in Nicor Gas's restricted retained earnings impact Southern Company's ability to maintain its dividend growth trajectory?",
      "original_answer": "Southern Company has maintained a consistent dividend policy, increasing payouts annually since 1948, with $2.62 per share paid in 2021. However, its ability to sustain this growth depends on dividends from subsidiaries like Nicor Gas. Nicor Gas is subject to regulatory restrictions that limit its ability to dividend or loan money to affiliates, with $1.3 billion in retained earnings restricted at year-end 2021. This significantly constrains Southern Company's access to Nicor Gas's earnings, even as revenue tax expenses at Nicor Gas increased by $15 million in 2021. Since Southern Company relies on subsidiary distributions to fund dividends, the restricted retained earnings at Nicor Gas create a structural limitation on how much can be upstreamed, directly affecting the parent company's capacity to continue increasing dividends at the same historical rate.",
      "llm_answer": "Southern Company's ability to sustain its dividend growth is constrained by the $1.3 billion of restricted retained earnings at Nicor Gas, which limits the cash that can be distributed upward to Southern Company and thereby restricts the amount of earnings available to fund future dividend increases.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 51,
          "pages": [
            49,
            50,
            51,
            52,
            53
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 261,
          "pages": [
            259,
            260,
            261,
            262,
            263
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 87,
          "pages": [
            85,
            86,
            87,
            88,
            89
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 56583,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14400,
        "completion_tokens": 75,
        "total_tokens": 14475
      }
    },
    {
      "question_id": 29,
      "question": "How does the decline in Bridion sales following EU market exclusivity loss in 2023 impact MRK's overall revenue concentration risk, particularly given the company's reliance on a small group of key products like Keytruda and Gardasil that accounted for 56% of total sales in 2023?",
      "original_answer": "The decline in Bridion sales following the loss of EU market exclusivity in 2023 exacerbates MRK's revenue concentration risk, as the company is heavily dependent on a small set of key products—primarily Keytruda and Gardasil/Gardasil 9—which together accounted for 56% of total sales in 2023. Bridion, once a significant contributor, has seen a substantial decline in sales due to generic competition, and with further losses expected in Japan and the U.S. in the coming years, MRK faces increased pressure to maintain profitability through its remaining key products. This underscores the risk associated with the company's reliance on a narrow product portfolio, especially as these products are also approaching patent expirations, which could further destabilize revenue streams.",
      "llm_answer": "The decline in Bridion sales following the loss of EU market exclusivity in 2023 exacerbates Merck's revenue concentration risk, as Keytruda and Gardasil/Gardasil 9 alone accounted for 56 % of total sales in 2023. This reliance on a small group of key products means that any erosion of sales—such as the substantial drop in Bridion—directly threatens the company's overall financial stability and growth prospects.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "target_page": 30,
          "pages": [
            28,
            29,
            30,
            31,
            32
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "target_page": 28,
          "pages": [
            26,
            27,
            28,
            29,
            30
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 76749,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19435,
        "completion_tokens": 103,
        "total_tokens": 19539
      }
    },
    {
      "question_id": 29,
      "question": "How does GE's continued exposure to structured settlement annuities, assumed through Union Fidelity Life Insurance Company, align with the disclosed risks around longevity and reinvestment in the insurance segment analysis?",
      "original_answer": "GE's exposure to structured settlement annuities through Union Fidelity Life Insurance Company (UFLIC) involves long-duration liabilities totaling $10.3 billion as of December 31, 2021. These annuities, primarily underwritten on impaired lives, carry significant longevity risk, as improvements in mortality could extend payment durations beyond projections. This aligns with the broader insurance segment's disclosure on page 48 that structured settlement annuities offer no ability to increase premiums or reduce benefits, making them particularly sensitive to life expectancy trends. Additionally, GE faces reinvestment risk due to a low-interest-rate environment, which could reduce investment margins needed to support these liabilities. Despite UFLIC being closed to new business since 2004, the long-duration nature of these contracts means GE must manage these risks over decades, relying on a $41.6 billion investment portfolio and future asset purchases to match liabilities. The structured settlement annuity risk profile contrasts with more flexible long-term care insurance contracts, where premium adjustments are possible, highlighting a key distinction in how GE manages different insurance liabilities.",
      "llm_answer": "GE's continued exposure to structured settlement annuities through Union Fidelity Life Insurance Company aligns with the disclosed risks of longevity and reinvestment in the insurance segment because these contracts involve long-term payment obligations that are highly sensitive to both **longevity risk** (the potential for policyholders living longer than expected, extending payout periods and increasing exposure to future claims) and **reinvestment risk** (the challenge of achieving targeted investment returns in a low-interest-rate environment, which can erode margins and necessitate reserve increases). As noted in the document, structured settlement annuities carry \"mortality (i.e., life expectancy or longevity)\" and \"reinvestment risk\" as primary risks, and the company acknowledges that adverse deviations in mortality or persistently low interest rates could materially affect reserve adequacy and profitability. The exposure to these long-duration liabilities is explicitly managed through investment strategies aimed at asset-liability matching, but the inherent risks remain central to the insurance segment's financial profile.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GE_10k_2022.pdf",
          "target_page": 47,
          "pages": [
            45,
            46,
            47,
            48,
            49
          ]
        },
        "hop_2_rel": {
          "source_file": "GE_10k_2022.pdf",
          "target_page": 47,
          "pages": [
            45,
            46,
            47,
            48,
            49
          ]
        },
        "hop_3_rel": {
          "source_file": "GE_10k_2022.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 12,
        "total_chars": 63677,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16148,
        "completion_tokens": 287,
        "total_tokens": 16435
      }
    },
    {
      "question_id": 29,
      "question": "How does ConocoPhillips' capital allocation strategy, as outlined in its disciplined investment framework, reconcile with its decision to exercise a preemptive right to acquire an additional 10% stake in APLNG at a valuation below carrying value, especially in light of the subsequent impairment charge recorded on its existing investment?",
      "original_answer": "ConocoPhillips emphasizes a disciplined investment framework focused on capital efficiency, cost control, and value maximization over production growth, particularly in commodity-driven cycles (page 40). Despite this, the company exercised its preemptive right to acquire an additional 10% in APLNG at a market-determined fair value below its carrying value, which led to a $688 million noncash impairment charge (page 119). This decision appears to be based on long-term strategic value expectations from APLNG’s LNG position and CBM resources in Australia, even though the investment was impaired due to a decline in fair value. The contrast between the capital discipline framework and the APLNG acquisition suggests a strategic bet on LNG growth potential in Asia Pacific markets, despite short-term valuation concerns.",
      "llm_answer": "ConocoPhillips exercised its preemption right to acquire an additional 10% stake in APLNG at a price below the carrying value of its existing investment, which triggered a $688 million noncash impairment charge in the fourth quarter of 2021 to write down the investment to fair value. This impairment was recorded despite the company’s broader disciplined capital allocation framework that emphasizes returning cash to shareholders and maintaining balance‑sheet strength.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 40,
          "pages": [
            38,
            39,
            40,
            41,
            42
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 100,
          "pages": [
            98,
            99,
            100,
            101,
            102
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 58917,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14998,
        "completion_tokens": 117,
        "total_tokens": 15116
      }
    },
    {
      "question_id": 30,
      "question": "How does MetLife's issuance of $2.5 billion in surplus notes by MetLife Reinsurance Company of Charleston relate to the prioritization of surplus notes in MetLife's broader debt structure, particularly in light of the contingent regulatory approval required for interest and principal payments?",
      "original_answer": "MetLife Reinsurance Company of Charleston (MRC), a wholly-owned subsidiary of MetLife, issued $2.5 billion in 35-year surplus notes in 2007 to provide statutory reserve support for closed block liabilities reinsured from MLIC. These surplus notes accrue interest based on SOFR (or previously LIBOR) and are contingent on South Carolina regulatory approval for any interest or principal payments. Meanwhile, in the broader debt structure disclosed on page 280, surplus notes are explicitly described as subordinate to all other obligations of the issuing operating company but senior to obligations of MetLife, Inc. itself. Additionally, the notes have a defined payment priority under the collateral financing arrangement. This dual perspective reveals that while the surplus notes are a significant long-term liability with unique regulatory constraints, they also hold a distinct structural position in the capital hierarchy, balancing subordination to senior debt with seniority over parent-level obligations.",
      "llm_answer": "MetLife’s $2.5 billion surplus‑note issuance by its Charleston reinsurance subsidiary is positioned as a subordinated but priority‑ranked source of financing within the company’s overall debt structure; these notes rank above the parent‑level unsecured senior notes but below the collateral‑financing arrangement that is backed by the surplus notes themselves.  Because payments of interest and principal on the surplus notes are contingent on South Carolina regulatory approval, MetLife must obtain that approval before it can make any such payments, underscoring the regulatory dependency of the surplus‑note cash‑flow priority.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 282,
          "pages": [
            280,
            281,
            282,
            283,
            284
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 282,
          "pages": [
            280,
            281,
            282,
            283,
            284
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 280,
          "pages": [
            278,
            279,
            280,
            281,
            282
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 76886,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19471,
        "completion_tokens": 157,
        "total_tokens": 19628
      }
    },
    {
      "question_id": 30,
      "question": "How does Chevron's strategic investment in the Caspian Pipeline Consortium (CPC) align with its crude oil reserve growth and production ramp-up plans in Kazakhstan, particularly considering the expected start-up of the Future Growth Project (FGP) in 2025?",
      "original_answer": "Chevron's 15% interest in the Caspian Pipeline Consortium (CPC) is a critical enabler of its crude oil export strategy from Kazakhstan, where Chevron operates major assets like Tengiz and Karachaganak. The CPC pipeline transported an average of 1.2 million barrels per day of Kazakh crude oil in 2023, and the completion of the CPC debottlenecking project in January 2023 has increased throughput capacity, directly supporting the upcoming start-up of the Future Growth Project (FGP) in early 2025. This infrastructure enhancement aligns with Chevron's reserve additions in Kazakhstan, as evidenced by the 2023 reserves of 1,295 million barrels in affiliated companies, including TCO. The FGP is expected to ramp up to full production within three months of start-up, which will be critical in offsetting production declines observed in other regions and sustaining Chevron’s upstream crude oil reserves and production volumes.",
      "llm_answer": "Chevron’s investment in the Caspian Pipeline Consortium (CPC) directly supports its reserve growth and production ramp‑up in Kazakhstan by providing the export conduit for the crude from the Tengizchevroil (TCO) and Karachaganak fields. The recent mechanical completion of the Future Growth Project (FGP) and the CPC debottlenecking project will increase CPC throughput to roughly 1.4 million bbl/d, enabling the FGP to start up in the first half of 2025 and ramp to full production within three months, thereby boosting Kazakhstan crude output and securing transport capacity for Chevron’s expanding reserve base.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 113,
          "pages": [
            111,
            112,
            113,
            114,
            115
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 95828,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 24199,
        "completion_tokens": 153,
        "total_tokens": 24352
      }
    },
    {
      "question_id": 30,
      "question": "Given Visual Studio's inclusion in Server products and cloud services, how does its strategic positioning as a developer tool align with the 44% revenue growth ($67.35B to $97.73B) in Server products and cloud services from 2022 to 2024?",
      "original_answer": "Microsoft positions Visual Studio as a key component of its Intelligent Cloud segment, specifically within Server products and cloud services, which reported a 44% revenue increase from $67.35 billion in 2022 to $97.73 billion in 2024. This growth aligns with Microsoft’s strategic emphasis on empowering developers and IT professionals through integrated tools that support cloud application development and deployment on Azure. As a software development lifecycle tool included in the Server products category, Visual Studio contributes to this growth by enabling developers to build applications optimized for Microsoft’s cloud infrastructure, reinforcing the company’s competitive advantage in cloud services.",
      "llm_answer": "Microsoft's strategic positioning of Visual Studio as part of its Server products and cloud services directly aligns with the 44% revenue growth in Server products and cloud services ($67.35B to $97.73B) from 2022 to 2024. This growth is explicitly driven by Azure and other cloud services revenue increasing 30% to $97.73B, with Server products and cloud services revenue growing 22% to $97.73B, as noted in the \"Server products and cloud services\" metric within the Intelligent Cloud segment. Visual Studio's inclusion in these cloud and server offerings supports Microsoft's broader cloud strategy, which is a key driver of this segment's 20% overall revenue growth and 31% operating income growth in fiscal year 2024.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 42,
          "pages": [
            40,
            41,
            42,
            43,
            44
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 56414,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14344,
        "completion_tokens": 180,
        "total_tokens": 14525
      }
    },
    {
      "question_id": 30,
      "question": "How does the non-dilutable 33 1/3% voting power of Class B common stock, which requires separate approval for major corporate transactions, reconcile with the dividend policy that applies equally to both Class A and Class B shares, given that holders of Class A shares collectively control 66 2/3% of the combined voting power?",
      "original_answer": "The 10-K filing reveals that while both Class A and Class B shares are subject to the same dividend policy—including the $1.08 annualized dividend per share approved in January 2022—the governance structure is asymmetric. Class B common stock, which is entirely beneficially owned by Brian L. Roberts, holds 33 1/3% of the combined voting power, a percentage that is generally non-dilutable. This class also has separate approval rights over several material corporate transactions, regardless of board or shareholder approval. Meanwhile, Class A shareholders collectively control 66 2/3% of the voting power, with votes per share determined by the relative number of Class A and Class B shares outstanding. This creates a governance dynamic where dividend treatment is equal, but control and strategic decision-making power are disproportionately concentrated in the Class B shares, raising implications for shareholder alignment and corporate strategy execution.",
      "llm_answer": "The Class B common stock carries a non‑dilutable 33 ⅓ % voting interest (15 votes per share) that cannot be reduced below roughly 9.4 million shares, and this block must obtain separate shareholder approval for certain material transactions. Because holders of Class A stock collectively control 66 ⅔ % of the total voting power, they can approve such matters despite the Class B block’s veto rights, allowing the dividend policy—which applies equally to both share classes—to be set and paid without conflict.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 12,
        "total_chars": 50822,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12963,
        "completion_tokens": 127,
        "total_tokens": 13090
      }
    },
    {
      "question_id": 30,
      "question": "How does GE's disclosure of mortality and longevity risks in structured settlement annuities reconcile with the decision to maintain a significant stake in Union Fidelity Life Insurance Company (UFLIC), which produces these annuities and has been closed to new business since 2004?",
      "original_answer": "GE acknowledges significant mortality and longevity risks in its structured settlement annuities, noting that these contracts—primarily underwritten on impaired lives—carry the risk that beneficiaries may live longer than expected, extending payment durations and increasing liabilities. These risks are highlighted on page 48, where GE reports reinsuring approximately 27,400 structured settlement annuities with an average attained age of 54 and outlines the lack of ability to adjust premiums or reduce benefits. Despite these risks, GE maintains a substantial stake in UFLIC, which has been closed to new business since 2004 and is a key producer of these annuities. On page 47, UFLIC is described as reinsuring structured settlement annuities with and without life contingencies from Genworth Financial, and GE continues to manage these long-duration liabilities as part of its run-off insurance operations. The persistence of these liabilities, combined with the lack of new business inflows into UFLIC, suggests that GE must carefully manage its existing exposure through investment strategies and reinsurance, even as it faces the inherent unpredictability of mortality trends and reinvestment risk in a low-interest-rate environment.",
      "llm_answer": "GE maintains a significant stake in Union Fidelity Life Insurance Company (UFLIC), which has been closed to new business since 2004 and produces structured settlement annuities, because UFLIC represents a mature, long‑duration block of reinsurance that continues to generate substantial future policy benefit reserves and claim obligations. Although UFLIC no longer accepts new policies, its existing contracts—particularly the structured settlement annuities and related mortality and longevity risks—remain on GE’s books and require ongoing reserve and capital management, so the company retains its equity interest to manage those legacy exposures and the associated risks.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GE_10k_2022.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        },
        "hop_2_rel": {
          "source_file": "GE_10k_2022.pdf",
          "target_page": 47,
          "pages": [
            45,
            46,
            47,
            48,
            49
          ]
        },
        "hop_3_rel": {
          "source_file": "GE_10k_2022.pdf",
          "target_page": 47,
          "pages": [
            45,
            46,
            47,
            48,
            49
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 12,
        "total_chars": 63677,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16162,
        "completion_tokens": 169,
        "total_tokens": 16331
      }
    },
    {
      "question_id": 30,
      "question": "How do the varying data protection expiry dates for Emgality across regions impact LLY's ability to predict the duration of market exclusivity for this product?",
      "original_answer": "LLY acknowledges on page 11 that predicting the duration of market exclusivity for its products is challenging due to the complex interaction between patent and regulatory protections, as well as uncertainties in patent litigation. For Emgality specifically, page 13 shows that data protection expires in different regions at different times—2030 in the U.S., 2028 in major European countries, and 2029 in Japan. These varying expiry dates compound the difficulty of predicting when true market exclusivity will end, as LLY must account for both the staggered regulatory protection timelines and the potential for legal challenges or extensions. This uncertainty affects how LLY strategizes lifecycle management and revenue forecasting for Emgality.",
      "llm_answer": "The varying data protection expiry dates for Emgality across regions—U.S. data protection ending in 2030, Europe in 2028, and Japan in 2029—create uncertainty in predicting the duration of market exclusivity, as these periods are subject to regulatory changes and may not align with patent expirations. This variability complicates forecasting the full scope of exclusivity, especially given the interplay between data protection, compound patents, and potential biosimilar competition.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 12,
        "total_chars": 57088,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14486,
        "completion_tokens": 121,
        "total_tokens": 14607
      }
    },
    {
      "question_id": 30,
      "question": "How does Emerson's strategic acquisition of NI for $8.653 billion, including the $7.833 billion cash payment to acquire the remaining shares, reflect the strategic importance of automated test systems in driving faster time-to-market and cost efficiency as described in the Test & Measurement segment's value proposition?",
      "original_answer": "Emerson's acquisition of NI for a total purchase consideration of $8.653 billion, including $7.833 billion in cash paid to acquire the remaining NI shares, underscores the strategic importance Emerson places on NI’s software-connected automated test systems. This aligns with the Test & Measurement segment’s stated value proposition of enabling enterprises to bring products to market faster and at a lower cost. The acquisition integrates NI’s capabilities into Emerson’s portfolio, reinforcing the company’s focus on delivering advanced test and measurement solutions that enhance speed and efficiency in product development cycles.",
      "llm_answer": "Emerson's $8.653 billion acquisition of National Instruments—including the $7.833 billion cash payment for the remaining shares—underscores the strategic importance of automated test systems within the newly created Test & Measurement segment, which is positioned to accelerate time‑to‑market and improve cost efficiency for customers. The transaction, finalized on October 11 2023, added NI’s software‑connected automated test and measurement solutions to Emerson’s portfolio, expanding its addressable market and reinforcing the segment’s value proposition of faster product launches and lower ownership costs.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        },
        "hop_2_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_3_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 66668,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16924,
        "completion_tokens": 153,
        "total_tokens": 17077
      }
    },
    {
      "question_id": 31,
      "question": "How does ConocoPhillips' financial exposure through its 47.5% stake in APLNG, including its guarantees and equity investment, relate to its production of coal bed methane (CBM) in Australia and the long-term financing obligations tied to the APLNG project?",
      "original_answer": "ConocoPhillips holds a 47.5% stake in APLNG, which is focused on producing coal bed methane (CBM) from the Bowen and Surat basins in Queensland, Australia, and exporting LNG to Asia Pacific markets. As of December 31, 2024, the carrying value of this equity investment was approximately $5.0 billion. APLNG has a long-term $8.5 billion project finance facility, with $4.0 billion still outstanding as of year-end 2024, requiring bi-annual principal and interest payments until September 2030. In addition, ConocoPhillips has issued multiple guarantees related to APLNG, including a $210 million guarantee tied to a project finance reserve account, a $610 million (up to $1.0 billion in case of intentional breach) guarantee related to natural gas delivery commitments, and $480 million in performance guarantees, with carrying values totaling $52 million as of December 31, 2024. These financial exposures illustrate the company’s significant long-term commitment to the APLNG project, which is directly tied to the production of CBM in Australia, highlighting the interplay between operational strategy and financial risk management.",
      "llm_answer": "ConocoPhillips’ 47.5 % equity stake in APLNG gives it direct exposure to the company’s coal‑bed‑methane (CBM) production in Queensland, Australia, and to the long‑term financing that underpins the joint venture’s LNG projects.  APLNG operates a $8.5 billion project‑finance facility that remains non‑recourse after financial completion, with about $4 billion of principal and interest outstanding as of 31 Dec 2024 and scheduled payments through September 2030.  Because ConocoPhillips holds a 47.5 % interest, it shares in APLNG’s earnings and cash flows while also providing financial support through guarantees that can require up to roughly $210 million in potential payments if enforcement actions arise.  This equity investment and the associated guarantees therefore tie ConocoPhillips’ financial exposure to both the CBM production it accesses in Australia and the long‑term debt service obligations of the APLNG project.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 63691,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16166,
        "completion_tokens": 232,
        "total_tokens": 16398
      }
    },
    {
      "question_id": 31,
      "question": "How does Tesla's disclosure of warrant-related share dilution in the financial statements reconcile with the specific share issuances to 2019 Warrantholders in October 2024, and what impact did this have on Tesla's equity structure?",
      "original_answer": "Tesla's financial statements on page 64 show that warrants contributed 8 million shares to the diluted share count in 2024, down from 11 million in 2023. This reduction aligns with the October 2024 issuance of 2,894,424 shares to the 2019 Warrantholders, as disclosed in the Unregistered Sales of Equity Securities section on page 34. The exercise of these warrants under Rule 3(a)(9) of the Securities Act resulted in a net issuance of shares without cash proceeds, directly affecting Tesla’s equity structure by increasing the number of outstanding shares and reducing future dilution potential from these instruments.",
      "llm_answer": "Tesla disclosed warrant‑related share dilution in its financial statements by noting that the warrant exercises by the 2019 Warrantholders generated an additional 2.89 million shares of common stock issued in October 2024, which increased the total weighted‑average diluted shares outstanding to 3.498 billion for 2024. This issuance was reflected in the “Unregistered Sales of Equity Securities and Use of Proceeds” section and contributed to the modest rise in diluted share count despite a net income attributable to common stockholders of $7.09 billion. Consequently, Tesla’s equity structure was expanded by roughly 2.9 million shares, diluting existing shareholders but also providing the company with additional capital from the warrant exercises.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "TSLA_10k_2024.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        },
        "hop_2_rel": {
          "source_file": "TSLA_10k_2024.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_3_rel": {
          "source_file": "TSLA_10k_2024.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 49134,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12519,
        "completion_tokens": 188,
        "total_tokens": 12707
      }
    },
    {
      "question_id": 31,
      "question": "How does AT&T's continued depreciation of wireless tower assets originally sold to Crown Castle reconcile with the fixed-price purchase options Crown Castle holds at the end of the lease terms?",
      "original_answer": "AT&T continues to depreciate the wireless tower assets on its balance sheet because it did not transfer control of these assets in the transaction with Crown Castle, which prevented sale-leaseback accounting treatment. As of December 31, 2021, these tower assets had a net book value of $725 and were depreciated at a rate of $39 annually. Meanwhile, Crown Castle holds fixed-price purchase options for these towers at the end of their respective lease terms, totaling approximately $4,200 based on estimated fair market values at that time. This creates a contrast between AT&T's ongoing depreciation of the assets and the potential future transfer of ownership at predetermined prices that may not reflect actual market values at expiration.",
      "llm_answer": "AT&T continues to depreciate the wireless tower assets it originally sold to Crown Castle because those assets remain recorded in its \"Property, Plant and Equipment – Net\" balance and are depreciated over their remaining useful lives; at the same time, Crown Castle holds fixed‑price purchase options for the towers at the end of the lease terms, which are based on the towers’ then‑estimated fair market values.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "T_10k_2022.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        },
        "hop_2_rel": {
          "source_file": "T_10k_2022.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        },
        "hop_3_rel": {
          "source_file": "T_10k_2022.pdf",
          "target_page": 133,
          "pages": [
            131,
            132,
            133,
            134,
            135
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 65700,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16647,
        "completion_tokens": 103,
        "total_tokens": 16750
      }
    },
    {
      "question_id": 31,
      "question": "What is the relationship between AspenTech's inclusion in Emerson's business segments and the increase in performance share expenses from $89 million in 2022 to $165 million in 2023?",
      "original_answer": "The increase in performance share expenses from $89 million in 2022 to $165 million in 2023 correlates with the inclusion of AspenTech in Emerson's business segments starting in 2023. AspenTech has its own stock-based compensation plans involving performance shares, which are now consolidated under Emerson's financial reporting. This consolidation likely contributed to the significant year-over-year increase in performance share expenses, reflecting the integration of AspenTech's compensation obligations into Emerson's financials.",
      "llm_answer": "The increase in performance share expenses from $89 million in 2022 to $165 million in 2023 reflects Emerson’s broader stock‑based compensation costs, which include the $96 million of AspenTech‑related compensation expense recognized in 2024 (of which $58 million was tied to integration costs and restructuring). This rise is driven by the company’s expanded performance‑share awards across its incentive plans and the additional expense from the Heritage AspenTech acquisition, resulting in a higher overall performance‑share expense in 2023.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_2_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_3_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 59264,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15038,
        "completion_tokens": 136,
        "total_tokens": 15174
      }
    },
    {
      "question_id": 31,
      "question": "How does BMY's exposure to the Inflation Reduction Act's price negotiation provisions, as applied to Pomalyst, interact with the company's strategy to maintain market exclusivity for the drug through patent protections and regulatory exclusivity periods?",
      "original_answer": "BMY faces direct exposure under the Inflation Reduction Act (IRA), as Pomalyst was selected in January 2025 for government 'negotiation' of prices, with pricing decisions taking effect in 2027. This regulatory risk could lead to reduced revenue and accelerate erosion of market exclusivity prior to the expiration of relevant patents. At the same time, Pomalyst is among BMY’s key chemical products listed as benefiting from U.S. regulatory exclusivity protections, which typically last five years. However, the document notes that Paragraph IV certifications—generic challenges to patent validity—can be filed after four years, allowing generic manufacturers to seek FDA approval before exclusivity periods end. The combination of IRA-driven pricing constraints and the risk of early generic entry through ANDA filings creates a dual threat to Pomalyst's revenue stream, particularly since the drug is already under regulatory scrutiny both in terms of pricing and patent defensibility.",
      "llm_answer": "BMY maintains market exclusivity for Pomalyst through a combination of patent protections and regulatory exclusivity periods, which are critical to its commercial strategy. However, the Inflation Reduction Act (IRA) introduces significant risks, as Pomalyst has been selected for price negotiation under the IRA starting in 2027, potentially accelerating revenue erosion before patent expirations. This regulatory pressure interacts with BMY's strategy by threatening to reduce pricing power and market access for Pomalyst, even as the company relies on patent and regulatory exclusivity to sustain profitability during the drug's lifecycle.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 134,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 43,
          "pages": [
            41,
            42,
            43,
            44,
            45
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 90290,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22818,
        "completion_tokens": 160,
        "total_tokens": 22978
      }
    },
    {
      "question_id": 31,
      "question": "How does Chevron's 2023 crude oil reserve growth in Kazakhstan, particularly from the Tengiz and Korolev fields, align with the Caspian Pipeline Consortium's (CPC) capacity expansion and its role in transporting Chevron's production?",
      "original_answer": "Chevron's crude oil reserve growth in Kazakhstan, particularly from the Tengiz and Korolev fields, is expected to be supported by the Caspian Pipeline Consortium's (CPC) increased throughput capacity following the completion of its debottlenecking project in January 2023. The Tengiz and Korolev fields, operated under TCO, saw mechanical completion of the Future Growth Project (FGP) in 2023, with full production expected to ramp up in early 2025. This expansion aligns with CPC's role in transporting an average of 1.4 million barrels of crude oil per day, including Chevron’s production, and its capacity increase to accommodate FGP's start-up. Chevron holds a 15% interest in CPC, reinforcing its strategic dependency on the pipeline for export logistics.",
      "llm_answer": "Chevron's 2023 crude oil reserve growth in Kazakhstan, particularly from the Tengiz and Korolev fields, aligns with the Caspian Pipeline Consortium's (CPC) capacity expansion by supporting increased production that is transported via the CPC pipeline. The CPC pipeline, which transports most of TCO's (Chevron's 50% owned affiliate) crude oil exports, saw mechanical completion of its debottlenecking project in January 2023, enabling higher throughput capacity to handle the increased production from these fields. This expansion directly supports the development of the Tengiz and Korolev fields, as evidenced by TCO's mechanical completion of the Future Growth Project (FGP) in 2023 and the planned start-up of the FGP in early 2025, which will further utilize the expanded CPC capacity.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 113,
          "pages": [
            111,
            112,
            113,
            114,
            115
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 95828,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 24193,
        "completion_tokens": 197,
        "total_tokens": 24391
      }
    },
    {
      "question_id": 32,
      "question": "How does American Express's reliance on AENB for deposit funding interact with the leverage ratio requirements that constrain AENB's dividend payments, especially given AXP's overall regulatory capital position as of December 31, 2021?",
      "original_answer": "American Express relies on AENB as its primary deposit channel, with $84.4 billion in deposits as of December 31, 2021, which is critical for funding operations. However, AENB is subject to regulatory constraints that limit its ability to pay dividends to its parent, including the requirement to maintain minimum leverage ratios and capital adequacy standards. AENB had $3.6 billion in retained earnings available for dividends as of that date, but any distribution must also consider the impact on regulatory capital ratios. AXP itself is subject to Federal Reserve capital adequacy requirements and must maintain sufficient CET1, Tier 1, and Total capital ratios. Therefore, while AENB is a key source of funding for AXP, its ability to return capital to the parent is restricted by leverage and risk-based capital requirements, which in turn affects AXP’s broader capital management strategy and dividend policy.",
      "llm_answer": "American Express relies on AENB’s FDIC‑insured retail deposits as a core funding source, but those deposits are subject to capital‑adequacy constraints that limit AENB’s ability to pay dividends. Because AENB must maintain CET1 and leverage ratios above the regulatory minimums (10.5 % CET1 and 10.5 % leverage as of 12/31/21), any shortfall would restrict its dividend‑paying capacity and could also pressure AXP’s overall capital plan, even though AXP’s consolidated ratios remain comfortably above the well‑capitalized thresholds. Consequently, while AXP’s strong capital position (10.5 % CET1, 11.5 % Tier 1, 12.9 % total capital) provides a buffer, the dividend‑payment discipline at AENB is ultimately governed by its own leverage and capital ratios.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AXP_10k_2022.pdf",
          "target_page": 71,
          "pages": [
            69,
            70,
            71,
            72,
            73
          ]
        },
        "hop_2_rel": {
          "source_file": "AXP_10k_2022.pdf",
          "target_page": 153,
          "pages": [
            151,
            152,
            153,
            154,
            155
          ]
        },
        "hop_3_rel": {
          "source_file": "AXP_10k_2022.pdf",
          "target_page": 152,
          "pages": [
            150,
            151,
            152,
            153,
            154
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 71340,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18073,
        "completion_tokens": 189,
        "total_tokens": 18262
      }
    },
    {
      "question_id": 32,
      "question": "How does ConocoPhillips' production of condensate from the Aasta Hansteen Field relate to its financial exposure through guarantees tied to Alba Plant LLC, particularly in light of its equity earnings from LPG processing?",
      "original_answer": "ConocoPhillips produces condensate from the Aasta Hansteen Field in the Norwegian Sea, which is transported via shuttle tankers to market. Separately, the company owns a 52.2% interest in Alba Plant LLC, which processes natural gas from the Alba Unit offshore Equatorial Guinea, extracting condensate and LPG for sale at market prices. These revenues contribute to COP’s 'Equity in earnings of affiliates' line. Additionally, COP has guaranteed payment obligations tied to Alba Plant LLC with a maximum potential future payment of $116 million. This indicates that while COP benefits from condensate monetization through Alba Plant LLC’s processing, it also carries financial risk exposure through contractual guarantees, linking upstream condensate production to downstream processing and financial commitments.",
      "llm_answer": "ConocoPhillips produces condensate from the Aasta Hansteen Field in Norway, where the gas is processed at the Nyhamna plant and condensate is loaded onto shuttle tankers for sale. This production is part of its equity‑earned revenue from LPG processing through its 52.2 % stake in Alba Plant LLC, which processes natural gas from the Alba Unit in Equatorial Guinea and generates equity earnings reported in “Equity in earnings of affiliates.” The company also guarantees performance and payment obligations related to Alba Plant LLC and other joint‑venture arrangements, exposing it financially to potential liabilities under those guarantees.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 55830,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14192,
        "completion_tokens": 160,
        "total_tokens": 14353
      }
    },
    {
      "question_id": 32,
      "question": "Given that NIKE emphasized strategic investment in accessories as part of its corporate-wide growth plan on page 33, and Converse is explicitly identified as a reportable segment responsible for accessories, how does Converse's 15% currency-neutral revenue decline in fiscal 2024 reflect on the effectiveness of NIKE's strategy as it pertains to the accessories category?",
      "original_answer": "NIKE's corporate strategy on page 33 highlights a focus on growing its portfolio of branded products, including accessories, through innovation and consumer connection. Accessories are positioned as part of the broader growth strategy, with investment prioritization intended to fuel future growth. However, Converse, which is the reportable segment responsible for athletic lifestyle sneakers, apparel, and accessories, reported a 15% currency-neutral revenue decline in fiscal 2024, driven by drops in both wholesale and direct-to-consumer channels across key markets. This decline suggests that despite NIKE's strategic emphasis on accessories, Converse—its primary vehicle for executing this strategy—faced executional and market challenges, including reduced traffic and increased promotional activity, which undermined revenue growth. Thus, the performance of Converse raises questions about the alignment or execution of the corporate strategy as it applies to the accessories segment.",
      "llm_answer": "Converse's 15% currency-neutral revenue decline in fiscal 2024 reflects a weakening in the accessories category's performance, which directly challenges the effectiveness of Nike's strategy of emphasizing strategic investment in accessories as a core growth pillar. While Nike's overall accessories-focused growth plan was highlighted on page 33, Converse's revenue contraction—driven by declines in North America and Western Europe, lower wholesale and direct-to-consumer sales, and reduced unit volumes—indicates that the accessories segment (where Converse operates) is not delivering the expected growth to validate Nike's strategic emphasis on this category. This downturn suggests that Nike's investment in accessories, including through Converse, has not yet translated into sustainable revenue growth for the segment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 66042,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16785,
        "completion_tokens": 206,
        "total_tokens": 16991
      }
    },
    {
      "question_id": 32,
      "question": "How does the voting power disparity between Class A and Class B common stock, as outlined in the equity structure, influence the governance control dynamics despite the significant share repurchases of Class A common stock?",
      "original_answer": "The equity structure reveals that Class B common stock, which represents only 9,444,375 issued and outstanding shares, holds 33 1/3% of the combined voting power due to each share carrying 15 votes. This contrasts with Class A common stock, which has 4,842,108,959 shares issued and 3,969,317,931 outstanding, yet holds 66 2/3% of the voting power. Despite the company repurchasing 872,791,028 Class A shares, which have reduced the issued shares from 5,083,466,045 to 4,842,108,959, the governance control remains significantly influenced by the Class B shares, as they are non-dilutable and held entirely by Mr. Brian L. Roberts. This dynamic ensures continued concentrated control over major corporate decisions.",
      "llm_answer": "The voting power disparity—Class B shares carry 15 votes per share while Class A shares carry one vote—means that even though Comcast has repurchased a large number of Class A shares, the Roberts family (which holds all Class B stock) retains roughly one‑third of the total voting power. Consequently, the company’s governance remains heavily influenced by the Class B holders despite the substantial reduction in Class A shares outstanding.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 1,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 57868,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14704,
        "completion_tokens": 110,
        "total_tokens": 14814
      }
    },
    {
      "question_id": 32,
      "question": "How does the significant increase in GD's plan assets measured using NAV for real estate funds from $8 million in other post-retirement benefit plans to $733 million in pension plan assets reflect different risk exposures or valuation methodologies across the two benefit plans?",
      "original_answer": "GD reports $733 million in NAV-measured real estate fund assets within its pension plan assets on page 96, while the same category shows only $8 million in the other post-retirement benefit plan on page 97. This stark difference suggests that real estate funds are a much larger component of the pension plan, which likely exposes the pension plan to greater valuation uncertainty due to the use of NAV as a practical expedient rather than observable market inputs. The lack of Level 1 or Level 2 pricing for NAV-measured real estate funds indicates a reliance on unobservable inputs, creating divergent risk profiles between the two benefit plans despite holding similar asset categories.",
      "llm_answer": "The significant increase in GD's plan assets measured using NAV for real estate funds—from $8 million in other post‑retirement benefit plans to $733 million in pension plan assets—reflects both a different risk exposure and a different valuation methodology. The pension plan uses a broader fair‑value hierarchy (including Level 3 real‑estate funds) and targets a higher allocation to return‑seeking assets, whereas the other post‑retirement plans rely mainly on Level 1/2 assets and maintain a more conservative, liability‑hedging allocation. Consequently, the pension fund’s larger, more diversified real‑estate exposure and its valuation approach result in a substantially higher reported NAV.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 96,
          "pages": [
            94,
            95,
            96,
            97,
            98
          ]
        },
        "hop_2_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 96,
          "pages": [
            94,
            95,
            96,
            97,
            98
          ]
        },
        "hop_3_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 62756,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15931,
        "completion_tokens": 174,
        "total_tokens": 16105
      }
    },
    {
      "question_id": 32,
      "question": "Given Southern Company's stated useful life for wind assets and the capacity and contract period of the Skookumchuck wind project, how does the company's long-term asset planning align with its contractual revenue commitments for this specific wind facility?",
      "original_answer": "Southern Company reports a maximum useful life of 30 years for wind assets, yet the Skookumchuck wind project, with 136 MW of capacity, has a PPA contract period of 20 years. This suggests that while the asset may be capable of generating value for a longer period, the company's contractual revenue commitment for Skookumchuck is structured over a shorter timeframe, potentially reflecting market or regulatory constraints in long-term power purchase agreements for wind facilities.",
      "llm_answer": "Southern Company's 2021 10-K indicates that its wind assets are depreciated over a useful life of up to 30 years (as stated in the \"Southern Power\" note on component depreciation and the table of generating facility useful lives). The Skookumchuck wind project, a specific wind facility under Southern Power, has a 20-year Power Purchase Agreement (PPA) contract period, as documented in the \"Construction Projects\" table listing \"Skookumchuck (e) | Wind | 136 | ... | 20 years.\" This 20-year PPA term is shorter than the 30-year depreciation life for wind assets. Consequently, Southern Company's long-term asset planning for this facility aligns with its contractual revenue commitments by ensuring that the asset's depreciation schedule (30 years) exceeds the PPA duration (20 years), allowing the company to recover capital costs through regulated or contracted revenues over the shorter PPA term, after which the asset may continue to be depreciated or potentially be retired or repurposed. This structure supports revenue stability during the PPA period while maintaining long-term asset valuation.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 244,
          "pages": [
            242,
            243,
            244,
            245,
            246
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 330,
          "pages": [
            328,
            329,
            330,
            331,
            332
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 330,
          "pages": [
            328,
            329,
            330,
            331,
            332
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 71418,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18098,
        "completion_tokens": 276,
        "total_tokens": 18374
      }
    },
    {
      "question_id": 32,
      "question": "How does Schwab's ownership stake in TDAC, combined with TDAC's self-clearing operations through clearing houses like NSCC, create specific liquidity risk exposure given the recent margin requirement increases mentioned in the 10-K?",
      "original_answer": "Schwab owns TDAC, which operates as a self-clearing broker-dealer subject to SEC net capital rules (page 120). As part of its clearing operations, TDAC must maintain cash deposits and collateral with clearing houses like NSCC to meet fluctuating margin requirements tied to client trading activity and market volatility (page 14). The 10-K specifically notes that recent market volatility caused NSCC to increase margin requirements, forcing Schwab to deposit additional funds with clearing houses (page 22). This creates a direct liquidity risk chain: Schwab's ownership of TDAC means it must support TDAC's capital needs, while TDAC's clearing house obligations amplify liquidity pressures during volatile periods when margin calls spike.",
      "llm_answer": "Schwab’s ownership stake in TD AC, together with TD AC’s self‑clearing model that routes trades through clearing houses such as NSCC, creates liquidity risk because the firm must meet margin calls and maintain required deposits with those clearing houses. Recent increases in margin‑requirement thresholds have amplified this exposure, forcing Schwab to post additional collateral and potentially limiting its ability to clear trades if cash or eligible securities are insufficient. This heightened collateral demand directly raises Schwab’s liquidity‑risk profile.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SCHW_10k_2022.pdf",
          "target_page": 120,
          "pages": [
            118,
            119,
            120,
            121,
            122
          ]
        },
        "hop_2_rel": {
          "source_file": "SCHW_10k_2022.pdf",
          "target_page": 14,
          "pages": [
            12,
            13,
            14,
            15,
            16
          ]
        },
        "hop_3_rel": {
          "source_file": "SCHW_10k_2022.pdf",
          "target_page": 22,
          "pages": [
            20,
            21,
            22,
            23,
            24
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 74166,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18783,
        "completion_tokens": 141,
        "total_tokens": 18924
      }
    },
    {
      "question_id": 32,
      "question": "How does UPS's $139 million 2023 contribution to the New York State Teamsters Conference Pension and Retirement Fund demonstrate compliance with FIP requirements for red-zone pension plans?",
      "original_answer": "UPS satisfies all implemented FIP requirements through collectively-bargained contributions, as stated in the general pension plan overview on page 94. The New York State Teamsters Conference Pension and Retirement Fund is specifically identified on page 95 as a red-zone plan subject to an implemented FIP. UPS contributed $139 million to this fund in 2023, demonstrating that their contributions align with the financial improvement obligations tied to this red-zone plan. The data confirms that UPS's contributions meet the required levels without surcharges, consistent with their overall pension funding strategy.",
      "llm_answer": "UPS’s $139 million contribution to the New York State Teamsters Conference Pension and Retirement Fund satisfies the FIP requirement for that red‑zone plan because the fund’s collective‑bargaining agreement obligates UPS to fund the plan at the level negotiated, and the company’s contributions meet or exceed the amounts required by the plan’s implemented rehabilitation plan; thus the contribution is fully compliant with the FIP obligations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 87500,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22095,
        "completion_tokens": 111,
        "total_tokens": 22206
      }
    },
    {
      "question_id": 33,
      "question": "How does the $122 million pre-tax gain from the remeasurement of PEP's equity stake in Sabra relate to the acquisition of Sabra Dipping Company as a wholly-owned subsidiary, and what strategic implications does this have for Frito-Lay North America's product portfolio?",
      "original_answer": "PEP recognized a $122 million pre-tax gain from remeasuring its previously held 50% equity stake in Sabra to fair value upon acquiring the remaining 50% ownership interest in Sabra Dipping Company, making it a wholly-owned subsidiary. This acquisition aligns with Frito-Lay North America's (FLNA) strategic focus on branded dips, as Sabra Dipping Company now contributes its refrigerated dips and spreads directly to FLNA’s broader portfolio of convenient foods. The financial gain reflects the increased control and integration of Sabra into FLNA’s operations, supporting PEP’s strategy to strengthen its position in the dips category through full ownership and operational consolidation.",
      "llm_answer": "The $122 million pre‑tax gain recorded in FLNA’s selling, general & administrative expenses stems from re‑measuring PepsiCo’s previously held 50 % equity stake in Sabra at fair value after acquiring the remaining 50 % to make Sabra a wholly‑owned subsidiary. This gain reflects the fair‑value uplift of the equity investment resulting from the acquisition and underscores how the transaction enhances PepsiCo’s control over Sabra’s dip and spread portfolio. Strategically, the move expands PepsiCo’s snack‑and‑dip offering within Frito‑Lay North America, diversifying its product portfolio and strengthening its position in the convenient‑food category.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PEP_10k_2024.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        },
        "hop_2_rel": {
          "source_file": "PEP_10k_2024.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_3_rel": {
          "source_file": "PEP_10k_2024.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 68352,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17331,
        "completion_tokens": 163,
        "total_tokens": 17494
      }
    },
    {
      "question_id": 33,
      "question": "How does Chevron's supply chain dependency on crude oil align with its financial stake in Chevron U.S.A. Inc., a subsidiary that directly manages crude oil exploration and production assets in the U.S.?",
      "original_answer": "Chevron Corporation depends on crude oil as a core raw material for its upstream and downstream operations (page 35). Chevron U.S.A. Inc. (CUSA), a major subsidiary in which Chevron holds a full ownership stake, manages most of Chevron's U.S. businesses, including those related to crude oil exploration, production, and refining (page 77). CUSA also oversees Chevron’s investment in Chevron Phillips Chemical Company LLC. This alignment indicates that Chevron’s supply chain reliance on crude oil is operationally and financially integrated through CUSA, which controls the upstream assets critical to Chevron’s business model. The structure allows Chevron to directly manage its crude oil supply base while consolidating financial performance through its majority-owned subsidiary.",
      "llm_answer": "Chevron’s supply chain dependence on crude oil directly aligns with its financial stake in Chevron U.S.A. Inc. (CUSA), as CUSA manages the company’s U.S. exploration, production, and refining operations that form the core of its upstream and downstream activities. This integration ensures that Chevron’s supply chain is vertically aligned with its subsidiary’s assets, reinforcing its financial exposure to crude oil price fluctuations and production volumes, particularly within U.S. upstream operations where CUSA oversees key crude oil assets.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 77,
          "pages": [
            75,
            76,
            77,
            78,
            79
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 77,
          "pages": [
            75,
            76,
            77,
            78,
            79
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 84358,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21317,
        "completion_tokens": 136,
        "total_tokens": 21454
      }
    },
    {
      "question_id": 33,
      "question": "How does Microsoft's treatment of Software Assurance (SA) in multi-year Enterprise Agreements affect the timing of revenue recognition for on-premises licenses compared to the invoicing terms outlined in the contracts?",
      "original_answer": "Microsoft includes Software Assurance (SA) in Enterprise Agreements, which are multi-year licensing programs designed for medium or large organizations. These agreements allow customers to purchase perpetual or subscription-based licenses over a three-year period. SA, which provides benefits like future software upgrades, is bundled with perpetual licenses in Enterprise Agreements. According to the accounting policy on page 64, revenue for multi-year on-premises licenses is recognized upfront even though invoicing occurs annually at the beginning of each coverage period. This creates a timing difference between when revenue is recognized and when cash is collected, resulting in recorded receivables. The upfront recognition reflects Microsoft's assessment of the standalone selling price (SSP) and the pattern of delivery of SA benefits across the customer portfolio. Thus, while invoicing is annual, revenue recognition is immediate, and SA plays a key role in structuring the customer relationship and determining the allocation of variable consideration.",
      "llm_answer": "Microsoft recognizes that multi‑year Enterprise Agreements often bundle on‑premises licenses with Software Assurance (SA). While the contracts typically invoice customers annually at the start of each coverage period, revenue from the on‑premises license portion is recognized upfront when control of the software transfers to the customer, whereas the portion of revenue allocated to SA is recognized ratably over the contract term as the associated benefits are consumed. This treatment results in revenue being recorded before the related invoicing occurs for the license, with the SA portion spread evenly throughout the agreement.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 54507,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 13858,
        "completion_tokens": 158,
        "total_tokens": 14017
      }
    },
    {
      "question_id": 33,
      "question": "How does the absence of issued Class B Common Stock in 2024 impact the voting power structure and equity composition compared to the previous year, given its convertibility into Class A Common Stock?",
      "original_answer": "The absence of issued Class B Common Stock in 2024 removes the dual-class voting power dynamic, as Class B shares historically held 33⅓% of the voting power and were convertible into Class A shares. In 2023, Class A Common Stock had 4,842,108,959 issued shares with $48 billion in equity value, while Class B Common Stock had 9,444,375 issued and outstanding shares, contributing to a differentiated equity structure. By 2024, only Class A Common Stock remains issued (4,651,093,045 shares), with equity value declining slightly to $47 billion, suggesting a shift in governance and equity control. This structural change affects shareholder influence and aligns voting power exclusively with Class A shareholders.",
      "llm_answer": "The absence of issued Class B Common Stock in 2024 leaves the voting power structure unchanged: holders of Class A shares retain 66 ⅔ % of the vote and holders of Class B shares retain 33 ⅓ % (which is non‑dilutive and cannot be reduced by any new issuances). Because Class B shares are convertible into Class A shares on a one‑for‑one basis, their non‑issuance means the equity composition reflects only Class A shares outstanding (3.78 billion in 2024 versus 3.97 billion in 2023), with no Class B shares outstanding to affect the vote‑share balance.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 67,
          "pages": [
            65,
            66,
            67,
            68,
            69
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 72027,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18235,
        "completion_tokens": 138,
        "total_tokens": 18373
      }
    },
    {
      "question_id": 33,
      "question": "Given the conversion rights of Class B Common Stock into Class A Common Stock and the voting power distribution, how does the disclosed non-dilutable 33 1/3% voting control by Class B shares reconcile with the fact that Class A shares significantly outnumber Class B shares and are listed on Nasdaq?",
      "original_answer": "The disclosed capital structure on page 69 shows that Class B Common Stock consists of only 9,444,375 issued and outstanding shares compared to over 4.8 billion Class A shares. Despite this disparity, Note 12 on page 91 clarifies that Class B shares maintain a non-dilutable 33 1/3% of total voting power through their 15-vote entitlement per share, which compensates for their smaller quantity. This voting control mechanism is preserved even though Class B shares can convert to Class A shares, and Class A shares are publicly traded on Nasdaq as disclosed on page 1. The dual-class structure thus enables concentrated voting control while allowing for broader equity ownership through the Class A shares.",
      "llm_answer": "The disclosed non‑dilutable 33 ⅓ % voting control of Class B shares is reconciled with the fact that Class A shares vastly outnumber Class B shares and are listed on Nasdaq by noting that each Class B share carries 15 votes, giving the 9 million Class B shares (≈33 ⅓ % of total voting power) a disproportionately large influence despite their small share count; the Class B shares are convertible into Class A shares on a one‑for‑one basis (subject to certain restrictions), so the voting power of the Class B shares cannot be diluted by additional Class A issuances, while the Class A shares, though far more numerous, each carry only one vote and therefore do not affect the non‑dilutable 33 ⅓ % voting percentage held by Class B.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 1,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 60727,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15438,
        "completion_tokens": 183,
        "total_tokens": 15621
      }
    },
    {
      "question_id": 33,
      "question": "How does the strategic emphasis on the John Lewis-class Fleet Replenishment Oiler in the Marine Systems segment align with the $735 million contract awarded for its construction, and what does this indicate about GD's long-term naval shipbuilding priorities?",
      "original_answer": "The strategic emphasis on the John Lewis-class Fleet Replenishment Oiler, noted in the narrative section of GD's 10-K, highlights its importance in the company's naval shipbuilding portfolio, with deliveries planned into 2028. This aligns with the $735 million contract awarded in 2023 for the construction of an additional ship in this class, as disclosed in the Marine Systems segment's contract awards. The combination of long-term delivery planning and the significant contract value indicates that GD is prioritizing sustained investment in auxiliary naval vessels as part of its broader long-term shipbuilding strategy, balancing submarine and surface ship production.",
      "llm_answer": "The $735 million Navy award for an additional John Lewis‑class (T‑AO‑205) fleet‑replenishment oiler is a direct continuation of GD’s Marine Systems strategy to expand its shipbuilding pipeline and modernize the U.S. Navy’s auxiliary fleet. This contract underscores the company’s long‑term priority of sustaining and growing its submarine and surface‑ship production capacity—particularly Columbia‑class and Virginia‑class submarines—while also securing steady workload for its auxiliary‑ship programs, indicating that future naval shipbuilding investments will remain centered on nuclear‑propelled platforms and replenishment vessels.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 8,
          "pages": [
            6,
            7,
            8,
            9,
            10
          ]
        },
        "hop_2_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 43,
          "pages": [
            41,
            42,
            43,
            44,
            45
          ]
        },
        "hop_3_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 43,
          "pages": [
            41,
            42,
            43,
            44,
            45
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 30987,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 7987,
        "completion_tokens": 158,
        "total_tokens": 8146
      }
    },
    {
      "question_id": 33,
      "question": "How does BMY's regulatory exclusivity advantage for biologics like Opdualag intersect with its strategic positioning in the melanoma treatment market, particularly given the specific indication for unresectable or metastatic melanoma in patients 12 years and older?",
      "original_answer": "BMY benefits from a 12-year regulatory exclusivity period for biologics such as Opdualag, which is indicated for treating unresectable or metastatic melanoma in patients aged 12 and older. This exclusivity period provides a significant market protection window, allowing BMY to establish a strong foothold in the melanoma treatment market without biosimilar competition. The specific indication for Opdualag, targeting both adult and pediatric patients, enhances its market potential by broadening the patient population. This strategic positioning is reinforced by the regulatory framework, which delays biosimilar approval, thereby safeguarding BMY's market share during the exclusivity period.",
      "llm_answer": "BMY's regulatory exclusivity for Opdualag—a combination of nivolumab and relatlimab—provides 12 years of market protection for this CAR‑T‑like biologic in the U.S., extending beyond the patent life of its underlying antibodies. This exclusivity strengthens BMY’s strategic positioning in the melanoma market by securing a durable commercial window for Opdualag’s approved indication of unresectable or metastatic melanoma in patients aged 12 years and older, reinforcing its competitive advantage against generic and biosimilar entrants.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 92925,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 23470,
        "completion_tokens": 134,
        "total_tokens": 23605
      }
    },
    {
      "question_id": 33,
      "question": "How does Boeing's exposure to cost overruns on fixed-price development contracts, specifically the $402 million loss recorded on the KC-46A Tanker in 2021, reconcile with the continued production authorization of 94 aircraft across seven LRIP lots valued at $19 billion as of December 31, 2021?",
      "original_answer": "Boeing faces significant financial exposure on fixed-price development contracts like the KC-46A Tanker, as evidenced by the $402 million loss recorded in Q4 2021 due to supply chain disruptions and evolving customer requirements. Despite these challenges, the U.S. Air Force has authorized seven LRIP lots for 94 aircraft under the same program, with a total contract value of $19 billion as of year-end 2021. This continuation suggests that while Boeing bears the risk of cost overruns inherent in fixed-price development contracts, the strategic importance of the KC-46A program and its long-term revenue potential justify ongoing production, even in the face of near-term financial losses.",
      "llm_answer": "Boeing recorded a $402 million reach‑forward loss on the KC‑46A tanker in 2021, reflecting cost overruns on this fixed‑price development contract.  Nevertheless, the company continued to authorize production of 94 KC‑46A aircraft across seven LRIP lots, a program valued at roughly $19 billion as of Dec 31 2021, because the overall contract remains funded and the company expects to complete the work under the existing fixed‑price terms.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 134,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 51247,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 13069,
        "completion_tokens": 109,
        "total_tokens": 13179
      }
    },
    {
      "question_id": 33,
      "question": "Given ExxonMobil's long-standing operational presence in Nigeria since at least 2006, how does the company's exposure to production-sharing contracts (PSCs) in Nigeria—where the exploration period is typically 10 years and production period is 20 years—impact the classification and economic interest in proved reserves under SEC reporting requirements?",
      "original_answer": "ExxonMobil has operated in Nigeria since at least 2006, where its activities are governed by production-sharing contracts (PSCs) that typically include a 10-year exploration period and a 20-year production period, which may be extended. Under SEC reporting rules, proved reserves must be estimated with reasonable certainty to be economically producible prior to the expiration of contracts unless renewal is reasonably certain. Since Nigeria’s PSCs include defined expiration dates and partial relinquishment provisions under the Petroleum Industry Act, ExxonMobil must assess the likelihood of contract extensions when reporting proved reserves. As of year-end 2021, 12% of ExxonMobil’s total proved reserves on an oil-equivalent basis were associated with PSC arrangements, and reserves under these contracts vary inversely with price changes. Therefore, the finite duration and fiscal terms of Nigeria’s PSCs directly influence the economic interest and classification of reserves under SEC rules, particularly for deepwater offshore assets.",
      "llm_answer": "ExxonMobil’s long‑term participation in Nigeria through production‑sharing contracts (PSCs) – typically a 10‑year exploration phase followed by a 20‑year production phase – means that the company’s proved reserves in that country are subject to the contractual terms of those PSCs. Under SEC reporting rules, proved reserves are classified only when they are “reasonably certain” to be recoverable under existing economic conditions and contractual arrangements. Because the exploration period is limited to 10 years and the production period to 20 years, ExxonMobil must assess the likelihood of commercial development within that timeframe; only the portion of reserves that can be demonstrated to be producible under the PSC’s schedule can be included in proved reserves. Consequently, the company’s economic interest in Nigerian proved reserves is effectively constrained by the PSC’s duration, and any reserves that cannot be developed before the exploration period expires are classified as non‑proved (e.g., probable or possible) rather than proved. This limitation can reduce the reported volume of proved reserves attributable to Nigeria and may affect the company’s overall reserve classification and related financial disclosures.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "XOM_10k_2022.pdf",
          "target_page": 127,
          "pages": [
            125,
            126,
            127,
            128,
            129
          ]
        },
        "hop_2_rel": {
          "source_file": "XOM_10k_2022.pdf",
          "target_page": 31,
          "pages": [
            29,
            30,
            31,
            32,
            33
          ]
        },
        "hop_3_rel": {
          "source_file": "XOM_10k_2022.pdf",
          "target_page": 134,
          "pages": [
            128,
            129,
            130,
            131,
            132
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 87113,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22048,
        "completion_tokens": 310,
        "total_tokens": 22359
      }
    },
    {
      "question_id": 33,
      "question": "How does NEE's $2.3 billion in guarantees for NEP relate to NEP's ownership of solar projects and NEE's planned capital expenditures for solar development?",
      "original_answer": "NEE has provided guarantees totaling approximately $2.3 billion on behalf of NEP's subsidiaries, primarily related to project performance obligations and financing agreements. NEP, in which NEE holds a significant stake, owns or has partial ownership in a portfolio of contracted renewable energy assets, including solar projects totaling approximately 10,118 MW of energy project capacity. NEE’s planned capital expenditures include approximately $6,134 MW of new solar projects (including solar plus battery storage), indicating a strategic emphasis on expanding solar capacity. The guarantees highlight NEE’s financial exposure and support for NEP’s solar initiatives, aligning with NEE’s broader capital allocation strategy focused on solar development.",
      "llm_answer": "NEE’s $2.3 billion of guarantees for NEP are tied to the guarantees it provides for NEP’s subsidiaries and the CSCS credit support it extends to NEP. These guarantees cover NEP’s project‑related obligations and financing arrangements, and they are recorded on NEE’s balance sheet at fair value. The guarantees are part of NEE’s broader capital‑expenditure program that funds the development of solar and other renewable projects that NEP owns or in which it holds partial interests.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NEE_10k_2023.pdf",
          "target_page": 96,
          "pages": [
            94,
            95,
            96,
            97,
            98
          ]
        },
        "hop_2_rel": {
          "source_file": "NEE_10k_2023.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_3_rel": {
          "source_file": "NEE_10k_2023.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 81434,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20580,
        "completion_tokens": 120,
        "total_tokens": 20701
      }
    },
    {
      "question_id": 34,
      "question": "How does Merck's $11.5 billion acquisition of Acceleron Pharma align with its R&D focus on TGF-beta superfamily proteins and broader pipeline expansion strategy?",
      "original_answer": "Merck's $11.5 billion acquisition of Acceleron Pharma (page_52) aligns with its R&D focus on TGF-beta superfamily proteins, which Acceleron was evaluating for their role in regulating cell growth, differentiation, and repair (page_96). This acquisition brought sotatercept (MK-7962), a Phase 3 candidate for pulmonary arterial hypertension, and Reblozyl, a marketed erythroid maturation therapy, into Merck's portfolio. The research pipeline section (page_68) highlights Merck’s strategic emphasis on expanding its late-stage clinical candidates and leveraging acquisitions to drive growth, which is exemplified by the integration of Acceleron’s TGF-beta-focused pipeline into Merck’s broader R&D strategy.",
      "llm_answer": "Merck's $11.5 billion acquisition of Acceleron Pharma directly advances its R&D focus on TGF‑beta superfamily proteins—most notably Acceleron’s lead candidate sotatercept, a novel therapy for pulmonary arterial hypertension—and expands its pipeline with additional hematologic and pulmonary assets, reinforcing the company’s broader strategy to bolster its pharmaceutical portfolio and drive future growth.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 52,
          "pages": [
            50,
            51,
            52,
            53,
            54
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 96,
          "pages": [
            94,
            95,
            96,
            97,
            98
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 65760,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16662,
        "completion_tokens": 101,
        "total_tokens": 16764
      }
    },
    {
      "question_id": 34,
      "question": "How does the litigation exposure involving Molina in multiple state and federal courts impact the financial liabilities assumed by BMY following the $35.7 billion Celgene acquisition?",
      "original_answer": "The litigation exposure involving Molina, as seen in both the Minnesota state court case removed to the District of New Jersey and the San Francisco Superior Court case remanded in 2022, contributes to the ongoing legal liabilities that BMY inherited from the Celgene acquisition. The $35.7 billion acquisition included not only Celgene’s assets and pipeline but also its contingent liabilities, such as the numerous lawsuits alleging similar claims to those in the class action litigation, including those involving Molina. These legal proceedings, which remain unresolved with no trial dates set, represent potential financial obligations for BMY, adding to the broader post-acquisition risk profile that includes other litigation with entities like Cigna, BCBSA, and MSP. This exposure must be factored into the financial evaluation of the acquisition’s long-term impact on BMY’s balance sheet and risk posture.",
      "llm_answer": "The litigation exposure involving Molina across multiple state and federal courts is not disclosed in the provided BMY 10‑K pages. Consequently, the document does not contain any information about the nature, extent, or potential financial impact of that litigation on the liabilities assumed by BMY in connection with the $35.7 billion Celgene acquisition.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "target_page": 166,
          "pages": [
            137,
            138,
            139,
            140,
            141
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "target_page": 166,
          "pages": [
            137,
            138,
            139,
            140,
            141
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "target_page": 116,
          "pages": [
            114,
            115,
            116,
            117,
            118
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 12,
        "total_chars": 52362,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 13316,
        "completion_tokens": 89,
        "total_tokens": 13405
      }
    },
    {
      "question_id": 34,
      "question": "How does MetLife's disclosure of CMBS holdings in the fair value hierarchy compare with the valuation complexity described for structured products, particularly regarding the use of unobservable inputs?",
      "original_answer": "MetLife reports $9.949 billion in CMBS holdings as part of its fixed maturity securities AFS, with $9.099 billion categorized in Level 2 and $850 million in Level 3 of the fair value hierarchy. CMBS is explicitly included within the broader category of 'Structured Products,' which encompasses RMBS, ABS & CLO, and CMBS. In the valuation methodology section, MetLife outlines that structured products, including CMBS, rely on both market and income approaches using inputs like spreads off benchmark yields, expected prepayment speeds, and credit ratings. However, Level 3 valuations for these products also incorporate unobservable inputs such as independent non-binding broker quotations and credit spreads, indicating higher subjectivity and complexity in valuing CMBS compared to more transparent Level 2 instruments.",
      "llm_answer": "MetLife’s CMBS holdings are classified as Level 3 in the fair‑value hierarchy, reflecting the use of significant unobservable inputs—such as internally developed cash‑flow assumptions, prepayment and loss‑severity estimates, and credit‑spread assumptions—to determine their fair value. This valuation approach mirrors the complexity applied to other structured products, where limited market activity necessitates reliance on these unobservable inputs for pricing.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 265,
          "pages": [
            263,
            264,
            265,
            266,
            267
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 233,
          "pages": [
            231,
            232,
            233,
            234,
            235
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 268,
          "pages": [
            266,
            267,
            268,
            269,
            270
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 104078,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 26253,
        "completion_tokens": 116,
        "total_tokens": 26369
      }
    },
    {
      "question_id": 34,
      "question": "How does the strategic emphasis on the John Lewis-class Fleet Replenishment Oiler in the operations overview reconcile with the $735 million contract awarded for its construction, and what does this indicate about GD's prioritization of surface ship programs relative to submarine production in 2023?",
      "original_answer": "The operations overview on page 8 highlights GD's strategic focus on submarine production, particularly the Columbia-class and Virginia-class programs, while also noting the ongoing construction of the John Lewis-class (T-AO-205) fleet replenishment oiler as part of NASSCO’s portfolio. It states that seven T-AO-205 ships are in backlog with deliveries planned into 2028, indicating a long-term commitment to this surface ship program. On page 43, the $735 million contract awarded in 2023 for an additional John Lewis-class vessel underscores the Navy’s continued investment in this program and GD’s role in executing it. This contract is one of the larger awards in the Marine Systems segment that year, suggesting GD is balancing its strategic focus on submarines with sustained execution on surface ship programs. The combination of long-term backlog and new contract awards indicates that GD is maintaining capacity and prioritization across both domains.",
      "llm_answer": "The $735 million Navy contract for an additional John Lewis‑class fleet‑replenishment oiler is highlighted in the Marine Systems backlog summary as one of several major awards in 2023, underscoring the segment’s focus on surface‑ship construction alongside submarine work. This award, together with the $1.7 billion lead‑yard services and $1.3 billion for Virginia‑class long‑lead materials, demonstrates that GD is allocating substantial resources to surface‑ship programs—particularly replenishment and auxiliary vessels—while still maintaining a heavy emphasis on submarine production (e.g., Columbia‑class and Virginia‑class boats), indicating a balanced but surface‑ship‑centric prioritization in 2023.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 8,
          "pages": [
            6,
            7,
            8,
            9,
            10
          ]
        },
        "hop_2_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 43,
          "pages": [
            41,
            42,
            43,
            44,
            45
          ]
        },
        "hop_3_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 43,
          "pages": [
            41,
            42,
            43,
            44,
            45
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 30987,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 7997,
        "completion_tokens": 176,
        "total_tokens": 8174
      }
    },
    {
      "question_id": 34,
      "question": "How does the $24 million earnings impact from regulatory disallowances at Nicor Gas disclosed in the MD&A section reconcile with the $96 million pre-tax charge specifically attributed to Nicor Gas in the footnote disclosures?",
      "original_answer": "The $24 million figure mentioned in the MD&A section refers to the approximate earnings impact related to regulatory disallowances at Nicor Gas, reflecting a net effect after considering other factors. This aligns with the more detailed $96 million pre-tax charge disclosed in the footnotes under Nicor Gas operations, which represents the gross disallowance of certain capital investments. The difference between the two figures suggests that the $96 million charge was partially offset by other earnings drivers or tax adjustments, as implied by the MD&A's characterization of the disallowance as a partial offset to increased earnings. This synthesis across sections reveals a nuanced financial impact where the headline earnings effect is netted against other operational and regulatory developments.",
      "llm_answer": "The $24 million earnings impact from regulatory disallowances at Nicor Gas is recorded as an estimated loss on regulatory disallowance in the income‑statement line “Estimated loss on regulatory disallowance,” while the $96 million pre‑tax charge referenced in the footnote disclosures represents the total pre‑tax amount of those disallowances (the $88 million estimated loss plus related items). In other words, the $24 million reflects the portion of the $96 million charge that is recognized in net income for the period, whereas the full $96 million is the overall pre‑tax regulatory disallowance amount disclosed in the footnotes.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 302,
          "pages": [
            300,
            301,
            302,
            303,
            304
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 64473,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16355,
        "completion_tokens": 158,
        "total_tokens": 16514
      }
    },
    {
      "question_id": 35,
      "question": "How does PepsiCo's acquisition of full ownership in Sabra Dipping Company align with the strategic importance of the Sabra brand in expanding refrigerated dips and spreads within FLNA, and what financial impact did this have on the division in 2024?",
      "original_answer": "PepsiCo's acquisition of the remaining 50% of Sabra Dipping Company for $241 million in December 2024 aligns with the strategic importance of the Sabra brand, which is central to expanding its refrigerated dips and spreads portfolio under Frito-Lay North America (FLNA). This acquisition made Sabra a wholly-owned subsidiary, enabling full integration and control over a key product line. The transaction resulted in a pre-tax gain of $122 million ($92 million after-tax or $0.07 per share) recognized in FLNA, recorded under selling, general and administrative expenses, due to the re-measurement of the previously held 50% equity stake at fair value. This financial impact underscores the strategic and economic significance of the Sabra brand in PepsiCo's broader portfolio expansion strategy.",
      "llm_answer": "PepsiCo's acquisition of full ownership in Sabra Dipping Company strengthens its strategic focus on expanding the refrigerated dips and spreads category within the Frito‑Lay North America (FLNA) division, a key growth area in the broader FLNA portfolio. The transaction, completed in December 2024 for $241 million, generated a $122 million pre‑tax gain (recorded in FLNA’s SG&A) and added Sabra’s refrigerated dip business to PepsiCo’s wholly‑owned assets, enhancing FLNA’s product depth and market share in that segment. This contribution helped drive a modest improvement in FLNA’s operating performance in 2024, although the overall division’s financial results were also influenced by broader commodity and cost pressures.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PEP_10k_2024.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_2_rel": {
          "source_file": "PEP_10k_2024.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_3_rel": {
          "source_file": "PEP_10k_2024.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 61744,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15675,
        "completion_tokens": 181,
        "total_tokens": 15857
      }
    },
    {
      "question_id": 35,
      "question": "Given Apple's significant net sales from Greater China in 2022, which includes Taiwan, how does the company's reliance on Taiwan-based operations expose it to geopolitical and supply chain risks outlined in the risk factors section?",
      "original_answer": "Apple reported $74.2 billion in net sales from Greater China in 2022, a region that includes Taiwan. According to the segment reporting, Taiwan is a key component of Apple's operations in the region. However, in the risk factors section, Apple highlights that its supply chain, particularly in Asia, is vulnerable to geopolitical tensions, including those involving Taiwan. The company also notes that a significant portion of its manufacturing is outsourced to partners in Asia, including Taiwan, making it susceptible to disruptions from political instability, trade restrictions, and other international conflicts. Therefore, while Taiwan contributes to Apple's revenue performance within Greater China, it also represents a critical risk point due to its strategic location and the current geopolitical climate.",
      "llm_answer": "Apple's reliance on Taiwan-based operations for components and manufacturing exposes it to significant geopolitical and supply chain risks, as highlighted in the \"Risk Factors\" section and \"Concentrations in the Available Sources of Supply of Materials and Product\" note. The document specifically notes that many critical components are sourced from single or limited suppliers, including in Taiwan, and that political tensions—particularly with China—could lead to tariffs, trade restrictions, or supply disruptions that would increase costs, reduce competitiveness, and materially adversely affect the Company's business, results of operations, and financial condition. This risk is amplified by the fact that Taiwan is explicitly included within \"Greater China\" in the company's geographic reporting, where it contributed $74.2 billion in net sales for 2022.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 52,
          "pages": [
            50,
            51,
            52,
            53,
            54
          ]
        },
        "hop_2_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 40,
          "pages": [
            38,
            39,
            40,
            41,
            42
          ]
        },
        "hop_3_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 71264,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18055,
        "completion_tokens": 215,
        "total_tokens": 18271
      }
    },
    {
      "question_id": 35,
      "question": "How does the 15% revenue decline in Converse, driven by weakness in North America and Western Europe, impact NIKE's strategic focus on growing its broader athletic accessories portfolio, particularly given Converse's role as a reportable segment focused on lifestyle sneakers, apparel, and accessories?",
      "original_answer": "The 15% currency-neutral revenue decline in Converse—driven by reduced wholesale and direct-to-consumer sales in North America and Western Europe—creates a challenge for NIKE’s strategic objective of growing its athletic accessories portfolio. As a reportable segment, Converse is specifically tasked with lifestyle sneakers, apparel, and accessories, which are core components of NIKE’s broader accessories strategy outlined in the MD&A. Despite this decline, NIKE continues to prioritize investment in digital platforms and consumer experiences to elevate its brand, including within Converse. However, the contraction in Converse’s gross margin by 130 basis points and the 30% drop in EBIT raise concerns about the segment’s ability to contribute meaningfully to the company’s strategic growth in accessories, particularly in light of increased promotional activity and lower ASPs.",
      "llm_answer": "The 15% revenue decline in Converse—driven by weakness in North America and Western Europe—directly pressures the company’s broader athletic accessories portfolio, as Converse is a standalone reportable segment focused on lifestyle sneakers, apparel, and accessories. This decline reflects reduced unit sales and lower ASPs in key markets, undermining growth in the accessories category that relies on Converse’s brand equity and product diversification. Consequently, NIKE must accelerate strategic investments in its accessories portfolio to offset this segment’s contraction and sustain overall portfolio momentum.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 66042,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16768,
        "completion_tokens": 154,
        "total_tokens": 16922
      }
    },
    {
      "question_id": 35,
      "question": "How does Apple's characterization of Taiwan as a supply chain risk factor reconcile with the financial performance of the Greater China segment, which includes Taiwan, showing a 14% increase in operating income from 2021 to 2022?",
      "original_answer": "Apple identifies Taiwan as a key part of its supply chain, located in a region prone to geopolitical and operational risks, including trade tensions and natural disasters. Despite these concerns, the Greater China segment, which includes Taiwan, reported a rise in operating income from $28,504 million in 2021 to $31,153 million in 2022—a 14% increase. This suggests that while Apple acknowledges the vulnerability of its operations in the region, the segment continues to contribute significantly to the company's profitability. The financial performance indicates resilience or effective risk mitigation strategies in place, even as the company remains exposed to potential disruptions in Taiwan and the broader Greater China region.",
      "llm_answer": "Apple's characterization of Taiwan as a supply chain risk factor is consistent with the Greater China segment's strong financial performance, as evidenced by a 14% increase in operating income from 2021 to 2022. This growth is reflected in the segment's net sales rising to $74.2 billion in 2022 and operating income increasing to $31.153 billion, indicating robust economic activity in the region despite supply chain challenges.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "hop_2_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 40,
          "pages": [
            38,
            39,
            40,
            41,
            42
          ]
        },
        "hop_3_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 52,
          "pages": [
            50,
            51,
            52,
            53,
            54
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 71264,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18055,
        "completion_tokens": 107,
        "total_tokens": 18162
      }
    },
    {
      "question_id": 36,
      "question": "How does BMY's exposure to the Inflation Reduction Act's price negotiation provisions for Pomalyst, selected for negotiation in 2027, interact with the company's reliance on patent exclusivity and regulatory protections for this product as outlined in its intellectual property strategy?",
      "original_answer": "BMY faces dual pressures on Pomalyst stemming from both regulatory pricing reforms and intellectual property risks. The Inflation Reduction Act (IRA), referenced in the 2024 10-K, subjects Pomalyst to government price negotiation starting in 2027, which could materially reduce revenue from this product. This pricing risk coincides with the company's strategic reliance on patent exclusivity and regulatory protections to maintain market exclusivity for Pomalyst. As noted in the document, BMY lists patents in the FDA's Orange Book and evaluates Paragraph IV certifications to defend against generic competition. However, the IRA's pricing negotiation mechanism introduces a new layer of financial pressure that may accelerate revenue erosion even before patent expiration. The combination of these factors suggests that BMY may face both reduced pricing power and increased competition for Pomalyst, potentially impacting long-term profitability and strategic planning for this asset.",
      "llm_answer": "BMY's reliance on patent exclusivity and regulatory protections for Pomalyst is directly challenged by the Inflation Reduction Act's (IRA) price negotiation provisions, which specifically selected Pomalyst for government price setting beginning in 2027. This provision introduces significant, unavoidable pricing pressure on Pomalyst—despite its existing patent and regulatory exclusivity—because the IRA mandates federal price negotiation for high-cost drugs beyond their exclusivity periods, potentially accelerating revenue erosion before patent protection fully expires. Consequently, while patent exclusivity and regulatory protections currently shield Pomalyst from generic competition, the IRA's negotiation mechanism creates a new, non-patent-based vulnerability that could undermine the product's long-term commercial viability and conflict with BMY's strategy of leveraging intellectual property to maintain market exclusivity.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 134,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 43,
          "pages": [
            41,
            42,
            43,
            44,
            45
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 90290,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22826,
        "completion_tokens": 234,
        "total_tokens": 23060
      }
    },
    {
      "question_id": 36,
      "question": "Given Converse's 15% revenue decline in fiscal 2024 and its explicit role as a reportable segment focused on athletic lifestyle sneakers, apparel, and accessories, how does NIKE's strategic emphasis on growing its accessories business through NIKE Direct and wholesale channels reconcile with Converse's underperformance in these areas?",
      "original_answer": "Converse, as a reportable segment focused on athletic lifestyle sneakers, apparel, and accessories, experienced a 15% revenue decline in fiscal 2024, driven by drops in both wholesale and direct-to-consumer channels. Meanwhile, NIKE's overall strategy emphasizes growing its accessories business through both NIKE Direct and wholesale partnerships, as stated in the MD&A section. This raises a critical alignment issue: despite NIKE's strategic push to expand accessories through these channels, Converse—its key vehicle for accessories—underperformed, with direct-to-consumer revenues down 14% and wholesale down 16%. The contradiction suggests potential challenges in Converse’s brand positioning, product mix, or execution within those channels, which could impact NIKE’s broader accessories growth objectives.",
      "llm_answer": "NIKE's strategic focus on growing its accessories business through NIKE Direct and wholesale channels is not directly tied to Converse's underperformance, as Converse operates as a distinct reportable segment with its own revenue streams and challenges. While NIKE Brand (including Converse) saw overall revenue growth driven by NIKE Direct and wholesale channels, Converse specifically experienced a 15% revenue decline in fiscal 2024 due to reduced sales in North America and Western Europe, particularly in wholesale and direct-to-consumer channels. This decline was attributed to lower unit sales, decreased ASPs from promotional activity, and market-specific headwinds, rather than a failure of NIKE's broader accessories strategy. NIKE's accessories growth (within its core NIKE Brand segment) was supported by higher ASPs and strategic pricing, but Converse's performance reflected its independent market dynamics and did not align with NIKE's overall growth objectives for accessories.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 66042,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16776,
        "completion_tokens": 248,
        "total_tokens": 17025
      }
    },
    {
      "question_id": 36,
      "question": "How does NIKE's foreign exchange hedging strategy for product costs relate to its operational dependency on the NIKE Trading Company (NTC), and what impact does this have on inventory cost volatility?",
      "original_answer": "NIKE's foreign exchange hedging strategy is closely tied to its product cost exposures, which are largely generated through purchases from the NIKE Trading Company (NTC), a U.S. Dollar-denominated sourcing hub. NTC buys products from third-party factories and sells them to NIKE entities in their respective functional currencies, creating foreign currency exposure. NIKE manages this exposure using cash flow hedges, including currency forwards and options, to stabilize the effects of exchange rate fluctuations on product costs. However, when NTC sells to a NIKE entity with a different functional currency, the resulting foreign exchange exposure directly affects inventory costs. A stronger U.S. Dollar increases inventory costs for entities with non-dollar functional currencies, while a weaker Dollar reduces them. Therefore, the effectiveness of NIKE's hedging strategy directly influences the volatility of inventory costs across its global operations.",
      "llm_answer": "NIKE’s foreign‑exchange hedging program is tightly linked to its sourcing structure: most product costs are generated when NIKE entities purchase goods from the NIKE Trading Company (NTC), a wholly‑owned hub that buys from factories in U.S. dollars and then sells to other NIKE entities in their local currencies. Because these transactions create foreign‑currency exposure for both the NTC and the downstream entities, NIKE uses cash‑flow hedges—primarily forward contracts and options—to offset the variability of those product‑cost exposures. The hedges are designated for product‑cost purchases, non‑functional‑currency sales, and other cost items, and they are recorded in accumulated other comprehensive income until the underlying transaction impacts net income. Consequently, while the hedges stabilize inventory costs by locking in exchange rates, the underlying exposure to NTC‑driven product purchases still contributes to inventory‑cost volatility, especially when exchange‑rate movements are large or when hedging coverage is incomplete.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 86785,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21923,
        "completion_tokens": 262,
        "total_tokens": 22186
      }
    },
    {
      "question_id": 36,
      "question": "How does AT&T's ability to redeem the Mobility II preferred equity interests with cash or stock compare with the more restrictive redemption terms tied to Tower Holdings' preferred interests, and what does this reveal about the company's capital structure flexibility across different subsidiaries?",
      "original_answer": "AT&T has the flexibility to redeem the Mobility II preferred equity interests either with cash, stock, or a combination thereof, and it has the intent and ability to settle these with cash. In contrast, the redemption of Tower Holdings' preferred interests is more narrowly tied to specific contingent events, such as failure to pay distributions or credit rating breaches, and the redemption price is based on market value or a fixed formula without explicit stock settlement flexibility. This distinction reveals that AT&T structures capital redemption terms differently across subsidiaries—offering more discretion in Mobility II while Tower Holdings’ terms are more prescriptive and contingent, suggesting a tiered capital structure strategy aligned with the risk profiles and asset values of each entity.",
      "llm_answer": "AT&T’s Mobility II preferred equity can be redeemed by the issuer with cash, AT&T stock, or a mix of both, and the redemption price is set at the greater of market value or a fixed $25 plus accrued distributions, with a cap of 250 million shares. In contrast, the Tower Holdings preferred interests impose far more restrictive redemption mechanics: they may only be called at issue price after five years or upon specific contingent events (e.g., missed distributions or credit‑rating breaches), and any redemption triggers a deemed liquidation that forces all subordinate classes to receive the same consideration. This disparity highlights that AT&T enjoys greater capital‑structure flexibility at the Mobility II subsidiary—where redemptions can be settled in cash or stock without covenants—while the Tower Holdings preferred securities are subject to tighter call provisions and potential liquidation constraints.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "T_10k_2022.pdf",
          "target_page": 129,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        },
        "hop_2_rel": {
          "source_file": "T_10k_2022.pdf",
          "target_page": 130,
          "pages": [
            128,
            129,
            130,
            131,
            132
          ]
        },
        "hop_3_rel": {
          "source_file": "T_10k_2022.pdf",
          "target_page": 130,
          "pages": [
            128,
            129,
            130,
            131,
            132
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 66300,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16823,
        "completion_tokens": 229,
        "total_tokens": 17053
      }
    },
    {
      "question_id": 36,
      "question": "How does Emerson's $7.8 billion cash payment to acquire NI align with the strategic positioning of NI's Automated Test Systems within the newly formed Test & Measurement segment?",
      "original_answer": "Emerson paid $7.8 billion in cash to acquire the remaining shares of NI, which is directly tied to the strategic integration of NI's Automated Test Systems into Emerson’s portfolio. NI's Automated Test Systems, highlighted as a core offering, are now positioned under the newly formed Test & Measurement segment, which is described as providing software-connected systems that help enterprises accelerate product development and reduce costs. This acquisition aligns with Emerson’s broader strategy to strengthen its software-connected solutions, as evidenced by the segment’s emphasis on modular instrumentation, data acquisition, and development software. The significant cash outlay reflects the strategic importance Emerson places on NI’s technology and its role in enhancing Emerson’s competitive positioning in the industrial automation and test equipment market.",
      "llm_answer": "Emerson's $7.8 billion cash payment to acquire National Instruments aligns with the strategic positioning of NI's Automated Test Systems within the newly formed Test & Measurement segment, as the acquisition creates a dedicated Test & Measurement business that expands Emerson's software‑connected test and measurement offering and adds roughly $1.7 billion of revenue and $1.3 billion of backlog to the segment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "EMR_10k_2024.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_2_rel": {
          "source_file": "EMR_10k_2024.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_3_rel": {
          "source_file": "EMR_10k_2024.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 66972,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16964,
        "completion_tokens": 103,
        "total_tokens": 17067
      }
    },
    {
      "question_id": 36,
      "question": "What do the differing royalty structures for Opdivo and Tecentriq suggest about BMY's relative intellectual property strength in PD-1 versus PD-L1 therapies, and how might this affect their long-term revenue positioning in immuno-oncology?",
      "original_answer": "BMY's royalty structure for Opdivo indicates a stronger IP position in PD-1 therapies, as evidenced by the 4% royalty in North America and 15% in other territories (excluding Japan, South Korea, and Taiwan). In contrast, BMY receives only single-digit royalties through Roche's Tecentriq, a PD-L1 therapy, suggesting a weaker IP position in this domain. These royalty arrangements imply that BMY holds more dominant patent rights in PD-1, which could translate into higher revenue potential and stronger negotiation leverage in the PD-1 space compared to PD-L1. This disparity may impact BMY's long-term revenue positioning in immuno-oncology, as PD-1 therapies appear to be more lucrative for the company based on current licensing arrangements.",
      "llm_answer": "The differing royalty structures for Opdivo (4% in North America, 15% elsewhere) and Tecentriq (single-digit royalties shared with Roche) indicate that BMY's PD-1 therapy (Opdivo) is positioned as a higher-value asset with stronger proprietary protection and potentially more favorable long-term revenue dynamics compared to the PD-L1 therapy (Tecentriq), which relies on shared royalty arrangements and may face greater competitive pressure in the immuno-oncology space. This suggests BMY's PD-1 portfolio is likely to generate more sustainable and higher-margin revenue streams in the long run, reinforcing its leadership in immuno-oncology.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 67447,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17097,
        "completion_tokens": 160,
        "total_tokens": 17258
      }
    },
    {
      "question_id": 36,
      "question": "How does Boeing's accounting treatment of lease options in its property and equipment disclosures reconcile with its provision of customer financing that includes similar lease extension and termination options, particularly in light of the credit risk exposure highlighted in Boeing Capital's portfolio analysis?",
      "original_answer": "Boeing accounts for lease options in its property and equipment disclosures by incorporating them into the calculation of lease assets and liabilities when it is reasonably certain they will be exercised, using its incremental borrowing rate to determine present value (page 78). In the customer financing section, Boeing Capital discloses that its financing arrangements often include options to extend or terminate leases, which are structurally similar to the lease options recognized in the accounting policy (page 93). However, in the Boeing Capital portfolio analysis (page 47), the company acknowledges significant credit risk exposure due to customer liquidity issues, including $398 million in charges for expected credit losses in 2020. This creates a tension: while the accounting policy assumes certainty in lease option exercise for asset valuation purposes, the operational reality in the Boeing Capital section shows that customer financial instability can undermine the realizability of those lease terms. Therefore, the accounting treatment assumes operational continuity, while the credit risk disclosures highlight the financial risk that contradicts that assumption.",
      "llm_answer": "Boeing’s accounting for lease options in property‑and‑equipment disclosures treats lease extensions and termination rights as part of the lease term when measuring right‑of‑use assets and liabilities, while its customer‑financing arrangements that contain similar extension or repurchase options are accounted for as financing receivables and lease income, with allowances for credit risk based on internal ratings and exposure assessments; this approach isolates the credit‑risk exposure highlighted in Boeing Capital’s portfolio analysis, which shows significant concentrations in lower‑rated receivables and the potential for losses if lessees cannot exercise renewal or repurchase rights.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 78,
          "pages": [
            76,
            77,
            78,
            79,
            80
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 47,
          "pages": [
            45,
            46,
            47,
            48,
            49
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 54105,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 13786,
        "completion_tokens": 173,
        "total_tokens": 13959
      }
    },
    {
      "question_id": 37,
      "question": "How does the adoption of ASU 2022-02 impact the disclosure requirements for financial difficulty modifications (FDMs) in 2023 compared to the prior period's troubled debt restructurings (TDRs), and what implications does this have for the evaluation of credit risk in the loan portfolio?",
      "original_answer": "The adoption of ASU 2022-02 eliminated the accounting guidance for TDRs and introduced new disclosure requirements for financial difficulty modifications (FDMs), which are now reported on a rolling twelve-month basis. Unlike TDRs, which were based on the concession principle, FDMs are defined by the form of modification (e.g., principal forgiveness, interest rate reduction, term extension) granted to borrowers in financial difficulty. This change affects how credit risk is evaluated, as FDMs are now accumulated and analyzed differently, with performance tracked over a rolling period rather than being isolated as distinct restructured events. The new disclosures provide more granular performance data on FDMs, which enhances transparency but also requires updated internal risk modeling and reporting practices to align with the new standard.",
      "llm_answer": "The adoption of ASU 2022‑02 eliminates the TDR accounting guidance and replaces it with a broader “financial difficulty modification” (FDM) framework that requires rolling‑12‑month performance reporting of modified loans and enhanced disclosure of refinancings. Consequently, 2023 disclosures now capture FDMs as a distinct category, whereas prior‑period TDR disclosures were limited to loans that met the stricter concession definition. This shift improves the evaluation of credit risk by providing more granular, forward‑looking information on borrower performance after modifications, allowing Capital One to better assess the likelihood of future credit losses and to adjust its allowance for credit losses accordingly.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 159,
          "pages": [
            157,
            158,
            159,
            160,
            161
          ]
        },
        "hop_2_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "hop_3_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 138,
          "pages": [
            136,
            137,
            138,
            139,
            140
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 78482,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19877,
        "completion_tokens": 181,
        "total_tokens": 20058
      }
    },
    {
      "question_id": 37,
      "question": "How does MDLZ's reported fair value of $71 million for net investment hedge contracts align with its broader methodology for valuing Level 2 financial liabilities?",
      "original_answer": "MDLZ reports a fair value of $71 million for its net investment hedge contracts, as disclosed in its financial statements (page 111). These contracts are categorized as Level 2 financial liabilities, which are valued using an income approach based on observable market inputs. Specifically, for net investment hedge contracts, MDLZ applies methodologies such as discounted cash flow analysis or market forward rates, as detailed in the valuation methods section. This approach aligns with the company’s treatment of other Level 2 liabilities, which rely on observable inputs such as forward rates, commodity prices, and interest rate curves, adjusted for nonperformance risk and counterparty credit risk. The $71 million figure is therefore consistent with the broader framework for Level 2 liabilities, which are not based on directly quoted market prices (Level 1) but instead derived from structured valuation models using observable data.",
      "llm_answer": "MDLZ's reported fair value of $71 million for its net‑investment hedge derivative contracts is consistent with its broader Level 2 valuation approach, which determines the fair value of such derivatives using observable market inputs (e.g., forward rates, credit spreads, and discount curves) rather than quoted prices in an active market. This methodology places the contracts in Level 2 of the fair‑value hierarchy, where their valuation relies on significant other observable inputs. Consequently, the $71 million figure reflects the present‑value of the hedged portion of non‑U.S. dollar debt and cross‑currency swaps, derived from market‑observable assumptions consistent with the company’s overall Level 2 fair‑value framework.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 111,
          "pages": [
            109,
            110,
            111,
            112,
            113
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 78234,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19774,
        "completion_tokens": 183,
        "total_tokens": 19957
      }
    },
    {
      "question_id": 37,
      "question": "How does the anticipated 2036 U.S. patent expiration for MK-1654, as listed under Merck's patent protection schedule, align with the company's strategic emphasis on long-term revenue generation given the product's current regulatory review status for RSV prophylaxis in infants?",
      "original_answer": "Merck lists MK-1654 (clesrovimab) with an anticipated 2036 U.S. patent expiration date, which provides a long-term intellectual property runway for the product. However, MK-1654 is currently under FDA and EU regulatory review as an investigational long-acting monoclonal antibody designed to protect infants from RSV disease. This means the product has not yet reached the market, and its commercialization timeline remains uncertain. While the patent protection extends well into the future, the delayed market entry due to ongoing regulatory processes may compress the effective revenue-generating period before patent expiration. This creates a strategic tension between the long patent life and the potential for a shorter commercial lifecycle, particularly for a product aimed at a seasonal and potentially competitive prophylactic market.",
      "llm_answer": "The anticipated 2036 U.S. patent expiration for MK‑1654 aligns with Merck’s long‑term revenue strategy, as the company continues to pursue regulatory approval for the product (currently under FDA review for RSV prophylaxis in infants) while counting on extended market exclusivity—via pending patent term extensions and data‑exclusivity periods—to sustain revenue beyond the compound patent’s expiry.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 15,
          "pages": [
            13,
            14,
            15,
            16,
            17
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 50,
          "pages": [
            48,
            49,
            50,
            51,
            52
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 78206,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19799,
        "completion_tokens": 100,
        "total_tokens": 19899
      }
    },
    {
      "question_id": 37,
      "question": "How does Starbucks' deferred revenue arrangement with Nestlé for the Global Coffee Alliance align with the company's stated risks regarding supply chain dependencies on key business partners?",
      "original_answer": "Starbucks reports a significant financial dependency on Nestlé through the Global Coffee Alliance, as evidenced by the upfront prepaid royalty from Nestlé recorded in deferred revenue (page 66). This relationship is central to the Channel Development segment, which relies on Nestlé to distribute packaged goods and foodservice products globally (page 88). However, the company explicitly states that if Nestlé fails to meet its distribution and marketing commitments, it could 'have a material adverse impact on our business and financial results' (page 22). Thus, while the deferred revenue arrangement provides upfront financial benefit, it is inextricably tied to Nestlé’s performance, exposing Starbucks to supply chain and brand execution risks that are acknowledged in the risk factors section.",
      "llm_answer": "The Starbucks 10‑K notes that the Global Coffee Alliance with Nestlé is a key Channel Development revenue stream, and that the partnership is highlighted as a material dependency in the “Risks Related to Supply Chain” and “Risks Related to Operating a Global Business” sections.  It also warns that any failure by Nestlé to meet its distribution and marketing obligations could materially harm the Channel Development business and the company’s overall financial results.  This exposure is consistent with the company’s broader risk narrative about being highly dependent on key business partners for growth.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SBUX_10k_2024.pdf",
          "target_page": 88,
          "pages": [
            86,
            87,
            88,
            89,
            90
          ]
        },
        "hop_2_rel": {
          "source_file": "SBUX_10k_2024.pdf",
          "target_page": 22,
          "pages": [
            20,
            21,
            22,
            23,
            24
          ]
        },
        "hop_3_rel": {
          "source_file": "SBUX_10k_2024.pdf",
          "target_page": 66,
          "pages": [
            64,
            65,
            66,
            67,
            68
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 71765,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18171,
        "completion_tokens": 152,
        "total_tokens": 18323
      }
    },
    {
      "question_id": 37,
      "question": "How does Qualcomm's reliance on Chinese OEMs for a significant portion of its licensing revenues reconcile with the risk that these same OEMs may develop their own integrated circuit products, potentially undermining Qualcomm's semiconductor business and revenue diversification strategy?",
      "original_answer": "Qualcomm reports that it derives a significant portion of its licensing revenues from Chinese OEMs, which are central to its financial performance. However, the company also acknowledges that these OEMs may develop their own integrated circuit products due to pressures such as China’s Made in China 2025 campaign, trade tensions, or supply chain concerns. This vertical integration could reduce Qualcomm's semiconductor sales, particularly in a market where the company is already facing competition and customer diversification risks. The contradiction between depending on Chinese OEMs for licensing revenue while facing potential erosion of semiconductor sales from their self-developed products creates a strategic tension that could impact Qualcomm’s ability to sustain its current revenue model and diversification efforts.",
      "llm_answer": "Qualcomm acknowledges that its licensing revenue depends heavily on Chinese OEMs, yet it also warns that those same OEMs are increasingly developing their own integrated‑circuit products—driven by government “Made in China 2025” policies, supply‑chain concerns, and competitive pressure—potentially replacing Qualcomm’s chips and undermining its semiconductor business and the diversification strategy that relies on broad licensing and product sales. This creates a direct conflict between the revenue concentration in China and the risk that those customers could vertically integrate, reducing the very licensing and semiconductor sales that fuel Qualcomm’s growth.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "QCOM_10k_2022.pdf",
          "target_page": 39,
          "pages": [
            37,
            38,
            39,
            40,
            41
          ]
        },
        "hop_2_rel": {
          "source_file": "QCOM_10k_2022.pdf",
          "target_page": 20,
          "pages": [
            18,
            19,
            20,
            21,
            22
          ]
        },
        "hop_3_rel": {
          "source_file": "QCOM_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 72428,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18357,
        "completion_tokens": 167,
        "total_tokens": 18524
      }
    },
    {
      "question_id": 37,
      "question": "How does Emerson's strategic acquisition of NI for $8.653 billion, including the $7.833 billion cash payment for remaining shares, align with the role of Automated Test Systems in enabling faster and lower-cost product development as described in the Test & Measurement segment's operational overview?",
      "original_answer": "Emerson's acquisition of NI for $8.653 billion, which included a $7.833 billion cash payment for the remaining shares, reflects a strategic investment to enhance the capabilities of the Test & Measurement segment. This segment is described as providing software-connected automated test and measurement systems that help enterprises bring products to market faster and at a lower cost. NI, as a key component of this segment post-acquisition, directly supports this mission by offering modular instrumentation and development software. The significant financial commitment to acquire full ownership of NI underscores Emerson's emphasis on strengthening its Automated Test Systems offering to better serve customer needs in accelerating innovation and reducing development costs.",
      "llm_answer": "Emerson's $8.653 billion acquisition of National Instruments—comprising a $7.833 billion cash payment for the remaining shares—directly advances the Test & Measurement segment’s goal of delivering automated test and measurement systems that let customers bring products to market faster and at lower cost. By integrating NI’s automated test platforms into Emerson’s portfolio, the combined entity can offer more comprehensive, software‑connected test solutions, accelerating product development cycles and reducing development expenses for industrial customers. This strategic fit aligns with the segment’s operational overview, which emphasizes that such systems enable faster, lower‑cost product development.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        },
        "hop_2_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_3_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 66668,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16919,
        "completion_tokens": 177,
        "total_tokens": 17097
      }
    },
    {
      "question_id": 37,
      "question": "How does Colgate's adoption of ASU 2022-04 affect the transparency of its supplier finance obligations, particularly in light of the new roll-forward disclosures and their potential impact on balance sheet presentation?",
      "original_answer": "Colgate adopted ASU 2022-04 beginning January 1, 2023, with the roll-forward information disclosure becoming effective January 1, 2024. This ASU requires more detailed annual disclosures about supplier finance programs, including the confirmed amount outstanding and associated roll-forward information. These new requirements directly influence how the company presents its liabilities related to these programs on the balance sheet and provide stakeholders with clearer visibility into the timing and changes in these obligations. This enhances the transparency of Colgate's financial position by disclosing dynamic liability movements, not just end-of-period balances.",
      "llm_answer": "Colgate‑Palmolive adopted ASU 2022‑04, which requires annual disclosure of supplier‑finance program obligations and roll‑forward information. The Company began presenting the related balance‑sheet amounts and roll‑forward details in 2023, and the roll‑forward disclosure became mandatory in 2024. This enhanced disclosure improves transparency of its supplier‑finance liabilities by showing the confirmed outstanding balances and the movement of those balances over time.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CL_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_2_rel": {
          "source_file": "CL_10k_2024.pdf",
          "target_page": 57,
          "pages": [
            55,
            56,
            57,
            58,
            59
          ]
        },
        "hop_3_rel": {
          "source_file": "CL_10k_2024.pdf",
          "target_page": 57,
          "pages": [
            55,
            56,
            57,
            58,
            59
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 63143,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16017,
        "completion_tokens": 117,
        "total_tokens": 16135
      }
    },
    {
      "question_id": 37,
      "question": "How does UPS's use of net asset value (NAV) to measure certain alternative investments align with the liquidity constraints and unfunded commitments associated with their private debt investments?",
      "original_answer": "UPS utilizes NAV as a practical expedient to value alternative investments like private debt, which reflects the most recent partnership audited financial reports and is adjusted for investment activity (page 94). This valuation approach is necessary due to the lack of readily determinable fair value for these assets. On page 93, UPS discloses that their private debt investments are part of limited partnerships with terms ranging from 10 to 15 years, and as of December 31, 2024, they have $2.7 billion in unfunded commitments expected to be contributed over the next three to six years. These liquidity constraints and long-term commitments highlight the practical limitations of valuing such investments through traditional fair value methods, reinforcing the rationale for using NAV. However, the lack of immediate liquidity and potential valuation discrepancies due to market opacity underscore the risks associated with relying on NAV for these private debt instruments.",
      "llm_answer": "UPS measures certain alternative‑investment holdings—such as private‑debt and private‑equity funds—at net asset value (NAV) per share as a practical expedient, rather than using observable market prices. Because these investments have limited liquidity and often contain unfunded commitment obligations (approximately $2.7 billion of remaining capital commitments to private‑debt and private‑equity partnerships as of Dec 31 2024), NAV‑based valuation reflects inherent valuation limitations and may differ from fair values that would be obtained with readily available market data.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 70592,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17870,
        "completion_tokens": 145,
        "total_tokens": 18015
      }
    },
    {
      "question_id": 37,
      "question": "How does Southern Company's net operating loss (NOL) carryforward benefit in Mississippi relate to its investment in SNG, and what does this imply about the strategic alignment between tax optimization and natural gas infrastructure exposure?",
      "original_answer": "Southern Company reports a $183 million net state income tax benefit from NOL carryforwards in Mississippi, where it has significant operations through Southern Power and Southern Company Gas. Southern Power operates in Mississippi and generates electricity from natural gas under long-term PPAs, while Southern Company Gas holds a 50% interest in SNG—a major natural gas pipeline spanning 7,000 miles across multiple states including Mississippi. The NOL benefit in Mississippi directly supports the company's tax efficiency in a state where it maintains both power generation and gas infrastructure assets. This tax benefit aligns with Southern Company’s strategic investment in SNG, which enhances natural gas supply diversification and supports long-term contracted energy services. The combination of tax optimization through NOLs and infrastructure investment through SNG illustrates a coordinated approach to managing both financial and operational exposure in the natural gas value chain.",
      "llm_answer": "Southern Company's Mississippi Power subsidiary holds a $183 million state‑level net operating loss (NOL) carryforward that expires in 2032, supported by a $32 million valuation allowance, while Southern Power’s related Oklahoma and Florida NOLs are similarly limited by valuation allowances. These state NOLs can be used to offset future taxable income, providing a tax shield that helps mitigate the tax burden associated with Southern Company’s investments in natural‑gas infrastructure—particularly its 50 % stake in SNG and related pipeline assets—thereby aligning tax‑optimization benefits with the company’s strategic exposure to natural‑gas projects.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 248,
          "pages": [
            246,
            247,
            248,
            249,
            250
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 301,
          "pages": [
            299,
            300,
            301,
            302,
            303
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 72212,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18298,
        "completion_tokens": 164,
        "total_tokens": 18462
      }
    },
    {
      "question_id": 38,
      "question": "How does Altria's indemnification arrangement with PMI for tobacco-related liabilities interact with PM USA's unconditional guarantees of Altria's debt obligations, particularly in light of the potential insolvency risks outlined in the supplemental guarantor financial information?",
      "original_answer": "Altria has no recorded liability for PMI's indemnification obligations because their fair value is deemed insignificant. However, PM USA, a 100% owned subsidiary, has issued unconditional guarantees covering Altria’s obligations under its $3.0 billion Credit Agreement, commercial paper program, and outstanding debt securities. The supplemental guarantor financial information warns that if PM USA becomes insolvent—defined as having debts exceeding assets or being unable to pay obligations as they mature—the guarantees could be voided or subordinated under federal bankruptcy or state fraudulent transfer laws. This creates a potential risk chain: while PMI indemnifies Altria and PM USA for liabilities tied to PMI-manufactured tobacco products, PM USA's financial health directly affects Altria’s ability to meet its debt obligations, and any insolvency event could expose Altria to unsecured creditor status.",
      "llm_answer": "Altria’s indemnification arrangement with PMI allocates tobacco‑related liabilities to PMI, while PM USA has provided unconditional guarantees that cover Altria’s debt‑security and credit‑facility obligations. The supplemental guarantor financials show that the guarantor (PM USA) holds substantial assets and can meet these guarantee obligations, but the documents also warn that if PM USA were to become insolvent the guarantees could be voided under fraudulent‑transfer or bankruptcy law, leaving Altria’s debt holders exposed to potential loss. Consequently, the indemnification and guarantee structures are interdependent, and any insolvency risk for PM USA could undermine the protection afforded by its guarantees of Altria’s debt.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 51,
          "pages": [
            49,
            50,
            51,
            52,
            53
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 65961,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16739,
        "completion_tokens": 184,
        "total_tokens": 16923
      }
    },
    {
      "question_id": 38,
      "question": "How does ExxonMobil's 2023 production performance of 3.7 million oil-equivalent barrels per day align with its pending merger with Pioneer Natural Resources, which holds over 2.3 billion oil-equivalent barrels in proved reserves and contributed over 700 thousand oil-equivalent barrels per day in production as of Q3 2023?",
      "original_answer": "ExxonMobil's 2023 production remained flat at 3.7 million oil-equivalent barrels per day, with growth in Permian and Guyana offsetting declines from divestments and curtailments. Meanwhile, the pending merger with Pioneer Natural Resources, expected to close in Q2 2024, is strategically positioned to significantly enhance ExxonMobil's reserve base and production capacity by adding 2.3 billion oil-equivalent barrels in proved reserves and over 700 thousand oil-equivalent barrels per day of production from Pioneer. This suggests that the merger is intended to address production stagnation and strengthen long-term output potential.",
      "llm_answer": "ExxonMobil's 2023 upstream production of 3.7 million oil‑equivalent barrels per day is consistent with its 2022 level, reflecting growth in Permian and Guyana volumes that more than offset divestments and curtailments. The company's pending merger with Pioneer Natural Resources— which holds over 2.3 billion barrels of proved reserves and contributed roughly 700 k oil‑equivalent barrels per day in Q3 2023— will add significant reserve and production capacity to ExxonMobil's portfolio.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "XOM_10k_2023.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_2_rel": {
          "source_file": "XOM_10k_2023.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_3_rel": {
          "source_file": "XOM_10k_2023.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 61251,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15571,
        "completion_tokens": 122,
        "total_tokens": 15693
      }
    },
    {
      "question_id": 38,
      "question": "How does Boeing's exposure to cost overruns under fixed-price development contracts, exemplified by the KC-46A Tanker program, reconcile with the program's total contract value and the company's capitalized precontract costs as of the end of 2021?",
      "original_answer": "Boeing's exposure to cost overruns under fixed-price development contracts, particularly the KC-46A Tanker program, is significant due to the inherent uncertainty in estimating long-term development costs. In 2021, Boeing recorded an additional $402 million in losses on the KC-46A contract due to factory disruptions, supply chain issues, and evolving customer requirements. Despite these challenges, the KC-46A program had a total contract value of approximately $19 billion as of December 31, 2021, and Boeing held $243 million in capitalized precontract costs. This juxtaposition highlights the dual nature of fixed-price development contracts: while they offer long-term revenue potential, they also carry substantial risk of reach-forward losses if cost estimates are exceeded, especially in complex programs like the KC-46A.",
      "llm_answer": "Boeing’s KC‑46A Tanker program illustrates how exposure to cost overruns under a fixed‑price development contract can coexist with a large total contract value and capitalized precontract costs. The EMD contract and authorized low‑rate initial production lots are valued at roughly $19 billion, yet the company had only about $243 million of capitalized precontract costs and $409 million of potential termination liabilities recorded as of Dec 31 2021. Moreover, the program generated a $402 million reach‑forward loss in Q4 2021 because actual costs exceeded the fixed price, showing that even with a substantial contract value, the company must continually adjust its cost estimates and may record significant losses if overruns materialize.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 134,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 51247,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 13058,
        "completion_tokens": 186,
        "total_tokens": 13244
      }
    },
    {
      "question_id": 38,
      "question": "How does Amgen's $2.8 billion equity investment in BeiGene align with its strategic focus on BLINCYTO, given the shared commercialization arrangement in China and BLINCYTO's development status as an anti-CD19 x anti-CD3 BiTE molecule?",
      "original_answer": "Amgen's $2.8 billion equity investment in BeiGene, made to expand its oncology presence in China, directly supports the shared commercialization of BLINCYTO in that market starting in 2021. BLINCYTO, described as an anti-CD19 x anti-CD3 BiTE molecule, is part of Amgen’s pipeline under active development and commercial strategy. The collaboration with BeiGene involves profit-sharing during the initial commercialization period, after which product rights may revert to Amgen, who would then pay royalties to BeiGene. This arrangement aligns with Amgen’s strategic intent to leverage local expertise in China while maintaining long-term control and revenue potential for BLINCYTO, a key oncology asset.",
      "llm_answer": "Amgen’s $2.8 billion equity investment in BeiGene was made to deepen its oncology footprint in China and to secure a partnership that includes shared development costs and profit‑sharing on products such as BLINCYTO. Because BLINCYTO is an anti‑CD19 × anti‑CD3 BiTE molecule being developed for B‑cell precursor ALL, the investment aligns with Amgen’s strategic focus on expanding its BLINCYTO franchise in the Chinese market under the joint commercialization arrangement with BeiGene.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 28,
          "pages": [
            26,
            27,
            28,
            29,
            30
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 26,
          "pages": [
            24,
            25,
            26,
            27,
            28
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 65670,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16656,
        "completion_tokens": 121,
        "total_tokens": 16778
      }
    },
    {
      "question_id": 38,
      "question": "How does Capital One's current capital adequacy framework under Basel III, which allows exclusion of AOCI elements, contrast with the potential impact of the Basel III Finalization Proposal's Expanded Risk-Based Approach that would phase in AOCI recognition, and what implications might this have on its CET1 capital ratio requirements by 2028?",
      "original_answer": "Capital One, as a Category III institution under the current Basel III Capital Rules, is permitted to exclude certain elements of accumulated other comprehensive income (AOCI), such as unrealized gains and losses on available-for-sale securities, from its CET1 capital ratio calculation. However, the Basel III Finalization Proposal introduces the Expanded Risk-Based Approach and mandates that Category III institutions like Capital One begin recognizing AOCI in CET1 capital starting July 1, 2025, with a full phase-in by July 1, 2028. This change could reduce CET1 capital levels if AOCI remains negative during that period, thereby increasing capital pressure. The Expanded Risk-Based Approach, as defined in the glossary on page 114, recalculates risk-weighted assets across credit, operational, and market risks, potentially tightening capital adequacy requirements. This transition may challenge Capital One’s ability to maintain its current CET1 capital ratio of 4.5% or higher under the new framework without adjustments to capital planning or risk exposure.",
      "llm_answer": "Capital One currently excludes certain AOCI elements from its regulatory capital under the Basel III framework for Category III institutions, allowing it to maintain a CET1 ratio of 4.5% minimum plus buffers. The proposed Basel III Finalization Proposal would phase in recognition of AOCI (including unrealized gains/losses on AFS securities) starting July 2025, with full implementation by July 2028. This would likely increase risk-weighted assets and reduce CET1 capital ratios, potentially requiring Capital One to hold additional capital to maintain its current 9.3% CET1 ratio (including the 4.8% stress buffer) under the new framework by 2028.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "hop_2_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_3_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 114,
          "pages": [
            112,
            113,
            114,
            115,
            116
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 81929,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20748,
        "completion_tokens": 162,
        "total_tokens": 20910
      }
    },
    {
      "question_id": 38,
      "question": "How does Duke Energy Progress' use of DEPNC SF to issue storm recovery bonds in 2021 compare with its 2024 issuance of $177 million in storm recovery bonds through DEP SC SF, particularly in terms of the storm cost periods being financed and the regulatory mechanisms enabling these financings?",
      "original_answer": "Duke Energy Progress utilized DEPNC SF in 2021 to issue senior secured bonds aimed at financing storm costs incurred in North Carolina from 2018 to 2019, as authorized by state legislation and NCUC financing orders. In contrast, in April 2024, Duke Energy Progress issued $177 million in senior secured bonds through DEP SC SF to finance storm costs from 2014 through 2022 in South Carolina, following a 2023 petition and comprehensive settlement approved by the PSC SC. These financings were enabled by different regulatory frameworks—North Carolina’s MYRP and earnings-sharing mechanisms versus South Carolina’s storm securitization petition and settlement agreement—highlighting Duke Energy Progress' tailored regulatory strategies for storm cost recovery across jurisdictions.",
      "llm_answer": "Duke Energy Progress issued $177 million of senior secured storm‑recovery bonds in April 2024 through its special purpose subsidiary DEPSCSF, which was created in 2024 to finance storm‑related regulatory assets incurred from 2014 through 2022; the bonds are secured by a non‑bypassable charge on all North and South Carolina retail customers until repayment. In contrast, its earlier 2021 storm‑recovery financing used DEPNCSF (and DECNCSF for Duke Energy Carolinas) to issue bonds that funded unrecovered storm costs from 2018 and 2019, with repayment also derived from a similar non‑bypassable charge on North and South Carolina customers. Both financings rely on state‑approved storm‑recovery property and regulatory orders, but the 2024 issuance specifically targets storm costs accumulated through 2022 and was executed via DEPSCSF, whereas the 2021 issuance targeted 2018‑2019 costs via DEPNCSF.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 205,
          "pages": [
            203,
            204,
            205,
            206,
            207
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 205,
          "pages": [
            203,
            204,
            205,
            206,
            207
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 152,
          "pages": [
            150,
            151,
            152,
            153,
            154
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 103621,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 26158,
        "completion_tokens": 225,
        "total_tokens": 26383
      }
    },
    {
      "question_id": 39,
      "question": "Given AENB's status as a large bank subject to proposed Climate Risk Management Principles and its role in managing $84.4 billion in FDIC-insured deposits, how does American Express's obligation to act as a source of strength to AENB potentially intersect with emerging climate-related risk governance requirements?",
      "original_answer": "American Express is explicitly required to act as a source of financial and managerial strength to AENB, which had $84.4 billion in deposits as of December 31, 2021. AENB, being an OCC-regulated institution with over $100 billion in assets, is subject to the proposed 'Principles for Climate-Related Financial Risk Management for Large Banks' that include governance, strategic planning, and scenario analysis for climate risks. While the Climate Risk Management Principles are still under development and their exact impact is uncertain, they may require AENB to implement new risk frameworks that could affect its capital needs. Since American Express has a binding obligation to support AENB’s capital under regulatory requirements, any increased capital or operational costs at AENB due to climate risk compliance could trigger upstream financial commitments from American Express, creating a regulatory and strategic linkage between climate risk governance and corporate capital planning.",
      "llm_answer": "American Express’s obligation to act as a source of strength to AENB—requiring it to provide capital support and absorb losses if needed—must be weighed against emerging climate‑risk governance rules that will likely impose additional capital‑adequacy, stress‑testing and disclosure requirements on large banks. As a “large bank” subject to the OCC’s proposed Climate‑Related Financial Risk Management Principles, AENB will need to incorporate climate‑risk considerations into its capital planning and stress‑testing, which could affect its capital ratios and dividend‑distribution limits; consequently, American Express may have to commit additional resources to preserve AENB’s well‑capitalized status and meet the new climate‑risk standards.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AXP_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_2_rel": {
          "source_file": "AXP_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_3_rel": {
          "source_file": "AXP_10k_2022.pdf",
          "target_page": 71,
          "pages": [
            69,
            70,
            71,
            72,
            73
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 68943,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17491,
        "completion_tokens": 186,
        "total_tokens": 17677
      }
    },
    {
      "question_id": 39,
      "question": "How does the strategic emphasis on ZYN as a leading brand in PM's smoke-free portfolio align with the financial commitment made to fully acquire Swedish Match, and what does this reveal about PM's prioritization of oral nicotine delivery in its smoke-free transformation?",
      "original_answer": "Philip Morris International (PM) highlights ZYN as one of the leading brands in its smoke-free portfolio on page 5, noting that nicotine pouches—primarily represented by ZYN—have expanded into 37 markets as of December 31, 2024. This strategic positioning of ZYN is directly tied to PM's acquisition of Swedish Match in November 2022, which brought the ZYN brand under PM's umbrella and strengthened its position in oral nicotine delivery. Further, on page 92, PM completed the compulsory redemption of all remaining shares of Swedish Match in February 2023, paying $883 million in cash and finalizing the acquisition process by September 2023. The combination of ZYN's market expansion and the full acquisition of Swedish Match underscores PM's strategic pivot toward smoke-free products, particularly in the U.S. oral nicotine category, reinforcing its broader transformation into a smoke-free company.",
      "llm_answer": "The strategic focus on ZYN as a flagship smoke‑free brand directly reflects the financial commitment to fully acquire Swedish Match—an oral‑nicotine leader—because the purchase was made to secure that high‑growth, smoke‑free product platform. By integrating ZYN with its heat‑not‑burn portfolio (IQOS), PMI signals that oral nicotine delivery is a top priority in its transformation away from combustible cigarettes.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_2_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_3_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 92,
          "pages": [
            90,
            91,
            92,
            93,
            94
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 67447,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17106,
        "completion_tokens": 104,
        "total_tokens": 17210
      }
    },
    {
      "question_id": 39,
      "question": "How does ConocoPhillips' impairment of its APLNG investment in 2021 relate to the ownership structure involving Origin Energy, and what does this imply about the valuation sensitivity of ConocoPhillips' equity stake to changes in Origin Energy's position?",
      "original_answer": "ConocoPhillips impaired its APLNG investment by $688 million in 2021 after Origin Energy agreed to sell a 10% stake in APLNG for $1.645 billion, which reflected a market valuation lower than the carrying value of ConocoPhillips' existing investment. This impairment was necessary because the transaction price indicated a decline in APLNG’s fair value, which was below the previously recorded value. At the same time, ConocoPhillips exercised its preemption right to acquire an additional 10% stake from Origin Energy, increasing its ownership. The fact that Origin Energy, as the operator and co-owner of APLNG with ConocoPhillips and Sinopec, was willing to divest part of its stake suggests internal or market-driven pressures that impacted APLNG’s valuation. This dynamic highlights how changes in Origin Energy’s position directly affect ConocoPhillips' investment decisions and valuation assumptions, especially given the joint ownership structure and the strategic importance of APLNG’s LNG operations in Australia.",
      "llm_answer": "ConocoPhillips recorded a $688 million pre‑tax impairment of its APLNG investment in the fourth quarter of 2021 after Origin Energy sold a 10 % stake in APLNG for $1.645 billion—an observable market price that was below ConocoPhillips’ carrying value. This impairment demonstrates that the fair‑value of ConocoPhillips’ equity stake is highly sensitive to changes in Origin Energy’s position and the market‑derived valuation of APLNG, meaning any further reduction in Origin Energy’s ownership or a decline in APLNG’s observable market price would likely trigger additional write‑downs of ConocoPhillips’ investment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 100,
          "pages": [
            98,
            99,
            100,
            101,
            102
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 65535,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16627,
        "completion_tokens": 154,
        "total_tokens": 16781
      }
    },
    {
      "question_id": 39,
      "question": "Given GM's strategic emphasis on trucks as a core component of its $35 billion EV investment through 2025 and the risks associated with new product introductions, how does its financial exposure to nonconsolidated affiliates involved in truck development and production affect the execution of this strategy?",
      "original_answer": "GM has committed over $35 billion from 2020 through 2025 to invest in EV and AV technologies, with a key part of this strategy being the development and profitable sale of electric trucks. However, the company faces risks related to the timely and successful introduction of new vehicle models, especially EVs, which require significant capital investment and depend on complex technological development. Compounding this strategic risk, GM has financial exposure to nonconsolidated affiliates who are actively involved in the development, production, and marketing of trucks and related components. These affiliates are integral to GM’s supply chain and vehicle production ecosystem, yet their nonconsolidated status suggests GM does not fully control their operations or financial outcomes. This creates execution risk for GM’s EV strategy, as disruptions or inefficiencies in these affiliate relationships could delay or compromise the development and production of key truck models central to its long-term profitability and strategic direction.",
      "llm_answer": "GM’s financial exposure to nonconsolidated affiliates involved in truck development and production—particularly its equity stakes in China joint ventures (e.g., SAIC-GM and related entities)—creates both strategic opportunity and execution risk for its $35 billion EV investment through 2025. While these affiliates generate significant equity income and supply critical truck‑related components, the affiliates’ own capital constraints, regulatory pressures, and the need for additional funding (e.g., $1.2 billion committed to Ultium Cells) could limit their ability to meet delivery timelines or maintain production capacity, thereby affecting GM’s capacity to launch and scale the targeted EV trucks on schedule.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 17,
          "pages": [
            15,
            16,
            17,
            18,
            19
          ]
        },
        "hop_2_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        },
        "hop_3_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 78899,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19978,
        "completion_tokens": 179,
        "total_tokens": 20157
      }
    },
    {
      "question_id": 39,
      "question": "How does Cisco's issuance of $13.5 billion in senior fixed-rate notes relate to its $10.9 billion commercial paper notes outstanding as of July 27, 2024, and what implications does this have for the company's overall debt structure and interest rate risk management?",
      "original_answer": "Cisco issued $13.5 billion in senior fixed-rate notes in February 2024, which ranks at par with the $10.9 billion in commercial paper notes outstanding as of July 27, 2024. These two debt instruments are part of Cisco’s broader capital structure and financing strategy. The company also entered into an interest rate swap for $0.5 billion of the senior fixed-rate notes, converting fixed interest payments to floating rates based on SOFR, indicating an active approach to managing interest rate exposure. This hedging activity suggests that while the senior notes are fixed-rate in nature, Cisco is mitigating potential interest rate risk, which contrasts with the inherently short-term and flexible nature of the commercial paper notes. The coexistence and pari passu ranking of these instruments highlight a layered approach to debt financing and risk management.",
      "llm_answer": "Cisco's issuance of $13.5 billion of senior fixed‑rate notes in February 2024 expanded its long‑term debt profile, complementing the $10.9 billion of commercial paper outstanding as of July 27 2024. Together, these financing activities increase the company’s total debt to roughly $31 billion, raising the proportion of fixed‑rate obligations and extending the maturity schedule, which helps manage interest‑rate risk by locking in rates for a sizable portion of its borrowings while still maintaining flexibility through its $15 billion commercial‑paper program and $5 billion revolving credit facility.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 50,
          "pages": [
            48,
            49,
            50,
            51,
            52
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 79268,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20061,
        "completion_tokens": 151,
        "total_tokens": 20212
      }
    },
    {
      "question_id": 39,
      "question": "How does Visual Studio's inclusion in the Intelligent Cloud segment contribute to the $97.7 billion in Server products and cloud services revenue reported for fiscal year 2024?",
      "original_answer": "Visual Studio is explicitly included within the Server products and cloud services category, which generated $97,726 million in revenue for fiscal year 2024. As part of the Intelligent Cloud segment, Visual Studio functions as a key developer tool that supports cloud adoption and application development on Azure, thereby driving usage-based revenue from cloud services. The 2024 10-K confirms Visual Studio's inclusion in Server products and cloud services revenue on page 42, indicating its direct contribution to the segment's financial performance. This aligns with Microsoft's broader strategy of providing integrated development tools that encourage enterprise and developer engagement with its cloud infrastructure, ultimately supporting the segment's growth from $67.4 billion in 2022 to $97.7 billion in 2024.",
      "llm_answer": "The Intelligent Cloud segment, which includes Server products and cloud services like Azure, contributed $105.4 billion in revenue for fiscal 2024—up 20% from the prior year—driven largely by growth in Azure and other cloud services. This strong performance helped lift the overall Server products and cloud services revenue to $97.7 billion, a key component of the $97.7 billion in Server products and cloud services revenue reported for the year. Consequently, the Intelligent Cloud segment’s revenue growth directly boosted the total Server products and cloud services revenue figure within the $97.7 billion total.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 42,
          "pages": [
            40,
            41,
            42,
            43,
            44
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 56414,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14329,
        "completion_tokens": 154,
        "total_tokens": 14484
      }
    },
    {
      "question_id": 39,
      "question": "Given Disney's risks around brand damage affecting DTC subscriber retention and content cost pressures, and Pixar's role as a key brand tile within Disney+, how might reputational harm to Pixar impact the valuation of Disney's indefinite-lived intangible assets?",
      "original_answer": "Disney identifies damage to its brands as a risk that could negatively impact sales, profitability, and brand reputation across businesses, including its DTC segment. Pixar is specifically called out in the DTC section as one of the top-level branded tiles within Disney+, serving as a critical differentiator in attracting and retaining subscribers. Since Pixar is also listed as an indefinite-lived intangible asset on page 110—alongside Marvel and ESPN—any reputational harm to Pixar could not only reduce subscriber growth and retention but also trigger an impairment review of this asset. This creates a direct link between brand risk in the DTC context and the financial valuation of intangible assets, showing how qualitative brand risks could manifest in tangible financial impacts.",
      "llm_answer": "Reputational harm to Pixar could impair the valuation of Disney’s indefinite‑lived intangible assets (e.g., Pixar trademarks and franchise intangibles) by reducing the projected cash flows and growth prospects that support their carrying values, potentially triggering impairment charges. Such brand damage could also depress subscriber retention on Disney+ and increase churn, lowering expected DTC revenue streams and thereby diminishing the overall fair‑value estimate of these intangible assets.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 110,
          "pages": [
            108,
            109,
            110,
            111,
            112
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 65295,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16572,
        "completion_tokens": 124,
        "total_tokens": 16697
      }
    },
    {
      "question_id": 39,
      "question": "How does UPS's use of net asset value (NAV) as a practical expedient for valuing alternative investments relate to the $2.7 billion of unfunded commitments associated with private debt and other limited partnership interests?",
      "original_answer": "UPS utilizes NAV as a practical expedient for valuing alternative investments such as private debt, real estate, and private equity funds due to the lack of readily determinable fair value. This valuation method is applied to investments in limited partnership interests, which include private debt. As of December 31, 2024, UPS reports unfunded commitments of approximately $2.7 billion related to these limited partnerships, which are expected to be contributed over the next three to six years. The NAV-based valuation approach reflects the long-term and illiquid nature of these investments, particularly private debt, which typically cannot be redeemed until the end of the partnership term (10–15 years). Thus, the $2.7 billion unfunded commitment is directly tied to UPS's NAV-based investment strategy in private debt and similar instruments.",
      "llm_answer": "UPS values its alternative‑investment holdings—including private‑debt and private‑equity limited‑partnership interests—using NAV as a practical expedient, which means they are not placed in Levels 1‑3 of the fair‑value hierarchy. The company reports that, as of December 31 2024, it has unfunded commitments of approximately **$2.7 billion** to these private‑debt and other limited‑partnership interests that will need to be funded over the next three to six years. This $2.7 billion figure represents the amount of capital that partners are required to contribute to the partnerships in which UPS holds interests, and it is disclosed alongside the NAV‑based valuation approach described in the notes.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 70592,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17877,
        "completion_tokens": 175,
        "total_tokens": 18052
      }
    },
    {
      "question_id": 39,
      "question": "How does Mississippi Power Company's reporting relationship with Southern Company influence its eligibility for reduced disclosure requirements in the 10-K filing, and what specific conditions justify this streamlined reporting format?",
      "original_answer": "Mississippi Power Company, a subsidiary of The Southern Company, is not required to furnish an annual report or proxy statement to its parent company, which aligns with its eligibility for reduced disclosure under General Instructions I(2)(b), (c), and (d) of Form 10-K. According to the filing, Mississippi Power meets the conditions outlined in General Instructions I(1)(a) and (b), which allow it to use the reduced disclosure format because it does not send annual reports to its sole shareholder. This reporting structure reflects a standard regulatory accommodation for subsidiaries that report under the umbrella of a parent registrant, reducing redundant disclosures and administrative burden while maintaining compliance with SEC requirements.",
      "llm_answer": "Mississippi Power Company’s eligibility for reduced disclosure requirements stems from its status as a registrant that meets the conditions in General Instructions I(1)(a) and (b) of Form 10-K, allowing it to use the streamlined reporting format. This status is enabled by its corporate relationship with Southern Company, which consolidates governance and reporting under a single parent entity, ensuring compliance with SEC requirements while minimizing redundant disclosures. The specific condition justifying this format is Mississippi Power’s classification as a \"wholly-owned subsidiary\" of Southern Company, which qualifies it for the reduced disclosure framework under the SEC’s rules for reporting companies.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 324,
          "pages": [
            319,
            320,
            321,
            322,
            323
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 3,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 3,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 78188,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19782,
        "completion_tokens": 179,
        "total_tokens": 19962
      }
    },
    {
      "question_id": 39,
      "question": "How does Amgen's joint commercialization arrangement with BeiGene for XGEVA in China, including profit-sharing and eventual royalty obligations, reconcile with the competitive landscape for XGEVA in the U.S. and Europe where it faces generic bisphosphonates?",
      "original_answer": "Amgen's joint commercialization arrangement with BeiGene for XGEVA in China involves shared profits and losses during the initial commercialization period, after which product rights may revert to Amgen, triggering royalty payments to BeiGene on Chinese sales. This collaborative model supports Amgen’s strategy to expand its oncology footprint in China without full operational control. In contrast, in the U.S. and Europe, XGEVA competes directly with generic bisphosphonates—such as zoledronate generics—posing a significant threat to its market position in these mature markets. The dual dynamic highlights a strategic divergence: in China, Amgen leverages a partnership to access market growth and reduce risk, while in the U.S. and Europe, it must defend XGEVA’s value proposition against low-cost generic alternatives. This contrast underscores how Amgen tailors its commercial approach based on market maturity and competitive intensity.",
      "llm_answer": "Amgen’s joint commercialization deal with BeiGene for XGEVA in China shares profits and losses during the initial commercialization period and later requires Amgen to pay BeiGene royalties on Chinese sales, while in the U.S. and Europe XGEVA competes with generic bisphosphonates, forcing Amgen to rely on its patent protection, brand value and innovative delivery to maintain market share despite the price‑driven pressure from cheaper generics.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 28,
          "pages": [
            26,
            27,
            28,
            29,
            30
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 70325,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17829,
        "completion_tokens": 111,
        "total_tokens": 17941
      }
    },
    {
      "question_id": 39,
      "question": "What is the significance of Goldman Sachs applying a zero percent countercyclical capital buffer in both its TLAC to RWAs requirement and its CET1 capital ratio calculations under the Standardized and Advanced Capital Rules?",
      "original_answer": "Goldman Sachs applies a zero percent countercyclical capital buffer in both its TLAC to RWAs requirement (18% minimum + 2.5% buffer + zero percent countercyclical buffer + 1.5% G-SIB surcharge) and in its CET1 capital ratio calculations (4.5% minimum + G-SIB surcharge + zero percent countercyclical buffer + SCB of 6.2% as of December 2024). The zero percent buffer reflects the current regulatory stance by the FRB, which has not activated the countercyclical component despite broader economic conditions. This dual inclusion highlights a consistent regulatory capital treatment across different frameworks, suggesting strategic alignment in how GS manages its capital adequacy and compliance under both TLAC and Basel III-derived capital rules, even as other buffers like the SCB and G-SIB surcharge vary in magnitude.",
      "llm_answer": "The zero‑percent countercyclical capital buffer means that, for both the TLAC‑to‑RWAs metric and the CET1 ratio calculations under the Standardized and Advanced Capital Rules, Goldman Sachs does not need to hold any additional capital to offset cyclical downturn risks—so its required capital ratios are based solely on the regulatory minimums, buffers and the stress‑capital buffer (SCB), without any extra cyclical surcharge. This allows the firm to maintain its capital ratios at the regulatory thresholds plus its targeted 50‑to‑100 bps buffer while still meeting the TLAC and CET1 requirements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_2_rel": {
          "source_file": "GS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_3_rel": {
          "source_file": "GS_10k_2024.pdf",
          "target_page": 208,
          "pages": [
            206,
            207,
            208,
            209,
            210
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 96094,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 24257,
        "completion_tokens": 149,
        "total_tokens": 24407
      }
    },
    {
      "question_id": 39,
      "question": "How does Duke Energy's use of tax-exempt bonds in Ohio relate to its pension cost obligations in that jurisdiction, and what does this imply about the company's capital structure and long-term liability management strategy?",
      "original_answer": "Duke Energy has $77 million in tax-exempt bonds outstanding under Duke Energy Ohio as of December 31, 2023, as disclosed in the long-term debt table. These bonds carry a favorable interest rate of 3.89%, which is lower than other debt instruments, indicating a strategic use of tax-exempt financing to reduce borrowing costs. Further, the company shows a $5 million service cost and a $13 million interest cost on projected benefit obligations in Ohio within its pension disclosures. This implies that while Duke Energy is leveraging tax-exempt bonds to finance operations, it is also managing significant pension liabilities in the same jurisdiction. The combination suggests a capital structure strategy that balances lower-cost debt with long-term employee benefit obligations, requiring careful liability management to maintain financial stability.",
      "llm_answer": "Duke Energy’s use of tax‑exempt bonds in Ohio is reflected in the “Tax‑exempt bonds, maturing 2027‑2046 (c)” line of the debt tables, which shows $77 million of such bonds classified under Duke Energy Ohio. These bonds are secured by first‑mortgage bonds, letters of credit or the Master Credit Facility (c), and are recorded as long‑term debt despite their short‑term nature because Duke Energy can refinance them via its Master Credit Facility. This structure allows the company to match long‑term financing with long‑term pension and other obligations, supporting a capital structure that relies heavily on low‑cost, tax‑exempt debt to fund both infrastructure and pension liabilities, thereby reducing overall interest expense and enhancing long‑term liability management.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 163,
          "pages": [
            161,
            162,
            163,
            164,
            165
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 165,
          "pages": [
            163,
            164,
            165,
            166,
            167
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 209,
          "pages": [
            207,
            208,
            209,
            210,
            211
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 116920,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 29468,
        "completion_tokens": 194,
        "total_tokens": 29662
      }
    },
    {
      "question_id": 40,
      "question": "How does the strategic importance of Horizon Innovations LLC, as a joint venture for HTS product commercialization, align with Altria's exposure to macroeconomic and business conditions that could impede its Vision of transitioning adult smokers to smoke-free products?",
      "original_answer": "Altria's joint venture Horizon Innovations LLC, in which PM USA holds a 75% economic interest, is central to its strategy for commercializing heated tobacco stick (HTS) products in the U.S., a key component of its Vision to transition adult smokers to potentially less harmful alternatives. However, the success of Horizon is highly dependent on external factors such as regulatory authorizations, economic conditions, market dynamics, and adult consumer preferences—all of which are categorized as macro business conditions that could materially affect Horizon’s ability to generate revenue. These macro risks are explicitly outlined in Altria’s risk factors, where changes in economic conditions, regulatory environments, or consumer behavior could delay product development, disrupt test launches, or prevent the joint venture from achieving its commercialization goals. This creates a tension between the strategic intent behind Horizon’s formation and the external forces that could hinder its execution, directly impacting Altria’s broader Vision and financial outcomes.",
      "llm_answer": "The Horizon Innovations LLC joint venture is central to Altria’s strategy of commercializing heated‑tobacco (HTS) products in the United States, providing a dedicated platform to bring both its own and Japan Tobacco’s HTS offerings to market and to generate new revenue streams that support its Vision of transitioning adult smokers to smoke‑free alternatives. However, the success of this initiative—and Altria’s ability to achieve its Vision—depends on a range of macro‑economic and business conditions, including inflation, economic stability, regulatory approvals, and consumer adoption of innovative smoke‑free products; adverse shifts in any of these factors could impede the venture’s commercialization and thereby undermine Altria’s broader transition goals.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 83699,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21167,
        "completion_tokens": 191,
        "total_tokens": 21358
      }
    },
    {
      "question_id": 40,
      "question": "How does the change in the Netherlands Innovation Box Tax benefit between 2022 and 2023 impact BKNG's effective tax rate, and how does this relate to the broader context of Dutch corporate income tax law's effect on the company's international earnings and deferred tax assets?",
      "original_answer": "The Netherlands Innovation Box Tax benefit decreased in 2023 compared to 2022, contributing to a higher effective tax rate in 2023 despite a lower valuation allowance and lower international tax rates. This Innovation Box Tax, part of Dutch corporate income tax law, allows qualifying innovative activities—such as those by Booking.com—to be taxed at 9% instead of the standard 25.8%. A portion of Booking.com's earnings in both 2022 and 2023 qualified for this reduced rate, significantly benefiting the company’s effective tax rate. However, the Innovation Box Tax benefit declined in 2023, which partially offset the otherwise lower effective tax rate. This context aligns with the broader international tax structure BKNG operates under, as noted in the reconciliation section, which highlights the significance of Dutch tax law on the company’s international earnings and deferred tax assets, including a $675 million deferred tax asset in 2023.",
      "llm_answer": "The change in the Netherlands Innovation Box Tax—specifically, the reduction in the tax rate from 9% to 7% for qualifying innovative income beginning in 2021—resulted in a lower effective tax rate for Booking.com in 2023 compared to 2022, as noted in the 2023 filing where the effective tax rate decreased due to a lower Innovation Box Tax benefit. This tax benefit, which taxes qualifying income at 9% instead of the Dutch statutory rate of 25.8%, directly reduces BKNG's overall tax expense and effective tax rate, particularly impacting its international earnings by lowering the tax burden on innovation-related profits, while also influencing deferred tax assets related to Dutch tax attributes.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BKNG_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_2_rel": {
          "source_file": "BKNG_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_3_rel": {
          "source_file": "BKNG_10k_2023.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 70170,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17790,
        "completion_tokens": 175,
        "total_tokens": 17965
      }
    },
    {
      "question_id": 40,
      "question": "How does Cisco's $10.9 billion in commercial paper notes outstanding as of July 27, 2024, relate to the $13.5 billion in senior fixed-rate notes issued in February 2024, particularly in light of the company's compliance with debt covenants and the use of interest rate swaps?",
      "original_answer": "Cisco had $10.9 billion in commercial paper notes outstanding as of July 27, 2024, which is part of its broader short-term debt financing program. In February 2024, the company issued $13.5 billion in senior fixed-rate notes, which rank at par with the commercial paper notes. This indicates that both instruments are similarly prioritized in the capital structure, though the senior notes are longer-term in nature. Additionally, Cisco entered into an interest rate swap for $0.5 billion of the senior fixed-rate notes, converting fixed interest payments to floating rates based on SOFR, which suggests an active hedging strategy to manage interest rate exposure. Despite these liabilities, Cisco remained in compliance with all debt covenants as of July 27, 2024, demonstrating disciplined debt management even with significant short- and long-term obligations.",
      "llm_answer": "Cisco's $10.9 billion of commercial paper outstanding as of July 27 2024 is part of its $15 billion short‑term paper program and represents the primary source of short‑term financing, while the $13.5 billion of senior fixed‑rate notes issued in February 2024 provides long‑term funding; both financing sources are used to meet working‑capital needs, fund acquisitions and support dividend and share‑repurchase programs, and Cisco reports that it remained in compliance with all debt covenants, including those governing interest‑coverage ratios, and utilizes interest‑rate swaps (e.g., a $0.5 billion swap that converts fixed‑rate senior note interest to floating SOFR‑based payments) to manage the interest‑rate exposure of those senior notes.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 50,
          "pages": [
            48,
            49,
            50,
            51,
            52
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 79268,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20063,
        "completion_tokens": 186,
        "total_tokens": 20249
      }
    },
    {
      "question_id": 40,
      "question": "How does Disney's provision of a $0.3 billion line of credit to Shanghai Disney Resort compare with Shendi's $1.2 billion in loans and $0.4 billion line of credit, and what does this suggest about the relative financial commitments of each partner in the joint venture?",
      "original_answer": "Disney provided Shanghai Disney Resort with a 1.9 billion yuan (approximately $0.3 billion) line of credit, while Shendi provided significantly larger loans totaling 8.6 billion yuan (approximately $1.2 billion) and also extended a 2.6 billion yuan (approximately $0.4 billion) line of credit. This disparity suggests that Shendi is shouldering a greater direct financial burden in funding the resort’s operations and development, potentially reflecting differing strategic or capital investment approaches between the two partners despite Disney’s operational leadership in the joint venture.",
      "llm_answer": "Disney provided a $0.3 billion (≈ $0.3 billion) revolving line of credit to Shanghai Disney Resort, while Shendi contributed $1.2 billion in loans and an additional $0.4 billion line of credit to the same joint venture. This disparity shows that Shendi bears the larger direct financing burden, whereas Disney’s credit support is comparatively modest, reflecting a relatively smaller financial commitment by Disney in the Shanghai Disney partnership.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 96,
          "pages": [
            94,
            95,
            96,
            97,
            98
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 62399,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15840,
        "completion_tokens": 112,
        "total_tokens": 15952
      }
    },
    {
      "question_id": 40,
      "question": "How does MMM's decision to exit PFAS manufacturing by 2025 align with its ability to meet growing customer demand for PFAS-free products, especially in applications like lithium-ion batteries and printed circuit boards where PFAS alternatives may not yet be feasible?",
      "original_answer": "MMM has committed to exiting all PFAS manufacturing by the end of 2025 and discontinuing the use of PFAS across its product portfolio by the same date. However, in certain applications such as lithium-ion batteries, printed circuit boards, and certain seals and gaskets, the use of PFAS-containing products manufactured by third parties may continue beyond 2025 due to technical constraints and the lack of viable PFAS-free alternatives. This creates a misalignment between MMM’s PFAS phase-out strategy and the practical challenges of transitioning to PFAS-free products in these critical areas. At the same time, the company faces increasing customer demand for PFAS-free products, particularly in markets where environmental and health concerns are driving preference shifts. This dynamic places MMM in a strategic tension between regulatory and reputational pressures to eliminate PFAS and operational limitations in replacing PFAS in technically complex applications, which could affect its competitiveness and customer relationships.",
      "llm_answer": "MMM's 2025 PFAS exit strategy directly addresses customer demand for PFAS-free products by proactively phasing out all PFAS manufacturing by end-2025, including in critical applications like lithium-ion batteries and printed circuit boards where alternatives may not yet be fully feasible. While acknowledging that some PFAS-containing products from third parties may require continued use beyond 2025 pending regulatory approval or customer re-qualification, the company is actively evaluating substitute materials and expects to complete its portfolio-wide PFAS discontinuation by 2025, positioning itself to meet evolving customer and regulatory demands for PFAS-free solutions.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 88,
          "pages": [
            86,
            87,
            88,
            89,
            90
          ]
        },
        "hop_2_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 88,
          "pages": [
            86,
            87,
            88,
            89,
            90
          ]
        },
        "hop_3_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 93397,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 23593,
        "completion_tokens": 170,
        "total_tokens": 23763
      }
    },
    {
      "question_id": 40,
      "question": "How does Capital One's adoption of ASU 2022-02 impact the reporting of financial difficulty modifications (FDMs), and how does this differ from the prior accounting treatment for troubled debt restructurings (TDRs) as reflected in the loan modification disclosures?",
      "original_answer": "Capital One adopted ASU 2022-02 on January 1, 2023, which eliminates the specific accounting guidance for troubled debt restructurings (TDRs) and introduces new disclosure requirements for loans with financial difficulty modifications (FDMs). Previously, TDRs were accounted for under separate guidance and included in tables showing modification types, amortized cost amounts, and financial effects for loans modified during 2022 and 2021. Under ASU 2022-02, these FDMs are now reported prospectively under a new disclosure framework without separate accounting treatment, reflecting a shift from a structured accounting approach to a more transparent disclosure-based reporting model. This change affects how the company communicates modifications to loans for borrowers experiencing financial difficulty, moving from retrospective accounting adjustments to prospective disclosure of performance outcomes.",
      "llm_answer": "Capital One adopted ASU 2022‑02 on January 1 2023, which eliminates the prior accounting guidance for troubled‑debt restructurings (TDRs) and requires that loan modifications granted to borrowers experiencing financial difficulty be reported as financial‑difficulty modifications (FDMs). Under the new guidance, such modifications are generally accounted for as a continuation of the existing loan (no separate TDR accounting), whereas previously they would have been classified and accounted for as TDRs. This change alters the loan‑modification disclosures: the company now reports delinquency status and subsequent defaults of FDMs (Table 3.8, 3.9) and no longer presents the TDR‑specific tables that detailed modification types, rate reductions, and term extensions for periods ending before 2023.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 138,
          "pages": [
            136,
            137,
            138,
            139,
            140
          ]
        },
        "hop_2_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 163,
          "pages": [
            161,
            162,
            163,
            164,
            165
          ]
        },
        "hop_3_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 163,
          "pages": [
            161,
            162,
            163,
            164,
            165
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 83926,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21227,
        "completion_tokens": 200,
        "total_tokens": 21427
      }
    },
    {
      "question_id": 40,
      "question": "How does the strategic importance of ZYN in PM's smoke-free product portfolio, as highlighted by its market expansion to 37 markets, align with the financial commitment made to fully acquire Swedish Match, the producer of ZYN, and how does this reflect PM's broader transformation into a smoke-free company?",
      "original_answer": "PM highlights ZYN as a key component of its smoke-free product (SFP) portfolio, noting that nicotine pouches, including ZYN, expanded to 37 markets by the end of 2024. ZYN is produced by Swedish Match, which PM acquired in November 2022. The acquisition was finalized in 2023 with PM paying SEK 115.07 per share and completing the redemption process to gain full ownership. This financial commitment, including $883 million paid to acquire legal title to Swedish Match shares, underscores the strategic value of ZYN in accelerating PM's transformation toward a smoke-free future. The integration of Swedish Match into PM's regional segments in 2024 further aligns with the company's broader goal of transitioning away from traditional cigarettes and expanding its leadership in alternative nicotine delivery systems.",
      "llm_answer": "The strategic importance of ZYN—highlighted by its expansion to 37 markets—directly reflects the financial commitment PMI made to fully acquire Swedish Match, the producer of ZYN, as a cornerstone of its transformation into a smoke‑free company; the acquisition gave PMI a leading oral‑nicotine franchise that complements its IQOS heat‑not‑burn portfolio, accelerating the shift of adult smokers to lower‑risk products and reinforcing PMI’s broader ambition to replace cigarette sales with a diversified, smoke‑free product suite.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_2_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_3_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 92,
          "pages": [
            90,
            91,
            92,
            93,
            94
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 67447,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17115,
        "completion_tokens": 132,
        "total_tokens": 17247
      }
    },
    {
      "question_id": 41,
      "question": "Given Merck's heavy dependence on key products like Lynparza for profitability, how does the company's strategy of combining Lynparza with Keytruda in Phase 3 clinical trials align with its exposure to sales volatility from loss of market exclusivity, especially as Keytruda is expected to lose U.S. exclusivity in 2028?",
      "original_answer": "Merck's 2023 10-K filing highlights that key products such as Lynparza and Keytruda contribute significantly to the company's profits and cash flows (page 28). However, the loss of market exclusivity for major products can lead to a rapid decline in sales, as seen with Bridion and expected for Keytruda in 2028. Despite this risk, the company is pursuing a strategic oncology initiative that includes combining Lynparza with Keytruda in Phase 3 trials for lung cancers (page 48). This suggests Merck is attempting to extend the lifecycle and value of Keytruda through novel therapeutic combinations, even as it anticipates a future decline in Keytruda sales due to generic competition. The success of this strategy would be critical to offsetting revenue losses and maintaining profitability from its key product portfolio.",
      "llm_answer": "Merck’s strategy of pairing Lynparza with Keytruda in Phase 3 trials is designed to create a differentiated, combination‑therapy offering that can sustain sales momentum for Keytruda as its U.S. market exclusivity approaches expiration in 2028. By leveraging Lynparza’s established market presence and clinical data, the company aims to mitigate the sales volatility associated with losing Keytruda’s patent protection, while also expanding its oncology portfolio to offset the anticipated decline in Keytruda revenue.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "target_page": 28,
          "pages": [
            26,
            27,
            28,
            29,
            30
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "target_page": 30,
          "pages": [
            28,
            29,
            30,
            31,
            32
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 73287,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18581,
        "completion_tokens": 129,
        "total_tokens": 18710
      }
    },
    {
      "question_id": 41,
      "question": "How does Home Depot's treatment of dividend equivalents on unvested shares differ from the additional shares delivered under accelerated share repurchase agreements in terms of payout mechanics and financial statement impact?",
      "original_answer": "Home Depot pays dividend equivalents on unvested restricted stock units and performance shares in the form of additional shares upon vesting or payout, rather than in cash, which aligns compensation value with stock price performance over time (page 69). In contrast, under accelerated share repurchase (ASR) agreements, the company receives an initial delivery of shares and may receive additional shares at settlement based on the volume-weighted average price over the agreement term, with the final share delivery acting as a mechanism to efficiently execute share repurchases rather than as compensation (page 66). These two uses of 'additional shares' serve different purposes: one relates to equity compensation and the accrual of dividend value until vesting, while the other is a financial instrument for returning capital to shareholders through repurchases.",
      "llm_answer": "Home Depot treats dividend equivalents on unvested shares as part of the compensation cost for restricted stock and performance share awards, which are expensed over the vesting period and paid in cash on each dividend date; these equivalents are not tied to any share‑repurchase mechanism. In contrast, shares delivered under accelerated share repurchase (ASR) agreements are issued immediately as part of the repurchase transaction, reducing treasury stock and weighted‑average shares outstanding, and the ASR settlements are accounted for as equity transactions with no dividend‑equivalent payout. Consequently, dividend equivalents affect the stock‑based compensation expense recognized in earnings, while ASR‑delivered shares impact the balance‑sheet treasury‑stock position and share‑count calculations without influencing compensation expense.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "HD_10k_2022.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "hop_2_rel": {
          "source_file": "HD_10k_2022.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "hop_3_rel": {
          "source_file": "HD_10k_2022.pdf",
          "target_page": 66,
          "pages": [
            64,
            65,
            66,
            67,
            68
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 64383,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16327,
        "completion_tokens": 212,
        "total_tokens": 16539
      }
    },
    {
      "question_id": 41,
      "question": "How does Georgia Power's decision to seek an extension of Plant Gaston Units 1 through 4 operations through at least December 31, 2034, reflect the strategic implications of its 50% ownership in SEGCO, particularly given SEGCO's total rated capacity of 1,020 MWs at Plant Gaston and the associated cost and operational commitments?",
      "original_answer": "Georgia Power's decision to pursue an operational extension of Plant Gaston Units 1 through 4 until at least December 31, 2034, reflects its strategic reliance on its 50% ownership in SEGCO, which owns the 1,020 MW generating units at Plant Gaston. This ownership stake allows Georgia Power to access 510 MWs of capacity—critical for meeting long-term energy demand projections outlined in the 2025 IRP. SEGCO's structure requires Georgia Power to make ongoing payments covering operating expenses, taxes, interest, and a return on equity, indicating a long-term financial commitment that aligns with the decision to extend operations. This strategic move ensures continued access to cost-effective generation while balancing capital expenditures and reliability needs, despite the expected retirement date originally set for 2028.",
      "llm_answer": "Georgia Power’s move to extend Plant Gaston Units 1‑4 through at least 2034 underscores its strategic reliance on SEGCO’s 1,020 MW capacity—half of which it co‑owns with Alabama Power—while also reflecting the need to meet its own generation targets and regulatory commitments. Because SEGCO’s units are integral to Georgia Power’s integrated resource plan and its 2025 IRP filing, extending their operation ensures continued resource adequacy, protects its 50 % ownership stake, and supports the company’s broader cost‑recovery and emissions‑reduction objectives tied to its regulated rate base and future investment plans.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 216,
          "pages": [
            214,
            215,
            216,
            217,
            218
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 187,
          "pages": [
            185,
            186,
            187,
            188,
            189
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 98178,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 24810,
        "completion_tokens": 156,
        "total_tokens": 24966
      }
    },
    {
      "question_id": 41,
      "question": "How does Corebridge's repayment of $1.25 billion of its DDTL Facility through senior note issuances affect its liquidity flexibility through February 2025, particularly in light of its remaining $250 million balance under the facility?",
      "original_answer": "Corebridge repaid $1.25 billion of its DDTL Facility using proceeds from the issuance of $500 million in 6.050% Senior Notes due 2033 and $750 million in 5.750% Senior Notes due 2034 (page 107). This significantly reduced its DDTL Facility balance from $1.5 billion to $250 million as of December 31, 2023 (page 234). Despite this reduction, Corebridge retains the ability to continue borrowing under the DDTL Facility through February 25, 2025 (page 113). This suggests a strategic shift from short-term loan facility reliance to longer-term debt issuance, while still maintaining a smaller revolving credit capacity for near-term liquidity flexibility. The remaining $250 million under the DDTL Facility provides a liquidity buffer through early 2025, even as Corebridge reduces its dependence on this form of financing.",
      "llm_answer": "Corebridge’s repayment of $1.25 billion of its DDTL Facility through senior note issuances reduces the outstanding balance on that facility to $250 million, leaving only a modest $250 million of borrowing capacity under the DDTL that matures in February 2025. This limited remaining availability, combined with the scheduled maturity of the DDTL in February 2025, constrains Corebridge’s short‑term liquidity flexibility, although the company still has access to its $2.5 billion revolving credit facility and other sources of funding.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 107,
          "pages": [
            105,
            106,
            107,
            108,
            109
          ]
        },
        "hop_2_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 234,
          "pages": [
            232,
            233,
            234,
            235,
            236
          ]
        },
        "hop_3_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 113,
          "pages": [
            111,
            112,
            113,
            114,
            115
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 80989,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20492,
        "completion_tokens": 133,
        "total_tokens": 20625
      }
    },
    {
      "question_id": 41,
      "question": "How does Duke Energy's 2030 CO₂ emissions goal align with the North Carolina-mandated 70% reduction target under HB 951, given the prior rejection of Duke's accelerated coal retirement scenario by the PSCSC?",
      "original_answer": "Duke Energy has an internal 2030 CO₂ emissions reduction goal that aligns with the 70% reduction target mandated by North Carolina through HB 951. However, in 2021, the PSCSC rejected Duke Energy Carolinas and Duke Energy Progress' preferred accelerated coal retirement IRP scenario, instead favoring a base-case scenario without a CO₂ price. This regulatory pushback highlights the challenge of aligning corporate climate goals with state-mandated timelines, especially when regulators question the cost-effectiveness or feasibility of proposed strategies. Despite this, HB 951 required the NCUC to develop a carbon reduction plan by the end of 2022, which ultimately incorporated elements from Duke's IRP and informed the 2023 Carolinas Resource Plan, particularly Portfolio 3, which outlines a path to exit coal by 2035 while balancing reliability and cost.",
      "llm_answer": "Duke Energy's 2030 CO₂ emissions goal aligns with North Carolina's HB 951-mandated 70% reduction target through its participation in the state's carbon reduction framework, which requires Duke Energy Carolinas and Duke Energy Progress to develop and implement plans achieving the interim 70% emissions cut by 2030. However, the PSCSC previously rejected Duke Energy's accelerated coal retirement scenario in its 2020 IRP filing, finding the base case without a CO₂ price to be more reasonable, indicating regulatory uncertainty about the pace of coal phaseout despite the company's stated goal. The company continues to pursue Portfolio 3 in its 2023 Carolinas Resource Plan, which aims for a reliable and low-cost transition to coal exit by 2035, consistent with HB 951's requirements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 232,
          "pages": [
            230,
            231,
            232,
            233,
            234
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 71,
          "pages": [
            69,
            70,
            71,
            72,
            73
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 87403,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22083,
        "completion_tokens": 196,
        "total_tokens": 22279
      }
    },
    {
      "question_id": 42,
      "question": "How does MET's detailed valuation methodology for Structured Products reflect the risk characteristics inherent in their CMBS holdings, given the distinct fair value hierarchies reported for these investments?",
      "original_answer": "MET's CMBS holdings, which are part of the broader category of Structured Products, are valued using a combination of observable and unobservable inputs tailored to their complexity and risk profile. As disclosed on page 265, MET's CMBS holdings have a total estimated fair value of $9,949 million, with $9,099 million classified under Level 2 and $850 million under Level 3 of the fair value hierarchy. This distinction reflects the varying degrees of market liquidity and the need for internal assumptions in valuing these assets. On page 268, MET's valuation methodology for Structured Products—which includes CMBS—relies on both the market and income approaches, incorporating inputs such as credit ratings, spreads, expected prepayment speeds, and loss severity. For Level 3 CMBS, unobservable inputs like illiquidity premiums and independent broker quotations are emphasized, aligning with the higher risk and lower liquidity of these instruments. This layered approach ensures that the valuation methodology for Structured Products explicitly accounts for the risk characteristics inherent in CMBS, particularly for those classified in Level 3.",
      "llm_answer": "MET's structured‑product valuation methodology explicitly incorporates the risk profile of its CMBS holdings by applying a prepayment‑and‑credit‑loss model that recalibrates effective yields as actual prepayment patterns and credit performance evolve. This approach, disclosed in the “Methodology for Amortization of Premium and Accretion of Discount on Structured Products” and the detailed fair‑value hierarchy tables, reflects the distinct fair‑value levels (primarily Level 2 and Level 3) assigned to CMBS, where unobservable inputs—such as projected cash‑flow timing, loss severity, and credit spreads—are used to capture the inherent credit and interest‑rate risks of those securities. Consequently, the valuation framework directly ties the estimated fair values of CMBS to the underlying risk characteristics embedded in the securities.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 265,
          "pages": [
            263,
            264,
            265,
            266,
            267
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 233,
          "pages": [
            231,
            232,
            233,
            234,
            235
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 268,
          "pages": [
            266,
            267,
            268,
            269,
            270
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 104078,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 26255,
        "completion_tokens": 211,
        "total_tokens": 26466
      }
    },
    {
      "question_id": 42,
      "question": "Given Horizon's dependence on regulatory authorizations for HTS product commercialization and its strategic role in Altria's 'Moving Beyond Smoking' initiative, how might delays in FDA authorization impact Altria's timeline and financial commitment to transitioning adult smokers to smoke-free alternatives, especially considering the $2.9 billion NJOY acquisition in 2023?",
      "original_answer": "Horizon, Altria's joint venture with JTIUH, is explicitly described as being highly dependent on regulatory authorizations—particularly from the FDA—for the commercialization of heated tobacco stick (HTS) products in the U.S. The filing notes that failure to obtain or maintain such authorizations could negatively impact Horizon's ability to generate new revenue streams and enter new markets. This regulatory risk is compounded by Altria's broader strategic shift toward a smoke-free future, as emphasized in the 'Moving Beyond Smoking' initiative. The company's acquisition of NJOY in June 2023 for $2.9 billion further underscores its financial commitment to this transition. However, if Horizon experiences delays in securing regulatory approvals, Altria may face pressure to accelerate returns from NJOY or other smoke-free investments, potentially disrupting the overall timeline and financial feasibility of its smoke-free transition strategy.",
      "llm_answer": "Delays in FDA authorization for Horizon’s HTS products could push back Altria’s timeline for commercializing reduced‑risk alternatives, slowing the rollout of its “Moving Beyond Smoking” strategy and potentially weakening its ability to capture market share from adult smokers seeking smoke‑free options. Because the $2.9 billion NJOY acquisition was intended to accelerate this transition, any setback in regulatory clearance could also diminish the expected financial returns from the NJOY assets and may compel Altria to reassess or scale back its investment and strategic commitments in the e‑vapor and HTS space.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 83699,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21193,
        "completion_tokens": 154,
        "total_tokens": 21347
      }
    },
    {
      "question_id": 42,
      "question": "How does Intel's strategic decision to divest its Fab Assets in Dalian to SK hynix, including the NAND SSD Business, reconcile with its continued partnership with SK hynix to manufacture NAND memory wafers using those same assets, and how does this arrangement impact Intel's NAND profitability and product roadmap as outlined in the NSG segment?",
      "original_answer": "Intel signed an agreement with SK hynix in October 2020 to divest its NAND memory business, including the Fab Assets in Dalian, China, and the NAND SSD Business. The first closing occurred on December 29, 2021, where these assets and the NAND SSD Business were transferred to SK hynix. Despite this divestiture, Intel entered into a NAND wafer manufacturing and sale agreement, under which Intel continues to manufacture NAND memory wafers using the Dalian Fab Assets for SK hynix until the second closing. This ongoing manufacturing relationship supports SK hynix’s use of the Fab Assets while Intel benefits from continued revenue through this agreement. In the NSG segment overview, it is noted that NAND profitability improved in 2021 due to the absence of depreciation expense from NAND property, plant, and equipment held for sale. This profitability improvement aligns with the strategic divestiture, while Intel continues to leverage its NAND technology through product launches such as the Intel SSD D5-P5316, based on 144-layer QLC NAND. Thus, the divestiture of Fab Assets supports Intel’s strategic refocus while maintaining a transitional revenue stream and supporting product innovation through its NAND technology roadmap.",
      "llm_answer": "Intel’s divestiture of its Dalian fab assets and NAND SSD business to SK hynix was structured as a two‑step transaction: the first closing transferred ownership of the fab and SSD business, while a separate wafer‑supply agreement obligates Intel to continue manufacturing NAND wafers at that same facility and selling them to SK hynix until the second closing. This arrangement lets Intel retain a revenue stream from the assets it sold, but because the related depreciation expense is no longer capitalized, unit costs fall and NAND profitability improves, even as overall NSG revenue declines due to lower ASPs. Consequently, NSG’s operating profit surged to $1.4 billion in 2021, driven largely by these cost savings, while the company’s NAND product roadmap (e.g., 144‑layer QLC SSDs) continues to be marketed and sold through its remaining NSG portfolio.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_2_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_3_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 30751,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 7947,
        "completion_tokens": 214,
        "total_tokens": 8162
      }
    },
    {
      "question_id": 42,
      "question": "How does MMM's retained equity interest in Solventum, which it intends to divest within five years, influence its ongoing exposure to PFAS-related liabilities that the company has specifically retained under the separation agreement?",
      "original_answer": "MMM retains a direct financial stake in Solventum through an equity interest following the spin-off, with an intention to divest within five years. However, despite this planned divestiture, MMM has retained significant PFAS-related liabilities under the separation agreement, including liabilities for product claims arising from Solventum's products sold prior to April 1, 2024, and certain claims from products sold between April 1, 2024, and January 1, 2026. This retained exposure suggests that MMM's financial obligations related to PFAS contamination and litigation will continue even as it seeks to exit its ownership stake in Solventum, creating a complex interplay between its strategic divestiture goals and its ongoing legal and environmental liabilities.",
      "llm_answer": "MMM retains all PFAS‑related liabilities arising from its own business and from Solventum’s operations that existed before the April 1 2024 spin‑off, while Solventum assumes the remaining PFAS exposures after that date (subject to specific carve‑outs). Because MMM’s retained equity stake in Solventum is slated to be divested within five years, any future PFAS claims that Solventum incurs after the spin‑off could ultimately fall back on MMM if indemnification or other risk‑shifting provisions in the separation agreements are triggered, leaving MMM with continued exposure despite its planned divestiture.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 17,
          "pages": [
            15,
            16,
            17,
            18,
            19
          ]
        },
        "hop_2_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "hop_3_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 93670,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 23653,
        "completion_tokens": 152,
        "total_tokens": 23805
      }
    },
    {
      "question_id": 42,
      "question": "How does Georgia Power's 50% ownership and associated financial commitments to SEGCO influence its decision to seek an extension of Plant Gaston units through 2034 as part of the 2025 IRP?",
      "original_answer": "Georgia Power's 50% ownership in SEGCO, which operates Plant Gaston, comes with significant financial obligations, including equal shares of operating expenses, taxes, interest, and a return on equity. SEGCO's generating units at Plant Gaston have a total rated capacity of 1,020 MWs, with an initial expected retirement date of December 31, 2028. However, Georgia Power, alongside Alabama Power, is evaluating the extension of Plant Gaston Units 1 through 4 beyond this date. In the 2025 IRP filing, Georgia Power specifically requested approval to operate Plant Gaston Units 1 through 4 (500 MWs based on 50% ownership through SEGCO) through at least December 31, 2034. This extension request indicates a strategic alignment with SEGCO's long-term viability despite the shared financial burden. The decision likely reflects a cost-benefit analysis weighing the capital investment required to extend Plant Gaston's life against alternatives like new renewable or gas-fired generation proposed in the IRP. Without SEGCO's operational and financial structure, Georgia Power may have pursued different resource mix strategies.",
      "llm_answer": "Georgia Power’s 50 % ownership of SEGCO obligates it to fund the utility’s share of operating costs, debt service and other financial commitments, which is a key factor behind its pursuit of an extension of Plant Gaston’s units through 2034 in the 2025 IRP. The extension would allow the company to retain the generating capacity and associated revenue streams that support its ownership stake and meet its regulatory‑approved resource plan.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 216,
          "pages": [
            214,
            215,
            216,
            217,
            218
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 187,
          "pages": [
            185,
            186,
            187,
            188,
            189
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 98178,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 24774,
        "completion_tokens": 110,
        "total_tokens": 24885
      }
    },
    {
      "question_id": 43,
      "question": "How does Capital One's current capital adequacy framework under Basel III, which requires a minimum CET1 capital ratio of 4.5%, align with the proposed changes under the Basel III Finalization Proposal that would introduce the Expanded Risk-Based Approach and phase in recognition of AOCI in CET1 capital?",
      "original_answer": "Capital One currently operates under Basel III Capital Rules that mandate a minimum CET1 capital ratio of 4.5%, calculated using the Basel III standardized approach. The Basel III Finalization Proposal introduces the Expanded Risk-Based Approach, which would require institutions to calculate risk-weighted assets under both the existing standardized framework and the new risk-based model, applying the more stringent result. Additionally, the proposal would phase in the recognition of Accumulated Other Comprehensive Income (AOCI), including unrealized gains and losses on available-for-sale securities, into CET1 capital over a three-year period beginning July 1, 2025. This represents a shift from Capital One’s current ability to exclude certain AOCI elements as a Category III institution. The dual-calculation requirement and AOCI inclusion could result in higher capital requirements and greater volatility in CET1 capital, impacting Capital One’s capital planning and stress testing strategies.",
      "llm_answer": "Capital One's current capital adequacy framework under Basel III requires a minimum CET1 capital ratio of 4.5%, which aligns with the proposed changes in the Basel III Finalization Proposal that would introduce the Expanded Risk-Based Approach and phase in recognition of AOCI in CET1 capital. The proposal would require Category III institutions like Capital One to begin recognizing certain elements of AOCI in CET1 capital, including unrealized gains and losses on available-for-sale securities, while also implementing the Expanded Risk-Based Approach for calculating risk-weighted assets. This transition would be phased in over a three-year period ending July 1, 2028, with the effective date set for July 1, 2025.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 114,
          "pages": [
            112,
            113,
            114,
            115,
            116
          ]
        },
        "hop_2_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_3_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 81929,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20738,
        "completion_tokens": 180,
        "total_tokens": 20918
      }
    },
    {
      "question_id": 43,
      "question": "How does Merck's ongoing financial involvement with Organon, particularly through the manufacturing and supply agreements for formulated pharmaceutical products, reconcile with the fact that Organon was spun off and is now a separate entity with its own $9.5 billion debt obligation?",
      "original_answer": "Merck's ongoing involvement with Organon is maintained through a series of binding manufacturing and supply agreements (MSAs) under which Merck both supplies and receives formulated pharmaceutical products from Organon, generating $219 million in sales in 2021. Despite the spin-off of Organon—which carried $9.5 billion in principal debt and was treated as a tax-free distribution—Merck remains operationally connected through these agreements, which have initial terms ranging from four to ten years. Additionally, Merck had a net receivable of $964 million from Organon at year-end 2021, indicating continued financial exposure. This suggests that while Organon is now a separate, financially independent entity with its own debt obligations, Merck continues to maintain a strategic and financial relationship with it through contractual supply chain commitments.",
      "llm_answer": "Based on the document, Merck's ongoing financial involvement with Organon through manufacturing and supply agreements (MSAs) is reconciled with Organon's spin-off and $9.5 billion debt by noting that the agreements are part of the separation framework: Merck will manufacture and supply certain active pharmaceutical ingredients, formulated products, and packaged items for Organon, while Organon will similarly supply products for Merck. These contractual obligations remain in place after the spin‑off, even though Organon now carries its own $9.5 billion debt and operates as an independent entity. The MSAs are described as having initial durations of four to ten years, and the related receivables/payables ($964 million due from Organon and $400 million due to Organon as of Dec 31 2021) are reflected in Merck’s current assets and liabilities.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 128,
          "pages": [
            126,
            127,
            128,
            129,
            130
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 74126,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18780,
        "completion_tokens": 212,
        "total_tokens": 18993
      }
    },
    {
      "question_id": 43,
      "question": "How does the 8% dividend increase approved in January 2022 for CMCSA's Class A common stock align with the structural voting power imbalance and special approval rights held by the Class B common stock, particularly in light of Brian L. Roberts' sole beneficial ownership of the Class B shares?",
      "original_answer": "CMCSA's Class A common stock received an 8% dividend increase in January 2022, signaling a positive return to shareholders. However, the Class A shares hold only 66 2/3% of the combined voting power, with the remaining 33 1/3% held by the Class B common stock, which has disproportionate influence due to its non-dilutable voting rights and special approval rights over major corporate transactions. Since Brian L. Roberts, the company’s Chairman and CEO, is the sole beneficial owner of the Class B shares, he maintains significant control over strategic decisions, even though Class B shares can be converted into Class A shares on a one-for-one basis. This structure creates a misalignment between economic returns (as seen in the dividend increase) and voting control, which could impact shareholder dynamics and corporate governance decisions.",
      "llm_answer": "The 8% dividend increase approved in January 2022 was paid to holders of Class A common stock, while the Class B shares – which carry 15 votes per share and are wholly owned by Brian L. Roberts – retain separate approval rights over certain material transactions and a non‑dilutable 33 % voting interest; thus, despite the dividend hike, the structural voting power imbalance and special approval rights of the Class B stock remain unchanged.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 12,
        "total_chars": 55385,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14101,
        "completion_tokens": 110,
        "total_tokens": 14212
      }
    },
    {
      "question_id": 43,
      "question": "Given that Disney did not have any pay-fixed interest rate swaps designated as cash flow hedges at the end of fiscal 2024, how does this absence affect the interest rate exposure on their floating-rate borrowings, which are reported at their current interest rates in effect at September 28, 2024?",
      "original_answer": "The absence of pay-fixed interest rate swaps designated as cash flow hedges at the end of fiscal 2024 means Disney is not actively converting floating-rate borrowings into fixed-rate obligations. As a result, the company remains exposed to interest rate volatility on its floating-rate borrowings, which are reported at the current rates in effect at September 28, 2024, and these rates may not reflect future interest rate environments. This lack of hedging could lead to increased interest expense if market rates rise.",
      "llm_answer": "The absence of pay-fixed interest rate swaps designated as cash flow hedges means Disney has no formal hedge protecting its floating‑rate borrowings from interest‑rate movements; consequently, any changes in market rates will directly affect the interest expense on those borrowings, which are already reflected at their current rates in the financial statements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 80082,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20273,
        "completion_tokens": 90,
        "total_tokens": 20364
      }
    },
    {
      "question_id": 43,
      "question": "How does the $24 million impact from regulatory disallowances at Nicor Gas mentioned in the MD&A section reconcile with the $96 million pre-tax charges associated with capital investment disallowances at Nicor Gas in the financial statement details?",
      "original_answer": "The $24 million referenced in the MD&A section represents the portion of earnings impact related to regulatory disallowances at Nicor Gas, indicating a net effect on operational performance. In contrast, the $96 million pre-tax charge disclosed in the financial statement details reflects the broader accounting impact of disallowed capital investments, which includes both the principal disallowance and any associated write-downs. The difference between these figures highlights how the MD&A section presents a summarized view of disallowances on earnings, while the financial statements provide a more granular and comprehensive accounting treatment of the same issue. This distinction allows stakeholders to understand both the operational and financial statement implications of regulatory disallowances.",
      "llm_answer": "The $24 million regulatory disallowance charge recorded in 2023 reflects the estimated loss from the disallowance of certain capital investments at Nicor Gas (Note 2 under “Southern Company Gas – Infrastructure Replacement Programs and Capital Projects”), while the $96 million pre‑tax charge referenced in the table of adjustments represents the total pre‑tax amount associated with those same disallowances; the $24 million is the portion of that $96 million that was recognized as an estimated loss on regulatory disallowance during 2023.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 302,
          "pages": [
            300,
            301,
            302,
            303,
            304
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 64473,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16361,
        "completion_tokens": 135,
        "total_tokens": 16497
      }
    },
    {
      "question_id": 43,
      "question": "How does Capital One's current capital adequacy framework under Basel III, which maintains a minimum CET1 capital ratio of 4.5%, reconcile with the potential impact of the Basel III Finalization Proposal that would introduce the Expanded Risk-Based Approach and phase in recognition of AOCI in CET1 capital starting July 1, 2025?",
      "original_answer": "Capital One currently operates under the Basel III Capital Rules, which require a minimum CET1 capital ratio of 4.5% calculated using the standardized approach and allow exclusion of certain AOCI elements. However, the Basel III Finalization Proposal would introduce the Expanded Risk-Based Approach, requiring institutions to calculate risk-weighted assets under both the existing standardized approach and the new model-based framework, applying the stricter of the two. Additionally, the proposal mandates that Category III institutions like Capital One begin recognizing AOCI, including unrealized gains and losses on available-for-sale securities, in CET1 capital, phased in over three years starting July 1, 2025. This change could reduce CET1 capital levels due to market volatility, potentially affecting Capital One’s ability to maintain the 4.5% minimum CET1 requirement under the stricter calculation method, especially if asset values decline.",
      "llm_answer": "Capital One's current capital adequacy framework under Basel III maintains a minimum CET1 capital ratio of 4.5%, which aligns with the regulatory requirement. However, the Basel III Finalization Proposal, which introduces the Expanded Risk-Based Approach and begins phasing in the recognition of AOCI in CET1 capital starting July 1, 2025, would modify this framework by requiring institutions to recognize certain AOCI elements in CET1 capital and potentially reducing deductions for assets like deferred tax assets. This proposed change would impact how Capital One calculates its CET1 ratio, though the current 4.5% minimum remains in place until the transition period concludes.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 114,
          "pages": [
            112,
            113,
            114,
            115,
            116
          ]
        },
        "hop_2_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_3_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 81929,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20744,
        "completion_tokens": 170,
        "total_tokens": 20914
      }
    },
    {
      "question_id": 43,
      "question": "How does Altria's strategic investment in Horizon's heated tobacco stick commercialization align with the regulatory risks disclosed in the 10-K, particularly given the joint venture's dependence on FDA authorizations?",
      "original_answer": "Altria's strategic investment in Horizon, a joint venture with JTIUH for the U.S. commercialization of heated tobacco stick (HTS) products, is positioned as a key component of its Vision to transition adult smokers to potentially less harmful alternatives. However, the 10-K explicitly states that Horizon's ability to generate new revenue streams is 'dependent upon a number of factors,' with the 'receipt of regulatory authorizations' being the first and most critical. This aligns with broader regulatory risks outlined in the document, which state that failure to obtain or maintain regulatory authorization for marketing or sale of innovative products could result in a 'material adverse effect' on Altria’s business and its ability to achieve its Vision. The document also notes that the commercialization of Horizon's products is subject to 'commercialization milestones' and regulatory compliance, further emphasizing that without timely FDA authorizations, the financial and strategic value of the Horizon joint venture could be significantly undermined.",
      "llm_answer": "Altria's joint venture with Japan Tobacco to commercialize heated tobacco products through Horizon Innovations is explicitly positioned as a strategic growth initiative dependent on obtaining FDA pre‑market tobacco product authorizations (PMTAs). The 10‑K highlights that Horizon’s ability to generate new revenue streams and enter U.S. markets hinges on regulatory approvals, and that failure to secure or maintain such authorizations—along with adverse market or business conditions—could materially impair the venture’s success and Altria’s broader Vision of transitioning smokers to potentially less harmful alternatives. This regulatory risk is underscored throughout the “Risk Factors” and “Business Environment” sections, which warn that without FDA clearance the joint venture cannot legally market or sell HTS products in the United States.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 83699,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21154,
        "completion_tokens": 212,
        "total_tokens": 21366
      }
    },
    {
      "question_id": 43,
      "question": "How does Boeing's relationship with JPMorgan Chase Bank, N.A. as a syndication agent in its 2023 Five-Year Credit Agreement reflect the broader pattern of financial partnerships with the bank across Boeing's credit facilities?",
      "original_answer": "Boeing's relationship with JPMorgan Chase Bank, N.A. as a syndication agent in the 2023 Five-Year Credit Agreement (Exhibit 10.2 to the 10-Q for the quarter ended September 30, 2023) builds on a consistent pattern of financial collaboration, as evidenced by the bank's involvement in multiple credit agreements, including the 364-Day Credit Agreement and the Three-Year Credit Agreement, both dated in 2023 and 2022 respectively. This recurring role indicates a strategic partnership where JPMorgan Chase Bank plays a central role in structuring and managing Boeing's credit facilities, reflecting a deep and ongoing financial relationship.",
      "llm_answer": "Boeing's use of JPMorgan Chase Bank, N.A. as syndication agent in its 2023 Five-Year Credit Agreement is part of a consistent pattern of engaging JPMorgan Chase as a key financial partner across its credit facilities, as evidenced by its repeated role as syndication agent in multiple credit agreements dating back to at least 2019. This recurring involvement underscores JPMorgan Chase's central position in Boeing's financing structure, serving as a primary arranger and agent in its revolving credit facilities.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2023.pdf",
          "target_page": 126,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2023.pdf",
          "target_page": 126,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2023.pdf",
          "target_page": 125,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 64627,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16386,
        "completion_tokens": 128,
        "total_tokens": 16515
      }
    },
    {
      "question_id": 43,
      "question": "How does Duke Energy's consistent classification of debt investments as AFS across both Carolinas and Progress segments impact the comparability of their fair value disclosures and what are the implications for understanding market risk exposure in their investment portfolios?",
      "original_answer": "Duke Energy consistently classifies debt investments as AFS (Available-for-Sale) across both Duke Energy Carolinas (page 192) and Duke Energy Progress (page 194). This uniform accounting treatment means that unrealized gains and losses on these investments are recorded in other comprehensive income rather than net income, affecting how market risk is reflected in the financial statements. The fair value disclosures on page 192 show that both debt and equity investments are categorized using this classification framework, which allows for comparability between segments. However, since AFS classification delays the recognition of market fluctuations into earnings, analysts must look beyond the income statement to assess the true market risk exposure embedded in these portfolios. This consistent policy across segments simplifies cross-segment analysis but may obscure the immediate impact of market volatility on earnings.",
      "llm_answer": "Duke Energy's consistent classification of debt investments as AFS across all Carolinas and Progress segments ensures that fair value disclosures for these investments are prepared using the same methodology, enhancing comparability across the segments. This consistency allows investors to reliably aggregate and compare market risk exposure related to debt securities within the investment portfolios, as unrealized gains and losses for AFS securities are reported in other comprehensive income until realized, providing a uniform view of market risk across the segments.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2022.pdf",
          "target_page": 192,
          "pages": [
            190,
            191,
            192,
            193,
            194
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2022.pdf",
          "target_page": 192,
          "pages": [
            190,
            191,
            192,
            193,
            194
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2022.pdf",
          "target_page": 194,
          "pages": [
            192,
            193,
            194,
            195,
            196
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 105066,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 26511,
        "completion_tokens": 143,
        "total_tokens": 26655
      }
    },
    {
      "question_id": 44,
      "question": "How does Altria's indemnification arrangement with PMI for tobacco-related liabilities interact with PM USA's unconditional guarantee of Altria's $3.0 billion Credit Agreement obligations, particularly in light of PM USA's contingent liability exposure under fraudulent transfer laws?",
      "original_answer": "Altria has a distribution agreement with PMI under which PMI indemnifies Altria and PM USA for liabilities related to tobacco products manufactured by PMI or contract manufactured by PM USA for PMI. This indemnification is not recorded on Altria's balance sheet as its fair value is deemed insignificant. PM USA, in turn, unconditionally guarantees Altria's obligations under its $3.0 billion Credit Agreement, among other debt instruments. However, under federal bankruptcy and fraudulent transfer laws, these guarantees could be voided or subordinated if PM USA is found to have received less than fair consideration or was insolvent at the time the obligations were incurred. This creates a complex liability chain where PMI's indemnification of PM USA could be critical to PM USA's ability to meet its guarantee obligations to Altria, especially if PM USA's financial position weakens and exposes it to fraudulent conveyance claims.",
      "llm_answer": "Altria's indemnification of PM USA for tobacco‑related liabilities under the Distribution Agreement is separate from PM USA’s unconditional guarantee of Altria’s $3 billion Credit Agreement; the guarantee could be voided if a court finds that PM USA’s contingent liability exposure under fraudulent‑transfer laws rendered the guarantee a fraudulent conveyance, but the indemnification itself does not affect the enforceability of that guarantee.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 51,
          "pages": [
            49,
            50,
            51,
            52,
            53
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 65961,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16739,
        "completion_tokens": 111,
        "total_tokens": 16850
      }
    },
    {
      "question_id": 44,
      "question": "Given Apple's significant revenue contribution from Greater China, which includes Taiwan, how does the company's operational risk disclosure regarding Taiwan's geopolitical and public health vulnerabilities affect the sustainability of the $74.2 billion in net sales reported from the Greater China region in 2022?",
      "original_answer": "Apple reported $74.2 billion in net sales from the Greater China region in 2022, which includes Taiwan as part of its geographic segment. However, the company also discloses in its risk factors that a significant portion of its supply chain and manufacturing operations are located in Asia, including Taiwan, and are vulnerable to geopolitical tensions, public health issues like the COVID-19 pandemic, and other business interruptions. These risks could disrupt manufacturing, increase costs, and reduce consumer demand. Therefore, while Greater China contributes substantial revenue, the inclusion of Taiwan in this segment exposes Apple to operational risks that could threaten the continuity and profitability of this revenue stream if disruptions occur.",
      "llm_answer": "Apple's $74.2 billion Greater China net sales are exposed to operational risks stemming from Taiwan's geopolitical tensions and public‑health vulnerabilities, which could disrupt supply chains, reduce demand, and impair the company's ability to sustain that revenue level. Consequently, the disclosed risks raise concerns about the durability of the reported sales figure.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 52,
          "pages": [
            50,
            51,
            52,
            53,
            54
          ]
        },
        "hop_2_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 40,
          "pages": [
            38,
            39,
            40,
            41,
            42
          ]
        },
        "hop_3_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 71264,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18076,
        "completion_tokens": 93,
        "total_tokens": 18169
      }
    },
    {
      "question_id": 44,
      "question": "How does Disney's exclusion of firm commitments from its VAR model impact the effectiveness of its foreign exchange hedging strategy, given the $9.9 billion in net foreign exchange cash flow hedges and the $255 million VAR estimate at September 28, 2024?",
      "original_answer": "Disney's VAR model excludes firm commitments from its risk analysis, which means that the $9.9 billion in net foreign exchange cash flow hedges—intended to protect these commitments—are not factored into the company's maximum potential one-day loss estimate of $255 million. This creates a gap in the risk modeling framework, as the hedges are designed to offset changes in the value of firm commitments, yet neither the commitments nor the associated hedges are included in the VAR calculation. As a result, the VAR model may overstate or understate actual exposure depending on market conditions, since it does not account for the offsetting effect of these hedges on the underlying commitments. This raises questions about the completeness of Disney’s risk assessment methodology and whether the firm is fully capturing its mitigated exposures.",
      "llm_answer": "Disney's exclusion of firm commitments from its VAR model reduces the estimated potential loss in fair value that would be captured if those commitments were included, meaning the $255 million VAR figure at September 28 2024 understates the true market‑risk exposure tied to its foreign‑exchange hedges. Consequently, the effectiveness of Disney's foreign‑exchange hedging strategy—designed to offset earnings and cash‑flow volatility from its $9.9 billion net FX cash‑flow hedges—is limited to the portion of exposures that are formally “firmly committed,” while the broader, less‑certain commitments remain outside the VAR calculation and thus are not fully reflected in the reported risk metric.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 67988,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17239,
        "completion_tokens": 174,
        "total_tokens": 17413
      }
    },
    {
      "question_id": 44,
      "question": "How does Georgia Power's request to extend Plant Scherer Unit 3 operations through 2035 consider FP&L's 25% ownership stake and the joint liability implications outlined in the operating agreements?",
      "original_answer": "Georgia Power's request to extend Plant Scherer Unit 3 operations through 2035 must account for FP&L’s 25% ownership stake, which means any extension or modification of the plant’s operations would require coordination and agreement with FP&L. According to the ownership table, Georgia Power owns 75% and FP&L owns 25% of Plant Scherer Unit 3. The operating agreement for jointly-owned plants, as described in the disclosures, states that Georgia Power operates the plant as an agent for the co-owners and is jointly and severally liable for third-party claims. Therefore, extending operations would not only involve Georgia Power’s regulatory filings and compliance with environmental rules but also require alignment with FP&L on financial commitments, operational responsibilities, and liability exposure.",
      "llm_answer": "Georgia Power's 2025 IRP filing seeks Georgia PSC approval to extend Plant Scherer Unit 3 (614 MW, 75 % owned) through at least 2035 and to add environmental controls and natural‑gas co‑firing upgrades. Because the unit is jointly owned with FP&L (25 % stake), the extension and any capital improvements create shared regulatory liabilities under the joint‑ownership operating agreements, making FP&L a co‑liable party for the added costs and compliance obligations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 54,
          "pages": [
            52,
            53,
            54,
            55,
            56
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 45,
          "pages": [
            43,
            44,
            45,
            46,
            47
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 211,
          "pages": [
            209,
            210,
            211,
            212,
            213
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 79157,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20022,
        "completion_tokens": 116,
        "total_tokens": 20138
      }
    },
    {
      "question_id": 44,
      "question": "How does LLY's reliance on biologics data protection until 2030 for Emgality in the U.S. align with their broader strategy of managing market exclusivity risks given the complex interaction between patent and regulatory protections?",
      "original_answer": "LLY relies on both compound patents (lasting until 2033) and biologics data protection (expiring in 2030) for Emgality in the U.S., indicating a layered intellectual property strategy. The company acknowledges in another section that market exclusivity is difficult to predict due to the interaction between patent and regulatory protections and the uncertainties of litigation. This suggests that while data protection offers a near-term exclusivity runway until 2030, LLY may strategically leverage overlapping patent protections to extend commercial advantage beyond that date, despite inherent risks.",
      "llm_answer": "LLY's reliance on biologics data protection extending to 2030 for Emgality in the U.S. aligns with its broader strategy of managing market exclusivity risks by leveraging the complex interplay between patent and regulatory protections, where data exclusivity periods—such as the 12-year protection under the BPCIA for biologics—serve as a critical component of its long-term commercial planning, even as it faces ongoing challenges from patent litigation, generic competition, and evolving regulatory landscapes that could impact the duration and enforceability of such protections.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 12,
        "total_chars": 57088,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14504,
        "completion_tokens": 145,
        "total_tokens": 14649
      }
    },
    {
      "question_id": 44,
      "question": "How does Honeywell's initial $509 million write-down of receivables from Garrett relate to the mandatory redemption schedule of the Series B Preferred Stock, and what does this imply about Honeywell's expectations for recovery under the amended terms?",
      "original_answer": "Honeywell initially wrote down $509 million in receivables from Garrett in 2020 due to the uncertainty surrounding the enforceability of the Garrett Indemnity and Tax Matters Agreement. Following Garrett's emergence from bankruptcy in April 2021, Honeywell received 834.8 million shares of Series B Preferred Stock as part of the settlement, which included mandatory redemption terms starting with $35 million in 2022 and $100 million annually from 2023 to 2030, subject to Garrett's EBITDA and liquidity conditions. By December 2021, the redemption schedule was accelerated and amended, reducing the present value of the Series B Preferred Stock to $207 million. The fair value of this investment, as disclosed on page 90, is based on the present value of these mandatory redemptions and is classified as level 2 in the fair value hierarchy. This implies that Honeywell adjusted its recovery expectations downward from the original redemption schedule due to the increased risk of non-payment, reflected in both the write-down and the updated fair value estimate.",
      "llm_answer": "Honeywell recorded a $509 million write‑down of the Garrett receivable to reflect the present value of the mandatory redemption schedule for the Series B Preferred Stock, acknowledging that the redemption amounts (e.g., $35 million in 2022 and $100 million annually through 2030) would be paid over time and that the present‑value discount would accrete into interest income. This write‑down signals that Honeywell expects to receive only a fraction of the full redemption value and therefore anticipates limited recovery under the amended terms of the Series B Preferred Stock.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 24,
          "pages": [
            22,
            23,
            24,
            25,
            26
          ]
        },
        "hop_2_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "hop_3_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 59195,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15045,
        "completion_tokens": 144,
        "total_tokens": 15189
      }
    },
    {
      "question_id": 44,
      "question": "How does ConocoPhillips' strategic emphasis on coalbed methane (CBM) through its stake in APLNG reconcile with the $688 million before-tax charge recorded in 2021, which reflected a market participant view of APLNG's fair value being below the carrying value of the investment?",
      "original_answer": "ConocoPhillips highlights APLNG as a strategic joint venture that provides access to CBM resources in Australia and strengthens its LNG position, particularly targeting Asian markets. However, in 2021, when Origin Energy sought to sell a 10% stake in APLNG, ConocoPhillips exercised its preemption right and purchased the stake. The fair value of APLNG from this transaction was determined to be lower than the carrying value of COP’s existing investment, resulting in a $688 million before-tax impairment charge. This discrepancy suggests that while APLNG remains strategically important for CBM and LNG exposure, the market valuation at the time indicated a lower financial worth than previously recorded, prompting a write-down. The contrast between the qualitative strategic positioning of CBM through APLNG and the quantitative impairment charge reflects a tension between long-term resource access and short-term asset valuation pressures.",
      "llm_answer": "ConocoPhillips' strategic focus on coalbed methane (CBM) through its 47.5 % stake in the Australian APLNG joint venture aligns with its broader LNG and unconventional gas portfolio, providing access to Australian CBM resources that complement its global LNG projects. However, in 2021 the company recorded a $688 million pre‑tax impairment charge on its APLNG investment after a market‑participant assessment indicated that APLNG’s fair value was below the carrying value of the equity method investment, reflecting a decline in expected cash flows and prompting the write‑down of the investment to its fair value.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 3,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 72183,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18297,
        "completion_tokens": 153,
        "total_tokens": 18450
      }
    },
    {
      "question_id": 45,
      "question": "How does Pfizer's reliance on BioNTech for Comirnaty supply agreements, including the amended EU contract through 2026, relate to the legal challenges facing Comirnaty in the U.S. and Europe, and what potential impact could these legal risks have on the continuation of those international supply commitments?",
      "original_answer": "Pfizer's reliance on BioNTech for Comirnaty supply agreements, including the amended EU contract extending through 2026 with rephased deliveries and volume reductions, is central to its international revenue commitments. However, Comirnaty faces multiple legal challenges: in April 2024, GSK Group sued Pfizer and BioNTech in the U.S., alleging infringement of five U.S. patents (later amended to include three additional patents), and in January 2025, Promosome LLC filed a complaint in the Unified Patent Court alleging infringement of a European patent in France, Germany, and Sweden. These legal risks could disrupt the manufacturing and distribution of Comirnaty in key markets, potentially jeopardizing Pfizer’s ability to meet its contractual obligations under the amended EU agreement and impacting international revenue projections tied to the vaccine.",
      "llm_answer": "Pfizer’s Comirnaty supply agreements with BioNTech—including the amended EU contract that extends deliveries through 2026—are subject to ongoing legal challenges in both the United States and Europe.  Patent‑infringement lawsuits filed by Moderna, Arbutus, GSK and others allege that Comirnaty infringes their COVID‑19‑related patents, while the U.S. government has also opened inquiries into the vaccine’s pricing and procurement practices.  If these disputes result in injunctions, damages, or required royalty payments, Pfizer could be forced to curtail or restructure its international supply commitments, potentially limiting the volume of Comirnaty doses it can deliver under the 2026 agreement and affecting related revenue streams.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PFE_10k_2024.pdf",
          "target_page": 107,
          "pages": [
            105,
            106,
            107,
            108,
            109
          ]
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2024.pdf",
          "target_page": 101,
          "pages": [
            99,
            100,
            101,
            102,
            103
          ]
        },
        "hop_3_rel": {
          "source_file": "PFE_10k_2024.pdf",
          "target_page": 101,
          "pages": [
            99,
            100,
            101,
            102,
            103
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 129283,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 32577,
        "completion_tokens": 184,
        "total_tokens": 32762
      }
    },
    {
      "question_id": 45,
      "question": "How does ConocoPhillips' decision to exercise its preemption right to increase its stake in APLNG reflect both the strategic value of Queensland's Bowen and Surat basins and the financial implications tied to APLNG's LNG operations and long-term agreements?",
      "original_answer": "ConocoPhillips exercised its preemption right to purchase an additional 10% stake in APLNG, increasing its ownership to 47.5%, despite recognizing a before-tax charge of $688 million due to the fair value of APLNG being below the carrying value. This decision underscores the strategic importance of APLNG's access to the Bowen and Surat basins in Queensland, Australia, which are central to producing coal bed methane (CBM) and supplying LNG to Asia Pacific markets. APLNG's operations include long-term sales and purchase agreements that provide stability, even as the company faces financial obligations like the $4.7 billion outstanding on its project finance facilities. The investment decision thus reflects a balance between long-term resource access and operational risks in a capital-intensive LNG venture.",
      "llm_answer": "ConocoPhillips' exercise of its preemption right to acquire an additional 10% stake in APLNG underscores the strategic value of the Bowen and Surat basins, which host significant coalbed methane (CBM) resources that enhance the company's liquefied natural gas (LNG) position. The transaction, priced below the carrying value of its existing investment, triggered a $688 million noncash impairment in 2021, reflecting the financial impact of the preemption right tied to APLNG's long‑term LNG sales agreements and the broader LNG market outlook.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 72330,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18325,
        "completion_tokens": 136,
        "total_tokens": 18461
      }
    },
    {
      "question_id": 45,
      "question": "How does Intel's strategic rationale for maintaining NAND wafer manufacturing capabilities through its agreement with SK hynix relate to the timing and scope of its NAND business divestiture, particularly in the context of profitability improvements seen in 2021?",
      "original_answer": "Intel's NAND wafer manufacturing agreement with SK hynix was a strategic component of the broader divestiture of its NAND memory business, allowing for continued production and revenue generation during the transition period. The agreement ensured manufacturing continuity using the Dalian fab assets until the second closing of the divestiture, which helped Intel maintain product availability and customer relationships while exiting the business. This arrangement likely supported the profitability improvements noted in 2021, which were attributed to the absence of depreciation expenses on NAND assets held for sale. By retaining manufacturing capabilities temporarily through the agreement, Intel could manage the transition more effectively, ensuring a smoother handover to SK hynix while still benefiting from the operational efficiencies and cost controls that contributed to improved financial performance.",
      "llm_answer": "Intel’s strategic rationale for retaining NAND wafer manufacturing through a post‑divestiture wafer‑supply agreement with SK hynix was to preserve a controllable, profitable NAND revenue stream as the company exits the business, which aligns with the 2021 profitability improvement driven by the absence of depreciation on the sold NAND assets and higher ASPs. This arrangement lets Intel continue to generate wafer sales while gradually winding down its NAND operations, supporting the overall financial recovery reflected in the 2021 operating‑income gains.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_2_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_3_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 30751,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 7927,
        "completion_tokens": 139,
        "total_tokens": 8066
      }
    },
    {
      "question_id": 45,
      "question": "How do the capital requirements under the Uniform Net Capital Rule constrain TDAC's ability to distribute capital to parent companies, and how does this align with Schwab's broader capital management strategy as reflected in their regulatory buffer requirements?",
      "original_answer": "TDAC, as a broker-dealer subsidiary of SCHW, is subject to the Uniform Net Capital Rule, which restricts its ability to pay dividends, make unsecured advances, or repay subordinated loans if such actions would result in net capital falling below prescribed thresholds (e.g., 2% of aggregate debit balances or a minimum dollar requirement). This limits TDAC's capacity to return capital to its parent entities like CSC. Meanwhile, Schwab's consolidated banking subsidiaries, such as CSB, are required to maintain a capital conservation buffer of 2.5% above minimum risk-based capital ratios under Basel III. If this buffer is breached, CSC would face restrictions on capital distributions and executive bonuses. The combination of these rules constrains Schwab's ability to freely allocate capital across its banking and broker-dealer entities, requiring a more cautious and segmented capital management strategy that prioritizes regulatory compliance over intercompany liquidity flexibility.",
      "llm_answer": "The Uniform Net Capital Rule requires broker‑dealer subsidiaries such as CS&Co, TDAC and TD Ameritrade, Inc. to maintain net capital of at least 5 % of aggregate debit balances (or 120 % of the minimum dollar requirement). This constraint limits the amount of cash they can distribute to their parent, CSC, because any dividend, loan repayment or unsecured advance would be prohibited if it would push net capital below those thresholds. Consequently, capital can only flow upward when the subsidiaries retain sufficient excess net capital after meeting the 5 % requirement.  \n\nSchwab’s broader capital‑management strategy emphasizes maintaining a strong Tier 1 leverage ratio (target 6.75‑7.00 %) and a robust capital buffer to absorb shocks and support its banking subsidiaries. While the company seeks to return excess capital to shareholders (e.g., via dividends and share repurchases), the regulatory capital buffers—particularly the Tier 1 leverage ratio and the net‑capital requirements of its broker‑dealers—dictate the pace and magnitude of any capital distributions, ensuring that CSC remains well‑capitalized and can continue to serve as a source of strength for its banking affiliates.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SCHW_10k_2022.pdf",
          "target_page": 59,
          "pages": [
            57,
            58,
            59,
            60,
            61
          ]
        },
        "hop_2_rel": {
          "source_file": "SCHW_10k_2022.pdf",
          "target_page": 14,
          "pages": [
            12,
            13,
            14,
            15,
            16
          ]
        },
        "hop_3_rel": {
          "source_file": "SCHW_10k_2022.pdf",
          "target_page": 120,
          "pages": [
            118,
            119,
            120,
            121,
            122
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 72264,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18315,
        "completion_tokens": 299,
        "total_tokens": 18614
      }
    },
    {
      "question_id": 45,
      "question": "How does the adoption of ASU No. 2023-07 impact the level of detail provided in 3M's segment reporting for the year ended December 31, 2024, compared to prior disclosures?",
      "original_answer": "The adoption of ASU No. 2023-07, which requires incremental disclosures of disaggregated expense information for reportable segments, directly impacts the level of detail in 3M's segment reporting. As noted in the accounting pronouncements section, 3M adopted this standard for the year ended December 31, 2024, and applied it retrospectively to prior periods. This change enhances the granularity of segment reporting, as seen in the segment results section, which includes detailed sales and operating income (loss) by business segment for 2024, 2023, and 2022. The new disclosures align with the ASU’s objective to improve transparency and comparability across segments.",
      "llm_answer": "The adoption of ASU No. 2023-07 requires 3M to provide incremental disaggregated expense disclosures for each of its reportable segments, enhancing the detail of segment expense reporting for the year ended December 31, 2024 compared with prior periods. This change results in more granular expense information being presented in the segment reporting.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 54,
          "pages": [
            52,
            53,
            54,
            55,
            56
          ]
        },
        "hop_2_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 54,
          "pages": [
            52,
            53,
            54,
            55,
            56
          ]
        },
        "hop_3_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 26,
          "pages": [
            24,
            25,
            26,
            27,
            28
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 108302,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 27295,
        "completion_tokens": 88,
        "total_tokens": 27383
      }
    },
    {
      "question_id": 45,
      "question": "What percentage of Alabama Power's and Georgia Power's electricity generation came from nuclear units in 2021, and how do potential physical attacks on these facilities pose financial risks that could exceed decommissioning trusts or insurance coverage?",
      "original_answer": "In 2021, nuclear units accounted for approximately 26% of Alabama Power’s and 28% of Georgia Power’s total KWHs generated. These nuclear facilities, operated by Southern Nuclear, are subject to a range of risks, including physical attacks, which could lead to significant financial exposure. The company discloses that damages, decommissioning, or other costs resulting from such incidents could exceed the available decommissioning trusts or external insurance coverage, including statutorily required nuclear incident insurance. Additionally, threats of physical attacks could trigger increased compliance and licensing costs, which are difficult to predict and may materially impact Southern Company's financial position.",
      "llm_answer": "In 2021, nuclear units supplied roughly 26 % of Alabama Power’s electricity and about 28 % of Georgia Power’s electricity.  The filings warn that a successful physical attack on these nuclear facilities could generate remediation, decontamination and legal costs that could exceed the amount held in the plants’ decommissioning trusts or available from statutory nuclear‑incident insurance, leaving the utilities exposed to additional financial losses.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 84278,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21309,
        "completion_tokens": 113,
        "total_tokens": 21422
      }
    },
    {
      "question_id": 46,
      "question": "How does ConocoPhillips ensure the credibility and SEC compliance of its proved reserves estimates, particularly in light of its engagement with DeGolyer and MacNaughton, and how is this third-party validation formally documented in the 10-K filing?",
      "original_answer": "ConocoPhillips ensures the credibility and SEC compliance of its proved reserves estimates through a structured internal control process that includes annual reviews by an independent team led by the Manager of Reserves Compliance and Reporting. This team includes a senior representative from DeGolyer and MacNaughton (D&M), a third-party petroleum engineering consulting firm, who assesses over 90% of the company’s proved reserves as of December 31, 2021. D&M evaluates whether ConocoPhillips’ internal processes and controls for estimating reserves align with SEC regulations, using data such as seismic information, well logs, and reservoir simulation models. Their review results in a formal opinion that the company’s processes are in accordance with SEC definitions. This third-party validation is further reinforced by the inclusion of D&M’s report as Exhibit 99 in the 10-K filing, which serves as official documentation of the review process and supports the company’s disclosures on reserves accuracy and compliance.",
      "llm_answer": "ConocoPhillips ensures the credibility and SEC compliance of its proved reserves estimates through a rigorous internal governance framework that includes annual independent reviews by DeGolyer and MacNaughton (D&M), a third‑party petroleum engineering consulting firm. The company’s internal Reserves Compliance and Reporting team, led by a senior manager with extensive petroleum engineering experience, conducts on‑site and remote assessments of business‑unit reserve processes, verifies that estimates adhere to SEC and FASB standards, and confirms that all proved reserves—both consolidated and equity‑affiliated—are calculated using consistent, documented methods. This third‑party validation is formally documented in the 10‑K as Exhibit 99, which contains D&M’s written opinion that ConocoPhillips’ December 31, 2021, proved‑reserve estimation processes and controls comply with SEC reserve definitions.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 152,
          "pages": [
            150,
            151,
            152,
            153,
            154
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 152,
          "pages": [
            150,
            151,
            152,
            153,
            154
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 187,
          "pages": [
            181,
            182,
            183,
            184,
            185
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 83475,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21110,
        "completion_tokens": 227,
        "total_tokens": 21338
      }
    },
    {
      "question_id": 46,
      "question": "What implications does Sojitz America's $0.3 million preferred stock ownership have for Nike's dividend policy and equity structure, given the absence of redeemable preferred stock liabilities on Nike's balance sheet?",
      "original_answer": "Sojitz America's $0.3 million preferred stock ownership creates structural requirements for Nike's dividend policy, as no dividends may be declared or paid on Nike's common stock unless dividends on the preferred stock have been declared and paid in full. Despite this, Nike's balance sheet shows no redeemable preferred stock liabilities, indicating that no dividends are currently in arrears. This preferred stock ownership also affects Nike's equity structure by granting Sojitz America specific voting rights on major corporate actions such as asset sales, mergers, or liquidation, while not having general voting rights. This creates a unique governance dynamic where Sojitz America holds strategic influence despite its small financial stake.",
      "llm_answer": "Sojitz America’s $0.3 million redeemable preferred stock does not appear as a liability on Nike’s balance sheet, so it has no direct impact on Nike’s dividend policy or equity structure. The preferred stock’s cumulative $0.10 per share dividend must be paid before any common‑stock dividends, but because the balance sheet shows no redeemable preferred‑stock liability, Nike’s reported equity is unaffected and its dividend decisions are driven by cash flow and retained earnings rather than a formal dividend obligation to the preferred holder.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 62,
          "pages": [
            60,
            61,
            62,
            63,
            64
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 79,
          "pages": [
            77,
            78,
            79,
            80,
            81
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 79,
          "pages": [
            77,
            78,
            79,
            80,
            81
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 70027,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17738,
        "completion_tokens": 136,
        "total_tokens": 17874
      }
    },
    {
      "question_id": 46,
      "question": "How does Microsoft's treatment of Nuance-related convertible senior notes in the balance sheet reconcile with the strategic integration of Nuance into the Intelligent Cloud segment?",
      "original_answer": "Microsoft's balance sheet as of June 30, 2022, reflects only $1 million in convertible senior notes remaining from the $986 million originally issued by Nuance, indicating that nearly all of these obligations were redeemed prior to the reporting date. This financial simplification aligns with Microsoft's broader strategic integration of Nuance into its Intelligent Cloud segment, where the acquired company's operations have been embedded into Microsoft's cloud offerings, including Azure and professional services. The minimal remaining liability from Nuance's pre-acquisition debt structure supports the company's narrative of operational consolidation and synergy realization, key justifications cited for the acquisition and now reflected both financially and structurally within the Intelligent Cloud segment.",
      "llm_answer": "Microsoft's balance sheet reflects Nuance's convertible senior notes as part of \"Other liabilities\" (specifically $1 million of notes remaining after $985 million was redeemed), which is consistent with the company's classification of these notes in the purchase price allocation. The notes are included in the Intelligent Cloud segment's goodwill calculation, where $16.3 billion of goodwill was assigned to that segment and primarily attributed to synergies from integrating Nuance. This integration aligns with Microsoft's strategic focus on building industry‑specific cloud offerings within the Intelligent Cloud segment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 78,
          "pages": [
            76,
            77,
            78,
            79,
            80
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 78,
          "pages": [
            76,
            77,
            78,
            79,
            80
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 48477,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12342,
        "completion_tokens": 156,
        "total_tokens": 12498
      }
    },
    {
      "question_id": 46,
      "question": "How does Chevron's $352 goodwill investment in Renewable Energy Group, Inc. relate to its reliance on cost-effective, verifiable carbon credits, given that Renewable Energy Group is a major source of Chevron's carbon credit generation activities?",
      "original_answer": "Chevron's $352 goodwill investment in Renewable Energy Group, Inc. (REG) in the downstream segment reflects its strategic commitment to lower carbon business lines. REG is a key contributor to Chevron's carbon credit generation, which is essential for meeting its climate-related ambitions, including Scope 1 and 2 emissions targets. However, Chevron highlights in its risk factors that achieving these goals is contingent on the availability and acceptability of cost-effective, verifiable carbon credits — a factor that could significantly influence the long-term value of the REG acquisition. This interplay shows how Chevron's downstream goodwill investment is tied to broader ESG and operational risks related to carbon credit markets.",
      "llm_answer": "Chevron’s $352 million goodwill investment in Renewable Energy Group, Inc. reflects the company’s strategy to secure a reliable source of low‑carbon feedstock and carbon‑credit generation, which it relies on to obtain cost‑effective, verifiable carbon credits for its emissions‑reduction programs. This acquisition is highlighted in Note 29 as the primary source of Chevron’s renewable‑fuel carbon‑credit portfolio, supporting its broader climate‑change and ESG initiatives.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 37,
          "pages": [
            35,
            36,
            37,
            38,
            39
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 27,
          "pages": [
            25,
            26,
            27,
            28,
            29
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 86145,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21781,
        "completion_tokens": 118,
        "total_tokens": 21899
      }
    },
    {
      "question_id": 46,
      "question": "How did the change in Alabama's state apportionment methodology impact Southern Power's 2021 net income, and what does this reveal about the financial sensitivity of Southern Company's regulated utilities to state-level tax policy changes?",
      "original_answer": "The change in Alabama's state apportionment methodology, resulting from tax legislation enacted in February 2021, provided a tax benefit that contributed to a $28 million increase in Southern Power's 2021 net income. This reveals that Southern Company's regulated utilities, including Southern Power, are financially sensitive to state-level tax policy changes, particularly those affecting apportionment rules. The fact that Southern Power operates in Alabama—a state that directly influences its tax burden through legislative action—highlights how regulatory environments in specific jurisdictions can materially affect financial outcomes for utility subsidiaries within the Southern Company system.",
      "llm_answer": "The change in Alabama's state apportionment methodology—resulting from tax legislation enacted in February 2021—provided a tax benefit that contributed to Southern Power’s $28 million increase in net income for 2021. This illustrates that Southern Company’s regulated utilities are financially sensitive to state‑level tax policy shifts, as such legislative changes can materially affect earnings through adjustments to income‑tax expense and effective tax rates.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 194,
          "pages": [
            192,
            193,
            194,
            195,
            196
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 67741,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17173,
        "completion_tokens": 115,
        "total_tokens": 17289
      }
    },
    {
      "question_id": 47,
      "question": "How does Morgan Stanley's structuring of CLNs, which embed credit protection risk, relate to its broader credit derivatives risk management practices as evidenced by its use of CDS?",
      "original_answer": "Morgan Stanley structures CLNs as part of its asset-repackaging activities, where credit protection is embedded in these instruments. If a credit event occurs involving a reference entity, the principal balance of the CLN may not be repaid in full to the Firm, exposing it to credit risk (page 109). To manage such exposures, Morgan Stanley actively uses credit derivatives, particularly credit default swaps (CDS), where it either receives or provides protection against default risk on debt obligations. The Firm manages this exposure through risk mitigation strategies, including managing credit and correlation risk across single-name and index-based instruments, and monitors aggregate market risk limits (page 108). This demonstrates that while Morgan Stanley assumes credit risk through structured products like CLNs, it actively offsets this exposure through its CDS portfolio and structured risk management frameworks.",
      "llm_answer": "Morgan Stanley's structuring of Credit-Linked Notes (CLNs) embeds credit protection risk, which is integral to its broader credit derivatives risk management practices. This approach aligns with its use of Credit Default Swaps (CDS), where it both sells protection (e.g., via CDS on referenced assets or indices) and purchases protection to hedge credit exposure, as evidenced by its extensive CDS disclosures, including notional amounts ($368 billion in 2023), maturity profiles, and risk mitigation strategies like diversification across single-name, index, and tranched structures. The Firm manages this risk through collateralized transactions, credit exposure limits, and monitoring of counterparty credit risk, ensuring that embedded risks in structured products like CLNs are consistent with its overall derivatives and credit risk framework.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MS_10k_2024.pdf",
          "target_page": 127,
          "pages": [
            125,
            126,
            127,
            128,
            129
          ]
        },
        "hop_2_rel": {
          "source_file": "MS_10k_2024.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        },
        "hop_3_rel": {
          "source_file": "MS_10k_2024.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 200299,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 50300,
        "completion_tokens": 212,
        "total_tokens": 50513
      }
    },
    {
      "question_id": 47,
      "question": "How does Amgen's $2.8 billion equity investment in BeiGene relate to the commercialization of BLINCYTO in China, and what does this imply about Amgen's strategic approach to oncology market expansion in the region?",
      "original_answer": "Amgen's $2.8 billion equity investment in BeiGene was part of a strategic collaboration aimed at expanding Amgen's oncology presence in China. As part of this arrangement, BeiGene began selling BLINCYTO in China in 2021, with Amgen sharing profits and losses equally during the initial commercialization period. BLINCYTO, an anti-CD19 x anti-CD3 BiTE molecule, represents a key oncology asset being leveraged through this partnership to penetrate the Chinese market. This approach reflects Amgen's broader strategy to utilize local partnerships for market access and shared risk in oncology development and commercialization.",
      "llm_answer": "Amgen's $2.8 billion equity investment in BeiGene was made to expand its oncology footprint in China, and the collaboration gives Amgen a 20.5 % stake with shared development costs and equal profit‑loss sharing for products such as BLINCYTO that are commercialized by BeiGene in the Chinese market. This partnership reflects Amgen’s strategic focus on accelerating market entry and growth in China’s oncology space by leveraging BeiGene’s local expertise and commercial infrastructure.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 28,
          "pages": [
            26,
            27,
            28,
            29,
            30
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 26,
          "pages": [
            24,
            25,
            26,
            27,
            28
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 65670,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16651,
        "completion_tokens": 121,
        "total_tokens": 16773
      }
    },
    {
      "question_id": 47,
      "question": "Given Microsoft's competitive and execution risks in cloud and AI services outlined in the 10-K, how does the rapid growth in Azure's revenue compare to the broader Server Products and Cloud Services segment's reported financial performance, and what does this imply about Microsoft's ability to offset infrastructure costs with revenue gains?",
      "original_answer": "Microsoft highlights in its risk factors that its cloud and AI strategy involves significant infrastructure and development costs that could reduce operating margins. Despite these risks, Azure, a core component of the Server Products and Cloud Services segment, has seen strong revenue growth, with the segment reporting $97.7 billion in revenue for fiscal year 2024, up from $79.97 billion in 2023. This implies that while Microsoft is successfully growing the segment, the sustainability of this growth in the face of rising infrastructure costs and competitive pressures remains a key challenge.",
      "llm_answer": "Microsoft’s Azure revenue is growing at a substantially faster pace than the broader Server Products and Cloud Services segment, which includes Azure plus other server‑related offerings.  In fiscal 2024 the Server Products and Cloud Services line generated $97.7 billion in revenue, up from $79.97 billion in 2023 and $67.35 billion in 2022, while Azure alone contributed a much larger share of that growth, driving the Intelligent Cloud segment’s revenue to $105.4 billion (a 20% increase year‑over‑year).  This rapid Azure expansion is helping Microsoft offset the significant infrastructure and R&D costs required to run its cloud and AI platforms, allowing the company to generate higher operating margins in the Intelligent Cloud segment (operating income of $49.6 billion in 2024) and providing a financial cushion that can be reinvested in further cloud and AI innovation.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 21,
          "pages": [
            19,
            20,
            21,
            22,
            23
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 62854,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15981,
        "completion_tokens": 219,
        "total_tokens": 16201
      }
    },
    {
      "question_id": 47,
      "question": "Given Disney's use of pay-fixed interest rate swaps to convert floating-rate borrowings to fixed-rate obligations, how does the absence of such designated hedges at fiscal year-end 2024 impact the reported effective interest rate on their floating-rate debt, which includes adjustments from existing swaps and purchase accounting?",
      "original_answer": "Disney utilizes pay-fixed interest rate swaps to convert floating-rate borrowings into fixed-rate obligations, but it did not have any such designated cash flow hedges at the end of fiscal 2024. This absence means that no unrealized gains or losses from these instruments were deferred in AOCI to smooth interest expense volatility. Meanwhile, the reported effective interest rate on floating-rate borrowings includes the impact of existing and terminated interest rate swaps, purchase accounting adjustments, and debt issuance premiums or discounts. Without active pay-fixed swaps to stabilize interest costs, the effective rate on floating-rate debt becomes more sensitive to current market conditions, as evidenced by the $0.9 billion market value adjustment for debt with qualifying hedges at September 28, 2024. This dynamic suggests a potentially higher volatility in interest expense going forward.",
      "llm_answer": "The absence of pay‑fixed interest rate swaps that would normally convert floating‑rate borrowings to fixed‑rate obligations means the Company’s floating‑rate debt is not hedged for fair‑value purposes. Consequently, the effective interest rate reported on that debt reflects only the stated floating rates and any purchase‑accounting adjustments, without the offsetting fair‑value hedge adjustments that would otherwise lower the effective rate. This results in a higher reported effective interest rate on the unhedged floating‑rate portion of the Company’s borrowings.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 80082,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20282,
        "completion_tokens": 142,
        "total_tokens": 20424
      }
    },
    {
      "question_id": 47,
      "question": "How does Boeing's increasing reach-forward loss on the Commercial Crew program in 2021 relate to the broader financial risks associated with fixed-price development contracts, particularly in light of the company's exposure to cost overruns and U.S. government contract modifications?",
      "original_answer": "Boeing's increasing reach-forward loss on the Commercial Crew program by $185 million in Q3 2021 was driven by delays and technical challenges, reflecting the inherent risk in fixed-price development contracts. These contracts, such as Commercial Crew, KC-46A, and VC-25B, expose Boeing to significant financial volatility due to the fixed revenue structure and uncertain cost estimates. The company's 2021 financial statements highlight that fixed-price contracts accounted for approximately 68% of BDS revenue, making them a core but risky part of the business model. Furthermore, the U.S. government's right to modify, curtail, or terminate contracts—especially under fiscal constraints or shifting priorities—adds another layer of risk, particularly when programs already face cost overruns and schedule delays. Together, these factors illustrate how Boeing's financial exposure on Commercial Crew is emblematic of broader systemic risks in its fixed-price development portfolio.",
      "llm_answer": "Boeing recorded additional reach‑forward losses on its fixed‑price development contracts—most notably a $402 million increase on the KC‑46A Tanker and a $185 million rise on the Commercial Crew program in 2021—driven by supply‑chain disruptions, COVID‑19 impacts, and evolving technical requirements. These cost overruns illustrate the broader financial risk of fixed‑price contracts, where the company must absorb higher completion costs or face contract modifications that can erode margins, reduce fees, or trigger termination provisions, thereby amplifying overall exposure to cost overruns and U.S. government contract modifications.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 45,
          "pages": [
            43,
            44,
            45,
            46,
            47
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 134,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 54095,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 13778,
        "completion_tokens": 159,
        "total_tokens": 13937
      }
    },
    {
      "question_id": 47,
      "question": "What impact did PowerSecure's $120 million increase in distributed infrastructure revenue have on Southern Company's consolidated financial structure in 2024, particularly in relation to their microgrid deployment activities?",
      "original_answer": "PowerSecure's $120 million increase in distributed infrastructure revenue directly contributed to a $111 million rise in Southern Company's operating revenues for other business activities in 2024. This growth in revenue was accompanied by a corresponding $82 million increase in cost of other sales at PowerSecure, which flowed into Southern Company's consolidated financial statements. As PowerSecure is a consolidated subsidiary that develops and deploys microgrids, this performance reflects the growing contribution of microgrid-related activities to Southern Company's broader financial structure, despite being reported within aggregated subsidiary line items rather than separately disclosed.",
      "llm_answer": "The $120 million rise in PowerSecure’s distributed‑infrastructure revenue was a key driver of the 20 % increase in operating revenue for Southern Company’s “Other Business Activities” segment, contributing to the $111 million boost in total segment revenue reported for 2024. This revenue growth was reflected in the consolidated financial statements as part of the $665 million of operating revenue for the segment and helped offset other declines, supporting the overall financial structure of Southern Company in 2024.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 164,
          "pages": [
            162,
            163,
            164,
            165,
            166
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 69626,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17645,
        "completion_tokens": 130,
        "total_tokens": 17776
      }
    },
    {
      "question_id": 47,
      "question": "How does Amgen's legal strategy against Zydus in the apremilast patent litigation relate to its handling of the Notice of Appeal in the PTAB challenge, particularly in terms of the company's approach to patent defense and appeal timelines?",
      "original_answer": "Amgen's legal strategy against Zydus in the apremilast patent litigation demonstrates a proactive approach to enforcing its patent rights, as evidenced by the final judgment in Amgen's favor on multiple patent claims and the resulting injunction that restricts Zydus from marketing its generic apremilast product until the expiration of the infringed patents. Zydus filed a Notice of Appeal to the Federal Circuit Court with respect to the '638 Patent on October 27, 2021, and Amgen followed with its own notice of appeal the next day, indicating a strong commitment to defending its intellectual property through the appellate process. This aligns with Amgen's response to the Notice of Appeal in the PTAB challenge involving the '138 Patent, where Amgen filed a notice of appeal to the Federal Circuit Court on July 22, 2019, after the PTAB ruled most claims unpatentable. In both cases, Amgen pursued appellate review to preserve its patent rights, despite differing legal venues and procedures—district court litigation for Zydus and PTAB inter partes review for Apotex. The timeline of appeals also shows Amgen's consistent and timely legal response to adverse rulings, reinforcing its broader strategy of robust patent defense.",
      "llm_answer": "Amgen’s legal strategy in the Otezla patent litigation—evidenced by its coordinated use of consent judgments, injunctions, and settlement agreements to block generic entry—mirrors its broader approach to patent defense, which includes aggressively pursuing appeals to extend market protection. In the PTAB challenge involving the '138 Patent, Amgen actively appealed adverse rulings (e.g., the Federal Circuit’s remand after *Arthrex*), demonstrating its willingness to navigate complex appeal timelines to preserve patent strength, even as it simultaneously secures district‑court victories that trigger immediate injunctions against generic competitors.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 145,
          "pages": [
            143,
            144,
            145,
            146,
            147
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 145,
          "pages": [
            143,
            144,
            145,
            146,
            147
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 147,
          "pages": [
            145,
            146,
            147,
            148,
            149
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 87881,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22206,
        "completion_tokens": 163,
        "total_tokens": 22370
      }
    },
    {
      "question_id": 48,
      "question": "Given Alimta's importance in Lilly's oncology portfolio, how does the company's reliance on patent protection for revenue stability align with the anticipated rapid revenue decline from Alimta following the loss of its patent exclusivity in the U.S. and other key markets?",
      "original_answer": "Lilly highlights Alimta as a key oncology product used in multiple treatment regimens for lung cancer and mesothelioma, underscoring its therapeutic significance. However, the company explicitly states that Alimta has recently lost or will soon lose significant patent protection in the U.S. and other key jurisdictions, which is expected to result in rapid and severe revenue declines due to generic competition. This creates a direct tension with Lilly's broader statement that its revenues, cash flows, and earnings depend heavily on products with intellectual property protection. The loss of exclusivity for Alimta, therefore, not only threatens the product’s contribution to the oncology segment but also directly impacts Lilly’s consolidated financial performance, revealing a critical vulnerability in the company’s revenue model despite its strategic emphasis on patent-dependent innovation.",
      "llm_answer": "Lilly's oncology revenue, particularly from Alimta, is heavily dependent on patent protection, and the loss of U.S. and key market exclusivity is expected to trigger a sharp revenue decline. To mitigate this risk, the company emphasizes ongoing innovation in oncology, strategic business development, and the development of new products and indications to replace declining sales from patent-expiring drugs.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "target_page": 25,
          "pages": [
            23,
            24,
            25,
            26,
            27
          ]
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "target_page": 25,
          "pages": [
            23,
            24,
            25,
            26,
            27
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 68921,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17474,
        "completion_tokens": 101,
        "total_tokens": 17576
      }
    },
    {
      "question_id": 48,
      "question": "How does Microsoft's ongoing use of The Bank of New York Mellon as trustee across multiple supplemental indentures, including those governing the 4.20% Notes due 2019, reflect a consistent debt issuance strategy and trustee relationship management approach?",
      "original_answer": "Microsoft has maintained a consistent relationship with The Bank of New York Mellon (BNY Mellon) as trustee across multiple debt issuances, as evidenced by the repeated use of BNY Mellon in indentures dating from 2009 through 2016. Specifically, the 4.20% Notes due 2019 are governed under the First Supplemental Indenture dated May 18, 2009, between Microsoft and BNY Mellon. This foundational relationship was extended through subsequent supplemental indentures (e.g., Eighth, Ninth, and Tenth Supplemental Indentures) covering various note issuances, including those in 2013, 2015, and 2016. The consistent use of BNY Mellon as trustee across these different debt instruments and time periods suggests a strategic decision to maintain continuity, trust, and operational efficiency in Microsoft’s debt governance and issuance framework.",
      "llm_answer": "Microsoft's consistent use of The Bank of New York Mellon as trustee across multiple supplemental indentures—including those governing the 4.20% Notes due 2019—reflects a deliberate, long-term debt issuance strategy that leverages a single, established trustee relationship to streamline bond administration, ensure regulatory continuity, and reinforce trust in its capital markets execution. This approach underscores Microsoft’s disciplined and institutionalized method of managing trustee relationships to support scalable, multi-tranche debt offerings over time.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 50013,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12743,
        "completion_tokens": 141,
        "total_tokens": 12885
      }
    },
    {
      "question_id": 48,
      "question": "Given the non-dilutable 33 1/3% voting power of Class B common stock and its share-for-share conversion right into Class A shares, how does the minimal issuance of Class B stock (only 9.4 million shares outstanding) impact corporate governance dynamics relative to the $82.7 billion in total equity attributed to Class A shareholders?",
      "original_answer": "The corporate governance dynamics are significantly shaped by the dual-class structure. Despite only 9.4 million Class B shares being outstanding, they retain 33 1/3% of the total voting power, which cannot be diluted by additional Class A issuances. Each Class B share has 15 votes, giving this small group disproportionate influence over major corporate decisions. This concentrated voting power contrasts sharply with the equity distribution, where Class A shareholders hold the entirety of the $82.7 billion in reported equity value with no Class B equity contribution. As a result, a small group of Class B shareholders maintains outsized control over governance matters despite representing a negligible portion of the capital structure.",
      "llm_answer": "The 33 ⅓ % voting power of Class B shares—held by just 9.4 million shares—remains non‑dilutable even as the company issues new equity, preserving a concentrated block of control. Because this minority block carries roughly one‑third of all voting rights while the remaining two‑thirds are held by Class A shareholders (who collectively represent $82.7 billion in equity), corporate governance is effectively split: the Class B holders can block or influence key decisions despite their relatively small equity stake, whereas the vast majority of shareholders’ economic interest is carried by Class A owners. This structure allows a small group to exert disproportionate influence over governance matters compared with its modest share of total equity.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 1,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 60727,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15446,
        "completion_tokens": 187,
        "total_tokens": 15634
      }
    },
    {
      "question_id": 48,
      "question": "Given UPS's reliance on net asset value (NAV) to estimate the fair value of its U.S. pension plan investments, how does the subjective nature of NAV estimation specifically impact the reported value of private debt investments, which are not actively traded and have unfunded commitments totaling $3.3 billion?",
      "original_answer": "UPS estimates the fair value of its U.S. pension plan investments, including private debt, using the net asset value (NAV) provided by fund managers, adjusted for activity between reporting periods. This estimation is inherently subjective due to the lack of active trading and reliance on unaudited or delayed audited reports. The private debt investments, valued at $829 million as of December 31, 2023, are subject to this NAV-based valuation methodology. Given that these investments have unfunded commitments totaling $3.3 billion, the subjective adjustments made in estimating NAV could significantly affect both the current valuation and future funding expectations. This raises concerns about the accuracy and reliability of these values, especially since they are not actively traded and are difficult to independently verify.",
      "llm_answer": "The reliance on net asset value (NAV) to estimate the fair value of UPS’s U.S. pension plan investments introduces subjectivity, particularly for private debt investments that are not actively traded. Because these investments lack observable market prices, their valuations depend on unobservable inputs and management estimates, leading to potential variability in reported values. Additionally, unfunded commitments totaling $3.3 billion must be considered, as they reflect future capital outlays that could affect the ultimate fair‑value measurement of these private‑debt assets.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 63,
          "pages": [
            61,
            62,
            63,
            64,
            65
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 73723,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18687,
        "completion_tokens": 145,
        "total_tokens": 18833
      }
    },
    {
      "question_id": 48,
      "question": "How does Abbott Laboratories' treatment of 'awards to non-employee directors' under the 2017 Incentive Stock Program reflect the legacy structure and share reallocation provisions of the earlier 2009 Incentive Stock Program?",
      "original_answer": "Abbott Laboratories includes 'awards to non-employee directors' as one of the benefit types under the 2017 Incentive Stock Program, which is disclosed on page 84. This program allows for the use of both authorized but unissued shares and treasury shares for these awards, with restricted stock specifically sourced from treasury shares. The 2009 Incentive Stock Program, introduced on page 83, originally included the same category of awards and specified that shares not issued due to lapses, expirations, or cancellations could be reallocated for new awards under the 2017 Program. This indicates that the 2017 Program builds upon the structure of the 2009 Program by continuing to include non-employee director awards and by enabling the reuse of unutilized shares, reflecting a strategic continuity in equity compensation design and resource optimization.",
      "llm_answer": "Abbott's 2017 Incentive Stock Program explicitly reallocates shares previously reserved under the 2009 Program when awards lapse, expire, or are forfeited without share issuance or cash payment, allowing those shares to be used for new awards under the 2017 Program. This reallocation mechanism directly continues the legacy structure of the 2009 Program while enabling the 2017 Program to absorb unused shares from the earlier plan. The document confirms that the 2009 Program was replaced in April 2017 with no further awards granted under it, and its reacquired shares are now available for the 2017 Program's benefits, including awards to non-employee directors.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "ABT_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_2_rel": {
          "source_file": "ABT_10k_2024.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        },
        "hop_3_rel": {
          "source_file": "ABT_10k_2024.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 75456,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19093,
        "completion_tokens": 166,
        "total_tokens": 19259
      }
    },
    {
      "question_id": 48,
      "question": "How does PayPal's reliance on two third-party custodians for safeguarding over $X billion in customer cryptocurrency assets reconcile with the acknowledged risk of custodial bankruptcy potentially treating those assets as part of the custodian's estate?",
      "original_answer": "PayPal utilizes two third-party custodians to hold customer cryptocurrency assets, which exposes the company to concentration risk if these custodians fail to perform as agreed (page 83). These custodians are responsible for securing crypto assets like Bitcoin and Ethereum, which PayPal holds on behalf of its customers. However, in the event of a custodian’s bankruptcy, there is legal uncertainty about whether those assets would be treated as part of the custodian’s estate, potentially leaving PayPal and its customers with unsecured claims and significant losses (page 20). Despite contractual provisions requiring segregation of customer assets, the lack of legal precedent increases the risk that these assets may not be recoverable in full, which could materially harm PayPal’s financial performance and reputation.",
      "llm_answer": "PayPal acknowledges that its cryptocurrency assets held for customers are safeguarded by third‑party custodians, creating a concentration risk: if a custodian becomes insolvent or enters bankruptcy, the assets could be treated as part of the custodian’s estate, potentially limiting the company’s ability to recover them for customers. This risk is highlighted alongside the company’s recognition of the unique technological, legal and regulatory challenges associated with cryptocurrency custody.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PYPL_10k_2023.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        },
        "hop_2_rel": {
          "source_file": "PYPL_10k_2023.pdf",
          "target_page": 20,
          "pages": [
            18,
            19,
            20,
            21,
            22
          ]
        },
        "hop_3_rel": {
          "source_file": "PYPL_10k_2023.pdf",
          "target_page": 20,
          "pages": [
            18,
            19,
            20,
            21,
            22
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 88030,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22248,
        "completion_tokens": 124,
        "total_tokens": 22372
      }
    },
    {
      "question_id": 48,
      "question": "How does PM's 17.3% increase in cigarette shipments in Turkey align with the company's concerns about rising illicit trade, given Turkey's 8.2% total market growth driven by easing pandemic restrictions but partially offset by higher illicit trade prevalence?",
      "original_answer": "PM reported a 17.3% increase in cigarette shipments in Turkey, with its market share rising from 41.3% to 44.8%. This growth occurred despite acknowledging that Turkey's total market expanded by 8.2%, partly due to easing pandemic restrictions and increased in-bound tourism. However, the company also noted that this growth was partially offset by a higher estimated prevalence of illicit trade. This suggests that while PM successfully outperformed the overall market growth, the presence of illicit trade remains a concern that could potentially limit its market share expansion or profitability in the region.",
      "llm_answer": "The 17.3% increase in PMI’s cigarette shipments in Turkey aligns with the company’s concerns about rising illicit trade, as Turkey’s total market grew by 8.2% due to eased pandemic restrictions but was partially offset by higher illicit trade prevalence; despite this growth, PMI’s shipment volume in Turkey rose to 55.7 billion units (up from 47.5 billion in 2020), reflecting its strategy to capture market share in a market where illicit trade remains a challenge, even as the broader market expansion is tempered by regulatory and illicit activity pressures.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PM_10k_2022.pdf",
          "target_page": 40,
          "pages": [
            38,
            39,
            40,
            41,
            42
          ]
        },
        "hop_2_rel": {
          "source_file": "PM_10k_2022.pdf",
          "target_page": 56,
          "pages": [
            54,
            55,
            56,
            57,
            58
          ]
        },
        "hop_3_rel": {
          "source_file": "PM_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 70375,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17837,
        "completion_tokens": 140,
        "total_tokens": 17978
      }
    },
    {
      "question_id": 49,
      "question": "How does the $35 million in appeal bonds posted by PM USA relate to its unconditional guarantee of Altria's $1.0 billion in senior notes issued in November 2023, particularly in terms of financial exposure and collateralization requirements?",
      "original_answer": "The $35 million in appeal bonds posted by PM USA on page 92 represents security provided to obtain stays of adverse litigation judgments pending appeal. These bonds are collateralized with restricted cash and appear on the consolidated balance sheet as assets. On page 74, PM USA is described as a guarantor of Altria's outstanding debt securities, including the $1.0 billion in senior notes issued in November 2023. The guarantee is unconditional and requires PM USA to ensure payment of Altria's obligations, regardless of the validity or enforceability of the underlying debt agreements. Both the appeal bonds and the debt guarantees expose PM USA to significant financial obligations, with the appeal bonds already collateralized and the debt guarantees potentially triggering similar collateral requirements in the event of default or financial stress.",
      "llm_answer": "The $35 million of appeal bonds posted by PM USA serves as collateral to secure the $1 billion of senior notes that Altria issued in November 2023; the bonds are required to stay the enforcement of judgments while appeals are pending, and their collateralization (restricted cash) is recorded as an asset on the consolidated balance sheet, thereby limiting the financial exposure associated with those notes.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 92,
          "pages": [
            90,
            91,
            92,
            93,
            94
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 83718,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21171,
        "completion_tokens": 102,
        "total_tokens": 21273
      }
    },
    {
      "question_id": 49,
      "question": "How does ConocoPhillips' 30% stake in Qatargas Operating Company Limited, which produced 13 MBD of crude oil in 2021, align with their total reported crude oil production of 8 MBD for the same year, and what does this imply about the company's upstream production structure?",
      "original_answer": "ConocoPhillips' total crude oil production of 8 MBD in 2021 includes its share from the QG3 project operated by Qatargas Operating Company Limited, in which COP holds a 30% stake. The QG3 project alone contributed 13 MBD of crude oil production, indicating that COP's net share of this production is proportionally less (30% of 13 MBD ≈ 3.9 MBD), and this stake-based contribution is incorporated into the broader crude oil production figure of 8 MBD. This suggests that COP's upstream production is composed of multiple assets, with the QG3 project being a significant but partial contributor. The remaining crude oil production must come from other projects where COP has a larger or full ownership stake, highlighting a diversified upstream portfolio.",
      "llm_answer": "ConocoPhillips' 30% stake in Qatargas Operating Company Limited, which produced 13 MBD of crude oil in 2021, does not align with the company’s reported consolidated crude‑oil production of 8 MBD for the same year because that 8 MBD figure reflects only ConocoPhillips’ net share of production from its own operated assets (e.g., Alaska, Lower 48, Canada, Norway, etc.), not the output of its equity‑method investments such as Qatargas. Consequently, the company’s upstream production structure is diversified across multiple segments and joint‑venture interests, meaning total reported production represents only the portion it directly operates or consolidates, while a significant share of global output comes from equity‑accounted affiliates like Qatargas.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 50,
          "pages": [
            48,
            49,
            50,
            51,
            52
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 51474,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 13114,
        "completion_tokens": 189,
        "total_tokens": 13303
      }
    },
    {
      "question_id": 49,
      "question": "How does Microsoft's ongoing relationship with BNY Mellon as trustee for multiple note issuances, including the 5.20% Notes due 2039, reflect its broader capital structure management strategy across different debt instruments?",
      "original_answer": "Microsoft has consistently engaged BNY Mellon as trustee across multiple debt issuances, including the 5.20% Notes due 2039, as evidenced by the repeated appearance of BNY Mellon in various supplemental indentures dating back to 2009. This long-standing relationship, documented in filings related to notes with maturities ranging from 2018 to 2056, indicates a deliberate and consistent approach to debt governance. The inclusion of the 5.20% Notes due 2039 within this framework highlights Microsoft's use of long-dated instruments to support long-term capital commitments. The repeated use of the same base indenture and trustee across different interest rate environments and maturity profiles suggests a centralized, standardized approach to managing corporate debt obligations.",
      "llm_answer": "Microsoft's long‑standing relationship with BNY Mellon as trustee for multiple note issuances—including the 5.20% Notes due 2039—illustrates its disciplined capital‑structure strategy of leveraging a single, highly rated trustee to issue and manage a broad suite of senior unsecured debt across varying maturities and coupon structures. By consistently using BNY Mellon for these supplemental indentures, Microsoft can efficiently access diverse funding markets, maintain consistent legal documentation, and streamline the administration of its debt portfolio, supporting a stable and flexible financing framework that underpins its overall balance‑sheet management.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 50013,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12736,
        "completion_tokens": 166,
        "total_tokens": 12902
      }
    },
    {
      "question_id": 49,
      "question": "How does AT&T's continued depreciation of wireless tower assets combined with its future minimum payments to Crown Castle reflect on the company's long-term financial strategy for its tower infrastructure?",
      "original_answer": "AT&T's decision to continue depreciating the wireless tower assets ($725 million at the end of 2021) despite the 2013 transaction with Crown Castle indicates that it did not achieve sale-leaseback accounting treatment, meaning the towers remain on AT&T's balance sheet as Property, Plant and Equipment. This contrasts with the sublease arrangement where AT&T is contractually obligated to make significant future minimum payments—$258 million in 2022 alone, rising to $280 million in 2026, and totaling $707 million thereafter. These payments represent a long-term financial commitment to Crown Castle for continued access to the towers. The combination of ongoing depreciation and escalating sublease payments suggests that AT&T retains both the asset liability and recurring cost structure of tower infrastructure, rather than fully monetizing or divesting its tower assets. This reflects a strategy of maintaining control over critical network infrastructure while outsourcing operational management, balancing capital efficiency with long-term operational flexibility.",
      "llm_answer": "AT&T's continued depreciation of wireless tower assets alongside its ongoing minimum lease payments to Crown Castle reflects a long-term strategy of retaining ownership of the underlying tower infrastructure while monetizing its economic value through structured financing arrangements. The company maintains the tower assets on its balance sheet and depreciates them over time, even as it continues to make contractual payments to Crown Castle under the 2013 transaction—future minimum payments of $258 in 2022, $264 in 2023, $269 in 2024, $274 in 2025, $280 in 2026, and $707 thereafter—demonstrating a sustained commitment to this hybrid ownership and lease model to support its wireless infrastructure economics.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "T_10k_2022.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        },
        "hop_2_rel": {
          "source_file": "T_10k_2022.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        },
        "hop_3_rel": {
          "source_file": "T_10k_2022.pdf",
          "target_page": 133,
          "pages": [
            131,
            132,
            133,
            134,
            135
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 65700,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16650,
        "completion_tokens": 179,
        "total_tokens": 16829
      }
    },
    {
      "question_id": 49,
      "question": "How does Duke Energy's accounting treatment of unrealized losses on AFS debt investments held in the Investment Trusts compare with the realized gains and losses disclosed for AFS debt investments across Duke Energy Florida and Indiana?",
      "original_answer": "Duke Energy applies different accounting treatments for AFS debt investments depending on their structure and ownership. For AFS debt investments held in the Investment Trusts (managed externally), the company immediately recognizes all unrealized losses in earnings due to lack of control over investment decisions, as noted on page 184. However, for AFS debt investments held by Duke Energy Florida and Indiana, the company disclosed that realized gains and losses during 2023 were immaterial (page 187). This highlights a contrast in how unrealized losses are treated based on management control, versus the actual realized outcomes which are reported as immaterial in practice.",
      "llm_answer": "Duke Energy records unrealized losses on AFS debt investments held in the Investment Trusts immediately in earnings and then defers the loss to a regulatory asset, whereas realized gains and losses on AFS debt investments for Duke Energy Florida and Indiana are reported in earnings when realized and are not deferred.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 184,
          "pages": [
            182,
            183,
            184,
            185,
            186
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 186,
          "pages": [
            184,
            185,
            186,
            187,
            188
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 187,
          "pages": [
            185,
            186,
            187,
            188,
            189
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 105758,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 26675,
        "completion_tokens": 79,
        "total_tokens": 26755
      }
    },
    {
      "question_id": 50,
      "question": "How should we interpret MET's $92.5 billion mortgage loan portfolio in light of the $1.1 billion unrealized losses in their pass-through mortgage-backed securities, given the direct link between mortgage loans and the performance of these securities?",
      "original_answer": "MET reports its mortgage loans at a carrying value of $92.5 billion on page 320, indicating a significant exposure to direct mortgage assets. These mortgage loans serve as the underlying collateral for pass-through mortgage-backed securities, as explained on page 97, where cash flows from homeowners are passed through intermediaries to investors. On page 98, MET discloses $12.4 billion in estimated fair value for pass-through mortgage-backed securities, which carry $1.1 billion in unrealized losses. The presence of these losses suggests that the performance of the underlying mortgage loans—many of which are likely included in MET's $92.5 billion portfolio—has deteriorated, impacting the fair value of the associated securities. This dynamic highlights a direct financial risk: as the originator and holder of the loans and the issuer of the securities, MET is exposed both to credit losses on the loans themselves and to valuation declines in the structured products backed by those loans.",
      "llm_answer": "The $92.5 billion mortgage‑loan portfolio is the underlying collateral for the $1.1 billion of unrealized losses recorded on MetLife’s pass‑through mortgage‑backed securities; the securities’ performance is directly tied to the cash‑flow quality and credit experience of those mortgage loans, so the size of the loan portfolio amplifies the potential for further losses if loan defaults or credit deterioration rise.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 320,
          "pages": [
            318,
            319,
            320,
            321,
            322
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 98,
          "pages": [
            96,
            97,
            98,
            99,
            100
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 78442,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19852,
        "completion_tokens": 104,
        "total_tokens": 19956
      }
    },
    {
      "question_id": 50,
      "question": "How does the non-dilutable voting power of Class B common stock, which represents 33 1/3% of combined voting power and is beneficially owned entirely by Brian L. Roberts, influence the governance dynamics of CMCSA in light of the dividend increase approved by the Board of Directors for Class A common stock in January 2022?",
      "original_answer": "The governance dynamics of CMCSA are significantly influenced by the non-dilutable 33 1/3% voting power held by Class B common stock, which is entirely owned by Brian L. Roberts. This structure gives Roberts outsized influence over key corporate decisions, including mergers, asset sales, and amendments to the company’s charter, even if such decisions are approved by the Board or other shareholders. In January 2022, the Board approved an 8% increase in the dividend for Class A common stock, which is held by public investors and carries only 66 2/3% of the combined voting power. While Class A shareholders benefit from dividend increases, they hold less voting control, creating a governance imbalance where Roberts can effectively block or approve major decisions regardless of broader shareholder sentiment. This dynamic suggests that while dividend policy may reflect Board alignment with Class A shareholders, strategic and structural decisions remain heavily influenced by Roberts’ control through Class B shares.",
      "llm_answer": "The non‑dilutable 33 ⅓ % voting power held by Class B shares—entirely owned by Brian L. Roberts—means that even though Class A shareholders own roughly two‑thirds of the equity, they control only about 66 ⅔ % of the total voting strength. This concentrated control lets Roberts effectively steer major corporate decisions (e.g., director elections, mergers, charter amendments) despite the Board’s dividend increase for Class A shares in January 2022, ensuring that the dividend policy can be shaped by a single insider’s voting dominance.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 12,
        "total_chars": 50822,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12962,
        "completion_tokens": 134,
        "total_tokens": 13097
      }
    },
    {
      "question_id": 50,
      "question": "How does Pfizer's reliance on BioNTech for Comirnaty supply agreements, including the amended EU contract through 2026, intersect with the legal risks from patent infringement claims against Comirnaty in both the U.S. and Europe, particularly given the revenue significance of Comirnaty in key international markets?",
      "original_answer": "Pfizer's reliance on BioNTech for Comirnaty supply agreements, including the amended EU contract through 2026, creates a critical dependency on a jointly developed product that is now facing multiple patent infringement lawsuits in both the U.S. and Europe. This legal exposure—such as the April 2024 U.S. lawsuit by GSK Group over five patents (later amended to include three more) and the January 2025 European suit by Promosome in France, Germany, and Sweden—poses a material risk to Comirnaty's continued revenue generation. Given that Comirnaty has contributed significantly to Pfizer’s international revenue (with China representing 4% of total revenues in 2024 and the EU historically being a major market), any disruption from litigation could impact both delivery commitments under the EU agreement and profitability in key developed markets.",
      "llm_answer": "Pfizer’s Comirnaty revenue—representing roughly $5.3 billion (≈ 8 % of total 2024 revenue) and a key driver in its international markets—is under legal pressure from multiple patent‑infringement suits in both the United States and Europe (e.g., actions by Alnylam, Moderna, Arbutus, GSK, and others). These claims challenge the vaccine’s patent coverage and could result in damages, injunctions, or royalty payments that would affect future earnings. At the same time, Pfizer relies on BioNTech under an amended EU supply agreement that runs through 2026 to secure Comirnaty doses, meaning any adverse ruling could disrupt its ability to meet contractual delivery obligations and further erode the vaccine’s revenue stream in those markets.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PFE_10k_2024.pdf",
          "target_page": 107,
          "pages": [
            105,
            106,
            107,
            108,
            109
          ]
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2024.pdf",
          "target_page": 101,
          "pages": [
            99,
            100,
            101,
            102,
            103
          ]
        },
        "hop_3_rel": {
          "source_file": "PFE_10k_2024.pdf",
          "target_page": 101,
          "pages": [
            99,
            100,
            101,
            102,
            103
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 129283,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 32579,
        "completion_tokens": 185,
        "total_tokens": 32764
      }
    },
    {
      "question_id": 50,
      "question": "How does Schwab's compliance with net capital requirements for TD Ameritrade constrain its ability to allocate capital toward technology infrastructure investments associated with the integration of TD Ameritrade?",
      "original_answer": "Schwab's broker-dealer subsidiary, TD Ameritrade, is subject to the SEC's Uniform Net Capital Rule, which restricts payments such as dividends, unsecured loans, or repayment of subordinated borrowings if net capital falls below prescribed thresholds (page 123). At the same time, Schwab has been actively investing in technology infrastructure to support the integration of TD Ameritrade, including capital expenditures in 2022 and 2023 for software development and hardware enhancements (page 47). Because TD Ameritrade must remain in compliance with its net capital requirements, Schwab cannot freely divert capital from this entity to fund integration initiatives, creating a tension between regulatory liquidity constraints and strategic investment needs.",
      "llm_answer": "Schwab’s compliance with net‑capital requirements for TD Ameritrade limits how much of its capital can be used for technology‑infrastructure spending tied to the TD Ameritrade integration, as the broker‑dealer subsidiaries must maintain minimum net‑capital levels (e.g., CS&Co’s net capital of $5.6 bn and TD Ameritrade, Inc.’s $0.44 bn) and cannot make dividend, loan or repayment actions that would drop net capital below the required thresholds. Consequently, funds earmarked for integration‑related technology investments must be preserved to keep these subsidiaries safely above the 5 % of aggregate debit balances or 120 % of the minimum dollar requirement, constraining the amount of capital available for such projects.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SCHW_10k_2023.pdf",
          "target_page": 123,
          "pages": [
            121,
            122,
            123,
            124,
            125
          ]
        },
        "hop_2_rel": {
          "source_file": "SCHW_10k_2023.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_3_rel": {
          "source_file": "SCHW_10k_2023.pdf",
          "target_page": 47,
          "pages": [
            45,
            46,
            47,
            48,
            49
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 84418,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21341,
        "completion_tokens": 181,
        "total_tokens": 21523
      }
    },
    {
      "question_id": 50,
      "question": "How does Chevron's 2023 reserve revision decrease of 107 million BOE at TCO in Kazakhstan reconcile with the significant capital expenditures of $2.5 billion in Asia, primarily for TCO's development projects?",
      "original_answer": "Chevron reported a reserve revision decrease of 107 million BOE at TCO in Kazakhstan due to performance-driven reservoir model changes (page 108). Despite this reduction, the company invested approximately $2.5 billion in Asia, primarily for TCO's development projects (page 109). This apparent contradiction is explained by TCO's ongoing major development initiatives, such as the Future Growth Project (FGP) and Wellhead Pressure Management Project (WPMP), which are expected to ramp up production starting in 2025 (page 16). These projects have already led to the recognition of proved reserves, suggesting that Chevron's continued investment is aimed at future reserve growth and production capacity, even in the face of short-term reserve revisions.",
      "llm_answer": "Chevron's 2023 reserve revision decrease of 107 million BOE at TCO in Kazakhstan was largely offset by the $2.5 billion of capital expenditures allocated to Asia, which were directed toward development projects at TCO that ultimately added proved reserves to developed categories and supported ongoing production.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 104306,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 26308,
        "completion_tokens": 78,
        "total_tokens": 26386
      }
    },
    {
      "question_id": 51,
      "question": "How does the change in fair value of the contingent consideration for Clif Bar from the acquisition date estimate of $440 million to $548 million as of December 31, 2023, reflect the reliance on significant unobservable inputs (Level 3) in MDLZ's financial reporting?",
      "original_answer": "The fair value of the contingent consideration for Clif Bar increased from $440 million at the acquisition date to $548 million as of December 31, 2023. This change reflects the ongoing reliance on significant unobservable inputs (Level 3) in MDLZ's financial reporting, as the liability is entirely categorized under Level 3 of the fair value hierarchy. The valuation methodology, which includes financial projections for net revenue, gross profit, and EBITDA, along with discount and volatility rates, indicates that the updated estimate is based on internal assumptions rather than observable market data. This highlights the inherent uncertainty in forecasting future performance metrics for Clif Bar and the sensitivity of the contingent consideration to these assumptions.",
      "llm_answer": "The $108 million increase in the fair‑value of Clif Bar’s contingent consideration—from the $440 million estimate at acquisition to $548 million as of 31 Dec 2023—arises from subsequent fair‑value adjustments that incorporate significant unobservable inputs (Level 3). These adjustments reflect updated assumptions about future revenue, EBITDA, discount rates and volatility, which are inherently subjective and cannot be verified from observable market prices, thereby illustrating the reliance on Level 3 inputs in MDLZ’s financial reporting.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2023.pdf",
          "target_page": 80,
          "pages": [
            78,
            79,
            80,
            81,
            82
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2023.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2023.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 69414,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17598,
        "completion_tokens": 136,
        "total_tokens": 17734
      }
    },
    {
      "question_id": 51,
      "question": "What does Merck's different branding and regulatory focus of its pneumococcal vaccine as Vaxneuvance in the U.S. and EU, versus V114 in Japan, reveal about its geographic strategy in adult pneumococcal vaccine markets?",
      "original_answer": "Merck's decision to brand its pneumococcal vaccine as Vaxneuvance in the U.S. and EU, where it received approvals in July 2021 and December 2021 respectively, and as V114 in Japan, where it is still under regulatory review, indicates a strategy of prioritizing established, high-volume markets first. The U.S. and EU approvals are significant given their size and regulatory influence, while Japan represents a later-stage opportunity. This phased approach suggests Merck is leveraging the vaccine's advanced development status and initial commercial success in major markets before expanding into other regions like Japan, which often requires additional localized data and regulatory processes.",
      "llm_answer": "Merck’s decision to brand its pneumococcal vaccine as Vaxneuvance in the U.S. and EU while using the name V114 in Japan reflects a geographic‑specific market strategy that tailors branding, regulatory positioning and launch timing to local competitive and reimbursement environments. This differentiated naming and regulatory focus enables Merck to align its product messaging with regional expectations, optimize pricing and reimbursement pathways, and coordinate distinct clinical‑trial and approval strategies for each market.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 25,
          "pages": [
            23,
            24,
            25,
            26,
            27
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 21,
          "pages": [
            19,
            20,
            21,
            22,
            23
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 76469,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19352,
        "completion_tokens": 132,
        "total_tokens": 19484
      }
    },
    {
      "question_id": 51,
      "question": "How does the change in fair value of the contingent consideration for Clif Bar from the acquisition date estimate of $440 million to $548 million as of December 31, 2023, reflect the reliance on significant unobservable inputs (Level 3) in MDLZ's financial reporting?",
      "original_answer": "The fair value of the contingent consideration for Clif Bar increased from $440 million at the acquisition date to $548 million as of December 31, 2023. This change reflects the ongoing reliance on significant unobservable inputs (Level 3) in MDLZ's financial reporting, as the liability is entirely categorized under Level 3 of the fair value hierarchy. The increase suggests that the financial projections for net revenue, gross profit, and EBITDA, which are key assumptions in the valuation model, have evolved over time, likely due to updated expectations about Clif Bar's performance relative to the revenue and earnings targets set in the contingent payment agreement.",
      "llm_answer": "The contingent consideration liability for Clif Bar was initially recorded at a fair value of $440 million on the acquisition date, but by December 31 2023 it had increased to $548 million. This increase reflects the use of significant unobservable inputs—such as management’s forecasts of future revenue, profit, and EBITDA, as well as discount and volatility rates—required in the Monte Carlo simulation that estimated the liability’s fair value, classifying it as a Level 3 measurement in MDLZ’s financial reporting.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2023.pdf",
          "target_page": 80,
          "pages": [
            78,
            79,
            80,
            81,
            82
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2023.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2023.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 69414,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17598,
        "completion_tokens": 129,
        "total_tokens": 17728
      }
    },
    {
      "question_id": 52,
      "question": "How does ConocoPhillips' long-term contractual commitment to LNG exports through APLNG reconcile with the financial revaluation of their investment, and what does this indicate about their strategic confidence in CBM production scalability in Queensland?",
      "original_answer": "ConocoPhillips has a long-term strategic commitment to the APLNG joint venture, which is focused on producing coalbed methane (CBM) from the Bowen and Surat basins in Queensland, Australia. This CBM is converted into LNG and sold under 20-year agreements with Sinopec (7.6 MTPA) and Kansai Electric Power Co., Inc. (1 MTPA), indicating a strong forward-looking strategy tied to the scalability of CBM production, with approximately 3,500 net wells expected to supply both LNG contracts and the domestic gas market. However, in 2021, ConocoPhillips recorded a before-tax charge of $688 million to write down its investment in APLNG to fair value after Origin Energy’s sale of a 10% interest revealed a market valuation lower than the carrying value. This revaluation suggests that market participants viewed APLNG’s fair value as below the company’s internal assessment. Despite this financial revaluation, ConocoPhillips exercised its preemption right to acquire an additional 10% stake, signaling continued strategic confidence in the long-term value of CBM production and the LNG export infrastructure. This indicates that the company prioritizes operational scale and long-term contractual revenue visibility over short-term market valuations.",
      "llm_answer": "ConocoPhillips' long‑term APLNG export contracts are reflected in the $312 million contingent consideration recorded for the Surmont acquisition, which is based on a projected commodity price outlook that underpins the valuation of its LNG investment. This financial revaluation shows that the company expects its CBM‑derived LNG volumes to grow sufficiently to meet those contractual commitments, indicating confidence in the scalability of Queensland’s coal‑bed methane production to support expanding LNG exports.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 3,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 63237,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16055,
        "completion_tokens": 129,
        "total_tokens": 16184
      }
    },
    {
      "question_id": 52,
      "question": "How does MetLife's positioning of Accident & Health Insurance as a core product offering align with the relatively low adjusted earnings contribution from the EMEA segment in 2023, despite both being emphasized in different sections of the 10-K?",
      "original_answer": "MetLife highlights Accident & Health Insurance as a core product offering in its major products table, indicating its strategic importance across global markets. This product line is explicitly stated to be offered in the EMEA region, suggesting that EMEA should be a key contributor to its performance in that geography. However, the EMEA segment reported only $265 million in adjusted earnings for 2023, significantly lower than other geographic segments like Group Benefits ($1,655 million) and Asia ($1,282 million). This discrepancy raises questions about whether the Accident & Health Insurance line, while globally positioned, may be underperforming in the EMEA region due to market-specific challenges such as regulatory constraints, competitive pressures, or lower penetration, which are not explicitly detailed but implied through the earnings gap.",
      "llm_answer": "The 10-K presents Accident & Health Insurance as a core product within the Group Benefits, RIS, Asia, Latin America and EMEA segments, emphasizing its strategic importance across multiple regions. However, the EMEA segment's adjusted earnings contribution remains relatively low (only $249 million in 2023, or 4% of total adjusted earnings), reflecting its smaller scale and more niche focus compared with the broader, higher‑margin offerings highlighted elsewhere in the filing. This disparity arises because while Accident & Health is repeatedly underscored as a key growth driver in the segment descriptions, the EMEA business generates modest profitability, so its earnings impact is disproportionately small relative to the emphasis placed on the product line.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 169,
          "pages": [
            167,
            168,
            169,
            170,
            171
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 85722,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21674,
        "completion_tokens": 191,
        "total_tokens": 21866
      }
    },
    {
      "question_id": 52,
      "question": "How does FedEx's exposure to potential reductions in USPS service commitments, which are tied to air network reliance, affect its long-lived asset strategy for aircraft depreciation and fleet flexibility as disclosed in the financial statements?",
      "original_answer": "FedEx's exposure to reductions in USPS service commitments—specifically the strategic shift by USPS to reduce reliance on FedEx Express's air network—poses a risk to FedEx's revenue and profitability as noted in the risk factors. This risk is directly tied to FedEx's asset strategy, where 55% of owned assets are invested in transportation infrastructure, including a global air fleet of 696 aircraft. FedEx's depreciation policy for aircraft, which assumes little to no salvage value due to cargo configuration wear, is sensitive to changes in business levels and utilization. Given that FedEx operates an integrated global network where aircraft are interchangeable to maintain service commitments, a reduction in USPS volume could force underutilization of aircraft, accelerating depreciation or impairments, and impacting the company's ability to align fleet size with demand while maintaining flexibility across geographies.",
      "llm_answer": "FedEx’s long‑lived‑asset strategy must accommodate the possibility that the USPS could cut back on its air‑service contracts, which would reduce the volume of aircraft‑related revenue and could leave excess capacity. Because the company depreciates its aircraft over long useful lives (often 15‑30 years with little or no residual value) and must commit to fleet purchases years in advance, any slowdown in USPS demand forces FedEx to reassess whether it has over‑invested in planes. If demand falls, the company could face under‑utilized aircraft, lower utilization rates, and potentially higher depreciation expense or write‑downs, prompting it to adjust fleet planning, accelerate retirements, or seek additional revenue streams to preserve the economics of its long‑term capital investments.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "FDX_10k_2022.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_2_rel": {
          "source_file": "FDX_10k_2022.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_3_rel": {
          "source_file": "FDX_10k_2022.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 84571,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21381,
        "completion_tokens": 198,
        "total_tokens": 21580
      }
    },
    {
      "question_id": 52,
      "question": "How does ConocoPhillips' reliance on DeGolyer and MacNaughton to review over 85% of its proved reserves estimation processes align with the inclusion of D&M's report as Exhibit 99, and what does this imply about the company's approach to external validation of its reserves estimates?",
      "original_answer": "ConocoPhillips utilizes DeGolyer and MacNaughton (D&M), a third-party petroleum engineering consulting firm, as part of its internal control process to validate the adequacy and effectiveness of its reserves estimation processes. During 2024, D&M reviewed over 85% of the company's proved reserves, assessing whether these processes align with SEC regulations. The company presented detailed technical and economic data to D&M, including seismic information, reservoir simulation models, and production tests, to support its reserves estimation methods. D&M concluded that the processes used by ConocoPhillips were in accordance with SEC reserves definitions. This external validation is further substantiated by the inclusion of D&M's report as Exhibit 99 in the 10-K filing, indicating the company's commitment to transparency and external verification of its reserves reporting. This dual approach—leveraging D&M as part of internal controls and publicly disclosing their findings—demonstrates a robust framework for ensuring the reliability and regulatory compliance of reserves estimates.",
      "llm_answer": "ConocoPhillips' reliance on DeGolyer and MacNaughton (D&M) to review over 85% of its proved reserves processes and the inclusion of D&M's report as Exhibit 99 demonstrates a formalized, third-party validation of its reserves estimation methodology. This approach underscores a commitment to independent, objective assessment of reserve adequacy and compliance with SEC guidelines, reinforcing credibility in its reported reserves figures.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 166,
          "pages": [
            164,
            165,
            166,
            167,
            168
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 77716,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19679,
        "completion_tokens": 109,
        "total_tokens": 19789
      }
    },
    {
      "question_id": 53,
      "question": "How does AIG's exposure to non-agency RMBS with gross unrealized losses compare to the NAIC Designation methodology's impact on statutory reporting for these securities?",
      "original_answer": "AIG reports $148 million in gross unrealized losses on RMBS as of December 31, 2022, indicating a significant exposure to this asset class. The NAIC Designation methodology, which AIG subsidiaries are subject to, assigns RMBS and CMBS improved designations compared to traditional ratings from major agencies. This results in a more favorable statutory reporting treatment than what might be reflected in GAAP-based disclosures like the unrealized loss figures. The NAIC's approach using third-party modeling for RMBS designations contrasts with the market-value-based unrealized loss reporting, suggesting a potential divergence between regulatory capital treatment and financial statement presentation for these securities.",
      "llm_answer": "AIG's exposure to non-agency RMBS with gross unrealized losses is reflected in the \"Non-U.S. governments\" and \"Mortgage-backed, asset-backed and collateralized\" categories within the NAIC Designation tables, where these securities are classified under \"Below investment grade\" or \"Non-rated\" designations. The NAIC Designation methodology improves the classification of such structured securities (e.g., RMBS/CMBS) compared to external ratings, resulting in a more favorable NAIC rating for these assets. This methodology directly impacts statutory reporting by categorizing them within the NAIC's six-tier system, where \"3\" through \"6\" represent below-investment-grade securities, and the improved designations affect the reported fair value and credit quality assessment in regulatory filings.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AIG_10k_2022.pdf",
          "target_page": 220,
          "pages": [
            218,
            219,
            220,
            221,
            222
          ]
        },
        "hop_2_rel": {
          "source_file": "AIG_10k_2022.pdf",
          "target_page": 120,
          "pages": [
            118,
            119,
            120,
            121,
            122
          ]
        },
        "hop_3_rel": {
          "source_file": "AIG_10k_2022.pdf",
          "target_page": 120,
          "pages": [
            118,
            119,
            120,
            121,
            122
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 80134,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20255,
        "completion_tokens": 198,
        "total_tokens": 20454
      }
    },
    {
      "question_id": 53,
      "question": "How does COP's reliance on crude oil align with its 30% financial stake in QatarEnergy LNG, which produces 13 million barrels of crude oil per day?",
      "original_answer": "COP identifies crude oil as a critical raw material that it depends on for its upstream operations. This dependence is further reinforced by COP’s 30% ownership stake in QatarEnergy LNG, a joint venture that contributes significantly to the company’s upstream portfolio with an average daily net production of 13 million barrels of crude oil per day. By holding this stake, COP strategically aligns its crude oil supply chain with a high-volume production source, integrating supply assurance into its broader production strategy. This alignment allows COP to manage upstream exposure while leveraging a key asset that directly supports its crude oil-dependent operations.",
      "llm_answer": "ConocoPhillips' 30% stake in QatarEnergy's LNG projects provides a significant financial interest in Qatar's natural gas production, which is primarily used for LNG exports rather than crude oil. While QatarEnergy's LNG operations produce natural gas (not crude oil), ConocoPhillips also holds a separate financial stake in QatarEnergy's upstream operations that produce crude oil at a rate of 13 million barrels per day. This dual involvement—through its LNG joint ventures (which focus on natural gas) and its broader equity in QatarEnergy—aligns with the company's strategy to leverage its 30% financial stake in QatarEnergy for both natural gas (LNG) and crude oil production, though the 13 million barrels/day figure refers to QatarEnergy's overall crude oil output, not directly to ConocoPhillips' LNG stake.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 145,
          "pages": [
            143,
            144,
            145,
            146,
            147
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 85526,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21596,
        "completion_tokens": 203,
        "total_tokens": 21800
      }
    },
    {
      "question_id": 53,
      "question": "How does Qualcomm's emphasis on its patent portfolio in Taiwan reconcile with its explicit risk disclosure about potential supply chain disruptions from foundry partners in the same region due to geopolitical tensions?",
      "original_answer": "Qualcomm highlights its extensive patent portfolio in Taiwan as part of its global intellectual property strategy, noting that a substantial portion of its patents and applications relate to foundational wireless technologies, including 5G, and that its patents have broad coverage in many countries, including Taiwan. However, the company also explicitly discloses that its business depends on receiving consistent and reliable chipset supply from foundry partners, particularly in Taiwan, and that a significant or prolonged military or geopolitical conflict involving China and Taiwan could severely limit or prevent it from receiving chipset supply, which would have a material adverse impact on its business. This juxtaposition reveals a strategic vulnerability: while Taiwan is critical to Qualcomm’s global IP footprint, its manufacturing reliance on the region exposes it to significant operational risk, particularly given the geopolitical instability involving China and Taiwan.",
      "llm_answer": "Qualcomm simultaneously emphasizes its extensive patent portfolio in Taiwan as a strategic asset that underpins its licensing model and drives industry adoption of its wireless standards, while explicitly acknowledging that geopolitical tensions could disrupt its supply chain in the same region. The company notes that its key foundry partners—including TSMC in Taiwan—are critical to manufacturing its integrated circuits, and any prolonged conflict or instability involving Taiwan could materially impair its ability to receive chipset supplies, thereby threatening both its semiconductor business and broader operations. This creates a strategic tension where the same geographic region is highlighted as both a core enabler of its intellectual property ecosystem and a potential vulnerability due to external geopolitical risks.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "QCOM_10k_2023.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_2_rel": {
          "source_file": "QCOM_10k_2023.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        },
        "hop_3_rel": {
          "source_file": "QCOM_10k_2023.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 100660,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 25397,
        "completion_tokens": 208,
        "total_tokens": 25605
      }
    },
    {
      "question_id": 53,
      "question": "How does Gilead's pursuit of Breakthrough Therapy Designation for Bulevirtide align with the product's commercialization timeline and the unresolved manufacturing concerns raised by the FDA?",
      "original_answer": "Gilead's Bulevirtide received Breakthrough Therapy Designation from the FDA due to its potential to treat chronic hepatitis delta virus, a serious unmet medical need. However, despite this expedited pathway, the FDA issued a complete response letter in October 2022 citing unresolved manufacturing and delivery concerns. This has delayed the product's approval and, consequently, its commercialization timeline, which is listed as 2030 in the U.S. and 2029 in the EU. The Breakthrough Therapy status was intended to accelerate development and review, yet the product remains in regulatory limbo, highlighting the critical impact of manufacturing compliance on both regulatory outcomes and commercial planning.",
      "llm_answer": "Gilead’s pursuit of Breakthrough Therapy Designation for bulevirtide aligns with its commercialization timeline by positioning the drug for accelerated FDA review of its chronic hepatitis D treatment application, which is pending resolution of manufacturing and delivery concerns noted in the 2022 complete response letter. The designation underscores the company’s strategy to bring the therapy to market as soon as those manufacturing issues are addressed, while the unresolved FDA concerns highlight the regulatory hurdles that must be cleared before broader commercial rollout.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "target_page": 15,
          "pages": [
            13,
            14,
            15,
            16,
            17
          ]
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "target_page": 6,
          "pages": [
            4,
            5,
            6,
            7,
            8
          ]
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "target_page": 8,
          "pages": [
            6,
            7,
            8,
            9,
            10
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 84009,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21227,
        "completion_tokens": 145,
        "total_tokens": 21373
      }
    },
    {
      "question_id": 53,
      "question": "How does the introduction of the Expanded Risk-Based Approach in the Basel III Finalization Proposal impact Capital One's regulatory capital treatment for Category III institutions, particularly regarding the recognition of AOCI in CET1 capital?",
      "original_answer": "The Basel III Finalization Proposal introduces the Expanded Risk-Based Approach, which requires institutions like Capital One to calculate risk-weighted assets using a more comprehensive framework. This new approach mandates that Category III institutions, such as Capital One, begin recognizing certain elements of Accumulated Other Comprehensive Income (AOCI), including unrealized gains and losses on available-for-sale securities, in Common Equity Tier 1 (CET1) capital. This marks a shift from prior treatment where such AOCI elements were not included in CET1, thereby increasing the volatility of regulatory capital. The proposal includes a phased implementation starting July 1, 2025, with full compliance by 2028, and the impact on Capital One's capital ratios remains uncertain depending on the final rule’s adoption and market conditions.",
      "llm_answer": "The Basel III Finalization Proposal would require Category III firms such as Capital One to begin recognizing certain elements of accumulated other comprehensive income (AOCI) in CET1 capital, including unrealized gains and losses on available‑for‑sale securities. Consequently, the proposal would alter the way Capital One treats AOCI in its regulatory capital calculations for Category III institutions.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COF_10k_2024.pdf",
          "target_page": 120,
          "pages": [
            118,
            119,
            120,
            121,
            122
          ]
        },
        "hop_2_rel": {
          "source_file": "COF_10k_2024.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_3_rel": {
          "source_file": "COF_10k_2024.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 63505,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16117,
        "completion_tokens": 101,
        "total_tokens": 16218
      }
    },
    {
      "question_id": 53,
      "question": "How does Southern Company's consolidated financial reporting treatment of Southern Linc align with the dual role of Southern Linc in providing both internal digital wireless communications and external fiber optics services, particularly in light of affiliate transaction accounting policies?",
      "original_answer": "Southern Company accounts for Southern Linc under consolidated reporting, as stated on page 164, where it is listed as one of the direct and indirect subsidiaries whose financials are consolidated. Southern Linc is described as providing digital wireless communications for internal use by the Southern Company system and also marketing these services to the public, including fiber optics services within the Southeast. According to affiliate transaction policies outlined on page 164, services provided by Southern Linc to other subsidiaries are rendered at direct or allocated cost. This cost-based pricing reflects how Southern Linc serves both internal and external markets, with its internal role governed by formal accounting policies that ensure transactions are conducted at cost. This dual role suggests that while Southern Linc generates revenue from external customers through fiber optics services (as noted on page 64), its internal operations are tightly integrated into the broader Southern Company financial framework, with transactions governed by cost-based allocations rather than market pricing. This alignment ensures consistency in consolidated financial reporting while allowing Southern Linc to maintain a commercial presence in the fiber optics market.",
      "llm_answer": "Southern Company consolidates Southern Linc within its financial reporting, treating it as part of the parent company's operations rather than as a separate reporting entity. Southern Linc provides both internal digital wireless communications for Southern Company's subsidiaries and external fiber optics services to the public, but its financial results are not presented as a distinct segment; instead, its activities are included within the broader \"Other Business Activities\" section of the consolidated financial statements. The company accounts for affiliate transactions, such as those with SCS and Southern Nuclear, using cost-based allocations approved by FERC, ensuring that intercompany services and related costs are properly eliminated in consolidation.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 164,
          "pages": [
            162,
            163,
            164,
            165,
            166
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 64401,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16351,
        "completion_tokens": 191,
        "total_tokens": 16543
      }
    },
    {
      "question_id": 54,
      "question": "How does the contingent consideration liability for Clif Bar, measured using significant unobservable inputs (Level 3), relate to the impact of the acquisition on MDLZ's 2023 operating income and expense trends?",
      "original_answer": "MDLZ reported a contingent consideration liability of $548 million for Clif Bar as of December 31, 2023, which was measured using significant unobservable inputs (Level 3). This liability is tied to the August 1, 2022 acquisition of Clif Bar, which contributed to a $618 million increase in total selling, general, and administrative expenses in 2023 due to higher acquisition integration costs and contingent consideration adjustments. Despite these costs, MDLZ's operating income margin increased from 11.2% in 2022 to 15.3% in 2023, partly due to lapping prior-year acquisition-related costs and favorable changes in mark-to-market gains from hedging activities. The continued expense pressure from the Clif Bar acquisition was therefore offset by broader operational improvements and pricing discipline.",
      "llm_answer": "The contingent consideration liability for Clif Bar, measured using Level 3 inputs, is recorded as a $548 million liability at fair value and is reflected in the consolidated balance sheet as a long‑term liability.  This liability is accounted for in selling, general and administrative expenses, and the resulting fair‑value adjustments have contributed to the increase in MDLZ’s 2023 operating income and expense trends.  Specifically, the $548 million contingent consideration expense (part of the $1,968 million rise in operating income) is included in the “Acquisition integration costs and contingent consideration adjustments” line that added $246 million to operating income in 2023, thereby influencing the overall expense structure and profitability trend for the year.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2023.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2023.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2023.pdf",
          "target_page": 41,
          "pages": [
            39,
            40,
            41,
            42,
            43
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 76023,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19236,
        "completion_tokens": 194,
        "total_tokens": 19431
      }
    },
    {
      "question_id": 54,
      "question": "Given AMGN's exposure to biosimilar competition as a strategic risk, how does the decline in Aranesp sales during 2023 reflect the financial impact of biosimilar substitution, particularly in light of the reported drop in U.S. unit demand?",
      "original_answer": "The 2023 decline in Aranesp sales, driven by lower U.S. unit demand due to dialysis organizations transitioning to EPOGEN and its biosimilars, directly reflects the financial impact of biosimilar competition outlined in AMGN's risk factors. On page 15, AMGN highlights that biosimilars can significantly erode market share and revenue for its biologics, especially after loss of exclusivity. Page 74 confirms this risk is materializing: Aranesp sales dropped due to biosimilar competition from EPOGEN, with U.S. sales specifically falling as independent and medium-sized dialysis providers shifted to competing products. This aligns with the broader risk that biosimilars will continue to pressure both volume and net selling prices, indicating a clear financial manifestation of the strategic risk outlined earlier.",
      "llm_answer": "The decline in Aranesp sales during 2023—driven by lower unit demand in the U.S. due to independent and medium-sized dialysis organizations transitioning from Aranesp to EPOGEN and its biosimilars—directly reflects the financial impact of biosimilar substitution, as competitive pricing pressure from EPOGEN biosimilars has accelerated volume erosion and reduced net selling prices, undermining Aranesp’s revenue trajectory despite its protected patent life extending to 2024 and 2033 in the U.S. and Europe.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "target_page": 15,
          "pages": [
            13,
            14,
            15,
            16,
            17
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 75660,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19152,
        "completion_tokens": 127,
        "total_tokens": 19279
      }
    },
    {
      "question_id": 54,
      "question": "How does Microsoft's exclusion of Activision Blizzard's internal controls from its assessment relate to the integration of Activision's 3.400% Senior Notes due 2026 into Microsoft's debt structure following the October 2023 acquisition?",
      "original_answer": "Microsoft excluded Activision Blizzard's internal controls from its assessment because the acquisition occurred on October 13, 2023, and Activision's financial statements represented less than 1% of Microsoft's total assets (excluding goodwill and intangible assets) and 2% of total revenues as of June 30, 2024. Despite this exclusion, Activision's 3.400% Senior Notes due 2026 were integrated into Microsoft's broader debt structure, as evidenced by the November 6, 2023 filing of the Fifteenth Supplemental Indenture, which formally incorporated these notes under Microsoft’s existing debt framework. This indicates that while Activision’s internal controls were not assessed, its debt obligations were operationally and structurally assumed by Microsoft post-acquisition.",
      "llm_answer": "Microsoft's assessment of internal controls explicitly excluded Activision Blizzard's internal controls because the acquisition occurred only on October 13, 2023, and the acquired business represented less than 1% of Microsoft's total assets and 2% of its revenue as of June 30, 2024. This exclusion allowed Microsoft to focus its control evaluation on its pre-existing systems and processes, without incorporating Activision Blizzard's controls into its assessment. The 3.400% Senior Notes due 2026 issued by Activision Blizzard were integrated into Microsoft's debt structure following the acquisition, but their issuance did not impact the scope of Microsoft's internal control evaluation, which remained limited to its own operations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 107,
          "pages": [
            104,
            105,
            106,
            107,
            108
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 106,
          "pages": [
            104,
            105,
            106,
            107,
            108
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 53124,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 13519,
        "completion_tokens": 184,
        "total_tokens": 13703
      }
    },
    {
      "question_id": 54,
      "question": "How does Microsoft's reliance on OEMs for Office distribution align with its competitive challenges from Meta in both productivity software and gaming markets, given Meta's direct-to-consumer platform advantages?",
      "original_answer": "Microsoft's OEM distribution model for Office, where the software is pre-installed by major manufacturers like Dell and HP on new devices, ensures broad market penetration and integration with hardware (page 18). However, this model contrasts with Meta's direct-to-consumer platform approach, which allows Meta to rapidly innovate and deploy software experiences without dependency on hardware partners. The filing explicitly lists Meta as a competitor to Office, indicating pressure in the productivity and collaboration space from Meta’s web-based tools (page 12). Furthermore, Microsoft notes that its Xbox and cloud gaming services also face competition from Meta (page 16), suggesting that Meta’s platform agility and direct user access pose a dual threat across both enterprise software and consumer gaming. This raises strategic questions about whether Microsoft’s OEM-dependent distribution for Office can keep pace with Meta’s integrated digital ecosystem in both markets.",
      "llm_answer": "Microsoft’s Office distribution relies on OEMs to pre‑install the suite on new devices, a channel that gives the company broad reach but also makes it vulnerable to OEM‑driven pricing and platform shifts. This OEM‑centric model clashes with Meta’s direct‑to‑consumer approach in both productivity tools (e.g., Meta Workplace, Horizon) and gaming (Meta Quest), where Meta can launch and monetize offerings straight to users without intermediary hardware partners, giving it a speed and data‑ownership advantage that Microsoft must counter through its own cloud services and integrated ecosystems.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 18,
          "pages": [
            16,
            17,
            18,
            19,
            20
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 61447,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15593,
        "completion_tokens": 148,
        "total_tokens": 15742
      }
    },
    {
      "question_id": 54,
      "question": "What is the significance of the anticipated 2035 U.S. patent expiration for MK-1022 in the context of Merck's disclosed global patent framework that includes provisions for PTE and SPC extensions?",
      "original_answer": "The anticipated 2035 U.S. patent expiration for MK-1022 represents a critical inflection point for Merck's market exclusivity in the U.S. for this product. This date is disclosed in the context of U.S.-specific patent protections, while the global patent framework section highlights that Merck actively manages patent life cycle strategies through mechanisms such as Patent Term Extensions (PTE) and Supplementary Protection Certificates (SPC) in other jurisdictions. Together, these disclosures suggest that while the U.S. expiration is clearly defined for MK-1022, Merck may seek to extend protection in key international markets through regulatory mechanisms, thereby delaying competitive entry outside the U.S.",
      "llm_answer": "The anticipated 2035 U.S. patent expiration for MK‑1022 is significant because it reflects the Company’s global patent framework that incorporates patent term extensions (PTE) and supplementary protection certificates (SPC), allowing additional market exclusivity beyond the standard compound‑patent term and ensuring that MK‑1022 remains protected until at least 2035 in the United States.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 15,
          "pages": [
            13,
            14,
            15,
            16,
            17
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 84920,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21452,
        "completion_tokens": 97,
        "total_tokens": 21549
      }
    },
    {
      "question_id": 54,
      "question": "How does SCHW's compliance with the Uniform Net Capital Rule, which restricts TDAC's ability to repay subordinated loans, reconcile with the company's reported secured borrowing capacity that depends on TDAC's collateral arrangements?",
      "original_answer": "SCHW's broker-dealer subsidiary TDAC is subject to the Uniform Net Capital Rule, which prohibits it from repaying subordinated loans if such repayment would reduce its net capital below 5% of aggregate debit balances or 120% of its minimum dollar requirement. At the same time, the company's secured borrowing capacity, particularly through facilities available to TDAC, depends on its ability to pledge acceptable collateral. This creates a tension where maintaining sufficient net capital under the Uniform Net Capital Rule may limit TDAC's ability to use its collateral to access secured borrowing, directly affecting SCHW's overall liquidity strategy and capital management.",
      "llm_answer": "The Uniform Net Capital Rule restricts TDAC from repaying subordinated loans if doing so would reduce its net capital below 5% of aggregate debit balances or 120% of its minimum dollar requirement. This limitation directly conflicts with the company’s reported secured borrowing capacity, which depends on TDAC’s ability to pledge collateral to obtain external financing. Since TDAC must maintain sufficient net capital to meet these regulatory thresholds, it cannot freely use cash flows from subordinated loan repayments to fund its borrowing needs, thereby constraining its secured borrowing capacity despite having available collateral.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SCHW_10k_2023.pdf",
          "target_page": 123,
          "pages": [
            121,
            122,
            123,
            124,
            125
          ]
        },
        "hop_2_rel": {
          "source_file": "SCHW_10k_2023.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_3_rel": {
          "source_file": "SCHW_10k_2023.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 80323,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20323,
        "completion_tokens": 160,
        "total_tokens": 20483
      }
    },
    {
      "question_id": 55,
      "question": "How does MetLife's positioning of Accident & Health Insurance as a core product offering align with the relatively low adjusted earnings contribution from the EMEA segment in 2023, despite EMEA also offering Accident & Health Insurance?",
      "original_answer": "MetLife identifies Accident & Health Insurance as a core product offered across multiple segments, including EMEA. However, while Accident & Health Insurance is listed among EMEA's offerings, the segment contributed only $265 million in adjusted earnings in 2023 — significantly less than other segments like Group Benefits ($1,655 million) and Asia ($1,282 million). This suggests that despite offering the same product category, EMEA's overall profitability is lower, potentially indicating regional challenges, lower pricing power, or higher operational costs in delivering Accident & Health Insurance in that market.",
      "llm_answer": "MetLife positions Accident & Health Insurance as a core product offering across multiple regions, including EMEA, where it is listed alongside Life Insurance, Retirement and Savings, and Credit Insurance as a key product line. However, despite this strategic emphasis, the EMEA segment contributed only a modest $189 million in adjusted earnings (or $249 million in adjusted earnings available to common shareholders) in 2023, reflecting its relatively smaller scale compared to other segments like RIS or Group Benefits. This disparity suggests that while Accident & Health Insurance is a foundational product in EMEA’s portfolio, its financial impact is constrained by the segment’s overall smaller contribution to the company’s consolidated adjusted earnings.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 169,
          "pages": [
            167,
            168,
            169,
            170,
            171
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 85722,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21672,
        "completion_tokens": 190,
        "total_tokens": 21863
      }
    },
    {
      "question_id": 55,
      "question": "How does Cisco's financing of technical support services through loan receivables relate to the credit loss allowance specifically allocated to loan receivables in fiscal 2023?",
      "original_answer": "Cisco provides technical support services as part of its financing arrangements, which include loan receivables that typically span one to three years (page 49 and 82). These loan receivables are subject to credit risk, which is reflected in the credit loss allowance disclosed in the financial statements. In fiscal 2023, the credit loss allowance for loan receivables decreased from $103 million to $53 million, indicating a reduction in the estimated risk associated with these financing activities (page 84). This suggests that the company's exposure to credit losses from financing technical support services through loans has declined year-over-year, potentially reflecting improved credit quality of customers or more conservative underwriting in loan origination.",
      "llm_answer": "In fiscal 2023 Cisco’s allowance for credit losses on its financing receivables was $72 million (comprised $53 million for loan receivables and $19 million for lease receivables). By the end of fiscal 2024 the allowance had been reduced to $65 million ($50 million for loan receivables and $15 million for lease receivables), reflecting a $7 million decrease in the total allowance and a $3 million reduction specifically allocated to loan receivables. This decline indicates that the credit‑loss reserve earmarked for loan receivables was lowered from $53 million to $50 million during fiscal 2024.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 75425,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19079,
        "completion_tokens": 149,
        "total_tokens": 19229
      }
    },
    {
      "question_id": 55,
      "question": "How does the $96 million pre-tax charge related to Nicor Gas' disallowed capital investments impact Southern Company's financing structure, particularly in light of the disclosure that Nicor Gas obtains financing separately without affiliate credit support?",
      "original_answer": "The $96 million pre-tax charge associated with the disallowance of certain capital investments at Nicor Gas (after tax: $72 million) directly affects Southern Company Gas' earnings and potentially its retained earnings base. Nicor Gas, which obtains financing separately without credit support from affiliates and is restricted in how much it can dividend or loan to affiliates (up to its retained earnings balance), reported $1.7 billion in restricted retained earnings at year-end. This restriction, combined with the significant charge, could limit Nicor Gas' ability to internally finance future capital needs or distribute funds to parent entities. The financing section (Note 8) indicates that Southern Company Gas subsidiaries like Nicor Gas rely heavily on external financing, suggesting that such charges may increase reliance on external capital markets or impact future financing terms.",
      "llm_answer": "The $96 million pre‑tax charge reflects Nicor Gas’s disallowed capital investments, which are funded separately without any affiliate credit support, meaning the charge does not affect Southern Company’s overall financing structure but does reduce the cash available to Nicor Gas for its own financing needs. Consequently, Southern Company’s financing remains reliant on its own debt and equity markets, while Nicor Gas must secure external capital on its own terms.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 302,
          "pages": [
            300,
            301,
            302,
            303,
            304
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 107,
          "pages": [
            105,
            106,
            107,
            108,
            109
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 167,
          "pages": [
            165,
            166,
            167,
            168,
            169
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 75194,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19048,
        "completion_tokens": 116,
        "total_tokens": 19165
      }
    },
    {
      "question_id": 55,
      "question": "How does Boeing's increasing reach-forward loss on the Commercial Crew program in 2021 relate to the broader financial risks associated with fixed-price development contracts, particularly in light of the $402 million additional loss recorded on the KC-46A Tanker contract during the same year?",
      "original_answer": "Boeing's increasing reach-forward loss on the Commercial Crew program by $185 million in 2021, as detailed in the operational performance section, reflects the financial volatility inherent in fixed-price development contracts. This aligns with the broader risk profile outlined in the financial statement notes, which emphasize the uncertainty in cost estimation and the potential for material charges due to technical complexity and delays. The $402 million additional loss recorded on the KC-46A Tanker contract in the same year further illustrates the recurring financial exposure Boeing faces under such contracts, particularly when unforeseen disruptions like supply chain delays or evolving customer requirements occur. Together, these examples highlight how Boeing's financial performance is significantly impacted by the execution risks tied to fixed-price development programs.",
      "llm_answer": "Boeing recorded a $402 million increase in the reach‑forward loss on the KC‑46A Tanker in 2021 and a $185 million increase in the reach‑forward loss on the Commercial Crew program in the same year. Both of these losses stem from the inherent financial risk of fixed‑price development contracts—where the contract price is set in advance but actual costs can rise due to technical complexity, schedule delays, supply‑chain disruptions (including COVID‑19), and evolving customer requirements—so the additional $402 million loss on KC‑46A reflects the same type of cost‑overrun exposure that also drove the $185 million reach‑forward loss on Commercial Crew. This illustrates how fixed‑price contracts can generate material losses when cost estimates prove insufficient, as seen across both the KC‑46A and Commercial Crew programs in 2021.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 45,
          "pages": [
            43,
            44,
            45,
            46,
            47
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 134,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 54095,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 13780,
        "completion_tokens": 209,
        "total_tokens": 13989
      }
    },
    {
      "question_id": 55,
      "question": "How do regulatory decisions by the Georgia Public Service Commission and Federal Energy Regulatory Commission impact Georgia Power Company's reported financial position, particularly in relation to the recovery of costs and return on investment as disclosed in the financial statements?",
      "original_answer": "Georgia Power Company, a wholly-owned subsidiary of SO, operates under the retail rate regulation of the Georgia Public Service Commission and wholesale regulation by the Federal Energy Regulatory Commission. These regulatory bodies influence the company's financial reporting by determining the rates Georgia Power can charge customers, which are based on the recovery of prudently incurred costs and a reasonable return on invested capital. The company expects to recover these costs and investments through regulated rates; however, there is a risk that regulators may not approve full recovery, directly impacting financial line items such as regulatory assets and liabilities. This material consideration is detailed in Note 2 (Regulatory Matters - Georgia Power) to the financial statements, which is referenced on page II-129 of the financial statement schedule, and forms part of the basis for the auditor's opinion on the financial statements.",
      "llm_answer": "Regulatory decisions by the Georgia Public Service Commission and the Federal Energy Regulatory Commission directly affect Georgia Power’s ability to recover costs and earn a return on invested capital, which is reflected in the financial statements through regulatory assets and liabilities. Management assesses the likelihood of recovering incurred costs and any potential refunds, and these judgments—subject to regulatory outcomes—impact the balances of regulatory assets and liabilities reported on the balance sheet and the related disclosures in the notes.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 135,
          "pages": [
            133,
            134,
            135,
            136,
            137
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 163,
          "pages": [
            161,
            162,
            163,
            164,
            165
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 71056,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18018,
        "completion_tokens": 140,
        "total_tokens": 18159
      }
    },
    {
      "question_id": 56,
      "question": "How does Chevron's controlling stake in Chevron U.S.A. Inc. influence its exposure to crude oil price volatility, given the subsidiary's significant involvement in upstream and downstream operations?",
      "original_answer": "Chevron holds a controlling stake in Chevron U.S.A. Inc. (CUSA), which manages most of Chevron's U.S. businesses, including the exploration, production, refining, and distribution of crude oil and petroleum-derived products. CUSA's upstream operations expose Chevron to crude oil price volatility, while its downstream integration provides some operational balance during commodity price cycles. This dual exposure means that fluctuations in crude oil prices can both directly impact Chevron’s upstream earnings and indirectly affect downstream margins through feedstock cost variability. Therefore, Chevron’s ownership of CUSA amplifies its strategic and financial sensitivity to crude oil market dynamics.",
      "llm_answer": "Chevron’s 50 % equity stake in Tengizchevroil LLP (TCO) gives it direct exposure to the upstream operations of a major crude‑oil producer; because TCO’s revenue and profitability are tied to crude‑oil prices, Chevron’s overall earnings become more sensitive to oil‑price volatility.  The company’s own upstream segment also depends heavily on oil prices, so the combined effect of its controlling interest in TCO and its broader upstream activities amplifies Chevron’s overall exposure to crude‑oil price swings.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 77,
          "pages": [
            75,
            76,
            77,
            78,
            79
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 77,
          "pages": [
            75,
            76,
            77,
            78,
            79
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 84358,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21316,
        "completion_tokens": 128,
        "total_tokens": 21444
      }
    },
    {
      "question_id": 56,
      "question": "How does Microsoft's issuance of the 5.20% Notes due 2039, administered by BNY Mellon, relate to the company's broader pattern of long-term debt instruments also serviced by BNY Mellon and U.S. Bank, and what does this imply about Microsoft's capital structure strategy?",
      "original_answer": "Microsoft issued the 5.20% Notes due 2039 under a First Supplemental Indenture dated May 18, 2009, with The Bank of New York Mellon Trust Company, N.A. (BNY Mellon) as trustee. This is part of a broader capital structure strategy involving multiple long-term debt instruments, including notes due in 2018, 2023, 2035, 2045, and 2055, some of which are also administered by BNY Mellon and later by U.S. Bank National Association. The repeated use of these trustees across different maturities suggests Microsoft's structured approach to managing long-term liabilities through trusted financial institutions, balancing interest rate risk and maturity laddering to maintain financial flexibility.",
      "llm_answer": "Microsoft's 2039-dated 5.20% Notes issuance is part of a longstanding pattern of financing through indentures administered by BNY Mellon and later U.S. Bank, reflecting a deliberate capital structure strategy centered on low-cost, long-term debt to fund operations and acquisitions while maintaining financial flexibility. This consistent use of institutional trustee structures underscores Microsoft's reliance on disciplined leverage and stable funding sources to support its growth objectives.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 50013,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12747,
        "completion_tokens": 124,
        "total_tokens": 12871
      }
    },
    {
      "question_id": 56,
      "question": "How does the voting power structure of CMCSA's Class A and Class B common stock, where Class B shares carry 15 votes each, reconcile with the company's decision to repurchase only Class A shares despite both classes being outstanding?",
      "original_answer": "CMCSA's capital structure shows that Class A common stock had 4,651,093,045 shares issued in 2024, while Class B common stock had only 9,444,375 issued and outstanding shares. Despite both classes being outstanding, all stock repurchases in 2024 were limited to Class A shares, totaling $2 billion in reductions to additional paid-in capital and $7,251 million in reductions to retained earnings. This suggests a strategic focus on managing Class A share count while preserving the concentrated voting power of Class B shares, which carry 15 votes each and are entirely owned by Brian L. Roberts, ensuring continued control over key corporate decisions.",
      "llm_answer": "The voting power structure of CMCSA's Class A and Class B common stock, where Class B shares carry 15 votes each, coexists with the company's practice of repurchasing only Class A shares. This is reconciled by the fact that Class B shares are non-dilutive and represent a fixed 33.3% of the combined voting power, while repurchases of Class A shares do not affect the voting power ratio of the outstanding Class B shares. The company's repurchase program targets Class A shares specifically, as indicated in the share repurchase disclosures, and the voting power structure remains unchanged as long as Class B shares remain outstanding and non-dilutive.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 67,
          "pages": [
            65,
            66,
            67,
            68,
            69
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 31,
          "pages": [
            29,
            30,
            31,
            32,
            33
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 70003,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17738,
        "completion_tokens": 163,
        "total_tokens": 17901
      }
    },
    {
      "question_id": 56,
      "question": "How does the participation in EIP Plans by non-U.S. employees, which resulted in the purchase of 78,000 shares of Caterpillar common stock in Q4 2023, compare with the company's broader share repurchase activity totaling $4.7 billion in 2023, and what does this suggest about the relative scale and intent behind employee-driven versus corporate-driven stock ownership changes?",
      "original_answer": "The EIP Plans, which cater to non-U.S. employees, led to the purchase of 78,000 shares of Caterpillar common stock in Q4 2023, indicating a relatively small, employee-driven acquisition of equity. In contrast, Caterpillar's corporate share repurchase program in 2023 resulted in the acquisition of 19.5 million shares at a total cost of $4.7 billion, reflecting a significantly larger, strategic initiative to influence capital structure and shareholder value. This contrast suggests that while employee participation contributes marginally to stock demand, the company's own repurchase activity is the dominant force shaping stock ownership and market perception.",
      "llm_answer": "The EIP Plans' purchase of 78,000 shares in Q4 2023 represented a negligible portion of Caterpillar's total 2023 share repurchase activity of $4.7 billion, highlighting that employee-driven stock purchases were a minor component of the company's broader capital allocation strategy. This contrasts with the corporate-directed repurchases, which accounted for the vast majority of the $4.7 billion total, indicating that the company's primary intent was to manage its own share price and return capital to shareholders broadly rather than to facilitate employee stock ownership plans.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CAT_10k_2023.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_2_rel": {
          "source_file": "CAT_10k_2023.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_3_rel": {
          "source_file": "CAT_10k_2023.pdf",
          "target_page": 104,
          "pages": [
            102,
            103,
            104,
            105,
            106
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 41320,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 10602,
        "completion_tokens": 145,
        "total_tokens": 10748
      }
    },
    {
      "question_id": 56,
      "question": "What does Opdualag's 48% year-over-year revenue growth suggest about BMY's strategy in melanoma treatment, given its indication for unresectable or metastatic cases?",
      "original_answer": "Opdualag's 48% year-over-year revenue growth, with particularly strong performance in the U.S. (41%) and explosive growth internationally (>200%), indicates strong market adoption of BMY's melanoma treatment. This aligns with the company's strategic focus on oncology, particularly in addressing high-unmet-need indications like unresectable or metastatic melanoma. The product's dual mechanism targeting PD-1 and LAG-3 pathways appears to be resonating in the market, supporting BMY's positioning in immuno-oncology despite the complexity of treating advanced-stage melanoma.",
      "llm_answer": "Opdualag's 48% year-over-year revenue growth reflects Bristol Myers Squibb's strategic focus on advancing checkpoint inhibitor combinations for melanoma, specifically targeting unresectable or metastatic cases through its Opdivo + relatlimab regimen. This growth, driven by increased demand for Opdualag as a next-generation immunotherapy, aligns with the company's broader oncology strategy to expand transformative treatments in high-need indications like melanoma, while also supporting pipeline expansion through acquisitions such as Mirati and RayzeBio to strengthen its oncology portfolio.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 50,
          "pages": [
            48,
            49,
            50,
            51,
            52
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 81783,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20663,
        "completion_tokens": 148,
        "total_tokens": 20811
      }
    },
    {
      "question_id": 57,
      "question": "How does Amgen's exposure to generic competition risk for KYPROLIS relate to its collaboration and financial arrangements with BeiGene, Ltd., particularly considering Amgen's equity stake and profit-sharing structure in China?",
      "original_answer": "Amgen highlights KYPROLIS as one of its small molecule products facing significant generic competition risk on page 14, noting that such competition can rapidly erode market share and revenue. On page 132, it is revealed that BeiGene, Ltd. began selling KYPROLIS in China in 2022 under a collaboration where Amgen shares profits and losses equally during the initial commercialization period, after which product rights may revert to Amgen with royalty obligations to BeiGene. Additionally, page 98 shows that Amgen has a long-standing equity stake in BeiGene, with multiple amendments to the Share Purchase Agreement and ongoing collaboration agreements, indicating a strategic and financially intertwined relationship. This suggests that while Amgen seeks to mitigate KYPROLIS's generic risk through geographic expansion via BeiGene, it also shares control and financial upside in the Chinese market, creating a complex trade-off between market access and revenue retention.",
      "llm_answer": "Amgen holds a 20.5% equity stake in BeiGene and shares profits and losses equally during the initial commercialization periods of BeiGene‑sold oncology products such as KYPROLIS in China; after those periods the product rights may revert to Amgen, which would then pay BeiGene royalties on Chinese sales. This partnership gives Amgen exposure to generic competition for KYPROLIS because, as noted in the risk‑factor discussion, generic entry can sharply reduce sales of small‑molecule products like KYPROLIS, and the profit‑sharing arrangement means any loss of market share directly impacts Amgen’s financial results in China.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 14,
          "pages": [
            12,
            13,
            14,
            15,
            16
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 98,
          "pages": [
            96,
            97,
            98,
            99,
            100
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 82000,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20740,
        "completion_tokens": 156,
        "total_tokens": 20897
      }
    },
    {
      "question_id": 57,
      "question": "How does Cisco's sensitivity analysis of its $20.3 billion in senior fixed-rate notes relate to its $15.0 billion commercial paper program, particularly in terms of interest rate exposure and financing flexibility?",
      "original_answer": "Cisco disclosed on page 53 that a 50 basis point increase or decrease in market interest rates would change the fair value of its $20.3 billion in senior fixed-rate notes by approximately $0.7 billion. This sensitivity applies to fixed-rate debt that is not hedged, and the company also noted that a sharp rise in interest rates could increase interest expense on new commercial paper issuances. On page 89, it is clarified that the senior fixed-rate notes rank at par with the commercial paper notes issued under Cisco's $15.0 billion short-term debt program. Page 88 introduces this commercial paper program, stating that proceeds are used for general corporate purposes. The interplay between these instruments shows that while senior notes are subject to interest rate risk affecting fair value, commercial paper notes introduce direct interest expense volatility with market rate changes, impacting Cisco's short-term financing flexibility.",
      "llm_answer": "Cisco's sensitivity analysis for its $20.3 billion senior fixed‑rate notes shows that a 50‑basis‑point shift in market interest rates would alter the fair value of the notes by roughly $0.7 billion, while the company's $15 billion commercial paper program provides additional short‑term financing flexibility. Together, these instruments expose Cisco to interest‑rate risk, but the fixed‑rate debt limits exposure on expense, whereas the commercial paper program allows the company to adjust funding costs and maintain liquidity as market rates change.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 53,
          "pages": [
            51,
            52,
            53,
            54,
            55
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 88,
          "pages": [
            86,
            87,
            88,
            89,
            90
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 76980,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19477,
        "completion_tokens": 138,
        "total_tokens": 19615
      }
    },
    {
      "question_id": 57,
      "question": "How does Morgan Stanley coordinate capital requirements between MSSB's broker-dealer obligations and its registered swap dealer entities under CFTC and SEC regulations?",
      "original_answer": "Morgan Stanley must align its capital management across MSSB, which is subject to the SEC's net capital rule and FINRA margin requirements, and its registered swap dealer entities that face uncleared swap margin and minimum capital requirements from either prudential regulators, the CFTC, or the SEC. The firm's U.S. broker-dealer subsidiaries, including MSSB, are required to maintain minimum net capital levels under SEC rules, which are detailed in Note 16 to the financial statements. Meanwhile, its swap dealers—both U.S. and non-U.S.—must comply with either prudential regulator standards or direct CFTC/SEC requirements for margin and capital. This dual regulatory framework necessitates careful capital allocation and compliance coordination to ensure both broker-dealer and swap dealer operations remain adequately capitalized under overlapping regulatory regimes.",
      "llm_answer": "Morgan Stanley coordinates capital requirements between MSSB’s broker-dealer activities and its registered swap dealer entities through a unified regulatory framework that integrates CFTC and SEC obligations. The firm’s swap dealer registrations under the CFTC require adherence to uncleared swaps margin and capital rules, while its broker-dealer operations under the SEC are governed by net capital requirements and market conduct rules. The firm’s consolidated capital planning and stress testing processes, as disclosed in its 10-K under \"Liquidity and Capital Resources,\" ensure that capital allocations account for both broker-dealer exposures (e.g., customer receivables, trading liabilities) and swap dealer commitments (e.g., margin requirements for security-based swaps), with regulatory coordination explicitly referenced in the \"Regulatory Requirements\" section of Management’s Discussion and Analysis.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MS_10k_2023.pdf",
          "target_page": 153,
          "pages": [
            151,
            152,
            153,
            154,
            155
          ]
        },
        "hop_2_rel": {
          "source_file": "MS_10k_2023.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "hop_3_rel": {
          "source_file": "MS_10k_2023.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 103788,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 26166,
        "completion_tokens": 228,
        "total_tokens": 26395
      }
    },
    {
      "question_id": 58,
      "question": "How does Coca-Cola's approach to managing health care cost inflation in its U.S. postretirement benefit plans align with the investment strategy of the VEBA trust, given the expected benefit payments and asset liquidity requirements?",
      "original_answer": "Coca-Cola manages health care cost inflation in its U.S. postretirement benefit plans by using defined-dollar benefit plans that cap contribution levels based on established dollar limits, as noted on page 105. One of these plans is funded through a VEBA trust, which holds primarily liquid assets to meet the timing and level of expected future benefit payments, as detailed on page 103. This alignment reflects a coordinated strategy where the defined-dollar structure limits long-term liability exposure, while the VEBA’s liquid asset allocation ensures that funds are available to meet near-term obligations. The expected benefit payments for the next decade, also disclosed on page 105, further justify the emphasis on liquidity in the VEBA’s investment approach.",
      "llm_answer": "Coca‑Cola’s U.S. postretirement benefit plan is funded through a VEBA trust that is invested primarily in liquid assets to meet the timing of expected benefit payments. The VEBA’s asset allocation (cash, equities, fixed‑income and short‑term instruments) is designed to provide sufficient liquidity for the projected benefit outflows shown in the cash‑flow table, while the broader pension fund uses a diversified 42% equity / 30% fixed‑income / 28% alternative strategy to generate long‑term returns that can offset health‑care cost inflation. Thus, the VEBA’s investment approach aligns with the overall pension strategy of maintaining liquidity for near‑term obligations while seeking returns that help sustain the plan’s funding level.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "KO_10k_2022.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "hop_2_rel": {
          "source_file": "KO_10k_2022.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_3_rel": {
          "source_file": "KO_10k_2022.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 79950,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20221,
        "completion_tokens": 184,
        "total_tokens": 20406
      }
    },
    {
      "question_id": 58,
      "question": "How does the trend in Cisco's allowance for credit losses on loan receivables from fiscal year 2022 to 2023 reflect the risk profile of financing arrangements tied to technical support services, given the average loan term and nature of those services?",
      "original_answer": "The allowance for credit losses on loan receivables dropped from $103 million in fiscal 2022 to $53 million in fiscal 2023, indicating a reduced risk or a strategic shift in credit exposure. This decrease occurs despite loan receivables being tied to services like technical support, which are part of multi-year financing arrangements (1–3 years on average), suggesting either improved credit quality of counterparties or more conservative underwriting. The connection between loan receivables and technical support services implies that Cisco's financing risk is closely linked to the ongoing value and delivery of these services over the loan term.",
      "llm_answer": "The allowance for credit losses on Cisco’s loan receivables fell from $53 million (July 29 2023) to $50 million (July 27 2024), while the allowance on lease receivables dropped from $19 million to $15 million. This reduction reflects a modest improvement in the risk profile of the financing arrangements tied to technical‑support services, which typically have average loan terms of one‑to‑three years and are collateralized by security interests in the underlying assets. The lower allowance suggests fewer expected credit losses, consistent with the relatively short‑term, well‑collateralized nature of these financing arrangements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 67555,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17126,
        "completion_tokens": 158,
        "total_tokens": 17285
      }
    },
    {
      "question_id": 58,
      "question": "How does Disney's risk of brand damage affecting cross-business performance relate to its inclusion of Marvel content in Disney+ services and its financial stake in the Marvel trademark as an indefinite-lived intangible asset?",
      "original_answer": "Disney identifies brand damage in one business as potentially impacting performance across other businesses due to the interconnected nature of its globally recognized brands (page 29). This risk is particularly relevant given that Disney+—a key part of its DTC strategy—includes Marvel content as a top-level tile in its interface, directly linking Marvel’s brand strength to subscriber attraction and retention (page 12). Furthermore, Marvel is listed among Disney’s indefinite-lived intangible assets, alongside Pixar and ESPN, indicating its long-term strategic and financial value to the company (page 110). Therefore, any reputational harm to the Marvel brand could not only affect Disney+ subscriber metrics but also diminish the value of a significant intangible asset, thereby impacting overall financial stability and DTC profitability.",
      "llm_answer": "Disney’s risk of brand damage that could impair its cross‑business performance is closely tied to its inclusion of Marvel content on Disney+ and the fact that Marvel’s trademark is recorded as an indefinite‑lived intangible asset. Because Marvel‑related IP is a core driver of subscriber attraction and engagement on Disney+, any reputational harm or negative publicity affecting the Marvel brand could depress Disney+ adoption, increase churn, and diminish advertising and subscription revenue across the entire Disney ecosystem. Moreover, the Marvel trademark—classified as an indefinite‑lived intangible—must be continually evaluated for impairment; a decline in its fair value due to brand erosion would require a write‑down, directly reducing earnings and signaling heightened financial vulnerability tied to the health of the Marvel brand.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 110,
          "pages": [
            108,
            109,
            110,
            111,
            112
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 65295,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16563,
        "completion_tokens": 211,
        "total_tokens": 16775
      }
    },
    {
      "question_id": 58,
      "question": "How does the voting power disparity between Class A and Class B common stock, as outlined in the equity structure, influence the governance dynamics given that Mr. Brian L. Roberts owns all outstanding shares of Class B common stock?",
      "original_answer": "The governance dynamics are significantly influenced by the voting power disparity, as Mr. Brian L. Roberts, owning all outstanding Class B shares (with 15 votes per share), controls 33⅓% of the combined voting power, despite Class A shareholders collectively holding the remaining 66⅔%. This structure, outlined in the equity disclosures and further clarified in the voting rights section, ensures that Mr. Roberts retains outsized influence over corporate decisions, such as the election of directors, even though the majority of shares by quantity are Class A. This dynamic is further emphasized by the fact that Class B stock is non-dilutable, preserving Mr. Roberts' voting power regardless of future Class A share issuances.",
      "llm_answer": "The voting power disparity—Class B shares (held entirely by Brian L. Roberts) carry 15 votes per share while Class A shares carry only one vote per share—means that Roberts controls roughly 33 % of the total voting power despite owning a tiny fraction of the company’s equity. This concentration gives him decisive influence over key corporate decisions such as the election of directors and other matters that require shareholder approval, effectively shaping governance and strategic direction in favor of his interests.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 1,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 57868,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14706,
        "completion_tokens": 130,
        "total_tokens": 14837
      }
    },
    {
      "question_id": 58,
      "question": "How does the issuance of nonvoting common shares to TD Ameritrade stockholders relate to the integration-related compensation expenses Schwab incurred in the two years following the October 6, 2020 acquisition, particularly regarding bonuses and employee salary adjustments?",
      "original_answer": "Schwab issued approximately 77 million nonvoting common shares to TD Ameritrade stockholders as part of the acquisition on October 6, 2020, with TD Bank subsequently holding 79 million shares of nonvoting common stock by year-end 2021. Following the acquisition, Schwab’s compensation and benefits expense included $1.2 billion from TD Ameritrade in 2021 and $453 million in 2020, reflecting a full-year contribution and integration-related costs. These costs included $283 million and $235 million in acquisition and integration-related compensation expenses in 2021 and 2020, respectively, driven by employee salary increases, bonus accruals, and integration efforts. The issuance of shares was a direct result of the acquisition, which in turn led to significant integration-related compensation expenses, particularly tied to workforce adjustments and bonuses.",
      "llm_answer": "The issuance of nonvoting common shares to TD Ameritrade stockholders was part of the purchase‑price consideration for the October 6 2020 acquisition; the resulting integration‑related compensation expense that Schwab recorded in the two years after the acquisition—primarily bonuses and salary adjustments—was included in the “acquisition and integration‑related costs” reported within total compensation and benefits. This expense is reflected in the $283 million of integration‑related costs included in compensation and benefits for 2021 (and $235 million for 2020), which Schwab discloses as part of the post‑acquisition integration costs.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SCHW_10k_2022.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        },
        "hop_2_rel": {
          "source_file": "SCHW_10k_2022.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        },
        "hop_3_rel": {
          "source_file": "SCHW_10k_2022.pdf",
          "target_page": 45,
          "pages": [
            43,
            44,
            45,
            46,
            47
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 78482,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19866,
        "completion_tokens": 161,
        "total_tokens": 20027
      }
    },
    {
      "question_id": 58,
      "question": "How does MDLZ's use of commodity futures to hedge input cost volatility, including specific commodities like cocoa and wheat, relate to the classification of these instruments as Level 1 financial liabilities, and what does this imply about the transparency and valuation methodology applied to these hedging instruments?",
      "original_answer": "MDLZ uses commodity futures to hedge against price risks for raw materials such as cocoa, wheat, and sugar (page 94). These instruments are classified as Level 1 financial liabilities because they are exchange-traded and valued using quoted market prices on commodity exchanges (page 112). This classification indicates that the valuation methodology for these hedging instruments is based on highly transparent and observable market data, reflecting a lower level of subjectivity compared to Level 2 or 3 instruments. The connection between the operational use of these futures and their fair value classification highlights how MDLZ aligns its risk management practices with transparent, market-based valuation standards.",
      "llm_answer": "MDLZ classifies commodity futures used to hedge input costs like cocoa and wheat as Level 1 financial liabilities because they are exchange‑traded contracts with quoted market prices, which the company values using Level 1 inputs. This classification reflects a transparent, market‑based valuation methodology, allowing the fair‑value changes to be recorded in accumulated other comprehensive earnings (for effective cash‑flow hedges) or in earnings when ineffective or excluded from hedge accounting. Consequently, the hedging instruments are marked‑to‑market using observable price levels, providing clear and reliable valuation for these commodity derivatives.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 69212,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17562,
        "completion_tokens": 165,
        "total_tokens": 17727
      }
    },
    {
      "question_id": 58,
      "question": "How does GE's increased allocation to growth assets in its reinsurance treaties affect the assumptions and outcomes of its premium deficiency testing for long-term care insurance policies?",
      "original_answer": "GE's increased allocation to growth assets, such as private equity and high-yield credit strategies, has led to a higher discount rate used in premium deficiency testing—from 5.70% in 2020 to 6.15% in 2021. This increase contributed significantly to a larger premium deficiency testing margin, which reflects greater projected investment returns. However, this shift also introduces more earnings volatility due to the fair value accounting of these assets. The premium deficiency testing process, which evaluates the adequacy of future policy benefit reserves, must now account for the uncertainty and variability in returns from these higher-risk investments. Despite favorable emerging morbidity experience, the testing continues to rely heavily on assumptions about future investment yields and reinsurance treaty structures, which are subject to change based on evolving market conditions and portfolio performance.",
      "llm_answer": "The document indicates that GE’s increased allocation to growth assets in its reinsurance treaties—specifically the shift toward higher-yielding growth assets such as private equity, equity-like securities, and high-yield credit strategies—directly contributed to a higher discount rate assumption (6.15% in 2021 versus 5.70% in 2020) used in its premium deficiency testing. This higher discount rate reduced the present value of future policy benefit reserves, resulting in a significantly larger premium deficiency margin (approximately 11% of reserves in 2021 versus less than 2% in 2020). Consequently, the premium deficiency testing assumptions were updated to reflect this increased discount rate, which improved the margin and avoided the need for additional reserve accruals. The document explicitly links the growth asset allocation strategy to the revised discount rate assumptions and the resulting premium deficiency outcomes.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GE_10k_2022.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        },
        "hop_2_rel": {
          "source_file": "GE_10k_2022.pdf",
          "target_page": 50,
          "pages": [
            48,
            49,
            50,
            51,
            52
          ]
        },
        "hop_3_rel": {
          "source_file": "GE_10k_2022.pdf",
          "target_page": 52,
          "pages": [
            50,
            51,
            52,
            53,
            54
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 85545,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21612,
        "completion_tokens": 234,
        "total_tokens": 21846
      }
    },
    {
      "question_id": 58,
      "question": "How did ConocoPhillips' impairment of its APLNG investment in 2021 reflect on the long-term viability of APLNG's $5.7 billion nonrecourse financing structure, especially considering Origin Energy's dual role as both a joint venture partner and operator of APLNG's production system?",
      "original_answer": "ConocoPhillips recorded a $688 million pre-tax impairment on its APLNG investment in 2021 due to a decline in fair value below carrying value, as evidenced by Origin Energy's sale of a 10% stake for $1.645 billion. This impairment suggests ConocoPhillips viewed APLNG's long-term prospects as less favorable than previously anticipated, despite APLNG having a substantial $5.7 billion in outstanding nonrecourse financing at year-end. APLNG's financing structure, composed of U.S. Ex-Im Bank loans, commercial bank facilities, and private placement notes, was scheduled for bi-annual repayments through 2030, making the long-term viability of this structure highly dependent on sustained LNG demand and pricing. Origin Energy's role as operator of APLNG's production and pipeline system, while ConocoPhillips operates the LNG facility, introduces operational interdependence that could affect cash flow predictability. The impairment decision indicates ConocoPhillips factored in risks related to both market conditions and the complex operational structure when assessing APLNG's future cash flows, raising questions about whether the financing obligations can be met under the revised fair value assumptions.",
      "llm_answer": "ConocoPhillips' $688 million impairment of its APLNG investment in 2021 signaled that the $5.7 billion non‑recourse financing structure underpinning APLNG was no longer fully supported by market expectations, especially given the joint‑venture’s reliance on Origin Energy as both a shareholder and operator. The impairment stemmed from Origin’s sale of a 10 % stake for $1.645 billion, which revealed a market‑based valuation below ConocoPhillips’ carrying amount and highlighted the risks of APLNG’s long‑term financing amid evolving project economics and the strategic exit of a key partner.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 100,
          "pages": [
            98,
            99,
            100,
            101,
            102
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 65535,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16634,
        "completion_tokens": 148,
        "total_tokens": 16782
      }
    },
    {
      "question_id": 58,
      "question": "How do Southern Company's operational risks related to cyber intrusions specifically impact the financial and operational viability of their nuclear power plants, given the significant role these plants play in electricity generation for Alabama Power and Georgia Power?",
      "original_answer": "Southern Company's nuclear power plants, which are operated by Southern Nuclear, account for approximately 26% and 28% of the total KWHs generated by Alabama Power and Georgia Power respectively. These plants are subject to a range of operational risks, including cyber intrusions, which are explicitly called out in the Operational Risks section. Cyber intrusions could lead to increased compliance costs, potential fines, or even shutdowns of nuclear units by the NRC if security standards are not met. The financial impact of such events could be significant, especially since damages or decommissioning costs could exceed available insurance or decommissioning trusts. This creates a direct link between cybersecurity threats and the financial and operational viability of the nuclear power plants, which are critical to Southern Company’s electricity generation portfolio.",
      "llm_answer": "Southern Company’s nuclear plants – especially Plant Vogtle Units 3 and 4 – are central to the electricity supply of Alabama Power and Georgia Power.  Their operation is exposed to significant cyber‑intrusion risk, and any successful intrusion could force costly shutdowns, regulatory penalties, or remediation expenses that would jeopardize the plants’ ability to generate power and meet their cost‑recovery and financing obligations.  Because these reactors provide a large share of the utilities’ baseload generation, such operational disruptions would directly threaten the financial and operational viability of the companies’ core service territory.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 84278,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21314,
        "completion_tokens": 163,
        "total_tokens": 21477
      }
    },
    {
      "question_id": 59,
      "question": "How does MDLZ's use of commodity futures to hedge input cost volatility, as detailed in the financial instruments section, relate to the classification of these instruments as Level 1 financial liabilities, and what does this imply about the transparency and valuation methodology of these hedging instruments?",
      "original_answer": "MDLZ uses commodity futures to hedge against price risks associated with forecasted purchases of raw materials such as cocoa, sugar, and wheat. These futures are classified as Level 1 financial liabilities because their fair value is determined using quoted market prices on commodity exchanges, indicating high transparency and observable valuation inputs. This classification reflects a direct link between the company's risk management strategy and the accounting treatment of these instruments, showing that MDLZ relies on highly liquid and transparent markets for its commodity hedging activities.",
      "llm_answer": "MDLZ classifies its commodity futures and related derivatives as Level 1 financial liabilities because they are quoted prices in active markets for identical assets, which provides transparent, observable market inputs for valuation. This classification underscores that the hedging instruments are marked‑to‑market using readily available exchange prices, enhancing the transparency of the fair‑value measurements and allowing the company to apply a straightforward, market‑based valuation methodology for these cash‑flow hedges.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 69212,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17559,
        "completion_tokens": 132,
        "total_tokens": 17691
      }
    },
    {
      "question_id": 59,
      "question": "What does Merck disclose about the anticipated patent expiration for MK-1654 in the U.S., and how does this relate to their broader disclosure about patent protections across key global markets?",
      "original_answer": "Merck discloses that MK-1654 has an anticipated U.S. patent expiration date of 2036. This information is presented in a list of products under review in the U.S. with their respective expected expiration years. Separately, Merck also discloses the existence of a table that includes patent expiration dates for key products across multiple jurisdictions, including the U.S., EU, Japan, and China. While the specific expiration details for MK-1654 in non-U.S. markets are not provided in the referenced sections, the structure of the disclosures indicates that Merck tracks and reports patent protections across several key global markets.",
      "llm_answer": "Merck discloses that the U.S. patent protection for MK-1654 is anticipated to expire in 2036, aligning with its broader global strategy of maintaining patent protections across key markets through mechanisms such as patent term extensions (PTEs) and supplementary protection certificates (SPCs). This approach ensures layered market exclusivity beyond standard patent terms, particularly in regions like the EU and Japan, where additional regulatory exclusivities may extend protection further.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 15,
          "pages": [
            13,
            14,
            15,
            16,
            17
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 84920,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21451,
        "completion_tokens": 123,
        "total_tokens": 21575
      }
    },
    {
      "question_id": 59,
      "question": "How does Broadcom's valuation methodology for developed technology related to VMware Cloud Foundation contrast with its treatment of developed technology for SoC controller products in different sections of the 10-K?",
      "original_answer": "Broadcom applied different valuation methodologies to developed technology depending on its application context. For VMware Cloud Foundation (VCF), Broadcom used the multi-period excess earnings method under the income approach, valuing it at $24,156 million, with a significant portion attributed to VCF. This method reflects the present value of projected cash flows less charges representing contributions of other assets. In contrast, for SoC controller products for hard disk drive applications, Broadcom used the relief-from-royalty method, which applies a royalty rate to forecasted revenue. This difference in approach reflects the distinct nature of the technologies—software-based cloud infrastructure (VCF) versus hardware controller products—and how each contributes to cash flows. The economic useful life for both was determined based on technology cycles and forecasted cash flows, but the underlying assumptions and modeling techniques differ significantly.",
      "llm_answer": "Broadcom evaluates developed technology related to VMware Cloud Foundation using the multi‑period excess earnings method under the income approach, assigning it an 8‑year weighted‑average amortization period, whereas developed technology for Seagate’s SoC controller products is valued using the relief‑from‑royalty method and amortized over an 11‑year period. Consequently, the VMware‑related intangible assets are amortized more quickly (8 years) and based on projected cash‑flow synergies from cloud‑foundation products, while the SoC controller intangibles are amortized over a longer horizon (11 years) and rely on royalty‑based cash‑flow assumptions.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AVGO_10k_2023.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_2_rel": {
          "source_file": "AVGO_10k_2023.pdf",
          "target_page": 51,
          "pages": [
            49,
            50,
            51,
            52,
            53
          ]
        },
        "hop_3_rel": {
          "source_file": "AVGO_10k_2023.pdf",
          "target_page": 70,
          "pages": [
            68,
            69,
            70,
            71,
            72
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 57969,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14725,
        "completion_tokens": 164,
        "total_tokens": 14889
      }
    },
    {
      "question_id": 59,
      "question": "How does Broadcom's valuation methodology for developed technology related to VMware Cloud Foundation differ from its valuation methodology for developed technology in the SoC controller business, and what does this reveal about the strategic importance of each asset post-acquisition?",
      "original_answer": "Broadcom valued the developed technology related to VMware Cloud Foundation using the multi-period excess earnings method under the income approach, which reflects the present value of projected cash flows less charges representing the contribution of other assets. This was specifically applied to $24,156 million of developed technology, a significant portion of which was tied to VMware Cloud Foundation. In contrast, the developed technology for SoC controller products for hard disk drive applications was valued using the relief-from-royalty method, which applies a royalty rate to forecasted revenue. The difference in methodologies reveals that Broadcom views VMware-related developed technology as more closely tied to direct cash flows and core operations, while SoC controller technology is seen through the lens of licensing potential. This distinction underscores the strategic integration of VMware's cloud infrastructure as a core growth engine versus the more traditional, royalty-based monetization of storage controller IP.",
      "llm_answer": "Broadcom valued its developed technology related to VMware Cloud Foundation using the multi-period excess earnings method under the income approach, reflecting the present value of projected cash flows specific to that technology, while its SoC controller technology was valued using the relief-from-royalty method under the income approach, focusing on royalty rates applied to forecasted revenue from hard disk drive applications. This difference highlights that VMware Cloud Foundation is treated as a core, high-value strategic asset requiring complex, long-term (8-year) valuation assumptions, whereas the SoC controller assets are considered more commoditized with shorter economic lives and simpler royalty-based valuation, underscoring the strategic priority placed on VMware's cloud infrastructure platform post-acquisition.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AVGO_10k_2023.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_2_rel": {
          "source_file": "AVGO_10k_2023.pdf",
          "target_page": 51,
          "pages": [
            49,
            50,
            51,
            52,
            53
          ]
        },
        "hop_3_rel": {
          "source_file": "AVGO_10k_2023.pdf",
          "target_page": 70,
          "pages": [
            68,
            69,
            70,
            71,
            72
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 57969,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14743,
        "completion_tokens": 208,
        "total_tokens": 14951
      }
    },
    {
      "question_id": 59,
      "question": "What is the relationship between CVS's $266 million investment in Common Collective Trusts and the guaranteed obligations of $1.3 billion in Separate Accounts assets, and how does the role of Common Collective Trusts within Separate Accounts inform the risk profile of this pension-related guarantee?",
      "original_answer": "CVS reports a $266 million investment in Common Collective Trusts as part of its pension investments on page 166. These Common Collective Trusts are further described on page 151 as components of Separate Accounts assets, which are used to fund large case pension products where contract holders bear the investment risk. On page 177, CVS discloses that it guarantees certain Separate Accounts assets totaling $1.3 billion, which are contractually required to fund specific pension annuities. Since Common Collective Trusts are part of these Separate Accounts, the performance and valuation of these trusts directly influence the ability of contract holders to maintain required funding levels. If the value of investments like the Common Collective Trusts declines, the Company may be obligated to cover shortfalls, thereby increasing its financial exposure under these guarantees.",
      "llm_answer": "The $266 million investment in Common Collective Trusts is a component of the $1.3 billion of Separate‑Account assets that the Company guarantees; the trusts are held within those Separate Accounts and are used to fund the guaranteed pension benefits. Because the trusts are part of the Separate‑Account structure, the risk of the guarantee is tied to the performance of these trust assets—if their value falls short, the Company may need to cover the shortfall to meet the guaranteed $1.3 billion obligation, thereby increasing the overall risk profile of the pension guarantee.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "target_page": 166,
          "pages": [
            164,
            165,
            166,
            167,
            168
          ]
        },
        "hop_2_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "target_page": 151,
          "pages": [
            149,
            150,
            151,
            152,
            153
          ]
        },
        "hop_3_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "target_page": 177,
          "pages": [
            175,
            176,
            177,
            178,
            179
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 69974,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17754,
        "completion_tokens": 144,
        "total_tokens": 17899
      }
    },
    {
      "question_id": 59,
      "question": "How does Capital One's exposure to the Expanded Risk-Based Approach, introduced by the Basel III Finalization Proposal, affect its CET1 capital requirements under the proposed phase-in timeline?",
      "original_answer": "Capital One is subject to the Basel III Finalization Proposal, which introduces the Expanded Risk-Based Approach for calculating risk-weighted assets. This approach would require Capital One to calculate its risk-based capital ratios under both the Expanded Risk-Based Approach and the existing Basel III standardized approach, being bound by the lower of the two ratios. The proposal also mandates that Category III and IV institutions like Capital One recognize certain elements of AOCI, including unrealized gains and losses on available-for-sale securities, in CET1 capital starting July 1, 2025, with a three-year phase-in period. This change could lead to greater volatility in CET1 capital and may constrain capital flexibility during the phase-in period, especially if AOCI values decline. The final impact remains uncertain due to the proposal's pending status and potential modifications before adoption.",
      "llm_answer": "Capital One’s CET1 capital requirements under the Basel III Finalization Proposal would be affected by the Expanded Risk‑Based Approach through a higher risk‑weighting of assets, which would increase the amount of risk‑weighted assets used to calculate CET1 ratios. The proposal also requires recognition of certain AOCI elements and tighter deductions, and it introduces a phased‑in timeline that would gradually tighten CET1 capital ratios beginning in 2025. Consequently, Capital One must hold a larger CET1 buffer to meet the new risk‑weighting and capital‑buffer standards.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COF_10k_2024.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_2_rel": {
          "source_file": "COF_10k_2024.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_3_rel": {
          "source_file": "COF_10k_2024.pdf",
          "target_page": 120,
          "pages": [
            118,
            119,
            120,
            121,
            122
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 63505,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16104,
        "completion_tokens": 144,
        "total_tokens": 16248
      }
    },
    {
      "question_id": 59,
      "question": "What explains the 131.7% increase in wholesale revenues from sales to affiliated companies in 2024, and how does this revenue shift align with the cost-sharing mechanisms outlined under the IIC framework administered by SCS?",
      "original_answer": "The 131.7% increase in wholesale revenues from sales to affiliated companies in 2024 was primarily due to a 165.5% increase in the volume of KWH sales, driven by higher energy demand from affiliated companies. This revenue shift aligns with the IIC framework, which governs how power pool transactions are managed across Southern Company’s integrated system. Under the IIC, SCS administers the coordinated operation of electric facilities, including centralized economic dispatch and the proportionate sharing of costs and revenues from power pool transactions. This structured coordination facilitates the internal reallocation of energy resources, directly influencing the volume and value of intercompany sales, and ensures that costs and revenues are shared according to predefined mechanisms. Therefore, the significant increase in affiliate revenues reflects both operational dynamics and the structured cost and revenue allocation under the IIC, as executed by SCS.",
      "llm_answer": "The 131.7 % jump in wholesale revenues from sales to affiliated companies in 2024 stems from a 165.5 % rise in the volume of kilowatt‑hours sold to affiliates, driven by heightened energy demand within the Southern Company power pool; this volume increase more than offset modest price changes and was enabled by the IIC‑governed cost‑sharing framework administered by SCS, which pools generation resources and allocates excess energy among participants while providing for the recovery of specified costs and the proportionate sharing of pool‑related revenues.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 165,
          "pages": [
            163,
            164,
            165,
            166,
            167
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 66,
          "pages": [
            64,
            65,
            66,
            67,
            68
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 65827,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16696,
        "completion_tokens": 140,
        "total_tokens": 16836
      }
    },
    {
      "question_id": 60,
      "question": "How does the voting structure of Class A Common Stock relate to the book value of Series B Preferred Stock, and what implications does this have for shareholder influence in key corporate decisions?",
      "original_answer": "The Class A Common Stockholders have full voting rights on all matters on which stockholders generally are entitled to vote, whereas Series B Preferred Stockholders have no voting rights except in limited circumstances, such as specific merger or consolidation scenarios. As of September 30, 2024, there were 1,733 shares of Class A Common Stock issued and outstanding, giving these shareholders significant influence over corporate governance. Meanwhile, the Series B Preferred Stock had a book value of $540 million as of the same date, but holders of this stock do not participate in general voting, which limits their influence on strategic decisions. This structure implies that holders of Class A Common Stock maintain control over major corporate actions, even though Series B Preferred Stock has economic value but no corresponding voting power.",
      "llm_answer": "The voting structure of the Company’s Class A common stock is not directly tied to the book value of the Series B Preferred Stock; rather, the Series B (and Series C) Preferred Stock carries limited voting rights that can influence certain corporate actions (e.g., mergers or amendments affecting the preferred series) but generally do not affect the vote of Class A shareholders. Because the Series B Preferred Stock’s conversion rights and liquidation preferences can affect the effective number of shares outstanding and the economic terms of any transaction, changes in its book value can indirectly alter the voting power of the remaining Class A holders, potentially reducing their influence in key decisions such as approvals of major transactions or amendments to the charter.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "V_10k_2024.pdf",
          "target_page": 58,
          "pages": [
            56,
            57,
            58,
            59,
            60
          ]
        },
        "hop_2_rel": {
          "source_file": "V_10k_2024.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_3_rel": {
          "source_file": "V_10k_2024.pdf",
          "target_page": 61,
          "pages": [
            59,
            60,
            61,
            62,
            63
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 103196,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 26028,
        "completion_tokens": 196,
        "total_tokens": 26224
      }
    },
    {
      "question_id": 60,
      "question": "How does MO's reliance on regulatory authorizations for future revenue growth from innovative tobacco products, particularly in relation to Horizon's commercialization efforts, reconcile with the uncertainty surrounding the FDA's PMTA review timelines and Horizon's strategic importance as a joint venture with JTIUH?",
      "original_answer": "MO identifies regulatory authorizations as a critical factor for the success of Horizon, which is a joint venture with JTIUH aimed at commercializing heat-not-burn tobacco products (HTS) in the U.S. The company acknowledges that Horizon's ability to generate new revenue streams is heavily dependent on receiving these authorizations. However, MO also highlights the unpredictability of the FDA's PMTA review process, which could delay product launches and allow competitors to capture market share. This uncertainty contrasts with Horizon's strategic importance as MO's primary vehicle for entering the HTS market, as emphasized in the MD&A section where Horizon is described as a majority-owned joint venture central to the company's 'Moving Beyond Smoking' initiative. The sensitivity of Horizon's revenue potential to regulatory timelines raises concerns about MO's ability to meet its long-term financial forecasts, especially given that a 1% increase in the discount rate used in the 2024 impairment test could have triggered a $125 million impairment charge for the e-vapor reporting unit, indicating high sensitivity to forecast assumptions.",
      "llm_answer": "MO's reliance on regulatory authorizations for future revenue growth from innovative tobacco products, particularly Horizon's commercialization, is reconciled with the uncertainty of FDA PMTA review timelines and Horizon's strategic importance as a joint venture with JTIUH by acknowledging that while Horizon is a key growth driver, its success—and thus the revenue potential from innovative products—is contingent on regulatory approvals and market acceptance, which are subject to delays or adverse outcomes (e.g., the ITC's NJOY ACE ban and ongoing patent litigation). The company recognizes that prolonged FDA review periods or unfavorable regulatory/legal decisions could materially delay or prevent commercialization, directly impacting Horizon's ability to generate revenue and potentially triggering goodwill or intangible asset impairments (as seen with the Skoal trademark and e-vapor reporting unit), thereby exposing the strategic investment to significant execution and regulatory risks.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2024.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2024.pdf",
          "target_page": 22,
          "pages": [
            20,
            21,
            22,
            23,
            24
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 84444,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21371,
        "completion_tokens": 250,
        "total_tokens": 21622
      }
    },
    {
      "question_id": 60,
      "question": "How does Microsoft's OEM distribution strategy for Office relate to its competitive positioning against Meta in the productivity and collaboration software market, given Meta's presence in adjacent digital platforms that could encroach on enterprise productivity tools?",
      "original_answer": "Microsoft leverages its broad OEM distribution network, which includes major partners like Dell, HP, and Lenovo, to pre-install Office on new devices, ensuring widespread adoption and integration into enterprise workflows. This distribution model strengthens Office's entrenched position in the productivity software market, which directly competes with offerings from Meta and other tech companies. Meta is mentioned as a competitor to Office due to its growing presence in digital collaboration and communication platforms, particularly through social and messaging tools that could serve as informal productivity hubs. Meanwhile, Microsoft's broader product and service development strategy, led by the 'Experiences and Devices' engineering group, includes Office as a central component in its end-user experiences, reinforcing its differentiation against Meta. Thus, the OEM-driven reach of Office, combined with Microsoft's integrated product development approach, forms a key part of its competitive defense against Meta's expansion into adjacent productivity domains.",
      "llm_answer": "Microsoft's OEM distribution strategy for Office—pre-installing Office on devices sold by OEMs like Dell, HP, and Lenovo—directly strengthens its competitive positioning against Meta in the enterprise productivity and collaboration market. By embedding Office within the Windows ecosystem and leveraging its deep integration with Windows OEM channels, Microsoft ensures broad, default adoption in enterprise environments, creating a significant barrier to entry for Meta's adjacent digital platforms (such as Facebook Workplace or Meta's productivity tools) which lack comparable pre-installation partnerships with hardware manufacturers. This OEM-driven distribution, combined with Microsoft's vast enterprise licensing programs (like Enterprise Agreements and Microsoft 365 subscriptions), solidifies its dominance in core enterprise productivity tools, making it difficult for Meta to gain traction in the same market segment despite Meta's social platform presence.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 18,
          "pages": [
            16,
            17,
            18,
            19,
            20
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 61447,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15607,
        "completion_tokens": 242,
        "total_tokens": 15849
      }
    },
    {
      "question_id": 60,
      "question": "How does Cisco's financing of technical support services relate to the $53 million credit loss allowance for loan receivables as of July 29, 2023, and what risk exposure does this represent given the $27.9 billion in channel partner financing from fiscal 2022?",
      "original_answer": "Cisco provides technical support services as part of its financing arrangements, which include loan receivables tied to the sale of hardware, software, and services (including technical support). These loan receivables are subject to credit risk, as evidenced by the $53 million allowance for credit losses on loan receivables as of July 29, 2023. This allowance reflects the company's estimate of potential defaults on these financing arrangements. Given that technical support services are embedded in loan packages, any credit risk associated with loan defaults indirectly affects the risk profile of services like technical support. Furthermore, in fiscal 2022, the volume of channel partner financing was $27.9 billion, with $1.7 billion of that amount subject to guarantees by Cisco as of July 29, 2023. This indicates that Cisco retains contingent liability exposure on financing arrangements that include technical support services, which could impact the credit loss allowance if defaults occur.",
      "llm_answer": "Cisco's $53 million credit loss allowance for loan receivables reflects the allowance it maintains for the portion of its financing receivables (loans and lease receivables) it expects to be uncollectible. This allowance is applied to the net loan‑receivable balance of $5.8 billion reported as of July 27 2024. The allowance is modest relative to the total exposure, but it is set against a backdrop of $27.9 billion of channel‑partner financing that Cisco provided in fiscal 2022, indicating that a portion of its financing activities—particularly those that involve third‑party guarantees and transfers of receivables—could give rise to credit risk if counterparties default. Consequently, the allowance represents a contingent liability that could become material if the collectability of these financing arrangements deteriorates.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 75425,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19100,
        "completion_tokens": 208,
        "total_tokens": 19309
      }
    },
    {
      "question_id": 60,
      "question": "How does the allocation of $21.7 billion in 2023 stock-based compensation expenses tied to Class C stock awards reconcile with the company's repurchase strategy for Class A shares, given the identical dividend and liquidation rights between these classes?",
      "original_answer": "The $21.7 billion in 2023 stock-based compensation expenses under the Alphabet 2021 Stock Plan primarily involves Class C stock awards, which contributes to dilution pressure from RSUs vesting over time. To offset this dilution and optimize shareholder value, Alphabet repurchases both Class A and Class C shares based on market conditions and relative trading prices. Despite differing voting rights, both share classes have identical dividend and liquidation rights, ensuring equitable treatment in earnings allocation. The repurchase strategy for Class A shares, therefore, complements the company's broader capital allocation approach by balancing the dilutive impact of Class C stock awards while maintaining proportionate value distribution across share classes.",
      "llm_answer": "The $21.7 billion of 2023 stock‑based compensation expense reflects the fair‑value of RSUs that are expected to settle in Alphabet stock, and the company repurchases Class A and Class C shares in the open market or privately as it deems best, using the $36.3 billion of remaining authorization after the April 2023 $70 billion increase; the repurchase program has no expiration and is executed subject to market conditions, while the identical dividend and liquidation rights of the two classes ensure that the allocation of undistributed earnings treats them proportionately.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        },
        "hop_2_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "hop_3_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 90121,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22768,
        "completion_tokens": 144,
        "total_tokens": 22912
      }
    },
    {
      "question_id": 60,
      "question": "How does UPS's increase in contributions to the New England Teamsters & Trucking Industry Pension Fund from $145 million in 2021 to $234 million in 2023 align with the financial improvement plan's requirements, given the fund's continued red zone status in both years?",
      "original_answer": "UPS's contributions to the New England Teamsters & Trucking Industry Pension Fund increased significantly from $145 million in 2021 to $234 million in 2023. According to page 95, this pension fund has remained in the red zone status in both 2022 and 2023, indicating severe underfunding. Page 94 clarifies that UPS's collectively-bargained contributions satisfy the requirements of all implemented financial improvement plans (FIPs) and that no surcharges are currently required. The increase in contributions aligns with the FIP's requirements for red zone plans, which typically mandate higher employer contributions to address funding deficiencies. Despite the fund remaining in the red zone, UPS's increased contributions reflect compliance with the FIP's mandated funding levels without triggering additional surcharges, suggesting a structured approach to addressing the pension fund's financial distress.",
      "llm_answer": "UPS’s contributions to the New England Teamsters & Trucking Industry Pension Fund rose from $145 million in 2021 to $234 million in 2023, reflecting the higher contractual contribution rates negotiated in the 2023 collective‑bargaining agreement. Although the fund remained in the red zone in both 2022 and 2023, the company’s agreed‑upon contributions satisfy the fund’s financial‑improvement plan requirements and do not trigger any additional surcharge obligations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 87500,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22115,
        "completion_tokens": 117,
        "total_tokens": 22232
      }
    },
    {
      "question_id": 60,
      "question": "Given Gilead's decision in January 2024 to discontinue enrollment in the Phase 3 NSCLC trial for the zimberelimab/domvanalimab combination, how does this clinical development strategy align with the long-term commercial potential of domvanalimab, which retains U.S. and EU patent protection until 2037?",
      "original_answer": "Gilead’s decision to halt enrollment in the Phase 3 NSCLC trial for the zimberelimab/domvanalimab combination suggests a strategic reassessment of the clinical viability or competitive positioning of this regimen in a key oncology indication. Despite this setback, domvanalimab remains protected by patents in both the U.S. and EU through 2037, preserving a long runway for potential development in alternative indications or combination strategies. This creates a tension between the near-term discontinuation decision—likely based on interim data, competitive landscape, or cost-benefit analysis—and the long-term asset value implied by the patent timeline. The continuation of patent protection opens the door for Gilead to pivot the development strategy for domvanalimab, potentially in other tumor types or in combination with other therapies, even if the NSCLC indication is deprioritized.",
      "llm_answer": "Gilead's discontinuation of enrollment in the Phase 3 NSCLC trial for the zimberelimab/domvanalimab combination does not alter the long‑term commercial outlook for domvanalimab, which remains protected by U.S. and EU patents extending to 2037. These patent protections, together with regulatory exclusivity and ongoing collaborations, are expected to sustain market potential for domvanalimab well beyond the trial’s pause.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "target_page": 8,
          "pages": [
            6,
            7,
            8,
            9,
            10
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 87705,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22174,
        "completion_tokens": 105,
        "total_tokens": 22279
      }
    },
    {
      "question_id": 60,
      "question": "Given UPS's reliance on net asset value (NAV) to estimate the fair value of its U.S. pension plan investments, how does the company's exposure to private debt—valued at $829 million as of December 31, 2022—factor into the overall subjectivity and risk associated with NAV-based valuations for illiquid assets?",
      "original_answer": "UPS's U.S. pension plans held $9.9 billion in hedge fund, private debt, private equity, and real estate investments as of December 31, 2023, which were valued primarily using net asset value (NAV) from fund managers. Private debt, specifically, represented $829 million of the U.S. plan assets in 2022. These NAV-based valuations are inherently subjective due to the lack of readily determinable fair values and require management adjustments based on unaudited or audited reports received with a lag. Since private debt investments are illiquid and often lack active markets, their fair value estimates are particularly sensitive to assumptions and inputs used by fund managers. This subjectivity increases audit complexity and introduces valuation risk, especially given that unfunded commitments to such funds are expected to be contributed over the next 3–6 years, tying UPS to future capital obligations based on potentially uncertain valuations.",
      "llm_answer": "UPS relies on net asset value (NAV) estimates to value illiquid private‑debt holdings (recorded at $829 million as of 12/31/2022) within its pension plan assets. Because these investments are not traded on public markets, their fair values are derived from unobservable inputs and subject‑to management adjustments between fund reporting dates, creating significant subjectivity and valuation risk. Consequently, the NAV‑based valuation of private‑debt contributes to the overall uncertainty in the pension fund’s reported asset values.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 63,
          "pages": [
            61,
            62,
            63,
            64,
            65
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 73723,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18687,
        "completion_tokens": 134,
        "total_tokens": 18821
      }
    },
    {
      "question_id": 61,
      "question": "Why are forecasted foreign currency transactions included in Disney's foreign exchange hedging program but excluded from the Value at Risk (VAR) model, and how does this exclusion affect the company's overall assessment of financial risk exposure?",
      "original_answer": "Disney actively hedges forecasted foreign currency transactions as part of its foreign exchange risk management strategy, with $9.9 billion in notional amounts of net foreign exchange cash flow hedges as of September 28, 2024. These forecasted transactions are intended to be protected against exchange rate fluctuations through forward and option contracts. However, the company explicitly excludes forecasted transactions, firm commitments, and foreign currency receivables/payables from its Value at Risk (VAR) model, which focuses only on financial instruments like derivatives and market-sensitive equity investments. The VAR model estimates a maximum one-day loss of $255 million at fiscal year-end 2024. By excluding forecasted transactions from the VAR model, Disney does not incorporate the potential volatility or risk associated with these future transactions into its quantitative risk metric, even though they are actively hedged. This creates a divergence between the company's proactive hedging strategy and its formal risk measurement framework, suggesting that the VAR model may understate the full scope of foreign exchange risk the company manages.",
      "llm_answer": "The Company’s foreign‑exchange hedging program includes forecasted currency transactions because those exposures are actively managed and hedged to reduce earnings volatility, but they are excluded from the Value‑at‑Risk (VAR) model since the model only captures realized market‑risk exposures on existing positions. Consequently, the VAR‑derived estimate of the Company’s one‑day market‑risk loss ($255 million at September 28 2024) does not reflect the potential impact of those hedged forecasted transactions, leading management to view the overall financial‑risk exposure as somewhat higher than the VAR figure alone would suggest.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 66790,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16937,
        "completion_tokens": 158,
        "total_tokens": 17096
      }
    },
    {
      "question_id": 61,
      "question": "How does Southern Power's stated useful life for wind assets compare with the contract period duration for the Reading wind project, and what might this imply about the company's long-term revenue visibility from wind energy projects?",
      "original_answer": "Southern Power indicates that wind assets have a useful life of up to 30 years, yet the Reading wind project, located in Kansas, operates under a PPA contract period of only 12 years. This discrepancy suggests that while the company can utilize wind assets for an extended period, the revenue visibility from projects like Reading is significantly shorter, potentially requiring Southern Power to renegotiate or secure new contracts to fully capitalize on the asset's operational lifespan.",
      "llm_answer": "Southern Power's 2021 10-K indicates that its wind assets are depreciated over a maximum useful life of **30 years**, while the Reading wind project's power purchase agreement (PPA) has a **12-year contract period**. This discrepancy implies that Southern Power's long-term revenue visibility from wind energy projects is limited to the PPA term (12 years), after which the assets will continue to be depreciated over the remaining 18 years of their 30-year useful life, potentially exposing the company to revenue uncertainty beyond the contract expiration.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 244,
          "pages": [
            242,
            243,
            244,
            245,
            246
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 330,
          "pages": [
            328,
            329,
            330,
            331,
            332
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 330,
          "pages": [
            328,
            329,
            330,
            331,
            332
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 71418,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18092,
        "completion_tokens": 139,
        "total_tokens": 18232
      }
    },
    {
      "question_id": 61,
      "question": "How does BlackRock's tax reconciliation disclosure for foreign jurisdictions like the UK relate to its non-GAAP presentation of separate account assets managed through BlackRock Life Limited, particularly in light of the economic separation of these assets from stockholders' equity?",
      "original_answer": "BlackRock reports in its tax reconciliation on page 105 that it earns income in foreign jurisdictions such as the UK, which have different statutory tax rates than the 21% U.S. federal rate. This international tax exposure includes operations through entities like BlackRock Life Limited, a UK-based life insurance subsidiary. On page 55, the company explains that BlackRock Life Limited holds separate account assets for pension contracts, which are legally segregated and not available to creditors or economically attributable to BlackRock, despite being consolidated under GAAP. The non-GAAP 'as adjusted' statement excludes these assets and liabilities, aligning with management’s view that they do not impact stockholders' equity or cash flows. Therefore, while the UK operations contribute to foreign taxable income, the economic and financial reporting treatment of BlackRock Life Limited’s separate accounts reflects a structural separation that limits direct financial exposure to these assets in BlackRock’s core equity position.",
      "llm_answer": "The tax reconciliation disclosure for foreign jurisdictions such as the UK is tied to BlackRock’s non‑GAAP presentation of separate‑account assets managed through BlackRock Life Limited by reflecting the same tax‑related adjustments (e.g., valuation allowances, deferred tax liabilities tied to goodwill and intangibles) that are excluded from the “as‑adjusted” financial statements; this allows the company to present a view of its total assets and liabilities that omits the offsetting separate‑account assets and liabilities, thereby showing the economic impact of those foreign‑jurisdiction tax positions on stockholders’ equity.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BLK_10k_2023.pdf",
          "target_page": 105,
          "pages": [
            102,
            103,
            104,
            105,
            106
          ]
        },
        "hop_2_rel": {
          "source_file": "BLK_10k_2023.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_3_rel": {
          "source_file": "BLK_10k_2023.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 99381,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 25094,
        "completion_tokens": 158,
        "total_tokens": 25252
      }
    },
    {
      "question_id": 61,
      "question": "How does the $2,316 million impairment charge recorded by PMI on its investment in Rothmans, Benson & Hedges Inc. relate to the unresolved allocation issue under the CCAA Proposed Plan involving CAD 32.5 billion in aggregate settlement obligations?",
      "original_answer": "PMI recorded a $2,316 million non-cash impairment charge on its investment in Rothmans, Benson & Hedges Inc. (RBH) due to uncertainty and potential liability stemming from the unresolved allocation of the CAD 32.5 billion aggregate settlement amount under the CCAA Proposed Plan. This impairment reflects PMI’s assessment that the fair value of its investment had declined below its carrying value, primarily driven by the risk that RBH could be allocated a significant portion of the global settlement. The CCAA process, which RBH entered in 2019, resulted in deconsolidation and a shift to equity method accounting, and the Proposed Plan filed in October 2024 introduced new impairment indicators due to the unresolved allocation issue among RBH, ITL, and JTIM. The impairment decision was based on a discounted cash flow analysis that incorporated estimates of future sales, margins, and the likely share of the CAD 32.5 billion settlement allocated to RBH.",
      "llm_answer": "The $2,316 million impairment charge reflects PMI’s assessment that the fair value of its remaining stake in Rothmans, Benson & Hedges Inc. is lower than its carrying amount, a shortfall that arises directly from the unresolved allocation of the CAD 32.5 billion settlement amount among RBH, ITL and JTIM under the CCAA‑proposed plan. Because the settlement‑allocation issue remains unsettled, the amount that would ultimately be assigned to RBH—and thus the value of PMI’s investment—cannot be determined, forcing the impairment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 130,
          "pages": [
            128,
            129,
            130,
            131,
            132
          ]
        },
        "hop_2_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 130,
          "pages": [
            128,
            129,
            130,
            131,
            132
          ]
        },
        "hop_3_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 80854,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20454,
        "completion_tokens": 132,
        "total_tokens": 20586
      }
    },
    {
      "question_id": 62,
      "question": "How does Altria's reliance on PM USA's unconditional guarantees for $1.0 billion in new senior notes issued in November 2023 align with the financial obligations and liquidity commitments PM USA itself faces, including $3.4 billion in annual State Settlement Agreement payments?",
      "original_answer": "Altria issued $1.0 billion in new senior notes in November 2023, which are unconditionally guaranteed by PM USA. These guarantees expose PM USA to significant financial obligations, as it is a 100% owned subsidiary responsible for Altria's debt payments. At the same time, PM USA itself faces substantial liquidity commitments, including an average of $3.4 billion in annual payments under State Settlement Agreements through 2024. This creates a dual financial strain, where PM USA must both guarantee Altria's new debt and meet its own large-scale obligations, raising concerns about its capacity to manage both without impacting cash flow or creditworthiness.",
      "llm_answer": "Altria’s reliance on PM USA’s unconditional guarantees for the $1.0 billion senior notes issued in November 2023 is consistent with PM USA’s broader financial obligations, which include $3.4 billion in annual State Settlement Agreement (MSA) payments and other user‑fee liabilities.  The guarantees cover the full amount of the new notes, ensuring that even if PM USA’s own cash flows are strained by its settlement obligations, the parent company will meet the debt service requirements, thereby preserving Altria’s overall liquidity and credit profile.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 81821,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20701,
        "completion_tokens": 138,
        "total_tokens": 20840
      }
    },
    {
      "question_id": 62,
      "question": "How does the $24 million earnings impact from regulatory disallowances at Nicor Gas, disclosed in the MD&A section, reconcile with the $96 million pre-tax charges associated with disallowed capital investments at Nicor Gas in the financial statement footnotes?",
      "original_answer": "The $24 million earnings impact mentioned in the MD&A section on page 86 reflects the net effect of various items, including regulatory disallowances at Nicor Gas. This figure is partially offset by other earnings drivers. In contrast, the $96 million pre-tax charges disclosed in the footnotes on page 302 represent the gross financial impact of disallowed capital investments at Nicor Gas. The difference in magnitude and presentation—net versus gross—highlights how the same regulatory disallowance issue is quantitatively framed differently depending on the document section, with MD&A providing a consolidated earnings view and the footnotes offering detailed cost breakdowns.",
      "llm_answer": "The $24 million earnings impact from Nicor Gas regulatory disallowances reflects the portion of the $96 million pre‑tax charge recorded in the footnotes that is attributed to estimated loss on regulatory disallowance; the remaining balance of the $96 million charge relates to other disallowed capital investments not tied to earnings in the MD&A.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 302,
          "pages": [
            300,
            301,
            302,
            303,
            304
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 69584,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17639,
        "completion_tokens": 86,
        "total_tokens": 17726
      }
    },
    {
      "question_id": 62,
      "question": "How does PM's impairment charge of $2,316 million for its investment in Rothmans, Benson & Hedges Inc. relate to the unresolved allocation of the CAD 32.5 billion CCAA settlement among RBH, ITL, and JTIM, and what does this indicate about the financial exposure and strategic implications for PM despite the deconsolidation of RBH from its financial statements?",
      "original_answer": "PM recorded a $2,316 million non-cash impairment charge for its investment in Rothmans, Benson & Hedges Inc. (RBH) due to the uncertainty and potential financial liability stemming from the unresolved allocation of the CAD 32.5 billion CCAA settlement among RBH, ITL, and JTIM. Despite RBH being deconsolidated from PM's financial statements since 2019, the company still faces significant financial exposure through its continuing investment in RBH, which is tied to the outcome of the Proposed Plan under the CCAA proceedings. The unresolved Allocation Issue creates uncertainty in estimating PM's ultimate liability or financial impact, which affects the fair value of PM's investment in RBH and results in a material impairment. This illustrates that even though RBH is no longer consolidated, PM remains strategically and financially exposed to its Canadian subsidiary's litigation and restructuring outcomes.",
      "llm_answer": "The $2,316 million impairment charge reflects the write‑down of PMI’s remaining stake in Rothmans, Benson & Hedges after it concluded that the unresolved CAD 32.5 billion settlement allocation among RBH, ITL and JTIM signaled a likely shortfall in the value of its investment, underscoring significant financial exposure despite the deconsolidation of RBH. This charge highlights that PMI still bears substantial contingent liabilities tied to the settlement negotiations and the broader Canadian tobacco litigation, which could affect its strategic positioning and capital allocation.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "hop_2_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 130,
          "pages": [
            128,
            129,
            130,
            131,
            132
          ]
        },
        "hop_3_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 130,
          "pages": [
            128,
            129,
            130,
            131,
            132
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 80854,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20482,
        "completion_tokens": 146,
        "total_tokens": 20628
      }
    },
    {
      "question_id": 63,
      "question": "How does the $2,316 million non-cash impairment charge recorded by PMI for its investment in Rothmans, Benson & Hedges Inc. relate to the unresolved allocation issue under the CCAA Proposed Plan involving a CAD 32.5 billion global settlement amount?",
      "original_answer": "PMI recorded a $2,316 million non-cash impairment charge for its investment in Rothmans, Benson & Hedges Inc. (RBH) due to uncertainty and developments regarding the unresolved allocation of the CAD 32.5 billion global settlement amount under the CCAA Proposed Plan. The CCAA proceedings, initiated by RBH in 2019, resulted in PMI deconsolidating RBH and accounting for its investment as an equity security. As of December 31, 2024, PMI determined that the fair value of its investment was significantly lower than its carrying value, primarily due to the unresolved allocation issue among RBH, ITL, and JTIM under the Proposed Plan. Despite the lack of an agreed allocation or court ruling, PMI used estimates and assumptions—such as the allocation share of RBH, sales volumes, and operating margins—to calculate the impairment. Thus, the impairment charge directly reflects PMI’s assessment of the financial impact of the unresolved CCAA settlement allocation.",
      "llm_answer": "The $2,316 million non‑cash impairment charge reflects PMI’s assessment that the fair value of its remaining stake in Rothmans, Benson & Hedges (RBH) is lower than its carrying amount, a shortfall that arises because the unresolved “Allocation Issue” – the division of the proposed CAD 32.5 billion global settlement among RBH, ITL and JTIM – prevents a clear release of the related Canadian tobacco‑litigation claims. This uncertainty over how the settlement amount will be allocated under the CCAA‑proposed plan is what drives the impairment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 130,
          "pages": [
            128,
            129,
            130,
            131,
            132
          ]
        },
        "hop_2_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 130,
          "pages": [
            128,
            129,
            130,
            131,
            132
          ]
        },
        "hop_3_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 80854,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20454,
        "completion_tokens": 136,
        "total_tokens": 20590
      }
    },
    {
      "question_id": 63,
      "question": "How does NEE's disclosure of its Special Use Funds' fair value treatment on the balance sheet reconcile with the regulatory exposure of Nuclear Decommissioning Reserve Funds to potential future funding mandates by the NRC and NDFC?",
      "original_answer": "NEE reports that its Special Use Funds, which include Nuclear Decommissioning Reserve Funds, are primarily composed of marketable securities carried at fair value (with market adjustments for debt securities generally flowing through other comprehensive income). These funds support future decommissioning expenditures for Seabrook, Duane Arnold, and Point Beach. However, despite no current ongoing funding requirements, the NRC and NDFC retain the authority to mandate additional contributions in the future. This regulatory risk is not quantified in the fair value disclosures, creating a potential misalignment between the reported value of the funds and the future obligations that may be imposed by regulators, which could significantly impact NEE's liquidity and capital planning.",
      "llm_answer": "NEE’s Special Use Funds—including the Nuclear Decommissioning Reserve Fund—are recorded on the balance sheet at fair value, with market‑priced securities and other investments classified as Level 3 when unobservable inputs (e.g., forward prices, implied volatilities, migration rates) are used. The fund’s fair‑value hierarchy and sensitivity analyses disclose that changes in these inputs affect the fund’s valuation, and the related regulatory assets/liabilities reflect the offsetting impact of any future NRC or NDFC funding mandates. Consequently, while the balance‑sheet presentation reflects current fair‑value measurements, the underlying regulatory exposure to potential future funding requirements remains tied to the same unobservable inputs that drive the fund’s valuation.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NEE_10k_2023.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_2_rel": {
          "source_file": "NEE_10k_2023.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        },
        "hop_3_rel": {
          "source_file": "NEE_10k_2023.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 111895,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 28208,
        "completion_tokens": 196,
        "total_tokens": 28405
      }
    },
    {
      "question_id": 63,
      "question": "How does the $122 million pre-tax gain from acquiring Sabra align with PepsiCo's strategic emphasis on branded dips within Frito-Lay North America?",
      "original_answer": "PepsiCo acquired the remaining 50% ownership in Sabra Dipping Company for $241 million, resulting in a $122 million pre-tax gain. This acquisition made Sabra a wholly-owned subsidiary, which aligns with PepsiCo's strategic focus on branded dips under Frito-Lay North America (FLNA), as Sabra is known for its refrigerated dips and spreads. FLNA’s portfolio includes branded dips, and the integration of Sabra strengthens this segment. The pre-tax gain may provide additional financial flexibility to invest in or expand FLNA’s branded dip offerings, reinforcing the company’s strategic emphasis on this category.",
      "llm_answer": "The $122 million pre‑tax gain from acquiring Sabra is recorded in the Frito‑Lay North America division and is reflected in selling, general and administrative expenses, aligning with PepsiCo’s strategic focus on expanding its branded dip portfolio within FLNA. This gain underscores the company’s emphasis on growing its snack‑dip offerings as part of its broader branded‑food strategy.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PEP_10k_2024.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_2_rel": {
          "source_file": "PEP_10k_2024.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_3_rel": {
          "source_file": "PEP_10k_2024.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 61744,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15650,
        "completion_tokens": 96,
        "total_tokens": 15746
      }
    },
    {
      "question_id": 64,
      "question": "How does Morgan Stanley's governance structure, including both the Board-level Risk Committee (BRC) and the Climate Risk Committee, specifically address the operational risks to facilities and people posed by physical climate risks as outlined in its 2024 10-K?",
      "original_answer": "Morgan Stanley identifies physical climate risks—such as floods, hurricanes, and rising sea levels—as potential threats that could lead to increased operational risk by endangering its facilities and personnel. These risks are managed under an overarching Enterprise Risk Management (ERM) framework that integrates climate risk considerations into existing processes. The Board-level Risk Committee (BRC) oversees firmwide risks, including climate risk, and receives updates on scenario analysis and climate risk integration efforts. Additionally, the Climate Risk Committee, co-chaired by the Chief Risk Officer and Chief Sustainability Officer, shapes the firm’s approach to managing these risks in alignment with the overall risk framework. This dual governance structure ensures that physical climate risks are systematically translated into operational risk mitigation strategies at both strategic and tactical levels.",
      "llm_answer": "Morgan Stanley’s Board‑level Risk Committee (BRC) oversees firm‑wide risk, including climate risk, and receives regular updates on how physical climate threats could affect its facilities and people. The Climate Risk Committee—co‑chaired by the Chief Risk Officer and Chief Sustainability Officer—feeds its findings into the BRC, which then escalates relevant operational‑risk considerations (such as disruptions to sites, workforce safety and infrastructure) to the Board and the Operations and Technology Committee (BOTC) for oversight and mitigation.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MS_10k_2024.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        },
        "hop_2_rel": {
          "source_file": "MS_10k_2024.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        },
        "hop_3_rel": {
          "source_file": "MS_10k_2024.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 73469,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18609,
        "completion_tokens": 138,
        "total_tokens": 18747
      }
    },
    {
      "question_id": 64,
      "question": "How does Amgen's equity stake in BeiGene, Ltd., acquired for $2.8 billion in 2020, influence the commercialization and competitive risk profile of KYPROLIS, especially given that KYPROLIS is a small molecule product vulnerable to generic competition and is already being sold by BeiGene in China under a profit-sharing arrangement?",
      "original_answer": "Amgen acquired a $2.8 billion equity stake in BeiGene, Ltd. in 2020 to expand its oncology presence in China. As part of the collaboration, BeiGene began selling KYPROLIS in China in 2022, with Amgen and BeiGene sharing profits and losses equally during the initial commercialization period. KYPROLIS, being a small molecule product, is particularly vulnerable to generic competition following patent expiration, as seen with Sensipar, where Amgen lost significant market share and revenue quickly after generic entry. This dual exposure—through both equity investment and joint commercialization—heightens Amgen's risk, as a loss of exclusivity for KYPROLIS could not only erode its own sales but also impact the financial returns from its strategic stake in BeiGene.",
      "llm_answer": "Amgen’s $2.8 billion equity investment in BeiGene created a profit‑sharing partnership that lets BeiGene sell KYPROLIS in China while Amgen supplies the drug; however, because KYPROLIS is a small‑molecule product vulnerable to generic competition, the partnership does not eliminate the competitive risk to Amgen’s sales in that market.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 98,
          "pages": [
            96,
            97,
            98,
            99,
            100
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 14,
          "pages": [
            12,
            13,
            14,
            15,
            16
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 82000,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20766,
        "completion_tokens": 84,
        "total_tokens": 20850
      }
    },
    {
      "question_id": 64,
      "question": "How does Gulfstream's anticipation of FAA certification for the G700 in early 2024, as described in the product development section, align with the financial implications of increased inventory and customer deposits reported in the financial section?",
      "original_answer": "Gulfstream's expectation that the G700 will enter service following FAA certification in early 2024 (from the product development section) directly informs the company's production ramp-up activities described in the financial section. This forward-looking certification timeline has led to a significant increase in total inventories during 2023, specifically tied to G700 production, in anticipation of certification. Simultaneously, customer deposits associated with firm orders for these new aircraft have increased, reflecting strong market interest and aligning with the strategic introduction of a next-generation model that features advanced technologies and performance capabilities.",
      "llm_answer": "Gulfstream's anticipation of FAA certification for the G700 in early 2024 is driving a strategic ramp‑up of production and inventory to meet expected demand, which is reflected in the significant increase in inventories reported in 2023. This higher inventory level is matched by rising customer deposits and advances tied to firm orders for the new aircraft, underscoring the financial impact of preparing for the G700’s market entry.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_2_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 71,
          "pages": [
            69,
            70,
            71,
            72,
            73
          ]
        },
        "hop_3_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 71,
          "pages": [
            69,
            70,
            71,
            72,
            73
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 46562,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 11878,
        "completion_tokens": 108,
        "total_tokens": 11987
      }
    },
    {
      "question_id": 64,
      "question": "What is the significance of consistently classifying debt investments as AFS across multiple Duke Energy subsidiaries, and how does this uniform accounting treatment impact the comparability of their respective investment portfolios?",
      "original_answer": "The consistent classification of debt investments as AFS across Duke Energy Carolinas (page 192), Duke Energy Florida, and Duke Energy Progress (page 194) indicates a standardized accounting policy for fixed-income securities within the regulated utility framework. This uniform treatment ensures that unrealized gains and losses on debt investments are recorded in other comprehensive income rather than net income, directly affecting how each subsidiary's financial performance is measured and compared. The identical disclosure language across subsidiaries suggests a coordinated approach to financial reporting, despite their separate regulatory environments.",
      "llm_answer": "The consistent classification of debt investments as AFS across Duke Energy’s subsidiaries ensures that unrealized gains and losses are recorded in other comprehensive income until realized, providing a uniform accounting treatment that enhances the comparability of investment portfolio performance across the various Duke Energy Registrants. This uniform treatment allows investors to consistently assess and compare the financial impact of investment activities across the different Duke Energy entities.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2022.pdf",
          "target_page": 192,
          "pages": [
            190,
            191,
            192,
            193,
            194
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2022.pdf",
          "target_page": 194,
          "pages": [
            192,
            193,
            194,
            195,
            196
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2022.pdf",
          "target_page": 194,
          "pages": [
            192,
            193,
            194,
            195,
            196
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 103061,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 25999,
        "completion_tokens": 126,
        "total_tokens": 26126
      }
    },
    {
      "question_id": 64,
      "question": "What financial or operational responsibilities does Kyowa Kirin have under the AMG 451 collaboration, and how does this reflect Amgen's global development and commercialization strategy for the product outside of Japan?",
      "original_answer": "Under the collaboration agreement, Kyowa Kirin Co., Ltd. (KKC) co-promotes AMG 451 with Amgen in the United States and has opt-in rights to co-promote the product in various markets outside the U.S., including Europe and Asia. Amgen leads global development, manufacturing, and commercialization of AMG 451, except in Japan. This reflects Amgen's strategy to maintain control over the product's development and manufacturing while leveraging regional partners like KKC to expand commercial reach and share promotional responsibilities in key markets. The structure suggests Amgen aims to optimize resource allocation by engaging local partners for market access and commercial execution, while retaining central oversight of the product lifecycle.",
      "llm_answer": "Under the AMG 451 collaboration, Kyowa Kirin will co‑promote the antibody in the United States and may opt‑in to co‑promote it in other markets, while Amgen leads global development, manufacturing and commercialization (except in Japan). Amgen paid a $400 million upfront fee and will share development costs equally (excluding Japan) and reimburse Kyowa Kirin for commercialization expenses outside the U.S. and Japan, and it will owe Kyowa Kirin double‑digit royalties on global sales (excluding Japan). This structure reflects Amgen’s broader global development and commercialization model—leveraging partnerships to share R&D and market‑entry costs while retaining primary control of product development and worldwide commercialization outside Japan.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 122,
          "pages": [
            120,
            121,
            122,
            123,
            124
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 122,
          "pages": [
            120,
            121,
            122,
            123,
            124
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 76152,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19271,
        "completion_tokens": 188,
        "total_tokens": 19460
      }
    },
    {
      "question_id": 64,
      "question": "How does AIG's borrowing relationship with the FHLB of Dallas, including the $3,357 million in obligations due by 2027-2028, relate to the role of The Variable Annuity Life Insurance Company, which is a member of that FHLB and holds an A.M. Best rating of A?",
      "original_answer": "AIG's Life and Retirement segment has significant borrowing obligations tied to the FHLB of Dallas, including $3,357 million due between 2027 and 2028. These borrowings are secured through funding agreements issued by AIG's life insurance subsidiaries, including The Variable Annuity Life Insurance Company, which is a member of the FHLB of Dallas. Membership allows AIG to pledge assets—such as the $8.7 billion in collateral reported—as security for these obligations. The A.M. Best rating of A for The Variable Annuity Life Insurance Company suggests a strong credit profile, which likely supports AIG's ability to access favorable borrowing terms through the FHLB system. This interplay shows how AIG leverages the credit strength and FHLB membership of its insurance subsidiaries to manage liquidity and borrowing costs.",
      "llm_answer": "The Variable Annuity Life Insurance Company (VALIC), a member of the FHLB of Dallas, holds an A.M. Best rating of A and is part of the $3,357 million of FHLB‑Dallas borrowing obligations that are due by 2027‑2028. These borrowing arrangements provide VALIC with collateralized liquidity and allow it to earn a spread on deposits, supporting its funding needs alongside its A‑rated status.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 228,
          "pages": [
            226,
            227,
            228,
            229,
            230
          ]
        },
        "hop_2_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 228,
          "pages": [
            226,
            227,
            228,
            229,
            230
          ]
        },
        "hop_3_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 113,
          "pages": [
            111,
            112,
            113,
            114,
            115
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 109272,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 27562,
        "completion_tokens": 97,
        "total_tokens": 27659
      }
    },
    {
      "question_id": 65,
      "question": "How does MDLZ's use of exchange-traded commodity futures as Level 1 financial liabilities impact earnings volatility, given their stated hedging strategy for raw material price risk?",
      "original_answer": "MDLZ's exchange-traded commodity futures, classified as Level 1 financial liabilities and valued at $X (hypothetical placeholder for actual value from page 112), directly impact earnings volatility because these instruments are marked-to-market through earnings without the deferral benefits of hedge accounting. This creates tension with MDLZ's stated hedging strategy (page 94), where they use commodity futures to mitigate price risk on forecasted purchases of raw materials like cocoa, sugar, and wheat. Despite these hedging activities, the fair value changes in Level 1 commodity futures are immediately recognized in earnings, exposing MDLZ to short-term volatility even as they attempt to manage long-term input cost risks. This accounting treatment contrasts with their Level 2 instruments, which may be designated as hedges and have their fair value changes deferred through accumulated other comprehensive earnings.",
      "llm_answer": "MDLZ's use of exchange-traded commodity futures as Level 1 financial liabilities—valued at fair market price through quoted exchange prices—contributes to earnings volatility through mark-to-market adjustments, as these instruments are recorded at fair value with changes in value directly impacting earnings (e.g., through gains/losses in interest and other expense, net). However, MDLZ mitigates raw material price risk via its hedging strategy, which includes designated commodity derivatives (e.g., forwards, futures, options) that may be accounted for as economic hedges (not designated as accounting hedges) or cash flow hedges, where ineffective portions or gains/losses on excluded amounts are recognized in earnings, thereby managing but not eliminating volatility from these Level 1 instruments.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 69212,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17527,
        "completion_tokens": 201,
        "total_tokens": 17728
      }
    },
    {
      "question_id": 65,
      "question": "How does Disney's strategy of bundling ESPN+ with Disney+ and Hulu relate to the financial interdependencies between ESPN's programming costs and ABC Network's affiliate fee structure?",
      "original_answer": "Disney's strategy of bundling ESPN+ with Disney+ and Hulu aims to drive subscriber growth for ESPN+ by leveraging the broader Disney ecosystem. ESPN+ offers live sports and on-demand content, and as of September 2024, had approximately 26 million paid subscribers. This bundling strategy likely enhances ESPN+'s distribution and monetization potential through combined subscription models. Meanwhile, ABC Network pays ESPN for programming rights, as noted in the Sports segment section, where fees paid by ABC Network to ESPN are recognized in segment revenues and later eliminated in consolidation. ESPN's operating expenses include significant programming and production costs, particularly for licensed sports rights. The financial interdependency arises because ESPN's ability to secure and retain valuable sports rights depends on revenue generated through these internal arrangements with ABC Network and other Disney segments. Therefore, ESPN+'s subscriber growth strategy must be evaluated in the context of how ESPN's broader programming costs are subsidized by internal payments from ABC Network, which itself relies on affiliate fees charged to MVPDs for the right to deliver its programming, including content from ESPN.",
      "llm_answer": "Disney's bundling of ESPN+ with Disney+ and Hulu is directly tied to the financial interdependencies between ESPN's programming costs and ABC Network's affiliate fee structure. By integrating ESPN+ into its broader DTC offering, Disney can leverage subscription revenue from the bundle to offset the high fixed costs of acquiring and producing sports rights (e.g., NFL, NBA, MLB), while simultaneously using the bundle to drive subscriber growth for Disney+ and Hulu. This strategy enhances the overall value proposition of the combined services, allowing Disney to negotiate more favorable affiliate fee terms with MVPDs for ESPN's linear networks (as increased DTC engagement strengthens its bargaining position) and potentially reduce reliance on traditional affiliate revenue alone. The bundling also supports Disney's goal of maximizing revenue from sports content across multiple platforms, including through pay-per-view events and sub-licensing, while mitigating the financial risk of high programming costs.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 78,
          "pages": [
            76,
            77,
            78,
            79,
            80
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 61994,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15726,
        "completion_tokens": 254,
        "total_tokens": 15980
      }
    },
    {
      "question_id": 65,
      "question": "How does the increase in stock compensation expense for AspenTech stock-based plans in fiscal 2023 compared to 2022 relate to the overall growth in Emerson's total stock compensation expense from continuing operations during the same period?",
      "original_answer": "The increase in AspenTech stock-based compensation expense from $32 million in fiscal 2022 to $82 million in fiscal 2023 significantly contributed to the overall growth in Emerson's total stock compensation expense from continuing operations, which rose from $125 million in 2022 to $250 million in 2023. This indicates that AspenTech's compensation plans played a key role in driving the doubling of Emerson’s continuing stock-based compensation costs, reflecting the integration and expanded use of AspenTech’s plans post-acquisition.",
      "llm_answer": "The increase in AspenTech stock‑based compensation expense for fiscal 2023 versus 2022 is reflected in the “AspenTech stock‑based compensation plans” line of the table showing total compensation expense and tax benefits.  In 2023 that expense rose to **$82 million** (up from $32 million in 2022), and the accompanying income‑tax benefit also grew to **$28 million** (up from $19 million).  Consequently, the overall growth in Emerson’s total stock‑compensation expense from continuing operations—from **$125 million in 2022 to $250 million in 2023**—is directly tied to the higher AspenTech‑related stock‑based compensation costs reported for 2023.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "EMR_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_2_rel": {
          "source_file": "EMR_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_3_rel": {
          "source_file": "EMR_10k_2024.pdf",
          "target_page": 26,
          "pages": [
            24,
            25,
            26,
            27,
            28
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 61799,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15687,
        "completion_tokens": 162,
        "total_tokens": 15849
      }
    },
    {
      "question_id": 65,
      "question": "How does Cyprus Mines Corporation's involvement in the Imerys bankruptcy mediation affect JNJ's $9 billion reserve for talc-related liabilities following the termination of the multi-state investigation mediation?",
      "original_answer": "Cyprus Mines Corporation, as a former owner of Imerys talc mines, is actively involved in the Imerys bankruptcy mediation, which seeks to resolve talc-related claims by channeling them into a trust along with Imerys’s indemnification rights against JNJ. This chain of liability could expose JNJ to future claims from the trust after initial payments are made by Imerys and Cyprus. Meanwhile, the multi-state investigation mediation involving 42 states was terminated in March 2023, with New Mexico and Mississippi proceeding in state court. This termination removes a centralized mechanism for resolving regulatory inquiries, potentially increasing JNJ’s exposure and complicating liability estimation. Since JNJ has already recorded a $9 billion reserve—of which approximately one-third is a current liability—this evolving legal landscape introduces uncertainty about whether the reserve remains sufficient, especially if additional claims or settlements emerge from either the Imerys/Cyprus mediation process or the ongoing state-level investigations.",
      "llm_answer": "The termination of the multi-state investigation mediation does not alter JNJ’s $9 billion talc reserve; the company continues to fund the $2 billion trust and an additional $7 billion reserve (totaling roughly $9 billion over 25 years) to resolve current and future talc claims, a commitment that remains in place despite the mediation’s end.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        },
        "hop_3_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 98,
          "pages": [
            96,
            97,
            98,
            99,
            100
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 91335,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 23060,
        "completion_tokens": 85,
        "total_tokens": 23146
      }
    },
    {
      "question_id": 65,
      "question": "How does Schwab's reliance on unsecured credit facilities provided by various external banks relate to TDAC's regulatory capital requirements, and what implications does this have for Schwab's risk exposure in maintaining liquidity under stress scenarios?",
      "original_answer": "Schwab depends on unsecured credit facilities totaling $600 million from various external banks, specifically for TDAC. This funding is critical for TDAC’s operations as a broker-dealer, which must comply with SEC net capital rules requiring it to maintain minimum net capital of the greater of 2% of aggregate debit balances or a minimum dollar requirement. At the same time, Schwab’s broader banking subsidiaries are considered 'well capitalized' under Basel III rules, which include buffers like the 2.5% capital conservation buffer. However, TDAC is not subject to Basel III but rather the SEC’s Uniform Net Capital Rule, making its capital adequacy dependent on brokerage-related liquidity and client transaction balances. Schwab’s reliance on external banks for TDAC’s credit facilities introduces counterparty risk and potential liquidity constraints during market stress, especially if TDAC fails to meet its regulatory capital thresholds or if external banks reduce available credit lines.",
      "llm_answer": "Schwab’s reliance on unsecured credit facilities from external banks—particularly the uncommitted lines of credit with various banks, the $1.5 billion commercial‑paper program, and the $600 million committed revolving facility for TDAC—provides a supplemental funding source that can be tapped when internal cash flows are insufficient. However, because these borrowings are unsecured and rank junior to CSC’s senior debt, they increase Schwab’s overall leverage and can affect its regulatory capital ratios, especially the leverage and supplementary leverage ratios that regulators monitor.  \n\nIn stress scenarios, the need to draw on these external facilities could strain Schwab’s liquidity if market conditions limit the availability or increase the cost of such borrowings, potentially forcing the company to sell assets or raise higher‑cost capital. Moreover, any downgrade in Schwab’s credit ratings or a sudden tightening of the credit markets could raise borrowing costs, erode net interest margins, and compress earnings, thereby amplifying risk exposure and potentially jeopardizing the company’s ability to meet regulatory capital and liquidity requirements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SCHW_10k_2022.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_2_rel": {
          "source_file": "SCHW_10k_2022.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_3_rel": {
          "source_file": "SCHW_10k_2022.pdf",
          "target_page": 120,
          "pages": [
            118,
            119,
            120,
            121,
            122
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 68773,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17435,
        "completion_tokens": 292,
        "total_tokens": 17728
      }
    },
    {
      "question_id": 65,
      "question": "How does Altria's commercial paper program relate to its November 2023 issuance of $1.0 billion in senior unsecured notes, particularly in light of PM USA's unconditional guarantee of the company's commercial paper obligations?",
      "original_answer": "Altria's commercial paper program, which is guaranteed by PM USA as noted on page 49, provides short-term liquidity to support the company's operations. This program is part of the broader capital structure that includes longer-term debt instruments like the $1.0 billion in senior unsecured notes issued in November 2023 (page 74). These notes, with maturities in 2028 and 2033 at interest rates of 6.200% and 6.875% respectively, are also guaranteed by PM USA. The unconditional guarantee from PM USA across both short-term (commercial paper) and long-term debt instruments enhances Altria's borrowing capacity and creditworthiness, allowing the company to access capital markets at favorable terms despite being a holding company that relies on subsidiary cash flows.",
      "llm_answer": "Altria’s commercial paper program provides short‑term financing that is fully and unconditionally guaranteed by its 100 % owned subsidiary PM USA. This guarantee underpins the company’s ability to issue commercial paper as needed, and it also supports the broader liquidity framework that includes its $3 billion revolving credit facility and the $1 billion senior unsecured notes issued in November 2023. The November 2023 note issuance therefore complements the commercial paper program, with PM USA’s guarantee ensuring that both short‑term paper and the longer‑term notes are backed by the same unconditional guarantee.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 81821,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20689,
        "completion_tokens": 155,
        "total_tokens": 20844
      }
    },
    {
      "question_id": 66,
      "question": "How does the limited voting rights structure of Series B Preferred Stock influence corporate governance dynamics in relation to the Class A Common Stock composition, given the $1,031 million book value of preferred stock and 1,733 million Class A shares outstanding?",
      "original_answer": "The Series B Preferred Stock has no voting rights except for specific defined matters such as mergers or changes in equity structure, where they vote as a separate class with limited scope (e.g., ensuring parity with Class A Common Stock in certain transactions). This restricted influence contrasts sharply with the broad voting rights of Class A Common Stockholders, who have the right to vote on all matters generally subject to shareholder approval. Given that the total book value of preferred stock is $1,031 million and there are 1,733 million Class A shares outstanding, the governance structure heavily favors Class A Common Stockholders, as they not only hold a larger number of shares but also wield comprehensive voting power, while preferred stockholders remain largely passive in decision-making outside narrowly defined scenarios.",
      "llm_answer": "The limited voting rights of the Series B Preferred Stock mean that, unlike Class A common stockholders, Series B holders can vote only on a narrow set of matters (e.g., certain mergers, charter amendments affecting their rights, and other defined issues) and must approve those matters as a single class. This restriction curtails the influence of Series B shareholders on governance decisions that affect the Company’s overall direction, even though the Series B Preferred Stock carries a substantial book value of $1.031 billion and 1,733 million Class A shares remain outstanding. Consequently, governance dynamics are skewed toward Class A common stockholders for most decisions, while Series B holders retain limited but critical veto power on the specified matters.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "V_10k_2024.pdf",
          "target_page": 61,
          "pages": [
            59,
            60,
            61,
            62,
            63
          ]
        },
        "hop_2_rel": {
          "source_file": "V_10k_2024.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_3_rel": {
          "source_file": "V_10k_2024.pdf",
          "target_page": 58,
          "pages": [
            56,
            57,
            58,
            59,
            60
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 103196,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 26045,
        "completion_tokens": 193,
        "total_tokens": 26238
      }
    },
    {
      "question_id": 66,
      "question": "How does the difference in voting rights between Class A and Class B common stock impact the concentration of corporate control, especially in light of Mr. Brian L. Roberts’ ownership of all outstanding Class B shares?",
      "original_answer": "The disparity in voting rights between Class A and Class B common stock significantly concentrates corporate control in the hands of Mr. Brian L. Roberts. Class A common stock, of which 4,842,108,959 shares were issued in 2023, grants voting rights that are dependent on the outstanding share count relative to Class B stock. In contrast, each share of Class B common stock carries 15 votes and represents approximately 33 1/3% of the combined voting power, a percentage that is non-dilutable under the company's articles of incorporation. Since Mr. Roberts owns all 9,444,375 outstanding shares of Class B common stock, he maintains outsized influence over key corporate decisions, including director elections, despite holding a minority of total shares. This structure ensures that his voting power remains structurally protected, regardless of share repurchases or changes in Class A ownership.",
      "llm_answer": "The Class B shares carry 15 votes per share and collectively represent about one‑third of the total voting power of Comcast’s common stock, while Class A shares carry one vote per share and hold the remaining two‑thirds. Because Mr. Brian L. Roberts owns all of the outstanding Class B shares, he controls roughly 33 % of the combined voting power, giving him a decisive influence over major corporate decisions despite his relatively small economic ownership stake. This concentrated voting structure amplifies the impact of his ownership on corporate control.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 1,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 57868,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14703,
        "completion_tokens": 140,
        "total_tokens": 14843
      }
    },
    {
      "question_id": 66,
      "question": "How does Southern Company's joint ownership structure of Plant Scherer Unit 3, in which Florida Power & Light holds a 25% stake, influence Georgia Power's 2025 Integrated Resource Plan request to extend the unit's operation through at least December 31, 2035?",
      "original_answer": "Southern Company's subsidiaries, including Georgia Power and Mississippi Power, operate under a complex joint ownership structure where multiple entities hold stakes in shared generation assets. Plant Scherer Unit 3 is owned 75% by Georgia Power and 25% by FP&L (as shown in the ownership table). This joint ownership arrangement means Georgia Power does not have unilateral control over the asset. Despite this, Georgia Power included a request in its 2025 IRP to extend Plant Scherer Unit 3's operation through at least December 31, 2035. The inclusion of this request in the IRP filing with the Georgia PSC suggests that Georgia Power is seeking regulatory support and alignment with FP&L to maintain the unit’s operational life, which is critical for meeting long-term generation reliability and capacity needs. The request also aligns with broader strategic goals to maintain dispatchable generation capacity while navigating environmental compliance requirements.",
      "llm_answer": "Southern Company’s 2025 Integrated Resource Plan (IRP) filed by Georgia Power seeks to extend the operation of Plant Scherer Unit 3—of which Georgia Power holds a 75 % undivided interest (with Florida Power & Light owning the remaining 25 %)—through at least December 31, 2035. Because the unit is jointly owned, Georgia Power’s request to continue operating it is tied to the joint‑ownership agreement and the need for co‑owner consent; the extension would keep the unit in service for the benefit of all owners, including the 25 % stake held by Florida Power & Light.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 211,
          "pages": [
            209,
            210,
            211,
            212,
            213
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 45,
          "pages": [
            43,
            44,
            45,
            46,
            47
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 54,
          "pages": [
            52,
            53,
            54,
            55,
            56
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 79157,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20037,
        "completion_tokens": 142,
        "total_tokens": 20179
      }
    },
    {
      "question_id": 67,
      "question": "How does Altria's reliance on its Commercial Paper Program, which is guaranteed by PM USA, affect its financial risk profile given PM USA's unconditional guarantee obligations and its role as a 100% owned subsidiary?",
      "original_answer": "Altria's reliance on its Commercial Paper Program introduces financial risk due to its dependence on PM USA's unconditional guarantees to support short-term liquidity needs. PM USA, as a 100% owned subsidiary, fully and unconditionally guarantees Altria's obligations under the commercial paper program, making it directly liable for any defaults. However, PM USA also faces significant fixed obligations, including $3.4 billion in annual payments related to State Settlement Agreements and FDA user fees, which could constrain its ability to fulfill guarantee obligations if cash flows are strained. This interdependency increases Altria's financial risk, as the parent company's access to operating cash flows is contingent on PM USA's financial health and its capacity to meet both its guaranteed obligations and its own fixed commitments.",
      "llm_answer": "Altria's reliance on its Commercial Paper Program, which is fully guaranteed by its 100% owned subsidiary PM USA, enhances its financial risk profile by shifting repayment risk to PM USA under its unconditional guarantee obligations. This structure allows Altria to access short-term financing through PM USA's creditworthiness, but exposes the parent company to potential contingent liabilities if PM USA's financial condition deteriorates or if guarantees are invoked due to defaults under debt instruments or commercial paper obligations. The guarantee is absolute and unconditional, meaning Altria could be required to fulfill PM USA's obligations if needed, though PM USA's status as a wholly owned subsidiary and the absence of contractual restrictions on dividend payments or distributions from its subsidiaries support the sustainability of this arrangement.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 81821,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20686,
        "completion_tokens": 216,
        "total_tokens": 20902
      }
    },
    {
      "question_id": 67,
      "question": "Given that BMY completed its acquisition of Celgene in November 2019, how might the ongoing litigation with Molina—initiated in May 2021 over claims related to Thalomid and Revlimid—affect BMY's financial exposure, particularly since these liabilities arose after the acquisition was finalized and are not included in the initial valuation?",
      "original_answer": "The litigation with Molina, which began in May 2021, centers on claims related to Celgene’s products Thalomid and Revlimid. Since the acquisition of Celgene by BMY was finalized in November 2019, these liabilities arose post-acquisition and would not have been included in the initial fair value assessment of assets and liabilities assumed at the time of the $35.7 billion transaction. As a result, any potential damages or settlements from this litigation would directly impact BMY’s current financial position rather than being absorbed as part of the acquisition accounting. The complaint also references off-label marketing allegations, which could carry significant financial or reputational risks, further exposing BMY to unforeseen costs not accounted for in the original acquisition valuation.",
      "llm_answer": "The litigation initiated by Molina in May 2021 over claims related to Thalomid and Revlimid—products acquired through the Celgene purchase—represents a post‑acquisition liability that was not reflected in the original purchase price. Because the lawsuit arose after the acquisition closed, any potential damages or settlements would have to be absorbed by BMS’s post‑deal financial position, increasing its contingent legal exposure and possibly affecting cash flow, earnings and the valuation of the acquired assets. Consequently, analysts would view this matter as an additional financial risk that could materially affect BMS’s results and balance sheet going forward.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "target_page": 166,
          "pages": [
            137,
            138,
            139,
            140,
            141
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "target_page": 166,
          "pages": [
            137,
            138,
            139,
            140,
            141
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "target_page": 116,
          "pages": [
            114,
            115,
            116,
            117,
            118
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 12,
        "total_chars": 52362,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 13355,
        "completion_tokens": 167,
        "total_tokens": 13523
      }
    },
    {
      "question_id": 67,
      "question": "What governance risks does the 15:1 voting disparity between Class B and Class A shares create for Comcast's minority shareholders, especially given that Class B shares are entirely owned by Mr. Brian L. Roberts?",
      "original_answer": "The 15:1 voting disparity between Class B and Class A shares grants Mr. Brian L. Roberts, who owns all Class B shares, outsized control over corporate decisions despite holding only one-third of the voting power. This creates governance risks for minority shareholders, as Mr. Roberts can disproportionately influence board elections and major corporate actions, potentially prioritizing his interests over those of the broader shareholder base. This dynamic is further amplified by the non-dilutable nature of Class B voting rights, which ensures his control remains intact regardless of future share issuances or buybacks.",
      "llm_answer": "The 15:1 voting disparity creates a governance risk for minority shareholders by concentrating voting power in Mr. Brian L. Roberts’ Class B shares, which represent roughly one‑third of the combined voting power despite having no economic ownership stake. This structure can enable decisions that may not align with the interests of the broader shareholder base, especially when Class B shares are fully owned by Roberts.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 1,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 57868,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14701,
        "completion_tokens": 105,
        "total_tokens": 14806
      }
    },
    {
      "question_id": 67,
      "question": "How does UPS's contribution approach to the New York State Teamsters Conference Pension and Retirement Fund in 2023 demonstrate compliance with financial improvement requirements for red-zone pension plans?",
      "original_answer": "UPS's contributions to the New York State Teamsters Conference Pension and Retirement Fund totaled $139 million in 2023, a decrease from $149 million in 2022 and $147 million in 2021. According to the 10-K filing, all red-zone plans, including this fund, have implemented financial improvement plans (FIPs), and UPS's contributions satisfy these FIP requirements. Despite the declining contribution trend, the company explicitly states that these payments meet all applicable financial improvement obligations without requiring surcharges or additional contributions beyond contractual rates. This demonstrates that UPS's contribution approach aligns with regulatory requirements while showing a measured reduction in payments as permitted under the implemented FIP framework for underfunded pension plans.",
      "llm_answer": "UPS's contributions to the New York State Teamsters Conference Pension and Retirement Fund—$139 million in 2023—are made under collective‑bargaining agreements that satisfy the funding requirements of any applicable rehabilitation plan (RP) for the red‑zone plan. Because the plan’s financial‑improvement plan (FIP) or RP has already been implemented and our contractually‑required contribution meets the RP’s funding schedule, UPS is not subject to additional surcharge contributions under the Pension Protection Act, demonstrating compliance with the required financial improvement obligations for the red‑zone pension plan.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 87500,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22099,
        "completion_tokens": 156,
        "total_tokens": 22256
      }
    },
    {
      "question_id": 67,
      "question": "Given that AMJEVITA is in a phase 3 study as a biosimilar to AbbVie's HUMIRA, which competes against both ENBREL and Otezla—two of Amgen’s marketed products—how might Amgen’s development of AMJEVITA impact its own revenue from ENBREL and Otezla, especially in light of HUMIRA’s strong competitive position in the same therapeutic areas?",
      "original_answer": "Amgen's development of AMJEVITA, a biosimilar to AbbVie’s HUMIRA, currently in a phase 3 study (page 25), introduces a complex competitive dynamic. HUMIRA is listed as a direct competitor to both ENBREL and Otezla in the U.S. and Canada (page 16), which are two of Amgen’s own marketed products in the autoimmune and inflammatory disease space. While AMJEVITA could potentially capture market share from HUMIRA and reduce AbbVie’s dominance, it may also inadvertently compete with Amgen’s own products. This raises concerns about internal cannibalization, particularly if AMJEVITA gains approval and is positioned as a lower-cost alternative in the same therapeutic areas. Thus, the development of AMJEVITA could have a dual financial impact: offering a new revenue stream by challenging HUMIRA, while simultaneously threatening Amgen’s existing revenue from ENBREL and Otezla.",
      "llm_answer": "The launch of AMJEVITA—a biosimilar to AbbVie’s HUMIRA—could erode sales of Amgen’s own HUMIRA‑derived products (ENBREL and Otezla) because HUMIRA competes directly with those drugs in the same therapeutic areas. As HUMIRA maintains a strong market position, Amgen may face heightened pricing and market‑share pressure, which could reduce its revenue from ENBREL and Otezla unless it can differentiate its biosimilar or secure favorable formulary placement.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 25,
          "pages": [
            23,
            24,
            25,
            26,
            27
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 25,
          "pages": [
            23,
            24,
            25,
            26,
            27
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 68835,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17470,
        "completion_tokens": 114,
        "total_tokens": 17584
      }
    },
    {
      "question_id": 67,
      "question": "How does the unresolved WTO customs valuation dispute involving Thailand affect Philip Morris's competitive positioning against local and international tobacco companies in the Thai market, given the company's stated challenges with import cost predictability and pricing strategy?",
      "original_answer": "The unresolved WTO customs valuation dispute between the Philippines and Thailand, where the WTO panel ruled that Thailand had no basis to challenge PM Thailand's declared import values and taxes, creates regulatory uncertainty that directly impacts Philip Morris's cost structure and pricing flexibility in Thailand. Despite Thailand agreeing to comply with the ruling, the Philippines asserts non-compliance, and the stalled WTO Appellate Body process has left the matter unresolved since 2010. This uncertainty likely affects PM Thailand’s ability to accurately forecast import costs, which are critical to pricing decisions. In a market where PMI competes against local and international tobacco firms like British American Tobacco, Japan Tobacco Inc., and state-owned enterprises in Thailand, the inability to stabilize customs costs could limit PM's ability to maintain competitive pricing. Additionally, the company notes on page 19 that in markets like Thailand, adult consumers are sensitive to price changes and may shift to lower-priced brands during economic uncertainty, further constraining profitability. Therefore, the unresolved dispute directly intersects with PM's stated risk of being unable to improve margins through price increases, especially in a market where cost predictability is essential for maintaining competitive positioning.",
      "llm_answer": "The unresolved WTO customs‑valuation dispute with Thailand creates uncertainty over import‑cost predictability and pricing for Philip Morris in the Thai market, weakening its competitive positioning against both local and international tobacco rivals. This regulatory ambiguity can limit the company’s ability to set stable prices and may erode market share relative to competitors that face fewer such hurdles.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_2_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_3_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 78101,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19772,
        "completion_tokens": 102,
        "total_tokens": 19875
      }
    },
    {
      "question_id": 67,
      "question": "What does EMR's increasing reported value of its AspenTech stake from $1 million in 2023 to $8 million in 2024 suggest about the strategic success of the 2022 business combination with Heritage AspenTech, particularly in relation to the $5.9 billion noncontrolling interest valuation recorded at the time of the transaction?",
      "original_answer": "EMR's increasing reported value of its AspenTech stake—from $1 million in 2023 to $8 million in 2024—suggests that the 2022 business combination with Heritage AspenTech has yielded positive strategic outcomes, at least in the context of stake valuation. This growth in value aligns with the broader goal of creating a stronger, more diversified industrial software entity. At the time of the transaction, EMR recorded a $5.9 billion noncontrolling interest for the 45% ownership stake held by former Heritage AspenTech stockholders, which was based on the fair value of AspenTech shares as of May 16, 2022. The subsequent increase in EMR’s reported stake value implies that AspenTech's overall valuation or performance likely improved post-transaction, supporting the strategic rationale behind the combination. This increase may reflect successful integration of the Emerson Industrial Software Business or improved market positioning of AspenTech following the transaction.",
      "llm_answer": "The $7 million increase in EMR’s reported value of its AspenTech stake—from $1 million in 2023 to $8 million in 2024—reflects the market‑based re‑valuation of the equity interest that resulted from the 2022 business combination with Heritage AspenTech.  At the time of that transaction, the non‑controlling interest in AspenTech was recorded at $5.9 billion, and the subsequent rise in the publicly‑quoted stake value demonstrates that the combined entity’s market valuation has appreciated substantially, confirming the strategic success of the 2022 combination.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_2_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 51,
          "pages": [
            49,
            50,
            51,
            52,
            53
          ]
        },
        "hop_3_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 52,
          "pages": [
            50,
            51,
            52,
            53,
            54
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 57370,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14599,
        "completion_tokens": 140,
        "total_tokens": 14740
      }
    },
    {
      "question_id": 67,
      "question": "How does Southern Company's wind energy portfolio life expectancy compare with the contract duration of its Reading wind facility, and what might this imply about long-term revenue alignment for this project?",
      "original_answer": "Southern Company estimates the useful life of its wind facilities at up to 30 years, as stated in the asset overview on page 244. However, the Reading wind facility, located in Kansas and with a nameplate capacity of 200 MW, has a PPA contract duration of only 12 years, as disclosed on page 330. This mismatch between the asset's expected operational life and the length of the contracted revenue period raises questions about the long-term financial viability and revenue strategy for the Reading facility beyond the initial PPA term.",
      "llm_answer": "Southern Power's Reading wind facility has a 12‑year power purchase agreement, while the useful life of its wind assets is estimated at up to 30 years. This mismatch means the project's revenue stream will end well before the turbines are fully depreciated, likely requiring repowering, repowering‑related investments, or asset write‑downs to maintain profitability once the PPA expires.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 244,
          "pages": [
            242,
            243,
            244,
            245,
            246
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 330,
          "pages": [
            328,
            329,
            330,
            331,
            332
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 330,
          "pages": [
            328,
            329,
            330,
            331,
            332
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 71418,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18086,
        "completion_tokens": 96,
        "total_tokens": 18182
      }
    },
    {
      "question_id": 68,
      "question": "How does MetLife's use of Trust-Owned Life Insurance to fund Nonqualified Benefit Programs, as disclosed in the Benefit Funding Solutions section, align with the liability information provided in the Policyholder Account Balances footnote regarding these same obligations?",
      "original_answer": "MetLife offers Trust-Owned Life Insurance as part of its Benefit Funding Solutions to finance Nonqualified Benefit Programs for executives (page 9). These products are specifically designed to fund postretirement benefits through insurance structures owned by trusts. The Policyholder Account Balances footnote (page 203) provides further context, indicating that the RIS segment includes these trust-owned life insurance policies as part of its liabilities. The alignment shows that MetLife actively structures and markets these insurance vehicles as funding mechanisms, while also recognizing the corresponding long-term obligations in its financial disclosures. This dual perspective highlights both the product offering and the associated liability management within the same business segment.",
      "llm_answer": "MetLife funds its nonqualified benefit programs through Trust-Owned Life Insurance (TOLI) within the Benefit Funding Solutions offering in the RIS segment. This aligns with the liability disclosures in the Policyholder Account Balances footnote, which details the RIS segment's institutional income annuities and benefit funding solutions—specifically identifying \"postretirement benefits and company-, bank- or trust-owned life insurance used to finance nonqualified benefit programs for executives\" as a component of its annuities and risk solutions portfolio. The footnote confirms these obligations are tracked in the segment's PABs, with the TOLI structure directly supporting the funding mechanism for these nonqualified benefits.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 203,
          "pages": [
            201,
            202,
            203,
            204,
            205
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 203,
          "pages": [
            201,
            202,
            203,
            204,
            205
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 89172,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22538,
        "completion_tokens": 184,
        "total_tokens": 22722
      }
    },
    {
      "question_id": 68,
      "question": "How does Altria's $2.9 billion acquisition of NJOY compare with its prior equity stake in JUUL, given NJOY's unique FDA market authorization status and Altria's stated strategic focus on transitioning adult smokers to less harmful alternatives?",
      "original_answer": "Altria's $2.9 billion acquisition of NJOY, which became a wholly owned subsidiary on June 1, 2023, represents a significant strategic commitment to the e-vapor category. This contrasts with Altria's earlier equity stake in JUUL, which it relinquished in March 2023 in exchange for a non-exclusive, irrevocable global license to certain heated tobacco intellectual property. Notably, NJOY is the only e-vapor manufacturer to have received market authorizations from the FDA for a pod-based e-vapor product, a regulatory milestone that likely factored into Altria's decision to directly acquire and integrate NJOY into its portfolio. This acquisition aligns with Altria’s stated Vision to transition adult smokers to potentially less harmful alternatives and supports its broader 'Moving Beyond Smoking' initiative, distinguishing it from the more limited rights retained from the JUUL relationship.",
      "llm_answer": "Altria's $2.9 billion acquisition of NJOY gave it full ownership of the e‑vapor company, which is the only U.S. e‑vapor manufacturer with FDA market authorizations for a pod‑based product, directly supporting its Vision of transitioning adult smokers to less‑harmful alternatives; this contrasts with its prior equity stake in JUUL, where it held a minority investment and received only a non‑exclusive global license to JUUL’s heated‑tobacco IP, without the same regulatory exclusivity or direct control over a product with FDA clearance.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 75985,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19233,
        "completion_tokens": 134,
        "total_tokens": 19368
      }
    },
    {
      "question_id": 68,
      "question": "How does Amgen's $2.8 billion equity investment in BeiGene to commercialize XGEVA in China align with the competitive pressures facing XGEVA in the U.S. and Europe, and what implications does this have for Amgen's revenue diversification strategy?",
      "original_answer": "Amgen's $2.8 billion equity investment in BeiGene (page 28) was part of a strategic collaboration to expand its oncology footprint in China, where BeiGene began selling XGEVA in 2020. Under the arrangement, Amgen and BeiGene share profits and losses equally during the initial commercialization period, after which product rights may revert to Amgen (page 121). Meanwhile, XGEVA faces direct competition in the U.S. and Europe from zoledronate generics (page 16), which typically erode branded drug revenues due to lower-cost alternatives entering the market. This suggests Amgen is strategically shifting focus toward growth markets like China to offset declining revenue potential in mature markets due to generic competition. The financial commitment to BeiGene underscores Amgen’s intent to diversify XGEVA’s revenue base geographically, mitigating the impact of competitive pressures in developed markets.",
      "llm_answer": "Amgen’s $2.8 billion equity investment in BeiGene is designed to secure a strong commercial partner for XGEVA in China, a market where XGEVA faces intense competition from biosimilars and other therapies. By sharing profits and development costs with BeiGene and granting it exclusive rights to sell XGEVA (and later other oncology products) in China, Amgen diversifies its revenue away from mature U.S. and European markets that are under pricing pressure, while leveraging BeiGene’s local expertise to sustain growth in a high‑potential region. This partnership is intended to offset the competitive pressures XGEVA experiences in the U.S. and Europe and to broaden Amgen’s geographic revenue base.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 28,
          "pages": [
            26,
            27,
            28,
            29,
            30
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 70325,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17826,
        "completion_tokens": 175,
        "total_tokens": 18001
      }
    },
    {
      "question_id": 68,
      "question": "How does Cisco's lower gross margin from Advanced Services relate to the credit risk exposure in their loan receivables tied to service offerings, given the reduction in allowance for credit losses from $126 million to $72 million year-over-year?",
      "original_answer": "Cisco acknowledges that Advanced Services have a lower gross margin compared to technical support services, partly due to strategic investments in headcount and delivery resources. These services are linked to loan receivables, which are financing arrangements tied to the sale of services, including Advanced Services. The allowance for credit losses on loan receivables decreased from $103 million in FY2022 to $53 million in FY2023, indicating reduced credit risk. However, this reduction in reserves must be weighed against the ongoing margin pressures in Advanced Services, which may affect the collectability of these receivables if clients face financial strain, thereby creating a potential risk to Cisco’s financial position despite the lower allowance.",
      "llm_answer": "Cisco's lower gross margin from Advanced Services is linked to higher credit risk exposure in its loan receivables tied to service offerings, as evidenced by the reduction in allowance for credit losses from $126 million to $72 million year‑over‑year, reflecting tighter credit risk management amid declining advanced‑service margins.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 43,
          "pages": [
            41,
            42,
            43,
            44,
            45
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 69629,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17648,
        "completion_tokens": 83,
        "total_tokens": 17731
      }
    },
    {
      "question_id": 68,
      "question": "How does the expected loss of market exclusivity for Bridion in the U.S. in 2026 impact MRK's strategic positioning in its key domestic market, especially considering the growth in alliance revenue from other products like Adempas and Verquvo in 2023?",
      "original_answer": "MRK faces a significant challenge with Bridion, a key Hospital Acute Care product, losing U.S. market exclusivity in 2026, which is expected to result in a substantial decline in sales in that market. This loss comes at a time when MRK is increasingly dependent on alliance revenue to offset declines in products losing exclusivity. In 2023, alliance revenue—particularly from products like Adempas and Verquvo—grew by 8%, driven by higher demand in Bayer's marketing territories and increased profit sharing. This growth suggests that MRK may be strategically leaning on collaborative partnerships to maintain revenue stability. However, Bridion's upcoming exclusivity loss in the U.S., a core market for MRK, could strain profitability unless offset by new product launches or expanded alliance-driven growth. The interplay between declining legacy product exclusivity and rising alliance revenue highlights a transitional phase in MRK’s U.S. market strategy.",
      "llm_answer": "The expected loss of U.S. market exclusivity for Bridion in 2026 will likely cause a substantial decline in Bridion sales, similar to the declines already observed after patent expirations in the EU and Japan, potentially pressuring Merck's revenue from this key hospital acute care product. However, this impact may be partially offset by growth in alliance revenue from other high-performing products like Adempas and Verquvo, which contributed $367 million in alliance revenue in 2023 and are positioned as growth drivers in Merck's cardiovascular portfolio.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "target_page": 30,
          "pages": [
            28,
            29,
            30,
            31,
            32
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "target_page": 54,
          "pages": [
            52,
            53,
            54,
            55,
            56
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 78530,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19876,
        "completion_tokens": 140,
        "total_tokens": 20016
      }
    },
    {
      "question_id": 69,
      "question": "How does Intel's strategic decision to divest its NAND SSD business to SK hynix, while continuing to manufacture NAND wafers for them, align with the company's stated focus on 144-layer QLC NAND SSD innovation and its broader market positioning in high-capacity storage solutions?",
      "original_answer": "Intel's decision to divest its NAND SSD Business and Fab Assets to SK hynix while retaining the ability to manufacture NAND memory wafers for them until the second closing reflects a strategic pivot. Despite this divestiture, Intel continued to innovate in NAND SSDs by launching the Intel SSD D5-P5316, a 144-layer QLC NAND SSD for data centers with up to 30.72TB capacity in multiple form factors. This indicates that Intel aimed to remain technologically competitive in NAND SSD development even as it transitioned the business to SK hynix. The company's broader strategy emphasizes leveraging 144-layer 3D NAND TLC and QLC solutions to meet growing data storage demands, suggesting that the divestiture was not a retreat from innovation but a reallocation of resources to focus on core competencies in system integration and advanced storage solutions.",
      "llm_answer": "Intel’s decision to divest its NAND SSD business to SK hynix while retaining wafer‑fabrication for the buyer aligns with its stated focus on 144‑layer QLC NAND innovation by allowing the company to concentrate R&D and product launches—such as the 144‑layer QLC SSD D5‑P5316—on high‑capacity, cost‑effective storage solutions, while leveraging the SK hynix partnership to bring those advanced NAND wafers to market. This strategy reinforces Intel’s broader positioning as a provider of leading‑edge, high‑capacity storage technologies for data‑center and enterprise customers.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_2_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_3_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 30751,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 7931,
        "completion_tokens": 143,
        "total_tokens": 8075
      }
    },
    {
      "question_id": 69,
      "question": "How might Qualcomm's customer concentration risk in China impact its ability to capitalize on growth opportunities in XR applications dependent on 5G technology?",
      "original_answer": "Qualcomm faces a significant customer concentration risk, particularly in China, where U.S./China trade tensions could disrupt revenue streams. This risk is heightened because a large portion of its business is tied to premium tier handset sales in this region. At the same time, Qualcomm has identified 5G as a foundational technology for next-generation applications like XR (augmented reality, virtual reality, and mixed reality), which are increasingly being integrated into consumer electronics, edge networking, and industrial applications. According to Qualcomm's revenue disclosures, XR is a key component of its IoT and consumer electronics segment, which is expected to grow alongside 5G adoption. However, if geopolitical risks in China disrupt Qualcomm's ability to deploy 5G technologies or sell into this market, it could hinder the company’s ability to scale XR-related product lines and delay its strategic expansion into these emerging use cases.",
      "llm_answer": "Qualcomm's heavy reliance on a small number of customers in China—particularly those selling premium handsets—creates concentration risk that could curtail its ability to capture growth in XR applications that depend on 5G. If sales to these key Chinese customers decline or shift to vertically integrated solutions, the company may lose a major revenue source and face reduced demand for its 5G‑enabled chips and licensing revenue needed to fund XR‑focused R&D and design wins. This exposure is highlighted in the \"Risks Related to Our Operating Businesses\" and \"Risks Related to Industry Dynamics and Competition\" sections of the filing.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "QCOM_10k_2024.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_2_rel": {
          "source_file": "QCOM_10k_2024.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        },
        "hop_3_rel": {
          "source_file": "QCOM_10k_2024.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 71055,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17982,
        "completion_tokens": 159,
        "total_tokens": 18142
      }
    },
    {
      "question_id": 69,
      "question": "Given the concentrated voting power of Brian L. Roberts through Class B common stock and the significant repurchase activity of Class A common stock in 2024, how does the company's equity structure reflect a potential imbalance in governance influence versus shareholder value distribution?",
      "original_answer": "The equity structure of CMCSA reveals a governance framework where Brian L. Roberts, through ownership of all outstanding Class B common stock, holds 33⅓% of the combined voting power, with each Class B share carrying 15 votes. This concentrated voting power contrasts with the company's financial activities around Class A common stock, which saw repurchases of $2 billion in 2024. Despite these repurchases reducing the number of outstanding Class A shares (from 4,842,108,959 to 4,651,093,045), the governance structure remains unaffected due to the non-dilutive nature of Class B voting rights. This dynamic suggests that while shareholder value is being redistributed through stock repurchases, the core governance influence remains insulated, creating a potential misalignment between ownership benefits and control.",
      "llm_answer": "The company's equity structure shows a stark governance imbalance: Class B common stock, held entirely by Brian L. Roberts, carries 15 votes per share and represents 33.3% of total voting power despite having negligible economic ownership, while Class A shares (held by the broader public) carry one vote per share. This concentrated control is reinforced by aggressive share repurchases—$9.1 billion in 2024 alone—primarily targeting Class A stock, which reduces public float and further amplifies Roberts' voting dominance relative to the economic value distributed to shareholders through dividends and buybacks.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 67,
          "pages": [
            65,
            66,
            67,
            68,
            69
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 31,
          "pages": [
            29,
            30,
            31,
            32,
            33
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 70003,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17752,
        "completion_tokens": 153,
        "total_tokens": 17905
      }
    },
    {
      "question_id": 69,
      "question": "How does SEGCO's ownership of electric generating units at Plant Gaston, with a total rated capacity of 1,020 MWs and expected retirement by 2028, reconcile with the declining book value of 'Electric generating units' listed under Southern Company's consolidated assets at $670 million in 2023 compared to $760 million in 2022?",
      "original_answer": "SEGCO, owned equally by Alabama Power and Georgia Power, operates electric generating units at Plant Gaston with a total rated capacity of 1,020 MWs and a planned retirement by December 31, 2028. However, Southern Company consolidates SEGCO, and the book value of 'Electric generating units' under Southern Company's consolidated assets has declined from $760 million in 2022 to $670 million in 2023. This decline may reflect depreciation, potential impairment, or the anticipated retirement of these units by 2028, which could impact their long-term valuation. The connection between SEGCO's generating units and Southern Company’s consolidated asset valuation suggests that the planned retirement and associated depreciation are factored into the asset's carrying value on the consolidated balance sheet.",
      "llm_answer": "The $670 million book value of “Electric generating units” on Southern Company’s 2023 consolidated balance sheet reflects the net carrying amount after accumulated depreciation, which is lower than the $760 million reported in 2022. This decline is consistent with the expected retirement of SEGCO’s 1,020 MW Plant Gaston units by 2028, as disclosed in Note 7 under “Southern Power – Variable Interest Entities.” The depreciation expense recognized each year reduces the net book value, so even though the underlying generating capacity remains, the reported asset value has fallen from $760 million to $670 million.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 211,
          "pages": [
            209,
            210,
            211,
            212,
            213
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 223,
          "pages": [
            221,
            222,
            223,
            224,
            225
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 235,
          "pages": [
            233,
            234,
            235,
            236,
            237
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 64106,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16294,
        "completion_tokens": 154,
        "total_tokens": 16448
      }
    },
    {
      "question_id": 69,
      "question": "How does Caterpillar's administration of the EIP Plans, which purchased 78,000 shares in Q4 2023, relate to the broader context of the company's $15.0 billion 2022 share repurchase authorization, especially in light of the 19.5 million shares repurchased during 2023?",
      "original_answer": "Caterpillar's EIP Plans, which purchased 78,000 shares in Q4 2023, represent a small but consistent component of the company's overall equity activity. These purchases are distinct from the broader $15.0 billion share repurchase program authorized in 2022, under which 19.5 million shares were repurchased during 2023. While the EIP Plans reflect ongoing employee participation in equity ownership, the repurchase program reflects strategic capital allocation decisions by the company. Together, they illustrate dual mechanisms influencing Caterpillar's equity base, with the EIP Plans contributing to employee engagement and the repurchase program aiming to enhance shareholder value.",
      "llm_answer": "Caterpillar's administration of the EIP Plans, which purchased approximately 78,000 shares in Q4 2023, is part of its broader $15.0 billion share repurchase authorization approved in May 2022. This authorization replaced the prior $10.0 billion 2018 Authorization, and as of December 31, 2023, approximately $7.8 billion remained available under the 2022 Authorization. The 19.5 million shares repurchased during 2023 (including those acquired through the EIP Plans) were executed under this new authorization, reflecting the company's ongoing commitment to returning capital to shareholders through systematic repurchases.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CAT_10k_2023.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_2_rel": {
          "source_file": "CAT_10k_2023.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_3_rel": {
          "source_file": "CAT_10k_2023.pdf",
          "target_page": 104,
          "pages": [
            102,
            103,
            104,
            105,
            106
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 41320,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 10575,
        "completion_tokens": 155,
        "total_tokens": 10731
      }
    },
    {
      "question_id": 70,
      "question": "How does MetLife's exposure to variable annuity guarantees, specifically those involving guaranteed minimum income benefits (GMIBs), relate to its assumed reinsurance obligations, and how is this connection reflected in the company's accounting policy disclosures?",
      "original_answer": "MetLife's exposure to variable annuity guarantees, particularly GMIBs, represents a significant liability tied to future annuitization risks, as outlined in the Market Risk Benefits section. This exposure is further amplified by an in-force block of assumed variable annuity guarantees from a third party, indicating that reinsurance plays a direct role in the company's risk profile for these products. The Reinsurance section, referenced under the company's accounting policies, shows that MetLife has a dedicated accounting policy (Note 9) for reinsurance, which governs how these assumed obligations are reported and managed. This three-hop connection reveals that MetLife's liability for GMIBs is not only a direct product risk but also a reinsurance risk, with specific accounting treatment guiding its recognition and measurement.",
      "llm_answer": "MetLife’s exposure to variable annuity guarantees with guaranteed minimum income benefits (GMIBs) is disclosed as part of its Market Risk Benefits (MRBs) in Note 6. The company records these guarantees at estimated fair value as a compound MRB liability, with changes in fair value reported in net income (except for non‑performance risk adjustments, which flow through OCI). The accounting policy explains that the fair‑value measurement uses actuarial and capital‑market assumptions—including policyholder behavior, mortality, lapse, withdrawal, and risk‑margin adjustments—while the non‑performance risk adjustment reflects observable spreads on MetLife’s debt. This methodology underpins the roll‑forward tables for both the Asia retirement assurance segment and the MetLife Holdings segment, which include the GMIB liabilities and the related “net amount at risk” disclosures.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2024.pdf",
          "target_page": 194,
          "pages": [
            192,
            193,
            194,
            195,
            196
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2024.pdf",
          "target_page": 193,
          "pages": [
            191,
            192,
            193,
            194,
            195
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2024.pdf",
          "target_page": 131,
          "pages": [
            129,
            130,
            131,
            132,
            133
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 78514,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19875,
        "completion_tokens": 220,
        "total_tokens": 20095
      }
    },
    {
      "question_id": 70,
      "question": "What percentage of CVS's total assets at year-end 2022 were represented by investments in Common Collective Trusts, and how does this allocation reflect the role of Separate Accounts in the company's pension investment strategy?",
      "original_answer": "At year-end 2022, CVS reported $5,087 million in Separate Accounts Assets, which included investments in Common Collective Trusts valued at $266 million. These Common Collective Trusts represented approximately 0.9% of the company’s total assets of $232,999 million. The Separate Accounts Assets are specifically tied to large case pension products, where contract holders bear the investment risk, and the corresponding liability mirrors the asset value. The allocation to Common Collective Trusts, which are classified as Level 2 investments based on NAV per share/unit, indicates a measured exposure to diversified pooled funds while maintaining legal segregation of these assets from other business risks. This aligns with CVS's broader pension investment strategy, which includes $5,865 million in total pension investments, showing a diversified but cautious approach to managing contract holder funds.",
      "llm_answer": "At the end of 2022, investments in Common Collective Trusts represented **$547 million** of the total assets of the Separate Accounts, which equated to **about 2.3 % of CVS’s total assets of $232.999 billion**. This allocation underscores the role of Separate Accounts in the pension strategy by directing a modest but dedicated portion of the pension fund into collective‑trust vehicles, allowing the company to manage risk and return characteristics distinct from the broader corporate portfolio while keeping the assets legally segregated for contract‑holder obligations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "target_page": 114,
          "pages": [
            112,
            113,
            114,
            115,
            116
          ]
        },
        "hop_2_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "target_page": 151,
          "pages": [
            149,
            150,
            151,
            152,
            153
          ]
        },
        "hop_3_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "target_page": 166,
          "pages": [
            164,
            165,
            166,
            167,
            168
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 77709,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19670,
        "completion_tokens": 143,
        "total_tokens": 19813
      }
    },
    {
      "question_id": 70,
      "question": "How does Microsoft's inclusion of SA in Enterprise Agreements impact the recognition of unearned revenue, particularly given the multi-year structure of these agreements and the pattern of delivery assumptions made for SA benefits?",
      "original_answer": "Microsoft includes SA in Enterprise Agreements, which are structured as three-year licensing programs. Since SA is bundled with perpetual licenses in these agreements, it contributes to unearned revenue that is recognized ratably over the multi-year coverage period. However, due to the nature of SA benefits and the pattern of their delivery across the portfolio, Microsoft must apply judgment in estimating standalone selling prices (SSP) and recognizing revenue, especially when SA is not sold separately. This creates a nuanced revenue recognition profile where unearned revenue from SA-inclusive agreements is invoiced annually but recognized over time, depending on the estimated delivery pattern of SA benefits.",
      "llm_answer": "Microsoft's inclusion of Software Assurance (SA) in Enterprise Agreements requires ratable recognition of revenue allocated to SA over the agreement's multi-year term, reflecting the pattern of benefit delivery where SA rights (including new software releases and upgrades) are consumed incrementally rather than upfront. This approach aligns with the multi-year structure of Enterprise Agreements, which typically span three years, and necessitates spreading revenue recognition evenly across the contract period as SA benefits are delivered over time.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 54507,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 13862,
        "completion_tokens": 138,
        "total_tokens": 14000
      }
    },
    {
      "question_id": 70,
      "question": "How does Southern Company's use of weather-adjusted KWH sales analysis in evaluating operational trends reconcile with its reported exposure to weather-driven customer consumption patterns in gas distribution operations?",
      "original_answer": "Southern Company uses weather-adjusted KWH sales analysis (noted on page 73) to evaluate historical operations apart from weather influence, revealing a 0.4% decrease in residential electricity sales due to reduced customer usage. Meanwhile, in gas distribution operations (page 86), the company acknowledges exposure to weather-driven consumption patterns, particularly during the heating season, which affects earnings. The company mitigates this exposure through mechanisms like weather normalization and weather derivative instruments (page 200). By combining these perspectives, we see that while Southern Company actively adjusts for weather effects in performance analysis, it still experiences weather-related revenue variability in gas operations, highlighting the limits of weather-adjusted metrics in fully insulating financial outcomes from climatic conditions.",
      "llm_answer": "Southern Company's use of weather-adjusted KWH sales analysis to evaluate operational trends aligns with its reported exposure to weather-driven consumption patterns in gas distribution operations by providing a metric that isolates volume trends from weather volatility. The document shows that weather-adjusted KWH sales (e.g., residential sales decreased 0.4% weather-adjusted in 2023) are used to assess underlying demand trends separate from weather impacts, while gas distribution operations explicitly acknowledge weather as a key driver of consumption (e.g., \"customer consumption patterns... are largely a function of weather conditions\"). This analytical approach allows the company to distinguish true operational performance from weather-related fluctuations, consistent with its regulatory disclosures about weather sensitivity in gas distribution.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 200,
          "pages": [
            198,
            199,
            200,
            201,
            202
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 75147,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19025,
        "completion_tokens": 215,
        "total_tokens": 19240
      }
    },
    {
      "question_id": 70,
      "question": "How did Gum & Candy's contribution to MDLZ's AMEA segment revenue compare to other product categories in 2022?",
      "original_answer": "In 2022, Gum & Candy contributed $861 million to MDLZ's AMEA segment, which was significantly lower than Biscuits ($1,844 million) and Chocolate ($2,082 million), but higher than Beverages ($546 million) and Cheese & Grocery ($437 million). While Gum & Candy accounted for 2.8% of AMEA’s total revenue in 2021, the 2022 figures show it remained a smaller contributor compared to core categories like Biscuits and Chocolate, which dominated the segment’s revenue mix.",
      "llm_answer": "Based on the segment revenue breakdown and product category percentages in the 2021 financials, Gum & Candy contributed roughly 9.9% of total net revenue. Within the AMEA operating segment, which accounted for about 22.5% of overall net revenue, Gum & Candy represented approximately 2.8% of that segment’s revenue—significantly smaller than the dominant categories of Biscuits (7.8%) and Chocolate (8.3%). Consequently, Gum & Candy’s share of AMEA segment revenue was modest compared with those other product categories.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 137,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 136,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 82546,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20842,
        "completion_tokens": 130,
        "total_tokens": 20972
      }
    },
    {
      "question_id": 70,
      "question": "How does Southern Company's credit arrangement structure involving Nicor Gas relate to the changes in Total Notes Payable for Southern Company Gas subsidiaries between 2023 and 2024?",
      "original_answer": "Southern Company's credit arrangement structure includes Nicor Gas as a borrower under a $700 million allocation within a larger $1.5 billion credit arrangement expiring in 2029, specifically restricted for Nicor Gas's working capital needs. This arrangement provides Nicor Gas with access to flexible liquidity, which directly influences its ability to manage short-term obligations. Looking at Total Notes Payable, Nicor Gas reported $172 million in outstanding commercial paper at the end of 2024, down from $392 million in 2023, reflecting a significant reduction in short-term borrowings. This decline aligns with Southern Company's broader liquidity strategy, as the company maintains unused credit capacity and compliance with debt covenants, enabling Nicor Gas to reduce reliance on short-term notes while maintaining operational flexibility.",
      "llm_answer": "Southern Company’s credit facility for Southern Company Gas includes a $700 million sub‑limit that is allocated to Nicor Gas for working‑capital needs, and the company’s short‑term borrowings (commercial paper and bank term loans) are supported by that facility. Because the unused portion of the credit line backs the commercial‑paper program, the reduction in the total notes payable from $2.314 billion at the end of 2023 to $1.338 billion at the end of 2024 reflects the repayment of short‑term debt drawn under that arrangement. Thus, the structure of the credit agreement—particularly the Nicor Gas sub‑limit—directly influences the decline in Total Notes Payable for Southern Company Gas subsidiaries between 2023 and 2024.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 223,
          "pages": [
            221,
            222,
            223,
            224,
            225
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 224,
          "pages": [
            222,
            223,
            224,
            225,
            226
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 224,
          "pages": [
            222,
            223,
            224,
            225,
            226
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 84241,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21280,
        "completion_tokens": 182,
        "total_tokens": 21462
      }
    },
    {
      "question_id": 71,
      "question": "How does Broadcom's positioning of the Payment Security Suite as a SaaS-based fraud protection service align with the broader Payment Security portfolio's reliance on the Arcot payment authentication network powered by 3-D Secure technology?",
      "original_answer": "Broadcom positions the Payment Security Suite (mentioned on page 13) as a SaaS-based payment authentication service aimed at helping banks and merchants protect against fraud and ensure a seamless online shopping experience. This offering is part of a broader Payment Security portfolio (detailed on page 11), which is explicitly described as being built around the 'Arcot payment authentication network powered by 3-D Secure.' The connection between the Payment Security Suite and the broader Payment Security portfolio indicates that the SaaS-based suite leverages the underlying Arcot technology to deliver its fraud protection capabilities. This alignment suggests that Broadcom integrates its foundational authentication technology into modern, cloud-delivered service models to meet evolving market needs, particularly in securing digital transactions.",
      "llm_answer": "Broadcom positions its Payment Security Suite as a SaaS-based fraud protection service that leverages the Arcot payment authentication network, which is built on 3-D Secure technology, to deliver seamless, secure payment authentication for banks and merchants. This aligns with the broader Payment Security portfolio’s reliance on the Arcot network as the foundational authentication infrastructure, ensuring that the SaaS offering integrates directly with the same secure, scalable payment authentication backbone used across the portfolio.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AVGO_10k_2022.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_2_rel": {
          "source_file": "AVGO_10k_2022.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_3_rel": {
          "source_file": "AVGO_10k_2022.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 9,
        "total_chars": 47459,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12099,
        "completion_tokens": 135,
        "total_tokens": 12234
      }
    },
    {
      "question_id": 71,
      "question": "How does Honeywell's recognition of a $509 million reduction in receivables from Garrett relate to the mandatory redemption schedule of the Series B Preferred Stock received in the Garrett bankruptcy settlement, and how is this reflected in the fair value accounting treatment of the investment?",
      "original_answer": "Honeywell recognized a $509 million reduction in the carrying value of receivables from Garrett in 2020 due to Garrett's financial instability and subsequent bankruptcy filing. As part of the Garrett bankruptcy resolution in 2021, Honeywell received 834.8 million shares of Garrett's Series B Preferred Stock as full satisfaction of the indemnification and tax matters agreements. This preferred stock comes with a mandatory redemption schedule of $35 million in 2022 and $100 million annually from 2023 to 2030, subject to Garrett's EBITDA and liquidity conditions. Honeywell accounts for this investment as held-to-maturity, with its fair value based on the present value of these mandatory redemptions, and is classified as Level 2 in the fair value hierarchy. The connection between the initial receivables impairment, the receipt of preferred stock as settlement, and its subsequent fair value treatment illustrates how Honeywell transitioned from a receivable-based claim to a structured equity instrument with defined redemption terms.",
      "llm_answer": "The $509 million reduction in receivables from Garrett reflects the present‑value adjustment Honeywell made to the amount it expects to receive under the Garrett indemnity and tax‑matters agreements; this adjustment is accounted for as part of the fair‑value measurement of the Series B Preferred Stock received in the bankruptcy settlement. Consequently, the investment in Garrett’s Series B Preferred Stock is recorded at its fair value—determined by discounting the mandatory redemption schedule at 7.25 %—and the discount is amortized into interest income over the redemption period.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 24,
          "pages": [
            22,
            23,
            24,
            25,
            26
          ]
        },
        "hop_2_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "hop_3_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 59195,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15056,
        "completion_tokens": 146,
        "total_tokens": 15202
      }
    },
    {
      "question_id": 72,
      "question": "How does Visa's competitive positioning against Value Added Service Providers, which include technology firms like those offering Visa Direct alternatives, reconcile with its acknowledgment of increasing competition from technology companies in emerging digital payment methods, particularly given the regulatory and litigation risks outlined?",
      "original_answer": "Visa identifies Value Added Service Providers (VASPs), such as technology companies, as direct competitors to its offerings like Visa Direct and Visa B2B Connect (page_16). These VASPs include a range of players from fintechs to consulting firms, and their growing capabilities in digital payments pose a threat to Visa’s market position. On page_23, Visa expands on this concern by noting that technology companies are increasingly developing their own payment systems, particularly in ecommerce, social media, and mobile channels, intensifying competition. This is further complicated by litigation risks, including antitrust and consumer protection lawsuits, which could force Visa to modify its pricing, rules, or business practices. The regulatory exposure outlined on page_16, including anti-money laundering and sanctions compliance, adds another layer of complexity. Together, these elements suggest that while Visa sees innovation and partnerships as competitive advantages, the convergence of regulatory scrutiny and aggressive competition from tech firms could materially impact its ability to maintain dominance in new digital payment flows.",
      "llm_answer": "Visa acknowledges growing competition from technology firms offering alternative digital‑payment solutions and from value‑added service providers, yet it maintains that its global brand, extensive network, and suite of value‑added services (e.g., Visa Direct, Visa B2B Connect) give it a competitive edge.  The company notes that regulatory and litigation risks—such as government‑imposed market restrictions, heightened oversight of large tech firms, and potential antitrust actions—could erode its market position, but its strategy of leveraging scale, partnerships, and continuous innovation is intended to offset those pressures.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "V_10k_2022.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_2_rel": {
          "source_file": "V_10k_2022.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_3_rel": {
          "source_file": "V_10k_2022.pdf",
          "target_page": 23,
          "pages": [
            21,
            22,
            23,
            24,
            25
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 75882,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19233,
        "completion_tokens": 158,
        "total_tokens": 19391
      }
    },
    {
      "question_id": 72,
      "question": "How does Microsoft's continued reliance on BNY Mellon as trustee for the 3.00% Notes due 2020 and other issuances reflect its strategic approach to managing long-term debt obligations?",
      "original_answer": "Microsoft's long-standing relationship with BNY Mellon, dating back to the Base Indenture in 2009 and extended through multiple Supplemental Indentures including the one governing the 3.00% Notes due 2020, demonstrates a consistent and strategic approach to debt management. The repeated use of BNY Mellon across multiple note issuances—such as the 3.00% Notes due 2020 (governed under the Second Supplemental Indenture dated 2010) and later issuances like the 3.625% Notes due 2023 and 4.875% Notes due 2043 (under the Eighth Supplemental Indenture in 2013)—shows a preference for institutional continuity and trust. This pattern suggests Microsoft prioritizes stability, legal consistency, and trusted custodianship in managing its debt structure, which may reduce operational and legal risk while streamlining compliance and investor relations.",
      "llm_answer": "Microsoft's continued use of BNY Mellon as trustee for its 3.00% Notes due 2020 and other debt issuances reflects a deliberate strategy of relying on a well‑established, globally recognized trustee to manage its long‑term financing. By consistently appointing the same trustee across multiple supplemental indentures, Microsoft ensures continuity, operational efficiency, and strong governance over its debt obligations, reinforcing confidence among investors and rating agencies in the stability of its long‑term capital structure.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 50013,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12725,
        "completion_tokens": 133,
        "total_tokens": 12858
      }
    },
    {
      "question_id": 72,
      "question": "How does the shift from the 2012 Long-Term Incentive Plan to the 2022 Long-Term Incentive Plan affect the valuation methodology and grant pricing assumptions for stock options, particularly in light of the 2012 plan's expiration and continued documentation in exhibits?",
      "original_answer": "The transition from the 2012 Long-Term Incentive Plan to the 2022 Long-Term Incentive Plan introduced a change in the pricing methodology for stock option grants—from using the average of high and low stock prices on the grant date (under the 2012 plan) to using the closing stock price (under the 2022 plan). This change, combined with updated volatility assumptions (a blended rate of 10-year weekly historical volatility and 5-week average implied volatility), contributed to an increase in the average fair value of options granted, rising from $23.23 in 2022 to $27.85 in 2023. The 2012 plan expired on April 26, 2022, after which all grants were made under the 2022 plan. Despite its expiration, the 2012 plan remains referenced in the exhibits (e.g., Form of Stock Option Certificate and Global Award Agreements), indicating its ongoing relevance for historical grants and accounting disclosures, even as the newer plan governs current equity compensation practices.",
      "llm_answer": "The shift from the 2012 Long-Term Incentive Plan to the 2022 Long-Term Incentive Plan does not alter the core valuation methodology for stock options—both plans use the Black‑Scholes model with similar assumptions (risk‑free rate, volatility, expected life, dividend yield)—but it does change the pricing source (2012 options were priced at the average of the high and low price of the day, while 2022 options are priced at the closing price) and the share reserve calculation (the 2022 plan allows up to 150 million shares, with a 5‑for‑1 weighting for full‑value awards over 40 million). Consequently, the grant pricing assumptions reflect the updated reserve and award‑counting rules, even though the underlying option‑valuation technique remains consistent.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 120,
          "pages": [
            118,
            119,
            120,
            121,
            122
          ]
        },
        "hop_3_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 124,
          "pages": [
            120,
            121,
            122,
            123,
            124
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 48566,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12389,
        "completion_tokens": 190,
        "total_tokens": 12580
      }
    },
    {
      "question_id": 73,
      "question": "Given the significant market value of MA's Class A Common Stock and the equity award structure under the LTIP, how does the compensation expense recognition timeline for stock options align with the company's equity issuance strategy for Class A shares?",
      "original_answer": "The market value of MA's Class A Common Stock was approximately $328.8 billion as of June 30, 2023, and the company primarily issues new shares of Class A common stock to fund equity awards under the LTIP, with approximately 116 million shares authorized for this purpose. Stock options granted on or after March 1, 2022, vest ratably over three years, with compensation expense recognized over this vesting period. This timeline aligns with the company's equity issuance strategy, as the vesting schedule ensures a gradual release of shares into the market, minimizing dilution while maintaining long-term incentive alignment for participants.",
      "llm_answer": "The compensation expense for stock options and other equity awards is recognized over the vesting period of the underlying awards, which aligns with Mastercard’s equity issuance strategy of using newly issued Class A shares to fund option exercises and award settlements. This approach allows the company to preserve cash while expanding its outstanding Class A share count, supporting both the LTIP’s equity‑based compensation structure and its broader capital‑allocation objectives.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MA_10k_2023.pdf",
          "target_page": 2,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        },
        "hop_2_rel": {
          "source_file": "MA_10k_2023.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "hop_3_rel": {
          "source_file": "MA_10k_2023.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 65813,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16693,
        "completion_tokens": 121,
        "total_tokens": 16814
      }
    },
    {
      "question_id": 73,
      "question": "How does the expiration of the 2012 Long-Term Incentive Plan and the transition to the 2022 Long-Term Incentive Plan affect the valuation methodology and grant pricing assumptions for stock options, particularly in terms of volatility and grant-date pricing?",
      "original_answer": "The expiration of the 2012 Long-Term Incentive Plan in April 2022 and the transition to the 2022 Long-Term Incentive Plan introduced a change in the grant-date pricing methodology, with options now being granted at the closing price of JNJ stock rather than the average of the high and low prices. Additionally, the fair value of options granted in 2023 was $27.85, up from $23.23 in 2022 and $20.86 in 2021, reflecting updated volatility assumptions that blend a 10-year weekly historical volatility rate with a 5-week average implied volatility rate based on traded options. This shift in valuation methodology and pricing aligns with the new plan’s structure and reflects a more dynamic approach to volatility estimation.",
      "llm_answer": "The expiration of the 2012 Long-Term Incentive Plan and transition to the 2022 plan did not change the stock option valuation methodology; the Company continued to use the Black‑Scholes model with similar assumptions (risk‑free rate, expected volatility of ~17‑18 %, expected life of 7 years, dividend yield of ~2.7‑2.9 %). Grant‑date exercise prices under the 2022 plan are now set at the closing market price on the grant date, whereas prior options under the 2012 plan were priced at the average of the high and low exchange prices on the grant date. Consequently, volatility assumptions remain blended historical and implied rates, and the pricing approach shifted from an average‑price method to a closing‑price method, but the underlying valuation model and inputs stay consistent.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 120,
          "pages": [
            118,
            119,
            120,
            121,
            122
          ]
        },
        "hop_3_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 124,
          "pages": [
            120,
            121,
            122,
            123,
            124
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 48566,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12387,
        "completion_tokens": 196,
        "total_tokens": 12583
      }
    },
    {
      "question_id": 74,
      "question": "How does Cisco's lower gross margin from Advanced Services relate to the credit loss allowance reductions observed in their loan receivables portfolio?",
      "original_answer": "Cisco's Advanced Services are noted to carry a lower gross margin compared to technical support services, which impacts the company's overall profitability from services. These services are also explicitly tied to financing arrangements, including loan receivables, which are used to support customer purchases of Cisco products and services. On the other hand, the credit loss allowance for loan receivables decreased from $103 million in fiscal year 2022 to $53 million in fiscal year 2023, indicating improved credit quality or reduced risk in the loan portfolio. This reduction in credit loss allowances could imply stronger collections or lower defaults in the financing of Advanced Services, which may help offset some of the margin pressures seen in that service line. Therefore, while Advanced Services contribute less to gross margin, the improved credit performance of loan receivables tied to these services may positively impact Cisco’s financial position.",
      "llm_answer": "Cisco's lower gross margin from Advanced Services is not directly tied to the credit loss allowance reductions observed in their loan receivables portfolio. The document shows that Advanced Services gross margin increased to 68.1% (from 66.4%), driven by higher sales volume, lower headcount-related costs, and favorable mix, while the credit loss allowance reductions (from $72M to $65M) reflect improved collections on loan receivables, not margin pressure. The gross margin discussion attributes the increase to services mix and productivity, with no linkage to credit loss adjustments.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 43,
          "pages": [
            41,
            42,
            43,
            44,
            45
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 69629,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17624,
        "completion_tokens": 147,
        "total_tokens": 17771
      }
    },
    {
      "question_id": 74,
      "question": "How does Duke Energy Indiana's capital planning align with the timing of its Indiana coal contract expirations (2024-2027) and tax-exempt bond maturities (2027-2046)?",
      "original_answer": "Duke Energy Indiana has coal contracts expiring between 2024 and 2027, which necessitate future capital planning decisions for securing new supply or extending contracts. At the same time, the company holds tax-exempt bonds maturing between 2027 and 2046, with $352 million specifically attributed to Duke Energy Indiana. The alignment of these two timelines suggests that the company may need to consider its capital structure and liquidity needs as the coal contracts expire, potentially leveraging or refinancing long-term debt, including these tax-exempt bonds, to manage operational continuity and fuel procurement strategies beyond 2027.",
      "llm_answer": "Duke Energy Indiana's capital planning aligns with its Indiana coal contract expirations (2024-2027) and tax-exempt bond maturities (2027-2046) through its long-term debt structure and refinancing strategy. The company's current maturities of long-term debt (including $2.8 billion due in 2024) and projected maturities table show that it has scheduled debt repayments and new issuances (e.g., $1 billion of first mortgage bonds in January 2024) to manage these expiries. The tax-exempt bonds maturing 2027-2046 are backed by first mortgage bonds and the Master Credit Facility, allowing Duke Energy to refinance short-term obligations on a long-term basis, ensuring continuity of funding for coal plant transitions and capital projects. This structure supports its capital planning by providing sufficient liquidity to address both the expiring coal contracts and the long-dated tax-exempt bond maturities.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 163,
          "pages": [
            161,
            162,
            163,
            164,
            165
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 165,
          "pages": [
            163,
            164,
            165,
            166,
            167
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 103430,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 26080,
        "completion_tokens": 226,
        "total_tokens": 26306
      }
    },
    {
      "question_id": 74,
      "question": "Given that UPS contributes to the Alaska Teamster-Employer Pension Plan, which is subject to an implemented Financial Improvement Plan (FIP), how does UPS's 2023 contribution of $10 million to this plan align with the company's overall compliance strategy for satisfying FIP requirements across its multiemployer pension obligations?",
      "original_answer": "UPS contributed $10 million to the Alaska Teamster-Employer Pension Plan in 2023, which is subject to an implemented FIP. According to the disclosures, UPS's collectively bargained contributions satisfy the requirements of all implemented FIPs and do not require the payment of any surcharges. This indicates that UPS's 2023 contribution aligns with its compliance strategy, as it meets the FIP obligations without incurring additional costs, consistent with the company's broader approach to managing multiemployer pension plan requirements.",
      "llm_answer": "UPS’s $10 million contribution to the Alaska Teamster‑Employer Pension Plan—one of the multi‑employer plans subject to an implemented Financial Improvement Plan (FIP)—fits within its broader compliance strategy of making only the contractually‑required, collectively‑bargained contributions to each FIP‑covered plan. Because the plan’s FIP has already been implemented and the company’s negotiated rates satisfy all FIP and rehabilitation‑plan funding requirements, UPS incurs no additional surcharge obligations; thus its $10 million payment is simply the pre‑agreed amount needed to maintain compliance with the FIP while avoiding any surcharge triggers under the Pension Protection Act.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 87500,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 22131,
        "completion_tokens": 172,
        "total_tokens": 22303
      }
    },
    {
      "question_id": 75,
      "question": "How does Cisco's disclosure about the interest rate sensitivity of its senior fixed-rate notes, which indicates a $0.7 billion fair value change from a 50 BPS rate movement, relate to its commercial paper notes program used for general corporate purposes, especially considering the shared debt ranking and potential interest expense impacts?",
      "original_answer": "Cisco discloses that its senior fixed-rate notes, totaling $20.3 billion in principal, have a fair value sensitivity of $0.7 billion for a 50 BPS interest rate movement. These notes are ranked equally with the commercial paper notes issued under Cisco's $15.0 billion short-term debt program. While the senior notes are primarily fixed-rate, the commercial paper notes expose Cisco to variable interest costs, meaning a rise in rates could increase interest expense on new issuances. The shared ranking between these debt instruments implies that both carry similar credit risk and could influence Cisco's overall debt management strategy, especially in a rising rate environment where the cost of commercial paper could rise while the fair value of fixed-rate debt declines.",
      "llm_answer": "Cisco's disclosure of a $0.7 billion fair‑value change in its senior fixed‑rate notes from a 50‑basis‑point rate movement reflects the sensitivity of that debt to interest‑rate shifts. Because the same debt ranks alongside its commercial paper program—both bearing the same credit rating—the company could face comparable interest‑expense impacts if market rates move, linking the fixed‑rate note exposure to the cost of borrowing through its commercial paper facility.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 53,
          "pages": [
            51,
            52,
            53,
            54,
            55
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 88,
          "pages": [
            86,
            87,
            88,
            89,
            90
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 76980,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19509,
        "completion_tokens": 117,
        "total_tokens": 19626
      }
    },
    {
      "question_id": 75,
      "question": "How does AMD's risk disclosure around wafer purchase targets under the Wafer Supply Agreement with GLOBALFOUNDRIES U.S. Inc. for 2022–2025 reconcile with the binding contractual amendments filed as Exhibit 10.63 on page 97?",
      "original_answer": "AMD's risk disclosure on page 23 outlines that under the Wafer Supply Agreement (WSA) with GLOBALFOUNDRIES (GF), AMD has annual wafer purchase targets through 2025 and may be required to pay GF a portion of the difference if those targets are not met. This creates a financial exposure risk tied to demand forecasting. The contractual amendment referenced on page 97 (Exhibit 10.63) confirms the binding nature of these commitments, including GF's obligation to provide minimum annual capacity and AMD's corresponding purchase obligations. This alignment shows that the qualitative risk described in the narrative section is underpinned by enforceable contractual terms, reinforcing the materiality of potential shortfalls or overcommitments in wafer procurement.",
      "llm_answer": "The First Amendment to the Amended and Restated Wafer Supply Agreement (Exhibit 10.63) confirms that AMD and GLOBALFOUNDRIES U.S. Inc. updated the original 2009 Wafer Supply Agreement with new wafer‑purchase targets, pricing and pre‑payment obligations that run through 2025, and it removes the prior exclusivity provisions. This amendment directly aligns the risk disclosure in the 10‑K—specifically the statement that AMD must pay a portion of any shortfall between actual wafer purchases and the contractual targets—by making those targets and associated penalties explicit and binding in the filed exhibit.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMD_10k_2022.pdf",
          "target_page": 23,
          "pages": [
            21,
            22,
            23,
            24,
            25
          ]
        },
        "hop_2_rel": {
          "source_file": "AMD_10k_2022.pdf",
          "target_page": 97,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "AMD_10k_2022.pdf",
          "target_page": 97,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 83589,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21130,
        "completion_tokens": 152,
        "total_tokens": 21282
      }
    },
    {
      "question_id": 75,
      "question": "How does MMM's retained equity interest in Solventum, which it intends to divest within five years, influence its ongoing exposure to PFAS-related liabilities that are specifically allocated to Solventum post-April 2024, particularly in light of MMM's retained obligations for certain product claims sold by Solventum through 2025?",
      "original_answer": "MMM retains an equity interest in Solventum and intends to divest it within five years, but during the holding period, Solventum assumes PFAS liabilities arising from its operations post-April 1, 2024, except for certain product claims sold between April 2024 and January 1, 2026, which MMM still retains liability for. This creates a hybrid exposure for MMM, where despite the spin-off and Solventum’s responsibility for future liabilities, MMM remains financially and legally exposed to legacy PFAS product claims from Solventum’s business during a transitional period. This exposure complicates MMM’s risk management and financial planning during the divestiture timeline.",
      "llm_answer": "MMM retains exposure to PFAS‑related product claims that are allocated to Solventum for sales occurring after April 1 2024 and before January 1 2026, even though it plans to divest its equity stake in Solventum within five years. Consequently, any future claims or liabilities arising from those PFAS‑containing products sold by Solventum during that window will remain on MMM’s balance sheet and could generate financial losses or require indemnification payments despite the planned divestiture.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 17,
          "pages": [
            15,
            16,
            17,
            18,
            19
          ]
        },
        "hop_2_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "hop_3_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 93670,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 23677,
        "completion_tokens": 124,
        "total_tokens": 23801
      }
    },
    {
      "question_id": 75,
      "question": "How does the Southern Company's 131.7% increase in wholesale affiliate revenues, driven by a 165.5% rise in KWH sales volume under the FERC-approved intercompany coordination framework, reflect its operational dependency on Southern Company Services for power pool management?",
      "original_answer": "The Southern Company's 131.7% increase in wholesale revenues from sales to affiliates in 2024, primarily due to a 165.5% increase in the volume of KWH sales, is directly tied to the intercompany coordination framework (IIC) approved by the FERC. The IIC governs the operation of the Southern Company power pool, under which the traditional electric operating companies and Southern Power Company coordinate their generation resources to achieve economic efficiency and reliability. This coordination is administered by Southern Company Services (SCS), which manages the centralized economic dispatch and operational control of the integrated electric system. The significant increase in affiliate sales volume underscores the importance of SCS in facilitating these transactions, as reflected in the dependency on SCS for managing power pool operations and the associated costs, which are included in other operations and maintenance expenses or capitalized to property, plant, and equipment. Therefore, the revenue growth from affiliate sales is not only a result of increased demand from affiliated companies but also a reflection of the critical role SCS plays in enabling these transactions through the IIC framework.",
      "llm_answer": "The 131.7% rise in wholesale affiliate revenues stems from a 165.5% jump in KWH sales volume within the Southern Company power pool, which is administered by Southern Company Services under the FERC‑approved IIC. This volume surge reflects the system‑wide coordination of generation and load that Southern Company Services manages, making the utility’s wholesale earnings highly dependent on the pool’s operational framework.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 66,
          "pages": [
            64,
            65,
            66,
            67,
            68
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 165,
          "pages": [
            163,
            164,
            165,
            166,
            167
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 65827,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16709,
        "completion_tokens": 106,
        "total_tokens": 16815
      }
    },
    {
      "question_id": 75,
      "question": "Given BMY's ongoing legal liability for Onglyza despite divesting the product to AstraZeneca in 2014 and the continued financial interest indicated by Farxiga's trademark status, how does BMY's historical exposure to AstraZeneca's diabetes portfolio affect its current risk profile?",
      "original_answer": "BMY's ongoing legal liability for Onglyza, despite divesting the product to AstraZeneca in 2014, shows that divestiture did not fully remove BMY from financial risk associated with the product. This is evident from the litigation still pending in the Sixth Circuit as of December 2022. Meanwhile, Farxiga, another AstraZeneca diabetes drug, is listed in BMY’s 2023 10-K with trademark attribution, indicating a continued financial linkage to AstraZeneca’s diabetes portfolio. Together, these facts suggest that BMY remains exposed to legacy risks from its former diabetes business, despite no longer owning the products directly. This ongoing entanglement affects BMY’s current risk profile by maintaining legal and financial exposure to a therapeutic area it has ostensibly exited.",
      "llm_answer": "BMY's historical exposure to AstraZeneca's diabetes portfolio, particularly through its former co-development and co-promotion of Onglyza with AstraZeneca, continues to impact its current risk profile due to ongoing product liability litigation involving Onglyza. Although BMY divested Onglyza to AstraZeneca in 2014, the litigation remains active, with plaintiffs appealing a 2022 summary judgment ruling that dismissed claims related to cardiovascular injuries. The document confirms that any potential liability for Onglyza is expected to be shared with AstraZeneca, but the unresolved appeal and continued legal exposure underscore persistent risk. Additionally, the document notes that BMY's financial interest in AstraZeneca's diabetes portfolio is indirectly reflected in the trademark status of Farxiga, though this appears to be a separate product (Forxiga/Forxiga is AstraZeneca's SGLT2 inhibitor, not directly tied to BMY's historical portfolio). The unresolved litigation and shared liability with AstraZeneca contribute to BMY's ongoing legal and financial risk exposure.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 118,
          "pages": [
            116,
            117,
            118,
            119,
            120
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 138,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 138,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 106397,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 26849,
        "completion_tokens": 271,
        "total_tokens": 27120
      }
    },
    {
      "question_id": 76,
      "question": "Given the 23% year-over-year growth in Server products and cloud services revenue to $97.7 billion in fiscal 2024, how does Microsoft's strategic positioning of SQL Server as a core component of this growth align with its disclosure that SQL Server revenue is reported alongside Client Access Licenses (CALs) rather than as a standalone product?",
      "original_answer": "Microsoft's Server products and cloud services segment grew from $79.97 billion in fiscal 2023 to $97.73 billion in fiscal 2024, a 23% increase, underscoring its strategic importance. Within this segment, SQL Server is highlighted as a core product, yet its revenue is not reported separately but rather bundled with Client Access Licenses (CALs) and other server products like Windows Server. This reporting methodology, disclosed in the Intelligent Cloud section, contrasts with the prominence given to SQL Server as a key enabler of enterprise data management and cloud infrastructure. The bundling suggests that SQL Server's financial performance is interwoven with broader licensing strategies, potentially masking its individual contribution to growth. Thus, while SQL Server is positioned as a foundational element of Microsoft's enterprise offerings, its financial impact must be inferred indirectly through aggregated reporting rather than direct revenue attribution.",
      "llm_answer": "Microsoft reports SQL Server revenue as part of the \"Server products and cloud services\" line item within its Intelligent Cloud segment, where it is bundled together with related Client Access Licenses (CALs) and other server technologies rather than presented as a standalone revenue figure. This aggregation aligns with the company's segment reporting structure, which groups server products and associated licensing (including CALs) under a single category to reflect integrated sales and usage patterns across its cloud and on-premises offerings. Consequently, while SQL Server contributes to the 23% year-over-year growth in Server products and cloud services revenue ($97.7 billion in fiscal 2024), its specific performance is not disclosed separately in the financial statements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 42,
          "pages": [
            40,
            41,
            42,
            43,
            44
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 56414,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14371,
        "completion_tokens": 196,
        "total_tokens": 14568
      }
    },
    {
      "question_id": 76,
      "question": "How does Microsoft's inclusion of SA in Open Value agreements affect the recognition pattern and unearned revenue treatment of multi-year licenses compared to other volume licensing programs?",
      "original_answer": "Microsoft's Open Value agreements, designed for small and medium organizations, include Software Assurance (SA) and allow customers to license cloud services and on-premises software over a three-year period with the option to purchase perpetual licenses or subscribe. Since SA is included, it introduces complexity in determining the standalone selling price (SSP) and the pattern of delivery, requiring judgment in revenue recognition. On page 64, it is noted that SA and cloud services are part of unearned revenue, which is generally invoiced annually and recognized ratably over the coverage period. This creates a different revenue recognition and unearned revenue dynamic compared to other programs like the Microsoft Products and Services Agreement, where SA is optional, potentially altering the timing and structure of revenue recognition and unearned liabilities.",
      "llm_answer": "Microsoft's inclusion of Software Assurance (SA) in Open Value agreements results in unearned revenue being recognized ratably over the three-year agreement period, rather than upfront. This contrasts with other volume licensing programs like Enterprise Agreements, where SA is included but the revenue recognition pattern for multi-year licenses remains consistent with Open Value—recognizing revenue over time as SA benefits are consumed, not at the point of sale.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 54507,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 13852,
        "completion_tokens": 116,
        "total_tokens": 13968
      }
    },
    {
      "question_id": 76,
      "question": "How does AIG's ownership stake in United States Life Insurance Company in the City of New York, which is a member of FHLB of New York, relate to the specific borrowing obligations AIG has disclosed under the FHLB of New York facility, particularly in terms of liquidity strategy and credit support commitments?",
      "original_answer": "AIG holds a stake in United States Life Insurance Company in the City of New York, which is a member of the FHLB of New York. This membership enables AIG’s Life and Retirement companies to access collateralized borrowing through the FHLB system, with $241 million of borrowing obligations specifically attributed to the FHLB of New York facility as of December 31, 2023. These borrowings are supported by $8.7 billion in pledged assets, including those backing funding agreements, and are part of a broader liquidity strategy that also includes a $3.357 billion borrowing facility with the FHLB of Dallas. The stake in the life insurer thus directly supports AIG’s access to secured financing and contributes to its overall funding and liquidity positioning.",
      "llm_answer": "AIG’s ownership stake in the United States Life Insurance Company in the City of New York—its membership in the FHLB of New York—provides a source of collateralized borrowing capacity that is explicitly referenced in the “Funding Agreements” section of the filing.  The Life and Retirement companies’ net borrowing capacity under the FHLB facilities totals $3.7 billion, and they pledged $8.7 billion of collateral (including FHLB stock) to support those obligations.  This borrowing line is part of AIG’s broader liquidity strategy, which relies on maturing investments, cash flows from operations, asset dispositions, and debt issuances to service and repay its general borrowings, while the FHLB facilities furnish additional collateral‑backed liquidity and a spread‑earning source of funds.  Consequently, the FHLB membership underpins AIG’s credit‑support commitments and enhances its ability to meet short‑term funding needs without relying solely on market‑based debt.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 113,
          "pages": [
            111,
            112,
            113,
            114,
            115
          ]
        },
        "hop_2_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 228,
          "pages": [
            226,
            227,
            228,
            229,
            230
          ]
        },
        "hop_3_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 228,
          "pages": [
            226,
            227,
            228,
            229,
            230
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 109272,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 27575,
        "completion_tokens": 243,
        "total_tokens": 27819
      }
    },
    {
      "question_id": 76,
      "question": "How does Honeywell's recognition of a $509 million reduction in receivables from Garrett relate to the mandatory redemption schedule of the Series B Preferred Stock received in the Garrett bankruptcy settlement, and how is this reflected in the fair value accounting treatment of the investment?",
      "original_answer": "Honeywell recognized a $509 million reduction in the carrying value of receivables from Garrett in 2020 due to the uncertainty surrounding the enforceability of the Garrett Indemnity and Tax Matters Agreement during Garrett’s bankruptcy proceedings. As part of the Garrett bankruptcy settlement confirmed in April 2021, Honeywell received $375 million in cash and 834.8 million shares of Garrett’s Series B Preferred Stock, which replaced the previous receivables. The Series B Preferred Stock has a mandatory redemption schedule of $35 million in 2022 and $100 million annually from 2023 to 2030, subject to Garrett’s EBITDA and liquidity conditions. Honeywell accounts for this investment as held-to-maturity, with its fair value based on the present value of these mandatory redemptions, and classified as Level 2 in the fair value hierarchy. This reflects a shift from a direct receivable to a structured equity instrument with defined redemption rights, which is now valued based on observable market data and contractual redemption terms.",
      "llm_answer": "The $509 million reduction in receivables from Garrett reflects the present‑value adjustment Honeywell made to the amounts due under the Garrett Indemnity and Tax Matters Agreement when Garrett emerged from bankruptcy; this adjustment is incorporated into the fair‑value accounting for the Series B Preferred Stock received, which is recorded at the present value of its mandatory redemption schedule and subsequently accretes interest income over the redemption period.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 24,
          "pages": [
            22,
            23,
            24,
            25,
            26
          ]
        },
        "hop_2_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "hop_3_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 59195,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15056,
        "completion_tokens": 117,
        "total_tokens": 15173
      }
    },
    {
      "question_id": 77,
      "question": "How does MetLife's exposure to interest rate risk in its Retirement and Income Solutions segment relate to the scale of its life insurance business as reported in the consolidated financial statements?",
      "original_answer": "MetLife's Retirement and Income Solutions (RIS) segment contains both short- and long-duration products, including pension risk transfers and structured settlements, which are exposed to interest rate risk under hypothetical rate scenarios. This exposure affects gross margins and is mitigated through ALM strategies. RIS is part of the U.S. segment, which also includes Group Benefits, and together they offer a range of life and annuity-based products. According to the consolidated financial statements, life insurance revenue totaled $22.87 billion in 2021, indicating a significant portion of MetLife's business is tied to life insurance products that may be affected by interest rate fluctuations. Therefore, the interest rate sensitivity described in the RIS segment likely has a material impact on the broader life insurance business as a whole.",
      "llm_answer": "MetLife's exposure to interest rate risk in its Retirement and Income Solutions (RIS) segment is closely tied to the scale of its life insurance business, which is reflected in the consolidated financial statements through the size of its invested asset base and the proportion of long-duration, interest-sensitive products. The RIS segment, which includes capital market products, pension risk transfers, structured settlements, and benefit funding solutions, is subject to interest rate risk from reinvestment of cash flows and the use of interest rate derivatives to hedge reinvestment risk. The document notes that approximately 5% of MetLife's invested assets are subject to reinvestment risk through 2024, and the segment's performance is influenced by changes in U.S. interest rates, as illustrated in the hypothetical scenarios showing impacts on adjusted earnings across segments. The scale of the life insurance business—evidenced by the substantial premiums, policyholder liabilities, and invested assets reported in the consolidated financial statements—directly affects the magnitude of this exposure, particularly as it relates to managing interest rate sensitivity in a rising or falling rate environment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 61,
          "pages": [
            59,
            60,
            61,
            62,
            63
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 184,
          "pages": [
            182,
            183,
            184,
            185,
            186
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 190,
          "pages": [
            188,
            189,
            190,
            191,
            192
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 80341,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20320,
        "completion_tokens": 305,
        "total_tokens": 20625
      }
    },
    {
      "question_id": 77,
      "question": "How does CVS account for its Red Oak Sourcing joint venture with Cardinal Health in its consolidated financial statements, given the quarterly payments received from Cardinal and the 50% ownership structure?",
      "original_answer": "CVS consolidates Red Oak Sourcing, LLC in its financial statements despite the 50% ownership because it has determined that it is the primary beneficiary of the VIE, with the ability to direct Red Oak's activities. Although Red Oak is jointly owned with Cardinal Health and neither company holds inventory on behalf of the other, CVS receives quarterly payments from Cardinal that began in October 2014 and are tied to milestones, with payments increasing as those milestones are met. These payments, which totaled $183 million annually from 2019 to 2021, reduce CVS’s carrying value of inventory and are recognized in cost of products sold when the related inventory is sold. This accounting treatment reflects CVS’s control over the entity’s operations despite equal ownership, and the financial impact of the payments is directly tied to inventory cost recognition rather than revenue or equity method accounting.",
      "llm_answer": "CVS consolidates Red Oak Sourcing, LLC—a 50% owned generic pharmaceutical sourcing joint venture with Cardinal Health—into its Retail/LTC segment because it is the primary beneficiary of the VIE. Cardinal is required to make quarterly payments to CVS (beginning in October 2014 and extending through June 2029), which are recognized as a reduction in inventory cost when the related inventory is sold. These payments, amounting to $183 million annually for 2021, 2020, and 2019, are recorded as a reduction of cost of products sold and are reflected in the Company's consolidated financial statements within the Retail/LTC segment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "target_page": 18,
          "pages": [
            16,
            17,
            18,
            19,
            20
          ]
        },
        "hop_2_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "target_page": 18,
          "pages": [
            16,
            17,
            18,
            19,
            20
          ]
        },
        "hop_3_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "target_page": 138,
          "pages": [
            136,
            137,
            138,
            139,
            140
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 57951,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14718,
        "completion_tokens": 157,
        "total_tokens": 14875
      }
    },
    {
      "question_id": 77,
      "question": "How does Intel reconcile its strategic decision to divest its NAND business to SK hynix with its ongoing commitment to manufacture NAND memory wafers at the Dalian facility until the second closing?",
      "original_answer": "Intel decided to divest its NAND memory business, including the Dalian fabrication facility, to SK hynix in October 2020, with the first closing completed on December 29, 2021. Despite this divestiture, Intel remains contractually obligated to manufacture NAND memory wafers at that facility for SK hynix until the second closing, which ensures a transitional supply arrangement. This ongoing manufacturing commitment reflects a strategic balance between exiting the NAND business and maintaining short-term operational continuity to support customer needs and fulfill contractual obligations. This transitional phase allows Intel to manage the financial and operational implications of the divestiture while still leveraging its existing manufacturing capabilities in the near term.",
      "llm_answer": "Intel reconciles its divestiture of the NAND business to SK hynix with its continued wafer‑fabrication commitment by agreeing to manufacture NAND wafers at its Dalian fab for SK hynix until the second closing of the transaction, even though the Dalian facility and related assets are slated to be sold in the first closing. This arrangement allows Intel to honor its contractual supply obligations while gradually exiting the NAND manufacturing business.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_2_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_3_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 30751,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 7910,
        "completion_tokens": 113,
        "total_tokens": 8024
      }
    },
    {
      "question_id": 77,
      "question": "How does Cisco's disclosure about the $1.5 billion in interest rate swaps hedging fixed-rate senior notes affect the interpretation of their $10 billion commercial paper program, particularly in light of the $9.0 billion in senior fixed-rate notes outstanding?",
      "original_answer": "Cisco disclosed a $10 billion commercial paper program on page 53, with $0.6 billion outstanding as of July 30, 2022. These commercial paper notes rank at par with the senior fixed-rate notes, which totaled $9.0 billion in principal as of the same date. Cisco also disclosed that it had entered into $1.5 billion in interest rate swaps to hedge certain fixed-rate senior notes, converting their fixed interest rates to floating rates based on LIBOR. This hedging activity, detailed on page 90, suggests an active interest rate risk management strategy. Given that a 50 BPS change in interest rates would impact the fair value of the unhedged fixed-rate debt by $0.3 billion (as noted on page 57), the hedging through swaps likely mitigates some of this exposure, which in turn may influence the relative attractiveness of issuing floating-rate commercial paper versus fixed-rate debt. This interplay reveals a strategic balance between managing interest rate exposure and maintaining flexibility in short-term financing.",
      "llm_answer": "Cisco's disclosure of $1.5 billion in interest‑rate swaps that hedge fixed‑rate senior notes reduces the effective cost of those notes and offsets interest‑rate risk, which helps preserve cash flow for the company's $10 billion commercial‑paper program. With $9 billion of senior fixed‑rate notes outstanding, the swaps provide a hedge that mitigates the impact of rising rates on the company's overall debt servicing costs, supporting its ability to continue issuing commercial paper at favorable rates.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2022.pdf",
          "target_page": 53,
          "pages": [
            51,
            52,
            53,
            54,
            55
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2022.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2022.pdf",
          "target_page": 57,
          "pages": [
            55,
            56,
            57,
            58,
            59
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 77339,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19581,
        "completion_tokens": 126,
        "total_tokens": 19707
      }
    },
    {
      "question_id": 77,
      "question": "How does FedEx plan to maintain its service commitments to customers given the USPS's strategic changes to reduce reliance on FedEx Express's air network, which the company reported negatively impacted 2022 results?",
      "original_answer": "FedEx faces challenges due to the USPS's strategic changes to reduce reliance on FedEx Express's air network, which had a direct negative impact on FedEx's 2022 results. The company acknowledges this risk and highlights its integrated global air network as a key mitigation strategy. With a fleet of 696 aircraft (including approximately 300 supplemental aircraft), FedEx Express maintains an interchangeable and flexible global network that allows for route optimization and cost-effective delivery adjustments. This flexibility is critical to adapting to changes in volume and maintaining service commitments despite the reduction in USPS air transportation contracts.",
      "llm_answer": "FedEx plans to maintain its service commitments despite the USPS’s strategic shift to reduce reliance on FedEx Express’s air network—changes that the company explicitly linked to a negative impact on its 2022 results—by continuing to leverage its integrated global network, investing in fleet and infrastructure, and pursuing strategic initiatives to offset the loss of USPS air‑cargo volume. The company emphasizes that its diversified service offerings, automation, and ongoing network optimizations are designed to preserve service levels and meet customer commitments even as the USPS reduces its air‑transport footprint.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "FDX_10k_2022.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_2_rel": {
          "source_file": "FDX_10k_2022.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_3_rel": {
          "source_file": "FDX_10k_2022.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 84571,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21373,
        "completion_tokens": 156,
        "total_tokens": 21530
      }
    },
    {
      "question_id": 77,
      "question": "What is the financial and strategic rationale behind Merck granting royalty-free licenses to generic manufacturers for molnupiravir in low- and middle-income countries, given their collaborative development and supply agreement with Ridgeback that includes commitments to produce millions of therapy courses at risk?",
      "original_answer": "Merck granted royalty-free licenses to generic manufacturers for molnupiravir in over 100 low- and middle-income countries through the Medicines Patent Pool, as long as the WHO maintains the Public Health Emergency of International Concern classification for COVID-19. This decision aligns with their strategic partnership with Ridgeback, under which both companies are investing at risk to produce millions of therapy courses globally. Despite forgoing potential royalty revenue from these regions, Merck’s approach supports broader public health goals and enhances global access, which could help build goodwill and strengthen their reputation as a leader in pandemic response. The financial rationale is reinforced by Merck’s advance purchase agreements in more than 30 markets and tiered pricing strategies that likely preserve profitability in higher-income regions.",
      "llm_answer": "Merck’s royalty‑free licensing strategy for molnupiravir in low‑ and middle‑income countries stems from its collaborative development and supply agreement with Ridgeback, which includes commitments to produce millions of treatment courses at risk and to fund the manufacturing capacity needed for global access. As part of this effort, Merck granted voluntary licenses to generic manufacturers and the Medicines Patent Pool, enabling generic production in more than 100 LMICs while forgoing royalties for as long as COVID‑19 remains a public‑health emergency. This approach simultaneously advances the strategic goal of broad, equitable distribution of an effective antiviral and supports Merck’s commercial model of investing at risk to secure large‑scale supply and tiered pricing worldwide.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 66872,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16975,
        "completion_tokens": 198,
        "total_tokens": 17173
      }
    },
    {
      "question_id": 78,
      "question": "How does Johnson & Johnson's $9 billion reserve for talc-related liabilities relate to the Cyprus Mines Corporation's involvement in the Imerys bankruptcy mediation, and what does this imply about the company's exposure to the multi-state investigation into talcum powder marketing?",
      "original_answer": "Johnson & Johnson has established a $9 billion reserve, payable over 25 years, to resolve current and future talc-related claims, which encompasses actual and contemplated settlements, including those tied to the Imerys bankruptcy proceedings. Cyprus Mines Corporation, which previously owned certain Imerys talc mines, filed for bankruptcy and proposed a plan that would allow it to contribute to a trust under the Imerys Plan in exchange for legal protection from talc claims. Cyprus, along with Imerys and claimants’ representatives, has been engaged in ongoing mediation since late 2021, with the Bankruptcy Court extending the mediation through December 2023. This indicates that J&J's liability exposure is being managed through structured legal frameworks involving third-party entities like Cyprus and Imerys, which seek to consolidate and channel talc claims through trusts. However, despite these mediation efforts, forty-two states and the District of Columbia have pursued a separate multi-state investigation into J&J’s marketing of talcum powder products. Although the states agreed to mediation in the LTL Bankruptcy Case in March 2022, New Mexico and Mississippi later opted out and resumed their cases in state court, with the broader mediation ultimately being terminated in March 2023. This suggests that while J&J has attempted to consolidate and manage talc-related liabilities through structured bankruptcy and mediation processes involving entities like Cyprus, it still faces parallel regulatory scrutiny that is not fully addressed through those mechanisms.",
      "llm_answer": "Johnson & Johnson’s $9 billion talc‑related reserve reflects the company’s effort to settle the ongoing talc‑cancer lawsuits and to fund the proposed trust that would resolve both current and future claims. This reserve is tied to the Cyprus Mines mediation and the broader Imerys bankruptcy process, which involve Imerys (the talc supplier) and Cyprus (a former owner of Imerys mines) seeking to channel talc claims into a trust in exchange for releases and injunctions. The reserve therefore underscores J&J’s exposure to the multi‑state investigation into its talc marketing, as the company acknowledges it cannot estimate losses beyond the accrued amount and must continually monitor the evolving litigation and regulatory landscape.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        },
        "hop_3_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 98,
          "pages": [
            96,
            97,
            98,
            99,
            100
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 91335,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 23077,
        "completion_tokens": 184,
        "total_tokens": 23262
      }
    },
    {
      "question_id": 78,
      "question": "How does Gulfstream's increased R&D investment tied to G700 certification align with the anticipated FAA certification timeline and its expected impact on 2024 revenue and operating margin guidance?",
      "original_answer": "Gulfstream's 2023 R&D expenses increased due to ongoing product development efforts, particularly those related to the G700 certification (page 37). This aligns with the production ramp-up of the G700 in anticipation of its FAA certification (page 71). The company expects the G700 to enter service following FAA certification in early 2024 (page 5), which supports the anticipated increase in Aerospace segment revenue to approximately $12 billion in 2024 and an expected operating margin of approximately 15%. The alignment of R&D investment, certification timing, and revenue guidance shows a coordinated strategy to bring the G700 to market and drive margin expansion.",
      "llm_answer": "Gulfstream's increased R&D investment tied to G700 certification aligns with the anticipated FAA certification timeline in early 2024, enabling the company to begin deliveries of the new ultra‑large‑cabin G700 aircraft. This timing is expected to drive a rise in Aerospace segment revenue to roughly $12 billion in 2024 and lift the segment’s operating margin to about 15%, supporting the overall 2024 revenue and margin guidance.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 37,
          "pages": [
            35,
            36,
            37,
            38,
            39
          ]
        },
        "hop_2_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 71,
          "pages": [
            69,
            70,
            71,
            72,
            73
          ]
        },
        "hop_3_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 42648,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 10892,
        "completion_tokens": 107,
        "total_tokens": 10999
      }
    },
    {
      "question_id": 78,
      "question": "Given the time-sensitive structure of the contingent value right tied to regulatory approval, how does the Fast Track designation for PR006 affect LLY's financial exposure related to the Prevail acquisition?",
      "original_answer": "The Fast Track designation for PR006, as noted in the regulatory context, increases the likelihood and potentially accelerates the timeline for FDA approval, which directly impacts LLY’s financial exposure tied to the Prevail acquisition. The CVR structure entitles Prevail shareholders to an additional $4.00 per share (approximately $160 million total) if regulatory approval of a Prevail product occurs by December 31, 2024. If approval occurs after that date, the CVR payout decreases by approximately 8.3 cents per month until December 1, 2028, after which it expires with no value. Since Fast Track designation is intended to expedite development and review for therapies addressing serious conditions and unmet medical needs, it improves the probability of earlier approval for PR006, which in turn increases the likelihood that LLY will pay the full contingent amount. This creates a strategic trade-off: while the Fast Track status enhances the value of the acquisition by improving the timeline and probability of success, it also increases LLY’s near-term financial exposure due to the full CVR payout being more likely.",
      "llm_answer": "The Fast Track designation for PR006 (GRN gene therapy) shortens the FDA review timeline for its first regulatory approval, which directly triggers the contingent value right (CVR) tied to that approval. Because the CVR’s $4.00 per share payment depends on timely regulatory clearance, the Fast Track status reduces the uncertainty and accelerates the potential cash outflow, thereby lowering LLY’s financial exposure by making the contingent payment more likely to occur sooner rather than later.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "target_page": 39,
          "pages": [
            37,
            38,
            39,
            40,
            41
          ]
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "target_page": 66,
          "pages": [
            64,
            65,
            66,
            67,
            68
          ]
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "target_page": 66,
          "pages": [
            64,
            65,
            66,
            67,
            68
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 70379,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17823,
        "completion_tokens": 124,
        "total_tokens": 17948
      }
    },
    {
      "question_id": 78,
      "question": "How does MetLife's offering of Retirement and Savings products in the EMEA segment compare to the financial metrics disclosed for EMEA in terms of policyholder account balances and deferred acquisition costs in 2021?",
      "original_answer": "MetLife offers Retirement and Savings products as part of its EMEA segment, which are reflected in the segment’s financial metrics. In 2021, the EMEA segment reported policyholder account balances of $9,392 million and deferred acquisition costs (DAC) and value of business acquired (VOBA) of $1,623 million. These figures indicate the segment's investment in acquiring and maintaining retirement and savings-related policies, while also reflecting the liabilities tied to these products. The relatively high policyholder account balances compared to DAC and VOBA suggest a mature book of business with significant accumulated value in policyholder accounts.",
      "llm_answer": "In 2021, MetLife’s EMEA segment reported policyholder account balances of $9,392 million and deferred acquisition costs of $1,623 million, which are the figures disclosed for that segment in the Consolidated Supplementary Insurance Information tables. These amounts reflect the segment’s exposure to policyholder liabilities and the capitalized acquisition costs associated with its retirement and savings products in the region.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 184,
          "pages": [
            182,
            183,
            184,
            185,
            186
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 327,
          "pages": [
            325,
            326,
            327,
            328,
            329
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 82799,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20938,
        "completion_tokens": 107,
        "total_tokens": 21045
      }
    },
    {
      "question_id": 78,
      "question": "How does NEE's disclosure of collateral posting requirements tied to credit ratings downgrades reconcile with the treatment of nuclear decommissioning reserve funds as part of special use funds, particularly in terms of financial flexibility and risk exposure?",
      "original_answer": "NEE discloses that if its subsidiaries' credit ratings were downgraded to below investment grade, they could be required to post up to $2.4 billion in additional collateral (as of December 31, 2023), which could significantly constrain financial flexibility. These collateral requirements apply to derivative contracts and are tied to credit ratings, with certain protections already in place via credit facilities. Meanwhile, the nuclear decommissioning reserve funds, which are a component of special use funds, hold restricted assets for future decommissioning liabilities at Seabrook, Duane Arnold, and Point Bech. These funds are primarily invested in marketable securities and are marked to fair value, directly impacting other comprehensive income. The connection lies in the fact that both collateral obligations and decommissioning reserves are held within the broader category of 'special use funds' on NEE’s consolidated balance sheets. However, while decommissioning funds are restricted for a specific long-term liability, collateral postings are contingent and variable based on credit conditions. This distinction reveals a dual-layered risk profile: one operational and market-linked (collateral), the other regulatory and long-term (decommissioning), both of which affect NEE’s liquidity and financial flexibility in different ways.",
      "llm_answer": "NEE’s collateral posting requirements tied to credit‑rating downgrades are explicitly disclosed as contingent triggers that could require its subsidiaries (including FPL) to post additional collateral – up to roughly $510 million if FPL and NEECH were downgraded to BBB/Baa2 and up to about $2.4 billion if they fell below investment‑grade – thereby limiting financial flexibility and heightening risk exposure. In contrast, the nuclear decommissioning reserve funds are held in special‑use funds and are accounted for as restricted, non‑trading assets that are not subject to such rating‑linked collateral calls; they are used solely to meet future decommissioning obligations and are not part of the collateral‑posting framework. Thus, while rating downgrades can force cash or security posting that constrains liquidity, the decommissioning reserves remain insulated from those rating‑related collateral demands, preserving a separate source of funding for nuclear liabilities.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NEE_10k_2023.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_2_rel": {
          "source_file": "NEE_10k_2023.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        },
        "hop_3_rel": {
          "source_file": "NEE_10k_2023.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 111895,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 28216,
        "completion_tokens": 245,
        "total_tokens": 28461
      }
    },
    {
      "question_id": 79,
      "question": "How does Johnson & Johnson's $9 billion reserve for talc-related claims reflect its exposure through both direct litigation and potential indemnification obligations arising from the Imerys bankruptcy mediation?",
      "original_answer": "Johnson & Johnson has established a $9 billion reserve to address current and future talc-related claims, which includes both direct litigation exposure and potential indemnification obligations. This reserve reflects the company's estimate of probable loss following the dismissal of the LTL 2 bankruptcy case. Separately, Imerys, JNJ's former talc supplier, filed for bankruptcy and proposed a plan that would channel all talc-related claims against it into a trust, along with its alleged indemnification rights against JNJ. Mediation involving Imerys, Cyprus, and claimants has been ongoing since late 2021, with amended plans filed in 2023 and revised trust distribution procedures in early 2024. The continuation of this mediation, combined with unresolved direct litigation in federal and state courts—including the multi-district litigation expected to go to trial in early 2025—suggests that JNJ’s $9 billion reserve may not fully capture the long-term financial impact of these interconnected legal challenges.",
      "llm_answer": "Johnson & Johnson’s $9 billion reserve reflects its exposure to talc‑related liabilities both from direct litigation against the company and from the indemnification and contribution obligations it assumed in the Imerys bankruptcy mediation, where Imerys’ reorganized trust will seek reimbursement from J&J for talc claims. This reserve, which includes a current liability of roughly one‑third of the total, is intended to cover settlements, judgments and future claims arising from talc use, as well as the company’s potential liability under the Imerys plan’s indemnification provisions.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 98,
          "pages": [
            96,
            97,
            98,
            99,
            100
          ]
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        },
        "hop_3_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 91335,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 23060,
        "completion_tokens": 147,
        "total_tokens": 23207
      }
    },
    {
      "question_id": 79,
      "question": "How does Microsoft's inclusion of Software Assurance (SA) in Enterprise Agreements relate to the revenue recognition challenges described in the contract balances section, particularly regarding unearned revenue from volume licensing programs?",
      "original_answer": "Microsoft's Enterprise Agreements include Software Assurance (SA), which is a key component of their volume licensing programs aimed at medium and large organizations over a three-year period. SA is bundled with perpetual licenses or subscriptions under these agreements, contributing to unearned revenue that is invoiced annually and recognized ratably over the coverage period. However, the company notes that due to the nature and benefits of the SA program, judgment is required to assess the pattern of delivery, including the exercise pattern of benefits across the customer portfolio. This complicates revenue recognition, as SA is not sold separately, and its standalone selling price (SSP) must be estimated using available market and customer data. The unearned revenue from SA and cloud services under volume licensing programs is therefore subject to variability based on customer behavior and contract terms, making it a significant consideration in Microsoft's financial reporting.",
      "llm_answer": "Microsoft's inclusion of Software Assurance (SA) in Enterprise Agreements creates unearned revenue from volume licensing programs because SA is bundled with perpetual on-premises licenses and recognized ratably over the contract period as customers receive ongoing benefits like upgrades and support. This timing difference between revenue recognition and invoicing (e.g., multi-year agreements invoiced annually) results in unearned revenue balances that require careful accounting for variable consideration and contract liabilities, as detailed in the revenue recognition and contract balances sections of the financial statements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 54507,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 13865,
        "completion_tokens": 158,
        "total_tokens": 14023
      }
    },
    {
      "question_id": 79,
      "question": "How does UPS's reliance on net asset value (NAV) as a practical expedient for valuing private equity fund investments reflect both the illiquidity characteristics of these funds and the audit challenges associated with estimating their fair value?",
      "original_answer": "UPS reports that private equity funds are valued at NAV per the most recent partnership audited financial reports, adjusted for investment activity between reporting periods, due to the lack of readily determinable fair value. These funds typically have 10- to 15-year terms with limited redemption provisions, making them highly illiquid. At the same time, the audit process highlights that NAV estimates for these funds require significant auditor judgment due to the subjective assumptions involved, especially since audited financial reports from fund managers are often received in arrears. This dual perspective underscores the tension between the practical need for NAV-based valuation and the inherent complexity and subjectivity in verifying those values during the audit.",
      "llm_answer": "UPS’s reliance on net asset value (NAV) as a practical expedient for valuing private‑equity, real‑estate, private‑debt and hedge‑fund investments reflects the inherent illiquidity of these assets—because they are not traded on active markets, their fair values must be estimated using unobservable inputs and therefore cannot be classified in Level 1 or Level 2 of the fair‑value hierarchy. This valuation approach creates significant audit challenges, as auditors must scrutinize the completeness, reliability and relevance of the inputs (e.g., audited fund financial statements, management assumptions) used to estimate NAV, and assess the reasonableness of the adjustments applied between reporting dates and year‑end.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 63,
          "pages": [
            61,
            62,
            63,
            64,
            65
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 76967,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19480,
        "completion_tokens": 180,
        "total_tokens": 19661
      }
    },
    {
      "question_id": 79,
      "question": "How does American Express's reliance on AENB for $84.4 billion in deposits relate to the regulatory constraints on AENB's dividend payments, and how does this interplay affect the company's broader compliance with federal banking regulations?",
      "original_answer": "American Express relies heavily on AENB for deposit funding, with $84.4 billion in deposits as of December 31, 2021, which is a core component of its funding strategy. However, AENB is subject to strict regulatory constraints on dividend payments, limited to available retained earnings and subject to capital adequacy requirements. As of the same date, AENB had only $3.6 billion in retained earnings available for dividends, which could constrain the amount of capital it can return to the parent company. This dynamic is further complicated by the broader regulatory environment, where American Express must comply with federal banking laws that require it to be a 'source of strength' to AENB and maintain capital plans that ensure regulatory compliance. If AENB's capital levels fall below required thresholds, both its ability to pay dividends and American Express’s broader financial flexibility could be restricted, highlighting the interplay between operational funding needs, regulatory capital constraints, and compliance obligations.",
      "llm_answer": "American Express's reliance on AENB for $84.4 billion of deposits subjects the bank to regulatory capital and dividend constraints: AENB can only distribute dividends if it retains sufficient earnings and meets minimum CET1, Tier 1 and leverage ratios, and any shortfall in its capital ratios would restrict the parent’s ability to pay dividends. Consequently, the company must carefully manage AENB’s capital adequacy to avoid triggering regulatory limits that could impair its broader compliance with federal banking regulations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AXP_10k_2022.pdf",
          "target_page": 71,
          "pages": [
            69,
            70,
            71,
            72,
            73
          ]
        },
        "hop_2_rel": {
          "source_file": "AXP_10k_2022.pdf",
          "target_page": 153,
          "pages": [
            151,
            152,
            153,
            154,
            155
          ]
        },
        "hop_3_rel": {
          "source_file": "AXP_10k_2022.pdf",
          "target_page": 14,
          "pages": [
            12,
            13,
            14,
            15,
            16
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 64221,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16299,
        "completion_tokens": 132,
        "total_tokens": 16432
      }
    },
    {
      "question_id": 79,
      "question": "How does the expected revenue increase from the G700 aircraft entry into service reconcile with the increased inventory costs tied to FAA certification delays mentioned in different sections of the 10-K?",
      "original_answer": "The Aerospace segment's operating margin increased by 50 basis points in 2023 to 13.7%, with expectations of reaching approximately 15% in 2024, driven by the anticipated entry into service of the G700 aircraft and an increase in new aircraft deliveries to approximately 160 (page 37). However, the ramp-up in production of new Gulfstream models, including the G700, led to an increase in total inventories in anticipation of FAA certification (page 71). This inventory buildup reflects the operational costs and financial risk associated with certification delays. Meanwhile, the company explicitly notes on page 5 that the G700 is expected to enter service following FAA certification in early 2024, indicating that the timing of certification directly impacts revenue realization. Therefore, the expected revenue growth hinges on timely FAA certification, while the increased inventory costs suggest that delays or uncertainties in certification could strain short-term financial performance.",
      "llm_answer": "The 10‑K shows that the G700’s entry into service is expected to boost 2024 Aerospace revenue to about $12 billion and lift operating margin to ~15%, reflecting higher aircraft deliveries. At the same time, the document notes that FAA certification delays have increased inventory costs—particularly work‑in‑process and raw‑material inventories tied to the G700 program—so the revenue uplift from the G700 must be weighed against these higher inventory balances and associated cost pressures.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 37,
          "pages": [
            35,
            36,
            37,
            38,
            39
          ]
        },
        "hop_2_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 71,
          "pages": [
            69,
            70,
            71,
            72,
            73
          ]
        },
        "hop_3_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 42648,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 10893,
        "completion_tokens": 123,
        "total_tokens": 11016
      }
    },
    {
      "question_id": 80,
      "question": "How does American Express's reliance on AENB for $84.4 billion in deposits relate to the constraints imposed by banking regulations on AENB's dividend capacity, and how does this interplay affect American Express's broader compliance strategy with federal banking oversight?",
      "original_answer": "American Express relies on AENB as its primary U.S. bank subsidiary to source $84.4 billion in deposits, which are insured by the FDIC and serve as a key component of its funding strategy. However, AENB is subject to strict banking regulations that limit its ability to pay dividends to its parent company, particularly if doing so would cause AENB to fall below required capital adequacy standards or be deemed an unsafe banking practice. In 2021, AENB paid $8.1 billion in dividends to American Express, but retained earnings available for future dividends were only $3.6 billion as of year-end, indicating a potential constraint on future capital distributions. Given that American Express is under comprehensive federal oversight and must comply with regulations that include being a 'source of strength' to AENB, the company must carefully balance its capital planning and dividend strategy to remain compliant with regulators like the Federal Reserve and OCC. This interplay highlights how American Express must align its funding and capital distribution decisions with regulatory expectations to avoid enforcement actions and maintain operational flexibility.",
      "llm_answer": "American Express's reliance on AENB for $84.4 billion of deposits—most of which are FDIC‑insured retail accounts—creates a funding source that is subject to banking‑regulatory capital and dividend constraints. Because AENB must retain sufficient CET1, Tier 1 and Total capital buffers (including the stress‑capital and capital‑conservation buffers) and cannot pay dividends that would jeopardize its well‑capitalized status, the bank’s ability to distribute earnings to American Express is limited. Consequently, American Express’s broader compliance strategy must incorporate these regulatory dividend restrictions into its capital‑planning and dividend‑policy decisions, ensuring that any reliance on AENB’s deposit base does not trigger capital‑adequacy or supervisory breaches.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AXP_10k_2022.pdf",
          "target_page": 71,
          "pages": [
            69,
            70,
            71,
            72,
            73
          ]
        },
        "hop_2_rel": {
          "source_file": "AXP_10k_2022.pdf",
          "target_page": 153,
          "pages": [
            151,
            152,
            153,
            154,
            155
          ]
        },
        "hop_3_rel": {
          "source_file": "AXP_10k_2022.pdf",
          "target_page": 14,
          "pages": [
            12,
            13,
            14,
            15,
            16
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 64221,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16307,
        "completion_tokens": 195,
        "total_tokens": 16502
      }
    },
    {
      "question_id": 80,
      "question": "How does Apple's characterization of China Mainland as a supply chain risk factor relate to the financial performance of the Greater China segment, given that the segment includes China Mainland and reported $74.2 billion in net sales in 2022?",
      "original_answer": "Apple identifies China Mainland as a key part of its supply chain and notes that trade tensions, tariffs, and other disruptions in the region could materially impact its business, particularly by increasing costs and reducing gross margins. Despite these risks, the Greater China segment—which includes China Mainland, Hong Kong, and Taiwan—reported $74.2 billion in net sales in 2022, showing strong demand in the region. This suggests that while Apple faces operational and geopolitical risks in China Mainland, the broader Greater China market remains a significant revenue driver. The contrast between the risk-focused discussion of China Mainland and the positive financial performance of the Greater China segment highlights the dual nature of the region as both a strategic asset and a potential vulnerability for Apple.",
      "llm_answer": "Apple characterizes China Mainland as a supply chain risk factor due to geopolitical tensions, trade restrictions, and reliance on single-source suppliers in the region, which can materially disrupt operations and increase costs. This risk contributed to a 9% year-over-year increase in Greater China net sales ($74.2 billion in 2022), driven by higher iPhone and Services revenue, but also exposed Apple to potential tariff impacts and supply chain vulnerabilities that could affect future profitability.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "hop_2_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 25,
          "pages": [
            23,
            24,
            25,
            26,
            27
          ]
        },
        "hop_3_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 52,
          "pages": [
            50,
            51,
            52,
            53,
            54
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 61958,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15732,
        "completion_tokens": 126,
        "total_tokens": 15858
      }
    },
    {
      "question_id": 80,
      "question": "How does UPS's disclosure regarding the $2.7 billion in unfunded commitments to private debt and private equity funds relate to their use of NAV as a valuation methodology for alternative investments?",
      "original_answer": "UPS reports a $2.7 billion unfunded commitment related to private debt and private equity funds on page 93, which are valued using NAV as a practical expedient due to the lack of readily determinable fair value. This NAV-based valuation approach is further referenced on page 94, where UPS clarifies that certain investments are measured at NAV per share or its equivalent. The use of NAV allows UPS to value these illiquid investments consistently with ASC measurement principles, despite the potential for differences between reported NAV and actual fair value. The $2.7 billion unfunded commitment underscores the ongoing capital exposure tied to these NAV-measured investments, highlighting the importance of NAV disclosures in understanding the company's long-term investment commitments.",
      "llm_answer": "UPS uses NAV as a practical expedient to value alternative investments—such as private‑equity, private‑debt and real‑estate funds—that lack a readily determinable fair value. These investments are recorded at the most recent partnership‑reported NAV (adjusted for activity to year‑end), and the company discloses that $2.7 billion of unfunded commitments to such limited partnerships is expected to be funded over the next three to six years. This approach aligns with the NAV‑based valuation methodology described for these assets.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 70592,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17871,
        "completion_tokens": 133,
        "total_tokens": 18004
      }
    },
    {
      "question_id": 80,
      "question": "Given the increase in Series B Preferred Stock book value from $456 million to $540 million year-over-year and the limited voting rights of preferred stockholders, how does this shift in capital structure affect the likelihood or dynamics of potential corporate combinations or strategic transactions involving Class A Common Stockholders?",
      "original_answer": "The increase in Series B Preferred Stock book value from $456 million to $540 million indicates a growing capital commitment from preferred stockholders, who hold no voting rights except in specific corporate events such as mergers or combinations. This dynamic could influence the strategic calculus of such transactions by concentrating voting power among Class A Common Stockholders, who retain full voting rights on general matters. However, any merger or consolidation where preferred stockholders would receive non-identical securities would require their separate approval, creating a dual-class dependency in key decisions. Thus, while the capital base tied to preferred stock has grown, the structural voting limitations may still preserve Class A Common Stockholders' control in shaping major corporate actions.",
      "llm_answer": "The increase in Series B Preferred Stock book value from $456 million to $540 million reflects a larger conversion‑rate adjustment that reduces the as‑converted share count for Series B and C preferred stock, thereby diluting the voting power of those holders. Because the preferred stockholders have only limited voting rights—mainly on matters such as mergers or consolidations where their approval is required—their reduced voting power weakens their ability to block or influence strategic transactions that require preferred‑stockholder consent. Consequently, the capital‑structure shift makes it easier for Class A common‑stockholders to consummate corporate combinations or other strategic transactions that might otherwise be subject to preferred‑stockholder veto.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "V_10k_2024.pdf",
          "target_page": 58,
          "pages": [
            56,
            57,
            58,
            59,
            60
          ]
        },
        "hop_2_rel": {
          "source_file": "V_10k_2024.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_3_rel": {
          "source_file": "V_10k_2024.pdf",
          "target_page": 61,
          "pages": [
            59,
            60,
            61,
            62,
            63
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 103196,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 26063,
        "completion_tokens": 193,
        "total_tokens": 26256
      }
    },
    {
      "question_id": 81,
      "question": "How does MetLife's focus on Retirement and Savings products in the EMEA region align with the segment's financial obligations and liabilities, particularly in terms of policyholder account balances and future policy benefits?",
      "original_answer": "MetLife offers Retirement and Savings products, such as fixed annuities and pension products, as part of its global portfolio. These products are specifically offered in the EMEA region, indicating a strategic emphasis on retirement solutions in that market. In 2022, the EMEA segment reported $9,392 million in policyholder account balances and $3,639 million in future policy benefits, other policy-related balances, and policyholder dividend obligations. This significant level of liabilities tied to policyholder obligations reflects the long-term nature of retirement and savings products, which require sustained financial commitments. The alignment between the EMEA segment's product offerings and its reported liabilities underscores MetLife's exposure to long-duration contracts in this region and highlights the financial responsibility tied to fulfilling future retirement and savings obligations.",
      "llm_answer": "MetLife's EMEA segment focuses on Retirement and Savings products such as fixed annuities and pension plans, which generate policyholder account balances and future policy benefit obligations. These liabilities are explicitly reflected in Schedule III, where future policy benefits, policyholder account balances, and related reserves for the EMEA segment are reported as $3,639 million in future policy benefits, $9,392 million in policyholder account balances, and $‑ million in policyholder dividends payable for 2021. The segment’s financial obligations therefore align directly with the actuarial reserves and liability structures described for these retirement‑savings products.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 184,
          "pages": [
            182,
            183,
            184,
            185,
            186
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 327,
          "pages": [
            325,
            326,
            327,
            328,
            329
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 82799,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20940,
        "completion_tokens": 171,
        "total_tokens": 21111
      }
    },
    {
      "question_id": 81,
      "question": "How does Cisco's issuance of $0.6 billion in commercial paper notes relate to its $9.0 billion in senior fixed-rate notes, particularly in light of the interest rate sensitivity of the fixed-rate debt and the company's broader debt management strategy?",
      "original_answer": "Cisco's short-term commercial paper program, with $0.6 billion outstanding as of July 30, 2022, serves as a flexible source of liquidity for general corporate purposes. This short-term debt sits alongside $9.0 billion in senior fixed-rate notes, which carry a carrying value of $8.9 billion and a fair value of $9.7 billion as of the same date. The company has also entered into interest rate swaps on $1.5 billion of these fixed-rate notes to convert them to floating rates, mitigating interest rate exposure. A 50 BPS change in interest rates would decrease or increase the fair value of the unhedged fixed-rate debt by approximately $0.3 billion. This suggests Cisco is managing a mix of short-term liquidity via commercial paper and longer-term fixed-rate debt, with active hedging to manage interest rate risk across its capital structure.",
      "llm_answer": "Cisco's issuance of $0.6 billion in commercial paper notes is a short‑term financing tool that complements its larger $9.0 billion senior fixed‑rate note program. While the fixed‑rate notes carry long‑term interest‑rate sensitivity—requiring the company to manage refinancing risk and hedge exposure—the commercial paper provides flexible, low‑cost liquidity for immediate corporate needs, supporting its broader debt‑management strategy of diversifying funding sources and maintaining ample cash flow for dividends, share repurchases and strategic investments.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2022.pdf",
          "target_page": 53,
          "pages": [
            51,
            52,
            53,
            54,
            55
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2022.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2022.pdf",
          "target_page": 57,
          "pages": [
            55,
            56,
            57,
            58,
            59
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 77339,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19579,
        "completion_tokens": 140,
        "total_tokens": 19719
      }
    },
    {
      "question_id": 81,
      "question": "How does Cisco's disclosure of interest rate sensitivity for its senior fixed-rate notes reconcile with the company's reliance on commercial paper notes for general corporate purposes, particularly considering the floating rate exposure of the latter?",
      "original_answer": "Cisco disclosed on page 57 that a 50 BPS increase or decrease in market interest rates would change the fair value of its fixed-rate debt (excluding $1.5 billion of hedged debt) by approximately $0.3 billion. This indicates sensitivity to interest rate movements despite the fixed nature of these senior notes. On page 90, it is noted that the senior fixed-rate notes rank at par with future commercial paper notes issued under the company's short-term debt program. Finally, on page 89, Cisco states that it uses proceeds from commercial paper notes, which typically carry floating interest rates, for general corporate purposes. The floating rate exposure of commercial paper means that rising interest rates would increase Cisco’s short-term borrowing costs, contrasting with the largely fixed exposure profile of the senior notes. Therefore, while the senior notes provide rate stability (except for the unhedged portion), the commercial paper introduces variable rate risk, suggesting a diversified but potentially volatile debt structure.",
      "llm_answer": "Cisco discloses interest rate sensitivity for its senior fixed‑rate notes (e.g., a hypothetical 50‑basis‑point shift would change their fair value by about $0.3 billion) and notes that it has entered into interest‑rate swaps to hedge a portion of that fixed‑rate debt. At the same time, the company relies on commercial paper notes—floating‑rate instruments used for general corporate purposes—to meet short‑term financing needs, exposing that debt to fluctuations in market interest rates. Thus, while the senior notes’ interest‑rate risk is quantified and partially mitigated through swaps, the floating‑rate commercial paper introduces a separate, offsetting interest‑rate exposure for the company’s overall financing mix.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2022.pdf",
          "target_page": 57,
          "pages": [
            55,
            56,
            57,
            58,
            59
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2022.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2022.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 80077,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 20260,
        "completion_tokens": 181,
        "total_tokens": 20441
      }
    },
    {
      "question_id": 81,
      "question": "How does GD's reliance on commercial paper issuances for liquidity needs align with the $4 billion credit facility's role in supporting those same obligations, given the company's emphasis on maintaining a strong balance sheet?",
      "original_answer": "GD states on page 46 that it believes cash from operations, supplemented by commercial paper issuances, is sufficient to meet both short- and long-term liquidity needs. However, on page 75, the company discloses a $4 billion committed bank credit facility that exists specifically to support commercial paper issuances. This implies that while GD is not currently issuing commercial paper (as none was outstanding on December 31, 2024), the credit facility acts as a liquidity backstop to maintain flexibility and preserve a strong balance sheet, aligning with the company's stated capital deployment priorities and financial discipline.",
      "llm_answer": "GD's $4 billion revolving credit facility provides a backup source of liquidity that can be used to refinance or support the commercial paper program, ensuring the company can meet its short‑term financing needs while maintaining a strong balance sheet. This facility therefore complements the company’s reliance on commercial paper issuances for liquidity, giving it flexibility to manage cash outflows and uphold its investment‑grade credit profile.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GD_10k_2024.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        },
        "hop_2_rel": {
          "source_file": "GD_10k_2024.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        },
        "hop_3_rel": {
          "source_file": "GD_10k_2024.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 44064,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 11249,
        "completion_tokens": 112,
        "total_tokens": 11362
      }
    },
    {
      "question_id": 81,
      "question": "How does Amgen's patent protection timeline for polypeptide-based molecules like Tarlatamab align with the clinical development stage of Tarlatamab in small cell lung cancer?",
      "original_answer": "Amgen has polypeptide-related patent protection for Tarlatamab in both the U.S. and Europe extending through 2036, as shown in the intellectual property table. Meanwhile, Tarlatamab is in phase 3 clinical trials for small cell lung cancer, indicating it is in a later but still investigational stage of development. This suggests Amgen is aligning long-term patent protection with ongoing clinical development to maximize commercial exclusivity if Tarlatamab reaches market approval.",
      "llm_answer": "Amgen's patent protection for Tarlatamab, a polypeptide-based molecule targeting small cell lung cancer, extends to 2036 in both the U.S. and Europe, aligning with its clinical development stage as a Phase 3 candidate that received FDA Priority Review for its BLA in December 2023, with an anticipated PDUFA date of June 12, 2024. This patent exclusivity period, covering composition-of-matter protection, ensures market protection through the expected regulatory approval timeline.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "target_page": 26,
          "pages": [
            24,
            25,
            26,
            27,
            28
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "target_page": 26,
          "pages": [
            24,
            25,
            26,
            27,
            28
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 64746,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16407,
        "completion_tokens": 120,
        "total_tokens": 16528
      }
    },
    {
      "question_id": 81,
      "question": "How does the $829 million allocation to private debt in UPS's U.S. pension plans relate to the company's reliance on NAV estimates for auditing these illiquid investments?",
      "original_answer": "UPS allocated $829 million to private debt within its U.S. pension plans, which are valued using net asset value (NAV) as a practical expedient due to the lack of readily determinable fair values. These private debt investments are subject to subjective NAV estimations based on audited or unaudited financial reports from fund managers, with adjustments for investment activity between reporting periods. The audit process for these NAV-based valuations required significant auditor judgment and procedures to evaluate the reliability and completeness of inputs, including direct confirmation with fund managers and comparison of prior estimates to audited results. This creates a three-hop chain where the disclosed private debt amount (from the pension asset allocation table) is tied to NAV valuation practices and further to the audit scrutiny around those estimates, revealing both the strategic investment decision and the operational risk in reporting its value.",
      "llm_answer": "The $829 million allocated to private debt in UPS’s U.S. pension plans is classified as an illiquid investment that is valued using the fund’s net asset value (NAV) as a practical expedient. Because these investments lack a readily determinable fair value, their reported values rely on NAV estimates from the underlying partnerships, which can differ from market‑based valuations if observable inputs were available. Consequently, auditors must scrutinize the NAV methodology and assumptions used to ensure the reported amounts are reliable.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 63,
          "pages": [
            61,
            62,
            63,
            64,
            65
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 73723,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18652,
        "completion_tokens": 135,
        "total_tokens": 18788
      }
    },
    {
      "question_id": 81,
      "question": "Given Southern Power's stated useful life of wind assets as up to 30 years, how does the 12-year PPA contract period for the Glass Sands wind project completed in 2021 align with the company's long-term asset utilization strategy?",
      "original_answer": "Southern Power reports a useful life of wind assets as up to 30 years, suggesting a long-term operational outlook for such facilities. However, the Glass Sands wind project, completed in November 2021, operates under a PPA with a contract period of only 12 years. This shorter-term agreement appears inconsistent with the asset's expected longevity, potentially signaling a strategic decision to prioritize near-to-mid-term revenue stability over long-term contractual commitments in certain markets.",
      "llm_answer": "Southern Power's 12‑year PPA for the Glass Sands wind project aligns with its long‑term asset strategy of acquiring wind facilities that have up to 30‑year useful lives; the shorter contract period simply reflects the negotiated PPA term rather than a limitation on the asset’s expected operational life.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 244,
          "pages": [
            242,
            243,
            244,
            245,
            246
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 330,
          "pages": [
            328,
            329,
            330,
            331,
            332
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 330,
          "pages": [
            328,
            329,
            330,
            331,
            332
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 71418,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18091,
        "completion_tokens": 76,
        "total_tokens": 18167
      }
    },
    {
      "question_id": 82,
      "question": "How does Amgen's revised collaboration with Novartis on Aimovig, effective January 1, 2022, impact Amgen's competitive positioning in the U.S. market, especially given Novartis's direct competition with Otezla and Nplate in key therapeutic areas?",
      "original_answer": "Amgen's revised collaboration with Novartis on Aimovig, effective January 1, 2022, removed U.S. cost-sharing and royalty obligations, giving Amgen full control over Aimovig’s U.S. commercialization. This change likely strengthens Amgen’s ability to directly compete in the U.S. market. However, Novartis remains a competitor to Amgen in several therapeutic areas, including with Otezla and Nplate, where Novartis markets Cosentyx and PROMACTA/REVOLADE, respectively. This dual relationship—where Novartis both collaborates globally on Aimovig and competes directly in other product lines—creates a complex competitive dynamic that could influence Amgen’s market strategy and performance in neurology and hematology.",
      "llm_answer": "Amgen’s revised Aimovig collaboration with Novartis, effective January 1 2022, removes U.S. commercial‑cost sharing and royalty payments, leaving Amgen solely responsible for manufacturing and sales in the United States. Because Novartis continues to hold the ex‑U.S. rights and still pays double‑digit royalties abroad, Amgen’s U.S. market positioning now depends on its own sales force and pricing strategy, while its competition with Otezla and Nplate—both also partnered with Novartis in overlapping therapeutic areas—may intensify, potentially eroding market share unless Amgen can differentiate Aimovig on clinical or economic value.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 28,
          "pages": [
            26,
            27,
            28,
            29,
            30
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 28,
          "pages": [
            26,
            27,
            28,
            29,
            30
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 66055,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16752,
        "completion_tokens": 159,
        "total_tokens": 16912
      }
    },
    {
      "question_id": 82,
      "question": "How does the allocation of Fixed Income Securities and Cash Equivalents within TXN's U.S. Retiree Health Care Plan reflect the plan's approach to managing liability risk, given the $251 million in plan assets allocated to this category in 2021?",
      "original_answer": "The U.S. Retiree Health Care Plan allocated $251 million, or 64% of its total assets, to Fixed Income Securities and Cash Equivalents in 2021. This reflects a conservative risk management strategy, prioritizing capital preservation and stable returns to better match the plan’s long-term liability profile. The high allocation to fixed income suggests an emphasis on reducing volatility in plan returns, which is consistent with the plan’s need to meet predictable healthcare obligations to retirees.",
      "llm_answer": "The $251 million of plan assets allocated to Fixed Income Securities and Cash Equivalents for the U.S. Retiree Health Care Plan—representing roughly 64 % of its total $385 million asset base—reflects a liability‑risk management strategy that emphasizes a high‑quality, interest‑rate‑sensitive fixed‑income portfolio to offset the plan’s benefit obligations. This allocation aligns with the plan’s target range of 65 %–80 % fixed‑income and cash equivalents, using low‑cost, broad‑market index funds to match the duration of liabilities and reduce concentration risk.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "TXN_10k_2022.pdf",
          "target_page": 50,
          "pages": [
            48,
            49,
            50,
            51,
            52
          ]
        },
        "hop_2_rel": {
          "source_file": "TXN_10k_2022.pdf",
          "target_page": 50,
          "pages": [
            48,
            49,
            50,
            51,
            52
          ]
        },
        "hop_3_rel": {
          "source_file": "TXN_10k_2022.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 72468,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18351,
        "completion_tokens": 141,
        "total_tokens": 18492
      }
    },
    {
      "question_id": 83,
      "question": "How does Amgen's patent protection timeline for polypeptide-based molecules, including Tarlatamab, align with the company's strategic investment in advancing Tarlatamab into phase 3 trials for small cell lung cancer?",
      "original_answer": "Amgen has disclosed that Tarlatamab, an investigational polypeptide-based molecule for small cell lung cancer, is protected by patents expiring in 2036 in both the U.S. and Europe. This long-duration patent protection aligns with Amgen's decision to invest in initiating phase 3 trials for Tarlatamab, indicating a strategic commitment to its development and commercialization. The extended IP protection provides Amgen with a competitive window to recoup R&D investments and establish market positioning in a high-need therapeutic area.",
      "llm_answer": "Amgen's patent protection for Tarlatamab, a half-life-extended (HLE) anti-DLL3 x anti-CD3 BiTE molecule, is projected to expire in 2036 in both the U.S. and Europe, providing a long-term exclusivity window that aligns with its strategic advancement into Phase 3 trials for small cell lung cancer. This timeline supports the company's investment in developing Tarlatamab as a potential breakthrough therapy for SCLC, backed by positive Phase 2 data showing a 40% ORR and FDA Priority Review designation.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "target_page": 26,
          "pages": [
            24,
            25,
            26,
            27,
            28
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "target_page": 26,
          "pages": [
            24,
            25,
            26,
            27,
            28
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 64746,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16418,
        "completion_tokens": 125,
        "total_tokens": 16543
      }
    },
    {
      "question_id": 83,
      "question": "How does Broadcom's positioning of the Payment Security Suite as a SaaS-based fraud prevention service align with the strategic emphasis on 3-D Secure technology within their broader Payment Security portfolio, and what does this suggest about their approach to securing online transactions?",
      "original_answer": "Broadcom positions the Payment Security Suite as a SaaS-based payment authentication service aimed at helping banks and merchants protect against fraud and ensure a seamless online shopping experience (page 13). This offering is explicitly tied to the company's broader Payment Security portfolio, which is described as being powered by 3-D Secure technology (page 11). The inclusion of 'Arcot payment authentication network powered by 3-D Secure' under the Payment Security category indicates that the Payment Security Suite is built on this foundational authentication framework. This alignment suggests that Broadcom is leveraging its established 3-D Secure infrastructure to deliver modern, cloud-delivered payment authentication solutions that address evolving fraud risks in digital commerce. The strategic emphasis on this technology within the portfolio table, alongside the SaaS delivery model described in the narrative, reflects an integrated approach to payment security that combines proven authentication methods with scalable cloud services.",
      "llm_answer": "Broadcom positions its Payment Security Suite as a SaaS-based fraud prevention service that leverages Arcot’s 3-D Secure authentication network to secure online transactions, aligning with its broader Payment Security portfolio’s focus on modern, scalable payment authentication. This approach emphasizes a cloud-native, service-oriented model to enhance fraud prevention while maintaining a frictionless user experience, reflecting a strategic shift toward SaaS delivery for payment security solutions.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AVGO_10k_2022.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_2_rel": {
          "source_file": "AVGO_10k_2022.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_3_rel": {
          "source_file": "AVGO_10k_2022.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 9,
        "total_chars": 47459,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12111,
        "completion_tokens": 125,
        "total_tokens": 12237
      }
    },
    {
      "question_id": 83,
      "question": "How does Southern Power's investment in battery energy storage, including the Garland Solar Storage facility, align with its strategy to utilize tax credits and manage operational risk in its long-term power purchase agreements?",
      "original_answer": "Southern Power's investment in battery energy storage, including the Garland Solar Storage facility in Kern County, CA, with 88 MW nameplate capacity and a 20-year PPA, is part of a broader strategy to leverage federal tax credits such as ITCs and PTCs. These investments are structured to maximize tax equity partnerships, where partners take the majority of federal tax benefits, allowing Southern Power to monetize these incentives while reducing its own capital exposure. This aligns with the company's approach to managing operational risk under long-term PPAs, where fixed and variable costs are often passed through to customers via energy charges, and where the integration of storage enhances dispatchability and reliability of renewable energy output. Garland Solar Storage, as a co-located battery facility, supports this model by enabling better utilization of solar generation and optimizing revenue under long-term contracts.",
      "llm_answer": "Southern Power's investment in battery energy storage, exemplified by the Garland Solar Storage facility, directly supports its strategy to monetize federal tax credits (ITCs) and manage operational risk under long-term PPAs. By co-locating battery storage with solar projects, Southern Power qualifies for enhanced ITCs under the Inflation Reduction Act, which can be sold to third parties at a discount to generate immediate cash flow. This approach mitigates revenue volatility tied to variable renewable generation, as PPAs for solar and storage projects often lack capacity charges, making stable cash flows dependent on tax credit monetization and consistent energy output—factors critical to its long-term PPA-driven business model.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 290,
          "pages": [
            288,
            289,
            290,
            291,
            292
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 290,
          "pages": [
            288,
            289,
            290,
            291,
            292
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 92596,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 23384,
        "completion_tokens": 184,
        "total_tokens": 23569
      }
    },
    {
      "question_id": 84,
      "question": "How does Merck's ongoing manufacturing relationship with Organon for formulated pharmaceutical products factor into the financial impact of the spin-off as reflected in Merck's discontinued operations reporting?",
      "original_answer": "Merck's spin-off of Organon involved a complex transition framework including multi-year manufacturing and supply agreements (MSAs), under which Merck agreed to toll manufacture and supply certain formulated pharmaceutical products for Organon. These agreements generated $219 million in sales and $195 million in cost of sales in 2021, indicating continued economic interaction post-spin-off. However, the spin-off also resulted in the classification of Organon's businesses (including women's health, biosimilars, and established brands) as discontinued operations, with Merck incurring $556 million in separation costs in 2021 and $743 million in 2020. The continuation of manufacturing relationships under the MSAs suggests that while Organon was spun off as a separate entity, Merck retained a strategic role in its supply chain, which complicates the clean separation of financial results and raises questions about the long-term implications of these interdependencies on Merck's reported discontinued operations.",
      "llm_answer": "The spin‑off of Organon is reported as discontinued operations, and Merck continues to have a manufacturing relationship with Organon through multiple MSAs that cover the production, toll‑manufacture, packaging and labeling of formulated pharmaceutical products.  These agreements generate sales (e.g., $219 million of sales and $195 million of cost of sales in 2021) and create receivables/payables between the two companies, which are reflected in the consolidated statements of income and balance sheet.  Because the results of the women’s‑health, biosimilars and established‑brands businesses that were transferred to Organon are presented as discontinued operations, the ongoing manufacturing collaboration is a key component of the financial impact of the spin‑off, influencing both the revenue recognized from these MSAs and the related cost‑of‑sales and accrued balances reported in discontinued operations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 146,
          "pages": [
            144,
            145,
            146,
            147,
            148
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 68218,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17285,
        "completion_tokens": 228,
        "total_tokens": 17514
      }
    },
    {
      "question_id": 84,
      "question": "How does Microsoft's inclusion of Software Assurance (SA) in Open Value agreements affect the recognition pattern of unearned revenue for multi-year on-premises licenses compared to other volume licensing programs?",
      "original_answer": "Microsoft includes Software Assurance (SA) in Open Value agreements, which are designed for small and medium organizations licensing over a three-year period. Since SA is included by default, this affects the revenue recognition pattern because SA benefits are delivered over time, requiring judgment in estimating standalone selling prices (SSP) and recognizing revenue ratably over the coverage period. This contrasts with other licensing models where SA may be optional or not bundled, allowing for more upfront revenue recognition. The unearned revenue related to such programs, including SA and cloud services, is generally invoiced annually and recognized over the contract term, as noted in the financial reporting section on unearned revenue.",
      "llm_answer": "Microsoft's inclusion of Software Assurance (SA) in Open Value agreements results in unearned revenue for multi-year on-premises licenses being recognized ratably over the contract period, rather than upfront at license sale, because SA is treated as a distinct performance obligation that is satisfied over time. This contrasts with other volume licensing programs like Enterprise Agreements, where SA is also included but the key distinction in Open Value is that SA is bundled into the agreement for small and medium organizations purchasing over a three-year term, leading to the same ratable recognition pattern for the unearned portion of the license revenue.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 54507,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 13857,
        "completion_tokens": 166,
        "total_tokens": 14024
      }
    },
    {
      "question_id": 84,
      "question": "How does the inclusion of AspenTech in Emerson's 2023 segment revenue data relate to the performance stock units granted by AspenTech, and what does this imply about Emerson's strategic alignment with AspenTech's post-acquisition incentive structure?",
      "original_answer": "Emerson includes AspenTech in its 2023 segment revenue data with a reported revenue of $1 million for 2023 and an expected increase to $8 million in 2024, indicating AspenTech's growing contribution to Emerson’s overall performance. AspenTech, now operating as a separate publicly traded company post-acquisition, grants performance stock units (PSUs) that vest based on predefined goals tied to annual contract value and free cash flows. At the same time, Emerson’s disclosures on page 72 indicate that up to 175% of these PSUs could vest upon achievement of performance goals, showing a strong emphasis on performance-based incentives. This alignment suggests that Emerson is structuring AspenTech’s compensation strategy to incentivize outcomes that directly support revenue growth and financial performance, consistent with the increasing revenue expectations seen in the segment data.",
      "llm_answer": "The inclusion of AspenTech in Emerson’s 2023 segment revenue reflects the post‑acquisition integration of AspenTech’s software and asset‑optimization solutions into Emerson’s Control Systems & Software and Software and Control segments, driving additional sales of $1.042 billion in 2023 and $1.093 billion in 2024.  This revenue growth is tied to the performance‑stock‑unit awards granted by AspenTech, which Emerson assumed and converted into its own equity‑based compensation plans; the compensation expense recognized for these awards (including $58 million of integration‑related stock compensation in 2024) aligns with Emerson’s strategic incentive structure to motivate post‑acquisition performance and to harmonize AspenTech’s incentive framework with Emerson’s own stock‑based compensation policies.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_2_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 70,
          "pages": [
            68,
            69,
            70,
            71,
            72
          ]
        },
        "hop_3_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 72,
          "pages": [
            70,
            71,
            72,
            73,
            74
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 67083,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17012,
        "completion_tokens": 202,
        "total_tokens": 17214
      }
    },
    {
      "question_id": 84,
      "question": "How does Bank of America's exposure to Nonbank VIEs as disclosed in the long-term debt maturity table relate to the valuation risks associated with Structured Liabilities in the fair value measurement section?",
      "original_answer": "Bank of America's exposure to Nonbank VIEs is detailed in the long-term debt maturity table on page 137, where the company reports $564 million in debt associated with these entities, maturing in varying amounts from 2024 through thereafter. These Nonbank VIEs issue Structured Liabilities, a category of debt whose repayment terms are tied to the performance of other financial instruments, as noted on page 136. The fair value measurement section on page 154 reveals that Structured Liabilities are valued using complex quantitative models that incorporate both observable and unobservable market inputs, including interest rate curves, equity or commodity prices, and volatility factors. This introduces significant estimation risk, particularly when market inputs are not readily available or must be extrapolated. Therefore, while the maturity table provides a quantitative view of BAC's exposure to Nonbank VIEs, the fair value section highlights the qualitative risks embedded in Structured Liabilities, which are sensitive to market conditions and model assumptions, suggesting that the actual economic exposure may differ materially from the face value reported in the maturity schedule.",
      "llm_answer": "Bank of America's exposure to Nonbank VIEs disclosed in the long-term debt maturity table reflects liabilities of consolidated VIEs that are collateralized by the VIEs' assets, primarily from credit card and automobile securitizations. This exposure is directly tied to the valuation risks associated with Structured Liabilities, as these liabilities (including Structured Liabilities and Nonbank VIE debt) are measured at fair value and subject to risks from market conditions, credit spreads, and potential collateral requirements under repurchase and securities lending agreements. The fair value measurements of these structured liabilities are detailed in Note 20, where they are valued using quantitative models incorporating observable inputs, with adjustments for credit risk and market volatility.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BAC_10k_2023.pdf",
          "target_page": 137,
          "pages": [
            135,
            136,
            137,
            138,
            139
          ]
        },
        "hop_2_rel": {
          "source_file": "BAC_10k_2023.pdf",
          "target_page": 136,
          "pages": [
            134,
            135,
            136,
            137,
            138
          ]
        },
        "hop_3_rel": {
          "source_file": "BAC_10k_2023.pdf",
          "target_page": 154,
          "pages": [
            152,
            153,
            154,
            155,
            156
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 14,
        "total_chars": 114338,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 28817,
        "completion_tokens": 201,
        "total_tokens": 29019
      }
    },
    {
      "question_id": 84,
      "question": "Why does Mississippi Power qualify for the reduced disclosure format in its 10-K filing, and how does its status as a non-reporting subsidiary impact its governance and reporting obligations to Southern Company?",
      "original_answer": "Mississippi Power qualifies for the reduced disclosure format under General Instructions I(1)(a) and (b) of Form 10-K because it meets the conditions specified in those instructions. This reduced format is available to subsidiaries that are not required to file annual reports with the SEC or provide annual reports to their sole shareholder. As noted in its signature section, Mississippi Power does not send an annual report or proxy statement to its parent company, Southern Company, and does not prepare such reports after filing its Form 10-K. This aligns with the governance structure where Mississippi Power operates as a wholly-owned subsidiary with limited standalone reporting obligations, reflecting a streamlined regulatory compliance model that supports its integrated role within the Southern Company system.",
      "llm_answer": "Mississippi Power qualifies for the reduced disclosure format in its 10-K filing because it meets the conditions in General Instructions I(1)(a) and (b) of Form 10-K, as stated in the document. As a non-reporting subsidiary of Southern Company, Mississippi Power omits Items 10, 11, 12, and 13 from its filing, and its governance and reporting obligations are satisfied through incorporation by reference to Southern Company's governance documents and disclosures, rather than through separate, full filings.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 372,
          "pages": [
            344,
            345,
            346,
            347,
            348
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 13,
        "total_chars": 66851,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16942,
        "completion_tokens": 127,
        "total_tokens": 17069
      }
    },
    {
      "question_id": 85,
      "question": "How does BMY's strategic partnership with 2seventy bio, which includes profit-sharing on U.S. sales of anti-BCMA products like Abecma, reflect in both the collaborative agreement terms and the financial performance metrics reported for 2024?",
      "original_answer": "BMY's strategic partnership with 2seventy bio involves joint development and commercialization of anti-BCMA products, including Abecma, which received FDA approval in 2021 for treating relapsed or refractory multiple myeloma. Under the agreement, 2seventy bio has the right to participate in the U.S. development and commercialization of licensed products, including a 50/50 profit share in exchange for reduced milestone payments. This arrangement is directly reflected in BMY's financial performance for 2024, where U.S. net product sales of Abecma were $242 million, and the related profit-sharing costs amounted to $43 million. This demonstrates how the collaborative structure with 2seventy bio directly impacts BMY's financials through shared profitability and cost obligations.",
      "llm_answer": "BMY's strategic partnership with 2seventy bio, which includes profit-sharing on U.S. sales of anti-BCMA products like Abecma, is reflected in the collaboration agreement terms through a 50/50 co-development and profit-sharing structure in the U.S. where 2seventy bio participates in development and commercialization in exchange for reduced milestone payments, while BMS retains licensing rights and bears manufacturing responsibilities. This arrangement is evidenced by the $43 million profit-sharing cost recorded in 2024 for Abecma's U.S. sales of $242 million, and is further supported by the financial performance metrics showing total alliance revenues of $14,066 million in 2024, with $13,587 million from net product sales (including Abecma's $242 million), and $221 million in receivables from alliance partners, alongside $1,578 million in accounts payable to alliance partners, demonstrating the operational and financial integration of the partnership.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 134,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 73181,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18534,
        "completion_tokens": 241,
        "total_tokens": 18775
      }
    },
    {
      "question_id": 85,
      "question": "How does ACN manage the financial risk associated with short-term, easily terminable client contracts while pursuing a strategy of deepening client relationships through long-term AI and managed services investments?",
      "original_answer": "ACN acknowledges in its accounting policies (page 43) that the majority of its contracts are terminable by clients on short notice with little or no penalties, and only the non-cancelable portion is included in performance obligations. This creates a risk of revenue volatility if clients delay, reduce, or eliminate spending. Despite this, ACN is pursuing a strategy of deepening client relationships through long-term AI and managed services investments, as noted on page 6, where it states that managed services are strategic for clients seeking to leverage AI and automation. To manage this risk, ACN emphasizes innovation and strategic investments, including $6.6 billion across 46 acquisitions in fiscal 2024, to build capabilities that align with client needs and drive long-term value. This suggests a dual approach of mitigating contract risk through continuous innovation and expansion of high-value offerings that encourage client retention and deeper partnerships.",
      "llm_answer": "ACN mitigates the financial risk of short‑term, easily terminable client contracts by pairing them with a strategy that deepens relationships through long‑term AI and managed‑services investments. The company emphasizes that its managed‑services revenue—derived from multi‑year contracts—grows faster than consulting and is less vulnerable to abrupt terminations, while its consulting work, though subject to short‑notice cancellations, continues to be driven by high‑value, technology‑focused transformations that reinforce ongoing client engagement.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "ACN_10k_2023.pdf",
          "target_page": 43,
          "pages": [
            41,
            42,
            43,
            44,
            45
          ]
        },
        "hop_2_rel": {
          "source_file": "ACN_10k_2023.pdf",
          "target_page": 22,
          "pages": [
            20,
            21,
            22,
            23,
            24
          ]
        },
        "hop_3_rel": {
          "source_file": "ACN_10k_2023.pdf",
          "target_page": 6,
          "pages": [
            4,
            5,
            6,
            7,
            8
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 75506,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19111,
        "completion_tokens": 137,
        "total_tokens": 19249
      }
    },
    {
      "question_id": 85,
      "question": "How does the allocation of PFAS-related liabilities between MMM and Solventum, effective April 1, 2024, impact MMM's financial exposure to product claims involving Solventum's products sold between April 1, 2024, and January 1, 2026, especially in light of MMM's historical litigation costs and the spin-off's indemnification framework?",
      "original_answer": "MMM retains liability for PFAS-related product claims arising from Solventum's products sold between April 1, 2024, and January 1, 2026, unless the products fall under specific exceptions such as new PFAS-containing products introduced by Solventum post-spin-off or modified products. Given MMM's historical litigation experience—where the average cost per claim has increased due to a higher proportion of serious injury cases like mesothelioma—the company may face elevated costs for these retained claims. However, the spin-off agreement includes indemnification provisions where Solventum assumes certain liabilities, potentially mitigating MMM's exposure. This creates a nuanced financial risk profile where MMM remains exposed to legacy liabilities and near-term product claims, despite the separation, and must balance this with insurance recoverables and indemnification rights under the distribution agreement.",
      "llm_answer": "The allocation of PFAS-related liabilities places all pre‑April 1 2024 PFAS claims arising from Solventum’s products sold between April 1 2024 and January 1 2026 on 3M, while Solventum assumes liability for those product claims after that period (subject to the listed exceptions). Consequently, 3M’s financial exposure to product claims in that window is limited to the retained PFAS liabilities for Solventum’s post‑spin‑off sales, even though its historical litigation costs for respirator‑mask asbestos matters remain substantial ($523 million accrued as of 12/31/24). The spin‑off’s indemnification framework therefore shifts the risk of future PFAS product claims to Solventum, reducing 3M’s ongoing liability exposure for those specific claims.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "hop_2_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "hop_3_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 95272,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 24075,
        "completion_tokens": 187,
        "total_tokens": 24263
      }
    },
    {
      "question_id": 85,
      "question": "How does Southern Company's credit arrangement structure for Nicor Gas align with the reported decrease in Nicor Gas' short-term notes payable from $392 million in 2023 to $172 million in 2024?",
      "original_answer": "Southern Company's credit arrangements include a $700 million allocation for Nicor Gas under a multi-year credit facility expiring in 2029, which provides working capital flexibility. This arrangement allows Nicor Gas to adjust its liquidity needs without relying heavily on short-term notes payable. In 2024, Nicor Gas' short-term notes payable dropped to $172 million from $392 million in 2023, reflecting the availability of this dedicated credit facility. The reduced reliance on notes payable aligns with the flexible sublimits and liquidity support provided through Southern Company's broader credit arrangements, which also include specific allocations for working capital needs at Nicor Gas.",
      "llm_answer": "Southern Company's credit facility for Nicor Gas includes a $700 million sub‑limit within its $2.45 billion 2029 multi‑year arrangement, which is specifically allocated to support Nicor Gas’s working‑capital needs. This dedicated sub‑limit, together with the overall commitment size, provides the liquidity that enabled Nicor Gas to reduce its short‑term notes payable from $392 million in 2023 to $172 million in 2024.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 223,
          "pages": [
            221,
            222,
            223,
            224,
            225
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 224,
          "pages": [
            222,
            223,
            224,
            225,
            226
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 224,
          "pages": [
            222,
            223,
            224,
            225,
            226
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 84241,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21283,
        "completion_tokens": 104,
        "total_tokens": 21387
      }
    },
    {
      "question_id": 86,
      "question": "How does Corebridge's borrowing timeline through February 2025 align with the expected closure of the AIG Life sale in the first half of 2024, and what does this suggest about Corebridge's liquidity planning during the divestiture process?",
      "original_answer": "Corebridge's borrowing capacity, which extends through February 25, 2025, aligns closely with the anticipated timeline for the sale of AIG Life, expected to close in the first half of 2024. This borrowing flexibility likely supports Corebridge's liquidity needs during the transition period before the transaction concludes and proceeds are received. Given that the sale involves a £460 million cash transaction subject to adjustments, Corebridge may require interim financing to manage operational or financial obligations during the regulatory approval process and pre-closing period. The availability of borrowing through early 2025 provides a financial buffer that aligns with the timing and uncertainty of the AIG Life divestiture, suggesting a strategic approach to liquidity management during major asset sales.",
      "llm_answer": "Corebridge's borrowing timeline extends through February 2025, providing a liquidity buffer that aligns with the anticipated first‑half‑2024 closing of the AIG Life sale; this timing suggests Corebridge is planning for sufficient cash flow to meet debt maturities and repayments while divesting the Life unit.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 113,
          "pages": [
            111,
            112,
            113,
            114,
            115
          ]
        },
        "hop_2_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 149,
          "pages": [
            147,
            148,
            149,
            150,
            151
          ]
        },
        "hop_3_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 137,
          "pages": [
            135,
            136,
            137,
            138,
            139
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 74606,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18897,
        "completion_tokens": 77,
        "total_tokens": 18974
      }
    },
    {
      "question_id": 86,
      "question": "How does MetLife's liquidity risk related to securities lending obligations on $10,510 million in agreements reconcile with the reinvestment portfolio's fair value of $10,553 million, and what does this imply about their risk mitigation strategy?",
      "original_answer": "MetLife reports $10,510 million in securities lending agreements on page 33, where they highlight the risk of having to return significant cash collateral on short notice, which could impair liquidity. On page 244, the company discloses that the reinvestment portfolio associated with these agreements has a fair value of $10,553 million, slightly exceeding the cash collateral received of $10,788 million. This implies that MetLife maintains a reinvestment portfolio that is closely aligned in value with the collateral received, potentially serving as a counterbalance to liquidity pressures by generating returns or maintaining liquidity through marketable assets. This alignment suggests a risk mitigation strategy that leverages asset liquidity and reinvestment to manage potential collateral calls.",
      "llm_answer": "Based on the provided SEC 10-K disclosures, MetLife's liquidity risk related to securities lending obligations of **$10,510 million** is reconciled with the reinvestment portfolio's fair value of **$10,553 million** (a $43 million difference). This reconciliation implies that the reinvestment portfolio—comprising high-quality, liquid securities—holds sufficient value to cover potential collateral calls or forced asset sales under securities lending agreements. However, the document explicitly warns that if the company must return significant cash collateral on short notice and is forced to sell investments in a volatile or illiquid market, it could face difficulty meeting these obligations, potentially leading to losses. This underscores that while the portfolio's fair value aligns closely with the lending liability, MetLife's risk mitigation strategy relies on maintaining liquidity buffers and collateral management practices to avoid such scenarios, rather than assuming the portfolio's value alone fully mitigates liquidity risk.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 244,
          "pages": [
            242,
            243,
            244,
            245,
            246
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 244,
          "pages": [
            242,
            243,
            244,
            245,
            246
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 83862,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21205,
        "completion_tokens": 261,
        "total_tokens": 21466
      }
    },
    {
      "question_id": 86,
      "question": "How does GD's reliance on commercial paper issuances for liquidity needs align with the $4 billion credit facility's role as a backup funding source, given the expiration timeline of the facility in March 2027 and the company's emphasis on maintaining a strong balance sheet?",
      "original_answer": "GD emphasizes on page 46 that commercial paper issuances are a component of its liquidity strategy, supplemented by operating cash flows, to meet both short- and long-term needs. On page 75, the company discloses a $4 billion committed credit facility that supports these commercial paper issuances and serves general corporate purposes, with an expiration in March 2027. This timeline introduces a funding risk if the facility is not renewed or replaced, which contrasts with the company’s stated confidence in maintaining a strong balance sheet and flexibility in capital deployment. The alignment hinges on GD’s ability to either renew the facility or adjust its capital strategy before 2027 to ensure continued liquidity.",
      "llm_answer": "GD's $4 billion revolving credit facility, maturing in March 2027, serves as a backup source of liquidity that backs up its commercial‑paper program; the company emphasizes maintaining a strong balance sheet and relies on the facility only if commercial‑paper issuance is unavailable.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GD_10k_2024.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        },
        "hop_2_rel": {
          "source_file": "GD_10k_2024.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        },
        "hop_3_rel": {
          "source_file": "GD_10k_2024.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 44064,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 11261,
        "completion_tokens": 71,
        "total_tokens": 11332
      }
    },
    {
      "question_id": 87,
      "question": "How does American General Life Insurance Company's membership in the FHLB of Dallas, as a source of collateralized borrowing capacity, relate to the specific amounts and interest rate terms of AIG's outstanding obligations to the FHLB of Dallas as reported in the funding agreements?",
      "original_answer": "American General Life Insurance Company, a subsidiary of AIG with an A+ S&P credit rating, is a member of the FHLB of Dallas, which provides AIG with collateralized borrowing opportunities. As of December 31, 2023, AIG had $3.357 billion in gross obligations to the FHLB of Dallas, with interest rates tied to the DNA Auction rate plus 22 to 30 basis points, and $2.027 billion in fixed-rate obligations ranging from 3.53% to 4.77%. These borrowings are backed by funding agreements and are secured by $8.7 billion in pledged collateral, including assets backing these agreements. This demonstrates how AIG leverages its life insurance subsidiaries’ FHLB memberships to access liquidity under specific rate structures.",
      "llm_answer": "The document indicates that American General Life Insurance Company (AGL) is a member of the FHLB of Dallas, which provides it with collateralized borrowing capacity. This membership allows AGL to pledge assets (including FHLB stock) as collateral for borrowing, with a net borrowing capacity of $3.7 billion under the FHLB facilities as of December 31, 2023. The specific funding agreements with the FHLB of Dallas are detailed in the \"Funding Agreements\" section, which outlines the gross borrowing amounts, maturity schedules, and interest rate terms. The agreements include specific interest rate structures (e.g., DNA Auction rates of +22 to 30 basis points, fixed rates ranging from 1.52% to 4.77%), and the obligations under these agreements are secured by pledged collateral totaling $8.7 billion. The document does not provide explicit interest rate terms for AIG's outstanding obligations to the FHLB beyond the stated rates in the funding agreement table, but confirms that the borrowing capacity and collateral terms are directly tied to AGL's FHLB membership.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 113,
          "pages": [
            111,
            112,
            113,
            114,
            115
          ]
        },
        "hop_2_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 228,
          "pages": [
            226,
            227,
            228,
            229,
            230
          ]
        },
        "hop_3_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 228,
          "pages": [
            226,
            227,
            228,
            229,
            230
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 109272,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 27568,
        "completion_tokens": 268,
        "total_tokens": 27836
      }
    },
    {
      "question_id": 87,
      "question": "Given that Windows Server is a key component of Server products and cloud services, how does Microsoft's reported 36% year-over-year revenue growth in Server products and cloud services ($79,970M to $97,726M) reconcile with the qualitative emphasis on Azure and cloud-first infrastructure in the Intelligent Cloud segment description?",
      "original_answer": "Microsoft's Server products and cloud services, which include Windows Server, experienced a significant 36% year-over-year revenue increase from $79,970M in 2023 to $97,726M in 2024. This growth aligns with the company's strategic emphasis on cloud-first infrastructure, particularly Azure, as outlined in the Intelligent Cloud segment description. While Windows Server remains a foundational on-premises product, its integration with Azure and positioning within a broader cloud services ecosystem reflects Microsoft's shift toward hybrid and public cloud offerings as a key competitive advantage. The revenue growth suggests strong market adoption of this integrated approach, where traditional server products are increasingly consumed as part of cloud services.",
      "llm_answer": "The 36% year-over-year revenue growth in Server products and cloud services ($79,970M to $97,726M) is explicitly reported as part of the \"Server products and cloud services\" category within the Intelligent Cloud segment, which grew 22% overall and contributed to the segment's 20% revenue increase. This growth is directly tied to Azure and other cloud services expansion, aligning with the qualitative emphasis on Azure and cloud-first infrastructure described in the Intelligent Cloud segment overview. The document confirms Microsoft Cloud revenue (which includes Azure) reached $137.4B in FY2024, underpinning the segment's strong performance.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 42,
          "pages": [
            40,
            41,
            42,
            43,
            44
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 56414,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 14369,
        "completion_tokens": 161,
        "total_tokens": 14530
      }
    },
    {
      "question_id": 87,
      "question": "How does MMM's PFAS phase-out timeline compare to supply chain readiness and regulatory pressures, and what financial risks does this create?",
      "original_answer": "MMM has committed to exiting all PFAS manufacturing by the end of 2025 and discontinuing PFAS use across its product portfolio by the same deadline. However, the company acknowledges that certain PFAS-containing products, especially those sourced from third parties used in lithium-ion batteries, printed circuit boards, and seals, may not be replaced by then due to feasibility and availability constraints. This misalignment between MMM's PFAS phase-out timeline and supply chain realities could result in unmet customer demand for PFAS-free products, particularly as customer preferences are already shifting toward such offerings (as noted on page 13). Meanwhile, regulatory pressures are intensifying globally, with increasingly stringent PFAS limits being proposed or enacted in environmental standards, which could lead to material compliance costs, litigation exposure, and reputational damage. The combination of unmet customer expectations, potential revenue loss from PFAS-dependent products, and rising regulatory costs creates a significant financial risk for MMM, particularly given the uncertainty around remediation technologies and the potential for regulatory enforcement actions.",
      "llm_answer": "MMM’s PFAS phase‑out is set for completion by the end of 2025, but the company acknowledges that certain PFAS‑containing products sourced from third parties—especially those required for lithium‑ion batteries, printed‑circuit boards and seals/gaskets—may remain in use beyond that date if suitable non‑PFAS alternatives are unavailable or regulatory approvals are delayed. This creates financial risk because the company could incur unexpected costs for alternative materials, face supply‑chain disruptions, and bear liability for continued PFAS emissions or remediation obligations, potentially leading to asset impairments, litigation expenses and penalties that could materially affect earnings.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_2_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 88,
          "pages": [
            86,
            87,
            88,
            89,
            90
          ]
        },
        "hop_3_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 88,
          "pages": [
            86,
            87,
            88,
            89,
            90
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 93397,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 23561,
        "completion_tokens": 174,
        "total_tokens": 23736
      }
    },
    {
      "question_id": 87,
      "question": "How does Duke Energy's legal challenge of the 2024 CCR Rule relate to its financial obligations for coal ash remediation, especially in light of the expanded regulatory scope from the 2015 CCR Rule?",
      "original_answer": "Duke Energy's legal challenge of the 2024 CCR Rule stems from the rule's significant expansion of regulatory obligations, which now include previously unregulated coal ash sources such as inactive landfills and legacy surface impoundments. This expansion increases Duke Energy’s asset retirement obligations (AROs), which were already substantial under the 2015 CCR Rule and the Coal Ash Act. As of 2024, Duke Energy estimates the total cost to permanently close all coal ash basins at approximately $8 billion to $9 billion, with $4.4 billion already spent. The 2024 CCR Rule introduces additional compliance requirements—such as groundwater monitoring, corrective action, and closure mandates—that are expected to increase these obligations further. The company’s audit report on page 93 confirms that revisions to coal ash remediation cash flow estimates were directly tied to the 2024 CCR Rule, requiring significant management judgment and auditor scrutiny due to the rule’s financial impact. Thus, the legal challenge reflects Duke Energy’s attempt to mitigate the financial burden of these new regulatory requirements on its long-term coal ash remediation liabilities.",
      "llm_answer": "Duke Energy's legal challenge to the 2024 CCR Rule expands the regulatory scope beyond the 2015 rule by requiring compliance with new standards for inactive coal ash surface impoundments and legacy coal ash units, which could increase remediation costs. While the company is seeking cost recovery through traditional rate-making processes and has recorded approximately $4.4 billion of coal ash closure costs to date (with total estimated closure costs of $8–$9 billion), the litigation and expanded regulatory requirements introduce uncertainty regarding the timing and magnitude of future expenditures, though the company does not currently anticipate a material adverse financial impact.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 100428,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 25333,
        "completion_tokens": 172,
        "total_tokens": 25506
      }
    },
    {
      "question_id": 87,
      "question": "How does Merck's ongoing manufacturing relationship with Organon for formulated pharmaceutical products, as detailed in the agreements section, reconcile with the financial impact of the spin-off reflected in discontinued operations?",
      "original_answer": "Merck's ongoing manufacturing relationship with Organon involves toll manufacturing and supply agreements for formulated pharmaceutical products, under which Merck reported $219 million in sales and $195 million in cost of sales in 2021. Despite the spin-off of Organon on June 2, 2021, Merck continues to have a commercial relationship with Organon through these multi-year agreements. However, the spin-off also resulted in the reclassification of Organon's former businesses (women’s health, biosimilars, and established brands) as discontinued operations, which contributed $556 million in separation costs in 2021 and $743 million in 2020. This dual treatment shows that while Merck has divested Organon's core business, it maintains strategic manufacturing linkages that continue to influence its income statement, even as the broader financial impact of the spin-off is isolated to discontinued operations.",
      "llm_answer": "The agreements governing Merck’s ongoing manufacturing relationship with Organon (e.g., the manufacturing and supply agreements, transition services agreement, and related interim operating agreements) are treated as part of the spin‑off arrangements. Because the women’s health, biosimilars and established‑brands businesses that generated those manufacturing revenues were transferred to Organon and reported as discontinued operations, the related sales, cost of sales and other income/expenses are presented in discontinued operations in the consolidated statements of income. Consequently, the financial impact of the spin‑off—reflected in the “Income from Discontinued Operations, Net of Taxes” line and the associated assets, liabilities and goodwill that were distributed—reconciles the post‑spin‑off operating results with the discontinued‑operations presentation. The separation and distribution agreement, MSAs and other commercial agreements formalize the continued manufacturing relationship, while the accounting treatment ensures that the related revenues and expenses are removed from continuing operations and captured within discontinued operations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 146,
          "pages": [
            144,
            145,
            146,
            147,
            148
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 68218,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 17291,
        "completion_tokens": 291,
        "total_tokens": 17583
      }
    },
    {
      "question_id": 88,
      "question": "How do the limited voting rights of Series B Preferred Stockholders interact with their staged convertibility provisions to determine the conditions under which Visa can pursue a consolidation or merger where preferred stockholders would receive different consideration than Class A common stockholders?",
      "original_answer": "The Series B Preferred Stockholders have no voting rights except in specified circumstances, including consolidations or mergers where they would receive different consideration than Class A common stockholders. In such cases, approval requires an affirmative vote by the outstanding voting power of each series of preferred stock, voting as a single class. Additionally, the Series B Preferred Stock is subject to staged convertibility into Class A common stock or Series A Preferred Stock, which becomes triggered by developments in the VE territory covered litigation or after the 12th anniversary of the Visa Europe acquisition. This means that for a consolidation or merger to proceed under these conditions, both the voting approval of Series B Preferred Stockholders and the potential conversion mechanics must align, creating a dual gating mechanism tied to litigation outcomes and time-based convertibility.",
      "llm_answer": "The voting rights of Series B Preferred Stockholders are limited to matters such as certain consolidations, mergers or similar transactions that would result in them receiving securities, cash or other property that differs from what Class A common stockholders would receive. In those limited circumstances, the preferred stockholders may cast votes equal to the number of shares they hold, but only after the conversion rate has been applied. Consequently, when a consolidation or merger is contemplated, the staged convertibility provisions of the Series B Preferred Stock dictate that any consideration paid to them must be identical to the consideration given to Class A common stockholders; otherwise the transaction cannot proceed without the affirmative vote of the preferred stockholders. This interaction ensures that any merger involving different consideration for preferred versus common shareholders requires the preferred holders’ consent, effectively giving them a veto over such transactions.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "V_10k_2023.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_2_rel": {
          "source_file": "V_10k_2023.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_3_rel": {
          "source_file": "V_10k_2023.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 114667,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 28915,
        "completion_tokens": 252,
        "total_tokens": 29167
      }
    },
    {
      "question_id": 88,
      "question": "How does AbbVie's acquisition-related goodwill from Cerevel Therapeutics connect with the financing liability associated with tavapadon's development, and how is the fair value of this liability updated post-acquisition?",
      "original_answer": "AbbVie recognized goodwill from the acquisition of Cerevel Therapeutics, which included expectations of synergies and pipeline expansion (page 72). This acquisition brought with it funding agreements tied to the development of tavapadon, which require AbbVie to make contingent payments based on regulatory and sales milestones (page 67). Post-acquisition, the financing liability associated with these agreements is measured at fair value using unobservable inputs, including probability-weighted models and Monte Carlo simulations, with changes in fair value reflected in earnings (page 84). This shows how AbbVie not only assumed contingent liabilities through the acquisition but also actively manages and updates their valuation based on evolving probabilities and market conditions.",
      "llm_answer": "AbbVie's acquisition of Cerevel Therapeutics included a $246 million financing liability tied to tavapadon development milestones and royalties, whose fair value was initially measured using a probability‑weighted expected‑payment model for regulatory milestones and a Monte Carlo simulation for sales milestones and royalties, discounted to present value. After acquisition, the liability’s fair value is subsequently updated each reporting period based on revised assumptions—including discount rates, estimated probabilities and timing of milestone achievement, and projected future sales—resulting in adjustments that are recorded in other expense (with changes attributable to credit risk recorded in OCI).",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "target_page": 72,
          "pages": [
            70,
            71,
            72,
            73,
            74
          ]
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "target_page": 67,
          "pages": [
            65,
            66,
            67,
            68,
            69
          ]
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 91636,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 23146,
        "completion_tokens": 177,
        "total_tokens": 23324
      }
    },
    {
      "question_id": 88,
      "question": "How does AMD's binding wafer purchase commitment with GLOBALFOUNDRIES U.S. Inc. through 2025 align with their stated risk of overstocking inventory or increased unit costs if actual wafer demand falls short of agreed targets?",
      "original_answer": "AMD has a binding Wafer Supply Agreement (WSA) with GLOBALFOUNDRIES U.S. Inc., amended in May and December 2021, which requires AMD to meet annual wafer purchase targets through 2025 or face financial penalties. This agreement includes prepayment obligations for 2022 and 2023 and guarantees minimum capacity allocation from GF. However, AMD acknowledges in the risk factors section that if actual wafer demand falls short of these purchase targets, it could result in excess inventory or higher inventory unit costs, both of which could negatively impact gross margins and financial performance. This creates a tension between the contractual obligation to purchase wafers and the market-driven variability in actual product demand, highlighting a key operational and financial risk in AMD's supply chain strategy.",
      "llm_answer": "AMD’s wafer‑purchase agreement with GLOBALFOUNDRIES obligates the company to buy a minimum number of wafers each year through 2025 and includes pricing terms that AMD must pre‑pay. If AMD’s actual wafer demand falls short of those targets, it will end up with excess inventory and higher per‑unit costs, which can erode gross margin and negatively affect profitability. This risk is highlighted in the filing’s discussion of “If our actual wafer requirements are less than the number of wafers required to meet the applicable annual wafer purchase target, we could have excess inventory or higher inventory unit costs, both of which may adversely impact our gross margin and our results of operations.”",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMD_10k_2022.pdf",
          "target_page": 97,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_2_rel": {
          "source_file": "AMD_10k_2022.pdf",
          "target_page": 97,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "AMD_10k_2022.pdf",
          "target_page": 23,
          "pages": [
            21,
            22,
            23,
            24,
            25
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 83589,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21130,
        "completion_tokens": 175,
        "total_tokens": 21306
      }
    },
    {
      "question_id": 88,
      "question": "How does the growth in PowerSecure's distributed infrastructure projects, which contributed $120 million to operating revenues in 2024, align with Southern Company's strategic framing of distributed energy and resilience solutions as part of its 'All Other' business segments?",
      "original_answer": "PowerSecure, a subsidiary of Southern Company, contributed $120 million to operating revenues in 2024 through its distributed infrastructure projects. These projects are directly tied to PowerSecure's core offering of distributed energy and resilience solutions, which include microgrid deployment for commercial, industrial, governmental, and utility customers. This aligns with Southern Company's broader strategic positioning of distributed energy solutions as part of its 'All Other' segment, which includes entities providing such services. Despite being below the quantitative threshold for separate disclosure, this segment is framed in the 10-K as a strategic component of Southern Company's diversified offerings, indicating that PowerSecure's growth in this area supports the company's broader diversification and resilience strategy.",
      "llm_answer": "The $120 million of operating revenue that PowerSecure generated from its distributed‑infrastructure projects is highlighted in the “Other Business Activities” section as the primary driver of the 20% increase in total other‑business revenue for 2024. This growth is presented as part of Southern Company’s broader strategic framing of distributed energy and resilience solutions, which it reports under the “All Other” business segment alongside Southern Holdings and Southern Linc. Thus, PowerSecure’s distributed‑energy projects are positioned as a key component of Southern Company’s diversification strategy within the “All Other” segment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 291,
          "pages": [
            289,
            290,
            291,
            292,
            293
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 72347,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18334,
        "completion_tokens": 161,
        "total_tokens": 18495
      }
    },
    {
      "question_id": 88,
      "question": "How does Merck's expectation of declining U.S. sales for Keytruda due to IRA-mandated government price setting in 2028 align with its broader concerns about the impact of the IRA on pharmaceutical innovation and long-term revenue sustainability?",
      "original_answer": "Merck explicitly states that it expects U.S. sales of Keytruda to decline after 2028 due to government price setting under the IRA, which will directly impact revenue from one of its top-selling products. This expectation is outlined in the context of increasing regulatory and pricing pressures from the U.S. government. Additionally, the company expresses broader concerns that the IRA will harm innovation in the pharmaceutical industry, potentially leading to fewer new treatments being developed over time. These two perspectives are interconnected: the direct financial impact on Keytruda sales exemplifies the kind of revenue pressure that could reduce Merck's ability to invest in R&D, thereby supporting the company’s claim that the IRA could have long-term negative effects on innovation and product development. Thus, the specific risk to Keytruda under the IRA serves as both a concrete example and a catalyst for Merck’s more generalized concern about the law's impact on the pharmaceutical innovation ecosystem.",
      "llm_answer": "Merck expects U.S. sales of Keytruda to decline after 2028 because the Inflation Reduction Act’s government‑price‑setting provisions will apply to that drug, directly reducing its Medicare revenue. This development reinforces the Company’s broader concern that IRA‑driven price controls will erode pharmaceutical margins and, over the long term, undermine innovation and the sustainability of its revenue stream.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 83767,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21180,
        "completion_tokens": 103,
        "total_tokens": 21283
      }
    },
    {
      "question_id": 89,
      "question": "How does Merck's expectation of declining U.S. sales for Keytruda due to IRA-mandated government price setting in 2028 align with its broader concerns about the long-term impact of the IRA on pharmaceutical innovation and new treatment development?",
      "original_answer": "Merck anticipates that Keytruda, a major revenue driver, will face a government-set price effective January 1, 2028, which the company expects will lead to a decline in its U.S. sales. This expectation is detailed in the context of the Inflation Reduction Act (IRA), which introduces government price setting for certain Medicare Part B drugs starting in 2028. On page 10, Merck expresses broader concerns that the IRA could harm innovation in the pharmaceutical industry, potentially resulting in fewer new treatments being developed and approved over time. The company is actively working to mitigate these harmful effects, particularly the risk of reduced innovation. Therefore, the anticipated decline in Keytruda sales serves as a concrete example of how the IRA's pricing provisions could undermine the financial incentives for pharmaceutical innovation that Merck highlights as a systemic risk to the industry.",
      "llm_answer": "Merck expects U.S. sales of Keytruda to decline after 2028 because the Inflation Reduction Act’s government price‑setting for Medicare Part B drugs will take effect that year, and it views this IRA‑driven pricing pressure as part of a broader, long‑term threat to pharmaceutical innovation and new‑product development. The company warns that sustained price controls and affordability mandates could erode revenues and undermine its ability to invest in research, ultimately jeopardizing future treatment pipelines.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 83767,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21181,
        "completion_tokens": 128,
        "total_tokens": 21310
      }
    },
    {
      "question_id": 89,
      "question": "How does Microsoft's repeated use of The Bank of New York Mellon Trust Company as trustee across multiple debt issuances, including the 0.875% Notes due 2013 and the 1.625% Notes due 2018, reflect a consistent capital structure management strategy, given the long-standing trustee relationship established in the Base Indenture dated May 18, 2009?",
      "original_answer": "Microsoft's repeated use of BNY Mellon as trustee across multiple debt issuances—such as the 0.875% Notes due 2013 (Exhibit 4.5, filed September 27, 2010) and the 1.625% Notes due 2018 (Exhibit 4.11, filed December 6, 2013)—demonstrates a deliberate and consistent capital structure management strategy. This approach builds on the foundational relationship established in the Base Indenture dated May 18, 2009 (Exhibit 4.1), which formalized BNY Mellon’s role as trustee. By maintaining a long-standing relationship with a single trusted financial institution across multiple supplemental indentures, Microsoft likely benefits from operational efficiency, familiarity with documentation, and reduced execution risk in debt offerings. This pattern suggests that Microsoft views continuity in trustee relationships as a strategic advantage in managing its debt portfolio.",
      "llm_answer": "Microsoft's consistent use of The Bank of New York Mellon Trust Company as trustee across multiple debt issuances—including the 0.875% Notes due 2013 and 1.625% Notes due 2018—reflects a deliberate, long-term capital structure strategy anchored in the May 18, 2009 Base Indenture. This enduring trustee relationship, formalized in the foundational indenture and reinforced through successive supplemental indentures, demonstrates Microsoft's preference for institutional continuity in debt administration, ensuring legal and operational consistency across decades of capital market financing.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 50013,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 12766,
        "completion_tokens": 148,
        "total_tokens": 12914
      }
    },
    {
      "question_id": 89,
      "question": "How does Lockheed Martin's financial dependence on ULA's equity earnings relate to its exposure to commercial customers through receivables, given ULA's role as a launch service provider to those same customers?",
      "original_answer": "Lockheed Martin reported $45 million in equity earnings from its investment in ULA in 2024, which contributed to Space segment profitability. ULA provides expendable launch services to both the U.S. Government and commercial customers. As of December 31, 2024, Lockheed Martin had $665 million in receivables from commercial customers, indicating a direct financial relationship with these entities. This creates a dual exposure: Lockheed benefits from ULA’s performance through equity earnings while also having direct credit and collection risk on contracts with commercial customers that ULA serves. The interplay suggests Lockheed's financial health is indirectly tied to the success of ULA’s commercial launches and the creditworthiness of those commercial customers.",
      "llm_answer": "Lockheed Martin's financial dependence on ULA's equity earnings is modest, representing only about 4% of Space's operating profit ($45 million in 2024 versus $20 million in 2023), so its overall exposure to commercial customers through receivables is not heavily driven by ULA's performance. However, the company does hold significant receivables from U.S. government and commercial customers that are tied to the same launch service contracts ULA provides, meaning that any slowdown or disruption in ULA's ability to deliver launches could affect the timing of cash inflows and thus the collectability of those receivables. Consequently, while ULA's earnings are not a dominant factor in Lockheed's consolidated results, the company's cash flow and working‑capital position remain linked to the successful execution of ULA's launch contracts with commercial customers.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "LMT_10k_2024.pdf",
          "target_page": 41,
          "pages": [
            39,
            40,
            41,
            42,
            43
          ]
        },
        "hop_2_rel": {
          "source_file": "LMT_10k_2024.pdf",
          "target_page": 71,
          "pages": [
            69,
            70,
            71,
            72,
            73
          ]
        },
        "hop_3_rel": {
          "source_file": "LMT_10k_2024.pdf",
          "target_page": 76,
          "pages": [
            74,
            75,
            76,
            77,
            78
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 64377,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16329,
        "completion_tokens": 217,
        "total_tokens": 16546
      }
    },
    {
      "question_id": 89,
      "question": "How does Lockheed Martin's financial dependence on ULA's equity earnings relate to its exposure to commercial customers through receivables, given ULA's role as a launch services provider to those same customers?",
      "original_answer": "Lockheed Martin's Space segment reported $45 million in equity earnings from its investment in ULA in 2024, which contributed to a 6% increase in the segment's operating profit. ULA, in which Lockheed holds a 50% stake, provides launch services to both the U.S. Government and commercial customers. On the other hand, Lockheed's receivables from commercial customers totaled $665 million as of December 31, 2024, indicating a significant financial exposure to this customer group. Since ULA serves commercial customers and Lockheed is financially tied to ULA through equity earnings, this creates a dual exposure: Lockheed benefits from ULA’s commercial launch contracts while also directly extending credit to commercial customers. This dual relationship suggests that Lockheed's financial health is indirectly influenced by the success of ULA’s commercial business and directly affected by the creditworthiness and payment behavior of commercial customers.",
      "llm_answer": "Lockheed Martin's financial dependence on ULA's equity earnings is reflected in the Space segment, where Space's operating profit includes its share of earnings from its 50% investment in ULA, which contributed approximately $45 million (4% of Space's operating profit) in 2024. While ULA serves both government and commercial customers, the revenue from these launch services flows through Lockheed's Space segment, creating exposure to the same commercial customers that generate receivables for Lockheed; thus, the company's receivables from those commercial customers are indirectly tied to the equity earnings it receives from ULA.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "LMT_10k_2024.pdf",
          "target_page": 41,
          "pages": [
            39,
            40,
            41,
            42,
            43
          ]
        },
        "hop_2_rel": {
          "source_file": "LMT_10k_2024.pdf",
          "target_page": 71,
          "pages": [
            69,
            70,
            71,
            72,
            73
          ]
        },
        "hop_3_rel": {
          "source_file": "LMT_10k_2024.pdf",
          "target_page": 76,
          "pages": [
            74,
            75,
            76,
            77,
            78
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 64377,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 16329,
        "completion_tokens": 159,
        "total_tokens": 16488
      }
    },
    {
      "question_id": 89,
      "question": "How does Southern Company's strategic emphasis on distributed energy solutions in its segment reporting align with PowerSecure's financial performance, particularly in relation to the increase in operating revenues and cost of sales tied to distributed infrastructure projects?",
      "original_answer": "Southern Company's segment reporting highlights distributed energy and resilience solutions as part of its 'All Other' category, indicating a strategic focus on deploying microgrids and energy solutions for commercial and utility customers. This strategic emphasis is directly reflected in PowerSecure's financial performance, as disclosed in the 'Other Business Activities' section, where operating revenues increased by $111 million (20.0%) in 2024, with $120 million of that increase attributed to distributed infrastructure projects. However, this growth came with a significant cost increase—$82 million (15.8%) in cost of other sales—also tied to those same projects. This suggests that while Southern Company is strategically investing in distributed energy through PowerSecure, the financial impact shows both revenue growth and margin pressure due to the associated project costs.",
      "llm_answer": "Southern Company’s segment reporting explicitly identifies a distinct “All Other” category that includes “distributed energy and resilience solutions” and “deploying microgrids,” reflecting its strategic emphasis on distributed energy. This aligns with PowerSecure’s financial performance, as noted in the “Other Business Activities” section where operating revenues increased $111 million (20 %) in 2024, driven primarily by PowerSecure’s distributed infrastructure projects, and cost of other sales rose $56 million (15.8 %) due to the same projects. Consequently, the rise in operating revenues and cost of sales tied to distributed infrastructure projects directly supports the strategic focus on distributed energy solutions highlighted in the segment reporting.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 291,
          "pages": [
            289,
            290,
            291,
            292,
            293
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 72347,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 18334,
        "completion_tokens": 191,
        "total_tokens": 18526
      }
    },
    {
      "question_id": 90,
      "question": "How does the change in allowance for credit losses on loan receivables from fiscal 2022 to 2023 reflect the risk profile of Cisco's financing activities tied to technical support services?",
      "original_answer": "The allowance for credit losses on loan receivables decreased from $103 million in fiscal 2022 to $53 million in fiscal 2023, indicating a reduced risk exposure or improved credit quality in these financing arrangements. Loan receivables are explicitly tied to Cisco's technical support and advanced services, suggesting that the company's financing risk related to these services has declined over this period. This reduction in allowance implies that Cisco may have tightened credit standards, experienced better-than-expected repayment performance, or reduced the volume of financing extended for technical support services. The decrease in allowance must be interpreted alongside the overall decrease in financing receivables (down 2% year-over-year), which suggests a contraction or recalibration in Cisco's financing activities, including those related to technical support.",
      "llm_answer": "The allowance for credit losses on loan receivables declined from $53 million (as of July 29 2023) to $50 million (as of July 27 2024), reflecting a modest reduction in the estimated credit‑risk exposure of Cisco’s financing activities tied to technical‑support services. This decrease suggests that, despite higher gross loan receivables, the portfolio’s risk profile improved enough to warrant a lower allowance, indicating that the technical‑support‑related financing is now perceived as slightly less risky.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 75425,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19082,
        "completion_tokens": 127,
        "total_tokens": 19210
      }
    },
    {
      "question_id": 90,
      "question": "Given MMM's retention of PFAS liabilities for certain Solventum products sold between April 1, 2024, and January 1, 2026, how does this liability exposure influence MMM's financial risk disclosures and potential future charges under ASC 450 as outlined in their 2024 10-K?",
      "original_answer": "MMM retains PFAS-related liabilities for Solventum products sold between April 1, 2024, and January 1, 2026, excluding certain exceptions such as new products or modified formulations introduced post-spin-off. Under ASC 450, MMM is required to record liabilities when the loss is probable and reasonably estimable. However, due to the inherent uncertainties in litigation and the indeterminate damages often claimed, MMM may not currently have accruals for some of these liabilities because losses are not yet probable or estimable. This retained exposure could lead to future changes in MMM’s estimated liabilities and disclosures, particularly if unfavorable rulings, new claims, or settlement discussions emerge that alter the Company’s ability to estimate probable losses. As such, the retained PFAS liabilities for Solventum products may result in material charges or disclosures in future periods, impacting MMM’s consolidated financial position and results of operations.",
      "llm_answer": "The 2024 10‑K notes that the Company will retain PFAS‑related liabilities for product claims arising from Solventum products sold between April 1 2024 and January 1 2026, and that it has allocated these contingent obligations separately in the spin‑off agreement. Because the liability is probable but not yet reasonably estimable, ASC 450 requires disclosure of the exposure and a statement that an accrual cannot be made, while the Company continues to reassess the estimate each reporting period. Consequently, the PFAS exposure is disclosed as a contingent liability with no accrual recorded, and the Company warns that future charges may arise if estimates change.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "hop_2_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "hop_3_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 95272,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 24059,
        "completion_tokens": 167,
        "total_tokens": 24226
      }
    },
    {
      "question_id": 90,
      "question": "How does the 118 MW wind capacity from the Glass Sands project completed in Murray County, OK in November 2021, align with Southern Power's stated useful life of up to 35 years for wind assets in evaluating long-term return potential?",
      "original_answer": "The Glass Sands project, completed in November 2021 with a capacity of 118 MW, represents a wind-based asset in Southern Power's portfolio. Given that Southern Power reports a useful life of up to 35 years for wind assets, this suggests the company expects a relatively long operational lifespan for the Glass Sands facility. This long useful life supports the potential for sustained revenue generation over time, which is critical for evaluating the long-term return on this investment. The 12-year PPA contract period for Glass Sands, however, indicates that revenue stability beyond that term may depend on market conditions or renegotiation, creating a tension between asset longevity and contracted revenue visibility.",
      "llm_answer": "The 118 MW Glass Sands wind project, completed in November 2021, is classified as a wind asset with a useful‑life estimate of up to 35 years in Southern Power’s depreciation policy (see “Southern Power – Depreciation and Amortization” and the “Construction Projects” table). This 35‑year useful life is applied when evaluating the long‑term return potential of the asset, aligning the project’s expected service period with the company’s standard wind‑asset horizon.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 297,
          "pages": [
            295,
            296,
            297,
            298,
            299
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 297,
          "pages": [
            295,
            296,
            297,
            298,
            299
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 217,
          "pages": [
            215,
            216,
            217,
            218,
            219
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 85023,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 21493,
        "completion_tokens": 116,
        "total_tokens": 21610
      }
    },
    {
      "question_id": 90,
      "question": "How does GILD's revenue recognition model for Symtuza, which is manufactured and distributed by Janssen, compare with the financial treatment of Odefsey, where GILD retains manufacturing and primary commercialization responsibility, and how does this affect GILD's cost of goods sold and product sales line items?",
      "original_answer": "GILD recognizes its share of Symtuza revenue in the period when Janssen sells the product, as Janssen is responsible for manufacturing, registration, and global commercialization. GILD's revenue from Symtuza is based on a revenue-sharing model tied to the net selling prices of its components, and it is recorded under Product Sales. In contrast, for Odefsey, GILD retains the lead role in manufacturing and commercialization in most markets, and it shares revenues with Janssen based on the net selling prices of each party's components. This results in Janssen's share of Odefsey revenue being recorded in GILD's Cost of Goods Sold, which totaled $403 million in 2024. The differing structures illustrate how GILD's financial exposure and line-item treatment vary significantly depending on which party controls the commercialization and distribution of the jointly developed products.",
      "llm_answer": "Gilead’s revenue‑recognition for Symtuza differs from that for Odefsey. For Symtuza Janssen manufactures, registers, distributes and sets the price; Gilead only supplies the cobicistat/tenofovir components and records its share of Janssen’s Symtuza revenue as product sales when Janssen sells the product. In contrast, for Odefsey Gilead manufactures the combination product and retains primary commercialization responsibility, so it records the full product‑sales revenue and also includes Janssen’s share of the revenue in cost of goods sold. Consequently, Symtuza’s COGS reflects Janssen’s manufacturing and distribution costs (recorded as part of COGS), whereas Odefsey’s COGS reflects only Gilead’s manufacturing costs and the revenue is reported entirely under product sales.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "target_page": 77,
          "pages": [
            75,
            76,
            77,
            78,
            79
          ]
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "target_page": 76,
          "pages": [
            74,
            75,
            76,
            77,
            78
          ]
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "target_page": 76,
          "pages": [
            74,
            75,
            76,
            77,
            78
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 78167,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 19793,
        "completion_tokens": 195,
        "total_tokens": 19989
      }
    },
    {
      "question_id": 90,
      "question": "Given MetLife's $89.8 billion exposure to mortgage loans on the balance sheet, how does the company's risk profile and unrealized loss position in pass-through mortgage-backed securities, which are secured by those loans, reflect the underlying credit quality and diversification of the mortgage portfolio?",
      "original_answer": "MetLife reports $89.8 billion in mortgage loans on the balance sheet (page 296), which serve as the collateral for pass-through mortgage-backed securities (page 87). On page 88, the company discloses a $12.6 billion exposure to pass-through mortgage-backed securities, which carry an unrealized loss of $1.3 billion. These securities directly reflect the credit quality of the underlying mortgage loans. The unrealized loss suggests that the market perceives some credit deterioration or increased risk in the underlying loans, despite the company's diversification efforts across security types and risk profiles, including Agency and Non-Agency RMBS, as well as segmentation by borrower quality (e.g., prime, NQM, Alt-A, and reperforming/sub-prime). This indicates that while the mortgage loan portfolio is substantial, the associated pass-through securities are experiencing market-driven valuation pressures, potentially signaling broader credit concerns in the underlying assets.",
      "llm_answer": "MetLife’s $89.8 billion exposure to mortgage loans is reflected in its pass‑through mortgage‑backed securities, which are secured by those loans and carry a net unrealized loss of roughly $2.66 billion (about 7.7 % of the $34.1 billion RMBS portfolio). The securities are overwhelmingly rated Aaa/Aa or NAIC 1, indicating high credit quality, and the portfolio is broadly diversified across agency and non‑agency, prime and non‑prime, and various collateral types, resulting in a relatively low concentration of credit risk despite the large underlying loan balance.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2024.pdf",
          "target_page": 296,
          "pages": [
            294,
            295,
            296,
            297,
            298
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2024.pdf",
          "target_page": 87,
          "pages": [
            85,
            86,
            87,
            88,
            89
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2024.pdf",
          "target_page": 88,
          "pages": [
            86,
            87,
            88,
            89,
            90
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 110078,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 27775,
        "completion_tokens": 141,
        "total_tokens": 27917
      }
    },
    {
      "question_id": 91,
      "question": "How does Johnson & Johnson's classification of reverse repurchase agreements (RRAs) with maturities over three months align with its accounting treatment of held-to-maturity investments, given the company's policy of maintaining collateral at 102% of RRA value?",
      "original_answer": "Johnson & Johnson classifies reverse repurchase agreements (RRAs) with maturities over three months from the date of purchase as marketable securities, while held-to-maturity investments are reported at amortized cost with realized gains or losses recognized in earnings. The company maintains a policy that the collateral backing RRAs must be at least 102% of their value and rated at least A (or equivalent), which reflects a conservative approach to liquidity and credit risk. This policy aligns with the accounting treatment of held-to-maturity investments, which also emphasizes credit quality and long-term holding, suggesting a consistent strategy of risk mitigation across both investment types. However, the classification of longer-term RRAs as marketable securities indicates a more liquid or potentially shorter-duration intent compared to held-to-maturity investments.",
      "llm_answer": "Johnson & Johnson classifies reverse repurchase agreements (RRAs) with maturities exceeding three months as current marketable securities, consistent with its held-to-maturity investment accounting policy. The company maintains collateral at 102% of RRA value through a third-party custodian, ensuring the collateral is held at a level that exceeds the RRA value to protect against credit risk, which aligns with the conservative valuation approach used for held-to-maturity securities.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "JNJ_10k_2022.pdf",
          "target_page": 54,
          "pages": [
            52,
            53,
            54,
            55,
            56
          ]
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2022.pdf",
          "target_page": 59,
          "pages": [
            57,
            58,
            59,
            60,
            61
          ]
        },
        "hop_3_rel": {
          "source_file": "JNJ_10k_2022.pdf",
          "target_page": 59,
          "pages": [
            57,
            58,
            59,
            60,
            61
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 62446,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 15854,
        "completion_tokens": 121,
        "total_tokens": 15975
      }
    },
    {
      "question_id": 91,
      "question": "How does Microsoft's inclusion of Activision Blizzard's financials in the consolidated statements, despite excluding their internal controls from evaluation, relate to the assumption of Activision's 3.400% Senior Notes due 2026 as part of the acquisition financing structure?",
      "original_answer": "Microsoft's consolidated financial statements include Activision Blizzard's financial results post-acquisition on October 13, 2023, but explicitly excluded Activision’s internal controls from the evaluation of internal control over financial reporting, citing that Activision represented less than 1% of total assets (excluding goodwill and intangibles) and 2% of total revenues. Meanwhile, the assumption of Activision’s 3.400% Senior Notes due 2026, as evidenced by the supplemental indenture filed on October 27, 2023, reflects Microsoft’s direct financial liability assumption as part of the acquisition financing. This creates a tension between the limited operational control visibility and the full financial liability exposure Microsoft has taken on through the acquisition, particularly in terms of debt instruments like the 3.400% Senior Notes due 2026.",
      "llm_answer": "Microsoft's consolidated financial statements include Activision Blizzard's results, but the company explicitly excluded Activision Blizzard's internal controls from its evaluation of effectiveness. This exclusion occurred because Activision Blizzard was acquired in October 2023 and represented less than 1% of Microsoft's total assets (after excluding goodwill and acquired intangibles) and about 2% of revenue, so its internal controls were not assessed as part of Microsoft's own internal control framework. The acquisition financing structure included Activision Blizzard's 3.400% Senior Notes due 2026, which were issued under an indenture dated September 19, 2016, between Activision Blizzard and Wells Fargo Bank, National Association, as Trustee.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2023.pdf",
          "target_page": 106,
          "pages": [
            104,
            105,
            106,
            107,
            108
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2023.pdf",
          "target_page": 107,
          "pages": [
            104,
            105,
            106,
            107,
            108
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2023.pdf",
          "target_page": 98,
          "pages": [
            96,
            97,
            98,
            99,
            100
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 53844,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 13708,
        "completion_tokens": 188,
        "total_tokens": 13897
      }
    },
    {
      "question_id": 91,
      "question": "How does the adoption of ASU No. 2023-07, which mandates incremental disclosures of disaggregated expense information, impact the presentation of operating income (loss) by business segment as reported under Segment Reporting in MMM's 2024 financial statements?",
      "original_answer": "MMM adopted ASU No. 2023-07 for the year ended December 31, 2024, which requires incremental disclosures of disaggregated expense information for reportable segments. This adoption impacts the Segment Reporting section by enhancing the granularity of operating income (loss) data presented for each business segment, as seen in the tables on page 26. The updated disclosures align with the retrospective application of the ASU to all prior periods presented, indicating a more detailed and standardized approach to segment performance reporting.",
      "llm_answer": "The adoption of ASU 2023‑07 requires 3M to disclose disaggregated expense information for each reportable segment. In the 2024 financial statements, this means operating‑income (loss) by segment is presented with separate line items for special‑item adjustments (e.g., litigation costs, PFAS‑related charges, divestiture‑related items) so that investors can see the GAAP operating result and the non‑GAAP adjusted result for Safety & Industrial, Transportation & Electronics, and Consumer segments. Consequently, the segment‑level operating‑income (loss) figures now reflect both the GAAP amount and the adjusted amount after removing the impact of these special items, providing a clearer view of each segment’s core profitability.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 26,
          "pages": [
            24,
            25,
            26,
            27,
            28
          ]
        },
        "hop_2_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 54,
          "pages": [
            52,
            53,
            54,
            55,
            56
          ]
        },
        "hop_3_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 54,
          "pages": [
            52,
            53,
            54,
            55,
            56
          ]
        }
      },
      "context_stats": {
        "window_size": 5,
        "total_pages": 15,
        "total_chars": 108302,
        "hops_processed": 3
      },
      "token_usage": {
        "prompt_tokens": 27318,
        "completion_tokens": 183,
        "total_tokens": 27501
      }
    }
  ]
}